<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />


<meta name="author" content="Xiaotang (Jeffrey) Zhou" />


<title>Shots, Shots, Shots: An Analysis of Studies of COVID-19 Vaccines in the NCBI Database</title>

<script src="data:application/javascript;base64,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"></script>
<script src="data:application/javascript;base64,/*! jQuery v3.6.0 | (c) OpenJS Foundation and other contributors | jquery.org/license */
!function(e,t){"use strict";"object"==typeof module&&"object"==typeof module.exports?module.exports=e.document?t(e,!0):function(e){if(!e.document)throw new Error("jQuery requires a window with a document");return t(e)}:t(e)}("undefined"!=typeof window?window:this,function(C,e){"use strict";var t=[],r=Object.getPrototypeOf,s=t.slice,g=t.flat?function(e){return t.flat.call(e)}:function(e){return t.concat.apply([],e)},u=t.push,i=t.indexOf,n={},o=n.toString,v=n.hasOwnProperty,a=v.toString,l=a.call(Object),y={},m=function(e){return"function"==typeof e&&"number"!=typeof e.nodeType&&"function"!=typeof e.item},x=function(e){return null!=e&&e===e.window},E=C.document,c={type:!0,src:!0,nonce:!0,noModule:!0};function b(e,t,n){var r,i,o=(n=n||E).createElement("script");if(o.text=e,t)for(r in c)(i=t[r]||t.getAttribute&&t.getAttribute(r))&&o.setAttribute(r,i);n.head.appendChild(o).parentNode.removeChild(o)}function w(e){return null==e?e+"":"object"==typeof e||"function"==typeof e?n[o.call(e)]||"object":typeof e}var f="3.6.0",S=function(e,t){return new S.fn.init(e,t)};function p(e){var t=!!e&&"length"in e&&e.length,n=w(e);return!m(e)&&!x(e)&&("array"===n||0===t||"number"==typeof t&&0<t&&t-1 in e)}S.fn=S.prototype={jquery:f,constructor:S,length:0,toArray:function(){return s.call(this)},get:function(e){return null==e?s.call(this):e<0?this[e+this.length]:this[e]},pushStack:function(e){var t=S.merge(this.constructor(),e);return t.prevObject=this,t},each:function(e){return S.each(this,e)},map:function(n){return this.pushStack(S.map(this,function(e,t){return n.call(e,t,e)}))},slice:function(){return this.pushStack(s.apply(this,arguments))},first:function(){return this.eq(0)},last:function(){return this.eq(-1)},even:function(){return this.pushStack(S.grep(this,function(e,t){return(t+1)%2}))},odd:function(){return this.pushStack(S.grep(this,function(e,t){return t%2}))},eq:function(e){var t=this.length,n=+e+(e<0?t:0);return this.pushStack(0<=n&&n<t?[this[n]]:[])},end:function(){return this.prevObject||this.constructor()},push:u,sort:t.sort,splice:t.splice},S.extend=S.fn.extend=function(){var e,t,n,r,i,o,a=arguments[0]||{},s=1,u=arguments.length,l=!1;for("boolean"==typeof a&&(l=a,a=arguments[s]||{},s++),"object"==typeof a||m(a)||(a={}),s===u&&(a=this,s--);s<u;s++)if(null!=(e=arguments[s]))for(t in e)r=e[t],"__proto__"!==t&&a!==r&&(l&&r&&(S.isPlainObject(r)||(i=Array.isArray(r)))?(n=a[t],o=i&&!Array.isArray(n)?[]:i||S.isPlainObject(n)?n:{},i=!1,a[t]=S.extend(l,o,r)):void 0!==r&&(a[t]=r));return a},S.extend({expando:"jQuery"+(f+Math.random()).replace(/\D/g,""),isReady:!0,error:function(e){throw new Error(e)},noop:function(){},isPlainObject:function(e){var t,n;return!(!e||"[object Object]"!==o.call(e))&&(!(t=r(e))||"function"==typeof(n=v.call(t,"constructor")&&t.constructor)&&a.call(n)===l)},isEmptyObject:function(e){var t;for(t in e)return!1;return!0},globalEval:function(e,t,n){b(e,{nonce:t&&t.nonce},n)},each:function(e,t){var n,r=0;if(p(e)){for(n=e.length;r<n;r++)if(!1===t.call(e[r],r,e[r]))break}else for(r in e)if(!1===t.call(e[r],r,e[r]))break;return e},makeArray:function(e,t){var n=t||[];return null!=e&&(p(Object(e))?S.merge(n,"string"==typeof e?[e]:e):u.call(n,e)),n},inArray:function(e,t,n){return null==t?-1:i.call(t,e,n)},merge:function(e,t){for(var n=+t.length,r=0,i=e.length;r<n;r++)e[i++]=t[r];return e.length=i,e},grep:function(e,t,n){for(var r=[],i=0,o=e.length,a=!n;i<o;i++)!t(e[i],i)!==a&&r.push(e[i]);return r},map:function(e,t,n){var r,i,o=0,a=[];if(p(e))for(r=e.length;o<r;o++)null!=(i=t(e[o],o,n))&&a.push(i);else for(o in e)null!=(i=t(e[o],o,n))&&a.push(i);return g(a)},guid:1,support:y}),"function"==typeof Symbol&&(S.fn[Symbol.iterator]=t[Symbol.iterator]),S.each("Boolean Number String Function Array Date RegExp Object Error Symbol".split(" "),function(e,t){n["[object "+t+"]"]=t.toLowerCase()});var d=function(n){var e,d,b,o,i,h,f,g,w,u,l,T,C,a,E,v,s,c,y,S="sizzle"+1*new Date,p=n.document,k=0,r=0,m=ue(),x=ue(),A=ue(),N=ue(),j=function(e,t){return e===t&&(l=!0),0},D={}.hasOwnProperty,t=[],q=t.pop,L=t.push,H=t.push,O=t.slice,P=function(e,t){for(var n=0,r=e.length;n<r;n++)if(e[n]===t)return n;return-1},R="checked|selected|async|autofocus|autoplay|controls|defer|disabled|hidden|ismap|loop|multiple|open|readonly|required|scoped",M="[\\x20\\t\\r\\n\\f]",I="(?:\\\\[\\da-fA-F]{1,6}"+M+"?|\\\\[^\\r\\n\\f]|[\\w-]|[^\0-\\x7f])+",W="\\["+M+"*("+I+")(?:"+M+"*([*^$|!~]?=)"+M+"*(?:'((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\"|("+I+"))|)"+M+"*\\]",F=":("+I+")(?:\\((('((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\")|((?:\\\\.|[^\\\\()[\\]]|"+W+")*)|.*)\\)|)",B=new RegExp(M+"+","g"),$=new RegExp("^"+M+"+|((?:^|[^\\\\])(?:\\\\.)*)"+M+"+$","g"),_=new RegExp("^"+M+"*,"+M+"*"),z=new RegExp("^"+M+"*([>+~]|"+M+")"+M+"*"),U=new RegExp(M+"|>"),X=new RegExp(F),V=new RegExp("^"+I+"$"),G={ID:new RegExp("^#("+I+")"),CLASS:new RegExp("^\\.("+I+")"),TAG:new RegExp("^("+I+"|[*])"),ATTR:new RegExp("^"+W),PSEUDO:new RegExp("^"+F),CHILD:new RegExp("^:(only|first|last|nth|nth-last)-(child|of-type)(?:\\("+M+"*(even|odd|(([+-]|)(\\d*)n|)"+M+"*(?:([+-]|)"+M+"*(\\d+)|))"+M+"*\\)|)","i"),bool:new RegExp("^(?:"+R+")$","i"),needsContext:new RegExp("^"+M+"*[>+~]|:(even|odd|eq|gt|lt|nth|first|last)(?:\\("+M+"*((?:-\\d)?\\d*)"+M+"*\\)|)(?=[^-]|$)","i")},Y=/HTML$/i,Q=/^(?:input|select|textarea|button)$/i,J=/^h\d$/i,K=/^[^{]+\{\s*\[native \w/,Z=/^(?:#([\w-]+)|(\w+)|\.([\w-]+))$/,ee=/[+~]/,te=new RegExp("\\\\[\\da-fA-F]{1,6}"+M+"?|\\\\([^\\r\\n\\f])","g"),ne=function(e,t){var n="0x"+e.slice(1)-65536;return t||(n<0?String.fromCharCode(n+65536):String.fromCharCode(n>>10|55296,1023&n|56320))},re=/([\0-\x1f\x7f]|^-?\d)|^-$|[^\0-\x1f\x7f-\uFFFF\w-]/g,ie=function(e,t){return t?"\0"===e?"\ufffd":e.slice(0,-1)+"\\"+e.charCodeAt(e.length-1).toString(16)+" ":"\\"+e},oe=function(){T()},ae=be(function(e){return!0===e.disabled&&"fieldset"===e.nodeName.toLowerCase()},{dir:"parentNode",next:"legend"});try{H.apply(t=O.call(p.childNodes),p.childNodes),t[p.childNodes.length].nodeType}catch(e){H={apply:t.length?function(e,t){L.apply(e,O.call(t))}:function(e,t){var n=e.length,r=0;while(e[n++]=t[r++]);e.length=n-1}}}function se(t,e,n,r){var i,o,a,s,u,l,c,f=e&&e.ownerDocument,p=e?e.nodeType:9;if(n=n||[],"string"!=typeof t||!t||1!==p&&9!==p&&11!==p)return n;if(!r&&(T(e),e=e||C,E)){if(11!==p&&(u=Z.exec(t)))if(i=u[1]){if(9===p){if(!(a=e.getElementById(i)))return n;if(a.id===i)return n.push(a),n}else if(f&&(a=f.getElementById(i))&&y(e,a)&&a.id===i)return n.push(a),n}else{if(u[2])return H.apply(n,e.getElementsByTagName(t)),n;if((i=u[3])&&d.getElementsByClassName&&e.getElementsByClassName)return H.apply(n,e.getElementsByClassName(i)),n}if(d.qsa&&!N[t+" "]&&(!v||!v.test(t))&&(1!==p||"object"!==e.nodeName.toLowerCase())){if(c=t,f=e,1===p&&(U.test(t)||z.test(t))){(f=ee.test(t)&&ye(e.parentNode)||e)===e&&d.scope||((s=e.getAttribute("id"))?s=s.replace(re,ie):e.setAttribute("id",s=S)),o=(l=h(t)).length;while(o--)l[o]=(s?"#"+s:":scope")+" "+xe(l[o]);c=l.join(",")}try{return H.apply(n,f.querySelectorAll(c)),n}catch(e){N(t,!0)}finally{s===S&&e.removeAttribute("id")}}}return g(t.replace($,"$1"),e,n,r)}function ue(){var r=[];return function e(t,n){return r.push(t+" ")>b.cacheLength&&delete e[r.shift()],e[t+" "]=n}}function le(e){return e[S]=!0,e}function ce(e){var t=C.createElement("fieldset");try{return!!e(t)}catch(e){return!1}finally{t.parentNode&&t.parentNode.removeChild(t),t=null}}function fe(e,t){var n=e.split("|"),r=n.length;while(r--)b.attrHandle[n[r]]=t}function pe(e,t){var n=t&&e,r=n&&1===e.nodeType&&1===t.nodeType&&e.sourceIndex-t.sourceIndex;if(r)return r;if(n)while(n=n.nextSibling)if(n===t)return-1;return e?1:-1}function de(t){return function(e){return"input"===e.nodeName.toLowerCase()&&e.type===t}}function he(n){return function(e){var t=e.nodeName.toLowerCase();return("input"===t||"button"===t)&&e.type===n}}function ge(t){return function(e){return"form"in e?e.parentNode&&!1===e.disabled?"label"in e?"label"in e.parentNode?e.parentNode.disabled===t:e.disabled===t:e.isDisabled===t||e.isDisabled!==!t&&ae(e)===t:e.disabled===t:"label"in e&&e.disabled===t}}function ve(a){return le(function(o){return o=+o,le(function(e,t){var n,r=a([],e.length,o),i=r.length;while(i--)e[n=r[i]]&&(e[n]=!(t[n]=e[n]))})})}function ye(e){return e&&"undefined"!=typeof e.getElementsByTagName&&e}for(e in d=se.support={},i=se.isXML=function(e){var t=e&&e.namespaceURI,n=e&&(e.ownerDocument||e).documentElement;return!Y.test(t||n&&n.nodeName||"HTML")},T=se.setDocument=function(e){var t,n,r=e?e.ownerDocument||e:p;return r!=C&&9===r.nodeType&&r.documentElement&&(a=(C=r).documentElement,E=!i(C),p!=C&&(n=C.defaultView)&&n.top!==n&&(n.addEventListener?n.addEventListener("unload",oe,!1):n.attachEvent&&n.attachEvent("onunload",oe)),d.scope=ce(function(e){return a.appendChild(e).appendChild(C.createElement("div")),"undefined"!=typeof e.querySelectorAll&&!e.querySelectorAll(":scope fieldset div").length}),d.attributes=ce(function(e){return e.className="i",!e.getAttribute("className")}),d.getElementsByTagName=ce(function(e){return e.appendChild(C.createComment("")),!e.getElementsByTagName("*").length}),d.getElementsByClassName=K.test(C.getElementsByClassName),d.getById=ce(function(e){return a.appendChild(e).id=S,!C.getElementsByName||!C.getElementsByName(S).length}),d.getById?(b.filter.ID=function(e){var t=e.replace(te,ne);return function(e){return e.getAttribute("id")===t}},b.find.ID=function(e,t){if("undefined"!=typeof t.getElementById&&E){var n=t.getElementById(e);return n?[n]:[]}}):(b.filter.ID=function(e){var n=e.replace(te,ne);return function(e){var t="undefined"!=typeof e.getAttributeNode&&e.getAttributeNode("id");return t&&t.value===n}},b.find.ID=function(e,t){if("undefined"!=typeof t.getElementById&&E){var n,r,i,o=t.getElementById(e);if(o){if((n=o.getAttributeNode("id"))&&n.value===e)return[o];i=t.getElementsByName(e),r=0;while(o=i[r++])if((n=o.getAttributeNode("id"))&&n.value===e)return[o]}return[]}}),b.find.TAG=d.getElementsByTagName?function(e,t){return"undefined"!=typeof t.getElementsByTagName?t.getElementsByTagName(e):d.qsa?t.querySelectorAll(e):void 0}:function(e,t){var n,r=[],i=0,o=t.getElementsByTagName(e);if("*"===e){while(n=o[i++])1===n.nodeType&&r.push(n);return r}return o},b.find.CLASS=d.getElementsByClassName&&function(e,t){if("undefined"!=typeof t.getElementsByClassName&&E)return t.getElementsByClassName(e)},s=[],v=[],(d.qsa=K.test(C.querySelectorAll))&&(ce(function(e){var t;a.appendChild(e).innerHTML="<a id='"+S+"'></a><select id='"+S+"-\r\\' msallowcapture=''><option selected=''></option></select>",e.querySelectorAll("[msallowcapture^='']").length&&v.push("[*^$]="+M+"*(?:''|\"\")"),e.querySelectorAll("[selected]").length||v.push("\\["+M+"*(?:value|"+R+")"),e.querySelectorAll("[id~="+S+"-]").length||v.push("~="),(t=C.createElement("input")).setAttribute("name",""),e.appendChild(t),e.querySelectorAll("[name='']").length||v.push("\\["+M+"*name"+M+"*="+M+"*(?:''|\"\")"),e.querySelectorAll(":checked").length||v.push(":checked"),e.querySelectorAll("a#"+S+"+*").length||v.push(".#.+[+~]"),e.querySelectorAll("\\\f"),v.push("[\\r\\n\\f]")}),ce(function(e){e.innerHTML="<a href='' disabled='disabled'></a><select disabled='disabled'><option/></select>";var t=C.createElement("input");t.setAttribute("type","hidden"),e.appendChild(t).setAttribute("name","D"),e.querySelectorAll("[name=d]").length&&v.push("name"+M+"*[*^$|!~]?="),2!==e.querySelectorAll(":enabled").length&&v.push(":enabled",":disabled"),a.appendChild(e).disabled=!0,2!==e.querySelectorAll(":disabled").length&&v.push(":enabled",":disabled"),e.querySelectorAll("*,:x"),v.push(",.*:")})),(d.matchesSelector=K.test(c=a.matches||a.webkitMatchesSelector||a.mozMatchesSelector||a.oMatchesSelector||a.msMatchesSelector))&&ce(function(e){d.disconnectedMatch=c.call(e,"*"),c.call(e,"[s!='']:x"),s.push("!=",F)}),v=v.length&&new RegExp(v.join("|")),s=s.length&&new RegExp(s.join("|")),t=K.test(a.compareDocumentPosition),y=t||K.test(a.contains)?function(e,t){var n=9===e.nodeType?e.documentElement:e,r=t&&t.parentNode;return e===r||!(!r||1!==r.nodeType||!(n.contains?n.contains(r):e.compareDocumentPosition&&16&e.compareDocumentPosition(r)))}:function(e,t){if(t)while(t=t.parentNode)if(t===e)return!0;return!1},j=t?function(e,t){if(e===t)return l=!0,0;var n=!e.compareDocumentPosition-!t.compareDocumentPosition;return n||(1&(n=(e.ownerDocument||e)==(t.ownerDocument||t)?e.compareDocumentPosition(t):1)||!d.sortDetached&&t.compareDocumentPosition(e)===n?e==C||e.ownerDocument==p&&y(p,e)?-1:t==C||t.ownerDocument==p&&y(p,t)?1:u?P(u,e)-P(u,t):0:4&n?-1:1)}:function(e,t){if(e===t)return l=!0,0;var n,r=0,i=e.parentNode,o=t.parentNode,a=[e],s=[t];if(!i||!o)return e==C?-1:t==C?1:i?-1:o?1:u?P(u,e)-P(u,t):0;if(i===o)return pe(e,t);n=e;while(n=n.parentNode)a.unshift(n);n=t;while(n=n.parentNode)s.unshift(n);while(a[r]===s[r])r++;return r?pe(a[r],s[r]):a[r]==p?-1:s[r]==p?1:0}),C},se.matches=function(e,t){return se(e,null,null,t)},se.matchesSelector=function(e,t){if(T(e),d.matchesSelector&&E&&!N[t+" "]&&(!s||!s.test(t))&&(!v||!v.test(t)))try{var n=c.call(e,t);if(n||d.disconnectedMatch||e.document&&11!==e.document.nodeType)return n}catch(e){N(t,!0)}return 0<se(t,C,null,[e]).length},se.contains=function(e,t){return(e.ownerDocument||e)!=C&&T(e),y(e,t)},se.attr=function(e,t){(e.ownerDocument||e)!=C&&T(e);var n=b.attrHandle[t.toLowerCase()],r=n&&D.call(b.attrHandle,t.toLowerCase())?n(e,t,!E):void 0;return void 0!==r?r:d.attributes||!E?e.getAttribute(t):(r=e.getAttributeNode(t))&&r.specified?r.value:null},se.escape=function(e){return(e+"").replace(re,ie)},se.error=function(e){throw new Error("Syntax error, unrecognized expression: "+e)},se.uniqueSort=function(e){var t,n=[],r=0,i=0;if(l=!d.detectDuplicates,u=!d.sortStable&&e.slice(0),e.sort(j),l){while(t=e[i++])t===e[i]&&(r=n.push(i));while(r--)e.splice(n[r],1)}return u=null,e},o=se.getText=function(e){var t,n="",r=0,i=e.nodeType;if(i){if(1===i||9===i||11===i){if("string"==typeof e.textContent)return e.textContent;for(e=e.firstChild;e;e=e.nextSibling)n+=o(e)}else if(3===i||4===i)return e.nodeValue}else while(t=e[r++])n+=o(t);return n},(b=se.selectors={cacheLength:50,createPseudo:le,match:G,attrHandle:{},find:{},relative:{">":{dir:"parentNode",first:!0}," ":{dir:"parentNode"},"+":{dir:"previousSibling",first:!0},"~":{dir:"previousSibling"}},preFilter:{ATTR:function(e){return e[1]=e[1].replace(te,ne),e[3]=(e[3]||e[4]||e[5]||"").replace(te,ne),"~="===e[2]&&(e[3]=" "+e[3]+" "),e.slice(0,4)},CHILD:function(e){return e[1]=e[1].toLowerCase(),"nth"===e[1].slice(0,3)?(e[3]||se.error(e[0]),e[4]=+(e[4]?e[5]+(e[6]||1):2*("even"===e[3]||"odd"===e[3])),e[5]=+(e[7]+e[8]||"odd"===e[3])):e[3]&&se.error(e[0]),e},PSEUDO:function(e){var t,n=!e[6]&&e[2];return G.CHILD.test(e[0])?null:(e[3]?e[2]=e[4]||e[5]||"":n&&X.test(n)&&(t=h(n,!0))&&(t=n.indexOf(")",n.length-t)-n.length)&&(e[0]=e[0].slice(0,t),e[2]=n.slice(0,t)),e.slice(0,3))}},filter:{TAG:function(e){var t=e.replace(te,ne).toLowerCase();return"*"===e?function(){return!0}:function(e){return e.nodeName&&e.nodeName.toLowerCase()===t}},CLASS:function(e){var t=m[e+" "];return t||(t=new RegExp("(^|"+M+")"+e+"("+M+"|$)"))&&m(e,function(e){return t.test("string"==typeof e.className&&e.className||"undefined"!=typeof e.getAttribute&&e.getAttribute("class")||"")})},ATTR:function(n,r,i){return function(e){var t=se.attr(e,n);return null==t?"!="===r:!r||(t+="","="===r?t===i:"!="===r?t!==i:"^="===r?i&&0===t.indexOf(i):"*="===r?i&&-1<t.indexOf(i):"$="===r?i&&t.slice(-i.length)===i:"~="===r?-1<(" "+t.replace(B," ")+" ").indexOf(i):"|="===r&&(t===i||t.slice(0,i.length+1)===i+"-"))}},CHILD:function(h,e,t,g,v){var y="nth"!==h.slice(0,3),m="last"!==h.slice(-4),x="of-type"===e;return 1===g&&0===v?function(e){return!!e.parentNode}:function(e,t,n){var r,i,o,a,s,u,l=y!==m?"nextSibling":"previousSibling",c=e.parentNode,f=x&&e.nodeName.toLowerCase(),p=!n&&!x,d=!1;if(c){if(y){while(l){a=e;while(a=a[l])if(x?a.nodeName.toLowerCase()===f:1===a.nodeType)return!1;u=l="only"===h&&!u&&"nextSibling"}return!0}if(u=[m?c.firstChild:c.lastChild],m&&p){d=(s=(r=(i=(o=(a=c)[S]||(a[S]={}))[a.uniqueID]||(o[a.uniqueID]={}))[h]||[])[0]===k&&r[1])&&r[2],a=s&&c.childNodes[s];while(a=++s&&a&&a[l]||(d=s=0)||u.pop())if(1===a.nodeType&&++d&&a===e){i[h]=[k,s,d];break}}else if(p&&(d=s=(r=(i=(o=(a=e)[S]||(a[S]={}))[a.uniqueID]||(o[a.uniqueID]={}))[h]||[])[0]===k&&r[1]),!1===d)while(a=++s&&a&&a[l]||(d=s=0)||u.pop())if((x?a.nodeName.toLowerCase()===f:1===a.nodeType)&&++d&&(p&&((i=(o=a[S]||(a[S]={}))[a.uniqueID]||(o[a.uniqueID]={}))[h]=[k,d]),a===e))break;return(d-=v)===g||d%g==0&&0<=d/g}}},PSEUDO:function(e,o){var t,a=b.pseudos[e]||b.setFilters[e.toLowerCase()]||se.error("unsupported pseudo: "+e);return a[S]?a(o):1<a.length?(t=[e,e,"",o],b.setFilters.hasOwnProperty(e.toLowerCase())?le(function(e,t){var n,r=a(e,o),i=r.length;while(i--)e[n=P(e,r[i])]=!(t[n]=r[i])}):function(e){return a(e,0,t)}):a}},pseudos:{not:le(function(e){var r=[],i=[],s=f(e.replace($,"$1"));return s[S]?le(function(e,t,n,r){var i,o=s(e,null,r,[]),a=e.length;while(a--)(i=o[a])&&(e[a]=!(t[a]=i))}):function(e,t,n){return r[0]=e,s(r,null,n,i),r[0]=null,!i.pop()}}),has:le(function(t){return function(e){return 0<se(t,e).length}}),contains:le(function(t){return t=t.replace(te,ne),function(e){return-1<(e.textContent||o(e)).indexOf(t)}}),lang:le(function(n){return V.test(n||"")||se.error("unsupported lang: "+n),n=n.replace(te,ne).toLowerCase(),function(e){var t;do{if(t=E?e.lang:e.getAttribute("xml:lang")||e.getAttribute("lang"))return(t=t.toLowerCase())===n||0===t.indexOf(n+"-")}while((e=e.parentNode)&&1===e.nodeType);return!1}}),target:function(e){var t=n.location&&n.location.hash;return t&&t.slice(1)===e.id},root:function(e){return e===a},focus:function(e){return e===C.activeElement&&(!C.hasFocus||C.hasFocus())&&!!(e.type||e.href||~e.tabIndex)},enabled:ge(!1),disabled:ge(!0),checked:function(e){var t=e.nodeName.toLowerCase();return"input"===t&&!!e.checked||"option"===t&&!!e.selected},selected:function(e){return e.parentNode&&e.parentNode.selectedIndex,!0===e.selected},empty:function(e){for(e=e.firstChild;e;e=e.nextSibling)if(e.nodeType<6)return!1;return!0},parent:function(e){return!b.pseudos.empty(e)},header:function(e){return J.test(e.nodeName)},input:function(e){return Q.test(e.nodeName)},button:function(e){var t=e.nodeName.toLowerCase();return"input"===t&&"button"===e.type||"button"===t},text:function(e){var t;return"input"===e.nodeName.toLowerCase()&&"text"===e.type&&(null==(t=e.getAttribute("type"))||"text"===t.toLowerCase())},first:ve(function(){return[0]}),last:ve(function(e,t){return[t-1]}),eq:ve(function(e,t,n){return[n<0?n+t:n]}),even:ve(function(e,t){for(var n=0;n<t;n+=2)e.push(n);return e}),odd:ve(function(e,t){for(var n=1;n<t;n+=2)e.push(n);return e}),lt:ve(function(e,t,n){for(var r=n<0?n+t:t<n?t:n;0<=--r;)e.push(r);return e}),gt:ve(function(e,t,n){for(var r=n<0?n+t:n;++r<t;)e.push(r);return e})}}).pseudos.nth=b.pseudos.eq,{radio:!0,checkbox:!0,file:!0,password:!0,image:!0})b.pseudos[e]=de(e);for(e in{submit:!0,reset:!0})b.pseudos[e]=he(e);function me(){}function xe(e){for(var t=0,n=e.length,r="";t<n;t++)r+=e[t].value;return r}function be(s,e,t){var u=e.dir,l=e.next,c=l||u,f=t&&"parentNode"===c,p=r++;return e.first?function(e,t,n){while(e=e[u])if(1===e.nodeType||f)return s(e,t,n);return!1}:function(e,t,n){var r,i,o,a=[k,p];if(n){while(e=e[u])if((1===e.nodeType||f)&&s(e,t,n))return!0}else while(e=e[u])if(1===e.nodeType||f)if(i=(o=e[S]||(e[S]={}))[e.uniqueID]||(o[e.uniqueID]={}),l&&l===e.nodeName.toLowerCase())e=e[u]||e;else{if((r=i[c])&&r[0]===k&&r[1]===p)return a[2]=r[2];if((i[c]=a)[2]=s(e,t,n))return!0}return!1}}function we(i){return 1<i.length?function(e,t,n){var r=i.length;while(r--)if(!i[r](e,t,n))return!1;return!0}:i[0]}function Te(e,t,n,r,i){for(var o,a=[],s=0,u=e.length,l=null!=t;s<u;s++)(o=e[s])&&(n&&!n(o,r,i)||(a.push(o),l&&t.push(s)));return a}function Ce(d,h,g,v,y,e){return v&&!v[S]&&(v=Ce(v)),y&&!y[S]&&(y=Ce(y,e)),le(function(e,t,n,r){var i,o,a,s=[],u=[],l=t.length,c=e||function(e,t,n){for(var r=0,i=t.length;r<i;r++)se(e,t[r],n);return n}(h||"*",n.nodeType?[n]:n,[]),f=!d||!e&&h?c:Te(c,s,d,n,r),p=g?y||(e?d:l||v)?[]:t:f;if(g&&g(f,p,n,r),v){i=Te(p,u),v(i,[],n,r),o=i.length;while(o--)(a=i[o])&&(p[u[o]]=!(f[u[o]]=a))}if(e){if(y||d){if(y){i=[],o=p.length;while(o--)(a=p[o])&&i.push(f[o]=a);y(null,p=[],i,r)}o=p.length;while(o--)(a=p[o])&&-1<(i=y?P(e,a):s[o])&&(e[i]=!(t[i]=a))}}else p=Te(p===t?p.splice(l,p.length):p),y?y(null,t,p,r):H.apply(t,p)})}function Ee(e){for(var i,t,n,r=e.length,o=b.relative[e[0].type],a=o||b.relative[" "],s=o?1:0,u=be(function(e){return e===i},a,!0),l=be(function(e){return-1<P(i,e)},a,!0),c=[function(e,t,n){var r=!o&&(n||t!==w)||((i=t).nodeType?u(e,t,n):l(e,t,n));return i=null,r}];s<r;s++)if(t=b.relative[e[s].type])c=[be(we(c),t)];else{if((t=b.filter[e[s].type].apply(null,e[s].matches))[S]){for(n=++s;n<r;n++)if(b.relative[e[n].type])break;return Ce(1<s&&we(c),1<s&&xe(e.slice(0,s-1).concat({value:" "===e[s-2].type?"*":""})).replace($,"$1"),t,s<n&&Ee(e.slice(s,n)),n<r&&Ee(e=e.slice(n)),n<r&&xe(e))}c.push(t)}return we(c)}return me.prototype=b.filters=b.pseudos,b.setFilters=new me,h=se.tokenize=function(e,t){var n,r,i,o,a,s,u,l=x[e+" "];if(l)return t?0:l.slice(0);a=e,s=[],u=b.preFilter;while(a){for(o in n&&!(r=_.exec(a))||(r&&(a=a.slice(r[0].length)||a),s.push(i=[])),n=!1,(r=z.exec(a))&&(n=r.shift(),i.push({value:n,type:r[0].replace($," ")}),a=a.slice(n.length)),b.filter)!(r=G[o].exec(a))||u[o]&&!(r=u[o](r))||(n=r.shift(),i.push({value:n,type:o,matches:r}),a=a.slice(n.length));if(!n)break}return t?a.length:a?se.error(e):x(e,s).slice(0)},f=se.compile=function(e,t){var n,v,y,m,x,r,i=[],o=[],a=A[e+" "];if(!a){t||(t=h(e)),n=t.length;while(n--)(a=Ee(t[n]))[S]?i.push(a):o.push(a);(a=A(e,(v=o,m=0<(y=i).length,x=0<v.length,r=function(e,t,n,r,i){var o,a,s,u=0,l="0",c=e&&[],f=[],p=w,d=e||x&&b.find.TAG("*",i),h=k+=null==p?1:Math.random()||.1,g=d.length;for(i&&(w=t==C||t||i);l!==g&&null!=(o=d[l]);l++){if(x&&o){a=0,t||o.ownerDocument==C||(T(o),n=!E);while(s=v[a++])if(s(o,t||C,n)){r.push(o);break}i&&(k=h)}m&&((o=!s&&o)&&u--,e&&c.push(o))}if(u+=l,m&&l!==u){a=0;while(s=y[a++])s(c,f,t,n);if(e){if(0<u)while(l--)c[l]||f[l]||(f[l]=q.call(r));f=Te(f)}H.apply(r,f),i&&!e&&0<f.length&&1<u+y.length&&se.uniqueSort(r)}return i&&(k=h,w=p),c},m?le(r):r))).selector=e}return a},g=se.select=function(e,t,n,r){var i,o,a,s,u,l="function"==typeof e&&e,c=!r&&h(e=l.selector||e);if(n=n||[],1===c.length){if(2<(o=c[0]=c[0].slice(0)).length&&"ID"===(a=o[0]).type&&9===t.nodeType&&E&&b.relative[o[1].type]){if(!(t=(b.find.ID(a.matches[0].replace(te,ne),t)||[])[0]))return n;l&&(t=t.parentNode),e=e.slice(o.shift().value.length)}i=G.needsContext.test(e)?0:o.length;while(i--){if(a=o[i],b.relative[s=a.type])break;if((u=b.find[s])&&(r=u(a.matches[0].replace(te,ne),ee.test(o[0].type)&&ye(t.parentNode)||t))){if(o.splice(i,1),!(e=r.length&&xe(o)))return H.apply(n,r),n;break}}}return(l||f(e,c))(r,t,!E,n,!t||ee.test(e)&&ye(t.parentNode)||t),n},d.sortStable=S.split("").sort(j).join("")===S,d.detectDuplicates=!!l,T(),d.sortDetached=ce(function(e){return 1&e.compareDocumentPosition(C.createElement("fieldset"))}),ce(function(e){return e.innerHTML="<a href='#'></a>","#"===e.firstChild.getAttribute("href")})||fe("type|href|height|width",function(e,t,n){if(!n)return e.getAttribute(t,"type"===t.toLowerCase()?1:2)}),d.attributes&&ce(function(e){return e.innerHTML="<input/>",e.firstChild.setAttribute("value",""),""===e.firstChild.getAttribute("value")})||fe("value",function(e,t,n){if(!n&&"input"===e.nodeName.toLowerCase())return e.defaultValue}),ce(function(e){return null==e.getAttribute("disabled")})||fe(R,function(e,t,n){var r;if(!n)return!0===e[t]?t.toLowerCase():(r=e.getAttributeNode(t))&&r.specified?r.value:null}),se}(C);S.find=d,S.expr=d.selectors,S.expr[":"]=S.expr.pseudos,S.uniqueSort=S.unique=d.uniqueSort,S.text=d.getText,S.isXMLDoc=d.isXML,S.contains=d.contains,S.escapeSelector=d.escape;var h=function(e,t,n){var r=[],i=void 0!==n;while((e=e[t])&&9!==e.nodeType)if(1===e.nodeType){if(i&&S(e).is(n))break;r.push(e)}return r},T=function(e,t){for(var n=[];e;e=e.nextSibling)1===e.nodeType&&e!==t&&n.push(e);return n},k=S.expr.match.needsContext;function A(e,t){return e.nodeName&&e.nodeName.toLowerCase()===t.toLowerCase()}var N=/^<([a-z][^\/\0>:\x20\t\r\n\f]*)[\x20\t\r\n\f]*\/?>(?:<\/\1>|)$/i;function j(e,n,r){return m(n)?S.grep(e,function(e,t){return!!n.call(e,t,e)!==r}):n.nodeType?S.grep(e,function(e){return e===n!==r}):"string"!=typeof n?S.grep(e,function(e){return-1<i.call(n,e)!==r}):S.filter(n,e,r)}S.filter=function(e,t,n){var r=t[0];return n&&(e=":not("+e+")"),1===t.length&&1===r.nodeType?S.find.matchesSelector(r,e)?[r]:[]:S.find.matches(e,S.grep(t,function(e){return 1===e.nodeType}))},S.fn.extend({find:function(e){var t,n,r=this.length,i=this;if("string"!=typeof e)return this.pushStack(S(e).filter(function(){for(t=0;t<r;t++)if(S.contains(i[t],this))return!0}));for(n=this.pushStack([]),t=0;t<r;t++)S.find(e,i[t],n);return 1<r?S.uniqueSort(n):n},filter:function(e){return this.pushStack(j(this,e||[],!1))},not:function(e){return this.pushStack(j(this,e||[],!0))},is:function(e){return!!j(this,"string"==typeof e&&k.test(e)?S(e):e||[],!1).length}});var D,q=/^(?:\s*(<[\w\W]+>)[^>]*|#([\w-]+))$/;(S.fn.init=function(e,t,n){var r,i;if(!e)return this;if(n=n||D,"string"==typeof e){if(!(r="<"===e[0]&&">"===e[e.length-1]&&3<=e.length?[null,e,null]:q.exec(e))||!r[1]&&t)return!t||t.jquery?(t||n).find(e):this.constructor(t).find(e);if(r[1]){if(t=t instanceof S?t[0]:t,S.merge(this,S.parseHTML(r[1],t&&t.nodeType?t.ownerDocument||t:E,!0)),N.test(r[1])&&S.isPlainObject(t))for(r in t)m(this[r])?this[r](t[r]):this.attr(r,t[r]);return this}return(i=E.getElementById(r[2]))&&(this[0]=i,this.length=1),this}return e.nodeType?(this[0]=e,this.length=1,this):m(e)?void 0!==n.ready?n.ready(e):e(S):S.makeArray(e,this)}).prototype=S.fn,D=S(E);var L=/^(?:parents|prev(?:Until|All))/,H={children:!0,contents:!0,next:!0,prev:!0};function O(e,t){while((e=e[t])&&1!==e.nodeType);return e}S.fn.extend({has:function(e){var t=S(e,this),n=t.length;return this.filter(function(){for(var e=0;e<n;e++)if(S.contains(this,t[e]))return!0})},closest:function(e,t){var n,r=0,i=this.length,o=[],a="string"!=typeof e&&S(e);if(!k.test(e))for(;r<i;r++)for(n=this[r];n&&n!==t;n=n.parentNode)if(n.nodeType<11&&(a?-1<a.index(n):1===n.nodeType&&S.find.matchesSelector(n,e))){o.push(n);break}return this.pushStack(1<o.length?S.uniqueSort(o):o)},index:function(e){return e?"string"==typeof e?i.call(S(e),this[0]):i.call(this,e.jquery?e[0]:e):this[0]&&this[0].parentNode?this.first().prevAll().length:-1},add:function(e,t){return this.pushStack(S.uniqueSort(S.merge(this.get(),S(e,t))))},addBack:function(e){return this.add(null==e?this.prevObject:this.prevObject.filter(e))}}),S.each({parent:function(e){var t=e.parentNode;return t&&11!==t.nodeType?t:null},parents:function(e){return h(e,"parentNode")},parentsUntil:function(e,t,n){return h(e,"parentNode",n)},next:function(e){return O(e,"nextSibling")},prev:function(e){return O(e,"previousSibling")},nextAll:function(e){return h(e,"nextSibling")},prevAll:function(e){return h(e,"previousSibling")},nextUntil:function(e,t,n){return h(e,"nextSibling",n)},prevUntil:function(e,t,n){return h(e,"previousSibling",n)},siblings:function(e){return T((e.parentNode||{}).firstChild,e)},children:function(e){return T(e.firstChild)},contents:function(e){return null!=e.contentDocument&&r(e.contentDocument)?e.contentDocument:(A(e,"template")&&(e=e.content||e),S.merge([],e.childNodes))}},function(r,i){S.fn[r]=function(e,t){var n=S.map(this,i,e);return"Until"!==r.slice(-5)&&(t=e),t&&"string"==typeof t&&(n=S.filter(t,n)),1<this.length&&(H[r]||S.uniqueSort(n),L.test(r)&&n.reverse()),this.pushStack(n)}});var P=/[^\x20\t\r\n\f]+/g;function R(e){return e}function M(e){throw e}function I(e,t,n,r){var i;try{e&&m(i=e.promise)?i.call(e).done(t).fail(n):e&&m(i=e.then)?i.call(e,t,n):t.apply(void 0,[e].slice(r))}catch(e){n.apply(void 0,[e])}}S.Callbacks=function(r){var e,n;r="string"==typeof r?(e=r,n={},S.each(e.match(P)||[],function(e,t){n[t]=!0}),n):S.extend({},r);var i,t,o,a,s=[],u=[],l=-1,c=function(){for(a=a||r.once,o=i=!0;u.length;l=-1){t=u.shift();while(++l<s.length)!1===s[l].apply(t[0],t[1])&&r.stopOnFalse&&(l=s.length,t=!1)}r.memory||(t=!1),i=!1,a&&(s=t?[]:"")},f={add:function(){return s&&(t&&!i&&(l=s.length-1,u.push(t)),function n(e){S.each(e,function(e,t){m(t)?r.unique&&f.has(t)||s.push(t):t&&t.length&&"string"!==w(t)&&n(t)})}(arguments),t&&!i&&c()),this},remove:function(){return S.each(arguments,function(e,t){var n;while(-1<(n=S.inArray(t,s,n)))s.splice(n,1),n<=l&&l--}),this},has:function(e){return e?-1<S.inArray(e,s):0<s.length},empty:function(){return s&&(s=[]),this},disable:function(){return a=u=[],s=t="",this},disabled:function(){return!s},lock:function(){return a=u=[],t||i||(s=t=""),this},locked:function(){return!!a},fireWith:function(e,t){return a||(t=[e,(t=t||[]).slice?t.slice():t],u.push(t),i||c()),this},fire:function(){return f.fireWith(this,arguments),this},fired:function(){return!!o}};return f},S.extend({Deferred:function(e){var o=[["notify","progress",S.Callbacks("memory"),S.Callbacks("memory"),2],["resolve","done",S.Callbacks("once memory"),S.Callbacks("once memory"),0,"resolved"],["reject","fail",S.Callbacks("once memory"),S.Callbacks("once memory"),1,"rejected"]],i="pending",a={state:function(){return i},always:function(){return s.done(arguments).fail(arguments),this},"catch":function(e){return a.then(null,e)},pipe:function(){var i=arguments;return S.Deferred(function(r){S.each(o,function(e,t){var n=m(i[t[4]])&&i[t[4]];s[t[1]](function(){var e=n&&n.apply(this,arguments);e&&m(e.promise)?e.promise().progress(r.notify).done(r.resolve).fail(r.reject):r[t[0]+"With"](this,n?[e]:arguments)})}),i=null}).promise()},then:function(t,n,r){var u=0;function l(i,o,a,s){return function(){var n=this,r=arguments,e=function(){var e,t;if(!(i<u)){if((e=a.apply(n,r))===o.promise())throw new TypeError("Thenable self-resolution");t=e&&("object"==typeof e||"function"==typeof e)&&e.then,m(t)?s?t.call(e,l(u,o,R,s),l(u,o,M,s)):(u++,t.call(e,l(u,o,R,s),l(u,o,M,s),l(u,o,R,o.notifyWith))):(a!==R&&(n=void 0,r=[e]),(s||o.resolveWith)(n,r))}},t=s?e:function(){try{e()}catch(e){S.Deferred.exceptionHook&&S.Deferred.exceptionHook(e,t.stackTrace),u<=i+1&&(a!==M&&(n=void 0,r=[e]),o.rejectWith(n,r))}};i?t():(S.Deferred.getStackHook&&(t.stackTrace=S.Deferred.getStackHook()),C.setTimeout(t))}}return S.Deferred(function(e){o[0][3].add(l(0,e,m(r)?r:R,e.notifyWith)),o[1][3].add(l(0,e,m(t)?t:R)),o[2][3].add(l(0,e,m(n)?n:M))}).promise()},promise:function(e){return null!=e?S.extend(e,a):a}},s={};return S.each(o,function(e,t){var n=t[2],r=t[5];a[t[1]]=n.add,r&&n.add(function(){i=r},o[3-e][2].disable,o[3-e][3].disable,o[0][2].lock,o[0][3].lock),n.add(t[3].fire),s[t[0]]=function(){return s[t[0]+"With"](this===s?void 0:this,arguments),this},s[t[0]+"With"]=n.fireWith}),a.promise(s),e&&e.call(s,s),s},when:function(e){var n=arguments.length,t=n,r=Array(t),i=s.call(arguments),o=S.Deferred(),a=function(t){return function(e){r[t]=this,i[t]=1<arguments.length?s.call(arguments):e,--n||o.resolveWith(r,i)}};if(n<=1&&(I(e,o.done(a(t)).resolve,o.reject,!n),"pending"===o.state()||m(i[t]&&i[t].then)))return o.then();while(t--)I(i[t],a(t),o.reject);return o.promise()}});var W=/^(Eval|Internal|Range|Reference|Syntax|Type|URI)Error$/;S.Deferred.exceptionHook=function(e,t){C.console&&C.console.warn&&e&&W.test(e.name)&&C.console.warn("jQuery.Deferred exception: "+e.message,e.stack,t)},S.readyException=function(e){C.setTimeout(function(){throw e})};var F=S.Deferred();function B(){E.removeEventListener("DOMContentLoaded",B),C.removeEventListener("load",B),S.ready()}S.fn.ready=function(e){return F.then(e)["catch"](function(e){S.readyException(e)}),this},S.extend({isReady:!1,readyWait:1,ready:function(e){(!0===e?--S.readyWait:S.isReady)||(S.isReady=!0)!==e&&0<--S.readyWait||F.resolveWith(E,[S])}}),S.ready.then=F.then,"complete"===E.readyState||"loading"!==E.readyState&&!E.documentElement.doScroll?C.setTimeout(S.ready):(E.addEventListener("DOMContentLoaded",B),C.addEventListener("load",B));var $=function(e,t,n,r,i,o,a){var s=0,u=e.length,l=null==n;if("object"===w(n))for(s in i=!0,n)$(e,t,s,n[s],!0,o,a);else if(void 0!==r&&(i=!0,m(r)||(a=!0),l&&(a?(t.call(e,r),t=null):(l=t,t=function(e,t,n){return l.call(S(e),n)})),t))for(;s<u;s++)t(e[s],n,a?r:r.call(e[s],s,t(e[s],n)));return i?e:l?t.call(e):u?t(e[0],n):o},_=/^-ms-/,z=/-([a-z])/g;function U(e,t){return t.toUpperCase()}function X(e){return e.replace(_,"ms-").replace(z,U)}var V=function(e){return 1===e.nodeType||9===e.nodeType||!+e.nodeType};function G(){this.expando=S.expando+G.uid++}G.uid=1,G.prototype={cache:function(e){var t=e[this.expando];return t||(t={},V(e)&&(e.nodeType?e[this.expando]=t:Object.defineProperty(e,this.expando,{value:t,configurable:!0}))),t},set:function(e,t,n){var r,i=this.cache(e);if("string"==typeof t)i[X(t)]=n;else for(r in t)i[X(r)]=t[r];return i},get:function(e,t){return void 0===t?this.cache(e):e[this.expando]&&e[this.expando][X(t)]},access:function(e,t,n){return void 0===t||t&&"string"==typeof t&&void 0===n?this.get(e,t):(this.set(e,t,n),void 0!==n?n:t)},remove:function(e,t){var n,r=e[this.expando];if(void 0!==r){if(void 0!==t){n=(t=Array.isArray(t)?t.map(X):(t=X(t))in r?[t]:t.match(P)||[]).length;while(n--)delete r[t[n]]}(void 0===t||S.isEmptyObject(r))&&(e.nodeType?e[this.expando]=void 0:delete e[this.expando])}},hasData:function(e){var t=e[this.expando];return void 0!==t&&!S.isEmptyObject(t)}};var Y=new G,Q=new G,J=/^(?:\{[\w\W]*\}|\[[\w\W]*\])$/,K=/[A-Z]/g;function Z(e,t,n){var r,i;if(void 0===n&&1===e.nodeType)if(r="data-"+t.replace(K,"-$&").toLowerCase(),"string"==typeof(n=e.getAttribute(r))){try{n="true"===(i=n)||"false"!==i&&("null"===i?null:i===+i+""?+i:J.test(i)?JSON.parse(i):i)}catch(e){}Q.set(e,t,n)}else n=void 0;return n}S.extend({hasData:function(e){return Q.hasData(e)||Y.hasData(e)},data:function(e,t,n){return Q.access(e,t,n)},removeData:function(e,t){Q.remove(e,t)},_data:function(e,t,n){return Y.access(e,t,n)},_removeData:function(e,t){Y.remove(e,t)}}),S.fn.extend({data:function(n,e){var t,r,i,o=this[0],a=o&&o.attributes;if(void 0===n){if(this.length&&(i=Q.get(o),1===o.nodeType&&!Y.get(o,"hasDataAttrs"))){t=a.length;while(t--)a[t]&&0===(r=a[t].name).indexOf("data-")&&(r=X(r.slice(5)),Z(o,r,i[r]));Y.set(o,"hasDataAttrs",!0)}return i}return"object"==typeof n?this.each(function(){Q.set(this,n)}):$(this,function(e){var t;if(o&&void 0===e)return void 0!==(t=Q.get(o,n))?t:void 0!==(t=Z(o,n))?t:void 0;this.each(function(){Q.set(this,n,e)})},null,e,1<arguments.length,null,!0)},removeData:function(e){return this.each(function(){Q.remove(this,e)})}}),S.extend({queue:function(e,t,n){var r;if(e)return t=(t||"fx")+"queue",r=Y.get(e,t),n&&(!r||Array.isArray(n)?r=Y.access(e,t,S.makeArray(n)):r.push(n)),r||[]},dequeue:function(e,t){t=t||"fx";var n=S.queue(e,t),r=n.length,i=n.shift(),o=S._queueHooks(e,t);"inprogress"===i&&(i=n.shift(),r--),i&&("fx"===t&&n.unshift("inprogress"),delete o.stop,i.call(e,function(){S.dequeue(e,t)},o)),!r&&o&&o.empty.fire()},_queueHooks:function(e,t){var n=t+"queueHooks";return Y.get(e,n)||Y.access(e,n,{empty:S.Callbacks("once memory").add(function(){Y.remove(e,[t+"queue",n])})})}}),S.fn.extend({queue:function(t,n){var e=2;return"string"!=typeof t&&(n=t,t="fx",e--),arguments.length<e?S.queue(this[0],t):void 0===n?this:this.each(function(){var e=S.queue(this,t,n);S._queueHooks(this,t),"fx"===t&&"inprogress"!==e[0]&&S.dequeue(this,t)})},dequeue:function(e){return this.each(function(){S.dequeue(this,e)})},clearQueue:function(e){return this.queue(e||"fx",[])},promise:function(e,t){var n,r=1,i=S.Deferred(),o=this,a=this.length,s=function(){--r||i.resolveWith(o,[o])};"string"!=typeof e&&(t=e,e=void 0),e=e||"fx";while(a--)(n=Y.get(o[a],e+"queueHooks"))&&n.empty&&(r++,n.empty.add(s));return s(),i.promise(t)}});var ee=/[+-]?(?:\d*\.|)\d+(?:[eE][+-]?\d+|)/.source,te=new RegExp("^(?:([+-])=|)("+ee+")([a-z%]*)$","i"),ne=["Top","Right","Bottom","Left"],re=E.documentElement,ie=function(e){return S.contains(e.ownerDocument,e)},oe={composed:!0};re.getRootNode&&(ie=function(e){return S.contains(e.ownerDocument,e)||e.getRootNode(oe)===e.ownerDocument});var ae=function(e,t){return"none"===(e=t||e).style.display||""===e.style.display&&ie(e)&&"none"===S.css(e,"display")};function se(e,t,n,r){var i,o,a=20,s=r?function(){return r.cur()}:function(){return S.css(e,t,"")},u=s(),l=n&&n[3]||(S.cssNumber[t]?"":"px"),c=e.nodeType&&(S.cssNumber[t]||"px"!==l&&+u)&&te.exec(S.css(e,t));if(c&&c[3]!==l){u/=2,l=l||c[3],c=+u||1;while(a--)S.style(e,t,c+l),(1-o)*(1-(o=s()/u||.5))<=0&&(a=0),c/=o;c*=2,S.style(e,t,c+l),n=n||[]}return n&&(c=+c||+u||0,i=n[1]?c+(n[1]+1)*n[2]:+n[2],r&&(r.unit=l,r.start=c,r.end=i)),i}var ue={};function le(e,t){for(var n,r,i,o,a,s,u,l=[],c=0,f=e.length;c<f;c++)(r=e[c]).style&&(n=r.style.display,t?("none"===n&&(l[c]=Y.get(r,"display")||null,l[c]||(r.style.display="")),""===r.style.display&&ae(r)&&(l[c]=(u=a=o=void 0,a=(i=r).ownerDocument,s=i.nodeName,(u=ue[s])||(o=a.body.appendChild(a.createElement(s)),u=S.css(o,"display"),o.parentNode.removeChild(o),"none"===u&&(u="block"),ue[s]=u)))):"none"!==n&&(l[c]="none",Y.set(r,"display",n)));for(c=0;c<f;c++)null!=l[c]&&(e[c].style.display=l[c]);return e}S.fn.extend({show:function(){return le(this,!0)},hide:function(){return le(this)},toggle:function(e){return"boolean"==typeof e?e?this.show():this.hide():this.each(function(){ae(this)?S(this).show():S(this).hide()})}});var ce,fe,pe=/^(?:checkbox|radio)$/i,de=/<([a-z][^\/\0>\x20\t\r\n\f]*)/i,he=/^$|^module$|\/(?:java|ecma)script/i;ce=E.createDocumentFragment().appendChild(E.createElement("div")),(fe=E.createElement("input")).setAttribute("type","radio"),fe.setAttribute("checked","checked"),fe.setAttribute("name","t"),ce.appendChild(fe),y.checkClone=ce.cloneNode(!0).cloneNode(!0).lastChild.checked,ce.innerHTML="<textarea>x</textarea>",y.noCloneChecked=!!ce.cloneNode(!0).lastChild.defaultValue,ce.innerHTML="<option></option>",y.option=!!ce.lastChild;var ge={thead:[1,"<table>","</table>"],col:[2,"<table><colgroup>","</colgroup></table>"],tr:[2,"<table><tbody>","</tbody></table>"],td:[3,"<table><tbody><tr>","</tr></tbody></table>"],_default:[0,"",""]};function ve(e,t){var n;return n="undefined"!=typeof e.getElementsByTagName?e.getElementsByTagName(t||"*"):"undefined"!=typeof e.querySelectorAll?e.querySelectorAll(t||"*"):[],void 0===t||t&&A(e,t)?S.merge([e],n):n}function ye(e,t){for(var n=0,r=e.length;n<r;n++)Y.set(e[n],"globalEval",!t||Y.get(t[n],"globalEval"))}ge.tbody=ge.tfoot=ge.colgroup=ge.caption=ge.thead,ge.th=ge.td,y.option||(ge.optgroup=ge.option=[1,"<select multiple='multiple'>","</select>"]);var me=/<|&#?\w+;/;function xe(e,t,n,r,i){for(var o,a,s,u,l,c,f=t.createDocumentFragment(),p=[],d=0,h=e.length;d<h;d++)if((o=e[d])||0===o)if("object"===w(o))S.merge(p,o.nodeType?[o]:o);else if(me.test(o)){a=a||f.appendChild(t.createElement("div")),s=(de.exec(o)||["",""])[1].toLowerCase(),u=ge[s]||ge._default,a.innerHTML=u[1]+S.htmlPrefilter(o)+u[2],c=u[0];while(c--)a=a.lastChild;S.merge(p,a.childNodes),(a=f.firstChild).textContent=""}else p.push(t.createTextNode(o));f.textContent="",d=0;while(o=p[d++])if(r&&-1<S.inArray(o,r))i&&i.push(o);else if(l=ie(o),a=ve(f.appendChild(o),"script"),l&&ye(a),n){c=0;while(o=a[c++])he.test(o.type||"")&&n.push(o)}return f}var be=/^([^.]*)(?:\.(.+)|)/;function we(){return!0}function Te(){return!1}function Ce(e,t){return e===function(){try{return E.activeElement}catch(e){}}()==("focus"===t)}function Ee(e,t,n,r,i,o){var a,s;if("object"==typeof t){for(s in"string"!=typeof n&&(r=r||n,n=void 0),t)Ee(e,s,n,r,t[s],o);return e}if(null==r&&null==i?(i=n,r=n=void 0):null==i&&("string"==typeof n?(i=r,r=void 0):(i=r,r=n,n=void 0)),!1===i)i=Te;else if(!i)return e;return 1===o&&(a=i,(i=function(e){return S().off(e),a.apply(this,arguments)}).guid=a.guid||(a.guid=S.guid++)),e.each(function(){S.event.add(this,t,i,r,n)})}function Se(e,i,o){o?(Y.set(e,i,!1),S.event.add(e,i,{namespace:!1,handler:function(e){var t,n,r=Y.get(this,i);if(1&e.isTrigger&&this[i]){if(r.length)(S.event.special[i]||{}).delegateType&&e.stopPropagation();else if(r=s.call(arguments),Y.set(this,i,r),t=o(this,i),this[i](),r!==(n=Y.get(this,i))||t?Y.set(this,i,!1):n={},r!==n)return e.stopImmediatePropagation(),e.preventDefault(),n&&n.value}else r.length&&(Y.set(this,i,{value:S.event.trigger(S.extend(r[0],S.Event.prototype),r.slice(1),this)}),e.stopImmediatePropagation())}})):void 0===Y.get(e,i)&&S.event.add(e,i,we)}S.event={global:{},add:function(t,e,n,r,i){var o,a,s,u,l,c,f,p,d,h,g,v=Y.get(t);if(V(t)){n.handler&&(n=(o=n).handler,i=o.selector),i&&S.find.matchesSelector(re,i),n.guid||(n.guid=S.guid++),(u=v.events)||(u=v.events=Object.create(null)),(a=v.handle)||(a=v.handle=function(e){return"undefined"!=typeof S&&S.event.triggered!==e.type?S.event.dispatch.apply(t,arguments):void 0}),l=(e=(e||"").match(P)||[""]).length;while(l--)d=g=(s=be.exec(e[l])||[])[1],h=(s[2]||"").split(".").sort(),d&&(f=S.event.special[d]||{},d=(i?f.delegateType:f.bindType)||d,f=S.event.special[d]||{},c=S.extend({type:d,origType:g,data:r,handler:n,guid:n.guid,selector:i,needsContext:i&&S.expr.match.needsContext.test(i),namespace:h.join(".")},o),(p=u[d])||((p=u[d]=[]).delegateCount=0,f.setup&&!1!==f.setup.call(t,r,h,a)||t.addEventListener&&t.addEventListener(d,a)),f.add&&(f.add.call(t,c),c.handler.guid||(c.handler.guid=n.guid)),i?p.splice(p.delegateCount++,0,c):p.push(c),S.event.global[d]=!0)}},remove:function(e,t,n,r,i){var o,a,s,u,l,c,f,p,d,h,g,v=Y.hasData(e)&&Y.get(e);if(v&&(u=v.events)){l=(t=(t||"").match(P)||[""]).length;while(l--)if(d=g=(s=be.exec(t[l])||[])[1],h=(s[2]||"").split(".").sort(),d){f=S.event.special[d]||{},p=u[d=(r?f.delegateType:f.bindType)||d]||[],s=s[2]&&new RegExp("(^|\\.)"+h.join("\\.(?:.*\\.|)")+"(\\.|$)"),a=o=p.length;while(o--)c=p[o],!i&&g!==c.origType||n&&n.guid!==c.guid||s&&!s.test(c.namespace)||r&&r!==c.selector&&("**"!==r||!c.selector)||(p.splice(o,1),c.selector&&p.delegateCount--,f.remove&&f.remove.call(e,c));a&&!p.length&&(f.teardown&&!1!==f.teardown.call(e,h,v.handle)||S.removeEvent(e,d,v.handle),delete u[d])}else for(d in u)S.event.remove(e,d+t[l],n,r,!0);S.isEmptyObject(u)&&Y.remove(e,"handle events")}},dispatch:function(e){var t,n,r,i,o,a,s=new Array(arguments.length),u=S.event.fix(e),l=(Y.get(this,"events")||Object.create(null))[u.type]||[],c=S.event.special[u.type]||{};for(s[0]=u,t=1;t<arguments.length;t++)s[t]=arguments[t];if(u.delegateTarget=this,!c.preDispatch||!1!==c.preDispatch.call(this,u)){a=S.event.handlers.call(this,u,l),t=0;while((i=a[t++])&&!u.isPropagationStopped()){u.currentTarget=i.elem,n=0;while((o=i.handlers[n++])&&!u.isImmediatePropagationStopped())u.rnamespace&&!1!==o.namespace&&!u.rnamespace.test(o.namespace)||(u.handleObj=o,u.data=o.data,void 0!==(r=((S.event.special[o.origType]||{}).handle||o.handler).apply(i.elem,s))&&!1===(u.result=r)&&(u.preventDefault(),u.stopPropagation()))}return c.postDispatch&&c.postDispatch.call(this,u),u.result}},handlers:function(e,t){var n,r,i,o,a,s=[],u=t.delegateCount,l=e.target;if(u&&l.nodeType&&!("click"===e.type&&1<=e.button))for(;l!==this;l=l.parentNode||this)if(1===l.nodeType&&("click"!==e.type||!0!==l.disabled)){for(o=[],a={},n=0;n<u;n++)void 0===a[i=(r=t[n]).selector+" "]&&(a[i]=r.needsContext?-1<S(i,this).index(l):S.find(i,this,null,[l]).length),a[i]&&o.push(r);o.length&&s.push({elem:l,handlers:o})}return l=this,u<t.length&&s.push({elem:l,handlers:t.slice(u)}),s},addProp:function(t,e){Object.defineProperty(S.Event.prototype,t,{enumerable:!0,configurable:!0,get:m(e)?function(){if(this.originalEvent)return e(this.originalEvent)}:function(){if(this.originalEvent)return this.originalEvent[t]},set:function(e){Object.defineProperty(this,t,{enumerable:!0,configurable:!0,writable:!0,value:e})}})},fix:function(e){return e[S.expando]?e:new S.Event(e)},special:{load:{noBubble:!0},click:{setup:function(e){var t=this||e;return pe.test(t.type)&&t.click&&A(t,"input")&&Se(t,"click",we),!1},trigger:function(e){var t=this||e;return pe.test(t.type)&&t.click&&A(t,"input")&&Se(t,"click"),!0},_default:function(e){var t=e.target;return pe.test(t.type)&&t.click&&A(t,"input")&&Y.get(t,"click")||A(t,"a")}},beforeunload:{postDispatch:function(e){void 0!==e.result&&e.originalEvent&&(e.originalEvent.returnValue=e.result)}}}},S.removeEvent=function(e,t,n){e.removeEventListener&&e.removeEventListener(t,n)},S.Event=function(e,t){if(!(this instanceof S.Event))return new S.Event(e,t);e&&e.type?(this.originalEvent=e,this.type=e.type,this.isDefaultPrevented=e.defaultPrevented||void 0===e.defaultPrevented&&!1===e.returnValue?we:Te,this.target=e.target&&3===e.target.nodeType?e.target.parentNode:e.target,this.currentTarget=e.currentTarget,this.relatedTarget=e.relatedTarget):this.type=e,t&&S.extend(this,t),this.timeStamp=e&&e.timeStamp||Date.now(),this[S.expando]=!0},S.Event.prototype={constructor:S.Event,isDefaultPrevented:Te,isPropagationStopped:Te,isImmediatePropagationStopped:Te,isSimulated:!1,preventDefault:function(){var e=this.originalEvent;this.isDefaultPrevented=we,e&&!this.isSimulated&&e.preventDefault()},stopPropagation:function(){var e=this.originalEvent;this.isPropagationStopped=we,e&&!this.isSimulated&&e.stopPropagation()},stopImmediatePropagation:function(){var e=this.originalEvent;this.isImmediatePropagationStopped=we,e&&!this.isSimulated&&e.stopImmediatePropagation(),this.stopPropagation()}},S.each({altKey:!0,bubbles:!0,cancelable:!0,changedTouches:!0,ctrlKey:!0,detail:!0,eventPhase:!0,metaKey:!0,pageX:!0,pageY:!0,shiftKey:!0,view:!0,"char":!0,code:!0,charCode:!0,key:!0,keyCode:!0,button:!0,buttons:!0,clientX:!0,clientY:!0,offsetX:!0,offsetY:!0,pointerId:!0,pointerType:!0,screenX:!0,screenY:!0,targetTouches:!0,toElement:!0,touches:!0,which:!0},S.event.addProp),S.each({focus:"focusin",blur:"focusout"},function(e,t){S.event.special[e]={setup:function(){return Se(this,e,Ce),!1},trigger:function(){return Se(this,e),!0},_default:function(){return!0},delegateType:t}}),S.each({mouseenter:"mouseover",mouseleave:"mouseout",pointerenter:"pointerover",pointerleave:"pointerout"},function(e,i){S.event.special[e]={delegateType:i,bindType:i,handle:function(e){var t,n=e.relatedTarget,r=e.handleObj;return n&&(n===this||S.contains(this,n))||(e.type=r.origType,t=r.handler.apply(this,arguments),e.type=i),t}}}),S.fn.extend({on:function(e,t,n,r){return Ee(this,e,t,n,r)},one:function(e,t,n,r){return Ee(this,e,t,n,r,1)},off:function(e,t,n){var r,i;if(e&&e.preventDefault&&e.handleObj)return r=e.handleObj,S(e.delegateTarget).off(r.namespace?r.origType+"."+r.namespace:r.origType,r.selector,r.handler),this;if("object"==typeof e){for(i in e)this.off(i,t,e[i]);return this}return!1!==t&&"function"!=typeof t||(n=t,t=void 0),!1===n&&(n=Te),this.each(function(){S.event.remove(this,e,n,t)})}});var ke=/<script|<style|<link/i,Ae=/checked\s*(?:[^=]|=\s*.checked.)/i,Ne=/^\s*<!(?:\[CDATA\[|--)|(?:\]\]|--)>\s*$/g;function je(e,t){return A(e,"table")&&A(11!==t.nodeType?t:t.firstChild,"tr")&&S(e).children("tbody")[0]||e}function De(e){return e.type=(null!==e.getAttribute("type"))+"/"+e.type,e}function qe(e){return"true/"===(e.type||"").slice(0,5)?e.type=e.type.slice(5):e.removeAttribute("type"),e}function Le(e,t){var n,r,i,o,a,s;if(1===t.nodeType){if(Y.hasData(e)&&(s=Y.get(e).events))for(i in Y.remove(t,"handle events"),s)for(n=0,r=s[i].length;n<r;n++)S.event.add(t,i,s[i][n]);Q.hasData(e)&&(o=Q.access(e),a=S.extend({},o),Q.set(t,a))}}function He(n,r,i,o){r=g(r);var e,t,a,s,u,l,c=0,f=n.length,p=f-1,d=r[0],h=m(d);if(h||1<f&&"string"==typeof d&&!y.checkClone&&Ae.test(d))return n.each(function(e){var t=n.eq(e);h&&(r[0]=d.call(this,e,t.html())),He(t,r,i,o)});if(f&&(t=(e=xe(r,n[0].ownerDocument,!1,n,o)).firstChild,1===e.childNodes.length&&(e=t),t||o)){for(s=(a=S.map(ve(e,"script"),De)).length;c<f;c++)u=e,c!==p&&(u=S.clone(u,!0,!0),s&&S.merge(a,ve(u,"script"))),i.call(n[c],u,c);if(s)for(l=a[a.length-1].ownerDocument,S.map(a,qe),c=0;c<s;c++)u=a[c],he.test(u.type||"")&&!Y.access(u,"globalEval")&&S.contains(l,u)&&(u.src&&"module"!==(u.type||"").toLowerCase()?S._evalUrl&&!u.noModule&&S._evalUrl(u.src,{nonce:u.nonce||u.getAttribute("nonce")},l):b(u.textContent.replace(Ne,""),u,l))}return n}function Oe(e,t,n){for(var r,i=t?S.filter(t,e):e,o=0;null!=(r=i[o]);o++)n||1!==r.nodeType||S.cleanData(ve(r)),r.parentNode&&(n&&ie(r)&&ye(ve(r,"script")),r.parentNode.removeChild(r));return e}S.extend({htmlPrefilter:function(e){return e},clone:function(e,t,n){var r,i,o,a,s,u,l,c=e.cloneNode(!0),f=ie(e);if(!(y.noCloneChecked||1!==e.nodeType&&11!==e.nodeType||S.isXMLDoc(e)))for(a=ve(c),r=0,i=(o=ve(e)).length;r<i;r++)s=o[r],u=a[r],void 0,"input"===(l=u.nodeName.toLowerCase())&&pe.test(s.type)?u.checked=s.checked:"input"!==l&&"textarea"!==l||(u.defaultValue=s.defaultValue);if(t)if(n)for(o=o||ve(e),a=a||ve(c),r=0,i=o.length;r<i;r++)Le(o[r],a[r]);else Le(e,c);return 0<(a=ve(c,"script")).length&&ye(a,!f&&ve(e,"script")),c},cleanData:function(e){for(var t,n,r,i=S.event.special,o=0;void 0!==(n=e[o]);o++)if(V(n)){if(t=n[Y.expando]){if(t.events)for(r in t.events)i[r]?S.event.remove(n,r):S.removeEvent(n,r,t.handle);n[Y.expando]=void 0}n[Q.expando]&&(n[Q.expando]=void 0)}}}),S.fn.extend({detach:function(e){return Oe(this,e,!0)},remove:function(e){return Oe(this,e)},text:function(e){return $(this,function(e){return void 0===e?S.text(this):this.empty().each(function(){1!==this.nodeType&&11!==this.nodeType&&9!==this.nodeType||(this.textContent=e)})},null,e,arguments.length)},append:function(){return He(this,arguments,function(e){1!==this.nodeType&&11!==this.nodeType&&9!==this.nodeType||je(this,e).appendChild(e)})},prepend:function(){return He(this,arguments,function(e){if(1===this.nodeType||11===this.nodeType||9===this.nodeType){var t=je(this,e);t.insertBefore(e,t.firstChild)}})},before:function(){return He(this,arguments,function(e){this.parentNode&&this.parentNode.insertBefore(e,this)})},after:function(){return He(this,arguments,function(e){this.parentNode&&this.parentNode.insertBefore(e,this.nextSibling)})},empty:function(){for(var e,t=0;null!=(e=this[t]);t++)1===e.nodeType&&(S.cleanData(ve(e,!1)),e.textContent="");return this},clone:function(e,t){return e=null!=e&&e,t=null==t?e:t,this.map(function(){return S.clone(this,e,t)})},html:function(e){return $(this,function(e){var t=this[0]||{},n=0,r=this.length;if(void 0===e&&1===t.nodeType)return t.innerHTML;if("string"==typeof e&&!ke.test(e)&&!ge[(de.exec(e)||["",""])[1].toLowerCase()]){e=S.htmlPrefilter(e);try{for(;n<r;n++)1===(t=this[n]||{}).nodeType&&(S.cleanData(ve(t,!1)),t.innerHTML=e);t=0}catch(e){}}t&&this.empty().append(e)},null,e,arguments.length)},replaceWith:function(){var n=[];return He(this,arguments,function(e){var t=this.parentNode;S.inArray(this,n)<0&&(S.cleanData(ve(this)),t&&t.replaceChild(e,this))},n)}}),S.each({appendTo:"append",prependTo:"prepend",insertBefore:"before",insertAfter:"after",replaceAll:"replaceWith"},function(e,a){S.fn[e]=function(e){for(var t,n=[],r=S(e),i=r.length-1,o=0;o<=i;o++)t=o===i?this:this.clone(!0),S(r[o])[a](t),u.apply(n,t.get());return this.pushStack(n)}});var Pe=new RegExp("^("+ee+")(?!px)[a-z%]+$","i"),Re=function(e){var t=e.ownerDocument.defaultView;return t&&t.opener||(t=C),t.getComputedStyle(e)},Me=function(e,t,n){var r,i,o={};for(i in t)o[i]=e.style[i],e.style[i]=t[i];for(i in r=n.call(e),t)e.style[i]=o[i];return r},Ie=new RegExp(ne.join("|"),"i");function We(e,t,n){var r,i,o,a,s=e.style;return(n=n||Re(e))&&(""!==(a=n.getPropertyValue(t)||n[t])||ie(e)||(a=S.style(e,t)),!y.pixelBoxStyles()&&Pe.test(a)&&Ie.test(t)&&(r=s.width,i=s.minWidth,o=s.maxWidth,s.minWidth=s.maxWidth=s.width=a,a=n.width,s.width=r,s.minWidth=i,s.maxWidth=o)),void 0!==a?a+"":a}function Fe(e,t){return{get:function(){if(!e())return(this.get=t).apply(this,arguments);delete this.get}}}!function(){function e(){if(l){u.style.cssText="position:absolute;left:-11111px;width:60px;margin-top:1px;padding:0;border:0",l.style.cssText="position:relative;display:block;box-sizing:border-box;overflow:scroll;margin:auto;border:1px;padding:1px;width:60%;top:1%",re.appendChild(u).appendChild(l);var e=C.getComputedStyle(l);n="1%"!==e.top,s=12===t(e.marginLeft),l.style.right="60%",o=36===t(e.right),r=36===t(e.width),l.style.position="absolute",i=12===t(l.offsetWidth/3),re.removeChild(u),l=null}}function t(e){return Math.round(parseFloat(e))}var n,r,i,o,a,s,u=E.createElement("div"),l=E.createElement("div");l.style&&(l.style.backgroundClip="content-box",l.cloneNode(!0).style.backgroundClip="",y.clearCloneStyle="content-box"===l.style.backgroundClip,S.extend(y,{boxSizingReliable:function(){return e(),r},pixelBoxStyles:function(){return e(),o},pixelPosition:function(){return e(),n},reliableMarginLeft:function(){return e(),s},scrollboxSize:function(){return e(),i},reliableTrDimensions:function(){var e,t,n,r;return null==a&&(e=E.createElement("table"),t=E.createElement("tr"),n=E.createElement("div"),e.style.cssText="position:absolute;left:-11111px;border-collapse:separate",t.style.cssText="border:1px solid",t.style.height="1px",n.style.height="9px",n.style.display="block",re.appendChild(e).appendChild(t).appendChild(n),r=C.getComputedStyle(t),a=parseInt(r.height,10)+parseInt(r.borderTopWidth,10)+parseInt(r.borderBottomWidth,10)===t.offsetHeight,re.removeChild(e)),a}}))}();var Be=["Webkit","Moz","ms"],$e=E.createElement("div").style,_e={};function ze(e){var t=S.cssProps[e]||_e[e];return t||(e in $e?e:_e[e]=function(e){var t=e[0].toUpperCase()+e.slice(1),n=Be.length;while(n--)if((e=Be[n]+t)in $e)return e}(e)||e)}var Ue=/^(none|table(?!-c[ea]).+)/,Xe=/^--/,Ve={position:"absolute",visibility:"hidden",display:"block"},Ge={letterSpacing:"0",fontWeight:"400"};function Ye(e,t,n){var r=te.exec(t);return r?Math.max(0,r[2]-(n||0))+(r[3]||"px"):t}function Qe(e,t,n,r,i,o){var a="width"===t?1:0,s=0,u=0;if(n===(r?"border":"content"))return 0;for(;a<4;a+=2)"margin"===n&&(u+=S.css(e,n+ne[a],!0,i)),r?("content"===n&&(u-=S.css(e,"padding"+ne[a],!0,i)),"margin"!==n&&(u-=S.css(e,"border"+ne[a]+"Width",!0,i))):(u+=S.css(e,"padding"+ne[a],!0,i),"padding"!==n?u+=S.css(e,"border"+ne[a]+"Width",!0,i):s+=S.css(e,"border"+ne[a]+"Width",!0,i));return!r&&0<=o&&(u+=Math.max(0,Math.ceil(e["offset"+t[0].toUpperCase()+t.slice(1)]-o-u-s-.5))||0),u}function Je(e,t,n){var r=Re(e),i=(!y.boxSizingReliable()||n)&&"border-box"===S.css(e,"boxSizing",!1,r),o=i,a=We(e,t,r),s="offset"+t[0].toUpperCase()+t.slice(1);if(Pe.test(a)){if(!n)return a;a="auto"}return(!y.boxSizingReliable()&&i||!y.reliableTrDimensions()&&A(e,"tr")||"auto"===a||!parseFloat(a)&&"inline"===S.css(e,"display",!1,r))&&e.getClientRects().length&&(i="border-box"===S.css(e,"boxSizing",!1,r),(o=s in e)&&(a=e[s])),(a=parseFloat(a)||0)+Qe(e,t,n||(i?"border":"content"),o,r,a)+"px"}function Ke(e,t,n,r,i){return new Ke.prototype.init(e,t,n,r,i)}S.extend({cssHooks:{opacity:{get:function(e,t){if(t){var n=We(e,"opacity");return""===n?"1":n}}}},cssNumber:{animationIterationCount:!0,columnCount:!0,fillOpacity:!0,flexGrow:!0,flexShrink:!0,fontWeight:!0,gridArea:!0,gridColumn:!0,gridColumnEnd:!0,gridColumnStart:!0,gridRow:!0,gridRowEnd:!0,gridRowStart:!0,lineHeight:!0,opacity:!0,order:!0,orphans:!0,widows:!0,zIndex:!0,zoom:!0},cssProps:{},style:function(e,t,n,r){if(e&&3!==e.nodeType&&8!==e.nodeType&&e.style){var i,o,a,s=X(t),u=Xe.test(t),l=e.style;if(u||(t=ze(s)),a=S.cssHooks[t]||S.cssHooks[s],void 0===n)return a&&"get"in a&&void 0!==(i=a.get(e,!1,r))?i:l[t];"string"===(o=typeof n)&&(i=te.exec(n))&&i[1]&&(n=se(e,t,i),o="number"),null!=n&&n==n&&("number"!==o||u||(n+=i&&i[3]||(S.cssNumber[s]?"":"px")),y.clearCloneStyle||""!==n||0!==t.indexOf("background")||(l[t]="inherit"),a&&"set"in a&&void 0===(n=a.set(e,n,r))||(u?l.setProperty(t,n):l[t]=n))}},css:function(e,t,n,r){var i,o,a,s=X(t);return Xe.test(t)||(t=ze(s)),(a=S.cssHooks[t]||S.cssHooks[s])&&"get"in a&&(i=a.get(e,!0,n)),void 0===i&&(i=We(e,t,r)),"normal"===i&&t in Ge&&(i=Ge[t]),""===n||n?(o=parseFloat(i),!0===n||isFinite(o)?o||0:i):i}}),S.each(["height","width"],function(e,u){S.cssHooks[u]={get:function(e,t,n){if(t)return!Ue.test(S.css(e,"display"))||e.getClientRects().length&&e.getBoundingClientRect().width?Je(e,u,n):Me(e,Ve,function(){return Je(e,u,n)})},set:function(e,t,n){var r,i=Re(e),o=!y.scrollboxSize()&&"absolute"===i.position,a=(o||n)&&"border-box"===S.css(e,"boxSizing",!1,i),s=n?Qe(e,u,n,a,i):0;return a&&o&&(s-=Math.ceil(e["offset"+u[0].toUpperCase()+u.slice(1)]-parseFloat(i[u])-Qe(e,u,"border",!1,i)-.5)),s&&(r=te.exec(t))&&"px"!==(r[3]||"px")&&(e.style[u]=t,t=S.css(e,u)),Ye(0,t,s)}}}),S.cssHooks.marginLeft=Fe(y.reliableMarginLeft,function(e,t){if(t)return(parseFloat(We(e,"marginLeft"))||e.getBoundingClientRect().left-Me(e,{marginLeft:0},function(){return e.getBoundingClientRect().left}))+"px"}),S.each({margin:"",padding:"",border:"Width"},function(i,o){S.cssHooks[i+o]={expand:function(e){for(var t=0,n={},r="string"==typeof e?e.split(" "):[e];t<4;t++)n[i+ne[t]+o]=r[t]||r[t-2]||r[0];return n}},"margin"!==i&&(S.cssHooks[i+o].set=Ye)}),S.fn.extend({css:function(e,t){return $(this,function(e,t,n){var r,i,o={},a=0;if(Array.isArray(t)){for(r=Re(e),i=t.length;a<i;a++)o[t[a]]=S.css(e,t[a],!1,r);return o}return void 0!==n?S.style(e,t,n):S.css(e,t)},e,t,1<arguments.length)}}),((S.Tween=Ke).prototype={constructor:Ke,init:function(e,t,n,r,i,o){this.elem=e,this.prop=n,this.easing=i||S.easing._default,this.options=t,this.start=this.now=this.cur(),this.end=r,this.unit=o||(S.cssNumber[n]?"":"px")},cur:function(){var e=Ke.propHooks[this.prop];return e&&e.get?e.get(this):Ke.propHooks._default.get(this)},run:function(e){var t,n=Ke.propHooks[this.prop];return this.options.duration?this.pos=t=S.easing[this.easing](e,this.options.duration*e,0,1,this.options.duration):this.pos=t=e,this.now=(this.end-this.start)*t+this.start,this.options.step&&this.options.step.call(this.elem,this.now,this),n&&n.set?n.set(this):Ke.propHooks._default.set(this),this}}).init.prototype=Ke.prototype,(Ke.propHooks={_default:{get:function(e){var t;return 1!==e.elem.nodeType||null!=e.elem[e.prop]&&null==e.elem.style[e.prop]?e.elem[e.prop]:(t=S.css(e.elem,e.prop,""))&&"auto"!==t?t:0},set:function(e){S.fx.step[e.prop]?S.fx.step[e.prop](e):1!==e.elem.nodeType||!S.cssHooks[e.prop]&&null==e.elem.style[ze(e.prop)]?e.elem[e.prop]=e.now:S.style(e.elem,e.prop,e.now+e.unit)}}}).scrollTop=Ke.propHooks.scrollLeft={set:function(e){e.elem.nodeType&&e.elem.parentNode&&(e.elem[e.prop]=e.now)}},S.easing={linear:function(e){return e},swing:function(e){return.5-Math.cos(e*Math.PI)/2},_default:"swing"},S.fx=Ke.prototype.init,S.fx.step={};var Ze,et,tt,nt,rt=/^(?:toggle|show|hide)$/,it=/queueHooks$/;function ot(){et&&(!1===E.hidden&&C.requestAnimationFrame?C.requestAnimationFrame(ot):C.setTimeout(ot,S.fx.interval),S.fx.tick())}function at(){return C.setTimeout(function(){Ze=void 0}),Ze=Date.now()}function st(e,t){var n,r=0,i={height:e};for(t=t?1:0;r<4;r+=2-t)i["margin"+(n=ne[r])]=i["padding"+n]=e;return t&&(i.opacity=i.width=e),i}function ut(e,t,n){for(var r,i=(lt.tweeners[t]||[]).concat(lt.tweeners["*"]),o=0,a=i.length;o<a;o++)if(r=i[o].call(n,t,e))return r}function lt(o,e,t){var n,a,r=0,i=lt.prefilters.length,s=S.Deferred().always(function(){delete u.elem}),u=function(){if(a)return!1;for(var e=Ze||at(),t=Math.max(0,l.startTime+l.duration-e),n=1-(t/l.duration||0),r=0,i=l.tweens.length;r<i;r++)l.tweens[r].run(n);return s.notifyWith(o,[l,n,t]),n<1&&i?t:(i||s.notifyWith(o,[l,1,0]),s.resolveWith(o,[l]),!1)},l=s.promise({elem:o,props:S.extend({},e),opts:S.extend(!0,{specialEasing:{},easing:S.easing._default},t),originalProperties:e,originalOptions:t,startTime:Ze||at(),duration:t.duration,tweens:[],createTween:function(e,t){var n=S.Tween(o,l.opts,e,t,l.opts.specialEasing[e]||l.opts.easing);return l.tweens.push(n),n},stop:function(e){var t=0,n=e?l.tweens.length:0;if(a)return this;for(a=!0;t<n;t++)l.tweens[t].run(1);return e?(s.notifyWith(o,[l,1,0]),s.resolveWith(o,[l,e])):s.rejectWith(o,[l,e]),this}}),c=l.props;for(!function(e,t){var n,r,i,o,a;for(n in e)if(i=t[r=X(n)],o=e[n],Array.isArray(o)&&(i=o[1],o=e[n]=o[0]),n!==r&&(e[r]=o,delete e[n]),(a=S.cssHooks[r])&&"expand"in a)for(n in o=a.expand(o),delete e[r],o)n in e||(e[n]=o[n],t[n]=i);else t[r]=i}(c,l.opts.specialEasing);r<i;r++)if(n=lt.prefilters[r].call(l,o,c,l.opts))return m(n.stop)&&(S._queueHooks(l.elem,l.opts.queue).stop=n.stop.bind(n)),n;return S.map(c,ut,l),m(l.opts.start)&&l.opts.start.call(o,l),l.progress(l.opts.progress).done(l.opts.done,l.opts.complete).fail(l.opts.fail).always(l.opts.always),S.fx.timer(S.extend(u,{elem:o,anim:l,queue:l.opts.queue})),l}S.Animation=S.extend(lt,{tweeners:{"*":[function(e,t){var n=this.createTween(e,t);return se(n.elem,e,te.exec(t),n),n}]},tweener:function(e,t){m(e)?(t=e,e=["*"]):e=e.match(P);for(var n,r=0,i=e.length;r<i;r++)n=e[r],lt.tweeners[n]=lt.tweeners[n]||[],lt.tweeners[n].unshift(t)},prefilters:[function(e,t,n){var r,i,o,a,s,u,l,c,f="width"in t||"height"in t,p=this,d={},h=e.style,g=e.nodeType&&ae(e),v=Y.get(e,"fxshow");for(r in n.queue||(null==(a=S._queueHooks(e,"fx")).unqueued&&(a.unqueued=0,s=a.empty.fire,a.empty.fire=function(){a.unqueued||s()}),a.unqueued++,p.always(function(){p.always(function(){a.unqueued--,S.queue(e,"fx").length||a.empty.fire()})})),t)if(i=t[r],rt.test(i)){if(delete t[r],o=o||"toggle"===i,i===(g?"hide":"show")){if("show"!==i||!v||void 0===v[r])continue;g=!0}d[r]=v&&v[r]||S.style(e,r)}if((u=!S.isEmptyObject(t))||!S.isEmptyObject(d))for(r in f&&1===e.nodeType&&(n.overflow=[h.overflow,h.overflowX,h.overflowY],null==(l=v&&v.display)&&(l=Y.get(e,"display")),"none"===(c=S.css(e,"display"))&&(l?c=l:(le([e],!0),l=e.style.display||l,c=S.css(e,"display"),le([e]))),("inline"===c||"inline-block"===c&&null!=l)&&"none"===S.css(e,"float")&&(u||(p.done(function(){h.display=l}),null==l&&(c=h.display,l="none"===c?"":c)),h.display="inline-block")),n.overflow&&(h.overflow="hidden",p.always(function(){h.overflow=n.overflow[0],h.overflowX=n.overflow[1],h.overflowY=n.overflow[2]})),u=!1,d)u||(v?"hidden"in v&&(g=v.hidden):v=Y.access(e,"fxshow",{display:l}),o&&(v.hidden=!g),g&&le([e],!0),p.done(function(){for(r in g||le([e]),Y.remove(e,"fxshow"),d)S.style(e,r,d[r])})),u=ut(g?v[r]:0,r,p),r in v||(v[r]=u.start,g&&(u.end=u.start,u.start=0))}],prefilter:function(e,t){t?lt.prefilters.unshift(e):lt.prefilters.push(e)}}),S.speed=function(e,t,n){var r=e&&"object"==typeof e?S.extend({},e):{complete:n||!n&&t||m(e)&&e,duration:e,easing:n&&t||t&&!m(t)&&t};return S.fx.off?r.duration=0:"number"!=typeof r.duration&&(r.duration in S.fx.speeds?r.duration=S.fx.speeds[r.duration]:r.duration=S.fx.speeds._default),null!=r.queue&&!0!==r.queue||(r.queue="fx"),r.old=r.complete,r.complete=function(){m(r.old)&&r.old.call(this),r.queue&&S.dequeue(this,r.queue)},r},S.fn.extend({fadeTo:function(e,t,n,r){return this.filter(ae).css("opacity",0).show().end().animate({opacity:t},e,n,r)},animate:function(t,e,n,r){var i=S.isEmptyObject(t),o=S.speed(e,n,r),a=function(){var e=lt(this,S.extend({},t),o);(i||Y.get(this,"finish"))&&e.stop(!0)};return a.finish=a,i||!1===o.queue?this.each(a):this.queue(o.queue,a)},stop:function(i,e,o){var a=function(e){var t=e.stop;delete e.stop,t(o)};return"string"!=typeof i&&(o=e,e=i,i=void 0),e&&this.queue(i||"fx",[]),this.each(function(){var e=!0,t=null!=i&&i+"queueHooks",n=S.timers,r=Y.get(this);if(t)r[t]&&r[t].stop&&a(r[t]);else for(t in r)r[t]&&r[t].stop&&it.test(t)&&a(r[t]);for(t=n.length;t--;)n[t].elem!==this||null!=i&&n[t].queue!==i||(n[t].anim.stop(o),e=!1,n.splice(t,1));!e&&o||S.dequeue(this,i)})},finish:function(a){return!1!==a&&(a=a||"fx"),this.each(function(){var e,t=Y.get(this),n=t[a+"queue"],r=t[a+"queueHooks"],i=S.timers,o=n?n.length:0;for(t.finish=!0,S.queue(this,a,[]),r&&r.stop&&r.stop.call(this,!0),e=i.length;e--;)i[e].elem===this&&i[e].queue===a&&(i[e].anim.stop(!0),i.splice(e,1));for(e=0;e<o;e++)n[e]&&n[e].finish&&n[e].finish.call(this);delete t.finish})}}),S.each(["toggle","show","hide"],function(e,r){var i=S.fn[r];S.fn[r]=function(e,t,n){return null==e||"boolean"==typeof e?i.apply(this,arguments):this.animate(st(r,!0),e,t,n)}}),S.each({slideDown:st("show"),slideUp:st("hide"),slideToggle:st("toggle"),fadeIn:{opacity:"show"},fadeOut:{opacity:"hide"},fadeToggle:{opacity:"toggle"}},function(e,r){S.fn[e]=function(e,t,n){return this.animate(r,e,t,n)}}),S.timers=[],S.fx.tick=function(){var e,t=0,n=S.timers;for(Ze=Date.now();t<n.length;t++)(e=n[t])()||n[t]!==e||n.splice(t--,1);n.length||S.fx.stop(),Ze=void 0},S.fx.timer=function(e){S.timers.push(e),S.fx.start()},S.fx.interval=13,S.fx.start=function(){et||(et=!0,ot())},S.fx.stop=function(){et=null},S.fx.speeds={slow:600,fast:200,_default:400},S.fn.delay=function(r,e){return r=S.fx&&S.fx.speeds[r]||r,e=e||"fx",this.queue(e,function(e,t){var n=C.setTimeout(e,r);t.stop=function(){C.clearTimeout(n)}})},tt=E.createElement("input"),nt=E.createElement("select").appendChild(E.createElement("option")),tt.type="checkbox",y.checkOn=""!==tt.value,y.optSelected=nt.selected,(tt=E.createElement("input")).value="t",tt.type="radio",y.radioValue="t"===tt.value;var ct,ft=S.expr.attrHandle;S.fn.extend({attr:function(e,t){return $(this,S.attr,e,t,1<arguments.length)},removeAttr:function(e){return this.each(function(){S.removeAttr(this,e)})}}),S.extend({attr:function(e,t,n){var r,i,o=e.nodeType;if(3!==o&&8!==o&&2!==o)return"undefined"==typeof e.getAttribute?S.prop(e,t,n):(1===o&&S.isXMLDoc(e)||(i=S.attrHooks[t.toLowerCase()]||(S.expr.match.bool.test(t)?ct:void 0)),void 0!==n?null===n?void S.removeAttr(e,t):i&&"set"in i&&void 0!==(r=i.set(e,n,t))?r:(e.setAttribute(t,n+""),n):i&&"get"in i&&null!==(r=i.get(e,t))?r:null==(r=S.find.attr(e,t))?void 0:r)},attrHooks:{type:{set:function(e,t){if(!y.radioValue&&"radio"===t&&A(e,"input")){var n=e.value;return e.setAttribute("type",t),n&&(e.value=n),t}}}},removeAttr:function(e,t){var n,r=0,i=t&&t.match(P);if(i&&1===e.nodeType)while(n=i[r++])e.removeAttribute(n)}}),ct={set:function(e,t,n){return!1===t?S.removeAttr(e,n):e.setAttribute(n,n),n}},S.each(S.expr.match.bool.source.match(/\w+/g),function(e,t){var a=ft[t]||S.find.attr;ft[t]=function(e,t,n){var r,i,o=t.toLowerCase();return n||(i=ft[o],ft[o]=r,r=null!=a(e,t,n)?o:null,ft[o]=i),r}});var pt=/^(?:input|select|textarea|button)$/i,dt=/^(?:a|area)$/i;function ht(e){return(e.match(P)||[]).join(" ")}function gt(e){return e.getAttribute&&e.getAttribute("class")||""}function vt(e){return Array.isArray(e)?e:"string"==typeof e&&e.match(P)||[]}S.fn.extend({prop:function(e,t){return $(this,S.prop,e,t,1<arguments.length)},removeProp:function(e){return this.each(function(){delete this[S.propFix[e]||e]})}}),S.extend({prop:function(e,t,n){var r,i,o=e.nodeType;if(3!==o&&8!==o&&2!==o)return 1===o&&S.isXMLDoc(e)||(t=S.propFix[t]||t,i=S.propHooks[t]),void 0!==n?i&&"set"in i&&void 0!==(r=i.set(e,n,t))?r:e[t]=n:i&&"get"in i&&null!==(r=i.get(e,t))?r:e[t]},propHooks:{tabIndex:{get:function(e){var t=S.find.attr(e,"tabindex");return t?parseInt(t,10):pt.test(e.nodeName)||dt.test(e.nodeName)&&e.href?0:-1}}},propFix:{"for":"htmlFor","class":"className"}}),y.optSelected||(S.propHooks.selected={get:function(e){var t=e.parentNode;return t&&t.parentNode&&t.parentNode.selectedIndex,null},set:function(e){var t=e.parentNode;t&&(t.selectedIndex,t.parentNode&&t.parentNode.selectedIndex)}}),S.each(["tabIndex","readOnly","maxLength","cellSpacing","cellPadding","rowSpan","colSpan","useMap","frameBorder","contentEditable"],function(){S.propFix[this.toLowerCase()]=this}),S.fn.extend({addClass:function(t){var e,n,r,i,o,a,s,u=0;if(m(t))return this.each(function(e){S(this).addClass(t.call(this,e,gt(this)))});if((e=vt(t)).length)while(n=this[u++])if(i=gt(n),r=1===n.nodeType&&" "+ht(i)+" "){a=0;while(o=e[a++])r.indexOf(" "+o+" ")<0&&(r+=o+" ");i!==(s=ht(r))&&n.setAttribute("class",s)}return this},removeClass:function(t){var e,n,r,i,o,a,s,u=0;if(m(t))return this.each(function(e){S(this).removeClass(t.call(this,e,gt(this)))});if(!arguments.length)return this.attr("class","");if((e=vt(t)).length)while(n=this[u++])if(i=gt(n),r=1===n.nodeType&&" "+ht(i)+" "){a=0;while(o=e[a++])while(-1<r.indexOf(" "+o+" "))r=r.replace(" "+o+" "," ");i!==(s=ht(r))&&n.setAttribute("class",s)}return this},toggleClass:function(i,t){var o=typeof i,a="string"===o||Array.isArray(i);return"boolean"==typeof t&&a?t?this.addClass(i):this.removeClass(i):m(i)?this.each(function(e){S(this).toggleClass(i.call(this,e,gt(this),t),t)}):this.each(function(){var e,t,n,r;if(a){t=0,n=S(this),r=vt(i);while(e=r[t++])n.hasClass(e)?n.removeClass(e):n.addClass(e)}else void 0!==i&&"boolean"!==o||((e=gt(this))&&Y.set(this,"__className__",e),this.setAttribute&&this.setAttribute("class",e||!1===i?"":Y.get(this,"__className__")||""))})},hasClass:function(e){var t,n,r=0;t=" "+e+" ";while(n=this[r++])if(1===n.nodeType&&-1<(" "+ht(gt(n))+" ").indexOf(t))return!0;return!1}});var yt=/\r/g;S.fn.extend({val:function(n){var r,e,i,t=this[0];return arguments.length?(i=m(n),this.each(function(e){var t;1===this.nodeType&&(null==(t=i?n.call(this,e,S(this).val()):n)?t="":"number"==typeof t?t+="":Array.isArray(t)&&(t=S.map(t,function(e){return null==e?"":e+""})),(r=S.valHooks[this.type]||S.valHooks[this.nodeName.toLowerCase()])&&"set"in r&&void 0!==r.set(this,t,"value")||(this.value=t))})):t?(r=S.valHooks[t.type]||S.valHooks[t.nodeName.toLowerCase()])&&"get"in r&&void 0!==(e=r.get(t,"value"))?e:"string"==typeof(e=t.value)?e.replace(yt,""):null==e?"":e:void 0}}),S.extend({valHooks:{option:{get:function(e){var t=S.find.attr(e,"value");return null!=t?t:ht(S.text(e))}},select:{get:function(e){var t,n,r,i=e.options,o=e.selectedIndex,a="select-one"===e.type,s=a?null:[],u=a?o+1:i.length;for(r=o<0?u:a?o:0;r<u;r++)if(((n=i[r]).selected||r===o)&&!n.disabled&&(!n.parentNode.disabled||!A(n.parentNode,"optgroup"))){if(t=S(n).val(),a)return t;s.push(t)}return s},set:function(e,t){var n,r,i=e.options,o=S.makeArray(t),a=i.length;while(a--)((r=i[a]).selected=-1<S.inArray(S.valHooks.option.get(r),o))&&(n=!0);return n||(e.selectedIndex=-1),o}}}}),S.each(["radio","checkbox"],function(){S.valHooks[this]={set:function(e,t){if(Array.isArray(t))return e.checked=-1<S.inArray(S(e).val(),t)}},y.checkOn||(S.valHooks[this].get=function(e){return null===e.getAttribute("value")?"on":e.value})}),y.focusin="onfocusin"in C;var mt=/^(?:focusinfocus|focusoutblur)$/,xt=function(e){e.stopPropagation()};S.extend(S.event,{trigger:function(e,t,n,r){var i,o,a,s,u,l,c,f,p=[n||E],d=v.call(e,"type")?e.type:e,h=v.call(e,"namespace")?e.namespace.split("."):[];if(o=f=a=n=n||E,3!==n.nodeType&&8!==n.nodeType&&!mt.test(d+S.event.triggered)&&(-1<d.indexOf(".")&&(d=(h=d.split(".")).shift(),h.sort()),u=d.indexOf(":")<0&&"on"+d,(e=e[S.expando]?e:new S.Event(d,"object"==typeof e&&e)).isTrigger=r?2:3,e.namespace=h.join("."),e.rnamespace=e.namespace?new RegExp("(^|\\.)"+h.join("\\.(?:.*\\.|)")+"(\\.|$)"):null,e.result=void 0,e.target||(e.target=n),t=null==t?[e]:S.makeArray(t,[e]),c=S.event.special[d]||{},r||!c.trigger||!1!==c.trigger.apply(n,t))){if(!r&&!c.noBubble&&!x(n)){for(s=c.delegateType||d,mt.test(s+d)||(o=o.parentNode);o;o=o.parentNode)p.push(o),a=o;a===(n.ownerDocument||E)&&p.push(a.defaultView||a.parentWindow||C)}i=0;while((o=p[i++])&&!e.isPropagationStopped())f=o,e.type=1<i?s:c.bindType||d,(l=(Y.get(o,"events")||Object.create(null))[e.type]&&Y.get(o,"handle"))&&l.apply(o,t),(l=u&&o[u])&&l.apply&&V(o)&&(e.result=l.apply(o,t),!1===e.result&&e.preventDefault());return e.type=d,r||e.isDefaultPrevented()||c._default&&!1!==c._default.apply(p.pop(),t)||!V(n)||u&&m(n[d])&&!x(n)&&((a=n[u])&&(n[u]=null),S.event.triggered=d,e.isPropagationStopped()&&f.addEventListener(d,xt),n[d](),e.isPropagationStopped()&&f.removeEventListener(d,xt),S.event.triggered=void 0,a&&(n[u]=a)),e.result}},simulate:function(e,t,n){var r=S.extend(new S.Event,n,{type:e,isSimulated:!0});S.event.trigger(r,null,t)}}),S.fn.extend({trigger:function(e,t){return this.each(function(){S.event.trigger(e,t,this)})},triggerHandler:function(e,t){var n=this[0];if(n)return S.event.trigger(e,t,n,!0)}}),y.focusin||S.each({focus:"focusin",blur:"focusout"},function(n,r){var i=function(e){S.event.simulate(r,e.target,S.event.fix(e))};S.event.special[r]={setup:function(){var e=this.ownerDocument||this.document||this,t=Y.access(e,r);t||e.addEventListener(n,i,!0),Y.access(e,r,(t||0)+1)},teardown:function(){var e=this.ownerDocument||this.document||this,t=Y.access(e,r)-1;t?Y.access(e,r,t):(e.removeEventListener(n,i,!0),Y.remove(e,r))}}});var bt=C.location,wt={guid:Date.now()},Tt=/\?/;S.parseXML=function(e){var t,n;if(!e||"string"!=typeof e)return null;try{t=(new C.DOMParser).parseFromString(e,"text/xml")}catch(e){}return n=t&&t.getElementsByTagName("parsererror")[0],t&&!n||S.error("Invalid XML: "+(n?S.map(n.childNodes,function(e){return e.textContent}).join("\n"):e)),t};var Ct=/\[\]$/,Et=/\r?\n/g,St=/^(?:submit|button|image|reset|file)$/i,kt=/^(?:input|select|textarea|keygen)/i;function At(n,e,r,i){var t;if(Array.isArray(e))S.each(e,function(e,t){r||Ct.test(n)?i(n,t):At(n+"["+("object"==typeof t&&null!=t?e:"")+"]",t,r,i)});else if(r||"object"!==w(e))i(n,e);else for(t in e)At(n+"["+t+"]",e[t],r,i)}S.param=function(e,t){var n,r=[],i=function(e,t){var n=m(t)?t():t;r[r.length]=encodeURIComponent(e)+"="+encodeURIComponent(null==n?"":n)};if(null==e)return"";if(Array.isArray(e)||e.jquery&&!S.isPlainObject(e))S.each(e,function(){i(this.name,this.value)});else for(n in e)At(n,e[n],t,i);return r.join("&")},S.fn.extend({serialize:function(){return S.param(this.serializeArray())},serializeArray:function(){return this.map(function(){var e=S.prop(this,"elements");return e?S.makeArray(e):this}).filter(function(){var e=this.type;return this.name&&!S(this).is(":disabled")&&kt.test(this.nodeName)&&!St.test(e)&&(this.checked||!pe.test(e))}).map(function(e,t){var n=S(this).val();return null==n?null:Array.isArray(n)?S.map(n,function(e){return{name:t.name,value:e.replace(Et,"\r\n")}}):{name:t.name,value:n.replace(Et,"\r\n")}}).get()}});var Nt=/%20/g,jt=/#.*$/,Dt=/([?&])_=[^&]*/,qt=/^(.*?):[ \t]*([^\r\n]*)$/gm,Lt=/^(?:GET|HEAD)$/,Ht=/^\/\//,Ot={},Pt={},Rt="*/".concat("*"),Mt=E.createElement("a");function It(o){return function(e,t){"string"!=typeof e&&(t=e,e="*");var n,r=0,i=e.toLowerCase().match(P)||[];if(m(t))while(n=i[r++])"+"===n[0]?(n=n.slice(1)||"*",(o[n]=o[n]||[]).unshift(t)):(o[n]=o[n]||[]).push(t)}}function Wt(t,i,o,a){var s={},u=t===Pt;function l(e){var r;return s[e]=!0,S.each(t[e]||[],function(e,t){var n=t(i,o,a);return"string"!=typeof n||u||s[n]?u?!(r=n):void 0:(i.dataTypes.unshift(n),l(n),!1)}),r}return l(i.dataTypes[0])||!s["*"]&&l("*")}function Ft(e,t){var n,r,i=S.ajaxSettings.flatOptions||{};for(n in t)void 0!==t[n]&&((i[n]?e:r||(r={}))[n]=t[n]);return r&&S.extend(!0,e,r),e}Mt.href=bt.href,S.extend({active:0,lastModified:{},etag:{},ajaxSettings:{url:bt.href,type:"GET",isLocal:/^(?:about|app|app-storage|.+-extension|file|res|widget):$/.test(bt.protocol),global:!0,processData:!0,async:!0,contentType:"application/x-www-form-urlencoded; charset=UTF-8",accepts:{"*":Rt,text:"text/plain",html:"text/html",xml:"application/xml, text/xml",json:"application/json, text/javascript"},contents:{xml:/\bxml\b/,html:/\bhtml/,json:/\bjson\b/},responseFields:{xml:"responseXML",text:"responseText",json:"responseJSON"},converters:{"* text":String,"text html":!0,"text json":JSON.parse,"text xml":S.parseXML},flatOptions:{url:!0,context:!0}},ajaxSetup:function(e,t){return t?Ft(Ft(e,S.ajaxSettings),t):Ft(S.ajaxSettings,e)},ajaxPrefilter:It(Ot),ajaxTransport:It(Pt),ajax:function(e,t){"object"==typeof e&&(t=e,e=void 0),t=t||{};var c,f,p,n,d,r,h,g,i,o,v=S.ajaxSetup({},t),y=v.context||v,m=v.context&&(y.nodeType||y.jquery)?S(y):S.event,x=S.Deferred(),b=S.Callbacks("once memory"),w=v.statusCode||{},a={},s={},u="canceled",T={readyState:0,getResponseHeader:function(e){var t;if(h){if(!n){n={};while(t=qt.exec(p))n[t[1].toLowerCase()+" "]=(n[t[1].toLowerCase()+" "]||[]).concat(t[2])}t=n[e.toLowerCase()+" "]}return null==t?null:t.join(", ")},getAllResponseHeaders:function(){return h?p:null},setRequestHeader:function(e,t){return null==h&&(e=s[e.toLowerCase()]=s[e.toLowerCase()]||e,a[e]=t),this},overrideMimeType:function(e){return null==h&&(v.mimeType=e),this},statusCode:function(e){var t;if(e)if(h)T.always(e[T.status]);else for(t in e)w[t]=[w[t],e[t]];return this},abort:function(e){var t=e||u;return c&&c.abort(t),l(0,t),this}};if(x.promise(T),v.url=((e||v.url||bt.href)+"").replace(Ht,bt.protocol+"//"),v.type=t.method||t.type||v.method||v.type,v.dataTypes=(v.dataType||"*").toLowerCase().match(P)||[""],null==v.crossDomain){r=E.createElement("a");try{r.href=v.url,r.href=r.href,v.crossDomain=Mt.protocol+"//"+Mt.host!=r.protocol+"//"+r.host}catch(e){v.crossDomain=!0}}if(v.data&&v.processData&&"string"!=typeof v.data&&(v.data=S.param(v.data,v.traditional)),Wt(Ot,v,t,T),h)return T;for(i in(g=S.event&&v.global)&&0==S.active++&&S.event.trigger("ajaxStart"),v.type=v.type.toUpperCase(),v.hasContent=!Lt.test(v.type),f=v.url.replace(jt,""),v.hasContent?v.data&&v.processData&&0===(v.contentType||"").indexOf("application/x-www-form-urlencoded")&&(v.data=v.data.replace(Nt,"+")):(o=v.url.slice(f.length),v.data&&(v.processData||"string"==typeof v.data)&&(f+=(Tt.test(f)?"&":"?")+v.data,delete v.data),!1===v.cache&&(f=f.replace(Dt,"$1"),o=(Tt.test(f)?"&":"?")+"_="+wt.guid+++o),v.url=f+o),v.ifModified&&(S.lastModified[f]&&T.setRequestHeader("If-Modified-Since",S.lastModified[f]),S.etag[f]&&T.setRequestHeader("If-None-Match",S.etag[f])),(v.data&&v.hasContent&&!1!==v.contentType||t.contentType)&&T.setRequestHeader("Content-Type",v.contentType),T.setRequestHeader("Accept",v.dataTypes[0]&&v.accepts[v.dataTypes[0]]?v.accepts[v.dataTypes[0]]+("*"!==v.dataTypes[0]?", "+Rt+"; q=0.01":""):v.accepts["*"]),v.headers)T.setRequestHeader(i,v.headers[i]);if(v.beforeSend&&(!1===v.beforeSend.call(y,T,v)||h))return T.abort();if(u="abort",b.add(v.complete),T.done(v.success),T.fail(v.error),c=Wt(Pt,v,t,T)){if(T.readyState=1,g&&m.trigger("ajaxSend",[T,v]),h)return T;v.async&&0<v.timeout&&(d=C.setTimeout(function(){T.abort("timeout")},v.timeout));try{h=!1,c.send(a,l)}catch(e){if(h)throw e;l(-1,e)}}else l(-1,"No Transport");function l(e,t,n,r){var i,o,a,s,u,l=t;h||(h=!0,d&&C.clearTimeout(d),c=void 0,p=r||"",T.readyState=0<e?4:0,i=200<=e&&e<300||304===e,n&&(s=function(e,t,n){var r,i,o,a,s=e.contents,u=e.dataTypes;while("*"===u[0])u.shift(),void 0===r&&(r=e.mimeType||t.getResponseHeader("Content-Type"));if(r)for(i in s)if(s[i]&&s[i].test(r)){u.unshift(i);break}if(u[0]in n)o=u[0];else{for(i in n){if(!u[0]||e.converters[i+" "+u[0]]){o=i;break}a||(a=i)}o=o||a}if(o)return o!==u[0]&&u.unshift(o),n[o]}(v,T,n)),!i&&-1<S.inArray("script",v.dataTypes)&&S.inArray("json",v.dataTypes)<0&&(v.converters["text script"]=function(){}),s=function(e,t,n,r){var i,o,a,s,u,l={},c=e.dataTypes.slice();if(c[1])for(a in e.converters)l[a.toLowerCase()]=e.converters[a];o=c.shift();while(o)if(e.responseFields[o]&&(n[e.responseFields[o]]=t),!u&&r&&e.dataFilter&&(t=e.dataFilter(t,e.dataType)),u=o,o=c.shift())if("*"===o)o=u;else if("*"!==u&&u!==o){if(!(a=l[u+" "+o]||l["* "+o]))for(i in l)if((s=i.split(" "))[1]===o&&(a=l[u+" "+s[0]]||l["* "+s[0]])){!0===a?a=l[i]:!0!==l[i]&&(o=s[0],c.unshift(s[1]));break}if(!0!==a)if(a&&e["throws"])t=a(t);else try{t=a(t)}catch(e){return{state:"parsererror",error:a?e:"No conversion from "+u+" to "+o}}}return{state:"success",data:t}}(v,s,T,i),i?(v.ifModified&&((u=T.getResponseHeader("Last-Modified"))&&(S.lastModified[f]=u),(u=T.getResponseHeader("etag"))&&(S.etag[f]=u)),204===e||"HEAD"===v.type?l="nocontent":304===e?l="notmodified":(l=s.state,o=s.data,i=!(a=s.error))):(a=l,!e&&l||(l="error",e<0&&(e=0))),T.status=e,T.statusText=(t||l)+"",i?x.resolveWith(y,[o,l,T]):x.rejectWith(y,[T,l,a]),T.statusCode(w),w=void 0,g&&m.trigger(i?"ajaxSuccess":"ajaxError",[T,v,i?o:a]),b.fireWith(y,[T,l]),g&&(m.trigger("ajaxComplete",[T,v]),--S.active||S.event.trigger("ajaxStop")))}return T},getJSON:function(e,t,n){return S.get(e,t,n,"json")},getScript:function(e,t){return S.get(e,void 0,t,"script")}}),S.each(["get","post"],function(e,i){S[i]=function(e,t,n,r){return m(t)&&(r=r||n,n=t,t=void 0),S.ajax(S.extend({url:e,type:i,dataType:r,data:t,success:n},S.isPlainObject(e)&&e))}}),S.ajaxPrefilter(function(e){var t;for(t in e.headers)"content-type"===t.toLowerCase()&&(e.contentType=e.headers[t]||"")}),S._evalUrl=function(e,t,n){return S.ajax({url:e,type:"GET",dataType:"script",cache:!0,async:!1,global:!1,converters:{"text script":function(){}},dataFilter:function(e){S.globalEval(e,t,n)}})},S.fn.extend({wrapAll:function(e){var t;return this[0]&&(m(e)&&(e=e.call(this[0])),t=S(e,this[0].ownerDocument).eq(0).clone(!0),this[0].parentNode&&t.insertBefore(this[0]),t.map(function(){var e=this;while(e.firstElementChild)e=e.firstElementChild;return e}).append(this)),this},wrapInner:function(n){return m(n)?this.each(function(e){S(this).wrapInner(n.call(this,e))}):this.each(function(){var e=S(this),t=e.contents();t.length?t.wrapAll(n):e.append(n)})},wrap:function(t){var n=m(t);return this.each(function(e){S(this).wrapAll(n?t.call(this,e):t)})},unwrap:function(e){return this.parent(e).not("body").each(function(){S(this).replaceWith(this.childNodes)}),this}}),S.expr.pseudos.hidden=function(e){return!S.expr.pseudos.visible(e)},S.expr.pseudos.visible=function(e){return!!(e.offsetWidth||e.offsetHeight||e.getClientRects().length)},S.ajaxSettings.xhr=function(){try{return new C.XMLHttpRequest}catch(e){}};var Bt={0:200,1223:204},$t=S.ajaxSettings.xhr();y.cors=!!$t&&"withCredentials"in $t,y.ajax=$t=!!$t,S.ajaxTransport(function(i){var o,a;if(y.cors||$t&&!i.crossDomain)return{send:function(e,t){var n,r=i.xhr();if(r.open(i.type,i.url,i.async,i.username,i.password),i.xhrFields)for(n in i.xhrFields)r[n]=i.xhrFields[n];for(n in i.mimeType&&r.overrideMimeType&&r.overrideMimeType(i.mimeType),i.crossDomain||e["X-Requested-With"]||(e["X-Requested-With"]="XMLHttpRequest"),e)r.setRequestHeader(n,e[n]);o=function(e){return function(){o&&(o=a=r.onload=r.onerror=r.onabort=r.ontimeout=r.onreadystatechange=null,"abort"===e?r.abort():"error"===e?"number"!=typeof r.status?t(0,"error"):t(r.status,r.statusText):t(Bt[r.status]||r.status,r.statusText,"text"!==(r.responseType||"text")||"string"!=typeof r.responseText?{binary:r.response}:{text:r.responseText},r.getAllResponseHeaders()))}},r.onload=o(),a=r.onerror=r.ontimeout=o("error"),void 0!==r.onabort?r.onabort=a:r.onreadystatechange=function(){4===r.readyState&&C.setTimeout(function(){o&&a()})},o=o("abort");try{r.send(i.hasContent&&i.data||null)}catch(e){if(o)throw e}},abort:function(){o&&o()}}}),S.ajaxPrefilter(function(e){e.crossDomain&&(e.contents.script=!1)}),S.ajaxSetup({accepts:{script:"text/javascript, application/javascript, application/ecmascript, application/x-ecmascript"},contents:{script:/\b(?:java|ecma)script\b/},converters:{"text script":function(e){return S.globalEval(e),e}}}),S.ajaxPrefilter("script",function(e){void 0===e.cache&&(e.cache=!1),e.crossDomain&&(e.type="GET")}),S.ajaxTransport("script",function(n){var r,i;if(n.crossDomain||n.scriptAttrs)return{send:function(e,t){r=S("<script>").attr(n.scriptAttrs||{}).prop({charset:n.scriptCharset,src:n.url}).on("load error",i=function(e){r.remove(),i=null,e&&t("error"===e.type?404:200,e.type)}),E.head.appendChild(r[0])},abort:function(){i&&i()}}});var _t,zt=[],Ut=/(=)\?(?=&|$)|\?\?/;S.ajaxSetup({jsonp:"callback",jsonpCallback:function(){var e=zt.pop()||S.expando+"_"+wt.guid++;return this[e]=!0,e}}),S.ajaxPrefilter("json jsonp",function(e,t,n){var r,i,o,a=!1!==e.jsonp&&(Ut.test(e.url)?"url":"string"==typeof e.data&&0===(e.contentType||"").indexOf("application/x-www-form-urlencoded")&&Ut.test(e.data)&&"data");if(a||"jsonp"===e.dataTypes[0])return r=e.jsonpCallback=m(e.jsonpCallback)?e.jsonpCallback():e.jsonpCallback,a?e[a]=e[a].replace(Ut,"$1"+r):!1!==e.jsonp&&(e.url+=(Tt.test(e.url)?"&":"?")+e.jsonp+"="+r),e.converters["script json"]=function(){return o||S.error(r+" was not called"),o[0]},e.dataTypes[0]="json",i=C[r],C[r]=function(){o=arguments},n.always(function(){void 0===i?S(C).removeProp(r):C[r]=i,e[r]&&(e.jsonpCallback=t.jsonpCallback,zt.push(r)),o&&m(i)&&i(o[0]),o=i=void 0}),"script"}),y.createHTMLDocument=((_t=E.implementation.createHTMLDocument("").body).innerHTML="<form></form><form></form>",2===_t.childNodes.length),S.parseHTML=function(e,t,n){return"string"!=typeof e?[]:("boolean"==typeof t&&(n=t,t=!1),t||(y.createHTMLDocument?((r=(t=E.implementation.createHTMLDocument("")).createElement("base")).href=E.location.href,t.head.appendChild(r)):t=E),o=!n&&[],(i=N.exec(e))?[t.createElement(i[1])]:(i=xe([e],t,o),o&&o.length&&S(o).remove(),S.merge([],i.childNodes)));var r,i,o},S.fn.load=function(e,t,n){var r,i,o,a=this,s=e.indexOf(" ");return-1<s&&(r=ht(e.slice(s)),e=e.slice(0,s)),m(t)?(n=t,t=void 0):t&&"object"==typeof t&&(i="POST"),0<a.length&&S.ajax({url:e,type:i||"GET",dataType:"html",data:t}).done(function(e){o=arguments,a.html(r?S("<div>").append(S.parseHTML(e)).find(r):e)}).always(n&&function(e,t){a.each(function(){n.apply(this,o||[e.responseText,t,e])})}),this},S.expr.pseudos.animated=function(t){return S.grep(S.timers,function(e){return t===e.elem}).length},S.offset={setOffset:function(e,t,n){var r,i,o,a,s,u,l=S.css(e,"position"),c=S(e),f={};"static"===l&&(e.style.position="relative"),s=c.offset(),o=S.css(e,"top"),u=S.css(e,"left"),("absolute"===l||"fixed"===l)&&-1<(o+u).indexOf("auto")?(a=(r=c.position()).top,i=r.left):(a=parseFloat(o)||0,i=parseFloat(u)||0),m(t)&&(t=t.call(e,n,S.extend({},s))),null!=t.top&&(f.top=t.top-s.top+a),null!=t.left&&(f.left=t.left-s.left+i),"using"in t?t.using.call(e,f):c.css(f)}},S.fn.extend({offset:function(t){if(arguments.length)return void 0===t?this:this.each(function(e){S.offset.setOffset(this,t,e)});var e,n,r=this[0];return r?r.getClientRects().length?(e=r.getBoundingClientRect(),n=r.ownerDocument.defaultView,{top:e.top+n.pageYOffset,left:e.left+n.pageXOffset}):{top:0,left:0}:void 0},position:function(){if(this[0]){var e,t,n,r=this[0],i={top:0,left:0};if("fixed"===S.css(r,"position"))t=r.getBoundingClientRect();else{t=this.offset(),n=r.ownerDocument,e=r.offsetParent||n.documentElement;while(e&&(e===n.body||e===n.documentElement)&&"static"===S.css(e,"position"))e=e.parentNode;e&&e!==r&&1===e.nodeType&&((i=S(e).offset()).top+=S.css(e,"borderTopWidth",!0),i.left+=S.css(e,"borderLeftWidth",!0))}return{top:t.top-i.top-S.css(r,"marginTop",!0),left:t.left-i.left-S.css(r,"marginLeft",!0)}}},offsetParent:function(){return this.map(function(){var e=this.offsetParent;while(e&&"static"===S.css(e,"position"))e=e.offsetParent;return e||re})}}),S.each({scrollLeft:"pageXOffset",scrollTop:"pageYOffset"},function(t,i){var o="pageYOffset"===i;S.fn[t]=function(e){return $(this,function(e,t,n){var r;if(x(e)?r=e:9===e.nodeType&&(r=e.defaultView),void 0===n)return r?r[i]:e[t];r?r.scrollTo(o?r.pageXOffset:n,o?n:r.pageYOffset):e[t]=n},t,e,arguments.length)}}),S.each(["top","left"],function(e,n){S.cssHooks[n]=Fe(y.pixelPosition,function(e,t){if(t)return t=We(e,n),Pe.test(t)?S(e).position()[n]+"px":t})}),S.each({Height:"height",Width:"width"},function(a,s){S.each({padding:"inner"+a,content:s,"":"outer"+a},function(r,o){S.fn[o]=function(e,t){var n=arguments.length&&(r||"boolean"!=typeof e),i=r||(!0===e||!0===t?"margin":"border");return $(this,function(e,t,n){var r;return x(e)?0===o.indexOf("outer")?e["inner"+a]:e.document.documentElement["client"+a]:9===e.nodeType?(r=e.documentElement,Math.max(e.body["scroll"+a],r["scroll"+a],e.body["offset"+a],r["offset"+a],r["client"+a])):void 0===n?S.css(e,t,i):S.style(e,t,n,i)},s,n?e:void 0,n)}})}),S.each(["ajaxStart","ajaxStop","ajaxComplete","ajaxError","ajaxSuccess","ajaxSend"],function(e,t){S.fn[t]=function(e){return this.on(t,e)}}),S.fn.extend({bind:function(e,t,n){return this.on(e,null,t,n)},unbind:function(e,t){return this.off(e,null,t)},delegate:function(e,t,n,r){return this.on(t,e,n,r)},undelegate:function(e,t,n){return 1===arguments.length?this.off(e,"**"):this.off(t,e||"**",n)},hover:function(e,t){return this.mouseenter(e).mouseleave(t||e)}}),S.each("blur focus focusin focusout resize scroll click dblclick mousedown mouseup mousemove mouseover mouseout mouseenter mouseleave change select submit keydown keypress keyup contextmenu".split(" "),function(e,n){S.fn[n]=function(e,t){return 0<arguments.length?this.on(n,null,e,t):this.trigger(n)}});var Xt=/^[\s\uFEFF\xA0]+|[\s\uFEFF\xA0]+$/g;S.proxy=function(e,t){var n,r,i;if("string"==typeof t&&(n=e[t],t=e,e=n),m(e))return r=s.call(arguments,2),(i=function(){return e.apply(t||this,r.concat(s.call(arguments)))}).guid=e.guid=e.guid||S.guid++,i},S.holdReady=function(e){e?S.readyWait++:S.ready(!0)},S.isArray=Array.isArray,S.parseJSON=JSON.parse,S.nodeName=A,S.isFunction=m,S.isWindow=x,S.camelCase=X,S.type=w,S.now=Date.now,S.isNumeric=function(e){var t=S.type(e);return("number"===t||"string"===t)&&!isNaN(e-parseFloat(e))},S.trim=function(e){return null==e?"":(e+"").replace(Xt,"")},"function"==typeof define&&define.amd&&define("jquery",[],function(){return S});var Vt=C.jQuery,Gt=C.$;return S.noConflict=function(e){return C.$===S&&(C.$=Gt),e&&C.jQuery===S&&(C.jQuery=Vt),S},"undefined"==typeof e&&(C.jQuery=C.$=S),S});
"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="data:text/css,html%7Bfont%2Dfamily%3Asans%2Dserif%3B%2Dwebkit%2Dtext%2Dsize%2Dadjust%3A100%25%3B%2Dms%2Dtext%2Dsize%2Dadjust%3A100%25%7Dbody%7Bmargin%3A0%7Darticle%2Caside%2Cdetails%2Cfigcaption%2Cfigure%2Cfooter%2Cheader%2Chgroup%2Cmain%2Cmenu%2Cnav%2Csection%2Csummary%7Bdisplay%3Ablock%7Daudio%2Ccanvas%2Cprogress%2Cvideo%7Bdisplay%3Ainline%2Dblock%3Bvertical%2Dalign%3Abaseline%7Daudio%3Anot%28%5Bcontrols%5D%29%7Bdisplay%3Anone%3Bheight%3A0%7D%5Bhidden%5D%2Ctemplate%7Bdisplay%3Anone%7Da%7Bbackground%2Dcolor%3Atransparent%7Da%3Aactive%2Ca%3Ahover%7Boutline%3A0%7Dabbr%5Btitle%5D%7Bborder%2Dbottom%3A1px%20dotted%7Db%2Cstrong%7Bfont%2Dweight%3A700%7Ddfn%7Bfont%2Dstyle%3Aitalic%7Dh1%7Bmargin%3A%2E67em%200%3Bfont%2Dsize%3A2em%7Dmark%7Bcolor%3A%23000%3Bbackground%3A%23ff0%7Dsmall%7Bfont%2Dsize%3A80%25%7Dsub%2Csup%7Bposition%3Arelative%3Bfont%2Dsize%3A75%25%3Bline%2Dheight%3A0%3Bvertical%2Dalign%3Abaseline%7Dsup%7Btop%3A%2D%2E5em%7Dsub%7Bbottom%3A%2D%2E25em%7Dimg%7Bborder%3A0%7Dsvg%3Anot%28%3Aroot%29%7Boverflow%3Ahidden%7Dfigure%7Bmargin%3A1em%2040px%7Dhr%7Bheight%3A0%3B%2Dwebkit%2Dbox%2Dsizing%3Acontent%2Dbox%3B%2Dmoz%2Dbox%2Dsizing%3Acontent%2Dbox%3Bbox%2Dsizing%3Acontent%2Dbox%7Dpre%7Boverflow%3Aauto%7Dcode%2Ckbd%2Cpre%2Csamp%7Bfont%2Dfamily%3Amonospace%2Cmonospace%3Bfont%2Dsize%3A1em%7Dbutton%2Cinput%2Coptgroup%2Cselect%2Ctextarea%7Bmargin%3A0%3Bfont%3Ainherit%3Bcolor%3Ainherit%7Dbutton%7Boverflow%3Avisible%7Dbutton%2Cselect%7Btext%2Dtransform%3Anone%7Dbutton%2Chtml%20input%5Btype%3Dbutton%5D%2Cinput%5Btype%3Dreset%5D%2Cinput%5Btype%3Dsubmit%5D%7B%2Dwebkit%2Dappearance%3Abutton%3Bcursor%3Apointer%7Dbutton%5Bdisabled%5D%2Chtml%20input%5Bdisabled%5D%7Bcursor%3Adefault%7Dbutton%3A%3A%2Dmoz%2Dfocus%2Dinner%2Cinput%3A%3A%2Dmoz%2Dfocus%2Dinner%7Bpadding%3A0%3Bborder%3A0%7Dinput%7Bline%2Dheight%3Anormal%7Dinput%5Btype%3Dcheckbox%5D%2Cinput%5Btype%3Dradio%5D%7B%2Dwebkit%2Dbox%2Dsizing%3Aborder%2Dbox%3B%2Dmoz%2Dbox%2Dsizing%3Aborder%2Dbox%3Bbox%2Dsizing%3Aborder%2Dbox%3Bpadding%3A0%7Dinput%5Btype%3Dnumber%5D%3A%3A%2Dwebkit%2Dinner%2Dspin%2Dbutton%2Cinput%5Btype%3Dnumber%5D%3A%3A%2Dwebkit%2Douter%2Dspin%2Dbutton%7Bheight%3Aauto%7Dinput%5Btype%3Dsearch%5D%7B%2Dwebkit%2Dbox%2Dsizing%3Acontent%2Dbox%3B%2Dmoz%2Dbox%2Dsizing%3Acontent%2Dbox%3Bbox%2Dsizing%3Acontent%2Dbox%3B%2Dwebkit%2Dappearance%3Atextfield%7Dinput%5Btype%3Dsearch%5D%3A%3A%2Dwebkit%2Dsearch%2Dcancel%2Dbutton%2Cinput%5Btype%3Dsearch%5D%3A%3A%2Dwebkit%2Dsearch%2Ddecoration%7B%2Dwebkit%2Dappearance%3Anone%7Dfieldset%7Bpadding%3A%2E35em%20%2E625em%20%2E75em%3Bmargin%3A0%202px%3Bborder%3A1px%20solid%20silver%7Dlegend%7Bpadding%3A0%3Bborder%3A0%7Dtextarea%7Boverflow%3Aauto%7Doptgroup%7Bfont%2Dweight%3A700%7Dtable%7Bborder%2Dspacing%3A0%3Bborder%2Dcollapse%3Acollapse%7Dtd%2Cth%7Bpadding%3A0%7D%40media%20print%7B%2A%2C%3Aafter%2C%3Abefore%7Bcolor%3A%23000%21important%3Btext%2Dshadow%3Anone%21important%3Bbackground%3A0%200%21important%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%21important%3Bbox%2Dshadow%3Anone%21important%7Da%2Ca%3Avisited%7Btext%2Ddecoration%3Aunderline%7Da%5Bhref%5D%3Aafter%7Bcontent%3A%22%20%28%22%20attr%28href%29%20%22%29%22%7Dabbr%5Btitle%5D%3Aafter%7Bcontent%3A%22%20%28%22%20attr%28title%29%20%22%29%22%7Da%5Bhref%5E%3D%22javascript%3A%22%5D%3Aafter%2Ca%5Bhref%5E%3D%22%23%22%5D%3Aafter%7Bcontent%3A%22%22%7Dblockquote%2Cpre%7Bborder%3A1px%20solid%20%23999%3Bpage%2Dbreak%2Dinside%3Aavoid%7Dthead%7Bdisplay%3Atable%2Dheader%2Dgroup%7Dimg%2Ctr%7Bpage%2Dbreak%2Dinside%3Aavoid%7Dimg%7Bmax%2Dwidth%3A100%25%21important%7Dh2%2Ch3%2Cp%7Borphans%3A3%3Bwidows%3A3%7Dh2%2Ch3%7Bpage%2Dbreak%2Dafter%3Aavoid%7D%2Enavbar%7Bdisplay%3Anone%7D%2Ebtn%3E%2Ecaret%2C%2Edropup%3E%2Ebtn%3E%2Ecaret%7Bborder%2Dtop%2Dcolor%3A%23000%21important%7D%2Elabel%7Bborder%3A1px%20solid%20%23000%7D%2Etable%7Bborder%2Dcollapse%3Acollapse%21important%7D%2Etable%20td%2C%2Etable%20th%7Bbackground%2Dcolor%3A%23fff%21important%7D%2Etable%2Dbordered%20td%2C%2Etable%2Dbordered%20th%7Bborder%3A1px%20solid%20%23ddd%21important%7D%7D%40font%2Dface%7Bfont%2Dfamily%3A%27Glyphicons%20Halflings%27%3Bsrc%3Aurl%28data%3Aapplication%2Fvnd%2Ems%2Dfontobject%3Bbase64%2Cn04AAEFNAAACAAIABAAAAAAABQAAAAAAAAABAJABAAAEAExQAAAAAAAAAAIAAAAAAAAAAAEAAAAAAAAAJxJ%2FLAAAAAAAAAAAAAAAAAAAAAAAACgARwBMAFkAUABIAEkAQwBPAE4AUwAgAEgAYQBsAGYAbABpAG4AZwBzAAAADgBSAGUAZwB1AGwAYQByAAAAeABWAGUAcgBzAGkAbwBuACAAMQAuADAAMAA5ADsAUABTACAAMAAwADEALgAwADAAOQA7AGgAbwB0AGMAbwBuAHYAIAAxAC4AMAAuADcAMAA7AG0AYQBrAGUAbwB0AGYALgBsAGkAYgAyAC4ANQAuADUAOAAzADIAOQAAADgARwBMAFkAUABIAEkAQwBPAE4AUwAgAEgAYQBsAGYAbABpAG4AZwBzACAAUgBlAGcAdQBsAGEAcgAAAAAAQlNHUAAAAAAAAAAAAAAAAAAAAAADAKncAE0TAE0ZAEbuFM3pjM%2FSEdmjKHUbyow8ATBE40IvWA3vTu8LiABDQ%2BpexwUMcm1SMnNryctQSiI1K5ZnbOlXKmnVV5YvRe6RnNMFNCOs1KNVpn6yZhCJkRtVRNzEufeIq7HgSrcx4S8h%2Fv4vnrrKc6oCNxmSk2uKlZQHBii6iKFoH0746ThvkO1kJHlxjrkxs%2BLWORaDQBEtiYJIR5IB9Bi1UyL4Rmr0BNigNkMzlKQmnofBHviqVzUxwdMb3NdCn69hy%2BpRYVKGVS%2F1tnsqv4LL7wCCPZZAZPT4aCShHjHJVNuXbmMrY5LeQaGnvAkXlVrJgKRAUdFjrWEah9XebPeQMj7KS7DIBAFt8ycgC5PLGUOHSE3ErGZCiViNLL5ZARfywnCoZaKQCu6NuFX42AEeKtKUGnr%2FCm2Cy8tpFhBPMW5Fxi4Qm4TkDWh4IWFDClhU2hRWosUWqcKLlgyXB%2BlSHaWaHiWlBAR8SeSgSPCQxdVQgzUixWKSTrIQEbU94viDctkvX%2BVSjJuUmV8L4CXShI11esnp0pjWNZIyxKHS4wVQ2ime1P4RnhvGw0aDN1OLAXGERsB7buFpFGGBAre4QEQR0HOIO5oYH305G%2BKspT%2FFupEGGafCCwxSe6ZUa%2B073rXHnNdVXE6eWvibUS27XtRzkH838mYLMBmYysZTM0EM3A1fbpCBYFccN1B%2FEnCYu%2FTgCGmr7bMh8GfYL%2BBfcLvB0gRagC09w9elfldaIy%2FhNCBLRgBgtCC7jAF63wLSMAfbfAlEggYU0bUA7ACCJmTDpEmJtI78w4%2FBO7dN7JR7J7ZvbYaUbaILSQsRBiF3HGk5fEg6p9unwLvn98r%2BvnsV%2B372uf1xBLq4qU%2F45fTuqaAP%2BpssmCCCTF0mhEow8ZXZOS8D7Q85JsxZ%2BAzok7B7O%2Ff6J8AzYBySZQB%2FQHYUSA%2BEeQhEWiS6AIQzgcsDiER4MjgMBAWDV4AgQ3g1eBgIdweCQmCjJEMkJ%2BPKRWyFHHmg1Wi%2F6xzUgA0LREoKJChwnQa9B%2B5RQZRB3IlBlkAnxyQNaANwHMowzlYSMCBgnbpzvqpl0iTJNCQidDI9ZrSYNIRBhHtUa5YHMHxyGEik9hDE0AKj72AbTCaxtHPUaKZdAZSnQTyjGqGLsmBStCejApUhg4uBMU6mATujEl%2BKdDPbI6Ag4vLr%2BhjY6lbjBeoLKnZl0UZgRX8gTySOeynZVz1wOq7e1hFGYIq%2BMhrGxDLak0PrwYzSXtcuyhXEhwOYofiW%2BEcI%2Fjw8P6IY6ed%2BetAbuqKp5QIapT77LnAe505lMuqL79a0ut4rWexzFttsOsLDy7zvtQzcq3U1qabe7tB0wHWVXji%2BzDbo8x8HyIRUbXnwUcklFv51fvTymiV%2BMXLSmGH9d9%2BaXpD5X6lao41anWGig7IwIdnoBY2ht%2FpO9mClLo4NdXHAsefqWUKlXJkbqPOFhMoR4aiA1BXqhRNbB2Xwi%2B7u%2FjpAoOpKJ0UX24EsrzMfHXViakCNcKjBxuQX8BO0ZqjJ3xXzf%2B61t2VXOSgJ8xu65QKgtN6FibPmPYsXbJRHHqbgATcSZxBqGiDiU4NNNsYBsKD0MIP%2FOfKnlk%2FLkaid%2FO2NbKeuQrwOB2Gq3YHyr6ALgzym5wIBnsdC1ZkoBFZSQXChZvlesPqvK2c5oHHT3Q65jYpNxnQcGF0EHbvYqoFw60WNlXIHQF2HQB7zD6lWjZ9rVqUKBXUT6hrkZOle0RFYII0V5ZYGl1JAP0Ud1fZZMvSomBzJ710j4Me8mjQDwEre5Uv2wQfk1ifDwb5ksuJQQ3xt423lbuQjvoIQByQrNDh1JxGFkOdlJvu%2FgFtuW0wR4cgd%2BZKesSV7QkNE2kw6AV4hoIuC02LGmTomyf8PiO6CZzOTLTPQ%2BHW06H%2Btx%2BbQ8LmDYg1pTFrp2oJXgkZTyeRJZM0C8aE2LpFrNVDuhARsN543%2FFV6klQ6Tv1OoZGXLv0igKrl%2FCmJxRmX7JJbJ998VSIPQRyDBICzl4JJlYHbdql30NvYcOuZ7a10uWRrgoieOdgIm4rlq6vNOQBuqESLbXG5lzdJGHw2m0sDYmODXbYGTfSTGRKpssTO95fothJCjUGQgEL4yKoGAF%2F0SrpUDNn8CBgBcSDQByAeNkCXp4S4Ro2Xh4OeaGRgR66PVOsU8bc6TR5%2FxTcn4IVMLOkXSWiXxkZQCbvKfmoAvQaKjO3EDKwkwqHChCDEM5loQRPd5ACBki1TjF772oaQhQbQ5C0lcWXPFOzrfsDGUXGrpxasbG4iab6eByaQkQfm0VFlP0ZsDkvvqCL6QXMUwCjdMx1ZOyKhTJ7a1GWAdOUcJ8RSejxNVyGs31OKMyRyBVoZFjqIkmKlLQ5eHMeEL4MkUf23cQ%2F1SgRCJ1dk4UdBT7OoyuNgLs0oCd8RnrEIb6QdMxT2QjD4zMrJkfgx5aDMcA4orsTtKCqWb%2FVeyceqa5OGSmB28YwH4rFbkQaLoUN8OQQYnD3w2eXpI4ScQfbCUZiJ4yMOIKLyyTc7BQ4uXUw6Ee6%2FxM%2B4Y67ngNBknxIPwuppgIhFcwJyr6EIj%2BLzNj%2FmfR2vhhRlx0BILZoAYruF0caWQ7YxO66UmeguDREAFHYuC7HJviRgVO6ruJH59h%2FC%2FPkgSle8xNzZJULLWq9JMDTE2fjGE146a1Us6PZDGYle6ldWRqn%2FpdpgHKNGrGIdkRK%2BKPETT9nKT6kLyDI8xd9A1FgWmXWRAIHwZ37WyZHOVyCadJEmMVz0MadMjDrPho%2BEIochkVC2xgGiwwsQ6DMv2P7UXqT4x7CdcYGId2BJQQa85EQKmCmwcRejQ9Bm4oATENFPkxPXILHpMPUyWTI5rjNOsIlmEeMbcOCEqInpXACYQ9DDxmFo9vcmsDblcMtg4tqBerNngkIKaFJmrQAPnq1dEzsMXcwjcHdfdCibcAxxA%2Bq%2Fj9m3LM%2FO7WJka4tSidVCjsvo2lQ%2F2ewyoYyXwAYyr2PlRoR5MpgVmSUIrM3PQxXPbgjBOaDQFIyFMJvx3Pc5RSYj12ySVF9fwFPQu2e2KWVoL9q3Ayv3IzpGHUdvdPdrNUdicjsTQ2ISy7QU3DrEytIjvbzJnAkmANXjAFERA0MUoPF3%2F5KFmW14bBNOhwircYgMqoDpUMcDtCmBE82QM2YtdjVLB4kBuKho%2FbcwQdeboqfQartuU3CsCf%2BcXkgYAqp%2F0Ee3RorAZt0AvvOCSI4JICIlGlsV0bsSid%2FNIEALAAzb6HAgyWHBps6xAOwkJIGcB82CxRQq4sJf3FzA70A%2BTRqcqjEMETCoez3mkPcpnoALs0ugJY8kQwrC%2BJE5ik3w9rzrvDRjAQnqgEVvdGrNwlanR0SOKWzxOJOvLJhcd8Cl4AshACUkv9czdMkJCVQSQhp6kp7StAlpVRpK0t0SW6LHeBJnE2QchB5Ccu8kxRghZXGIgZIiSj7gEKMJDClcnX6hgoqJMwiQDigIXg3ioFLCgDgjPtYHYpsF5EiA4kcnN18MZtOrY866dEQAb0FB34OGKHGZQjwW%2FWDHA60cYFaI%2FPjpzquUqdaYGcIq%2BmLez3WLFFCtNBN2QJcrlcoELgiPku5R5dSlJFaCEqEZle1AQzAKC%2B1SotMcBNyQUFuRHRF6OlimSBgjZeTBCwLyc6A%2BP%2FoFRchXTz5ADknYJHxzrJ5pGuIKRQISU6WyKTBBjD8WozmVYWIsto1AS5rxzKlvJu4E%2FvwOiKxRtCWsDM%2BeTHUrmwrCK5BIfMzGkD%2B0Fk5LzBs0jMYXktNDblB06LMNJ09U8pzSLmo14MS0OMjcdrZ31pyQqxJJpRImlSvfYAK8inkYU52QY2FPEVsjoWewpwhRp5yAuNpkqhdb7ku9Seefl2D0B8SMTFD90xi4CSOwwZy9IKkpMtI3FmFUg3%2FkFutpQGNc3pCR7gvC4sgwbupDu3DyEN%2BW6YGLNM21jpB49irxy9BSlHrVDlnihGKHwPrbVFtc%2Bh1rVQKZduxIyojccZIIcOCmhEnC7UkY68WXKQgLi2JCDQkQWJRQuk60hZp0D3rtCTINSeY9Ej2kIKYfGxwOs4j9qMM7fYZiipzgcf7TamnehqdhsiMiCawXnz4xAbyCkLAx5EGbo3Ax1u3dUIKnTxIaxwQTHehPl3V491H0%2BbC5zgpGz7Io%2BmjdhKlPJ01EeMpM7UsRJMi1nGjmJg35i6bQBAAxjO%2FENJubU2mg3ONySEoWklCwdABETcs7ck3jgiuU9pcKKpbgn%2B3YlzV1FzIkB6pmEDOSSyDfPPlQskznctFji0kpgZjW5RZe6x9kYT4KJcXg0bNiCyif%2BpZACCyRMmYsfiKmN9tSO65F0R2OO6ytlEhY5Sj6uRKfFxw0ijJaAx%2Fk3QgnAFSq27%2F2i4GEBA%2BUvTJKK%2F9eISNvG46Em5RZfjTYLdeD8kdXHyrwId%2FDQZUaMCY4gGbke2C8vfjgV%2FY9kkRQOJIn%2FxM9INZSpiBnqX0Q9GlQPpPKAyO5y%2BW5NMPSRdBCUlmuxl40ZfMCnf2Cp044uI9WLFtCi4YVxKjuRCOBWIb4XbIsGdbo4qtMQnNOQz4XDSui7W%2FN6l54qOynCqD3DpWQ%2BmpD7C40D8BZEWGJX3tlAaZBMj1yjvDYKwCJBa201u6nBKE5UE%2B7QSEhCwrXfbRZylAaAkplhBWX50dumrElePyNMRYUrC99UmcSSNgImhFhDI4BXjMtiqkgizUGCrZ8iwFxU6fQ8GEHCFdLewwxYWxgScAYMdMLmcZR6b7rZl95eQVDGVoUKcRMM1ixXQtXNkBETZkVVPg8LoSrdetHzkuM7DjZRHP02tCxA1fmkXKF3VzfN1pc1cv%2F8lbTIkkYpqKM9VOhp65ktYk%2BQ46myFWBapDfyWUCnsnI00QTBQmuFjMZTcd0V2NQ768Fhpby04k2IzNR1wKabuGJqYWwSly6ocMFGTeeI%2BejsWDYgEvr66QgqdcIbFYDNgsm0x9UHY6SCd5%2B7tpsLpKdvhahIDyYmEJQCqMqtCF6UlrE5GXRmbu%2Bvtm3BFSxI6ND6UxIE7GsGMgWqghXxSnaRJuGFveTcK5ZVSPJyjUxe1dKgI6kNF7EZhIZs8y8FVqwEfbM0Xk2ltORVDKZZM40SD3qQoQe0orJEKwPfZwm3YPqwixhUMOndis6MhbmfvLBKjC8sKKIZKbJk8L11oNkCQzCgvjhyyEiQSuJcgCQSG4Mocfgc0Hkwcjal1UNgP0CBPikYqBIk9tONv4kLtBswH07vUCjEaHiFGlLf8MgXKzSgjp2HolRRccAOh0ILHz9qlGgIFkwAnzHJRjWFhlA7ROwINyB5HFj59PRZHFor6voq7l23EPNRwdWhgawqbivLSjRA4htEYUFkjESu67icTg5S0aW1sOkCiIysfJ9UnIWevOOLGpepcBxy1wEhd2WI3AZg7sr9WBmHWyasxMcvY%2FiOmsLtHSWNUWEGk9hScMPShasUA1AcHOtRZlqMeQ0OzYS9vQvYUjOLrzP07BUAFikcJNMi7gIxEw4pL1G54TcmmmoAQ5s7TGWErJZ2Io4yQ0ljRYhL8H5e62oDtLF8aDpnIvZ5R3GWJyAugdiiJW9hQAVTsnCBHhwu7rkBlBX6r3b7ejEY0k5GGeyKv66v%2B6dg7mcJTrWHbtMywbedYqCQ0FPwoytmSWsL8WTtChZCKKzEF7vP6De4x2BJkkniMgSdWhbeBSLtJZR9CTHetK1xb34AYIJ37OegYIoPVbXgJ%2FqDQK%2BbfCtxQRVKQu77WzOoM6SGL7MaZwCGJVk46aImai9fmam%2BWpHG%2B0BtQPWUgZ7RIAlPq6lkECUhZQ2gqWkMYKcYMYaIc4gYCDFHYa2d1nzp3%2BJ1eCBay8IYZ0wQRKGAqvCuZ%2FUgbQPyllosq%2BXtfKIZOzmeJqRazpmmoP%2F76YfkjzV2NlXTDSBYB04SVlNQsFTbGPk1t%2FI4Jktu0XSgifO2ozFOiwd%2F0SssJDn0dn4xqk4GDTTKX73%2FwQyBLdqgJ%2BWx6AQaba3BA9CKEzjtQYIfAsiYamapq80LAamYjinlKXUkxdpIDk0puXUEYzSalfRibAeDAKpNiqQ0FTwoxuGYzRnisyTotdVTclis1LHRQCy%2FqqL8oUaQzWRxilq5Mi0IJGtMY02cGLD69vGjkj3p6pGePKI8bkBv5evq8SjjyU04vJR2cQXQwSJyoinDsUJHCQ50jrFTT7yRdbdYQMB3MYCb6uBzJ9ewhXYPAIZSXfeEQBZZ3GPN3Nbhh%2FwkvAJLXnQMdi5NYYZ5GHE400GS5rXkOZSQsdZgIbzRnF9ueLnsfQ47wHAsirITnTlkCcuWWIUhJSbpM3wWhXNHvt2xUsKKMpdBSbJnBMcihkoDqAd1Zml%2FR4yrzow1Q2A5G%2Bkzo%2FRhRxQS2lCSDRV8LlYLBOOoo1bF4jwJAwKMK1tWLHlu9i0j4Ig8qVm6wE1DxXwAwQwsaBWUg2pOOol2dHxyt6npwJEdLDDVYyRc2D0HbcbLUJQj8gPevQBUBOUHXPrsAPBERICpnYESeu2OHotpXQxRGlCCtLdIsu23MhZVEoJg8Qumj%2FUMMc34IBqTKLDTp76WzL%2FdMjCxK7MjhiGjeYAC%2Fkj%2FjY%2FRde7hpSM1xChrog6yZ7OWTuD56xBJnGFE%2BpT2ElSyCnJcwVzCjkqeNLfMEJqKW0G7OFIp0G%2B9mh50I9o8k1tpCY0xYqFNIALgIfc2me4n1bmJnRZ89oepgLPT0NTMLNZsvSCZAc3TXaNB07vail36%2FdBySis4m9%2FDR8izaLJW6bWCkVgm5T%2Bius3ZXq4xI%2BGnbveLbdRwF2mNtsrE0JjYc1AXknCOrLSu7Te%2Fr4dPYMCl5qtiHNTn%2BTPbh1jCBHH%2BdMJNhwNgs3nT%2BOhQoQ0vYif56BMG6WowAcHR3DjQolxLzyVekHj00PBAaW7IIAF1EF%2BuRIWyXjQMAs2chdpaKPNaB%2BkSezYt0%2BCA04sOg5vx8Fr7Ofa9sUv87h7SLAUFSzbetCCZ9pmyLt6l6%2FTzoA1%2FZBG9bIUVHLAbi%2FkdBFgYGyGwRQGBpkqCEg2ah9UD6EedEcEL3j4y0BQQCiExEnocA3SZboh%2Bepgd3YsOkHskZwPuQ5OoyA0fTA5AXrHcUOQF%2BzkJHIA7PwCDk1gGVmGUZSSoPhNf%2BTklauz98QofOlCIQ%2FtCD4dosHYPqtPCXB3agggQQIqQJsSkB%2Bqn0rkQ1toJjON%2FOtCIB9RYv3PqRA4C4U68ZMlZn6BdgEvi2ziU%2BTQ6NIw3ej%2BAtDwMGEZk7e2IjxUWKdAxyaw9OCwSmeADTPPleyk6UhGDNXQb%2B%2BW6Uk4q6F7%2Frg6WVTo82IoCxSIsFDrav4EPHphD3u4hR53WKVvYZUwNCCeM4PMBWzK%2BEfIthZOkuAwPo5C5jgoZgn6dUdvx5rIDmd58cXXdKNfw3l%2BwM2UjgrDJeQHhbD7HW2QDoZMCujgIUkk5Fg8VCsdyjOtnGRx8wgKRPZN5dR0zPUyfGZFVihbFRniXZFOZGKPnEQzU3AnD1KfR6weHW2XS6KbPJxUkOTZsAB9vTVp3Le1F8q5l%2BDMcLiIq78jxAImD2pGFw0VHfRatScGlK6SMu8leTmhUSMy8Uhdd6xBiH3Gdman4tjQGLboJfqz6fL2WKHTmrfsKZRYX6BTDjDldKMosaSTLdQS7oDisJNqAUhw1PfTlnacCO8vl8706Km1FROgLDmudzxg%2BEWTiArtHgLsRrAXYWdB0NmToNCJdKm0KWycZQqb%2BMw76Qy29iQ5up%2FX7oyw8QZ75kP5F6iJAJz6KCmqxz8fEa%2FxnsMYcIO%2FvEkGRuMckhr4rIeLrKaXnmIzlNLxbFspOphkcnJdnz%2FChp%2FVlpj2P7jJQmQRwGnltkTV5dbF9fE3%2FfxoSqTROgq9wFUlbuYzYcasE0ouzBo%2BdDCDzxKAfhbAZYxQiHrLzV2iVexnDX%2FQnT1fsT%2Fxuhu1ui5qIytgbGmRoQkeQooO8eJNNZsf0iALur8QxZFH0nCMnjerYQqG1pIfjyVZWxhVRznmmfLG00BcBWJE6hzQWRyFknuJnXuk8A5FRDCulwrWASSNoBtR%2BCtGdkPwYN2o7DOw%2FVGlCZPusRBFXODQdUM5zeHDIVuAJBLqbO%2Ff9Qua%2BpDqEPk230Sob9lEZ8BHiCorjVghuI0lI4JDgHGRDD%2FprQ84B1pVGkIpVUAHCG%2Biz3Bn3qm2AVrYcYWhock4jso5%2BJ7HfHVj4WMIQdGctq3psBCVVzupQOEioBGA2Bk%2BUILT7%2BVoX5mdxxA5fS42gISQVi%2FHTzrgMxu0fY6hE1ocUwwbsbWcezrY2n6S8%2F6cxXkOH4prpmPuFoikTzY7T85C4T2XYlbxLglSv2uLCgFv8Quk%2FwdesUdWPeHYIH0R729JIisN9Apdd4eB10aqwXrPt%2BSu9mA8k8n1sjMwnfsfF2j3jMUzXepSHmZ%2FBfqXvzgUNQQWOXO8YEuFBh4QTYCkOAPxywpYu1VxiDyJmKVcmJPGWk%2Fgc3Pov02StyYDahwmzw3E1gYC9wkupyWfDqDSUMpCTH5e5N8B%2F%2FlHiMuIkTNw4USHrJU67bjXGqNav6PBuQSoqTxc8avHoGmvqNtXzIaoyMIQIiiUHIM64cXieouplhNYln7qgc4wBVAYR104kO%2BCvKqsg4yIUlFNThVUAKZxZt1XA34h3TCUUiXVkZ0w8Hh2R0Z5L0b4LZvPd%2Fp1gi%2F07h8qfwHrByuSxglc9cI4QIg2oqvC%2Fqm0i7tjPLTgDhoWTAKDO2ONW5oe%2B%2FeKB9vZB8K6C25yCZ9RFVMnb6NRdRjyVK57CHHSkJBfnM2%2Fj4ODUwRkqrtBBCrDsDpt8jhZdXoy%2F1BCqw3sSGhgGGy0a5Jw6BP%2FTExoCmNFYjZl248A0osgPyGEmRA%2BfAsqPVaNAfytu0vuQJ7rk3J4kTDTR2AlCHJ5cls26opZM4w3jMULh2YXKpcqGBtuleAlOZnaZGbD6DHzMd6i2oFeJ8z9XYmalg1Szd%2FocZDc1C7Y6vcALJz2lYnTXiWEr2wawtoR4g3jvWUU2Ngjd1cewtFzEvM1NiHZPeLlIXFbBPawxNgMwwAlyNSuGF3zizVeOoC9bag1qRAQKQE%2FEZBWC2J8mnXAN2aTBboZ7HewnObE8CwROudZHmUM5oZ%2FUgd%2FJZQK8lvAm43uDRAbyW8gZ%2BZGq0EVerVGUKUSm%2FIdn8AQHdR4m7bue88WBwft9mSCeMOt1ncBwziOmJYI2ZR7ewNMPiCugmSsE4EyQ%2BQATJG6qORMGd4snEzc6B4shPIo4G1T7PgSm8PY5eUkPdF8JZ0VBtadbHXoJgnEhZQaODPj2gpODKJY5Yp4DOsLBFxWbvXN755KWylJm%2BoOd4zEL9Hpubuy2gyyfxh8oEfFutnYWdfB8PdESLWYvSqbElP9qo3u6KTmkhoacDauMNNjj0oy40DFV7Ql0aZj77xfGl7TJNHnIwgqOkenruYYNo6h724%2BzUQ7%2BvkCpZB%2BpGA562hYQiDxHVWOq0oDQl%2FQsoiY%2BcuI7iWq%2FZIBtHcXJ7kks%2Bh2fCNUPA82BzjnqktNts%2BRLdk1VSu%2BtqEn7QZCCsvEqk6FkfiOYkrsw092J8jsfIuEKypNjLxrKA9kiA19mxBD2suxQKCzwXGws7kEJvlhUiV9tArLIdZW0IORcxEzdzKmjtFhsjKy%2F44XYXdI5noQoRcvjZ1RMPACRqYg2V1%2BOwOepcOknRLLFdYgTkT5UApt%2FJhLM3jeFYprZV%2BZow2g8fP%2BU68hkKFWJj2yBbKqsrp25xkZX1DAjUw52IMYWaOhab8Kp05VrdNftqwRrymWF4OQSjbdfzmRZirK8FMJELEgER2PHjEAN9pGfLhCUiTJFbd5LBkOBMaxLr%2FA1SY9dXFz4RjzoU9ExfJCmx%2FI9FKEGT3n2cmzl2X42L3Jh%2BAbQq6sA%2BSs1kitoa4TAYgKHaoybHUDJ51oETdeI%2F9ThSmjWGkyLi5QAGWhL0BG1UsTyRGRJOldKBrYJeB8ljLJHfATWTEQBXBDnQexOHTB%2BUn44zExFE4vLytcu5NwpWrUxO%2F0ZICUGM7hGABXym0V6ZvDST0E370St9MIWQOTWngeoQHUTdCJUP04spMBMS8LSker9cReVQkULFDIZDFPrhTzBl6sed9wcZQTbL%2BBDqMyaN3RJPh%2Fanbx%2BIv%2BqgQdAa3M9Z5JmvYlh4qop%2BHo1F1W5gbOE9YKLgAnWytXElU4G8GtW47lhgFE6gaSs%2Bgs37sFvi0PPVvA5dnCBgILTwoKd%2F%2BDoL9F6inlM7H4rOTzD79KJgKlZO%2FZgt22UsKhrAaXU5ZcLrAglTVKJEmNJvORGN1vqrcfSMizfpsgbIe9zno%2BgBoKVXgIL%2FVI8dB1O5o%2FR3Suez%2FgD7M781ShjKpIIORM%2FnxG%2BjjhhgPwsn2IoXsPGPqYHXA63zJ07M2GPEykQwJBYLK808qYxuIew4frk52nhCsnCYmXiR6CuapvE1IwRB4%2FQftDbEn%2BAucIr1oxrLabRj9q4ae0%2BfXkHnteAJwXRbVkR0mctVSwEbqhJiMSZUp9DNbEDMmjX22m3ABpkrPQQTP3S1sib5pD2VRKRd%2BeNAjLYyT0hGrdjWJZy24OYXRoWQAIhGBZRxuBFMjjZQhpgrWo8SiFYbojcHO8V5DyscJpLTHyx9Fimassyo5U6WNtquUMYgccaHY5amgR3PQzq3ToNM5ABnoB9kuxsebqmYZm0R9qxJbFXCQ1UPyFIbxoUraTJFDpCk0Wk9GaYJKz%2F6oHwEP0Q14lMtlddQsOAU9zlYdMVHiT7RQP3XCmWYDcHCGbVRHGnHuwzScA0BaSBOGkz3lM8CArjrBsyEoV6Ys4qgDK3ykQQPZ3hCRGNXQTNNXbEb6tDiTDLKOyMzRhCFT%2BmAUmiYbV3YQVqFVp9dorv%2BTsLeCykS2b5yyu8AV7IS9cxcL8z4Kfwp%2BxJyYLv1OsxQCZwTB4a8BZ%2F5EdxTBJthApqyfd9u3ifr%2FWILTqq5VqgwMT9SOxbSGWLQJUUWCVi4k9tho9nEsbUh7U6NUsLmkYFXOhZ0kmamaJLRNJzSj%2Fqn4Mso6zb6iLLBXoaZ6AqeWCjHQm2lztnejYYM2eubnpBdKVLORZhudH3JF1waBJKA9%2BW8EhMj3Kzf0L4vi4k6RoHh3Z5YgmSZmk6ns4fjScjAoL8GoOECgqgYEBYUGFVO4FUv4%2FYtowhEmTs0vrvlD%2FCrisnoBNDAcUi%2FteY7OctFlmARQzjOItrrlKuPO6E2Ox93L4O%2F4DcgV%2FdZ7qR3VBwVQxP1GCieA4RIpweYJ5FoYrHxqRBdJjnqbsikA2Ictbb8vE1GYIo9dacK0REgDX4smy6GAkxlH1yCGGsk%2BtgiDhNKuKu3yNrMdxafmKTF632F8Vx4BNK57GvlFisrkjN9WDAtjsWA0ENT2e2nETUb%2Fn7qwhvGnrHuf5bX6Vh%2Fn3xffU3PeHdR%2BFA92i6ufT3AlyAREoNDh6chiMWTvjKjHDeRhOa9YkOQRq1vQXEMppAQVwHCuIcV2g5rBn6GmZZpTR7vnSD6ZmhdSl176gqKTXu5E%2BYbfL0adwNtHP7dT7t7b46DVZIkzaRJOM%2BS6KcrzYVg%2BT3wSRFRQashjfU18NutrKa%2F7PXbtuJvpIjbgPeqd%2BpjmRw6YKpnANFSQcpzTZgpSNJ6J7uiagAbir%2F8tNXJ%2FOsOnRh6iuIexxrmkIneAgz8QoLmiaJ8sLQrELVK2yn3wOHp57BAZJhDZjTBzyoRAuuZ4eoxHruY1pSb7qq79cIeAdOwin4GdgMeIMHeG%2BFZWYaiUQQyC5b50zKjYw97dFjAeY2I4Bnl105Iku1y0lMA1ZHolLx19uZnRdILcXKlZGQx%2FGdEqSsMRU1BIrFqRcV1qQOOHyxOLXEGcbRtAEsuAC2V4K3p5mFJ22IDWaEkk9ttf5Izb2LkD1MnrSwztXmmD%2FQi%2FEmVEFBfiKGmftsPwVaIoZanlKndMZsIBOskFYpDOq3QUs9aSbAAtL5Dbokus2G4%2FasthNMK5UQKCOhU97oaOYNGsTah%2BjfCKsZnTRn5TbhFX8ghg8CBYt%2FBjeYYYUrtUZ5jVij%2Fop7V5SsbA4mYTOwZ46hqdpbB6Qvq3AS2HHNkC15pTDIcDNGsMPXaBidXYPHc6PJAkRh29Vx8KcgX46LoUQBhRM%2B3SW6Opll%2FwgxxsPgKJKzr5QCmwkUxNbeg6Wj34SUnEzOemSuvS2OetRCO8Tyy%2BQbSKVJcqkia%2BGvDefFwMOmgnD7h81TUtMn%2BmRpyJJ349HhAnoWFTejhpYTL9G8N2nVg1qkXBeoS9Nw2fB27t7trm7d%2FQK7Cr4uoCeOQ7%2F8JfKT77KiDzLImESHw%2F0wf73QeHu74hxv7uihi4fTX%2BXEwAyQG3264dwv17aJ5N335Vt9sdrAXhPOAv8JFvzqyYXwfx8WYJaef1gMl98JRFyl5Mv5Uo%2FoVH5ww5OzLFsiTPDns7fS6EURSSWd%2F92BxMYQ8sBaH%2Bj%2BwthQPdVgDGpTfi%2BJQIWMD8xKqULliRH01rTeyF8x8q%2FGBEEEBrAJMPf25UQwi0b8tmqRXY7kIvNkzrkvRWLnxoGYEJsz8u4oOyMp8cHyaybb1HdMCaLApUE%2B%2F7xLIZGP6H9xuSEXp1zLIdjk5nBaMuV%2FyTDRRP8Y2ww5RO6d2D94o%2B6ucWIqUAvgHIHXhZsmDhjVLczmZ3ca0Cb3PpKwt2UtHVQ0BgFJsqqTsnzZPlKahRUkEu4qmkJt%2Bkqdae76ViWe3STan69yaF9%2BfESD2lcQshLHWVu4ovItXxO69bqC5p1nZLvI8NdQB9s9UNaJGlQ5mG947ipdDA0eTIw%2FA1zEdjWquIsQXXGIVEH0thC5M%2BW9pZe7IhAVnPJkYCCXN5a32HjN6nsvokEqRS44tGIs7s2LVTvcrHAF%2BRVmI8L4HUYk4x%2B67AxSMJKqCg8zrGOgvK9kNMdDrNiUtSWuHFpC8%2Fp5qIQrEo%2FH%2B1l%2F0cAwQ2nKmpWxKcMIuHY44Y6DlkpO48tRuUGBWT0FyHwSKO72Ud%2BtJUfdaZ4CWNijzZtlRa8%2BCkmO%2FEwHYfPZFU%2FhzjFWH7vnzHRMo%2BaF9u8qHSAiEkA2HjoNQPEwHsDKOt6hOoK3Ce%2F%2B%2F9boMWDa44I6FrQhdgS7OnNaSzwxWKZMcyHi6LN4WC6sSj0qm2PSOGBTvDs%2FGWJS6SwEN%2FULwpb4LQo9fYjUfSXRwZkynUazlSpvX9e%2BG2zor8l%2BYaMxSEomDdLHGcD6YVQPegTaA74H8%2BV4WvJkFUrjMLGLlvSZQWvi8%2FQA7yzQ8GPno%2F%2F5SJHRP%2FOqKObPCo81s%2F%2B6WgLqykYpGAgQZhVDEBPXWgU%2FWzFZjKUhSFInufPRiMAUULC6T11yL45ZrRoB4DzOyJShKXaAJIBS9wzLYIoCEcJKQW8GVCx4fihqJ6mshBUXSw3wWVj3grrHQlGNGhIDNNzsxQ3M%2BGWn6ASobIWC%2BLbYOC6UpahVO13Zs2zOzZC8z7FmA05JhUGyBsF4tsG0drcggIFzgg%2Fkpf3%2BCnAXKiMgIE8Jk%2FMhpkc8DUJEUzDSnWlQFme3d0sHZDrg7LavtsEX3cHwjCYA17pMTfx8Ajw9hHscN67hyo%2BRJQ4458RmPywXykkVcW688oVUrQhahpPRvTWPnuI0B%2BSkQu7dCyvLRyFYlC1LG1gRCIvn3rwQeINzZQC2KXq31FaR9UmVV2QeGVqBHjmE%2BVMd3b1fhCynD0pQNhCG6%2FWCDbKPyE7NRQzL3BzQAJ0g09aUzcQA6mUp9iZFK6Sbp%2FYbHjo%2B%2B7%2FWj8S4YNa%2BZdqAw1hDrKWFXv9%2BzaXpf8ZTDSbiqsxnwN%2FCzK5tPkOr4tRh2kY3Bn9JtalbIOI4b3F7F1vPQMfoDcdxMS8CW9m%2FNCW%2FHILTUVWQIPiD0j1A6bo8vsv6P1hCESl2abrSJWDrq5sSzUpwoxaCU9FtJyYH4QFMxDBpkkBR6kn0LMPO%2B5EJ7Z6bCiRoPedRZ%2FP0SSdii7ZnPAtVwwHUidcdyspwncz5uq6vvm4IEDbJVLUFCn%2FLvIHfooUBTkFO130FC7CmmcrKdgDJcid9mvVzsDSibOoXtIf9k6ABle3PmIxejodc4aob0QKS432srrCMndbfD454q52V01G4q913mC5HOsTzWF4h2No1av1VbcUgWAqyoZl%2B11PoFYnNv2HwAODeNRkHj%2B8SF1fcvVBu6MrehHAZK1Gm69ICcTKizykHgGFx7QdowTVAsYEF2tVc0Z6wLryz2FI1sc5By2znJAAmINndoJiB4sfPdPrTC8RnkW7KRCwxC6YvXg5ahMlQuMpoCSXjOlBy0Kij%2BbsCYPbGp8BdCBiLmLSAkEQRaieWo1SYvZIKJGj9Ur%2FeWHjiB7SOVdqMAVmpBvfRiebsFjger7DC%2B8kRFGtNrTrnnGD2GAJb8rQCWkUPYHhwXsjNBSkE6lGWUj5QNhK0DMNM2l%2BkXRZ0KLZaGsFSIdQz%2FHXDxf3%2FTE30%2BDgBKWGWdxElyLccJfEpjsnszECNoDGZpdwdRgCixeg9L4EPhH%2BRptvRMVRaahu4cySjS3P5wxAUCPkmn%2BrhyASpmiTaiDeggaIxYBmtLZDDhiWIJaBgzfCsAGUF1Q1SFZYyXDt9skCaxJsxK2Ms65dmdp5WAZyxik%2FzbrTQk5KmgxCg%2Ff45L0jywebOWUYFJQAJia7XzCV0x89rpp%2Ff3AVWhSPyTanqmik2SkD8A3Ml4NhIGLAjBXtPShwKYfi2eXtrDuKLk4QlSyTw1ftXgwqA2jUuopDl%2B5tfUWZNwBpEPXghzbBggYCw%2Fdhy0ntds2yeHCDKkF%2FYxQjNIL%2FF%2F37jLPHCKBO9ibwYCmuxImIo0ijV2Wbg3kSN2psoe8IsABv3RNFaF9uMyCtCYtqcD%2BqNOhwMlfARQUdJ2tUX%2BMNJqOwIciWalZsmEjt07tfa8ma4cji9sqz%2BQ9hWfmMoKEbIHPOQORbhQRHIsrTYlnVTNvcq1imqmmPDdVDkJgRcTgB8Sb6epCQVmFZe%2BjGDiNJQLWnfx%2BdrTKYjm0G8yH0ZAGMWzEJhUEQ4Maimgf%2Fbkvo8PLVBsZl152y5S8%2BHRDfZIMCbYZ1WDp4yrdchOJw8k6R%2B%2F2pHmydK4NIK2PHdFPHtoLmHxRDwLFb7eB%2BM4zNZcB9NrAgjVyzLM7xyYSY13ykWfIEEd2n5%2FiYp3ZdrCf7fL%2Ben%2BsIJu2W7E30MrAgZBD1rAAbZHPgeAMtKCg3NpSpYQUDWJu9bT3V7tOKv%2BNRiJc8JAKqqgCA%2FPNRBR7ChpiEulyQApMK1AyqcWnpSOmYh6yLiWkGJ2mklCSPIqN7UypWj3dGi5MvsHQ87MrB4VFgypJaFriaHivwcHIpmyi5LhNqtem4q0n8awM19Qk8BOS0EsqGscuuydYsIGsbT5GHnERUiMpKJl4ON7qjB4fEqlGN%2FhCky89232UQCiaeWpDYCJINXjT6xl4Gc7DxRCtgV0i1ma4RgWLsNtnEBRQFqZggCLiuyEydmFd7WlogpkCw5G1x4ft2psm3KAREwVwr1Gzl6RT7FDAqpVal34ewVm3VH4qn5mjGj%2BbYL1NgfLNeXDwtmYSpwzbruDKpTjOdgiIHDVQSb5%2FzBgSMbHLkxWWgghIh9QTFSDILixVwg0Eg1puooBiHAt7DzwJ7m8i8%2Fi%2BjHvKf0QDnnHVkVTIqMvIQImOrzCJwhSR7qYB5gSwL6aWL9hERHCZc4G2%2BJrpgHNB8eCCmcIWIQ6rSdyPCyftXkDlErUkHafHRlkOIjxGbAktz75bnh50dU7YHk%2BMz7wwstg6RFZb%2BTZuSOx1qqP5C66c0mptQmzIC2dlpte7vZrauAMm%2F7RfBYkGtXWGiaWTtwvAQiq2oD4YixPLXE2khB2FRaNRDTk%2B9sZ6K74Ia9VntCpN4BhJGJMT4Z5c5FhSepRCRWmBXqx%2BwhVZC4me4saDs2iNqXMuCl6iAZflH8fscC1sTsy4PHeC%2BXYuqMBMUun5YezKbRKmEPwuK%2BCLzijPEQgfhahQswBBLfg%2FGBgBiI4QwAqzJkkyYAWtjzSg2ILgMAgqxYfwERRo3zruBL9WOryUArSD8sQOcD7fvIODJxKFS615KFPsb68USBEPPj1orNzFY2xoTtNBVTyzBhPbhFH0PI5AtlJBl2aSgNPYzxYLw7XTDBDinmVoENwiGzmngrMo8OmnRP0Z0i0Zrln9DDFcnmOoBZjABaQIbPOJYZGqX%2BRCMlDDbElcjaROLDoualmUIQ88Kekk3iM4OQrADcxi3rJguS4MOIBIgKgXrjd1WkbCdqxJk%2F4efRIFsavZA7KvvJQqp3Iid5Z0NFc5aiMRzGN3vrpBzaMy4JYde3wr96PjN90AYOIbyp6T4zj8LoE66OGcX1Ef4Z3KoWLAUF4BTg7ug%2FAbkG5UNQXAMkQezujSHeir2uTThgd3gpyzDrbnEdDRH2W7U6PeRvBX1ZFMP5RM%2BZu6UUZZD8hDPHldVWntTCNk7To8IeOW9yn2wx0gmurwqC60AOde4r3ETi5pVMSDK8wxhoGAoEX9NLWHIR33VbrbMveii2jAJlrxwytTHbWNu8Y4N8vCCyZjAX%2FpcsfwXbLze2%2BD%2Bu33OGBoJyAAL3jn3RuEcdp5If8O%2Ba4NKWvxOTyDltG0IWoHhwVGe7dKkCWFT%2B%2Btm%2BhaBCikRUUMrMhYKZJKYoVuv%2FbsJzO8DwfVIInQq3g3BYypiz8baogH3r3GwqCwFtZnz4xMjAVOYnyOi5HWbFA8n0qz1OjSpHWFzpQOpvkNETZBGpxN8ybhtqV%2FDMUxd9uFZmBfKXMCn%2FSqkWJyKPnT6lq%2B4zBZni6fYRByJn6OK%2BOgPBGRAJluwGSk4wxjOOzyce%2FPKODwRlsgrVkdcsEiYrqYdXo0Er2GXi2GQZd0tNJT6c9pK1EEJG1zgDJBoTVuCXGAU8BKTvCO%2FcEQ1Wjk3Zzuy90JX4m3O5IlxVFhYkSUwuQB2up7jhvkm%2BbddRQu5F9s0XftGEJ9JSuSk%2BZachCbdU45fEqbugzTIUokwoAKvpUQF%2FCvLbWW5BNQFqFkJg2f30E%2F48StNe5QwBg8zz3YAJ82FZoXBxXSv4QDooDo79NixyglO9AembuBcx5Re3CwOKTHebOPhkmFC7wNaWtoBhFuV4AkEuJ0J%2B1pT0tLkvFVZaNzfhs%2FKd3%2BA9YsImlO4XK4vpCo%2FelHQi%2F9gkFg07xxnuXLt21unCIpDV%2BbbRxb7FC6nWYTsMFF8%2B1LUg4JFjVt3vqbuhHmDKbgQ4e%2BRGizRiO8ky05LQGMdL2IKLSNar0kNG7lHJMaXr5mLdG3nykgj6vB%2FKVijd1ARWkFEf3yiUw1v%2FWaQivVUpIDdSNrrKbjO5NPnxz6qTTGgYg03HgPhDrCFyYZTi3XQw3HXCva39mpLNFtz8AiEhxAJHpWX13gCTAwgm9YTvMeiqetdNQv6IU0hH0G%2BZManTqDLPjyrOse7WiiwOJCG%2BJ0pZYULhN8NILulmYYvmVcV2MjAfA39sGKqGdjpiPo86fecg65UPyXDIAOyOkCx5NQsLeD4gGVjTVDwOHWkbbBW0GeNjDkcSOn2Nq4cEssP54t9D749A7M1AIOBl0Fi0sSO5v3P7LCBrM6ZwFY6kp2FX6AcbGUdybnfChHPyu6WlRZ2Fwv9YM0RMI7kISRgR8HpQSJJOyTfXj%2F6gQKuihPtiUtlCQVPohUgzfezTg8o1b3n9pNZeco1QucaoXe40Fa5JYhqdTspFmxGtW9h5ezLFZs3j%2FN46f%2BS2rjYNC2JySXrnSAFhvAkz9a5L3pza8eYKHNoPrvBRESpxYPJdKVUxBE39nJ1chrAFpy4MMkf0qKgYALctGg1DQI1kIymyeS2AJNT4X240d3IFQb%2F0jQbaHJ2YRK8A%2Bls6WMhWmpCXYG5jqapGs5%2FeOJErxi2%2F2KWVHiPellTgh%2FfNl%2F2KYPKb7DUcAg%2BmCOPQFCiU9Mq%2FWLcU1xxC8aLePFZZlE%2BPCLzf7ey46INWRw2kcXySR9FDgByXzfxiNKwDFbUSMMhALPFSedyjEVM5442GZ4hTrsAEvZxIieSHGSgkwFh%2FnFNdrrFD4tBH4Il7fW6ur4J8Xaz7RW9jgtuPEXQsYk7gcMs2neu3zJwTyUerHKSh1iTBkj2YJh1SSOZL5pLuQbFFAvyO4k1Hxg2h99MTC6cTUkbONQIAnEfGsGkNFWRbuRyyaEZInM5pij73EA9rPIUfU4XoqQpHT9THZkW%2BoKFLvpyvTBMM69tN1Ydwv1LIEhHsC%2BueVG%2Bw%2BkyCPsvV3erRikcscHjZCkccx6VrBkBRusTDDd8847GA7p2Ucy0y0HdSRN6YIBciYa4vuXcAZbQAuSEmzw%2BH%2FAuOx%2BaH%2BtBL88H57D0MsqyiZxhOEQkF%2F8DR1d2hSPMj%2FsNOa5rxcUnBgH8ictv2J%2Bcb4BA4v3MCShdZ2vtK30vAwkobnEWh7rsSyhmos3WC93Gn9C4nnAd%2FPjMMtQfyDNZsOPd6XcAsnBE%2FmRHtHEyJMzJfZFLE9OvQa0i9kUmToJ0ZxknTgdl%2FXPV8xoh0K7wNHHsnBdvFH3sv52lU7UFteseLG%2FVanIvcwycVA7%2BBE1Ulyb20BvwUWZcMTKhaCcmY3ROpvonVMV4N7yBXTL7IDtHzQ4CCcqF66LjF3xUqgErKzolLyCG6Kb7irP%2FMVTCCwGRxfrPGpMMGvPLgJ881PHMNMIO09T5ig7AzZTX%2F5PLlwnJLDAPfuHynSGhV4tPqR3gJ4kg4c06c%2FF1AcjGytKm2Yb5jwMotF7vro4YDLWlnMIpmPg36NgAZsGA0W1spfLSue4xxat0Gdwd0lqDBOgIaMANykwwDKejt5YaNtJYIkrSgu0KjIg0pznY0SCd1qlC6R19g97UrWDoYJGlrvCE05J%2F5wkjpkre727p5PTRX5FGrSBIfJqhJE%2FIS876PaHFkx9pGTH3oaY3jJRvLX9Iy3Edoar7cFvJqyUlOhAEiOSAyYgVEGkzHdug%2BoRHIEOXAExMiTSKU9A6nmRC8mp8iYhwWdP2U%2F5EkFAdPrZw03YA3gSyNUtMZeh7dDCu8pF5x0VORCTgKp07ehy7NZqKTpIC4UJJ89lnboyAfy5OyXzXtuDRbtAFjZRSyGFTpFrXwkpjSLIQIG3N0Vj4BtzK3wdlkBJrO18MNsgseR4BysJilI0wI6ZahLhBFA0XBmV8d4LUzEcNVb0xbLjLTETYN8OEVqNxkt10W614dd1FlFFVTIgB7%2FBQQp1sWlNolpIu4ekxUTBV7NmxOFKEBmmN%2BnA7pvF78%2FRII5ZHA09OAiE%2F66MF6HQ%2BqVEJCHxwymukkNvzqHEh52dULPbVasfQMgTDyBZzx4007YiKdBuUauQOt27Gmy8ISclPmEUCIcuLbkb1mzQSqIa3iE0PJh7UMYQbkpe%2BhXjTJKdldyt2mVPwywoODGJtBV1lJTgMsuSQBlDMwhEKIfrvsxGQjHPCEfNfMAY2oxvyKcKPUbQySkKG6tj9AQyEW3Q5rpaDJ5Sns9ScLKeizPRbvWYAw4bXkrZdmB7CQopCH8NAmqbuciZChHN8lVGaDbCnmddnqO1PQ4ieMYfcSiBE5zzMz%2BJV%2F4eyzrzTEShvqSGzgWimkNxLvUj86iAwcZuIkqdB0VaIB7wncLRmzHkiUQpPBIXbDDLHBlq7vp9xwuC9AiNkIptAYlG7Biyuk8ILdynuUM1cHWJgeB%2BK3wBP%2FineogxkvBNNQ4AkW0hvpBOQGFfeptF2YTR75MexYDUy7Q%2F9uocGsx41O4IZhViw%2F2FvAEuGO5g2kyXBUijAggWM08bRhXg5ijgMwDJy40QeY%2FcQpUDZiIzmvskQpO5G1zyGZA8WByjIQU4jRoFJt56behxtHUUE%2Fom7Rj2psYXGmq3llVOCgGYKNMo4pzwntITtapDqjvQtqpjaJwjHmDzSVGLxMt12gEXAdLi%2FcaHSM3FPRGRf7dB7YC%2BcD2ho6oL2zGDCkjlf%2FDFoQVl8GS%2F56wur3rdV6ggtzZW60MRB3g%2BU1W8o8cvqIpMkctiGVMzXUFI7FacFLrgtdz4mTEr4aRAaQ2AFQaNeG7GX0yOJgMRYFziXdJf24kg%2FgBQIZMG%2FYcPEllRTVNoDYR6oSJ8wQNLuihfw81UpiKPm714bZX1KYjcXJdfclCUOOpvTxr9AAJevTY4HK%2FG7F3mUc3GOAKqh60zM0v34v%2BELyhJZqhkaMA8UMMOU90f8RKEJFj7EqepBVwsRiLbwMo1J2zrE2UYJnsgIAscDmjPjnzI8a719Wxp757wqmSJBjXowhc46QN4RwKIxqEE6E5218OeK7RfcpGjWG1jD7qND%2B%2FGTk6M56Ig4yMsU6LUW1EWE%2BfIYycVV1thldSlbP6ltdC01y3KUfkobkt2q01YYMmxpKRvh1Z48uNKzP%2FIoRIZ%2FF6buOymSnW8gICitpJjKWBscSb9JJKaWkvEkqinAJ2kowKoqkqZftRqfRQlLtKoqvTRDi2vg%2FRrPD%2Fd3a09J8JhGZlEkOM6znTsoMCsuvTmywxTCDhw5dd0GJOHCMPbsj3QLkTE3MInsZsimDQ3HkvthT7U9VA4s6G07sID0FW4SHJmRGwCl%2BMu4xf0ezqeXD2PtPDnwMPo86sbwDV%2B9PWcgFcARUVYm3hrFQrHcgMElFGbSM2A1zUYA3baWfheJp2AINmTJLuoyYD%2FOwA4a6V0ChBN97E8YtDBerUECv0u0TlxR5yhJCXvJxgyM73Bb6pyq0jTFJDZ4p1Am1SA6sh8nADd1hAcGBMfq4d%2FUfwnmBqe0Jun1n1LzrgKuZMAnxA3NtCN7Klf4BH%2B14B7ibBmgt0TGUafVzI4uKlpF7v8NmgNjg90D6QE3tbx8AjSAC%2BOA1YJvclyPKgT27QpIEgVYpbPYGBsnyCNrGz9XUsCHkW1QAHgL2STZk12QGqmvAB0NFteERkvBIH7INDsNW9KKaAYyDMdBEMzJiWaJHZALqDxQDWRntumSDPcplyFiI1oDpT8wbwe01AHhW6%2BvAUUBoGhY3CT2tgwehdPqU%2F4Q7ZLYvhRl%2FogOvR9O2%2BwkkPKW5vCTjD2fHRYXONCoIl4Jh1bZY0ZE1O94mMGn%2FdFSWBWzQ%2FVYk%2BGezi46RgiDv3EshoTmMSlioUK6MQEN8qeyK6FRninyX8ZPeUWjjbMJChn0n%2FyJvrq5bh5UcCAcBYSafTFg7p0jDgrXo2QWLb3WpSOET%2FHh4oSadBTvyDo10IufLzxiMLAnbZ1vcUmj3w7BQuIXjEZXifwukVxrGa9j%2BDXfpi12m1RbzYLg9J2wFergEwOxFyD0%2FJstNK06ZN2XdZSGWxcJODpQHOq4iKqjqkJUmPu1VczL5xTGUfCgLEYyNBCCbMBFT%2FcUP6pE%2FmujnHsSDeWxMbhrNilS5MyYR0nJyzanWXBeVcEQrRIhQeJA6Xt4f2eQESNeLwmC10WJVHqwx8SSyrtAAjpGjidcj1E2FYN0LObUcFQhafUKTiGmHWRHGsFCB%2BHEXgrzJEB5bp0QiF8ZHh11nFX8AboTD0PS4O1LqF8XBks2MpjsQnwKHF6HgaKCVLJtcr0XjqFMRGfKv8tmmykhLRzu%2BvqQ02%2BKpJBjaLt9ye1Ab%2BBbEBhy4EVdIJDrL2naV0o4wU8YZ2Lq04FG1mWCKC%2BUwkXOoAjneU%2FxHplMQo2cXUlrVNqJYczgYlaOEczVCs%2FOCgkyvLmTmdaBJc1iBLuKwmr6qtRnhowngsDxhzKFAi02tf8bmET8BO27ovJKF1plJwm3b0JpMh38%2BxsrXXg7U74QUM8ZCIMOpXujHntKdaRtsgyEZl5MClMVMMMZkZLNxH9%2Bb8fH6%2Bb8Lev30A9TuEVj9CqAdmwAAHBPbfOBFEATAPZ2CS0OH1Pj%2F0Q7PFUcC8hDrxESWdfgFRm%2B7vvWbkEppHB4T%2F1ApWnlTIqQwjcPl0VgS1yHSmD0OdsCVST8CQVwuiew1Y%2Bg3QGFjNMzwRB2DSsAk26cmA8lp2wIU4p93AUBiUHFGOxOajAqD7Gm6NezNDjYzwLOaSXRBYcWipTSONHjUDXCY4mMI8XoVCR%2FRrs%2FJLKXgEx%2BqkmeDlFOD1%2FyTQNDClRuiUyKYCllfMiQiyFkmuTz2vLsBNyRW%2Bxz%2B5FElFxWB28VjYIGZ0Yd%2B5wIjkcoMaggxswbT0pCmckRAErbRlIlcOGdBo4djTNO8FAgQ%2BlT6vPS60BwTRSUAM3ddkEAZiwtEyArrkiDRnS7LJ%2B2hwbzd2YDQagSgACpsovmjil5wfPuXq3GuH0CyE7FK3M4FgRaFoIkaodORrPx1%2BJpI9psyNYIFuJogZa0%2F1AhOWdlHQxdAgbwacsHqPZo8u%2FngAH2GmaTdhYnBfSDbBfh8CHq6Bx5bttP2%2BRdM%2BMAaYaZ0Y%2FADkbNCZuAyAVQa2OcXOeICmDn9Q%2FeFkDeFQg5MgHEDXq%2FtVjj%2Bjtd26nhaaolWxs1ixSUgOBwrDhRIGOLyOVk2%2FBc0UxvseQCO2pQ2i%2BKrfhu%2FWeBovNb5dJxQtJRUDv2mCwYVpNl2efQM9xQHnK0JwLYt%2FU0Wf%2BphiA4uw8G91slC832pmOTCAoZXohg1fewCZqLBhkOUBofBWpMPsqg7XEXgPfAlDo2U5WXjtFdS87PIqClCK5nW6adCeXPkUiTGx0emOIDQqw1yFYGHEVx20xKjJVYe0O8iLmnQr3FA9nSIQilUKtJ4ZAdcTm7%2BExseJauyqo30hs%2B1qSW211A1SFAOUgDlCGq7eTIcMAeyZkV1SQJ4j%2Fe1Smbq4HcjqgFbLAGLyKxlMDMgZavK5NAYH19Olz3la%2FQCTiVelFnU6O%2FGCvykqS%2FwZJDhKN9gBtSOp%2F1SP5VRgJcoVj%2Bkmf2wBgv4gjrgARBWiURYx8xENV3bEVUAAWWD3dYDKAIWk5opaCFCMR5ZjJExiCAw7gYiSZ2rkyTce4eNMY3lfGn%2B8p6%2BvBckGlKEXnA6Eota69OxDO9oOsJoy28BXOR0UoXNRaJD5ceKdlWMJlOFzDdZNpc05tkMGQtqeNF2lttZqNco1VtwXgRstLSQ6tSPChgqtGV5h2DcDReIQadaNRR6AsAYKL5gSFsCJMgfsaZ7DpKh8mg8Wz8V7H%2BgDnLuMxaWEIUPevIbClgap4dqmVWSrPgVYCzAoZHIa5z2Ocx1D%2FGvDOEqMOKLrMefWIbSWHZ6jbgA8qVBhYNHpx0P%2BjAgN5TB3haSifDcApp6yymEi6Ij%2FGsEpDYUgcHATJUYDUAmC1SCkJ4cuZXSAP2DEpQsGUjQmKJfJOvlC2x%2FpChkOyLW7KEoMYc5FDC4v2FGqSoRWiLsbPCiyg1U5yiHZVm1XLkHMMZL11%2Fyxyw0UnGig3MFdZklN5FI%2FqiT65T%2BjOXOdO7XbgWurOAZR6Cv9uu1cm5LjkXX4xi6mWn5r5NjBS0gTliHhMZI2WNqSiSphEtiCAwnafS11JhseDGHYQ5%2BbqWiAYiAv6Jsf79%2FVUs4cIl%2Bn6%2BWOjcgB%2F2l5TreoAV2717JzZbQIR0W1cl%2FdEqCy5kJ3ZSIHuU0vBoHooEpiHeQWVkkkOqRX27eD1FWw4BfO9CJDdKoSogQi3hAAwsPRFrN5RbX7bqLdBJ9JYMohWrgJKHSjVl1sy2xAG0E3sNyO0oCbSGOxCNBRRXTXenYKuwAoDLfnDcQaCwehUOIDiHAu5m5hMpKeKM4sIo3vxACakIxKoH2YWF2QM84e6F5C5hJU4g8uxuFOlAYnqtwxmHyNEawLW%2FPhoawJDrGAP0JYWHgAVUByo%2FbGdiv2T2EMg8gsS14%2FrAdzlOYazFE7w4OzxeKiWdm3nSOnQRRKXSlVo8HEAbBfyJMKqoq%2BSCcTSx5NDtbFwNlh8VhjGGDu7JG5%2FTAGAvniQSSUog0pNzTim8Owc6QTuSKSTXlQqwV3eiEnklS3LeSXYPXGK2VgeZBqNcHG6tZHvA3vTINhV0ELuQdp3t1y9%2BogD8Kk%2FW7QoRN1UWPqM4%2BxdygkFDPLoTaumKReKiLWoPHOfY54m3qPx4c%2B4pgY3MRKKbljG8w4wvz8pxk3AqKsy4GMAkAtmRjRMsCxbb4Q2Ds0Ia9ci8cMT6DmsJG00XaHCIS%2Bo3F8YVVeikw13w%2BOEDaCYYhC0ZE54kA4jpjruBr5STWeqQG6M74HHL6TZ3lXrd99ZX%2B%2B7LhNatQaZosuxEf5yRA15S9gPeHskBIq3Gcw81AGb9%2FO53DYi%2F5CsQ51EmEh8Rkg4vOciClpy4d04eYsfr6fyQkBmtD%2BP8sNh6e%2BXYHJXT%2FlkXxT4KXU5F2sGxYyzfniMMQkb9OjDN2C8tRRgTyL7GwozH14PrEUZc6oz05Emne3Ts5EG7WolDmU8OB1LDG3VrpQxp%2BpT0KYV5dGtknU64JhabdqcVQbGZiAxQAnvN1u70y1AnmvOSPgLI6uB4AuDGhmAu3ATkJSw7OtS%2F2ToPjqkaq62%2F7WFG8advGlRRqxB9diP07JrXowKR9tpRa%2BjGJ91zxNTT1h8I2PcSfoUPtd7NejVoH03EUcqSBuFZPkMZhegHyo2ZAITovmm3zAIdGFWxoNNORiMRShgwdYwFzkPw5PA4a5MIIQpmq%2Bnsp3YMuXt%2FGkXxLx%2FP6%2BZJS0lFyz4MunC3eWSGE8xlCQrKvhKUPXr0hjpAN9ZK4PfEDrPMfMbGNWcHDzjA7ngMxTPnT7GMHar%2BgMQQ3NwHCv4zH4BIMYvzsdiERi6gebRmerTsVwZJTRsL8dkZgxgRxmpbgRcud%2BYlCIRpPwHShlUSwuipZnx9QCsEWziVazdDeKSYU5CF7UVPAhLer3CgJOQXl%2Fzh575R5rsrmRnKAzq4POFdgbYBuEviM4%2BLVC15ssLNFghbTtHWerS1hDt5s4qkLUha%2FqpZXhWh1C6lTQAqCNQnaDjS7UGFBC6wTu8yFnKJnExCnAs3Ok9yj5KpfZESQ4lTy5pTGTnkAUpxI%2ByjEldJfSo4y0QhG4i4IwkRFGcjWY8%2BEzgYYJUK7BXQksLxAww%2FYYWBMhJILB9e8ePEJ4OP7z%2B4%2FwOQDl64iOYDp26DaONPxpKtBxq%2FaTzRGarm3VkPYTLJKx6Z%2FMw2YbBGseJhPMwhhNswrIkyvV2BYzrvZbxLpKwcWJhYmFtVZ%2BlPEq91FzVp1HlQY1bZVLqeNR9SAUn6n0E28k%2FUuGkNpP1DBI5ch%2FEehZfjUQ9aE41NhETExoPT2gGQz0IhWJbEOvTQ4wgcXCHHFBhewYUiFHuhRSAUVmEHeCRQHQkXGFwkAgyzREJCVN7TRnTon36Zw3tPhx4EALwNdwDv%2BJ41YSP4B2CQqz0EFgARZ4ESgBHQgROwAVn9GTI%2BHYexTUevLUeta4%2FDqKrbMVS%2BYqb8hUwYCrlgKtmAq1YCrFgKrd4qpXiqZcKn1oqdWipjYKpWwVPVYqW6xUpVipKqFR3QKjagVEtAqHpxUMTitsnFaJOKx2cVhswq35RVpyiq9lFVNIKnOQVMkgqtYxVNxiqQjFS7GKlSIVIsQqPIhUWwioigFQ%2B%2BKkN8VHr49HDw9Ebo9EDo9DTo9Crg9BDg9%2FWx7gWx7YWwlobYrOGxWPNisAaAHEyALpkAVDIAeWAArsABVXACYuAD5cAF6wAKFQAQqgAbVAAsoAAlQAUaYAfkwAvogBWQACOgAD9AAHSAAKT4GUdMiOvFngBTwCn2AZ7Dv6B6k%2F90B8%2ByRnkV144AIBoAMTQATGgAjNAA4YABgwABZgB%2FmQCwyAVlwCguASlwCEuAQFwB4uAMlwBYuAJlQAUVAAhUD2KgdpUDaJgaRMDFJgX5MC1JgWJEAokQCWRAHxEAWkQBMRADpEAMkQAYROAEecC484DRpwBDTnwNOdw05tjTmiNOYwtswhYFwLA7BYG4LA2BYGOLAwRYFuLAsxYFQJAohIEyJAMwkAwiQC0JAJgkAeiQBkJAFokAPCQA0JABwcD4Dgc4cDdDgaYcDIDgYgUC6CgWgUClCgUYUAVBQBOFAEYMALgwAgDA9QYAdIn8AZzeBB2L5EcWrenUT1KXienEsuJJ7x5U8XlTjc1NVzUyXFTGb1LlpUtWlTDIjqwE4LsagowoCi2gJLKAkpoBgJQNpAIhNqaEoneI6kiiqQ6Go%2Fn6j0cS%2Ba2gEU8gIHJ%2BBwfgZX4GL%2BBd%2FgW34FZ%2BBS%2FgUH4FN6BTegTvoEv6BJegRnYEF2A79gOvYDl2BdEjCkqkGtwXp0LNToIskOTXzh%2FF062yJ7AAAAEDAWAAABWhJ%2BKPEIJgBFxMVP7w2QJBGHASQnOBKXKFIdUK4igKA9IEaYJg%29%3Bsrc%3Aurl%28data%3Aapplication%2Fvnd%2Ems%2Dfontobject%3Bbase64%2Cn04AAEFNAAACAAIABAAAAAAABQAAAAAAAAABAJABAAAEAExQAAAAAAAAAAIAAAAAAAAAAAEAAAAAAAAAJxJ%2FLAAAAAAAAAAAAAAAAAAAAAAAACgARwBMAFkAUABIAEkAQwBPAE4AUwAgAEgAYQBsAGYAbABpAG4AZwBzAAAADgBSAGUAZwB1AGwAYQByAAAAeABWAGUAcgBzAGkAbwBuACAAMQAuADAAMAA5ADsAUABTACAAMAAwADEALgAwADAAOQA7AGgAbwB0AGMAbwBuAHYAIAAxAC4AMAAuADcAMAA7AG0AYQBrAGUAbwB0AGYALgBsAGkAYgAyAC4ANQAuADUAOAAzADIAOQAAADgARwBMAFkAUABIAEkAQwBPAE4AUwAgAEgAYQBsAGYAbABpAG4AZwBzACAAUgBlAGcAdQBsAGEAcgAAAAAAQlNHUAAAAAAAAAAAAAAAAAAAAAADAKncAE0TAE0ZAEbuFM3pjM%2FSEdmjKHUbyow8ATBE40IvWA3vTu8LiABDQ%2BpexwUMcm1SMnNryctQSiI1K5ZnbOlXKmnVV5YvRe6RnNMFNCOs1KNVpn6yZhCJkRtVRNzEufeIq7HgSrcx4S8h%2Fv4vnrrKc6oCNxmSk2uKlZQHBii6iKFoH0746ThvkO1kJHlxjrkxs%2BLWORaDQBEtiYJIR5IB9Bi1UyL4Rmr0BNigNkMzlKQmnofBHviqVzUxwdMb3NdCn69hy%2BpRYVKGVS%2F1tnsqv4LL7wCCPZZAZPT4aCShHjHJVNuXbmMrY5LeQaGnvAkXlVrJgKRAUdFjrWEah9XebPeQMj7KS7DIBAFt8ycgC5PLGUOHSE3ErGZCiViNLL5ZARfywnCoZaKQCu6NuFX42AEeKtKUGnr%2FCm2Cy8tpFhBPMW5Fxi4Qm4TkDWh4IWFDClhU2hRWosUWqcKLlgyXB%2BlSHaWaHiWlBAR8SeSgSPCQxdVQgzUixWKSTrIQEbU94viDctkvX%2BVSjJuUmV8L4CXShI11esnp0pjWNZIyxKHS4wVQ2ime1P4RnhvGw0aDN1OLAXGERsB7buFpFGGBAre4QEQR0HOIO5oYH305G%2BKspT%2FFupEGGafCCwxSe6ZUa%2B073rXHnNdVXE6eWvibUS27XtRzkH838mYLMBmYysZTM0EM3A1fbpCBYFccN1B%2FEnCYu%2FTgCGmr7bMh8GfYL%2BBfcLvB0gRagC09w9elfldaIy%2FhNCBLRgBgtCC7jAF63wLSMAfbfAlEggYU0bUA7ACCJmTDpEmJtI78w4%2FBO7dN7JR7J7ZvbYaUbaILSQsRBiF3HGk5fEg6p9unwLvn98r%2BvnsV%2B372uf1xBLq4qU%2F45fTuqaAP%2BpssmCCCTF0mhEow8ZXZOS8D7Q85JsxZ%2BAzok7B7O%2Ff6J8AzYBySZQB%2FQHYUSA%2BEeQhEWiS6AIQzgcsDiER4MjgMBAWDV4AgQ3g1eBgIdweCQmCjJEMkJ%2BPKRWyFHHmg1Wi%2F6xzUgA0LREoKJChwnQa9B%2B5RQZRB3IlBlkAnxyQNaANwHMowzlYSMCBgnbpzvqpl0iTJNCQidDI9ZrSYNIRBhHtUa5YHMHxyGEik9hDE0AKj72AbTCaxtHPUaKZdAZSnQTyjGqGLsmBStCejApUhg4uBMU6mATujEl%2BKdDPbI6Ag4vLr%2BhjY6lbjBeoLKnZl0UZgRX8gTySOeynZVz1wOq7e1hFGYIq%2BMhrGxDLak0PrwYzSXtcuyhXEhwOYofiW%2BEcI%2Fjw8P6IY6ed%2BetAbuqKp5QIapT77LnAe505lMuqL79a0ut4rWexzFttsOsLDy7zvtQzcq3U1qabe7tB0wHWVXji%2BzDbo8x8HyIRUbXnwUcklFv51fvTymiV%2BMXLSmGH9d9%2BaXpD5X6lao41anWGig7IwIdnoBY2ht%2FpO9mClLo4NdXHAsefqWUKlXJkbqPOFhMoR4aiA1BXqhRNbB2Xwi%2B7u%2FjpAoOpKJ0UX24EsrzMfHXViakCNcKjBxuQX8BO0ZqjJ3xXzf%2B61t2VXOSgJ8xu65QKgtN6FibPmPYsXbJRHHqbgATcSZxBqGiDiU4NNNsYBsKD0MIP%2FOfKnlk%2FLkaid%2FO2NbKeuQrwOB2Gq3YHyr6ALgzym5wIBnsdC1ZkoBFZSQXChZvlesPqvK2c5oHHT3Q65jYpNxnQcGF0EHbvYqoFw60WNlXIHQF2HQB7zD6lWjZ9rVqUKBXUT6hrkZOle0RFYII0V5ZYGl1JAP0Ud1fZZMvSomBzJ710j4Me8mjQDwEre5Uv2wQfk1ifDwb5ksuJQQ3xt423lbuQjvoIQByQrNDh1JxGFkOdlJvu%2FgFtuW0wR4cgd%2BZKesSV7QkNE2kw6AV4hoIuC02LGmTomyf8PiO6CZzOTLTPQ%2BHW06H%2Btx%2BbQ8LmDYg1pTFrp2oJXgkZTyeRJZM0C8aE2LpFrNVDuhARsN543%2FFV6klQ6Tv1OoZGXLv0igKrl%2FCmJxRmX7JJbJ998VSIPQRyDBICzl4JJlYHbdql30NvYcOuZ7a10uWRrgoieOdgIm4rlq6vNOQBuqESLbXG5lzdJGHw2m0sDYmODXbYGTfSTGRKpssTO95fothJCjUGQgEL4yKoGAF%2F0SrpUDNn8CBgBcSDQByAeNkCXp4S4Ro2Xh4OeaGRgR66PVOsU8bc6TR5%2FxTcn4IVMLOkXSWiXxkZQCbvKfmoAvQaKjO3EDKwkwqHChCDEM5loQRPd5ACBki1TjF772oaQhQbQ5C0lcWXPFOzrfsDGUXGrpxasbG4iab6eByaQkQfm0VFlP0ZsDkvvqCL6QXMUwCjdMx1ZOyKhTJ7a1GWAdOUcJ8RSejxNVyGs31OKMyRyBVoZFjqIkmKlLQ5eHMeEL4MkUf23cQ%2F1SgRCJ1dk4UdBT7OoyuNgLs0oCd8RnrEIb6QdMxT2QjD4zMrJkfgx5aDMcA4orsTtKCqWb%2FVeyceqa5OGSmB28YwH4rFbkQaLoUN8OQQYnD3w2eXpI4ScQfbCUZiJ4yMOIKLyyTc7BQ4uXUw6Ee6%2FxM%2B4Y67ngNBknxIPwuppgIhFcwJyr6EIj%2BLzNj%2FmfR2vhhRlx0BILZoAYruF0caWQ7YxO66UmeguDREAFHYuC7HJviRgVO6ruJH59h%2FC%2FPkgSle8xNzZJULLWq9JMDTE2fjGE146a1Us6PZDGYle6ldWRqn%2FpdpgHKNGrGIdkRK%2BKPETT9nKT6kLyDI8xd9A1FgWmXWRAIHwZ37WyZHOVyCadJEmMVz0MadMjDrPho%2BEIochkVC2xgGiwwsQ6DMv2P7UXqT4x7CdcYGId2BJQQa85EQKmCmwcRejQ9Bm4oATENFPkxPXILHpMPUyWTI5rjNOsIlmEeMbcOCEqInpXACYQ9DDxmFo9vcmsDblcMtg4tqBerNngkIKaFJmrQAPnq1dEzsMXcwjcHdfdCibcAxxA%2Bq%2Fj9m3LM%2FO7WJka4tSidVCjsvo2lQ%2F2ewyoYyXwAYyr2PlRoR5MpgVmSUIrM3PQxXPbgjBOaDQFIyFMJvx3Pc5RSYj12ySVF9fwFPQu2e2KWVoL9q3Ayv3IzpGHUdvdPdrNUdicjsTQ2ISy7QU3DrEytIjvbzJnAkmANXjAFERA0MUoPF3%2F5KFmW14bBNOhwircYgMqoDpUMcDtCmBE82QM2YtdjVLB4kBuKho%2FbcwQdeboqfQartuU3CsCf%2BcXkgYAqp%2F0Ee3RorAZt0AvvOCSI4JICIlGlsV0bsSid%2FNIEALAAzb6HAgyWHBps6xAOwkJIGcB82CxRQq4sJf3FzA70A%2BTRqcqjEMETCoez3mkPcpnoALs0ugJY8kQwrC%2BJE5ik3w9rzrvDRjAQnqgEVvdGrNwlanR0SOKWzxOJOvLJhcd8Cl4AshACUkv9czdMkJCVQSQhp6kp7StAlpVRpK0t0SW6LHeBJnE2QchB5Ccu8kxRghZXGIgZIiSj7gEKMJDClcnX6hgoqJMwiQDigIXg3ioFLCgDgjPtYHYpsF5EiA4kcnN18MZtOrY866dEQAb0FB34OGKHGZQjwW%2FWDHA60cYFaI%2FPjpzquUqdaYGcIq%2BmLez3WLFFCtNBN2QJcrlcoELgiPku5R5dSlJFaCEqEZle1AQzAKC%2B1SotMcBNyQUFuRHRF6OlimSBgjZeTBCwLyc6A%2BP%2FoFRchXTz5ADknYJHxzrJ5pGuIKRQISU6WyKTBBjD8WozmVYWIsto1AS5rxzKlvJu4E%2FvwOiKxRtCWsDM%2BeTHUrmwrCK5BIfMzGkD%2B0Fk5LzBs0jMYXktNDblB06LMNJ09U8pzSLmo14MS0OMjcdrZ31pyQqxJJpRImlSvfYAK8inkYU52QY2FPEVsjoWewpwhRp5yAuNpkqhdb7ku9Seefl2D0B8SMTFD90xi4CSOwwZy9IKkpMtI3FmFUg3%2FkFutpQGNc3pCR7gvC4sgwbupDu3DyEN%2BW6YGLNM21jpB49irxy9BSlHrVDlnihGKHwPrbVFtc%2Bh1rVQKZduxIyojccZIIcOCmhEnC7UkY68WXKQgLi2JCDQkQWJRQuk60hZp0D3rtCTINSeY9Ej2kIKYfGxwOs4j9qMM7fYZiipzgcf7TamnehqdhsiMiCawXnz4xAbyCkLAx5EGbo3Ax1u3dUIKnTxIaxwQTHehPl3V491H0%2BbC5zgpGz7Io%2BmjdhKlPJ01EeMpM7UsRJMi1nGjmJg35i6bQBAAxjO%2FENJubU2mg3ONySEoWklCwdABETcs7ck3jgiuU9pcKKpbgn%2B3YlzV1FzIkB6pmEDOSSyDfPPlQskznctFji0kpgZjW5RZe6x9kYT4KJcXg0bNiCyif%2BpZACCyRMmYsfiKmN9tSO65F0R2OO6ytlEhY5Sj6uRKfFxw0ijJaAx%2Fk3QgnAFSq27%2F2i4GEBA%2BUvTJKK%2F9eISNvG46Em5RZfjTYLdeD8kdXHyrwId%2FDQZUaMCY4gGbke2C8vfjgV%2FY9kkRQOJIn%2FxM9INZSpiBnqX0Q9GlQPpPKAyO5y%2BW5NMPSRdBCUlmuxl40ZfMCnf2Cp044uI9WLFtCi4YVxKjuRCOBWIb4XbIsGdbo4qtMQnNOQz4XDSui7W%2FN6l54qOynCqD3DpWQ%2BmpD7C40D8BZEWGJX3tlAaZBMj1yjvDYKwCJBa201u6nBKE5UE%2B7QSEhCwrXfbRZylAaAkplhBWX50dumrElePyNMRYUrC99UmcSSNgImhFhDI4BXjMtiqkgizUGCrZ8iwFxU6fQ8GEHCFdLewwxYWxgScAYMdMLmcZR6b7rZl95eQVDGVoUKcRMM1ixXQtXNkBETZkVVPg8LoSrdetHzkuM7DjZRHP02tCxA1fmkXKF3VzfN1pc1cv%2F8lbTIkkYpqKM9VOhp65ktYk%2BQ46myFWBapDfyWUCnsnI00QTBQmuFjMZTcd0V2NQ768Fhpby04k2IzNR1wKabuGJqYWwSly6ocMFGTeeI%2BejsWDYgEvr66QgqdcIbFYDNgsm0x9UHY6SCd5%2B7tpsLpKdvhahIDyYmEJQCqMqtCF6UlrE5GXRmbu%2Bvtm3BFSxI6ND6UxIE7GsGMgWqghXxSnaRJuGFveTcK5ZVSPJyjUxe1dKgI6kNF7EZhIZs8y8FVqwEfbM0Xk2ltORVDKZZM40SD3qQoQe0orJEKwPfZwm3YPqwixhUMOndis6MhbmfvLBKjC8sKKIZKbJk8L11oNkCQzCgvjhyyEiQSuJcgCQSG4Mocfgc0Hkwcjal1UNgP0CBPikYqBIk9tONv4kLtBswH07vUCjEaHiFGlLf8MgXKzSgjp2HolRRccAOh0ILHz9qlGgIFkwAnzHJRjWFhlA7ROwINyB5HFj59PRZHFor6voq7l23EPNRwdWhgawqbivLSjRA4htEYUFkjESu67icTg5S0aW1sOkCiIysfJ9UnIWevOOLGpepcBxy1wEhd2WI3AZg7sr9WBmHWyasxMcvY%2FiOmsLtHSWNUWEGk9hScMPShasUA1AcHOtRZlqMeQ0OzYS9vQvYUjOLrzP07BUAFikcJNMi7gIxEw4pL1G54TcmmmoAQ5s7TGWErJZ2Io4yQ0ljRYhL8H5e62oDtLF8aDpnIvZ5R3GWJyAugdiiJW9hQAVTsnCBHhwu7rkBlBX6r3b7ejEY0k5GGeyKv66v%2B6dg7mcJTrWHbtMywbedYqCQ0FPwoytmSWsL8WTtChZCKKzEF7vP6De4x2BJkkniMgSdWhbeBSLtJZR9CTHetK1xb34AYIJ37OegYIoPVbXgJ%2FqDQK%2BbfCtxQRVKQu77WzOoM6SGL7MaZwCGJVk46aImai9fmam%2BWpHG%2B0BtQPWUgZ7RIAlPq6lkECUhZQ2gqWkMYKcYMYaIc4gYCDFHYa2d1nzp3%2BJ1eCBay8IYZ0wQRKGAqvCuZ%2FUgbQPyllosq%2BXtfKIZOzmeJqRazpmmoP%2F76YfkjzV2NlXTDSBYB04SVlNQsFTbGPk1t%2FI4Jktu0XSgifO2ozFOiwd%2F0SssJDn0dn4xqk4GDTTKX73%2FwQyBLdqgJ%2BWx6AQaba3BA9CKEzjtQYIfAsiYamapq80LAamYjinlKXUkxdpIDk0puXUEYzSalfRibAeDAKpNiqQ0FTwoxuGYzRnisyTotdVTclis1LHRQCy%2FqqL8oUaQzWRxilq5Mi0IJGtMY02cGLD69vGjkj3p6pGePKI8bkBv5evq8SjjyU04vJR2cQXQwSJyoinDsUJHCQ50jrFTT7yRdbdYQMB3MYCb6uBzJ9ewhXYPAIZSXfeEQBZZ3GPN3Nbhh%2FwkvAJLXnQMdi5NYYZ5GHE400GS5rXkOZSQsdZgIbzRnF9ueLnsfQ47wHAsirITnTlkCcuWWIUhJSbpM3wWhXNHvt2xUsKKMpdBSbJnBMcihkoDqAd1Zml%2FR4yrzow1Q2A5G%2Bkzo%2FRhRxQS2lCSDRV8LlYLBOOoo1bF4jwJAwKMK1tWLHlu9i0j4Ig8qVm6wE1DxXwAwQwsaBWUg2pOOol2dHxyt6npwJEdLDDVYyRc2D0HbcbLUJQj8gPevQBUBOUHXPrsAPBERICpnYESeu2OHotpXQxRGlCCtLdIsu23MhZVEoJg8Qumj%2FUMMc34IBqTKLDTp76WzL%2FdMjCxK7MjhiGjeYAC%2Fkj%2FjY%2FRde7hpSM1xChrog6yZ7OWTuD56xBJnGFE%2BpT2ElSyCnJcwVzCjkqeNLfMEJqKW0G7OFIp0G%2B9mh50I9o8k1tpCY0xYqFNIALgIfc2me4n1bmJnRZ89oepgLPT0NTMLNZsvSCZAc3TXaNB07vail36%2FdBySis4m9%2FDR8izaLJW6bWCkVgm5T%2Bius3ZXq4xI%2BGnbveLbdRwF2mNtsrE0JjYc1AXknCOrLSu7Te%2Fr4dPYMCl5qtiHNTn%2BTPbh1jCBHH%2BdMJNhwNgs3nT%2BOhQoQ0vYif56BMG6WowAcHR3DjQolxLzyVekHj00PBAaW7IIAF1EF%2BuRIWyXjQMAs2chdpaKPNaB%2BkSezYt0%2BCA04sOg5vx8Fr7Ofa9sUv87h7SLAUFSzbetCCZ9pmyLt6l6%2FTzoA1%2FZBG9bIUVHLAbi%2FkdBFgYGyGwRQGBpkqCEg2ah9UD6EedEcEL3j4y0BQQCiExEnocA3SZboh%2Bepgd3YsOkHskZwPuQ5OoyA0fTA5AXrHcUOQF%2BzkJHIA7PwCDk1gGVmGUZSSoPhNf%2BTklauz98QofOlCIQ%2FtCD4dosHYPqtPCXB3agggQQIqQJsSkB%2Bqn0rkQ1toJjON%2FOtCIB9RYv3PqRA4C4U68ZMlZn6BdgEvi2ziU%2BTQ6NIw3ej%2BAtDwMGEZk7e2IjxUWKdAxyaw9OCwSmeADTPPleyk6UhGDNXQb%2B%2BW6Uk4q6F7%2Frg6WVTo82IoCxSIsFDrav4EPHphD3u4hR53WKVvYZUwNCCeM4PMBWzK%2BEfIthZOkuAwPo5C5jgoZgn6dUdvx5rIDmd58cXXdKNfw3l%2BwM2UjgrDJeQHhbD7HW2QDoZMCujgIUkk5Fg8VCsdyjOtnGRx8wgKRPZN5dR0zPUyfGZFVihbFRniXZFOZGKPnEQzU3AnD1KfR6weHW2XS6KbPJxUkOTZsAB9vTVp3Le1F8q5l%2BDMcLiIq78jxAImD2pGFw0VHfRatScGlK6SMu8leTmhUSMy8Uhdd6xBiH3Gdman4tjQGLboJfqz6fL2WKHTmrfsKZRYX6BTDjDldKMosaSTLdQS7oDisJNqAUhw1PfTlnacCO8vl8706Km1FROgLDmudzxg%2BEWTiArtHgLsRrAXYWdB0NmToNCJdKm0KWycZQqb%2BMw76Qy29iQ5up%2FX7oyw8QZ75kP5F6iJAJz6KCmqxz8fEa%2FxnsMYcIO%2FvEkGRuMckhr4rIeLrKaXnmIzlNLxbFspOphkcnJdnz%2FChp%2FVlpj2P7jJQmQRwGnltkTV5dbF9fE3%2FfxoSqTROgq9wFUlbuYzYcasE0ouzBo%2BdDCDzxKAfhbAZYxQiHrLzV2iVexnDX%2FQnT1fsT%2Fxuhu1ui5qIytgbGmRoQkeQooO8eJNNZsf0iALur8QxZFH0nCMnjerYQqG1pIfjyVZWxhVRznmmfLG00BcBWJE6hzQWRyFknuJnXuk8A5FRDCulwrWASSNoBtR%2BCtGdkPwYN2o7DOw%2FVGlCZPusRBFXODQdUM5zeHDIVuAJBLqbO%2Ff9Qua%2BpDqEPk230Sob9lEZ8BHiCorjVghuI0lI4JDgHGRDD%2FprQ84B1pVGkIpVUAHCG%2Biz3Bn3qm2AVrYcYWhock4jso5%2BJ7HfHVj4WMIQdGctq3psBCVVzupQOEioBGA2Bk%2BUILT7%2BVoX5mdxxA5fS42gISQVi%2FHTzrgMxu0fY6hE1ocUwwbsbWcezrY2n6S8%2F6cxXkOH4prpmPuFoikTzY7T85C4T2XYlbxLglSv2uLCgFv8Quk%2FwdesUdWPeHYIH0R729JIisN9Apdd4eB10aqwXrPt%2BSu9mA8k8n1sjMwnfsfF2j3jMUzXepSHmZ%2FBfqXvzgUNQQWOXO8YEuFBh4QTYCkOAPxywpYu1VxiDyJmKVcmJPGWk%2Fgc3Pov02StyYDahwmzw3E1gYC9wkupyWfDqDSUMpCTH5e5N8B%2F%2FlHiMuIkTNw4USHrJU67bjXGqNav6PBuQSoqTxc8avHoGmvqNtXzIaoyMIQIiiUHIM64cXieouplhNYln7qgc4wBVAYR104kO%2BCvKqsg4yIUlFNThVUAKZxZt1XA34h3TCUUiXVkZ0w8Hh2R0Z5L0b4LZvPd%2Fp1gi%2F07h8qfwHrByuSxglc9cI4QIg2oqvC%2Fqm0i7tjPLTgDhoWTAKDO2ONW5oe%2B%2FeKB9vZB8K6C25yCZ9RFVMnb6NRdRjyVK57CHHSkJBfnM2%2Fj4ODUwRkqrtBBCrDsDpt8jhZdXoy%2F1BCqw3sSGhgGGy0a5Jw6BP%2FTExoCmNFYjZl248A0osgPyGEmRA%2BfAsqPVaNAfytu0vuQJ7rk3J4kTDTR2AlCHJ5cls26opZM4w3jMULh2YXKpcqGBtuleAlOZnaZGbD6DHzMd6i2oFeJ8z9XYmalg1Szd%2FocZDc1C7Y6vcALJz2lYnTXiWEr2wawtoR4g3jvWUU2Ngjd1cewtFzEvM1NiHZPeLlIXFbBPawxNgMwwAlyNSuGF3zizVeOoC9bag1qRAQKQE%2FEZBWC2J8mnXAN2aTBboZ7HewnObE8CwROudZHmUM5oZ%2FUgd%2FJZQK8lvAm43uDRAbyW8gZ%2BZGq0EVerVGUKUSm%2FIdn8AQHdR4m7bue88WBwft9mSCeMOt1ncBwziOmJYI2ZR7ewNMPiCugmSsE4EyQ%2BQATJG6qORMGd4snEzc6B4shPIo4G1T7PgSm8PY5eUkPdF8JZ0VBtadbHXoJgnEhZQaODPj2gpODKJY5Yp4DOsLBFxWbvXN755KWylJm%2BoOd4zEL9Hpubuy2gyyfxh8oEfFutnYWdfB8PdESLWYvSqbElP9qo3u6KTmkhoacDauMNNjj0oy40DFV7Ql0aZj77xfGl7TJNHnIwgqOkenruYYNo6h724%2BzUQ7%2BvkCpZB%2BpGA562hYQiDxHVWOq0oDQl%2FQsoiY%2BcuI7iWq%2FZIBtHcXJ7kks%2Bh2fCNUPA82BzjnqktNts%2BRLdk1VSu%2BtqEn7QZCCsvEqk6FkfiOYkrsw092J8jsfIuEKypNjLxrKA9kiA19mxBD2suxQKCzwXGws7kEJvlhUiV9tArLIdZW0IORcxEzdzKmjtFhsjKy%2F44XYXdI5noQoRcvjZ1RMPACRqYg2V1%2BOwOepcOknRLLFdYgTkT5UApt%2FJhLM3jeFYprZV%2BZow2g8fP%2BU68hkKFWJj2yBbKqsrp25xkZX1DAjUw52IMYWaOhab8Kp05VrdNftqwRrymWF4OQSjbdfzmRZirK8FMJELEgER2PHjEAN9pGfLhCUiTJFbd5LBkOBMaxLr%2FA1SY9dXFz4RjzoU9ExfJCmx%2FI9FKEGT3n2cmzl2X42L3Jh%2BAbQq6sA%2BSs1kitoa4TAYgKHaoybHUDJ51oETdeI%2F9ThSmjWGkyLi5QAGWhL0BG1UsTyRGRJOldKBrYJeB8ljLJHfATWTEQBXBDnQexOHTB%2BUn44zExFE4vLytcu5NwpWrUxO%2F0ZICUGM7hGABXym0V6ZvDST0E370St9MIWQOTWngeoQHUTdCJUP04spMBMS8LSker9cReVQkULFDIZDFPrhTzBl6sed9wcZQTbL%2BBDqMyaN3RJPh%2Fanbx%2BIv%2BqgQdAa3M9Z5JmvYlh4qop%2BHo1F1W5gbOE9YKLgAnWytXElU4G8GtW47lhgFE6gaSs%2Bgs37sFvi0PPVvA5dnCBgILTwoKd%2F%2BDoL9F6inlM7H4rOTzD79KJgKlZO%2FZgt22UsKhrAaXU5ZcLrAglTVKJEmNJvORGN1vqrcfSMizfpsgbIe9zno%2BgBoKVXgIL%2FVI8dB1O5o%2FR3Suez%2FgD7M781ShjKpIIORM%2FnxG%2BjjhhgPwsn2IoXsPGPqYHXA63zJ07M2GPEykQwJBYLK808qYxuIew4frk52nhCsnCYmXiR6CuapvE1IwRB4%2FQftDbEn%2BAucIr1oxrLabRj9q4ae0%2BfXkHnteAJwXRbVkR0mctVSwEbqhJiMSZUp9DNbEDMmjX22m3ABpkrPQQTP3S1sib5pD2VRKRd%2BeNAjLYyT0hGrdjWJZy24OYXRoWQAIhGBZRxuBFMjjZQhpgrWo8SiFYbojcHO8V5DyscJpLTHyx9Fimassyo5U6WNtquUMYgccaHY5amgR3PQzq3ToNM5ABnoB9kuxsebqmYZm0R9qxJbFXCQ1UPyFIbxoUraTJFDpCk0Wk9GaYJKz%2F6oHwEP0Q14lMtlddQsOAU9zlYdMVHiT7RQP3XCmWYDcHCGbVRHGnHuwzScA0BaSBOGkz3lM8CArjrBsyEoV6Ys4qgDK3ykQQPZ3hCRGNXQTNNXbEb6tDiTDLKOyMzRhCFT%2BmAUmiYbV3YQVqFVp9dorv%2BTsLeCykS2b5yyu8AV7IS9cxcL8z4Kfwp%2BxJyYLv1OsxQCZwTB4a8BZ%2F5EdxTBJthApqyfd9u3ifr%2FWILTqq5VqgwMT9SOxbSGWLQJUUWCVi4k9tho9nEsbUh7U6NUsLmkYFXOhZ0kmamaJLRNJzSj%2Fqn4Mso6zb6iLLBXoaZ6AqeWCjHQm2lztnejYYM2eubnpBdKVLORZhudH3JF1waBJKA9%2BW8EhMj3Kzf0L4vi4k6RoHh3Z5YgmSZmk6ns4fjScjAoL8GoOECgqgYEBYUGFVO4FUv4%2FYtowhEmTs0vrvlD%2FCrisnoBNDAcUi%2FteY7OctFlmARQzjOItrrlKuPO6E2Ox93L4O%2F4DcgV%2FdZ7qR3VBwVQxP1GCieA4RIpweYJ5FoYrHxqRBdJjnqbsikA2Ictbb8vE1GYIo9dacK0REgDX4smy6GAkxlH1yCGGsk%2BtgiDhNKuKu3yNrMdxafmKTF632F8Vx4BNK57GvlFisrkjN9WDAtjsWA0ENT2e2nETUb%2Fn7qwhvGnrHuf5bX6Vh%2Fn3xffU3PeHdR%2BFA92i6ufT3AlyAREoNDh6chiMWTvjKjHDeRhOa9YkOQRq1vQXEMppAQVwHCuIcV2g5rBn6GmZZpTR7vnSD6ZmhdSl176gqKTXu5E%2BYbfL0adwNtHP7dT7t7b46DVZIkzaRJOM%2BS6KcrzYVg%2BT3wSRFRQashjfU18NutrKa%2F7PXbtuJvpIjbgPeqd%2BpjmRw6YKpnANFSQcpzTZgpSNJ6J7uiagAbir%2F8tNXJ%2FOsOnRh6iuIexxrmkIneAgz8QoLmiaJ8sLQrELVK2yn3wOHp57BAZJhDZjTBzyoRAuuZ4eoxHruY1pSb7qq79cIeAdOwin4GdgMeIMHeG%2BFZWYaiUQQyC5b50zKjYw97dFjAeY2I4Bnl105Iku1y0lMA1ZHolLx19uZnRdILcXKlZGQx%2FGdEqSsMRU1BIrFqRcV1qQOOHyxOLXEGcbRtAEsuAC2V4K3p5mFJ22IDWaEkk9ttf5Izb2LkD1MnrSwztXmmD%2FQi%2FEmVEFBfiKGmftsPwVaIoZanlKndMZsIBOskFYpDOq3QUs9aSbAAtL5Dbokus2G4%2FasthNMK5UQKCOhU97oaOYNGsTah%2BjfCKsZnTRn5TbhFX8ghg8CBYt%2FBjeYYYUrtUZ5jVij%2Fop7V5SsbA4mYTOwZ46hqdpbB6Qvq3AS2HHNkC15pTDIcDNGsMPXaBidXYPHc6PJAkRh29Vx8KcgX46LoUQBhRM%2B3SW6Opll%2FwgxxsPgKJKzr5QCmwkUxNbeg6Wj34SUnEzOemSuvS2OetRCO8Tyy%2BQbSKVJcqkia%2BGvDefFwMOmgnD7h81TUtMn%2BmRpyJJ349HhAnoWFTejhpYTL9G8N2nVg1qkXBeoS9Nw2fB27t7trm7d%2FQK7Cr4uoCeOQ7%2F8JfKT77KiDzLImESHw%2F0wf73QeHu74hxv7uihi4fTX%2BXEwAyQG3264dwv17aJ5N335Vt9sdrAXhPOAv8JFvzqyYXwfx8WYJaef1gMl98JRFyl5Mv5Uo%2FoVH5ww5OzLFsiTPDns7fS6EURSSWd%2F92BxMYQ8sBaH%2Bj%2BwthQPdVgDGpTfi%2BJQIWMD8xKqULliRH01rTeyF8x8q%2FGBEEEBrAJMPf25UQwi0b8tmqRXY7kIvNkzrkvRWLnxoGYEJsz8u4oOyMp8cHyaybb1HdMCaLApUE%2B%2F7xLIZGP6H9xuSEXp1zLIdjk5nBaMuV%2FyTDRRP8Y2ww5RO6d2D94o%2B6ucWIqUAvgHIHXhZsmDhjVLczmZ3ca0Cb3PpKwt2UtHVQ0BgFJsqqTsnzZPlKahRUkEu4qmkJt%2Bkqdae76ViWe3STan69yaF9%2BfESD2lcQshLHWVu4ovItXxO69bqC5p1nZLvI8NdQB9s9UNaJGlQ5mG947ipdDA0eTIw%2FA1zEdjWquIsQXXGIVEH0thC5M%2BW9pZe7IhAVnPJkYCCXN5a32HjN6nsvokEqRS44tGIs7s2LVTvcrHAF%2BRVmI8L4HUYk4x%2B67AxSMJKqCg8zrGOgvK9kNMdDrNiUtSWuHFpC8%2Fp5qIQrEo%2FH%2B1l%2F0cAwQ2nKmpWxKcMIuHY44Y6DlkpO48tRuUGBWT0FyHwSKO72Ud%2BtJUfdaZ4CWNijzZtlRa8%2BCkmO%2FEwHYfPZFU%2FhzjFWH7vnzHRMo%2BaF9u8qHSAiEkA2HjoNQPEwHsDKOt6hOoK3Ce%2F%2B%2F9boMWDa44I6FrQhdgS7OnNaSzwxWKZMcyHi6LN4WC6sSj0qm2PSOGBTvDs%2FGWJS6SwEN%2FULwpb4LQo9fYjUfSXRwZkynUazlSpvX9e%2BG2zor8l%2BYaMxSEomDdLHGcD6YVQPegTaA74H8%2BV4WvJkFUrjMLGLlvSZQWvi8%2FQA7yzQ8GPno%2F%2F5SJHRP%2FOqKObPCo81s%2F%2B6WgLqykYpGAgQZhVDEBPXWgU%2FWzFZjKUhSFInufPRiMAUULC6T11yL45ZrRoB4DzOyJShKXaAJIBS9wzLYIoCEcJKQW8GVCx4fihqJ6mshBUXSw3wWVj3grrHQlGNGhIDNNzsxQ3M%2BGWn6ASobIWC%2BLbYOC6UpahVO13Zs2zOzZC8z7FmA05JhUGyBsF4tsG0drcggIFzgg%2Fkpf3%2BCnAXKiMgIE8Jk%2FMhpkc8DUJEUzDSnWlQFme3d0sHZDrg7LavtsEX3cHwjCYA17pMTfx8Ajw9hHscN67hyo%2BRJQ4458RmPywXykkVcW688oVUrQhahpPRvTWPnuI0B%2BSkQu7dCyvLRyFYlC1LG1gRCIvn3rwQeINzZQC2KXq31FaR9UmVV2QeGVqBHjmE%2BVMd3b1fhCynD0pQNhCG6%2FWCDbKPyE7NRQzL3BzQAJ0g09aUzcQA6mUp9iZFK6Sbp%2FYbHjo%2B%2B7%2FWj8S4YNa%2BZdqAw1hDrKWFXv9%2BzaXpf8ZTDSbiqsxnwN%2FCzK5tPkOr4tRh2kY3Bn9JtalbIOI4b3F7F1vPQMfoDcdxMS8CW9m%2FNCW%2FHILTUVWQIPiD0j1A6bo8vsv6P1hCESl2abrSJWDrq5sSzUpwoxaCU9FtJyYH4QFMxDBpkkBR6kn0LMPO%2B5EJ7Z6bCiRoPedRZ%2FP0SSdii7ZnPAtVwwHUidcdyspwncz5uq6vvm4IEDbJVLUFCn%2FLvIHfooUBTkFO130FC7CmmcrKdgDJcid9mvVzsDSibOoXtIf9k6ABle3PmIxejodc4aob0QKS432srrCMndbfD454q52V01G4q913mC5HOsTzWF4h2No1av1VbcUgWAqyoZl%2B11PoFYnNv2HwAODeNRkHj%2B8SF1fcvVBu6MrehHAZK1Gm69ICcTKizykHgGFx7QdowTVAsYEF2tVc0Z6wLryz2FI1sc5By2znJAAmINndoJiB4sfPdPrTC8RnkW7KRCwxC6YvXg5ahMlQuMpoCSXjOlBy0Kij%2BbsCYPbGp8BdCBiLmLSAkEQRaieWo1SYvZIKJGj9Ur%2FeWHjiB7SOVdqMAVmpBvfRiebsFjger7DC%2B8kRFGtNrTrnnGD2GAJb8rQCWkUPYHhwXsjNBSkE6lGWUj5QNhK0DMNM2l%2BkXRZ0KLZaGsFSIdQz%2FHXDxf3%2FTE30%2BDgBKWGWdxElyLccJfEpjsnszECNoDGZpdwdRgCixeg9L4EPhH%2BRptvRMVRaahu4cySjS3P5wxAUCPkmn%2BrhyASpmiTaiDeggaIxYBmtLZDDhiWIJaBgzfCsAGUF1Q1SFZYyXDt9skCaxJsxK2Ms65dmdp5WAZyxik%2FzbrTQk5KmgxCg%2Ff45L0jywebOWUYFJQAJia7XzCV0x89rpp%2Ff3AVWhSPyTanqmik2SkD8A3Ml4NhIGLAjBXtPShwKYfi2eXtrDuKLk4QlSyTw1ftXgwqA2jUuopDl%2B5tfUWZNwBpEPXghzbBggYCw%2Fdhy0ntds2yeHCDKkF%2FYxQjNIL%2FF%2F37jLPHCKBO9ibwYCmuxImIo0ijV2Wbg3kSN2psoe8IsABv3RNFaF9uMyCtCYtqcD%2BqNOhwMlfARQUdJ2tUX%2BMNJqOwIciWalZsmEjt07tfa8ma4cji9sqz%2BQ9hWfmMoKEbIHPOQORbhQRHIsrTYlnVTNvcq1imqmmPDdVDkJgRcTgB8Sb6epCQVmFZe%2BjGDiNJQLWnfx%2BdrTKYjm0G8yH0ZAGMWzEJhUEQ4Maimgf%2Fbkvo8PLVBsZl152y5S8%2BHRDfZIMCbYZ1WDp4yrdchOJw8k6R%2B%2F2pHmydK4NIK2PHdFPHtoLmHxRDwLFb7eB%2BM4zNZcB9NrAgjVyzLM7xyYSY13ykWfIEEd2n5%2FiYp3ZdrCf7fL%2Ben%2BsIJu2W7E30MrAgZBD1rAAbZHPgeAMtKCg3NpSpYQUDWJu9bT3V7tOKv%2BNRiJc8JAKqqgCA%2FPNRBR7ChpiEulyQApMK1AyqcWnpSOmYh6yLiWkGJ2mklCSPIqN7UypWj3dGi5MvsHQ87MrB4VFgypJaFriaHivwcHIpmyi5LhNqtem4q0n8awM19Qk8BOS0EsqGscuuydYsIGsbT5GHnERUiMpKJl4ON7qjB4fEqlGN%2FhCky89232UQCiaeWpDYCJINXjT6xl4Gc7DxRCtgV0i1ma4RgWLsNtnEBRQFqZggCLiuyEydmFd7WlogpkCw5G1x4ft2psm3KAREwVwr1Gzl6RT7FDAqpVal34ewVm3VH4qn5mjGj%2BbYL1NgfLNeXDwtmYSpwzbruDKpTjOdgiIHDVQSb5%2FzBgSMbHLkxWWgghIh9QTFSDILixVwg0Eg1puooBiHAt7DzwJ7m8i8%2Fi%2BjHvKf0QDnnHVkVTIqMvIQImOrzCJwhSR7qYB5gSwL6aWL9hERHCZc4G2%2BJrpgHNB8eCCmcIWIQ6rSdyPCyftXkDlErUkHafHRlkOIjxGbAktz75bnh50dU7YHk%2BMz7wwstg6RFZb%2BTZuSOx1qqP5C66c0mptQmzIC2dlpte7vZrauAMm%2F7RfBYkGtXWGiaWTtwvAQiq2oD4YixPLXE2khB2FRaNRDTk%2B9sZ6K74Ia9VntCpN4BhJGJMT4Z5c5FhSepRCRWmBXqx%2BwhVZC4me4saDs2iNqXMuCl6iAZflH8fscC1sTsy4PHeC%2BXYuqMBMUun5YezKbRKmEPwuK%2BCLzijPEQgfhahQswBBLfg%2FGBgBiI4QwAqzJkkyYAWtjzSg2ILgMAgqxYfwERRo3zruBL9WOryUArSD8sQOcD7fvIODJxKFS615KFPsb68USBEPPj1orNzFY2xoTtNBVTyzBhPbhFH0PI5AtlJBl2aSgNPYzxYLw7XTDBDinmVoENwiGzmngrMo8OmnRP0Z0i0Zrln9DDFcnmOoBZjABaQIbPOJYZGqX%2BRCMlDDbElcjaROLDoualmUIQ88Kekk3iM4OQrADcxi3rJguS4MOIBIgKgXrjd1WkbCdqxJk%2F4efRIFsavZA7KvvJQqp3Iid5Z0NFc5aiMRzGN3vrpBzaMy4JYde3wr96PjN90AYOIbyp6T4zj8LoE66OGcX1Ef4Z3KoWLAUF4BTg7ug%2FAbkG5UNQXAMkQezujSHeir2uTThgd3gpyzDrbnEdDRH2W7U6PeRvBX1ZFMP5RM%2BZu6UUZZD8hDPHldVWntTCNk7To8IeOW9yn2wx0gmurwqC60AOde4r3ETi5pVMSDK8wxhoGAoEX9NLWHIR33VbrbMveii2jAJlrxwytTHbWNu8Y4N8vCCyZjAX%2FpcsfwXbLze2%2BD%2Bu33OGBoJyAAL3jn3RuEcdp5If8O%2Ba4NKWvxOTyDltG0IWoHhwVGe7dKkCWFT%2B%2Btm%2BhaBCikRUUMrMhYKZJKYoVuv%2FbsJzO8DwfVIInQq3g3BYypiz8baogH3r3GwqCwFtZnz4xMjAVOYnyOi5HWbFA8n0qz1OjSpHWFzpQOpvkNETZBGpxN8ybhtqV%2FDMUxd9uFZmBfKXMCn%2FSqkWJyKPnT6lq%2B4zBZni6fYRByJn6OK%2BOgPBGRAJluwGSk4wxjOOzyce%2FPKODwRlsgrVkdcsEiYrqYdXo0Er2GXi2GQZd0tNJT6c9pK1EEJG1zgDJBoTVuCXGAU8BKTvCO%2FcEQ1Wjk3Zzuy90JX4m3O5IlxVFhYkSUwuQB2up7jhvkm%2BbddRQu5F9s0XftGEJ9JSuSk%2BZachCbdU45fEqbugzTIUokwoAKvpUQF%2FCvLbWW5BNQFqFkJg2f30E%2F48StNe5QwBg8zz3YAJ82FZoXBxXSv4QDooDo79NixyglO9AembuBcx5Re3CwOKTHebOPhkmFC7wNaWtoBhFuV4AkEuJ0J%2B1pT0tLkvFVZaNzfhs%2FKd3%2BA9YsImlO4XK4vpCo%2FelHQi%2F9gkFg07xxnuXLt21unCIpDV%2BbbRxb7FC6nWYTsMFF8%2B1LUg4JFjVt3vqbuhHmDKbgQ4e%2BRGizRiO8ky05LQGMdL2IKLSNar0kNG7lHJMaXr5mLdG3nykgj6vB%2FKVijd1ARWkFEf3yiUw1v%2FWaQivVUpIDdSNrrKbjO5NPnxz6qTTGgYg03HgPhDrCFyYZTi3XQw3HXCva39mpLNFtz8AiEhxAJHpWX13gCTAwgm9YTvMeiqetdNQv6IU0hH0G%2BZManTqDLPjyrOse7WiiwOJCG%2BJ0pZYULhN8NILulmYYvmVcV2MjAfA39sGKqGdjpiPo86fecg65UPyXDIAOyOkCx5NQsLeD4gGVjTVDwOHWkbbBW0GeNjDkcSOn2Nq4cEssP54t9D749A7M1AIOBl0Fi0sSO5v3P7LCBrM6ZwFY6kp2FX6AcbGUdybnfChHPyu6WlRZ2Fwv9YM0RMI7kISRgR8HpQSJJOyTfXj%2F6gQKuihPtiUtlCQVPohUgzfezTg8o1b3n9pNZeco1QucaoXe40Fa5JYhqdTspFmxGtW9h5ezLFZs3j%2FN46f%2BS2rjYNC2JySXrnSAFhvAkz9a5L3pza8eYKHNoPrvBRESpxYPJdKVUxBE39nJ1chrAFpy4MMkf0qKgYALctGg1DQI1kIymyeS2AJNT4X240d3IFQb%2F0jQbaHJ2YRK8A%2Bls6WMhWmpCXYG5jqapGs5%2FeOJErxi2%2F2KWVHiPellTgh%2FfNl%2F2KYPKb7DUcAg%2BmCOPQFCiU9Mq%2FWLcU1xxC8aLePFZZlE%2BPCLzf7ey46INWRw2kcXySR9FDgByXzfxiNKwDFbUSMMhALPFSedyjEVM5442GZ4hTrsAEvZxIieSHGSgkwFh%2FnFNdrrFD4tBH4Il7fW6ur4J8Xaz7RW9jgtuPEXQsYk7gcMs2neu3zJwTyUerHKSh1iTBkj2YJh1SSOZL5pLuQbFFAvyO4k1Hxg2h99MTC6cTUkbONQIAnEfGsGkNFWRbuRyyaEZInM5pij73EA9rPIUfU4XoqQpHT9THZkW%2BoKFLvpyvTBMM69tN1Ydwv1LIEhHsC%2BueVG%2Bw%2BkyCPsvV3erRikcscHjZCkccx6VrBkBRusTDDd8847GA7p2Ucy0y0HdSRN6YIBciYa4vuXcAZbQAuSEmzw%2BH%2FAuOx%2BaH%2BtBL88H57D0MsqyiZxhOEQkF%2F8DR1d2hSPMj%2FsNOa5rxcUnBgH8ictv2J%2Bcb4BA4v3MCShdZ2vtK30vAwkobnEWh7rsSyhmos3WC93Gn9C4nnAd%2FPjMMtQfyDNZsOPd6XcAsnBE%2FmRHtHEyJMzJfZFLE9OvQa0i9kUmToJ0ZxknTgdl%2FXPV8xoh0K7wNHHsnBdvFH3sv52lU7UFteseLG%2FVanIvcwycVA7%2BBE1Ulyb20BvwUWZcMTKhaCcmY3ROpvonVMV4N7yBXTL7IDtHzQ4CCcqF66LjF3xUqgErKzolLyCG6Kb7irP%2FMVTCCwGRxfrPGpMMGvPLgJ881PHMNMIO09T5ig7AzZTX%2F5PLlwnJLDAPfuHynSGhV4tPqR3gJ4kg4c06c%2FF1AcjGytKm2Yb5jwMotF7vro4YDLWlnMIpmPg36NgAZsGA0W1spfLSue4xxat0Gdwd0lqDBOgIaMANykwwDKejt5YaNtJYIkrSgu0KjIg0pznY0SCd1qlC6R19g97UrWDoYJGlrvCE05J%2F5wkjpkre727p5PTRX5FGrSBIfJqhJE%2FIS876PaHFkx9pGTH3oaY3jJRvLX9Iy3Edoar7cFvJqyUlOhAEiOSAyYgVEGkzHdug%2BoRHIEOXAExMiTSKU9A6nmRC8mp8iYhwWdP2U%2F5EkFAdPrZw03YA3gSyNUtMZeh7dDCu8pF5x0VORCTgKp07ehy7NZqKTpIC4UJJ89lnboyAfy5OyXzXtuDRbtAFjZRSyGFTpFrXwkpjSLIQIG3N0Vj4BtzK3wdlkBJrO18MNsgseR4BysJilI0wI6ZahLhBFA0XBmV8d4LUzEcNVb0xbLjLTETYN8OEVqNxkt10W614dd1FlFFVTIgB7%2FBQQp1sWlNolpIu4ekxUTBV7NmxOFKEBmmN%2BnA7pvF78%2FRII5ZHA09OAiE%2F66MF6HQ%2BqVEJCHxwymukkNvzqHEh52dULPbVasfQMgTDyBZzx4007YiKdBuUauQOt27Gmy8ISclPmEUCIcuLbkb1mzQSqIa3iE0PJh7UMYQbkpe%2BhXjTJKdldyt2mVPwywoODGJtBV1lJTgMsuSQBlDMwhEKIfrvsxGQjHPCEfNfMAY2oxvyKcKPUbQySkKG6tj9AQyEW3Q5rpaDJ5Sns9ScLKeizPRbvWYAw4bXkrZdmB7CQopCH8NAmqbuciZChHN8lVGaDbCnmddnqO1PQ4ieMYfcSiBE5zzMz%2BJV%2F4eyzrzTEShvqSGzgWimkNxLvUj86iAwcZuIkqdB0VaIB7wncLRmzHkiUQpPBIXbDDLHBlq7vp9xwuC9AiNkIptAYlG7Biyuk8ILdynuUM1cHWJgeB%2BK3wBP%2FineogxkvBNNQ4AkW0hvpBOQGFfeptF2YTR75MexYDUy7Q%2F9uocGsx41O4IZhViw%2F2FvAEuGO5g2kyXBUijAggWM08bRhXg5ijgMwDJy40QeY%2FcQpUDZiIzmvskQpO5G1zyGZA8WByjIQU4jRoFJt56behxtHUUE%2Fom7Rj2psYXGmq3llVOCgGYKNMo4pzwntITtapDqjvQtqpjaJwjHmDzSVGLxMt12gEXAdLi%2FcaHSM3FPRGRf7dB7YC%2BcD2ho6oL2zGDCkjlf%2FDFoQVl8GS%2F56wur3rdV6ggtzZW60MRB3g%2BU1W8o8cvqIpMkctiGVMzXUFI7FacFLrgtdz4mTEr4aRAaQ2AFQaNeG7GX0yOJgMRYFziXdJf24kg%2FgBQIZMG%2FYcPEllRTVNoDYR6oSJ8wQNLuihfw81UpiKPm714bZX1KYjcXJdfclCUOOpvTxr9AAJevTY4HK%2FG7F3mUc3GOAKqh60zM0v34v%2BELyhJZqhkaMA8UMMOU90f8RKEJFj7EqepBVwsRiLbwMo1J2zrE2UYJnsgIAscDmjPjnzI8a719Wxp757wqmSJBjXowhc46QN4RwKIxqEE6E5218OeK7RfcpGjWG1jD7qND%2B%2FGTk6M56Ig4yMsU6LUW1EWE%2BfIYycVV1thldSlbP6ltdC01y3KUfkobkt2q01YYMmxpKRvh1Z48uNKzP%2FIoRIZ%2FF6buOymSnW8gICitpJjKWBscSb9JJKaWkvEkqinAJ2kowKoqkqZftRqfRQlLtKoqvTRDi2vg%2FRrPD%2Fd3a09J8JhGZlEkOM6znTsoMCsuvTmywxTCDhw5dd0GJOHCMPbsj3QLkTE3MInsZsimDQ3HkvthT7U9VA4s6G07sID0FW4SHJmRGwCl%2BMu4xf0ezqeXD2PtPDnwMPo86sbwDV%2B9PWcgFcARUVYm3hrFQrHcgMElFGbSM2A1zUYA3baWfheJp2AINmTJLuoyYD%2FOwA4a6V0ChBN97E8YtDBerUECv0u0TlxR5yhJCXvJxgyM73Bb6pyq0jTFJDZ4p1Am1SA6sh8nADd1hAcGBMfq4d%2FUfwnmBqe0Jun1n1LzrgKuZMAnxA3NtCN7Klf4BH%2B14B7ibBmgt0TGUafVzI4uKlpF7v8NmgNjg90D6QE3tbx8AjSAC%2BOA1YJvclyPKgT27QpIEgVYpbPYGBsnyCNrGz9XUsCHkW1QAHgL2STZk12QGqmvAB0NFteERkvBIH7INDsNW9KKaAYyDMdBEMzJiWaJHZALqDxQDWRntumSDPcplyFiI1oDpT8wbwe01AHhW6%2BvAUUBoGhY3CT2tgwehdPqU%2F4Q7ZLYvhRl%2FogOvR9O2%2BwkkPKW5vCTjD2fHRYXONCoIl4Jh1bZY0ZE1O94mMGn%2FdFSWBWzQ%2FVYk%2BGezi46RgiDv3EshoTmMSlioUK6MQEN8qeyK6FRninyX8ZPeUWjjbMJChn0n%2FyJvrq5bh5UcCAcBYSafTFg7p0jDgrXo2QWLb3WpSOET%2FHh4oSadBTvyDo10IufLzxiMLAnbZ1vcUmj3w7BQuIXjEZXifwukVxrGa9j%2BDXfpi12m1RbzYLg9J2wFergEwOxFyD0%2FJstNK06ZN2XdZSGWxcJODpQHOq4iKqjqkJUmPu1VczL5xTGUfCgLEYyNBCCbMBFT%2FcUP6pE%2FmujnHsSDeWxMbhrNilS5MyYR0nJyzanWXBeVcEQrRIhQeJA6Xt4f2eQESNeLwmC10WJVHqwx8SSyrtAAjpGjidcj1E2FYN0LObUcFQhafUKTiGmHWRHGsFCB%2BHEXgrzJEB5bp0QiF8ZHh11nFX8AboTD0PS4O1LqF8XBks2MpjsQnwKHF6HgaKCVLJtcr0XjqFMRGfKv8tmmykhLRzu%2BvqQ02%2BKpJBjaLt9ye1Ab%2BBbEBhy4EVdIJDrL2naV0o4wU8YZ2Lq04FG1mWCKC%2BUwkXOoAjneU%2FxHplMQo2cXUlrVNqJYczgYlaOEczVCs%2FOCgkyvLmTmdaBJc1iBLuKwmr6qtRnhowngsDxhzKFAi02tf8bmET8BO27ovJKF1plJwm3b0JpMh38%2BxsrXXg7U74QUM8ZCIMOpXujHntKdaRtsgyEZl5MClMVMMMZkZLNxH9%2Bb8fH6%2Bb8Lev30A9TuEVj9CqAdmwAAHBPbfOBFEATAPZ2CS0OH1Pj%2F0Q7PFUcC8hDrxESWdfgFRm%2B7vvWbkEppHB4T%2F1ApWnlTIqQwjcPl0VgS1yHSmD0OdsCVST8CQVwuiew1Y%2Bg3QGFjNMzwRB2DSsAk26cmA8lp2wIU4p93AUBiUHFGOxOajAqD7Gm6NezNDjYzwLOaSXRBYcWipTSONHjUDXCY4mMI8XoVCR%2FRrs%2FJLKXgEx%2BqkmeDlFOD1%2FyTQNDClRuiUyKYCllfMiQiyFkmuTz2vLsBNyRW%2Bxz%2B5FElFxWB28VjYIGZ0Yd%2B5wIjkcoMaggxswbT0pCmckRAErbRlIlcOGdBo4djTNO8FAgQ%2BlT6vPS60BwTRSUAM3ddkEAZiwtEyArrkiDRnS7LJ%2B2hwbzd2YDQagSgACpsovmjil5wfPuXq3GuH0CyE7FK3M4FgRaFoIkaodORrPx1%2BJpI9psyNYIFuJogZa0%2F1AhOWdlHQxdAgbwacsHqPZo8u%2FngAH2GmaTdhYnBfSDbBfh8CHq6Bx5bttP2%2BRdM%2BMAaYaZ0Y%2FADkbNCZuAyAVQa2OcXOeICmDn9Q%2FeFkDeFQg5MgHEDXq%2FtVjj%2Bjtd26nhaaolWxs1ixSUgOBwrDhRIGOLyOVk2%2FBc0UxvseQCO2pQ2i%2BKrfhu%2FWeBovNb5dJxQtJRUDv2mCwYVpNl2efQM9xQHnK0JwLYt%2FU0Wf%2BphiA4uw8G91slC832pmOTCAoZXohg1fewCZqLBhkOUBofBWpMPsqg7XEXgPfAlDo2U5WXjtFdS87PIqClCK5nW6adCeXPkUiTGx0emOIDQqw1yFYGHEVx20xKjJVYe0O8iLmnQr3FA9nSIQilUKtJ4ZAdcTm7%2BExseJauyqo30hs%2B1qSW211A1SFAOUgDlCGq7eTIcMAeyZkV1SQJ4j%2Fe1Smbq4HcjqgFbLAGLyKxlMDMgZavK5NAYH19Olz3la%2FQCTiVelFnU6O%2FGCvykqS%2FwZJDhKN9gBtSOp%2F1SP5VRgJcoVj%2Bkmf2wBgv4gjrgARBWiURYx8xENV3bEVUAAWWD3dYDKAIWk5opaCFCMR5ZjJExiCAw7gYiSZ2rkyTce4eNMY3lfGn%2B8p6%2BvBckGlKEXnA6Eota69OxDO9oOsJoy28BXOR0UoXNRaJD5ceKdlWMJlOFzDdZNpc05tkMGQtqeNF2lttZqNco1VtwXgRstLSQ6tSPChgqtGV5h2DcDReIQadaNRR6AsAYKL5gSFsCJMgfsaZ7DpKh8mg8Wz8V7H%2BgDnLuMxaWEIUPevIbClgap4dqmVWSrPgVYCzAoZHIa5z2Ocx1D%2FGvDOEqMOKLrMefWIbSWHZ6jbgA8qVBhYNHpx0P%2BjAgN5TB3haSifDcApp6yymEi6Ij%2FGsEpDYUgcHATJUYDUAmC1SCkJ4cuZXSAP2DEpQsGUjQmKJfJOvlC2x%2FpChkOyLW7KEoMYc5FDC4v2FGqSoRWiLsbPCiyg1U5yiHZVm1XLkHMMZL11%2Fyxyw0UnGig3MFdZklN5FI%2FqiT65T%2BjOXOdO7XbgWurOAZR6Cv9uu1cm5LjkXX4xi6mWn5r5NjBS0gTliHhMZI2WNqSiSphEtiCAwnafS11JhseDGHYQ5%2BbqWiAYiAv6Jsf79%2FVUs4cIl%2Bn6%2BWOjcgB%2F2l5TreoAV2717JzZbQIR0W1cl%2FdEqCy5kJ3ZSIHuU0vBoHooEpiHeQWVkkkOqRX27eD1FWw4BfO9CJDdKoSogQi3hAAwsPRFrN5RbX7bqLdBJ9JYMohWrgJKHSjVl1sy2xAG0E3sNyO0oCbSGOxCNBRRXTXenYKuwAoDLfnDcQaCwehUOIDiHAu5m5hMpKeKM4sIo3vxACakIxKoH2YWF2QM84e6F5C5hJU4g8uxuFOlAYnqtwxmHyNEawLW%2FPhoawJDrGAP0JYWHgAVUByo%2FbGdiv2T2EMg8gsS14%2FrAdzlOYazFE7w4OzxeKiWdm3nSOnQRRKXSlVo8HEAbBfyJMKqoq%2BSCcTSx5NDtbFwNlh8VhjGGDu7JG5%2FTAGAvniQSSUog0pNzTim8Owc6QTuSKSTXlQqwV3eiEnklS3LeSXYPXGK2VgeZBqNcHG6tZHvA3vTINhV0ELuQdp3t1y9%2BogD8Kk%2FW7QoRN1UWPqM4%2BxdygkFDPLoTaumKReKiLWoPHOfY54m3qPx4c%2B4pgY3MRKKbljG8w4wvz8pxk3AqKsy4GMAkAtmRjRMsCxbb4Q2Ds0Ia9ci8cMT6DmsJG00XaHCIS%2Bo3F8YVVeikw13w%2BOEDaCYYhC0ZE54kA4jpjruBr5STWeqQG6M74HHL6TZ3lXrd99ZX%2B%2B7LhNatQaZosuxEf5yRA15S9gPeHskBIq3Gcw81AGb9%2FO53DYi%2F5CsQ51EmEh8Rkg4vOciClpy4d04eYsfr6fyQkBmtD%2BP8sNh6e%2BXYHJXT%2FlkXxT4KXU5F2sGxYyzfniMMQkb9OjDN2C8tRRgTyL7GwozH14PrEUZc6oz05Emne3Ts5EG7WolDmU8OB1LDG3VrpQxp%2BpT0KYV5dGtknU64JhabdqcVQbGZiAxQAnvN1u70y1AnmvOSPgLI6uB4AuDGhmAu3ATkJSw7OtS%2F2ToPjqkaq62%2F7WFG8advGlRRqxB9diP07JrXowKR9tpRa%2BjGJ91zxNTT1h8I2PcSfoUPtd7NejVoH03EUcqSBuFZPkMZhegHyo2ZAITovmm3zAIdGFWxoNNORiMRShgwdYwFzkPw5PA4a5MIIQpmq%2Bnsp3YMuXt%2FGkXxLx%2FP6%2BZJS0lFyz4MunC3eWSGE8xlCQrKvhKUPXr0hjpAN9ZK4PfEDrPMfMbGNWcHDzjA7ngMxTPnT7GMHar%2BgMQQ3NwHCv4zH4BIMYvzsdiERi6gebRmerTsVwZJTRsL8dkZgxgRxmpbgRcud%2BYlCIRpPwHShlUSwuipZnx9QCsEWziVazdDeKSYU5CF7UVPAhLer3CgJOQXl%2Fzh575R5rsrmRnKAzq4POFdgbYBuEviM4%2BLVC15ssLNFghbTtHWerS1hDt5s4qkLUha%2FqpZXhWh1C6lTQAqCNQnaDjS7UGFBC6wTu8yFnKJnExCnAs3Ok9yj5KpfZESQ4lTy5pTGTnkAUpxI%2ByjEldJfSo4y0QhG4i4IwkRFGcjWY8%2BEzgYYJUK7BXQksLxAww%2FYYWBMhJILB9e8ePEJ4OP7z%2B4%2FwOQDl64iOYDp26DaONPxpKtBxq%2FaTzRGarm3VkPYTLJKx6Z%2FMw2YbBGseJhPMwhhNswrIkyvV2BYzrvZbxLpKwcWJhYmFtVZ%2BlPEq91FzVp1HlQY1bZVLqeNR9SAUn6n0E28k%2FUuGkNpP1DBI5ch%2FEehZfjUQ9aE41NhETExoPT2gGQz0IhWJbEOvTQ4wgcXCHHFBhewYUiFHuhRSAUVmEHeCRQHQkXGFwkAgyzREJCVN7TRnTon36Zw3tPhx4EALwNdwDv%2BJ41YSP4B2CQqz0EFgARZ4ESgBHQgROwAVn9GTI%2BHYexTUevLUeta4%2FDqKrbMVS%2BYqb8hUwYCrlgKtmAq1YCrFgKrd4qpXiqZcKn1oqdWipjYKpWwVPVYqW6xUpVipKqFR3QKjagVEtAqHpxUMTitsnFaJOKx2cVhswq35RVpyiq9lFVNIKnOQVMkgqtYxVNxiqQjFS7GKlSIVIsQqPIhUWwioigFQ%2B%2BKkN8VHr49HDw9Ebo9EDo9DTo9Crg9BDg9%2FWx7gWx7YWwlobYrOGxWPNisAaAHEyALpkAVDIAeWAArsABVXACYuAD5cAF6wAKFQAQqgAbVAAsoAAlQAUaYAfkwAvogBWQACOgAD9AAHSAAKT4GUdMiOvFngBTwCn2AZ7Dv6B6k%2F90B8%2ByRnkV144AIBoAMTQATGgAjNAA4YABgwABZgB%2FmQCwyAVlwCguASlwCEuAQFwB4uAMlwBYuAJlQAUVAAhUD2KgdpUDaJgaRMDFJgX5MC1JgWJEAokQCWRAHxEAWkQBMRADpEAMkQAYROAEecC484DRpwBDTnwNOdw05tjTmiNOYwtswhYFwLA7BYG4LA2BYGOLAwRYFuLAsxYFQJAohIEyJAMwkAwiQC0JAJgkAeiQBkJAFokAPCQA0JABwcD4Dgc4cDdDgaYcDIDgYgUC6CgWgUClCgUYUAVBQBOFAEYMALgwAgDA9QYAdIn8AZzeBB2L5EcWrenUT1KXienEsuJJ7x5U8XlTjc1NVzUyXFTGb1LlpUtWlTDIjqwE4LsagowoCi2gJLKAkpoBgJQNpAIhNqaEoneI6kiiqQ6Go%2Fn6j0cS%2Ba2gEU8gIHJ%2BBwfgZX4GL%2BBd%2FgW34FZ%2BBS%2FgUH4FN6BTegTvoEv6BJegRnYEF2A79gOvYDl2BdEjCkqkGtwXp0LNToIskOTXzh%2FF062yJ7AAAAEDAWAAABWhJ%2BKPEIJgBFxMVP7w2QJBGHASQnOBKXKFIdUK4igKA9IEaYJg%29%20format%28%27embedded%2Dopentype%27%29%2Curl%28data%3Aapplication%2Ffont%2Dwoff%3Bbase64%2Cd09GRgABAAAAAFuAAA8AAAAAsVwAAQAAAAAAAAAAAAAAAAAAAAAAAAAAAABGRlRNAAABWAAAABwAAAAcbSqX3EdERUYAAAF0AAAAHwAAACABRAAET1MvMgAAAZQAAABFAAAAYGe5a4ljbWFwAAAB3AAAAsAAAAZy2q3jgWN2dCAAAAScAAAABAAAAAQAKAL4Z2FzcAAABKAAAAAIAAAACP%2F%2FAANnbHlmAAAEqAAATRcAAJSkfV3Cb2hlYWQAAFHAAAAANAAAADYFTS%2FYaGhlYQAAUfQAAAAcAAAAJApEBBFobXR4AABSEAAAAU8AAAN00scgYGxvY2EAAFNgAAACJwAAAjBv%2B5XObWF4cAAAVYgAAAAgAAAAIAFqANhuYW1lAABVqAAAAZ4AAAOisyygm3Bvc3QAAFdIAAAELQAACtG6o%2BU1d2ViZgAAW3gAAAAGAAAABsMYVFAAAAABAAAAAMw9os8AAAAA0HaBdQAAAADQdnOXeNpjYGRgYOADYgkGEGBiYGRgZBQDkixgHgMABUgASgB42mNgZulmnMDAysDCzMN0gYGBIQpCMy5hMGLaAeQDpRCACYkd6h3ux%2BDAoPD%2FP%2FOB%2FwJAdSIM1UBhRiQlCgyMADGWCwwAAAB42u2UP2hTQRzHf5ekaVPExv6JjW3fvTQ0sa3QLA5xylBLgyBx0gzSWEUaXbIoBBQyCQGHLqXUqYNdtIIgIg5FHJxEtwqtpbnfaV1E1KFaSvX5vVwGEbW6OPngk8%2FvvXfv7pt3v4SImojIDw6BViKxRgIVBaZwVdSv%2BxvXA%2BIuzqcog2cOkkvDNE8Lbqs74k64i%2B5Sf3u8Z2AnIRLbyVCyTflVSEXVoEqrrMqrgiqqsqqqWQ5xlAc5zWOc5TwXucxVnuE5HdQhHdFRHdNJndZZndeFLc%2FzsKJLQ%2FWV6BcrCdWkwspVKZVROaw0qUqqoqZZcJhdTnGGxznHBS5xhad5VhNWCuturBTXKZ3RObuS98pb9c57k6ql9rp2v1as5deb1r6s9q1GV2IrHSt73T631424YXzjgPwqt%2BRn%2BVG%2BlRvyirwsS%2FKCPCfPytPypDwhj8mjctRZd9acF86y89x55jxxHjkPnXstXfbt%2FpNjj%2FnwXW%2BcHa6%2FSYvZ7yEwbDYazDcIgoUGzY3h2HtqgUcs1AFPWKgTXrRQF7xkoQhRf7uF9hPFeyzUTTSwY6EoUUJY6AC8bSGMS4Ys1Au3WaiPSGGsMtkdGH2rzJgYHAaYjxIwQqtB1CnYkEZ9BM6ALOpROAfyqI%2FDBQudgidBETXuqRIooz4DV0AV9UV4GsyivkTEyMMmw1UYGdhkuAYjA5sMGMvIwCbDDRgZeAz1TXgcmDy3YeRhk%2BcOjCxsMjyAkYFNhscwMrDJ8BQ2886gXoaRhedQvyTSkDZ7uA6HLLQBI5vGntAbGHugTc53cMxC7%2BE4SKL%2BACOzNpk3YWTWJid%2BiRo5NXIKM3fBItAPW55FdJLY3FeHBDr90606JCIU9Jk%2BMs3%2FY%2F8L8jUq3y79bJ%2F0%2F%2BROoP4v9v%2F4%2Fmj%2Bi7HBXUd0%2FelU6IHfHt8Aj9EPGAAoAvgAAAAB%2F%2F8AAnjaxb0JfBvVtTA%2BdxaN1hltI1m2ZVuSJVneLVlSHCdy9oTEWchqtrBEJRAgCYEsQNhC2EsbWmpI2dqkQBoSYgKlpaQthVL0yusrpW77aEubfq%2Fly%2BujvJampSTW5Dvnzmi1E%2Bjr%2F%2F3%2BXmbu3Llz77nnbuece865DMu0MAy5jGtiOEZkOp8lTNeUwyLP%2FDH%2BrEH41ZTDHAtB5lkOowWMPiwayNiUwwTjE46AI5xwhFrINPXYn%2F7ENY0dbWHfZAiTZbL8ID%2FInAd5xz2NpIH4STpDGonHIJNE3OP1KG4ISaSNeBuITAyRLgIxoiEUhFAnmUpEiXSRSGqAQEw0kuyFUIb0k2gnGSApyBFi0il2SI5YLGb5MdFjXCey4mNHzQ7WwLGEdZiPPgYR64we8THZHAt%2BwnT84D%2Fx8YTpGPgheKH4CMEDVF9xBOIeP3EbQgGH29BGgpGkIxCMTCW9qUTA0Zsir%2BQUP1mt%2BP2KusevwIO6Bx%2FIaj8%2FOD5O0VNrZW2EsqZBWbO1skRiEKE0DdlKKaSVO5VAuRpqk8VQJAqY7ydxaK44YJvrO2EWjOoDBoFYzQbDNkON%2BUbiKoRkywMWWf1j4bEY2iIY1AeMgvmEz%2FkVo9v4FSc%2FaMZMrFbjl4zWLL0%2BY5FlyzNlEVYDudJohg8gPUP7kcB%2Fmn%2BG6cd%2B5PV4Q72dXCgocWJADBgUuDTwiXiGSyZo14HOEQ2lE6k0XDIEusexDzZOMXwt1Dutz%2BtqmxTvlskNWXXUQIbhaurum9GrePqm9Yaeabjkiqf%2BbUvzDOvb2Y1E%2BEX2DnemcTP%2FzLcuu7xjQXdAtjR0Lo5n4%2FHs%2FGtntMlysHt%2B29NXbH6se%2F%2FWbFcyu%2Br28H0MwzI30DYeYTLMXIA2EG8QlHpAsyS0EfEToR0a3utIxFPJ3kiIHCCrZ66b0e2xEmL1dM9YN%2FMwS5p01N5jMX%2FBLKt%2F1R83l0LyC29M6%2BiYxo%2FUNg%2FEF7c2WyyW5tYl8WnhWg2%2FhyySbD5UhnDyS7OcU0dnrFw%2BDfGdI7v4QfYIIzOMq9hFtY55gmvC7jZ2FK7sEdrn6IXBuucYhjsGdQ8z0yEbWkkczjjsE5hNAIZrPx2zOLZDmKNXcXtg7EMqidAEEWg%2BSJCBBNwxvxJfc%2FbZa%2BKKf%2BxoKZybnq5vaqpPTye7CiF%2BZFjxZ8%2F7Qij0hfOG%2FcowPA1rT1l4ymWnrKmxxqfErTVrpgwPlz1kC%2BOy8NMDz6c%2BIO38K%2Fx0xkPnLW8Kx6qGAoQdL%2BTD9V9rb%2B%2Fctn%2F%2Ftrxz8dUrZrD%2Fzk%2FferF0cNt1BzctmX2FZPXt%2FjnFCQNz4Ah%2FiKllGiCMs1w5Lkg0kiEwj6VTXCDKsX9rMpnvIj9pcDecXAIXMnqn2dTUbN6w0XQ9ue6FV%2FnnXCH7S3lPWGltVcLsH75ub3ab7A8M28caNrIeOr3o5Q0yFsYL80xaa0EY%2FUEczV7icUMY5pnelAkmUAXmHYjvFWFGxuqlSaow3OM%2B%2FiYY7%2Fl%2FhVELF4EjRqNR%2FbvRbOY%2BDUGzGR%2FOh3EqmE%2FugIQQguGt%2FeMYz%2F%2BL0cimjeZfQDI3phXMbMQsqH%2BCjwVz%2Fhf4idHovgVmB8gLvjbicDcC%2FNypP536E%2F9N%2FpuMibExdohBmNwyiaZdJGoigos7GpF222xrfnZhML%2F7Z%2BylaqP63Hr%2Bm7bdUkQ6%2F2cXqdfmvwixY%2Bs2ksXFeXcE%2BiX0Z%2BIow76DBNgjJ7TOdUK18iPsPflfQD%2BDPsZG2Aj9VmKMMJ4fYRrhIaxhTDR0Elh2vA6h%2FAE6xUb29mj3sjmL72petXjejPy%2Boel60M99tFduCI59N3221xe7apOvxs6aHs7vab1IqY2tv7q2xsHeHGml%2FcV06u%2F8S%2FxTjJ%2BJYc0bWEX0ukW6YmIbGkJRMdjJ9mYIH5QIdJF4hvRGyK7cC7ctImQRcUET99fGXOoft35GYLMQu%2Bg2smnkgZUrH8AL%2F9Si217IssJ916nv14ZrJrvdxLkQvrvtBcjgPC0NXOicO8Qf4mcxPqh3hgUw3DDfdvLJXngg7N3dN2zbPJSaed3OfZnMU7dvmznp3C3bruO%2BNmue0LFsy7S%2B6265%2BfCKFYdvvuW6vmlblnUI8xCXp37CrOZv4B9gauDBlYp7adcUXB5DNCwYImlXOJJKkAdvExXxVvKEYnCo%2B3eIskP9qrrfIYs71CccBjfXRC52udTHHdaP1A1ui%2FVvH1otbrLrpNXBsGX5B89QghDyimlvNB2KfkxZ5C9%2Fem3%2Bd1%2Bd%2F%2FIfFp2%2B2Oxn%2Fs%2B9n%2F79p39S3s8idN6g0yZObwJOgKUpNB3GyU0Ls0PbRzIRq4lcarLKOJBkLRzJQD4j2090XrbA7DW8K3jNF5hlGS5e4V2D17zgss4T20egOJte5iD0bReM9yjTxnQxCRj3c5kFzGJmGbNKmwGw39IJDJcXJZGMkaAB4jyJAKw0jt5IAuIE%2BA%2BU3cVAZZrq9zhDyBrU8oosuxcGNTzCKJfla7JjNVmuSb%2F%2BtuzN2H%2BX4vlB%2BPpdfMXXmuVsNiub1T34SFbjYw5itEvVi0K0Nt9pNJUMI7SLGRhf2xipfCYf8z5OdlGKayOucFeVPeS%2Fdbo3lBrbSMmwUiQN5%2Fed7g0Ds1s17IuZC5kNzM3MZ6EWCa0DtekdJfAxz%2BR%2FOX28sND7yRMTBcf%2B%2Bs8mQCQWHya4qBv%2FufeMoWyslPA9DtMxUknxkH%2FyfTnm2CMYzs%2BCq3r7PxY%2FMXomrvTEsRpfEGHa%2BWN8E1AHjElb7d06ddA7oK%2F%2B5Mdsv9EtPms0jv0Z5kf1FqPxWdFtfFr0kHfgDX0Y%2B5PRSG7RUj0tQr7rmfX8DH4G5W28kKeJLtmQsQkuwMP1pk16EV4sl7vrMJATfyUWo%2FGwEco4rh4XFQgaiUX9qxZHrMQqKnz%2Fc2d8b9TysYrAuXpP%2FRf%2FGr8b1qwwc5a%2BeuLa6S6sneNXToG2XrEJi4R5SGs8Sq2S3d97bsfCRaTdaLwKClRHt37mkudvXbjwVrLhuYeGhh56bvfQkHpk2CwvwClqgWwuBfndC3c8dwmstj81KkagcUgbfPY8Zje0W%2F82VPWJHmSq6pP8hPWpotc%2FEexDOK3qU%2BwngPhOCiO9MJRm8TJefjelrzoKnG2Bn%2B1NCUmPE4gHFmBN9jrTigRIpsACrc9Gstg58ULkp9467%2BGf%2FeFnD5%2F31lNrt2967dhrm7bzI%2BVT5m%2BfzKhvf2MzpICEm79Bopkn07lt1762adNr127LwVqQLdJ5%2BlpQDcvHPQtVY5knhYrK6q8%2FJsiP6EuhGZdFdaNszjvpqvc%2BPI0CdjN0AXsFOC3ZfALDJwr4q2Xq%2BGF%2BGNbsxUg5NLLIEXi8otcDQcUts0D8eQ1iVDRAMBTsYiNdRIxE09EIBJO9A2xqgERTaW86BUFn0OD2xFO97FAgFhF6OoQ7prYt4XwSeUgQHiJyDbeke9IdQntciLQ1FlJMaYcUNvZBg%2BFB1ubjlnRNvl3o6IEU2w7fdNPhm%2Fhh%2BFLysUu6%2B%2BDLHkOkrSHYEjH0tEPe7WdD3uyDgvAgK%2Fm4szFFR7ch0toUgBTdWHr7EpaWru6%2B6dmbbnqWEbV2EtxAsXiZAPTtGPSbHsotI2leoM8TePEqgSQprs7AGFf8kuOkPdZPXGb55POAW1d%2FjLST9v5YflasP6v%2FCO7%2BGNAPC2BMZWmsOjp2NNbfHwMCJD%2BLPVL%2BD%2FOYlWEEI%2F9jpPddOFkB5d1GSuKZYggmCCd7JUxD7EXAzxyirYnNDLdDZoFdx14kivkvGc3579Jm36reTTvDgBnaO6vzyQ6chQmlsMoIkIQ2%2BbBDWBud1Va4pcCn8CPqxlh%2FfgtG8IPaPH8C5wk6%2FnZDv69jurV5QhtwE0x2iqOsj9Mx8B9%2F0EaUdiPfOYYDCi%2Fq9jhWRuupMDEU0%2BCtX0sDFxv07T%2FK5niBPqN9%2BtQjgEc31NGCXFeMcCEuQBIc%2FBK4CO78u7EPYvl3yaEfK3vcb6qP1R2tI7vUjVDDUdKubsSrNjYKY1qBEa2P50SJoaXiksIoLiCwnxS6EBuBde87botNfdEWwYvF%2FR0%2Fu5yCqhGeEOR2ynSeyXjt6ka7neyye8kryBSWE52y%2BRBgogrXPZ8E1yIHoHIFUM%2BAbJhE7lbMtt8ApL%2BxmZW7PwbjAO0fAVoXQOuiSP%2FksIVdFZ0aulsamKUzwPZ%2FNYDMJRBPCxsBqLzqHyneXF6Ej9HlIFo7%2Bpg%2BjUb3unRmGpstGkm6etOuDBGA5wCMefp1gTHcdZlvPBXlOslvYTp1cd8UjYLVd%2FJ5awNrIOKLnIt9MD9qdrKrWCvA6ALm3QV9VrsPm60Q7%2BRHJHP%2B2hqfugo%2FMvI2H%2Fmqr4b9tFnKSRY1Y5Ek80Nm%2FWIhr1ikKnxGz9TWXrokf9xwujfvcOTtNTWnxd0F37Y2W79tteBqZ4G5qLCuomw%2BnSr28QESCRVLTyYKILGJOPfcnaIFOsewhRdvv%2BrWa%2FWih0vlbX6Zb75T5C0qNKVFvH1QL%2FvazSWgC2s6oWXXIuUxQelKiJbowuJDQViatLmLijg9CQBMg8WiPgiw3LEeYRmm5f%2BXdnvkDnxLLjMLxtvX74C3OlwPQqx4xwIdpPx38LrlDphiyWUWHWKAzzxurS%2FxTo%2BP5wGFak62ap1PVFFN4v%2Fy%2BxuR39WnIO7lsWfwgVsK17wxrs9K8ltIKuhkw7f%2F6dhK6gQokFKhWX3urrjk%2FrnI0pgfpGMeuQIUaEM7%2BGF5q2iMkCaMQwxxOzcvU0eXbsnS9XknXvP7Gtw5dwPXlFu2ecvSHEZgNDsU6x%2FGdXBYXyOQjzZReSedeEPY6nEv9gJR4oBQJtFO6Kd0fwC6BO4LNHDeBujB6dSNcUQC9zIv2LnAzGk99bUDrdFY%2B9yGFQtEo0GQPNv6vS2drj4%2B1jHbv3aJSMUWP%2BQTZrmbNTjU8wyG%2FiXNNpskybLcJ3CiTF5Ir%2BJYzmJwE0mSVhlxbtbmvweB3ulB6Til5UuUZydpgiFVeobhU0WaBqpJ198d%2B%2FXeNRTZ9%2F1OPfG7%2B2hwzd5W3D%2BhmyjsRcUg%2F%2BCavb%2B%2BVh2ls3L7zT%2FetOnHNxeerv313vzLVqPai4nJv%2BK1FC6040%2F4udw7sAb3laSg0XCkAAs0npBO6VJabS4Elk%2FU%2BD4gTXW%2Bj0wnrMlqNamq4tMIYB87tE10i0FR3LZNhJsb7%2FR561btmes8YBCRkhYNByRtKd55mqTas9FYhJnbRGHuOh3M4QTdgQSqmgRxuzGdSvZGcbMxNQGk5C3ebLjoXIOFM4l%2BWKHmLTJwRv9E8GWJ6dYvf%2FFmEyEGr%2Bgyrr1p5zrgkz0Cw2j94Hv8Jdx7dIVegBSNtgsqGsRQEYiIBoXwD0LNvQ5d7s5Z00QzwNhqZA0b%2BtMG1tQq5nd84uq8R0zPvX35G8uRaze4jcOHzz0w1%2BQ2BIRvf6J6Kgatnrbiem%2BCFvAxfkrndzD9MFPP1GWTUHclpASUkCNAQkpCCcCgDSUDAhDZ%2BCuEkgn8J7i9nMA7pA4lISappxILKfAeSAbIcSDuN2bJcfZILqeO5rLs0MnngSHYRdrHjmaz7JEsEPw51ZqDJDmUIOZIe34WaQeegNsJn1qz8AIpT3yCjyEih%2FxELkuJ0lEMYTLVCiWpo5oYMleMH6USyYJcD%2BuOe%2BkWKpn1Qns34iyYDjkSLvgnZXcgVQNeqINXr48m3iS7cjm8tedyY0f1QvTnHHdsrKby%2F%2BSSbPY8%2FNH6vpl%2FEsq3Ae4ZU1HC44KFiI9o7CEgab%2FRqHbj7s5KAg06s39ZP%2FzxI%2FmVuF%2FTbTSy%2B3Fb8If9%2Fcv7%2Bwt91yy8RfP1QXtW5RzQn7qIiZyuFM5QfJ5E9uVnqT85TanFx0lkP3ukBAMprvsRyi%2FC8NAJL1xbIIirSvnSj4O5netb4JxmNANHPssHAcHMHsFRgEug816gDBeMbdfiuRcghqYcm0%2BXxx%2F5IAEtN3fqFF3LzAXqwoT0PN0OVTNqxo8sxMkd5Ig6k79Zk7VxxX6gMLOZFQgvpW2RrMW1D0BDihaXQ9wVRoBxPLfpknmkeMtoB%2FqM9cRc9IqmMD2XUmdZ7GSRKPUZvChf8BoykriM2MnKYbOHX8R7cLdNCxSFFVQqoYswnlWtlFS2mNkhswVpZiQW1J%2FUKFfipHGlUkM6UKBhMz1istELIHJLMSctu3ugzfaVSOjKvUgc%2FTHK4Sdg2Wscz69leKIkkrwuuWiOe9yGYKQXRumkC3qbRcMwrvhjNXgdZk3RxAUEhuSPvn3nnd%2B%2BU%2F3vlVOmrJzCD8JLxV1OHRjrZifbcFDOuRNTGqdgQm1tSNJ2OcQ04YiEXuxtII1ECSQRoQGYioEsgCfchB4ghAtw7FfJre4WZ9hkVi9MtjuWqtdNDlpMrfEG9fOT6q21okg%2Be4As38MfGquNt7oUws6Ysarj1%2FefE%2Byst86YUVNvDdts3Pv5c8m%2FaP0C%2Bf8%2FQb%2BIMnGq09BgwN01oIOAnAdagI8mBSrqk1gxTDUBOtk2ousEtBH2z4Ir2d3f6k8PXXVlt2qN9RODxRuoJT%2Fv27wm09jRYVc%2Fe%2B%2Biyx2tyzJb%2Fn3J0htXP87eSsQaf2Ly0s6Zmxela88REy1cf4273mI3iXNJ7KxrZibOm9xm6rl4fqy%2Ft27smU8tOfdW2ucBzg2UfmOIVyLIl3kpYlwphDISTXJXsctmiDtN7fNV6zelgxwnWxsVr83Aj%2FS5ki1jL%2Fa0GC6%2B2L6Um%2BaoddlNFuj%2BbJ8mH%2FiaLh8I0%2FU51NspIEfq0dohwyFXKgm4NggwQ4rRhCOUFtxxo8XnitT4cnGfT93IS8FaT85XE3H5LMY4zIEPL1hw443wz%2B1UmhTJyJGxZzw%2BwsKkKZgUiVtKOKMEb2AKHTv61FNc01PQFwKnvsZ%2F9pPA4RKTASWahmh%2B8MxwzHxKy74IRn5LGRjsPUUwTu64UYNY38caqd7HKucZ%2FtHnODtENw%2F2UfHRMaq1UUPDJQ0OKkWCeet5fYOhII1VRz8%2B%2FElg5j4Gxur3J8o2PJ4rg%2B2d08T%2FfwEzSVbyZ9XPro95T477lRKqUSRXQnauHNsISAl27oWi6Fv9z48JMv8r%2FaMMj8onCP%2FDuDZOuN%2BGPPr%2F%2Bp7bx%2B7JlbYdppcNhzKU%2F1Px5aiaGDn%2Fs1iGMaBcleKUo%2Fv9rcxkZj7DBEKOfrayytXNLYiUdBY%2BpleQXdnscKlQcpzuWluxsieeyuXIK6SdxozitWyGOV3vOHHjguyCQ6fpIYy2JwvrQEF%2FQa9Pdf%2FQqOSqCiE%2FEE1%2FXIVKTc2tzWbHnimrEd%2BVyz311Ml3P0GVTj7PD5aDnsvCvH36alEaPMePcMegXs7x8igTu4B9v7G9vTHvhCu%2FkzIdx%2BBxC0ay9zRSvoS0F2lIxI%2BX7klU63I40gLQ3w5ep5na%2BSFnba3z5D64zv%2BQtM4n4ffG3tq4aNHGRfxgrXPMim%2B5487abL7xhdseIRn1KDl%2B7aINixdv0OD%2BJSPwKf5%2BxoP6aiTeQIDVlIhMcL1H5R9PYXvprs3fv2bO7MOplCmweuiq2JRZ1zz%2B9a%2Fv2PH1Hfz9236w%2BZrPXvWfAxlj4NLLHpq3c%2FPQ3uvmvbrjG7fe%2Bo2y%2FcLdtE6VUlXi0ASb1VLUBVSUWSU4HdvAraTyS8xzM8NxvxFkXV6pUVRiJwcgC5zEeht4rwcp7ki0k41G0qlQhG1Vzlq8alEmnFi58caB5Q9vn988MLhqyVlHvLEWjtQFeupdiocF%2FtkkOGPW2ibWaBTkeZ%2FdvPWazXfOnnvL6jkRXpi85sFzZt%2B55ZptW3bl1cCCHZPD06MhySha7UFzjcjbp8fOecFCirzAG%2FyVjBX6OFIaadSjQq1nNhyIe8tVbaaSdHlXIWKacMeuZA1uxS95zILhyrxAdsXTL6m7kNQlx2P9uZf2qhufePFFbpI6%2FOU0WcP99RrCsrwseVot5mtytpf6Y0gm9sdeyKnPQ7onyK4nXlR%2Frg7H95M1upzu89DH6pgUcikoiihJ6NJKmRxV1x%2BMJiOA3YwhDRQrWU0u%2F0rvq0VYXnyCwsLeTJYBq3dAtJDavuzyoVpzZ99Z0%2Ba0uoiFH%2FxcqgDR7rUFeOrUn6Cywb8ZeNMbhLV5ugP9l0zv9UN5b5mFkjzxUcpPJCn3V402pRxtJd2GrnLdhtVk9ZSZh9W91fCSH5B7ofxPiWL%2Bj3D%2FuwhBRdyAyozeZwvQzs79soi%2BBKSnafLviZCcfrpBpLyimfLfTyJtbyruIQKD01tUwJyKEo%2FybaxkSNFUMdMkhQoJyRBQFhnUkDQSXhTM%2B3NmY0EDM7ffLIjqWEGt8lCO6mLia3PukFnghosJD5p5SIho%2FVDkzQfLE%2BIrYoJXkD19pdP7OwG%2FvoIUtagiWiZ4PAFTHHlTVhRZ7dYmPar%2BNJ%2B8JhmR6DFK5DV1foHoLNO%2FpHrvZfmWZ15RQlwvoVDKhCWNK3CCch9lfFBuAqUgpFSShmNaPj%2Bi5%2B%2BWZfKeViJfW5HnUakVL4UCNVkA4%2BETfIqx4B5xSaP2L1yn0zn2ltPn4%2BOqZGmwwEVCaCSqG53ldtL1oLGAhdMLd09MpCCF6tD6ZnAZBY9hDaYsP0jzZ0j5ZjKsF4i1UmLuhbJMCnYJPt5VwFNvmZawXjEvLJqIH8STonZjq7BZ8gKgR20C9MDFqJAX1H64QW2NEup6qgzLP8cvppL%2FNNTOBTCJABOHeWoXzLhw4Wuy7gaBtjKr9kgKq8ZlRYBS32Lpxc8vIhpNDTfyNXWybMJbn2RyQ5EmWc2QF9wmSZ0KYCE%2BcPuYO6b15Uotj2Kd4MItLS7gtFbkTdrFND6pvEZqv5Yv7jXAus7Pg7avo7KDot50NX3CPkP%2BKps8J9%2F3mGQIteY%2FLGPC%2BL7872SPR2br5fy8MtKBMHedGuM28%2FMZmPJMrGgi3Gb1S%2BSi1%2FL%2FzrZwO9XH1ce%2Fz7ZQ1WSoY%2F%2BpMb5FT4ua0Wm%2BJf%2F298nFmChEQ%2BTi71est4mq9VYI6RsymoRJKYidElT2FGnDTZvqtfhGAFTbeqEw68GqtfmbVa%2F1IFO1%2FjdWr%2F8BDRRtQh9XNjubEm4aWVpVonpTGR7PVGc%2BKJNoBIWF7kYi4gUV3r1U6723i6TxUl3n3%2FtM27aZfKb7THiHW9VzFSwHJ05VfK6Ar7kaB0XgPPE0BSkSFKsBUpaLihEWoA9wBt8qirh2VSOkZwXEwyrxZ5jyt2rJmSo9gX7cg6jsEUGJU9z9xJPOEM3uQQxKgkh35DNATnVyrmJ3mbCNyIB%2Fyox4wH1bg2DwN7q9kov4pFqny8oSm3RQbGgJ1QQTs6ZMLilOVYJ9v6Wha3HcJ9jddsXp9YhGUXLXt%2FqMDnvLpPNTXfNa60z5%2FyjXQOMq%2BlNmwh5egpYrdfZQZV9rI47xlRkuyTjpzsmCBSWNkAXVoK8sgYWqQJWbo1RLo6QH0YW6pxqfCnRgkd%2BRiFjUQUQ7poIaYoakgXxwFd9BuuI38H1xBxXSFb%2FpBDIKQFn7YB3dB36l7sG1FLaKiBdp1KxLvfswap%2F30lnVESgNnvjbUoT6w9N%2BXoio0qcYOIM%2Bheg940YimsucQVvli9NEcft2UZwGQwLuilj1fFr1i3NP94X%2BPE7Hpvtj6lBJfJ4R6NvWiaL6MgzWHxiN66DExa%2BdAdAbMYX6HVF8A%2B7rjEZIXAVbDe7PVI9rmN69JOLV1DOSvRPxWNPZBZf%2FNf%2BNy65BhYxxxV%2B77XJ2wfQ389%2FIQPgajXbwMsuAz%2F0IaQcXJavKbRqR2IqyZruXjVC2%2Bhdee%2F5vdnYOedpmVtR3NGXldxSzDSIiBVpkGb9by89UpEPKrSLZmyFDzMab%2FwXl2CNe7s%2FqCtTvWgG5kpBmCBlSzDS%2Fr8N4uwBwohRW63JTS1y32f0TQsPfXVGEHQrV8%2FNCfiOUVirYcBbIeA2%2BiF68rQIo3B%2FS628vYESr79ehzS7Q9LEL9UXmik9XVHb1yBO3Ngvt5935%2Bk1efkV51mzzrM0LL3%2F20avnwMeKuWyOUZg2TasSqZ%2BKcZQiOn1Iu2Vh497ALUVZiCKt%2Fgh6IvTIj1ZLRjWAkpHKOKovNwp00eqPROiAbiNEKieXwMLcXhVJ1%2FuzmLP4tfxaHR59cBdJVG1kTAgl9ze9QKUEQ946Hkb%2BokJ5JRDyf54Axur1D%2BWS49cLr0tTPEu7UmXrxcSr3XNvumv4yXzInXKH4F7Tc7p17Zt%2Bt%2FqW2%2B93k063X7VW6lALxTY7i1nBXMxcxmzQbabxz%2BtJo%2BwijYaIGMNS8AoSMgAPt84DdHOoMPfjXhF%2BkuH1tZvuFQrRCN07xGcXRX9MYxYchDe5BcHj%2BZ4i%2B42WyPc8Xofi7bbZJN5nJLJ5qr6IqRtzqNlM17SpFsnkEyTWoABEjz4JXOQvzWYuwdnV5LNGOwTM5v9r4RpQ8ZXsYodks3o31JBlzbYtNotisnm22MxiwGFXam5oN1n0TA%2FhRvshvTSDwHff4nNzRo9Dum6PaJbMXzDz%2Bx%2BFkj4L4bFNBb1asqsgH7Dyh4DvbkPtf5yMDKzEwyoaESMSNS9P9gJVA3%2FRTlwoMwZvxECFWxIPNw9gi01nOHjP32esZTtmXHnxvZd8ZtakqQ7ekajbXetpNa6ocTVxJtY%2BuSe69OLz77zh5bDR3xjZMzUz6fxrz1nqrZGcHQHfPVefN%2BfiK86LeXj%2BSc5lPKy%2Bk%2FvCUI%2FDaLFYCWHr6nbXuILTIsb5imNKY%2FrCm28fSMxPhkN1XbNMNZGuqwOBhtTSxWuTk6bw0ZaG86b1hKddePOKuBvmiguYBn4T%2FyOqOyGRBt7bKUI1GjioBC8aUKwF7Q319UgcmtFGIzCJGBqwQij0ynDsfdFGc3TS3BlNfJ25xmzniMkpXXTPvCaD3ZaZvyzjmZdudBostmhb0ORZNN2sJBeed1HXkrUsywueQH%2BL0eCPxmsa5ZpgRJSDZ11yDv%2Bjmbd86vxZfc1WcZJ3UkMq1BOOOVtvu%2F%2BpB%2Ben186d3GTwWAw2jheaJs09%2F%2BLNfZft37DALyrNj1wABMuUKbODyTVnT%2FKYbJ3Tpq8IrNh92dkxOj5P%2FYpZx4%2FycyiVcDYdn4JbEoKdQi9054iBKsygLW46FRGxAb0NPNCm8BSNCPjoKcj6EAus4SuP3rB%2BcV99%2FeTF6294dA8%2BTK6v74MHVpYNRt%2FI30e8QGTOOdfGWzzxcy%2B87a7bLjw37rHw1nPzp0KyyRSeZO%2BQQhInt3dYgvycjrPOv%2BT8s1rptaP84VeywdWX2T4ysr0%2F7TLIs6%2Bx9zib56ye1dM9e%2FXsZmePY3NDs9zlnNVt4%2BWgHJbbz3Livg4P9WWgviOMm4kCRT6I8vw0NbUUEnFvOuFKoxQW1gTsvFirsF5pb7qTUCx4i7VmtToveaDxvK9uOaedVvPRpVOnNz0Q6bry7uiSdQ8t7Vy4JQKVS%2BXPplV2ts4bvCwZu%2BKzgITtxepaPRzWdpv74muvv6RO0SorX6cu%2FdqKn%2FXWnrtp%2FZragz13DUCl5myiFW2Ycvb0PtsXnU%2Btx8pvLFbUspLX68mdegwmOif%2FNPDONajTGoUh6tU56HBJCTBASVvNUB5VIiKpc9kd7kludodSFz7xQbiOmMk5dOYk56gzL6uaf7N8a6MQOHm0ae6snZpFDfuT3%2FjdYzjzwkXXIVHoXNuCfQslQZqBZjTsoHMqrkE4jaYdgkGz2ATOgB3cPkSukD01DnV3ttb1wx%2B6arPqbkcNAHoFPzKUUQ%2BqL0k97pjbZv1I%2FegC9zTFbrrlFpNdmea%2BgIgfWW3wqkcis8ky5FAcRd1If5nNZrl2FFpungc8wpoCl1BpQV%2FScS%2BzjlASyUTVv%2FAJ46gkJI4bHX4lTnloctxPZE1ckS3%2BjG2fKIjkQFyzuo8jvYQG1OrGvJPSTu%2FnSp9PHNTl4z5hK%2F8gtXVKF6gEKiglgcKiRlCESsQCV5QIlKWKpr34lt%2FwkSx%2FJCmP5%2FcBKQfl%2F5gd%2BrOS%2F%2Bp91%2F%2BYCg5CXK2W4M9fu%2B%2F6xxX%2BvnelVuldIDCG0VQTpU9Dw4pRfei%2B6zWx0MLie0gPbyrkmRU7OwT16JGeyXLHqOLqAfVN1GPlBzWtFNzj0TRTCjogtP1NjIvu5habN5Aoa1k66wGpqriVetJgiGdwDZtKhnN0y4n9sXYnsqGmZfDSR15%2B5NLBlhoDaedEm7sxmpqRija6ZEEg2EAnTiAC8IrmFbGz1q08P9PSkjl%2F5bqzYqT9hMmptEXDgTqP3Wiye%2BsD4Wir4jCeoHbbp5hRfpB7BakUIppIlPCD30dR1GtslDz8OsqbXmejFC%2Fv8wu5X2myq7SJ8Avzv9DFUJySf5uNvq4%2BTi7W9D%2FOZrLChdwxmPNiBRqVjnpK%2FaGxRCDspVYKAW9AN1JANoo8wP4BJUlGqdgw6m1qPQ2QW3%2BOfU5%2FieLS%2FNuKpDU3uf8bcAXyBal5jMR2NEAbPAZt0K3hvxHBEDlUxfIGcD%2BN2gNSNx36nfqlAYow0puatNpRz0e4W2oahKzQHsjf2c16ad%2F3t2KTtPobnX6D8C8pd0MDP%2BKx7wnXqGGlLQcvikMErm6TmfsuxJXbSAxqNjOogJLQBLiKEHAE%2BJGTS3JoEhTrz8%2FCB%2B5YlupJ58aOat8Kv4JvregxwcU5Cp8GFAFm1FyOfto6GS2m1NGTS6CPNKkbsTdCBlnN9onMho55BX8IJZtEQ35lk%2BhtwN5A0V3RCPoD%2FyXAcv6pAtbZczRUA64JmcUf4q7Q89ZHLeJVZ5D1Ps%2Ft%2B0iCT3AHVtZC7JDCXfR7OSb%2FXja5H3zQbZL1B%2BULX1BMTEk3AseSpmnKEK4T9ekMIidUCRQFfcbj7z8gNLvzF7mbhQN8h6ZbRset%2BnQWdS%2FZX3k7WpS8P9sfo0iGS64wV516pOhjI6TZ2dApgI5%2BLhxywYoWxKUrykKJsIoDsR4mSrCTg0egMPnLW%2F3Q5Nn8BZEuzqEI7HK3n0%2BzFmuO3TtWQ5WJoG9YqCD6Gc32SxnbnVPfsxvrFXK2dILl7bLthDp6glhcsfp4bYvbSmj%2FmQ94uBTw0E73x2jbNRCvC6VL6GCFDwU7eWQDcC5FY5s0slieRDwtAbRsbLXbaXAuu14e2OJw1dc6jQ3ZdY8v7rv2%2FBWZLqvFWVvvcmwZkK9f5jS4muO9yR5res4kfkRxhV03L1RfPOiPtYi8pd7jNEsOpyTwxpaY%2FyCZu%2FAmd5Or9uS3DYaeqVOhH7gZN%2F8I%2Fwi1fEuLXvyNivibjuKvN%2B1Nc01HF%2F3h%2Bef%2FsOhox8MPd5SFucPjorQwXT%2BytA8EmA5mamHNFDVhBI5pjZbQpugBNkO8MvRub8KVDKST1Wag7D3xlin1ZF7LFP%2F79nbvCXFOY%2BPUjrT7%2FotsPXXZ4exdPzuhZuL5LUXVAn7k7PbhG89uz3b41X01gbjP1xwlu5rrvvf9%2Bpbs6E%2FVu7Nk642%2FPYRaAiUBdrmO6CDTBLPQFA1ur0uXoBR1INDMkypKpoTqnSMx5GiEdTEaSHLs0Alvu%2F19%2F5QW9Rv1U1ridT22i%2B53pzumbs%2BXFFXYC%2B%2BCGsTj5JUT%2FGCgRt3n78i2n71FHG4%2Fu6X%2B%2B9%2Braya7os3ZbDmgWfXun44e%2Bu2NZKuGZ0HiF8M4TlMPR%2BEU6rPKRJ8wOU2RFUFLex3egEsz3YqEAq0cqhAAW19dBZIlVzR61tuIdTnpXH7l%2BuXrbjPUyep%2B8cl6aXKWhPHpDcXl9KiTWDNr4mBQc8Tq%2BNzK%2FOKSbsfl79o9G20R%2BbrBXYvUg0rLHhtrc4TN81TTOWSZ0gL1ZVlOYH2ery%2F7XVUjFMbzYpg7UswcqJPQwBd0LKLabJ8IaCr2otcjSkIrGwootKECaUd4XH1%2BSdazRrfddkBU98t1htvWrbjqSqjaCguxrffM%2F5zDCpBALUycmajhd%2BR6ww4SWafuZ5eU%2BtPid4lgd3gt%2Bb%2FY9rQoZNmiXYPXyRHbRs8zX%2Ff4WIFjWZJtUdSD55AP3xtXH%2BZipC0EqdBGDA4CoYEU6gRLGPU11QhkLTBiEYPiqOeQgwTCl9aok1Qr5pFf71qEeNxjy%2F8F0GoqYPv75Yh9j3x4DuJ%2BuEzHRpAq2lMqb%2BqfTdiq6kGtzfOWsv0c7lSeMXDHBDe1MT%2BLUgx0Pg%2Fp87u2UicdIvqQi8DkxhcUwUXCedMpb4NQjwY3npTmgsURJavLwCRyEcN2HfWsDVGfv%2Fu9ZUWUx%2BPYFueUKwaNvbtu%2BXps3eVWbN1GcgVrdMnWJ7WmJz9SD66EBidag0NF1Ukep0t5A7sFCWdhzvYwHv6L%2FBehXuHqfaBwBEU7hfVLcXvS4VQv%2BT%2FvaSIl7cbeMc7ekv9i8S3e1L5xxpvMGcu1EYPbKyCiijjGXcDKckm43PqU2qNWlXusZMiqF82cuVzolUHN9NNR0HZPxFPV9V0wLtvq%2Bk4DqOwVWDlzuQLVdqFiP08cRX7aRlBVfR8cb55bWe5LExnlcsDp1vAP8Q9BucPMk1Ulh4GnN0SAdxcNHv3q9ohx1Ati4S%2FtkWjIDe3hQdkUGrGRaFBiUdiTSkI41UkMuuQHP%2BEaSQYlPQTFWJF03BNPpTu5KFAdkWgDukzsZKMG0Q1TAQQglScOaP%2FdsZ8%2BfP75D%2F9Uu5Gs3FY%2F2SxPld0DHOciXI9gqjcEidXjE%2B3BLosy0OcX3T7O5g65ROGyzQ2BZs7WbZVnO5ydLe32hMwTQ4wnnKXW6XW5LAa7oaXOIHoUl0FgLQLH2by8wSTWeAx2Y5PDazK3BqZbeJZwXGPaYhX87ZNszoDdaRxotXO1nNlpdvAPFWHDm8PqEE0sZxDEqGzxisFNnuCWetPcGrObN0p23tTZwMuRVodSV8%2BLTrOV3eRvzjQZiSjaLYS1WEJe0kNsJlZu9LFun7%2B%2BwW4gRDRbaxw2nrOGm%2BxOj9cmtbp9ZqeTM1m8UXfQQCSTVSQox6pvtjot%2FFpHvIUjJovFEoYvHYV9C5Y%2FxN9OfcalvII37UEhTbTg%2FAQIaPb4Vz6j5u8%2FaViycMod%2FfkDcpu8QZbZoeBi%2FvbzP3XPsZvOubMtaPHkD9jt6%2BU2O7vqU%2F9C9SMvgrXpQNG%2FE0oJxun%2BCiElUa0IKQSUwERxOntKSV7ekcuh9VBZBBo3VUcB58ofKBHCwLyf9qFosz9Ibf8dGqwaBMjRig4SGOZ2UkWI7UiO9OfUPdxOYFApUZyfpY7mgEc5rtNGGk2H1lPhAk1Hp%2FVAMqQEHEUfEYkkUQq1JMdzsX7kklRrTrUi1wMcDjmu1YYfATj7Y%2BpGpPEBXuoQIj8rR9mgCl4C9yqmF7xnVWxGVniNqtpVmXBvQ6iwni5YQ8a1jYrXtc2J13HvgkvqWxuva1sbr%2BP2S5ceKGyBwDv2DbrToe1u6BkAJV7xnVLUaq0sJB8pFqcUIPi3yuwxi4JuLr%2BP30f3OkPQ72aO0xYo3%2FEsmO3QO5qEF8S0qQH0UsKXv0brnl9%2B8M7jF174%2BDsfvPOl1au%2FRL5%2F9DsbNnwHL2pHR1NTRxMZhJtHktOOxLxErPF6YlLvpC9YP73x%2B4ofw%2B3xVdrHcDE0dQQCmCRgvt9b35xINDf1CDcRSfJ%2BpYl%2BSf8YcurfmXP5F%2Fkj6J82jNsrkWiEuhVlgFfyNkB3S5MUzLhoNiwSCYcxQ7Ui4J0Xh7fmqRbaPa1tzujxkBRlsEHy0%2FOM4pYLPb7g9O6BQJN6l9zQ0OGyCaZz0vMTbHOzXfQ7a2tsterTcqxeInODoemdktw%2B1SbVhKwtW9ffe8VKadK0OVuC3bWzyKm5LeddsWTeorWyY9IMtUFutdu5g%2BRn533qkocdvLs2HmhU75br%2FMmWtD8zA3OP2t1ea636jEzqYxJZGAwFiDEd61oTsrRuW3%2F3pYNi3bS%2BRd%2BGjOfVpAPNd6y64Gsz1GaZleWIPoYL%2Fv9mTeQBENVEguiF1aC4YeXxFETw6QyPfn0m9g8IrMFAvKM1EI11DARnbqibHk%2FIojy5rSdgCyZi06y8sS024PeuO4MfwQ5Y9yKRZCqyYaF30vzeHlmUprR21tR0t0yz8KZY66zWuGvxVQB%2F36kP%2BK38t2Hu6NQ9SFJfw0AdpqPEK2qTMpf2VCqJwqPoJezTL824b8akoL%2Bx03nhh%2BoNo5e77psxg9Q5LzebIKD%2BfsY34f2MtB9fk9v5b8PT6tYrgv4kRPwd0q9z3gdJSJ0653KjCYPwCaR5aUY63eW48O%2Fkdo33yxX9wCiMv2QTrk8eGSI6Ag6moG9t2P%2FF7GRNlDjl0gw7pJ5aOXXqyqn8SENnXBmbSwUYLyqJjv3UmY1nKr4t80no0faXsaIEiF%2FBRaIBnItSce4OUif7W6Vm9T9H1X9Vj71BEm%2BRdmIJQST%2FZfVdudUvh9S%2FqqNvqT98g9SQ3lHibZY0mRVHooyDN%2FFHmTgzjdozKw28NwQ0hwN6BCoPKaEk3YtKwNhwRLXuk076CGoZNXDQcRwZvreTZY9EZi%2Bd0s4%2Bztv8iei04JQl6ZbDD2eHV7X4uHuFVfPrOmcs6m6Kr7hssr%2B1VZFcEZ%2FPdJkn1hOs8SXS%2FNFFgqt94PIZzZ3tdaL6Q5vo6piSzdy737pwsX1VyxUrF15iJ4uNkq%2Brbyg1Z%2BO8VsNC1UmcvORPRfxtPrfRwL2p%2FoA1eZp6Z%2FaGffoewaXcA%2FxBlKlQLfhQL%2FoPgBGP3qsA7IQS8qDVNswHKRSheDUvA3Q7MZoRcJMxlEygujn1QdyzfPfq3dEp%2FbXh5e5YXW2Ngfvza0ZF6UgFL%2FE0fTq4LBlvTE2qb%2FKuuzYSXVnjTfM1osvqMHVbm9950quIZlbqaL6YP7jk3kUtA0GnX2nvq53f3WoSsvEdDRnULgo2fN7lNZJgI8%2FVWi33c3bBZnGY05%2Bdm%2B3qc7fNmj4YGKLj2nfqFP%2Bg7jdDlxEV5XsJQZP6hYrS1l0VQr4c69Xueixp90gnZPmE5OF22j%2BSYEWHlZ0K%2FHgsh%2FZtsbh6h2DNRlvv6jJh9XaJaHCZDiUDKNTMkvb8vsqCyf3ZNdSmO0fa0Y4baJTtpbKzuVzeeSI7fCKr2Z0WypapnXJ4gnoWy3PoUIlIQ1TXdqhQJIXp9Wx5fYdpeWh2TY5D%2BYVyKd0jw3iumwi%2FBC3cEy4o83QlZnW79MrCgCjbhWXBlRZVVZZv4rIKpXC01HFlHdHLoeWVl6UVc%2FJ5uGm6CViW5mulYMk%2BHqNYr0AyUPivLg2oMs2MPqtuhHyRyiwvNJej1Br%2BfcLyoAyu8D9B7bgmzUqfFobF5nKnK4%2Bt8MPJkI%2FxHUNWk117jugWF%2BxazTAALQn6%2BUE9lhoI5ApGA%2FiuJOsrlNP28SVVuBVajXmircLel46w2bJS1Q0Ft0KDuikDFL%2F3pYrid1Q4FvofwRIo4R9h2ftSwc6jHAMqLcCql8YPHtlzGoByNXYN6v8hXnRaOhUvx0sVLCexwupGDR4NOYC7PePa5keIPACnuAdD7dEadRuTIiS6Lb7uskb381My5yjzF8lGCjBRqdwrWJCagfB3yCy7XT1i92hbcZ5Ci1FJkgYMDf6n%2BjspIsHFjJrTOdzSMuOa9DbDcj%2FnH9N9bIoGVgzHPWIQuFuYtaMRaq8eCKI0gEF6lPOZjBz3EEvaaxwSUT9U%2F8JbJZPJJLBLolH1La%2FRbF9AbC8JJjv%2FmMnssKjLRBJyqj9QXxNko0Ux%2FX79epfiXkm6fmKwF%2Fen1HLc6LxloXWKvGa5rVCVL83VuiPcDEX%2FK5pTXOxHfx6HHB0t2FI0qI2rCZFTrvPWU67zVuS%2FkTsLnc7IKhFg30e4FOkqNSfH5PtkmUy6Cpiv%2F36k2sbqCeCFNa%2BURpoY0sZoYmCgCr3qgZz6s8I0gP1bYiR%2BD79H56NOz0EVWCTy2%2FfffvSCCx59W7uRV9995eqrX8GLesOXNm360iZ%2BT%2FEl3uZqL%2BFyzSZ8XxpTiI%2FG0nkT4zznFZ0t4ipMz5v4q9ssqbdKUZt6u82knPCrt6PZwsnn0XySVnyPR1ZXAn72yx48bWJsu7apnI3Hy8bygUK5Js32qcytapqgmn95uexccj205vGgJ%2BeuOeG2SORmKZr%2FqKzcx9SFctMJdwMUFZDJITs7dnOp1EKZCxg304Cevyfya%2BvlKqv6aXK1qIj3imL%2BL6hL%2ByvUlFfE0VKZ7E8gBY3M%2F8VoJCFgizH1W6VyC76nH6b7jiibYVxUmVIEspry%2FLgZIlCeP11Z4zs%2FAwvVwtGFEut5S1JY4lfyT0N%2FevOLo%2BrUEgjcqc9IkGpQbv3iW7Co5b%2BKgjvpzYdH85PLcc4X21ouwEGl%2FS4qnUAvoSlXUUhR1eKr2VWFTB%2BGMl6FsiQsVD1R3urlAAIoSn7JQkmiVVCHSpCwDH%2FqPepXQ0Db77CJOAImohB%2BRPWr31ev5g%2FkE%2BzTa4lbvZo8xdWPffQu9yJTPCNB66s%2BzXoJt%2F0L6hSoCuBIoK8fnBGG87OoRckJpLqyWe4YbpGi50g0%2B3I3UD85Oa0fzubfoXxPLbW3FDWzigmyJeM0tQkax7PqTy80%2BUxfUHPlBZIRVNQ%2Bv0xRm8REKPoLmNr0%2BUo48v9GFbXPKylqQ2IKm00QddgyWGMROCTxdLB9nCY8P7j2DjlsV%2F%2Bmfr0C0r%2FNkeXbbpPlOTBBwT0mVz1zx9S%2FwJecBF9Wgv3p032iP2v4VSgfgW2G%2BHUEdEXU6iq4CtpLJfIN9XQG8dwa1VoO8XC2SrPDDyCOQptXgbcPvlAgBfxBoGwftQKeKFrNTASPt3pGGqDt%2FQRasn2kri%2BH6L80MJRsmVYJrAKyDItpJUy3%2F15WYIJqcJ9Q5N%2FLFJ4c3dc1URpWl9hW6mu50MUIelg4ucTPf15zs5DFo1c0VSp1tKB9jkwIyuM45kb%2BIP8gHed%2B6jO3v0KbIknzLy636E8KPTdCuUpB0wLo9JKnAO6pv0vS31EtBha%2FfJemkgLVVnd8KCk4qBTpQ5m7FbifBKrPJcq0pZAFVG%2FXbOFz%2BTcq2MLrcmV28Nmi%2FOHskh82bau0k8eWCaPijQPWQ5lUvslwVCfHkXBMIehqUgtDNLeauH1huvZTbYmw%2BluPjyWoNGEuxRLR7LK5fSyXFUyK7PURQv2v8D3XOt2NJ6liBbmPGOsakw1kbeOs%2B31Wm5qpH%2BiJWSzqdPr2O7zc2TmtnrzCig6bBd%2FvgQmzOlz0STWIlmZEQfupogOZFHUZ7EkUnMn0RrpIMqAgHRJAOjIJ3yGw1I%2FMAp9q9S3Q%2FclADNm1wEeO%2Bxbwg5OIYHZLY3ehG5lJk2xhco%2B6JWybpEVz2wrR6hZyD0QXZbeDVB%2BonmlimpkWprdAs4WEZDSQppsDlcdCBJJESIYFuAtUnC4GIF2C3Uu2Kv7L1bdz6FxtqxpG4TqQOqOUNAJ2HLvPWA2GgDy4O4vaDrtyl6P%2B1fAll%2BSyFcQ28GHqh7fvvf37udylf0fNwhzgz87Y%2Bcf5x9GnF6ygHu18sAbipWeF0YPBgp2GaKeQduxxdEr3SgbH1kvH7tvqSLhedomOvZyts2dw8acu3dY%2Ff%2BucuMtCuP%2Fe4zC4XnH3OLZ8ZuxTWxy8dJfU5dhDeKPSlJy5pn%2F%2B7u3XrJhmr9C5CuleGflGQocKnlAUaRKp0BAHV0ZwUt9VCqk6zYOgRIuMfePJzdmBdpPJ7%2F6B23%2Bf%2Bsp9NMDZevovvfYHG5dGPISQq1DojqNckchVrCcCYz%2FQ0hI0m3NKDRfkgsrnamo%2Bp0CAq1FyvC3a3Nak%2Fs5VX282x9Ufy3E39VAx6o7LpCvO2wK%2Bch9jNqpJCutcIOooKnYWtDK8gTRVYygRQfwgzKM5%2BjP2jOZdx3r32Py7rQUPOzAnoRs95NvRAR0qLGU11Taqu1bUYSzMcWjMEir067JQQHfIrLBHsrgv00%2FWavd8HRLMEEYFSW3HCSNQehnrHztKqHcDyo4VfZ6gPKCR%2BgufwA8GegxUEo4A%2Bgd0BASHiH6jYMLIsUdQJTs%2FC641KN4oCHWolCMLlMfIdtWKScjx7SM5LD9HnfmhrGI0S139UWfUnxgOXdJFW%2BAMcGjKr6eHAttHF5sUoeArYKDcxMSYcKA%2FxUDhPiEOEAPafSIUFArN0r24ynI91EPARDXvIDYyvqZaWeroBOUABQA%2FE%2BDXC7PWafDLQY2oiwpUEyj4RQtVlUp1GrM7In2p2A7VuiOW6otMiGOo5Mrp05ejVuTy6dNX%2Fk%2F7mybZQ0nUmfrbx3U4KueDnlHm5wdh8FFeKnoaKKh%2FTK18StOPhwG9Xo5mqXAxvw%2F79YQwwDR%2BnAKQQ4izVXioB84qcppWB7IqjU45z4CE17OvF1Dw%2BoTFqxtz8dxwtogBnF9MjIl%2Fin%2BK8s3hM9laIn0TiCbTAXL0T798bPXqx36p3chrv0O%2BGC9Xaj48Ecv8U8UEeBvUEsDlTepiU5OvlpeNGvpnKF0RvUooWhIjnx6GeBapXCQYTw9DNg6%2FOC3gZjp76oNTj9Kz6Jqobxb9NDqc08vcKReOpcsQV2K8InXFaXW3aI6Ofr1k48rp7CX7rx%2Bv1UKPsfvzQU0Kc83i2VdILmd2%2FyX55zT9luN2%2BCu4nKfwPcK%2FCvDVU%2BpHh8%2BLaldIf1fA5h3ndT6Fln9%2FW%2F9Ce1vndfvJtnPVO2xhm3qbafHVCN1X363UXHq9xuVD8OSD29Z8pZ5cZrern9cAdGW%2Fuib%2Fud%2BVK0L9a42r6C90kL8KzxwLQw9NkIQJL0ASU8M%2BVG0KsUdgdvpgP%2F6NqqP0%2FgHZFUfGEijZLHpiIgvV5%2FBltrj8Qd7XQd5p4P%2B7tJo30NMO6VGBwahSPMYiaaBYoLY6uEnciyhhh1Z%2FvvacG%2Frjpsvnpzs0B1Id6fmX8119l88XnOxe%2FuGrzzHcdu7UtY3%2B2vmXN5zUyj3ZcPl8p1sZSs6%2FnGXtwrV7Ka0XZdz83fwjjINpZWYw85lL8BRK4nGyIir2RiOsEyipuEcIakpGjWgBjLiHWOgj0Yi34gW1kKPxHt2Na5q%2Blwg1RdRSpFDNzosb44YJXnAfoEOpZW%2F%2F6u1lhYA6leevezbI26zNHO811M2dc5HFxpk4i1jPC0s21%2FBWW5DnPQbn2X1WK43%2FaM2n18DfSoybbNHijFpamzXI31eRibGUOxSu%2FlT96YZlq1Yt20DaSBuG6knw2eusHs5EPBfNmVvHKdaQzcDfz9ZsXmLDWGXy2U5OsYSsIn8CS12jQIyD12KKqZrLPy7mSPdICmd6WGHG8NDZkkHuE4h9TU8FpmUO%2FVjC%2FEinToFyoNDz2p9XD6g78WgQdPG7Z3R0T%2FZ5dTM9lsL8Ktek7szl2L%2BgQwGgwkZHc2g5Su7NvVqwGy2Ua4KSXUwt1X4PaM5paaEu6jQ5zVFyNabxvUksVt2T%2F4VeamYPlLtffdQsk%2B2sUTY%2FzDXl%2F05W53%2FBz9UK3p7LjapZ2ZxOm%2BUlZXrL3HHGqO8%2BwVroDaCTTnTxitMxmiAAYQzVJQH%2Bnj3oIHnPaN6Zq6sNSLjBl8tKgVr2mj%2F9CWi9dnKca8rBQBsd5R1tzVlgrl5pbnPw6kZclCr2CHxMnHohLz%2B3KRQokzALyeIKFU1TNCiayJdoHvDYe7K6mZLm8S3uJ9dojuaJ62%2FqN%2FtjQxnSnhnKPw%2BLNrLi8ZKyJ3x1YhiI1aNAtP6NzCGzYv3DmaGh%2FLvQZnt0evgIhTFV0kE%2FPYxAnOHhCQUZdCWY5JWJwMzlAGl1mpNbDU7yyGnhRMILsYhH3VRAijrPcBU8%2FCj1Y9NY6cnGVW0CjTLaz7E3epvaT%2FLtTV72Rs%2B0WVVmd0dz%2FMGTI5F0OsIviaqDlbbO5X6xT3PeXbXHRtf%2Fz%2Bfdka%2BeKPr8KF7IF4vBsT9MFPuPJMBTBMq9hQxXelQ%2Bbewnf18ap4Ib%2BmSMrtDU5zqlD8QANa5MBGh%2FOwOvSDfcV2d66mfEWsbGWmIz6nsyZDWQSmqmxDneYyvjHPmRXHZxeueyRGLZzvRioKnGto9nIPkibAJA16adcOZRQr1iAP3bUyBR7T4RgAWTKxhkCYFwshq%2B7iV9r0whk50cmRcTg4fy5x4OmmNkHndIA2%2BYuMbmE9dwGYB4KFTsvnDE6Ah47r%2FfE3AYI%2BoXADpkdlENcZ8OZEEf8FFGZNxMs6ZLpG3SUFLL7Q2kcFU%2FA%2FJsw%2BvWDa%2F7emewLaoeibaF1B9qUNnuqWK3%2BUfXYVL1v%2FomD15xxeDkPnXTOKSVcCbDGtOu0YQNpGAP7U1HU58UrqGu8xIbHtkQ3LVhb7Dx46ET3Ffcm1q0YcOizNmf3bC3VjWfAcpSv3MyTlgJ23FHQgmgvk%2Bgk8pL0mcCDOn08MDAQlf%2B%2FSlTZ1z12fnqntOhbOTL9%2FZdevbAPN%2Byby1f%2FuUtC%2Fixm8ZBo59LTXEW060hGrTDplNprWd58fwB%2Fb%2FE27BdS%2Fs7U%2BrGVCeQ46nzaw9QccnmZerGZZs3Yw9aVHt%2BKh6HN4ti6lxIhT%2FwahnZtWwzlY9QHQ2c79C%2BdxzvVDKy8GqKWQERO9YAKbpsDUTLdWV5dE8PVPjvj9pqw7ah%2FPFVtkit7aj6G5xY9mfJrCz1j1e0BcnPol4UjtrCdbahIVtd2HaURujnFJR8CuOuUUfhrGhgKKgjCYNSvCc1WKlEp8wHUaAYynFNyzZn%2B2MnYv36dbMDBTonl%2FT%2Fma5IKAyEGz%2B4eRnVtaX6tss2o34u8mWorFtuFgm4A6qK%2Fyp%2FgLEBVat5WnPDdKA574ubuFJ%2FIUfZ%2FY2Nt6mN%2BZNNTSTaeI56gKwkXerTe9DDHUw8%2FH35FY3nNN7GGuBKWhrV9ep%2B0k1WjNWVaHkW1yA%2BQHWNu8rtBw2a5YXuE40rs7%2FGA%2Bj09V3hA98yRnFPOGr8ltGlsFdD%2F7tRce3LH6Trcneuiy7K7J3khKu%2B3qUaXPWaX7T6%2FKfj9BX2eZq2XAcZT79u1ClJzUtHUqfqSMWBcZS43Ena0cUGLgpkKxB1QM%2B0Fxz10wgg6r5rltnFpH05pepUq3Y2HfYqeKRntmUFNz%2BXmcOs1H31U6cC6RTVLfCg7RNBF1UF2%2FwBgu0fFQtPEU1sSg3VcNsR7dWq3af87tUFn1l3ltXpaJxpNvtcZkH2WmMst3JqRpxUH%2BWC0E1qOGtP66s1MYv%2BVLu8%2FXFXvV%2FZbunYYBeVN64ls0ur6NzpV9xzlmQwB5qC4Tq70WC0tk8dWJXeHvkD0h9zJOM0vD86%2F1NJMaIAolctvlByferCsqOKDKceOfUu1PsmoFCamV5mCrMUOCi6V6FJosMF22AcrKJgQDVhfYh6tepp%2FlYgvnCEAbJQ1L0rOpajEmRcasMiPfxhgGoVo4rwreQpV6fUJHH2e8fa1s2c13Apl1b89a58ozdoap2sjgLN9uISl7P1DrulyeIkt0zr6JjWocoPOZsaXPb6jtqBblsgsaRre2xHi4nELm0MhG1%2Bx1SXwLpFi53b%2BaHRYo%2FIrbZtuWAKu5cSEXfybnnmUCaXGTpQr0xK2O2WWY76f%2BnAjNVf7nCZHU5XqIkTnpt6VtvsFlPXg1031g%2FVRdpkkyVpD7jnmax88QwDvg%2F66NnMRdRXTcGTmQc3cuINwN5IQqi0yzb%2BYFVHuVqI5s4ADfg5oE4ybDLd28mFSFmYvRoomsWXEdLU2Wl3GJy93ZNb%2Fd5gqmNaqJZSO1l6PVRy0nZIj%2F45EetjLguh1rLqR%2BSK0hO6NrsqcNX8zoUdjQYDJ7tb4os6%2Bi%2BY0qpY2AWlnLRDWdGFTfGY1gV0zNAtJ7pdo24se0D88AwLY%2FgZmE9iuP4V5v7CSR%2FRThaHLh%2BUeBkXwU6BC7lGOevK65udTv%2BtS%2FPfW7qj3ljTcj3b9OkbV85t8xsMj7Ddj7DGpthZKwKPvso%2Fc%2F1K9aLE12fMWLV1y1D9ua8lyJdWXr%2FbG%2BnoCFutf%2FmLILe39ITUV4igr3876fpX5g2zeB52sWnIL4fXHlgeUzOx5QfIvJQyrKQE9wHUqVq%2BPEaOrz0wVvNbJZVSfsuMzxN4l9PkedFzw9V5Dj%2BnzpgoT4ZxCxJfC5RWLc74YVHxKlExCYt0JAOMatREhHBSCAtSfod6x6Ls8HCWECLwXZ9nd5Dz1T24JUdWs6fU3%2B%2BfcnT49Qe%2BkBs%2BwdsMZgPXMp3U5S958snPP%2FEE7bvkOPCuTUDTUQ%2FUzirLhML9yPahoe1D5Fj5jWsaoveyP00PehdUAHk%2FseDVWsvDWXXXsyn%2F4wfpXc2V3%2FQxli3jl%2F5hj%2F83avSCfpTNxOEKLmTjxOEKuxgNlsQn0xgct724mhynupNW1Ph6o3RYS3%2F%2B2TJrzLlkFz%2Bip3qCHKf6eqW02QJLjBYuuj4sobhCWqa%2FYHGEHpcnumuWSOhxeaL7sOakNR6vvmo%2BYcfFA8UFXEPZf9UjyudIOyNwx%2Fi90DdsujS%2FFX2UAwvWSVK4NxaMhAGw3oowp%2Fuc8CTi7D2rBgZWwb%2F60faR7SPsEbjkXy4G0XaqhXPwe2cePjxjxuHD6ssQuR1fq6PF0E%2Bo2t1nePTn8TUmxz%2FA3crMoCc7egESuoTHYc7mYdg6etORoOhR7BBGD%2BqJopELrl4S6cJNRtEAsLP%2FOdvnJq0Wo0GolY2Et9VFB2Kf%2B4bZvVyxfOMz3WdFfSIryj6DwWghre7aQbdiDrkTL3A3vNDuDpk93HqXwam%2BbWmUJZfNn5ozKV5Pmmq8PF%2FjVY%2B2Tlk2M2RzSXKjmbQ4RZcQavEYrN%2F9rlXwtIQqzxQNMzPPfHYLvuPoO9TbT8bpGw5CQPGd%2BSyX%2FCyf0Vxjd2R9NmsunnXYa8xGHzn%2BsSfM5J0y0DZEXWWxkXjcR75KBLNLHi7XvX2G8VOrf4Ykg0AMdBESIpo7MgAfyakA6rkqpI6UjNs0px7cMV%2BD5BF49Tez1VGnYmq0WIijp985m4Sn2gJR9b07riPPFo97OYbUZbxJCpot7H%2FlpZBicglCPN7WOfJkcHqc3ElWqvvz%2F1E6bIQrG%2Btz6WkM1SM9FBTR7FSs8KyBBytSmNEoquJNFN5EQyTiCrnKDx1h58yxCepPHU5nxGoxEQeeOZi2m80DxNxncVhr6BmEfUarxejw%2BWSiHhWk19bSY7aKR5MsteblJpfTLtjimBouXsm3d3djjYM%2BwEW0El9dM%2FueVRWIsXwe43R7SgbVZqrnqoJ1X%2FkuF7pcgf8duv4q6vayV5U9zMV91GxO59UUjW8rHV6u799WzKMT7umRCXbYUKM%2BfoaCcwgaoqZUtmodV3p%2BX7akb4dnU9B9La38RPFUG2SCC90tVA4XwEFhyOpZZrUCsgWYHsczLFBBVGNtstoN1bw0Z%2BO4fYIbvZVt4EUcJEKOhHeincWqONw%2Bq6w5Go%2BWGOSR7LhKV%2BKBqbBPpfUvOf9QqkpDyVhBeyyZQGMsdA5FBUqvFMtUyGq9vjnsAJU4UcrxldP1CCaofyDkSAifoP5QwWx%2BSyUGxp75BzGAvtG7uQ38LehlyEQMeh0TeE6Bm7tYdXqdkt0uOb3kfYlNwmOdDyacOq%2FqlFo1v%2BPTmTi3E%2FglC9W11b34A22zmLzvb231Q0L2Bgg60OTW4YdstO%2BYOJnO38TtpH7zy9ymokWyA79qlVSn38HtpFlImFnhu3b4boNWXklOXV0Iwo7lQ1hrZyPFcwtjwFP7iEKSHSSJw509kh8kj6pr%2BH1jR7km9vcvqN9657vffefkv%2BfKxge1X%2B7RdjYUPIESN7gTvRkB%2FRMYtEkaVkdHApmdBPpnKmz0n1xSWFOyVIuLrinZwpoCRe6kyiVZoHX088F%2BUX4%2BWKS4iBTP0IWxGtZgOdMaV4KTayqHQF%2FVihBwTbgDXTCmKoOBJeNhwJMzEVjtjIFLuU38fPR7hqNG1JS7g%2FqRCuy3vmQ3W9Vu8qbVbP%2BSzazGRJH83MzP90Ck2m31mMjP8TiLn5uwD2Ugr2PFvPQjB5BnSJvQxGQZZEB%2BLopqzGzDbMmbkAPkZVJjeO5FzOSBKCgJze2ZS4Gemc9twrwY6u9H61iUQTcRvtdT9RW3tRxAWwFs2tcuJRnI6xjmBdWjbgFNRHMHiF1uHYBfUR%2Fut5Ug2jXAaT96%2B9RH%2FFToRwIzGbKmVJ1AZQnoabSB1yyIg7ByAridHApPMjyw0OiV6RjSbCuzwLAvFizBliWJua1tsuAgvNPbmljYbpt8lkWam7b3XZiOiKJskMOtmfScnsbPW208knwjuXrXK4Q1iKIgNyYXXDVT9C2Ye%2F78GQ5BEEXfFdde2RwauOysdJNL5AzCy84ard%2FnGAVN8alecnFdgu5Gbd5DJTL%2BhHZK0vApVy3OfU8XTSJg1TlssivsPYUlIqvn66PzrVTymCc4wgF6SDNR0pDf%2B9Gp%2BVnsUH5WtpHYsuhOaey8zdwLN47V8MTbm78g687%2BP3cx6tcAeNpjYGRgYGBk8s0%2FzBIfz2%2FzlUGeZQNQhOFCWfF0GP0%2F8P8c1jusIkAuBwMTSBQAYwQM6HjaY2BkYGAV%2Bd8KJgP%2FXWG9wwAUQQGLAYqPBl942n1TvUoDQRCe1VM8kWARjNrZGIurBAsRBIuA2vkAFsJiKTYW4guIjT5ARMgTxCLoA1hcb5OgDyGHrY7f7M65e8fpLF%2B%2B2W%2FnZ2eTmGfaIJi5I0qGDlZZcD51QzTTJirZPAI9JIwVA%2BwT8L5nOdMaV0AuMJ%2BicRHq8of6LSD18fzq8ds7xjpwBnQiSI9V5QVl6NwPvgM15NXn%2FAtWZyj3W0HjEXitOc%2FdIdbetPdFTZ%2BP6t%2BX7xU0%2Fk6GJtOe1%2FB3arN0%2Fpmz1J4UZc%2BD6ExwjD7vioeGd5HvhvU%2BR%2BDZcGZ6YBPNfAi0G97iBPwFXqph2cW8%2BD7kjMfwtinHb6kLb6Wygk3cZytSEoptGrlScdHtLPeri1JKueACMZfU1ViJG1Sq5E43dIt7SZZFl1zuRhb%2FGOs44xFVDbrJzB5tYs35OmaXTrEmkv0DajnMWQB42mNgYNCCwk0MLxheMPrhgUuY2JiUmOqY2pjWMD1hdmPOY%2B5hPsLCwWLEksSyiOUOawzrLrYiti%2FsCuxJ7Kc45DiSOPZxmnG2cG7jvMelweXDNYXrEbcBdxf3KR4OngheLd443g18fHwZfFv4NfiX8T8TEBIIEZggsEpQS7BMcJsQl5CFUI3QAWEp4RLhCyJaIldEbURXiJ4RYxEzE0sQ2yD2TzxIfJkEk4SeRJbENIkNEg8k%2FklqSGZITpE8InlL8p2UmVSG1A6pb9Jx0ltkjGSmyDySlZF1kc2RnSK7R%2FaZnJ5cmdwB%2BST5SwpuCvsUjRTLFHcoOShNU9qhzKespGyhXKV8SPmBCpOKgUqcyjSVR6omqgmqe9RE1OrUnqkHqO9R%2F6FholGgsUZzgeYZLTUtL60WbS7tKh0OnQydXTpvdGV0O3S%2F6Gnopekt0ruhz6fvpl%2Bnv0n%2Fh4GdQYvBJUMhwwTDdYYvjFSM4oxmGd0zVjK2M84w3mYiYZJgssLkkqmO6TzTF2Z2ZjVmd8ylzP3MJ5lfsRCwcLJoszhhyWXpZdlhecZKxirHapbVPesF1ndsJGwCbBbZ%2FLA1sn1jZ2XXY3fFXsM%2Bz36V%2FS8HD4cGh2OOTI51ThJOK5zeOUs4OzmXOS9wPuUi4JLgss7lm2uU6zY3NrcSty1u39zN3Mvct7l%2F8xDzMPLw88jyaPM44ynkaeEZ59niucqLyUvPKwgAn3OqOQAAAQAAARcApwARAAAAAAACAAAAAQABAAAAQAAuAAAAAHjarZK9TgJBEMf%2Fd6CRaAyRhMLqCgsbL4ciglTGRPEjSiSKlnLycXJ86CEniU%2FhM9jYWPgIFkYfwd6nsDD%2Bd1mBIIUx3mZnfzs3MzszuwDCeIYG8UUwQxmAFgxxPeeuyxrmcaNYxzTuFAewi0fFQSTxqXgM11pC8TgS2oPiCUS1d8Uh8ofiSczpYcVT5LjiCPlY8Qui%2BncOr7D02y6%2FBTCrP%2Fm%2Bb5bdTrPi2I26Z9qNGtbRQBMdXMJBGRW0YOCecxEWYoiTCvxrYBunqHPdoX2bLOyrMKlZg8thDETw5K7Itci1TXlGy0124QRZZLDFU%2FexhxztMozlosTpMH6ZPge0L%2BOKGnFKjJ4WRwppHPL0PP3SI2P9jLQwFOu3GRhDfkeyDo%2F%2FG7IHgzllZQxLdquvrdCyBVvat3seJlYo06gxapUxhU2JWnFygR03sSxnEkvcpf5Y5eibGq315TDp7fKWm8zbUVl71Aqq%2FZtNnlkWmLnQtno9ycvXYbA6W2pF3aKfCayyC0Ja7Fr%2FPW70%2FHO4YM0OKxFvzf0C1MyPjwAAeNpt1VWUU2cYRuHsgxenQt1d8%2F3JOUnqAyR1d%2FcCLQVKO22pu7tQd3d3d3d3d3cXmGzumrWy3pWLs%2FNdPDMpZaWu1783l1Lpf14MnfzO6FbqVupfGkD30iR60JNe9KYP09CXfvRnAAMZxGCGMG3pW6ZjemZgKDMyEzMzC7MyG7MzB3MyF3MzD%2FMyH%2FOzAAuyEAuzCIuyGIuzBGWCRIUqOQU16jRYkqVYmmVYluVYng6GMZwRNGmxAiuyEiuzCquyGquzBmuyFmuzDuuyHuuzARuyERuzCZuyGZuzBVuyFVuzDduyHdszklGMZgd2ZAw7MZZxjGdnJrALu9LJbuzOHkxkT%2FZib%2FZhX%2FZjfw7gQA7iYA7hUA7jcI7gSI7iaI7hWI7jeE7gRE7iZE5hEqdyGqdzBmdyFmdzDudyHudzARdyERdzCZdyGZdzBVdyFVdzDddyHddzAzdyEzdzC7dyG7dzB3dyF3dzD%2FdyH%2FfzAA%2FyEA%2FzCI%2FyGI%2FzBE%2FyFE%2FzDM%2FyHM%2FzAi%2FyEi%2FzCq%2FyGq%2FzBm%2FyFm%2FzDu%2FyHu%2FzAR%2FyER%2FzCZ%2FyGZ%2FzBV%2FyFV%2FzDd%2FyHd%2FzAz%2FyEz%2FzC7%2FyG7%2FzB3%2FyF3%2FzD%2F9mpYwsy7pl3bMeWc%2BsV9Y765NNk%2FXN%2BmX9swHZwGxQNjgb0nPkmInjR0V7Uq%2FOsaPL5Y7ylE3l8tQNN7kVt%2BrmbuHW3LrbcDvam1rtzVvdm50TxrU%2FDBvRtZUY1rV5a3jXFn550Wo%2FXDNWK3dFmh7X9LimxzU9qulRTY9qelTTo5rlKLt2wk7YiaprL%2ByFvbAX9pK9ZC%2FZS%2FaSvWQv2Uv2kr1kr2KvYq9ir2KvYq9ir2KvYq9ir2Kvaq9qr2qvaq9qr2qvaq9qr2qvai%2B3l9vL7eX2cnu5vdxebi%2B3l9sr7BV2CjuFncJOYaewU9gp7NTs1LyrZq9mr2avZq9mr2avZq9mr26vbq9ur26vbq9ur26vbq9ur26vYa9hr2GvYa9hr2GvYa%2FR7oXuQ%2Feh%2B2j%2FUU7e3C3cqc%2FV3fYdof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D92H7kP3ofvQfeg%2BdB%2B6D92H7kP3ofvQfRT29B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6j6nuG3Ya7U5q%2F0hN3nCTW3Grbu4Wrs%2FrP%2Bk%2F6T%2FpP%2Bk%2F6T%2FpP%2Bk%2B6T7pPek86TzpPOk86TzpOuk66TrpOuk66TrpOlWmPu%2F36zrpOuk66TrpOuk66TrpOvl%2FPek76TvpO%2Bk76TvpO%2Bk76TvpO%2Bk76TvpO7V9t%2BqtVs%2FOaOURU6bo6PgPt6rZbwAAAAABVFDDFwAA%29%20format%28%27woff%27%29%2Curl%28data%3Aapplication%2Ffont%2Dsfnt%3Bbase64%2CAAEAAAAPAIAAAwBwRkZUTW0ql9wAAAD8AAAAHEdERUYBRAAEAAABGAAAACBPUy8yZ7lriQAAATgAAABgY21hcNqt44EAAAGYAAAGcmN2dCAAKAL4AAAIDAAAAARnYXNw%2F%2F8AAwAACBAAAAAIZ2x5Zn1dwm8AAAgYAACUpGhlYWQFTS%2FYAACcvAAAADZoaGVhCkQEEQAAnPQAAAAkaG10eNLHIGAAAJ0YAAADdGxvY2Fv%2B5XOAACgjAAAAjBtYXhwAWoA2AAAorwAAAAgbmFtZbMsoJsAAKLcAAADonBvc3S6o%2BU1AACmgAAACtF3ZWJmwxhUUAAAsVQAAAAGAAAAAQAAAADMPaLPAAAAANB2gXUAAAAA0HZzlwABAAAADgAAABgAAAAAAAIAAQABARYAAQAEAAAAAgAAAAMEiwGQAAUABAMMAtAAAABaAwwC0AAAAaQAMgK4AAAAAAUAAAAAAAAAAAAAAAIAAAAAAAAAAAAAAFVLV04AQAAg%2F%2F8DwP8QAAAFFAB7AAAAAQAAAAAAAAAAAAAAIAABAAAABQAAAAMAAAAsAAAACgAAAdwAAQAAAAAEaAADAAEAAAAsAAMACgAAAdwABAGwAAAAaABAAAUAKAAgACsAoAClIAogLyBfIKwgvSISIxsl%2FCYBJvonCScP4APgCeAZ4CngOeBJ4FngYOBp4HngieCX4QnhGeEp4TnhRuFJ4VnhaeF54YnhleGZ4gbiCeIW4hniIeIn4jniSeJZ4mD4%2F%2F%2F%2FAAAAIAAqAKAApSAAIC8gXyCsIL0iEiMbJfwmASb6JwknD%2BAB4AXgEOAg4DDgQOBQ4GDgYuBw4IDgkOEB4RDhIOEw4UDhSOFQ4WDhcOGA4ZDhl%2BIA4gniEOIY4iHiI%2BIw4kDiUOJg%2BP%2F%2F%2F%2F%2Fj%2F9r%2FZv9i4Ajf5N%2B132nfWd4F3P3aHdoZ2SHZE9kOIB0gHCAWIBAgCiAEH%2F4f%2BB%2F3H%2FEf6x%2FlH3wfdh9wH2ofZB9jH10fVx9RH0sfRR9EHt4e3B7WHtUezh7NHsUevx65HrMIFQABAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAADAAAAAACjAAAAAAAAAA1AAAAIAAAACAAAAADAAAAKgAAACsAAAAEAAAAoAAAAKAAAAAGAAAApQAAAKUAAAAHAAAgAAAAIAoAAAAIAAAgLwAAIC8AAAATAAAgXwAAIF8AAAAUAAAgrAAAIKwAAAAVAAAgvQAAIL0AAAAWAAAiEgAAIhIAAAAXAAAjGwAAIxsAAAAYAAAl%2FAAAJfwAAAAZAAAmAQAAJgEAAAAaAAAm%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%2FAADiUAAA4lkAAAEJAADiYAAA4mAAAAETAAD4%2FwAA%2BP8AAAEUAAH1EQAB9REAAAEVAAH2qgAB9qoAAAEWAAYCCgAAAAABAAABAAAAAAAAAAAAAAAAAAAAAQACAAAAAAAAAAIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAQAAAAAAAwAAAAAAAAAAAAAAAAAAAAAAAAAEAAUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAHAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAYAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAVAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAEUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAKAL4AAAAAf%2F%2FAAIAAgAoAAABaAMgAAMABwAusQEALzyyBwQA7TKxBgXcPLIDAgDtMgCxAwAvPLIFBADtMrIHBgH8PLIBAgDtMjMRIRElMxEjKAFA%2Fujw8AMg%2FOAoAtAAAQBkAGQETARMAFsAAAEyFh8BHgEdATc%2BAR8BFgYPATMyFhcWFRQGDwEOASsBFx4BDwEGJi8BFRQGBwYjIiYvAS4BPQEHDgEvASY2PwEjIiYnJjU0Nj8BPgE7AScuAT8BNhYfATU0Njc2AlgPJgsLCg%2BeBxYIagcCB57gChECBgMCAQIRCuCeBwIHaggWB54PCikiDyYLCwoPngcWCGoHAgee4AoRAgYDAgECEQrgngcCB2oIFgeeDwopBEwDAgECEQrgngcCB2oIFgeeDwopIg8mCwsKD54HFghqBwIHnuAKEQIGAwIBAhEK4J4HAgdqCBYHng8KKSIPJgsLCg%2BeBxYIagcCB57gChECBgAAAAABAAAAAARMBEwAIwAAATMyFhURITIWHQEUBiMhERQGKwEiJjURISImPQE0NjMhETQ2AcLIFR0BXhUdHRX%2Boh0VyBUd%2FqIVHR0VAV4dBEwdFf6iHRXIFR3%2BohUdHRUBXh0VyBUdAV4VHQAAAAABAHAAAARABEwARQAAATMyFgcBBgchMhYPAQ4BKwEVITIWDwEOASsBFRQGKwEiJj0BISImPwE%2BATsBNSEiJj8BPgE7ASYnASY2OwEyHwEWMj8BNgM5%2BgoFCP6UBgUBDAoGBngGGAp9ARMKBgZ4BhgKfQ8LlAsP%2Fu0KBgZ4BhgKff7tCgYGeAYYCnYFBv6UCAUK%2BhkSpAgUCKQSBEwKCP6UBgwMCKAIDGQMCKAIDK4LDw8LrgwIoAgMZAwIoAgMDAYBbAgKEqQICKQSAAABAGQABQSMBK4AOwAAATIXFhcjNC4DIyIOAwchByEGFSEHIR4EMzI%2BAzUzBgcGIyInLgEnIzczNjcjNzM%2BATc2AujycDwGtSM0QDkXEys4MjAPAXtk%2FtQGAZZk%2FtQJMDlCNBUWOUA0I64eYmunznYkQgzZZHABBdpkhhQ%2BH3UErr1oaS1LMCEPCx4uTzJkMjJkSnRCKw8PIjBKK6trdZ4wqndkLzVkV4UljQAAAgB7AAAETASwAD4ARwAAASEyHgUVHAEVFA4FKwEHITIWDwEOASsBFRQGKwEiJj0BISImPwE%2BATsBNSEiJj8BPgE7ARE0NhcRMzI2NTQmIwGsAV5DakIwFgwBAQwWMEJqQ7ICASAKBgZ4BhgKigsKlQoP%2FvUKBgZ4BhgKdf71CgYGeAYYCnUPtstALS1ABLAaJD8yTyokCwsLJCpQMkAlGmQMCKAIDK8LDg8KrwwIoAgMZAwIoAgMAdsKD8j%2B1EJWVEAAAAEAyAGQBEwCvAAPAAATITIWHQEUBiMhIiY9ATQ2%2BgMgFR0dFfzgFR0dArwdFcgVHR0VyBUdAAAAAgDIAAAD6ASwACUAQQAAARUUBisBFRQGBx4BHQEzMhYdASE1NDY7ATU0NjcuAT0BIyImPQEXFRQWFx4BFAYHDgEdASE1NCYnLgE0Njc%2BAT0BA%2BgdFTJjUVFjMhUd%2FOAdFTJjUVFjMhUdyEE3HCAgHDdBAZBBNxwgIBw3QQSwlhUdZFuVIyOVW5YdFZaWFR2WW5UjI5VbZB0VlshkPGMYDDI8MgwYYzyWljxjGAwyPDIMGGM8ZAAAAAEAAAAAAAAAAAAAAAAxAAAB%2F%2FIBLATCBEEAFgAAATIWFzYzMhYVFAYjISImNTQ2NyY1NDYB9261LCwueKqqeP0ST3FVQgLYBEF3YQ6teHmtclBFaw4MGZnXAAAAAgAAAGQEsASvABoAHgAAAB4BDwEBMzIWHQEhNTQ2OwEBJyY%2BARYfATc2AyEnAwL2IAkKiAHTHhQe%2B1AeFB4B1IcKCSAkCm9wCXoBebbDBLMTIxC7%2FRYlFSoqFSUC6rcQJBQJEJSWEPwecAIWAAAAAAQAAABkBLAETAALABcAIwA3AAATITIWBwEGIicBJjYXARYUBwEGJjURNDYJATYWFREUBicBJjQHARYGIyEiJjcBNjIfARYyPwE2MhkEfgoFCP3MCBQI%2FcwIBQMBCAgI%2FvgICgoDjAEICAoKCP74CFwBbAgFCvuCCgUIAWwIFAikCBQIpAgUBEwKCP3JCAgCNwgK2v74CBQI%2FvgIBQoCJgoF%2FvABCAgFCv3aCgUIAQgIFID%2BlAgKCggBbAgIpAgIpAgAAAAD%2F%2FD%2F8AS6BLoACQANABAAAAAyHwEWFA8BJzcTAScJAQUTA%2BAmDpkNDWPWXyL9mdYCZv4f%2FrNuBLoNmQ4mDlzWYP50%2FZrWAmb8anABTwAAAAEAAAAABLAEsAAPAAABETMyFh0BITU0NjsBEQEhArz6FR384B0V%2Bv4MBLACiv3aHRUyMhUdAiYCJgAAAAEADgAIBEwEnAAfAAABJTYWFREUBgcGLgE2NzYXEQURFAYHBi4BNjc2FxE0NgFwAoUnMFNGT4gkV09IQv2oWEFPiCRXT0hCHQP5ow8eIvzBN1EXGSltchkYEAIJm%2F2iKmAVGilucRoYEQJ%2FJioAAAACAAn%2F%2BAS7BKcAHQApAAAAMh4CFQcXFAcBFgYPAQYiJwEGIycHIi4CND4BBCIOARQeATI%2BATQmAZDItoNOAQFOARMXARY7GikT%2Fu13jgUCZLaDTk6DAXKwlFZWlLCUVlYEp06DtmQCBY15%2Fu4aJRg6FBQBEk0BAU6Dtsi2g1tWlLCUVlaUsJQAAQBkAFgErwREABkAAAE%2BAh4CFRQOAwcuBDU0PgIeAQKJMHt4dVg2Q3mEqD4%2Bp4V4Qzhadnh5A7VESAUtU3ZAOXmAf7JVVbJ%2FgHk5QHZTLQVIAAAAAf%2FTAF4EewSUABgAAAETNjIXEyEyFgcFExYGJyUFBiY3EyUmNjMBl4MHFQeBAaUVBhH%2BqoIHDxH%2Bqf6qEQ8Hgv6lEQYUAyABYRMT%2Fp8RDPn%2BbxQLDPb3DAsUAZD7DBEAAv%2FTAF4EewSUABgAIgAAARM2MhcTITIWBwUTFgYnJQUGJjcTJSY2MwUjFwc3Fyc3IycBl4MHFQeBAaUVBhH%2BqoIHDxH%2Bqf6qEQ8Hgv6lEQYUAfPwxUrBw0rA6k4DIAFhExP%2BnxEM%2Bf5vFAsM9vcMCxQBkPsMEWSO4ouM5YzTAAABAAAAAASwBLAAJgAAATIWHQEUBiMVFBYXBR4BHQEUBiMhIiY9ATQ2NyU%2BAT0BIiY9ATQ2Alh8sD4mDAkBZgkMDwr7ggoPDAkBZgkMJj6wBLCwfPouaEsKFwbmBRcKXQoPDwpdChcF5gYXCktoLvp8sAAAAA0AAAAABLAETAAPABMAIwAnACsALwAzADcARwBLAE8AUwBXAAATITIWFREUBiMhIiY1ETQ2FxUzNSkBIgYVERQWMyEyNjURNCYzFTM1BRUzNSEVMzUFFTM1IRUzNQchIgYVERQWMyEyNjURNCYFFTM1IRUzNQUVMzUhFTM1GQR%2BCg8PCvuCCg8PVWQCo%2F3aCg8PCgImCg8Pc2T8GGQDIGT8GGQDIGTh%2FdoKDw8KAiYKDw%2F872QDIGT8GGQDIGQETA8K%2B%2BYKDw8KBBoKD2RkZA8K%2FqIKDw8KAV4KD2RkyGRkZGTIZGRkZGQPCv6iCg8PCgFeCg9kZGRkZMhkZGRkAAAEAAAAAARMBEwADwAfAC8APwAAEyEyFhURFAYjISImNRE0NikBMhYVERQGIyEiJjURNDYBITIWFREUBiMhIiY1ETQ2KQEyFhURFAYjISImNRE0NjIBkBUdHRX%2BcBUdHQJtAZAVHR0V%2FnAVHR39vQGQFR0dFf5wFR0dAm0BkBUdHRX%2BcBUdHQRMHRX%2BcBUdHRUBkBUdHRX%2BcBUdHRUBkBUd%2FagdFf5wFR0dFQGQFR0dFf5wFR0dFQGQFR0AAAkAAAAABEwETAAPAB8ALwA%2FAE8AXwBvAH8AjwAAEzMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYhMzIWHQEUBisBIiY9ATQ2ATMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYhMzIWHQEUBisBIiY9ATQ2ATMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYhMzIWHQEUBisBIiY9ATQ2MsgVHR0VyBUdHQGlyBUdHRXIFR0dAaXIFR0dFcgVHR389cgVHR0VyBUdHQGlyBUdHRXIFR0dAaXIFR0dFcgVHR389cgVHR0VyBUdHQGlyBUdHRXIFR0dAaXIFR0dFcgVHR0ETB0VyBUdHRXIFR0dFcgVHR0VyBUdHRXIFR0dFcgVHf5wHRXIFR0dFcgVHR0VyBUdHRXIFR0dFcgVHR0VyBUd%2FnAdFcgVHR0VyBUdHRXIFR0dFcgVHR0VyBUdHRXIFR0ABgAAAAAEsARMAA8AHwAvAD8ATwBfAAATMzIWHQEUBisBIiY9ATQ2KQEyFh0BFAYjISImPQE0NgEzMhYdARQGKwEiJj0BNDYpATIWHQEUBiMhIiY9ATQ2ATMyFh0BFAYrASImPQE0NikBMhYdARQGIyEiJj0BNDYyyBUdHRXIFR0dAaUCvBUdHRX9RBUdHf6FyBUdHRXIFR0dAaUCvBUdHRX9RBUdHf6FyBUdHRXIFR0dAaUCvBUdHRX9RBUdHQRMHRXIFR0dFcgVHR0VyBUdHRXIFR3%2BcB0VyBUdHRXIFR0dFcgVHR0VyBUd%2FnAdFcgVHR0VyBUdHRXIFR0dFcgVHQAAAAABACYALAToBCAAFwAACQE2Mh8BFhQHAQYiJwEmND8BNjIfARYyAdECOwgUB7EICPzxBxUH%2FoAICLEHFAirBxYB3QI7CAixBxQI%2FPAICAGACBQHsQgIqwcAAQBuAG4EQgRCACMAAAEXFhQHCQEWFA8BBiInCQEGIi8BJjQ3CQEmND8BNjIXCQE2MgOIsggI%2FvUBCwgIsggVB%2F70%2FvQHFQiyCAgBC%2F71CAiyCBUHAQwBDAcVBDuzCBUH%2FvT%2B9AcVCLIICAEL%2FvUICLIIFQcBDAEMBxUIsggI%2FvUBDAcAAwAX%2F%2BsExQSZABkAJQBJAAAAMh4CFRQHARYUDwEGIicBBiMiLgI0PgEEIg4BFB4BMj4BNCYFMzIWHQEzMhYdARQGKwEVFAYrASImPQEjIiY9ATQ2OwE1NDYBmcSzgk1OASwICG0HFQj%2B1HeOYrSBTU2BAW%2BzmFhYmLOZWFj%2BvJYKD0sKDw8KSw8KlgoPSwoPDwpLDwSZTYKzYo15%2FtUIFQhsCAgBK01NgbTEs4JNWJmzmFhYmLOZIw8KSw8KlgoPSwoPDwpLDwqWCg9LCg8AAAMAF%2F%2FrBMUEmQAZACUANQAAADIeAhUUBwEWFA8BBiInAQYjIi4CND4BBCIOARQeATI%2BATQmBSEyFh0BFAYjISImPQE0NgGZxLOCTU4BLAgIbQcVCP7Ud45itIFNTYEBb7OYWFiYs5lYWP5YAV4KDw8K%2FqIKDw8EmU2Cs2KNef7VCBUIbAgIAStNTYG0xLOCTViZs5hYWJizmYcPCpYKDw8KlgoPAAAAAAIAFwAXBJkEsAAPAC0AAAEzMhYVERQGKwEiJjURNDYFNRYSFRQOAiIuAjU0EjcVDgEVFB4BMj4BNTQmAiZkFR0dFWQVHR0BD6fSW5vW6tabW9KnZ3xyxejFcnwEsB0V%2FnAVHR0VAZAVHeGmPv7ZuHXWm1tbm9Z1uAEnPqY3yHh0xXJyxXR4yAAEAGQAAASwBLAADwAfAC8APwAAATMyFhURFAYrASImNRE0NgEzMhYVERQGKwEiJjURNDYBMzIWFREUBisBIiY1ETQ2BTMyFh0BFAYrASImPQE0NgQBlgoPDwqWCg8P%2Ft6WCg8PCpYKDw%2F%2B3pYKDw8KlgoPD%2F7elgoPDwqWCg8PBLAPCvuCCg8PCgR%2BCg%2F%2BcA8K%2FRIKDw8KAu4KD%2F7UDwr%2BPgoPDwoBwgoPyA8K%2BgoPDwr6Cg8AAAAAAgAaABsElgSWAEcATwAAATIfAhYfATcWFwcXFh8CFhUUDwIGDwEXBgcnBwYPAgYjIi8CJi8BByYnNycmLwImNTQ%2FAjY%2FASc2Nxc3Nj8CNhIiBhQWMjY0AlghKSYFMS0Fhj0rUAMZDgGYBQWYAQ8YA1AwOIYFLDIFJisfISkmBTEtBYY8LFADGQ0ClwYGlwINGQNQLzqFBS0xBSYreLJ%2BfrJ%2BBJYFmAEOGQJQMDmGBSwxBiYrHiIoJgYxLAWGPSxRAxkOApcFBZcCDhkDUTA5hgUtMAYmKiAhKCYGMC0Fhj0sUAIZDgGYBf6ZfrF%2BfrEABwBkAAAEsAUUABMAFwAhACUAKQAtADEAAAEhMhYdASEyFh0BITU0NjMhNTQ2FxUhNQERFAYjISImNREXETMRMxEzETMRMxEzETMRAfQBLCk7ARMKD%2Fu0DwoBEzspASwBLDsp%2FUQpO2RkZGRkZGRkBRQ7KWQPCktLCg9kKTtkZGT%2B1PzgKTs7KQMgZP1EArz9RAK8%2FUQCvP1EArwAAQAMAAAFCATRAB8AABMBNjIXARYGKwERFAYrASImNREhERQGKwEiJjURIyImEgJsCBUHAmAIBQqvDwr6Cg%2F%2B1A8K%2BgoPrwoFAmoCYAcH%2FaAICv3BCg8PCgF3%2FokKDw8KAj8KAAIAZAAAA%2BgEsAARABcAAAERFBYzIREUBiMhIiY1ETQ2MwEjIiY9AQJYOykBLB0V%2FOAVHR0VA1L6FR0EsP5wKTv9dhUdHRUETBUd%2FnAdFfoAAwAXABcEmQSZAA8AGwAwAAAAMh4CFA4CIi4CND4BBCIOARQeATI%2BATQmBTMyFhURMzIWHQEUBisBIiY1ETQ2AePq1ptbW5vW6tabW1ubAb%2FoxXJyxejFcnL%2BfDIKD68KDw8K%2BgoPDwSZW5vW6tabW1ub1urWmztyxejFcnLF6MUNDwr%2B7Q8KMgoPDwoBXgoPAAAAAAL%2FnAAABRQEsAALAA8AACkBAyMDIQEzAzMDMwEDMwMFFP3mKfIp%2FeYBr9EVohTQ%2Fp4b4BsBkP5wBLD%2B1AEs%2FnD%2B1AEsAAAAAAIAZAAABLAEsAAVAC8AAAEzMhYVETMyFgcBBiInASY2OwERNDYBMzIWFREUBiMhIiY1ETQ2OwEyFh0BITU0NgImyBUdvxQLDf65DSYN%2FrkNCxS%2FHQJUMgoPDwr75goPDwoyCg8DhA8EsB0V%2Fj4XEP5wEBABkBAXAcIVHfzgDwr%2BogoPDwoBXgoPDwqvrwoPAAMAFwAXBJkEmQAPABsAMQAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JgUzMhYVETMyFgcDBiInAyY2OwERNDYB4%2BrWm1tbm9bq1ptbW5sBv%2BjFcnLF6MVycv58lgoPiRUKDd8NJg3fDQoViQ8EmVub1urWm1tbm9bq1ps7csXoxXJyxejFDQ8K%2Fu0XEP7tEBABExAXARMKDwAAAAMAFwAXBJkEmQAPABsAMQAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JiUTFgYrAREUBisBIiY1ESMiJjcTNjIB4%2BrWm1tbm9bq1ptbW5sBv%2BjFcnLF6MVycv7n3w0KFYkPCpYKD4kVCg3fDSYEmVub1urWm1tbm9bq1ps7csXoxXJyxejFAf7tEBf%2B7QoPDwoBExcQARMQAAAAAAIAAAAABLAEsAAZADkAABMhMhYXExYVERQGBwYjISImJyY1EzQ3Ez4BBSEiBgcDBhY7ATIWHwEeATsBMjY%2FAT4BOwEyNicDLgHhAu4KEwO6BwgFDBn7tAweAgYBB7kDEwKX%2FdQKEgJXAgwKlgoTAiYCEwr6ChMCJgITCpYKDAJXAhIEsA4K%2FXQYGf5XDB4CBggEDRkBqRkYAowKDsgOC%2F4%2BCw4OCpgKDg4KmAoODgsBwgsOAAMAFwAXBJkEmQAPABsAJwAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JgUXFhQPAQYmNRE0NgHj6tabW1ub1urWm1tbmwG%2F6MVycsXoxXJy%2Fov9ERH9EBgYBJlbm9bq1ptbW5vW6tabO3LF6MVycsXoxV2%2BDCQMvgwLFQGQFQsAAQAXABcEmQSwACgAAAE3NhYVERQGIyEiJj8BJiMiDgEUHgEyPgE1MxQOAiIuAjQ%2BAjMyA7OHBwsPCv6WCwQHhW2BdMVycsXoxXKWW5vW6tabW1ub1nXABCSHBwQL%2FpYKDwsHhUxyxejFcnLFdHXWm1tbm9bq1ptbAAAAAAIAFwABBJkEsAAaADUAAAE3NhYVERQGIyEiJj8BJiMiDgEVIzQ%2BAjMyEzMUDgIjIicHBiY1ETQ2MyEyFg8BFjMyPgEDs4cHCw8L%2FpcLBAeGboF0xXKWW5vWdcDrllub1nXAnIYHCw8LAWgKBQiFboJ0xXIEJIcHBAv%2BlwsPCweGS3LFdHXWm1v9v3XWm1t2hggFCgFoCw8LB4VMcsUAAAAKAGQAAASwBLAADwAfAC8APwBPAF8AbwB%2FAI8AnwAAEyEyFhURFAYjISImNRE0NgUhIgYVERQWMyEyNjURNCYFMzIWHQEUBisBIiY9ATQ2MyEyFh0BFAYjISImPQE0NgczMhYdARQGKwEiJj0BNDYzITIWHQEUBiMhIiY9ATQ2BzMyFh0BFAYrASImPQE0NjMhMhYdARQGIyEiJj0BNDYHMzIWHQEUBisBIiY9ATQ2MyEyFh0BFAYjISImPQE0Nn0EGgoPDwr75goPDwPA%2FK4KDw8KA1IKDw%2F9CDIKDw8KMgoPD9IBwgoPDwr%2BPgoPD74yCg8PCjIKDw%2FSAcIKDw8K%2Fj4KDw%2B%2BMgoPDwoyCg8P0gHCCg8PCv4%2BCg8PvjIKDw8KMgoPD9IBwgoPDwr%2BPgoPDwSwDwr7ggoPDwoEfgoPyA8K%2FK4KDw8KA1IKD2QPCjIKDw8KMgoPDwoyCg8PCjIKD8gPCjIKDw8KMgoPDwoyCg8PCjIKD8gPCjIKDw8KMgoPDwoyCg8PCjIKD8gPCjIKDw8KMgoPDwoyCg8PCjIKDwAAAAACAAAAAARMBLAAGQAjAAABNTQmIyEiBh0BIyIGFREUFjMhMjY1ETQmIyE1NDY7ATIWHQEDhHVT%2FtRSdmQpOzspA4QpOzsp%2FageFMgUHgMgyFN1dlLIOyn9qCk7OykCWCk7lhUdHRWWAAIAZAAABEwETAAJADcAABMzMhYVESMRNDYFMhcWFREUBw4DIyIuAScuAiMiBwYjIicmNRE%2BATc2HgMXHgIzMjc2fTIKD2QPA8AEBRADIUNAMRwaPyonKSxHHlVLBwgGBQ4WeDsXKC4TOQQpLUUdZ1AHBEwPCvvNBDMKDzACBhH%2BWwYGO1AkDQ0ODg8PDzkFAwcPAbY3VwMCAwsGFAEODg5XCAAAAwAAAAAEsASXACEAMQBBAAAAMh4CFREUBisBIiY1ETQuASAOARURFAYrASImNRE0PgEDMzIWFREUBisBIiY1ETQ2ITMyFhURFAYrASImNRE0NgHk6N6jYw8KMgoPjeT%2B%2BuSNDwoyCg9joyqgCAwMCKAIDAwCYKAIDAwIoAgMDASXY6PedP7UCg8PCgEsf9FyctF%2F%2FtQKDw8KASx03qP9wAwI%2FjQIDAwIAcwIDAwI%2FjQIDAwIAcwIDAAAAAACAAAA0wRHA90AFQA5AAABJTYWFREUBiclJisBIiY1ETQ2OwEyBTc2Mh8BFhQPARcWFA8BBiIvAQcGIi8BJjQ%2FAScmND8BNjIXAUEBAgkMDAn%2B%2FhUZ%2BgoPDwr6GQJYeAcUByIHB3h4BwciBxQHeHgHFAciBwd3dwcHIgcUBwMurAYHCv0SCgcGrA4PCgFeCg%2BEeAcHIgcUB3h4BxQHIgcHd3cHByIHFAd4eAcUByIICAAAAAACAAAA0wNyA90AFQAvAAABJTYWFREUBiclJisBIiY1ETQ2OwEyJTMWFxYVFAcGDwEiLwEuATc2NTQnJjY%2FATYBQQECCQwMCf7%2BFRn6Cg8PCvoZAdIECgZgWgYLAwkHHQcDBkhOBgMIHQcDLqwGBwr9EgoHBqwODwoBXgoPZAEJgaGafwkBAQYXBxMIZ36EaggUBxYFAAAAAAMAAADEBGID7AAbADEASwAAATMWFxYVFAYHBgcjIi8BLgE3NjU0JicmNj8BNgUlNhYVERQGJyUmKwEiJjURNDY7ATIlMxYXFhUUBwYPASIvAS4BNzY1NCcmNj8BNgPHAwsGh0RABwoDCQcqCAIGbzs3BgIJKgf9ggECCQwMCf7%2BFRn6Cg8PCvoZAdIECgZgWgYLAwkHHQcDBkhOBgMIHQcD7AEJs9lpy1QJAQYiBhQIlrJarEcJFAYhBb6sBgcK%2FRIKBwasDg8KAV4KD2QBCYGhmn8JAQEGFwcTCGd%2BhGoIFQYWBQAAAAANAAAAAASwBLAACQAVABkAHQAhACUALQA7AD8AQwBHAEsATwAAATMVIxUhFSMRIQEjFTMVIREjESM1IQURIREhESERBSM1MwUjNTMBMxEhETM1MwEzFSMVIzUjNTM1IzUhBREhEQcjNTMFIzUzASM1MwUhNSEB9GRk%2FnBkAfQCvMjI%2FtTIZAJY%2B7QBLAGQASz84GRkArxkZP1EyP4MyGQB9MhkyGRkyAEs%2FUQBLGRkZAOEZGT%2BDGRkAfT%2B1AEsA4RkZGQCWP4MZMgBLAEsyGT%2B1AEs%2FtQBLMhkZGT%2BDP4MAfRk%2FtRkZGRkyGTI%2FtQBLMhkZGT%2B1GRkZAAAAAAJAAAAAASwBLAAAwAHAAsADwATABcAGwAfACMAADcjETMTIxEzASMRMxMjETMBIxEzASE1IRcjNTMXIzUzBSM1M2RkZMhkZAGQyMjIZGQBLMjI%2FOD%2B1AEsyGRkyGRkASzIyMgD6PwYA%2Bj8GAPo%2FBgD6PwYA%2Bj7UGRkW1tbW1sAAAIAAAAKBKYEsAANABUAAAkBFhQHAQYiJwETNDYzBCYiBhQWMjYB9AKqCAj%2BMAgUCP1WAQ8KAUM7Uzs7UzsEsP1WCBQI%2FjAICAKqAdsKD807O1Q7OwAAAAADAAAACgXSBLAADQAZACEAAAkBFhQHAQYiJwETNDYzIQEWFAcBBiIvAQkBBCYiBhQWMjYB9AKqCAj%2BMAgUCP1WAQ8KAwYCqggI%2FjAIFAg4Aaj9RP7TO1M7O1M7BLD9VggUCP4wCAgCqgHbCg%2F9VggUCP4wCAg4AaoCvM07O1Q7OwAAAAABAGQAAASwBLAAJgAAASEyFREUDwEGJjURNCYjISIPAQYWMyEyFhURFAYjISImNRE0PwE2ASwDOUsSQAgKDwr9RBkSQAgFCgK8Cg8PCvyuCg8SixIEsEv8fBkSQAgFCgO2Cg8SQAgKDwr8SgoPDwoDzxkSixIAAAABAMj%2F%2FwRMBLAACgAAEyEyFhURCQERNDb6AyAVHf4%2B%2Fj4dBLAdFfuCAbz%2BQwR%2FFR0AAAAAAwAAAAAEsASwABUARQBVAAABISIGBwMGHwEeATMhMjY%2FATYnAy4BASMiBg8BDgEjISImLwEuASsBIgYVERQWOwEyNj0BNDYzITIWHQEUFjsBMjY1ETQmASEiBg8BBhYzITI2LwEuAQM2%2FkQLEAFOBw45BhcKAcIKFwY%2BDgdTARABVpYKFgROBBYK%2FdoKFgROBBYKlgoPDwqWCg8PCgLuCg8PCpYKDw%2F%2Bsf4MChMCJgILCgJYCgsCJgITBLAPCv7TGBVsCQwMCWwVGAEtCg%2F%2BcA0JnAkNDQmcCQ0PCv12Cg8PCpYKDw8KlgoPDwoCigoP%2FagOCpgKDg4KmAoOAAAAAAQAAABkBLAETAAdACEAKQAxAAABMzIeAh8BMzIWFREUBiMhIiY1ETQ2OwE%2BBAEVMzUEIgYUFjI2NCQyFhQGIiY0AfTIOF00JAcGlik7Oyn8GCk7OymWAgknM10ByGT%2Bz76Hh76H%2Fu9WPDxWPARMKTs7FRQ7Kf2oKTs7KQJYKTsIG0U1K%2F7UZGRGh76Hh74IPFY8PFYAAAAAAgA1AAAEsASvACAAIwAACQEWFx4BHwEVITUyNi8BIQYHBh4CMxUhNTY3PgE%2FAQEDIQMCqQGBFCgSJQkK%2Fl81LBFS%2Fnk6IgsJKjIe%2FpM4HAwaBwcBj6wBVKIEr%2FwaMioTFQECQkJXLd6RWSIuHAxCQhgcDCUNDQPu%2FVoByQAAAAADAGQAAAPwBLAAJwAyADsAAAEeBhUUDgMjITU%2BATURNC4EJzUFMh4CFRQOAgclMzI2NTQuAisBETMyNjU0JisBAvEFEzUwOyodN1htbDD%2BDCk7AQYLFyEaAdc5dWM%2BHy0tEP6Pi05pESpTPnbYUFJ9Xp8CgQEHGB0zOlIuQ3VONxpZBzMoAzsYFBwLEAkHRwEpSXNDM1s6KwkxYUopOzQb%2FK5lUFqBAAABAMgAAANvBLAAGQAAARcOAQcDBhYXFSE1NjcTNjQuBCcmJzUDbQJTQgeECSxK%2Fgy6Dq0DAw8MHxUXDQYEsDkTNSj8uTEoBmFhEFIDQBEaExAJCwYHAwI5AAAAAAL%2FtQAABRQEsAAlAC8AAAEjNC4FKwERFBYfARUhNTI%2BAzURIyIOBRUjESEFIxEzByczESM3BRQyCAsZEyYYGcgyGRn%2BcAQOIhoWyBkYJhMZCwgyA%2Bj7m0tLfX1LS30DhBUgFQ4IAwH8rhYZAQJkZAEFCRUOA1IBAwgOFSAVASzI%2FOCnpwMgpwACACH%2FtQSPBLAAJQAvAAABIzQuBSsBERQWHwEVITUyPgM1ESMiDgUVIxEhEwc1IRUnNxUhNQRMMggLGRMmGBnIMhkZ%2FnAEDiIaFsgZGCYTGQsIMgPoQ6f84KenAyADhBUgFQ4IAwH9dhYZAQJkZAEFCRUOAooBAwgOFSAVASz7gn1LS319S0sABAAAAAAEsARMAA8AHwAvAD8AABMhMhYdARQGIyEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2EyEyFh0BFAYjISImPQE0NhMhMhYdARQGIyEiJj0BNDYyAlgVHR0V%2FagVHR0VA%2BgVHR0V%2FBgVHR0VAyAVHR0V%2FOAVHR0VBEwVHR0V%2B7QVHR0ETB0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR0ABAAAAAAEsARMAA8AHwAvAD8AABMhMhYdARQGIyEiJj0BNDYDITIWHQEUBiMhIiY9ATQ2EyEyFh0BFAYjISImPQE0NgMhMhYdARQGIyEiJj0BNDb6ArwVHR0V%2FUQVHR2zBEwVHR0V%2B7QVHR3dArwVHR0V%2FUQVHR2zBEwVHR0V%2B7QVHR0ETB0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR0ABAAAAAAEsARMAA8AHwAvAD8AAAE1NDYzITIWHQEUBiMhIiYBNTQ2MyEyFh0BFAYjISImEzU0NjMhMhYdARQGIyEiJgE1NDYzITIWHQEUBiMhIiYB9B0VAlgVHR0V%2FagVHf5wHRUD6BUdHRX8GBUdyB0VAyAVHR0V%2FOAVHf7UHRUETBUdHRX7tBUdA7ZkFR0dFWQVHR3%2B6WQVHR0VZBUdHf7pZBUdHRVkFR0d%2FulkFR0dFWQVHR0AAAQAAAAABLAETAAPAB8ALwA%2FAAATITIWHQEUBiMhIiY9ATQ2EyEyFh0BFAYjISImPQE0NhMhMhYdARQGIyEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2MgRMFR0dFfu0FR0dFQRMFR0dFfu0FR0dFQRMFR0dFfu0FR0dFQRMFR0dFfu0FR0dBEwdFWQVHR0VZBUd%2FtQdFWQVHR0VZBUd%2FtQdFWQVHR0VZBUd%2FtQdFWQVHR0VZBUdAAgAAAAABLAETAAPAB8ALwA%2FAE8AXwBvAH8AABMzMhYdARQGKwEiJj0BNDYpATIWHQEUBiMhIiY9ATQ2ATMyFh0BFAYrASImPQE0NikBMhYdARQGIyEiJj0BNDYBMzIWHQEUBisBIiY9ATQ2KQEyFh0BFAYjISImPQE0NgEzMhYdARQGKwEiJj0BNDYpATIWHQEUBiMhIiY9ATQ2MmQVHR0VZBUdHQFBAyAVHR0V%2FOAVHR3%2B6WQVHR0VZBUdHQFBAyAVHR0V%2FOAVHR3%2B6WQVHR0VZBUdHQFBAyAVHR0V%2FOAVHR3%2B6WQVHR0VZBUdHQFBAyAVHR0V%2FOAVHR0ETB0VZBUdHRVkFR0dFWQVHR0VZBUd%2FtQdFWQVHR0VZBUdHRVkFR0dFWQVHf7UHRVkFR0dFWQVHR0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR0dFWQVHR0VZBUdAAAG%2F5wAAASwBEwAAwATACMAKgA6AEoAACEjETsCMhYdARQGKwEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2BQc1IzUzNQUhMhYdARQGIyEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2AZBkZJZkFR0dFWQVHR0VAfQVHR0V%2FgwVHR3%2B%2BqfIyAHCASwVHR0V%2FtQVHR0VAlgVHR0V%2FagVHR0ETB0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR36fUtkS68dFWQVHR0VZBUd%2FtQdFWQVHR0VZBUdAAAABgAAAAAFFARMAA8AEwAjACoAOgBKAAATMzIWHQEUBisBIiY9ATQ2ASMRMwEhMhYdARQGIyEiJj0BNDYFMxUjFSc3BSEyFh0BFAYjISImPQE0NhMhMhYdARQGIyEiJj0BNDYyZBUdHRVkFR0dA2dkZPyuAfQVHR0V%2FgwVHR0EL8jIp6f75gEsFR0dFf7UFR0dFQJYFR0dFf2oFR0dBEwdFWQVHR0VZBUd%2B7QETP7UHRVkFR0dFWQVHchkS319rx0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR0AAAAAAgAAAMgEsAPoAA8AEgAAEyEyFhURFAYjISImNRE0NgkCSwLuHywsH%2F0SHywsBIT%2B1AEsA%2BgsH%2F12HywsHwKKHyz9RAEsASwAAwAAAAAEsARMAA8AFwAfAAATITIWFREUBiMhIiY1ETQ2FxE3BScBExEEMhYUBiImNCwEWBIaGhL7qBIaGkr3ASpKASXs%2FNJwTk5wTgRMGhL8DBIaGhID9BIaZP0ftoOcAT7%2B4AH0dE5vT09vAAAAAAIA2wAFBDYEkQAWAB4AAAEyHgEVFAcOAQ8BLgQnJjU0PgIWIgYUFjI2NAKIdcZzRkWyNjYJIV5YbSk8RHOft7eCgreCBJF4ynVzj23pPz4IIWZomEiEdVijeUjDgriBgbgAAAACABcAFwSZBJkADwAXAAAAMh4CFA4CIi4CND4BAREiDgEUHgEB4%2BrWm1tbm9bq1ptbW5sBS3TFcnLFBJlbm9bq1ptbW5vW6tab%2FG8DVnLF6MVyAAACAHUAAwPfBQ8AGgA1AAABHgYVFA4DBy4DNTQ%2BBQMOAhceBBcWNj8BNiYnLgInJjc2IyYCKhVJT1dOPiUzVnB9P1SbfEokP0xXUEm8FykoAwEbITEcExUWAgYCCQkFEikMGiACCAgFD0iPdXdzdYdFR4BeRiYEBTpjl1lFh3ZzeHaQ%2Ff4hS4I6JUEnIw4IBwwQIgoYBwQQQSlZtgsBAAAAAwAAAAAEywRsAAwAKgAvAAABNz4CHgEXHgEPAiUhMhcHISIGFREUFjMhMjY9ATcRFAYjISImNRE0NgkBBzcBA%2BhsAgYUFR0OFgoFBmz9BQGQMje7%2FpApOzspAfQpO8i7o%2F5wpbm5Azj%2BlqE3AWMD9XMBAgIEDw4WKgsKc8gNuzsp%2FgwpOzsptsj%2BtKW5uaUBkKW5%2Ftf%2BljKqAWMAAgAAAAAEkwRMABsANgAAASEGByMiBhURFBYzITI2NTcVFAYjISImNRE0NgUBFhQHAQYmJzUmDgMHPgY3NT4BAV4BaaQ0wyk7OykB9Ck7yLml%2FnClubkCfwFTCAj%2BrAcLARo5ZFRYGgouOUlARioTAQsETJI2Oyn%2BDCk7OymZZ6W5uaUBkKW5G%2F7TBxUH%2Fs4GBAnLAQINFjAhO2JBNB0UBwHSCgUAAAAAAgAAAAAEnQRMAB0ANQAAASEyFwchIgYVERQWMyEyNj0BNxUUBiMhIiY1ETQ2CQE2Mh8BFhQHAQYiLwEmND8BNjIfARYyAV4BXjxDsv6jKTs7KQH0KTvIuaX%2BcKW5uQHKAYsHFQdlBwf97QcVB%2FgHB2UHFQdvCBQETBexOyn%2BDCk7OylFyNulubmlAZCluf4zAYsHB2UHFQf97AcH%2BAcVB2UHB28HAAAAAQAKAAoEpgSmADsAAAkBNjIXARYGKwEVMzU0NhcBFhQHAQYmPQEjFTMyFgcBBiInASY2OwE1IxUUBicBJjQ3ATYWHQEzNSMiJgE%2BAQgIFAgBBAcFCqrICggBCAgI%2FvgICsiqCgUH%2FvwIFAj%2B%2BAgFCq%2FICgj%2B%2BAgIAQgICsivCgUDlgEICAj%2B%2BAgKyK0KBAf%2B%2FAcVB%2F73BwQKrcgKCP74CAgBCAgKyK0KBAcBCQcVBwEEBwQKrcgKAAEAyAAAA4QETAAZAAATMzIWFREBNhYVERQGJwERFAYrASImNRE0NvpkFR0B0A8VFQ%2F%2BMB0VZBUdHQRMHRX%2BSgHFDggV%2FBgVCA4Bxf5KFR0dFQPoFR0AAAABAAAAAASwBEwAIwAAEzMyFhURATYWFREBNhYVERQGJwERFAYnAREUBisBIiY1ETQ2MmQVHQHQDxUB0A8VFQ%2F%2BMBUP%2FjAdFWQVHR0ETB0V%2FkoBxQ4IFf5KAcUOCBX8GBUIDgHF%2FkoVCA4Bxf5KFR0dFQPoFR0AAAABAJ0AGQSwBDMAFQAAAREUBicBERQGJwEmNDcBNhYVEQE2FgSwFQ%2F%2BMBUP%2FhQPDwHsDxUB0A8VBBr8GBUIDgHF%2FkoVCA4B4A4qDgHgDggV%2FkoBxQ4IAAAAAQDIABYEMwQ2AAsAABMBFhQHAQYmNRE0NvMDLhIS%2FNISGRkEMv4OCx4L%2Fg4LDhUD6BUOAAIAyABkA4QD6AAPAB8AABMzMhYVERQGKwEiJjURNDYhMzIWFREUBisBIiY1ETQ2%2BsgVHR0VyBUdHQGlyBUdHRXIFR0dA%2BgdFfzgFR0dFQMgFR0dFfzgFR0dFQMgFR0AAAEAyABkBEwD6AAPAAABERQGIyEiJjURNDYzITIWBEwdFfzgFR0dFQMgFR0DtvzgFR0dFQMgFR0dAAAAAAEAAAAZBBMEMwAVAAABETQ2FwEWFAcBBiY1EQEGJjURNDYXAfQVDwHsDw%2F%2BFA8V%2FjAPFRUPAmQBthUIDv4gDioO%2FiAOCBUBtv47DggVA%2BgVCA4AAAH%2F%2FgACBLMETwAjAAABNzIWFRMUBiMHIiY1AwEGJjUDAQYmNQM0NhcBAzQ2FwEDNDYEGGQUHgUdFWQVHQL%2BMQ4VAv4yDxUFFQ8B0gIVDwHSAh0ETgEdFfwYFR0BHRUBtf46DwkVAbX%2BOQ4JFAPoFQkP%2Fj4BthQJDv49AbYVHQAAAQEsAAAD6ARMABkAAAEzMhYVERQGKwEiJjURAQYmNRE0NhcBETQ2A1JkFR0dFWQVHf4wDxUVDwHQHQRMHRX8GBUdHRUBtv47DggVA%2BgVCA7%2BOwG2FR0AAAIAZADIBLAESAALABsAAAkBFgYjISImNwE2MgEhMhYdARQGIyEiJj0BNDYCrgH1DwkW%2B%2B4WCQ8B9Q8q%2FfcD6BUdHRX8GBUdHQQ5%2FeQPFhYPAhwP%2FUgdFWQVHR0VZBUdAAEAiP%2F8A3UESgAFAAAJAgcJAQN1%2FqABYMX92AIoA4T%2Bn%2F6fxgIoAiYAAAAAAQE7%2F%2FwEKARKAAUAAAkBJwkBNwQo%2FdnGAWH%2Bn8YCI%2F3ZxgFhAWHGAAIAFwAXBJkEmQAPADMAAAAyHgIUDgIiLgI0PgEFIyIGHQEjIgYdARQWOwEVFBY7ATI2PQEzMjY9ATQmKwE1NCYB4%2BrWm1tbm9bq1ptbW5sBfWQVHZYVHR0Vlh0VZBUdlhUdHRWWHQSZW5vW6tabW1ub1urWm7odFZYdFWQVHZYVHR0Vlh0VZBUdlhUdAAAAAAIAFwAXBJkEmQAPAB8AAAAyHgIUDgIiLgI0PgEBISIGHQEUFjMhMjY9ATQmAePq1ptbW5vW6tabW1ubAkX%2BDBUdHRUB9BUdHQSZW5vW6tabW1ub1urWm%2F5%2BHRVkFR0dFWQVHQACABcAFwSZBJkADwAzAAAAMh4CFA4CIi4CND4BBCIPAScmIg8BBhQfAQcGFB8BFjI%2FARcWMj8BNjQvATc2NC8BAePq1ptbW5vW6tabW1ubAeUZCXh4CRkJjQkJeHgJCY0JGQl4eAkZCY0JCXh4CQmNBJlbm9bq1ptbW5vW6tabrQl4eAkJjQkZCXh4CRkJjQkJeHgJCY0JGQl4eAkZCY0AAgAXABcEmQSZAA8AJAAAADIeAhQOAiIuAjQ%2BAQEnJiIPAQYUHwEWMjcBNjQvASYiBwHj6tabW1ub1urWm1tbmwEVVAcVCIsHB%2FIHFQcBdwcHiwcVBwSZW5vW6tabW1ub1urWm%2F4xVQcHiwgUCPEICAF3BxUIiwcHAAAAAAMAFwAXBJkEmQAPADsASwAAADIeAhQOAiIuAjQ%2BAQUiDgMVFDsBFjc%2BATMyFhUUBgciDgUHBhY7ATI%2BAzU0LgMTIyIGHQEUFjsBMjY9ATQmAePq1ptbW5vW6tabW1ubAT8dPEIyIRSDHgUGHR8UFw4TARkOGhITDAIBDQ6tBx4oIxgiM0Q8OpYKDw8KlgoPDwSZW5vW6tabW1ub1urWm5ELHi9PMhkFEBQQFRIXFgcIBw4UHCoZCBEQKDhcNi9IKhsJ%2FeMPCpYKDw8KlgoPAAADABcAFwSZBJkADwAfAD4AAAAyHgIUDgIiLgI0PgEFIyIGHQEUFjsBMjY9ATQmAyMiBh0BFBY7ARUjIgYdARQWMyEyNj0BNCYrARE0JgHj6tabW1ub1urWm1tbmwGWlgoPDwqWCg8PCvoKDw8KS0sKDw8KAV4KDw8KSw8EmVub1urWm1tbm9bq1ptWDwqWCg8PCpYKD%2F7UDwoyCg%2FIDwoyCg8PCjIKDwETCg8AAgAAAAAEsASwAC8AXwAAATMyFh0BHgEXMzIWHQEUBisBDgEHFRQGKwEiJj0BLgEnIyImPQE0NjsBPgE3NTQ2ExUUBisBIiY9AQ4BBzMyFh0BFAYrAR4BFzU0NjsBMhYdAT4BNyMiJj0BNDY7AS4BAg2WCg9nlxvCCg8PCsIbl2cPCpYKD2eXG8IKDw8KwhuXZw%2B5DwqWCg9EZheoCg8PCqgXZkQPCpYKD0RmF6gKDw8KqBdmBLAPCsIbl2cPCpYKD2eXG8IKDw8KwhuXZw8KlgoPZ5cbwgoP%2Fs2oCg8PCqgXZkQPCpYKD0RmF6gKDw8KqBdmRA8KlgoPRGYAAwAXABcEmQSZAA8AGwA%2FAAAAMh4CFA4CIi4CND4BBCIOARQeATI%2BATQmBxcWFA8BFxYUDwEGIi8BBwYiLwEmND8BJyY0PwE2Mh8BNzYyAePq1ptbW5vW6tabW1ubAb%2FoxXJyxejFcnKaQAcHfHwHB0AHFQd8fAcVB0AHB3x8BwdABxUHfHwHFQSZW5vW6tabW1ub1urWmztyxejFcnLF6MVaQAcVB3x8BxUHQAcHfHwHB0AHFQd8fAcVB0AHB3x8BwAAAAMAFwAXBJkEmQAPABsAMAAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JgcXFhQHAQYiLwEmND8BNjIfATc2MgHj6tabW1ub1urWm1tbmwG%2F6MVycsXoxXJyg2oHB%2F7ACBQIyggIagcVB0%2FFBxUEmVub1urWm1tbm9bq1ps7csXoxXJyxejFfWoHFQf%2BvwcHywcVB2oICE%2FFBwAAAAMAFwAXBJkEmQAPABgAIQAAADIeAhQOAiIuAjQ%2BAQUiDgEVFBcBJhcBFjMyPgE1NAHj6tabW1ub1urWm1tbmwFLdMVyQQJLafX9uGhzdMVyBJlbm9bq1ptbW5vW6tabO3LFdHhpAktB0P24PnLFdHMAAAAAAQAXAFMEsAP5ABUAABMBNhYVESEyFh0BFAYjIREUBicBJjQnAgoQFwImFR0dFf3aFxD99hACRgGrDQoV%2Ft0dFcgVHf7dFQoNAasNJgAAAAABAAAAUwSZA%2FkAFQAACQEWFAcBBiY1ESEiJj0BNDYzIRE0NgJ%2FAgoQEP32EBf92hUdHRUCJhcD8f5VDSYN%2FlUNChUBIx0VyBUdASMVCgAAAAEAtwAABF0EmQAVAAAJARYGIyERFAYrASImNREhIiY3ATYyAqoBqw0KFf7dHRXIFR3%2B3RUKDQGrDSYEif32EBf92hUdHRUCJhcQAgoQAAAAAQC3ABcEXQSwABUAAAEzMhYVESEyFgcBBiInASY2MyERNDYCJsgVHQEjFQoN%2FlUNJg3%2BVQ0KFQEjHQSwHRX92hcQ%2FfYQEAIKEBcCJhUdAAABAAAAtwSZBF0AFwAACQEWFAcBBiY1EQ4DBz4ENxE0NgJ%2FAgoQEP32EBdesKWBJAUsW4fHfhcEVf5VDSYN%2FlUNChUBIwIkRHVNabGdcUYHAQYVCgACAAAAAASwBLAAFQArAAABITIWFREUBi8BBwYiLwEmND8BJyY2ASEiJjURNDYfATc2Mh8BFhQPARcWBgNSASwVHRUOXvkIFAhqBwf5Xg4I%2FiH%2B1BUdFQ5e%2BQgUCGoHB%2FleDggEsB0V%2FtQVCA5e%2BQcHaggUCPleDhX7UB0VASwVCA5e%2BQcHaggUCPleDhUAAAACAEkASQRnBGcAFQArAAABFxYUDwEXFgYjISImNRE0Nh8BNzYyASEyFhURFAYvAQcGIi8BJjQ%2FAScmNgP2agcH%2BV4OCBX%2B1BUdFQ5e%2BQgU%2FQwBLBUdFQ5e%2BQgUCGoHB%2FleDggEYGoIFAj5Xg4VHRUBLBUIDl75B%2F3xHRX%2B1BUIDl75BwdqCBQI%2BV4OFQAAAAADABcAFwSZBJkADwAfAC8AAAAyHgIUDgIiLgI0PgEFIyIGFxMeATsBMjY3EzYmAyMiBh0BFBY7ATI2PQE0JgHj6tabW1ub1urWm1tbmwGz0BQYBDoEIxQ2FCMEOgQYMZYKDw8KlgoPDwSZW5vW6tabW1ub1urWm7odFP7SFB0dFAEuFB3%2BDA8KlgoPDwqWCg8AAAAABQAAAAAEsASwAEkAVQBhAGgAbwAAATIWHwEWHwEWFxY3Nj8BNjc2MzIWHwEWHwIeATsBMhYdARQGKwEiBh0BIREjESE1NCYrASImPQE0NjsBMjY1ND8BNjc%2BBAUHBhY7ATI2LwEuAQUnJgYPAQYWOwEyNhMhIiY1ESkBERQGIyERAQQJFAUFFhbEFQ8dCAsmxBYXERUXMA0NDgQZCAEPCj0KDw8KMgoP%2FnDI%2FnAPCjIKDw8KPQsOCRkFDgIGFRYfAp2mBwQK2woKAzMDEP41sQgQAzMDCgrnCwMe%2FokKDwGQAlgPCv6JBLAEAgIKDXYNCxUJDRZ2DQoHIREQFRh7LAkLDwoyCg8PCq8BLP7UrwoPDwoyCg8GBQQwgBkUAwgWEQ55ogcKDgqVCgSqnQcECo8KDgr8cg8KAXf%2BiQoPAZAAAAAAAgAAAAwErwSmACsASQAAATYWFQYCDgQuAScmByYOAQ8BBiY1NDc%2BATc%2BAScuAT4BNz4GFyYGBw4BDwEOBAcOARY2Nz4CNz4DNz4BBI0IGgItQmxhi2KORDg9EQQRMxuZGhYqCFUYEyADCQIQOjEnUmFch3vAJQgdHyaiPT44XHRZUhcYDhItIRmKcVtGYWtbKRYEBKYDEwiy%2Ft3IlVgxEQgLCwwBAQIbG5kYEyJAJghKFRE8Hzdff4U%2FM0o1JSMbL0QJGCYvcSEhHjZST2c1ODwEJygeW0AxJUBff1UyFAABAF0AHgRyBM8ATwAAAQ4BHgQXLgc%2BATceAwYHDgQHBicmNzY3PgQuAScWDgMmJy4BJyY%2BBDcGHgM3PgEuAicmPgMCjScfCic4R0IgBBsKGAoQAwEJEg5gikggBhANPkpTPhZINx8SBgsNJysiCRZOQQoVNU1bYC9QZwICBAUWITsoCAYdJzIYHw8YIiYHDyJJYlkEz0OAZVxEOSQMBzgXOB42IzElKRIqg5Gnl0o3Z0c6IAYWCwYNAwQFIDhHXGF1OWiqb0sdBxUknF0XNTQ8PEUiNWNROBYJDS5AQVUhVZloUSkAAAAAA%2F%2FcAGoE1ARGABsAPwBRAAAAMh4FFA4FIi4FND4EBSYGFxYVFAYiJjU0NzYmBwYHDgEXHgQyPgM3NiYnJgUHDgEXFhcWNj8BNiYnJicuAQIGpJ17bk85HBw6T257naKde25POhwcOU9uewIPDwYIGbD4sBcIBw5GWg0ECxYyWl%2BDiINfWjIWCwQMWv3%2FIw8JCSU4EC0OIw4DDywtCyIERi1JXGJcSSpJXGJcSS0tSVxiXEkqSVxiXEncDwYTOT58sLB8OzcTBg9FcxAxEiRGXkQxMEVeRSQSMRF1HiQPLxJEMA0EDyIPJQ8sSRIEAAAABP%2FcAAAE1ASwABQAJwA7AEwAACEjNy4ENTQ%2BBTMyFzczEzceARUUDgMHNz4BNzYmJyYlBgcOARceBBc3LgE1NDc2JhcHDgEXFhcWNj8CJyYnLgECUJQfW6l2WSwcOU9ue51SPUEglCYvbIknUGqYUi5NdiYLBAw2%2FVFGWg0ECxIqSExoNSlrjxcIB3wjDwkJJTgQLQ4MFgMsLQsieBRhdHpiGxVJXGJcSS0Pef5StVXWNBpacm5jGq0xiD8SMRFGckVzEDESHjxRQTkNmhKnbjs3EwZwJA8vEkQwDQQPC1YELEkSBAAAAAP%2FngAABRIEqwALABgAKAAAJwE2FhcBFgYjISImJSE1NDY7ATIWHQEhAQczMhYPAQ4BKwEiJi8BJjZaAoIUOBQCghUbJfryJRsBCgFZDwqWCg8BWf5DaNAUGAQ6BCMUNhQjBDoEGGQEKh8FIfvgIEdEhEsKDw8KSwLT3x0U%2FBQdHRT8FB0AAAABAGQAFQSwBLAAKAAAADIWFREBHgEdARQGJyURFh0BFAYvAQcGJj0BNDcRBQYmPQE0NjcBETQCTHxYAWsPFhgR%2FplkGhPNzRMaZP6ZERgWDwFrBLBYPv6t%2FrsOMRQpFA0M%2Bf75XRRAFRAJgIAJEBVAFF0BB%2FkMDRQpFDEOAUUBUz4AAAARAAAAAARMBLAAHQAnACsALwAzADcAOwA%2FAEMARwBLAE8AUwBXAFsAXwBjAAABMzIWHQEzMhYdASE1NDY7ATU0NjsBMhYdASE1NDYBERQGIyEiJjURFxUzNTMVMzUzFTM1MxUzNTMVMzUFFTM1MxUzNTMVMzUzFTM1MxUzNQUVMzUzFTM1MxUzNTMVMzUzFTM1A1JkFR0yFR37tB0VMh0VZBUdAfQdAQ8dFfwYFR1kZGRkZGRkZGRk%2FHxkZGRkZGRkZGT8fGRkZGRkZGRkZASwHRUyHRWWlhUdMhUdHRUyMhUd%2FnD9EhUdHRUC7shkZGRkZGRkZGRkyGRkZGRkZGRkZGTIZGRkZGRkZGRkZAAAAAMAAAAZBXcElwAZACUANwAAARcWFA8BBiY9ASMBISImPQE0NjsBATM1NDYBBycjIiY9ATQ2MyEBFxYUDwEGJj0BIyc3FzM1NDYEb%2FkPD%2FkOFZ%2F9qP7dFR0dFdECWPEV%2FamNetEVHR0VASMDGvkPD%2FkOFfG1jXqfFQSN5g4qDuYOCBWW%2FagdFWQVHQJYlhUI%2FpiNeh0VZBUd%2Fk3mDioO5g4IFZa1jXqWFQgAAAABAAAAAASwBEwAEgAAEyEyFhURFAYjIQERIyImNRE0NmQD6Ck7Oyn9rP7QZCk7OwRMOyn9qCk7%2FtQBLDspAlgpOwAAAAMAZAAABEwEsAAJABMAPwAAEzMyFh0BITU0NiEzMhYdASE1NDYBERQOBSIuBTURIRUUFRwBHgYyPgYmNTQ9AZbIFR3%2B1B0C0cgVHf7UHQEPBhgoTGacwJxmTCgYBgEsAwcNFB8nNkI2Jx8TDwUFAQSwHRX6%2BhUdHRX6%2BhUd%2FnD%2B1ClJalZcPigoPlxWakkpASz6CRIVKyclIRsWEAgJEBccISUnKhURCPoAAAAB%2F%2F8A1ARMA8IABQAAAQcJAScBBEzG%2Fp%2F%2Bn8UCJwGbxwFh%2Fp%2FHAicAAQAAAO4ETQPcAAUAAAkCNwkBBE392v3ZxgFhAWEDFf3ZAifH%2Fp8BYQAAAAAC%2F1EAZAVfA%2BgAFAApAAABITIWFREzMhYPAQYiLwEmNjsBESElFxYGKwERIRchIiY1ESMiJj8BNjIBlALqFR2WFQgO5g4qDuYOCBWW%2FoP%2BHOYOCBWWAYHX%2FRIVHZYVCA7mDioD6B0V%2FdkVDvkPD%2FkOFQGRuPkOFf5wyB0VAiYVDvkPAAABAAYAAASeBLAAMAAAEzMyFh8BITIWBwMOASMhFyEyFhQGKwEVFAYiJj0BIRUUBiImPQEjIiYvAQMjIiY0NjheERwEJgOAGB4FZAUsIf2HMAIXFR0dFTIdKh3%2B1B0qHR8SHQYFyTYUHh4EsBYQoiUY%2FiUVK8gdKh0yFR0dFTIyFR0dFTIUCQoDwR0qHQAAAAACAAAAAASwBEwACwAPAAABFSE1MzQ2MyEyFhUFIREhBLD7UMg7KQEsKTv9RASw%2B1AD6GRkKTs7Kcj84AACAAAAAAXcBEwADAAQAAATAxEzNDYzITIWFSEVBQEhAcjIyDspASwqOgH0ASz%2B1PtQASwDIP5wAlgpOzspyGT9RAK8AAEBRQAAA2sErwAbAAABFxYGKwERMzIWDwEGIi8BJjY7AREjIiY%2FATYyAnvmDggVlpYVCA7mDioO5g4IFZaWFQgO5g4qBKD5DhX9pxUO%2BQ8P%2BQ4VAlkVDvkPAAAAAQABAUQErwNrABsAAAEXFhQPAQYmPQEhFRQGLwEmND8BNhYdASE1NDYDqPkODvkPFf2oFQ%2F5Dg75DxUCWBUDYOUPKQ%2FlDwkUl5cUCQ%2FlDykP5Q8JFZWVFQkAAAAEAAAAAASwBLAACQAZAB0AIQAAAQMuASMhIgYHAwUhIgYdARQWMyEyNj0BNCYFNTMVMzUzFQSRrAUkFP1gFCQFrAQt%2FBgpOzspA%2BgpOzv%2Bq2RkZAGQAtwXLSgV%2FR1kOylkKTs7KWQpO8hkZGRkAAAAA%2F%2BcAGQEsARMAAsAIwAxAAAAMhYVERQGIiY1ETQDJSMTFgYjIisBIiYnAj0BNDU0PgE7ASUBFSIuAz0BND4CNwRpKh0dKh1k%2FV0mLwMRFQUCVBQdBDcCCwzIAqP8GAQOIhoWFR0dCwRMHRX8rhUdHRUDUhX8mcj%2B7BAIHBUBUQ76AgQQDw36%2FtT6AQsTKRwyGigUDAEAAAACAEoAAARmBLAALAA1AAABMzIWDwEeARcTFzMyFhQGBw4EIyIuBC8BLgE0NjsBNxM%2BATcnJjYDFjMyNw4BIiYCKV4UEgYSU3oPP3YRExwaEggeZGqfTzl0XFU%2BLwwLEhocExF2Pw96UxIGEyQyNDUxDDdGOASwFRMlE39N%2FrmtHSkoBwQLHBYSCg4REg4FBAgoKR2tAUdNfhQgExr7vgYGMT09AAEAFAAUBJwEnAAXAAABNwcXBxcHFycHJwcnBzcnNyc3Jxc3FzcDIOBO6rS06k7gLZubLeBO6rS06k7gLZubA7JO4C2bmy3gTuq0tOpO4C2bmy3gTuq0tAADAAAAZASwBLAAIQAtAD0AAAEzMhYdAQchMhYdARQHAw4BKwEiJi8BIyImNRE0PwI%2BARcPAREzFzMTNSE3NQEzMhYVERQGKwEiJjURNDYCijIoPBwBSCg8He4QLBf6B0YfHz0tNxSRYA0xG2SWZIjW%2Bv4%2BMv12ZBUdHRVkFR0dBLBRLJZ9USxkLR3%2BqBghMhkZJCcBkCQbxMYcKGTU1f6JZAF3feGv%2FtQdFf4MFR0dFQH0FR0AAAAAAwAAAAAEsARMACAAMAA8AAABMzIWFxMWHQEUBiMhFh0BFAYrASImLwImNRE0NjsBNgUzMhYVERQGKwEiJjURNDYhByMRHwEzNSchNQMCWPoXLBDuHTwo%2FrgcPCgyGzENYJEUNy09fP3pZBUdHRVkFR0dAl%2BIZJZkMjIBwvoETCEY%2FqgdLWQsUXYHlixRKBzGxBskAZAnJGRkHRX%2BDBUdHRUB9BUdZP6J1dSv4X0BdwADAAAAZAUOBE8AGwA3AEcAAAElNh8BHgEPASEyFhQGKwEDDgEjISImNRE0NjcXERchEz4BOwEyNiYjISoDLgQnJj8BJwUzMhYVERQGKwEiJjURNDYBZAFrHxZuDQEMVAEuVGxuVGqDBhsP%2FqoHphwOOmQBJYMGGw%2FLFRMSFv44AgoCCQMHAwUDAQwRklb9T2QVHR0VZBUdHQNp5hAWcA0mD3lMkE7%2BrRUoog0CDRElCkj%2BCVkBUxUoMjIBAgIDBQIZFrdT5B0V%2FgwVHR0VAfQVHQAAAAP%2FnABkBLAETwAdADYARgAAAQUeBBURFAYjISImJwMjIiY0NjMhJyY2PwE2BxcWBw4FKgIjIRUzMhYXEyE3ESUFMzIWFREUBisBIiY1ETQ2AdsBbgIIFBANrAf%2Bqg8bBoNqVW1sVAEuVQsBDW4WSpIRDAIDBQMHAwkDCgH%2BJd0PHAaCASZq%2FqoCUGQVHR0VZBUdHQRP5gEFEBEXC%2F3zDaIoFQFTTpBMeQ8mDXAWrrcWGQIFAwICAWQoFf6tWQH37OQdFf4MFR0dFQH0FR0AAAADAGEAAARMBQ4AGwA3AEcAAAAyFh0BBR4BFREUBiMhIiYvAQMmPwE%2BAR8BETQXNTQmBhURHAMOBAcGLwEHEyE3ESUuAQMhMhYdARQGIyEiJj0BNDYB3pBOAVMVKKIN%2FfMRJQoJ5hAWcA0mD3nGMjIBAgIDBQIZFrdT7AH3Wf6tFSiWAfQVHR0V%2FgwVHR0FDm5UaoMGGw%2F%2BqgemHA4OAWsfFm4NAQxUAS5U1ssVExIW%2FjgCCgIJAwcDBQMBDBGSVv6tZAElgwYb%2FQsdFWQVHR0VZBUdAAP%2F%2FQAGA%2BgFFAAPAC0ASQAAASEyNj0BNCYjISIGHQEUFgEVFAYiJjURBwYmLwEmNxM%2BBDMhMhYVERQGBwEDFzc2Fx4FHAIVERQWNj0BNDY3JREnAV4B9BUdHRX%2BDBUdHQEPTpBMeQ8mDXAWEOYBBRARFwsCDQ2iKBX9iexTtxYZAgUDAgIBMjIoFQFTWQRMHRVkFR0dFWQVHfzmalRubFQBLlQMAQ1uFh8BawIIEw8Mpgf%2Bqg8bBgHP%2Fq1WkhEMAQMFAwcDCQIKAv44FhITFcsPGwaDASVkAAIAFgAWBJoEmgAPACUAAAAyHgIUDgIiLgI0PgEBJSYGHQEhIgYdARQWMyEVFBY3JTY0AeLs1ptbW5vW7NabW1ubAob%2B7RAX%2Fu0KDw8KARMXEAETEASaW5vW7NabW1ub1uzWm%2F453w0KFYkPCpYKD4kVCg3fDSYAAAIAFgAWBJoEmgAPACUAAAAyHgIUDgIiLgI0PgENAQYUFwUWNj0BITI2PQE0JiMhNTQmAeLs1ptbW5vW7NabW1ubASX%2B7RAQARMQFwETCg8PCv7tFwSaW5vW7NabW1ub1uzWm%2BjfDSYN3w0KFYkPCpYKD4kVCgAAAAIAFgAWBJoEmgAPACUAAAAyHgIUDgIiLgI0PgEBAyYiBwMGFjsBERQWOwEyNjURMzI2AeLs1ptbW5vW7NabW1ubAkvfDSYN3w0KFYkPCpYKD4kVCgSaW5vW7NabW1ub1uzWm%2F5AARMQEP7tEBf%2B7QoPDwoBExcAAAIAFgAWBJoEmgAPACUAAAAyHgIUDgIiLgI0PgEFIyIGFREjIgYXExYyNxM2JisBETQmAeLs1ptbW5vW7NabW1ubAZeWCg%2BJFQoN3w0mDd8NChWJDwSaW5vW7NabW1ub1uzWm7sPCv7tFxD%2B7RAQARMQFwETCg8AAAMAGAAYBJgEmAAPAJYApgAAADIeAhQOAiIuAjQ%2BASUOAwcGJgcOAQcGFgcOAQcGFgcUFgcyHgEXHgIXHgI3Fg4BFx4CFxQGFBcWNz4CNy4BJy4BJyIOAgcGJyY2NS4BJzYuAQYHBicmNzY3HgIXHgMfAT4CJyY%2BATc%2BAzcmNzIWMjY3LgMnND4CJiceAT8BNi4CJwYHFB4BFS4CJz4BNxYyPgEB5OjVm1xcm9Xo1ZtcXJsBZA8rHDoKDz0PFD8DAxMBAzEFCRwGIgEMFhkHECIvCxU%2FOR0HFBkDDRQjEwcFaHUeISQDDTAMD0UREi4oLBAzDwQBBikEAQMLGhIXExMLBhAGKBsGBxYVEwYFAgsFAwMNFwQGCQcYFgYQCCARFwkKKiFBCwQCAQMDHzcLDAUdLDgNEiEQEgg%2FKhADGgMKEgoRBJhcm9Xo1ZtcXJvV6NWbEQwRBwkCAwYFBycPCxcHInIWInYcCUcYChQECA4QBAkuHgQPJioRFRscBAcSCgwCch0kPiAIAQcHEAsBAgsLIxcBMQENCQIPHxkCFBkdHB4QBgEBBwoMGBENBAMMJSAQEhYXDQ4qFBkKEhIDCQsXJxQiBgEOCQwHAQ0DBAUcJAwSCwRnETIoAwEJCwsLJQcKDBEAAAAAAQAAAAIErwSFABYAAAE2FwUXNxYGBw4BJwEGIi8BJjQ3ASY2AvSkjv79kfsGUE08hjv9rA8rD28PDwJYIk8EhVxliuh%2BWYcrIgsW%2FawQEG4PKxACV2XJAAYAAABgBLAErAAPABMAIwAnADcAOwAAEyEyFh0BFAYjISImPQE0NgUjFTMFITIWHQEUBiMhIiY9ATQ2BSEVIQUhMhYdARQGIyEiJj0BNDYFIRUhZAPoKTs7KfwYKTs7BBHIyPwYA%2BgpOzsp%2FBgpOzsEEf4MAfT8GAPoKTs7KfwYKTs7BBH%2B1AEsBKw7KWQpOzspZCk7ZGTIOylkKTs7KWQpO2RkyDspZCk7OylkKTtkZAAAAAIAZAAABEwEsAALABEAABMhMhYUBiMhIiY0NgERBxEBIZYDhBUdHRX8fBUdHQI7yP6iA4QEsB0qHR0qHf1E%2FtTIAfQB9AAAAAMAAABkBLAEsAAXABsAJQAAATMyFh0BITIWFREhNSMVIRE0NjMhNTQ2FxUzNQEVFAYjISImPQEB9MgpOwEsKTv%2BDMj%2BDDspASw7KcgB9Dsp%2FBgpOwSwOylkOyn%2BcGRkAZApO2QpO2RkZP1EyCk7OynIAAAABAAAAAAEsASwABUAKwBBAFcAABMhMhYPARcWFA8BBiIvAQcGJjURNDYpATIWFREUBi8BBwYiLwEmND8BJyY2ARcWFA8BFxYGIyEiJjURNDYfATc2MgU3NhYVERQGIyEiJj8BJyY0PwE2MhcyASwVCA5exwcHaggUCMdeDhUdAzUBLBUdFQ5exwgUCGoHB8deDgj%2BL2oHB8deDggV%2FtQVHRUOXscIFALLXg4VHRX%2B1BUIDl7HBwdqCBQIBLAVDl7HCBQIagcHx14OCBUBLBUdHRX%2B1BUIDl7HBwdqCBQIx14OFf0maggUCMdeDhUdFQEsFQgOXscHzl4OCBX%2B1BUdFQ5exwgUCGoHBwAAAAYAAAAABKgEqAAPABsAIwA7AEMASwAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JiQyFhQGIiY0JDIWFAYjIicHFhUUBiImNTQ2PwImNTQEMhYUBiImNCQyFhQGIiY0Advy3Z9fX5%2Fd8t2gXl6gAcbgv29vv%2BC%2Fb2%2F%2BLS0gIC0gAUwtICAWDg83ETNIMykfegEJ%2FoctICAtIAIdLSAgLSAEqF%2Bf3fLdoF5eoN3y3Z9Xb7%2Fgv29vv%2BC%2FBiAtISEtICAtIQqRFxwkMzMkIDEFfgEODhekIC0gIC0gIC0gIC0AAf%2FYAFoEuQS8AFsAACUBNjc2JicmIyIOAwcABw4EFx4BMzI3ATYnLgEjIgcGBwEOASY0NwA3PgEzMhceARcWBgcOBgcGIyImJyY2NwE2NzYzMhceARcWBgcBDgEnLgECIgHVWwgHdl8WGSJBMD8hIP6IDx4eLRMNBQlZN0ozAiQkEAcdEhoYDRr%2Bqw8pHA4BRyIjQS4ODyw9DQ4YIwwod26La1YOOEBGdiIwGkQB%2F0coW2tQSE5nDxE4Qv4eDyoQEAOtAdZbZWKbEQQUGjIhH%2F6JDxsdNSg3HT5CMwIkJCcQFBcMGv6uDwEcKQ4BTSIjIQEINykvYyMLKnhuiWZMBxtAOU6%2BRAH%2FSBg3ISSGV121Qv4kDwIPDyYAAAACAGQAWASvBEQAGQBEAAABPgIeAhUUDgMHLgQ1ND4CHgEFIg4DIi4DIyIGFRQeAhcWFx4EMj4DNzY3PgQ1NCYCiTB7eHVYNkN5hKg%2BPqeFeEM4WnZ4eQEjIT8yLSohJyktPyJDbxtBMjMPBw86KzEhDSIzKUAMBAgrKT8dF2oDtURIBS1TdkA5eYB%2FslVVsn%2BAeTlAdlMtBUgtJjY1JiY1NiZvTRc4SjQxDwcOPCouGBgwKEALBAkpKkQqMhNPbQACADn%2F8gR3BL4AFwAuAAAAMh8BFhUUBg8BJi8BNycBFwcvASY0NwEDNxYfARYUBwEGIi8BJjQ%2FARYfAQcXAQKru0KNQjgiHR8uEl%2F3%2FnvUaRONQkIBGxJpCgmNQkL%2B5UK6Qo1CQjcdLhJf9wGFBL5CjUJeKmsiHTUuEl%2F4%2FnvUahKNQrpCARv%2BRmkICY1CukL%2B5UJCjUK7Qjc3LxFf%2BAGFAAAAAAMAyAAAA%2BgEsAARABUAHQAAADIeAhURFAYjISImNRE0PgEHESERACIGFBYyNjQCBqqaZDo7Kf2oKTs8Zj4CWP7%2FVj09Vj0EsB4uMhX8Ryk7OykDuRUzLar9RAK8%2FRY9Vj09VgABAAAAAASwBLAAFgAACQEWFAYiLwEBEScBBRMBJyEBJyY0NjIDhgEbDx0qDiT%2B6dT%2BzP7oywEz0gEsAQsjDx0qBKH%2B5g8qHQ8j%2FvX%2B1NL%2BzcsBGAE01AEXJA4qHQAAAAADAScAEQQJBOAAMgBAAEsAAAEVHgQXIy4DJxEXHgQVFAYHFSM1JicuASczHgEXEScuBDU0PgI3NRkBDgMVFB4DFxYXET4ENC4CArwmRVI8LAKfBA0dMydAIjxQNyiym2SWVygZA4sFV0obLkJOMCAyVWg6HSoqFQ4TJhkZCWgWKTEiGBkzNwTgTgUTLD9pQiQuLBsH%2Fs0NBxMtPGQ%2Bi6oMTU8QVyhrVk1iEAFPCA4ZLzlYNkZwSCoGTf4SARIEDh02Jh0rGRQIBgPQ%2FsoCCRYgNEM0JRkAAAABAGQAZgOUBK0ASgAAATIeARUjNC4CIyIGBwYVFB4BFxYXMxUjFgYHBgc%2BATM2FjMyNxcOAyMiLgEHDgEPASc%2BBTc%2BAScjNTMmJy4CPgE3NgIxVJlemSc8OxolVBQpGxoYBgPxxQgVFS02ImIWIIwiUzUyHzY4HCAXanQmJ1YYFzcEGAcTDBEJMAwk3aYXFQcKAg4tJGEErVCLTig%2FIhIdFSw5GkowKgkFZDKCHj4yCg8BIh6TExcIASIfBAMaDAuRAxAFDQsRCjePR2QvORQrREFMIVgAAAACABn%2F%2FwSXBLAADwAfAAABMzIWDwEGIi8BJjY7AREzBRcWBisBESMRIyImPwE2MgGQlhUIDuYOKg7mDggVlsgCF%2BYOCBWWyJYVCA7mDioBLBYO%2Bg8P%2Bg4WA4QQ%2BQ4V%2FHwDhBUO%2BQ8AAAQAGf%2F%2FA%2BgEsAAHABcAGwAlAAABIzUjFSMRIQEzMhYPAQYiLwEmNjsBETMFFTM1EwczFSE1NyM1IQPoZGRkASz9qJYVCA7mDioO5g4IFZbIAZFkY8jI%2FtTIyAEsArxkZAH0%2FHwWDvoPD%2FoOFgOEZMjI%2FRL6ZJb6ZAAAAAAEABn%2F%2FwPoBLAADwAZACEAJQAAATMyFg8BBiIvASY2OwERMwUHMxUhNTcjNSERIzUjFSMRIQcVMzUBkJYVCA7mDioO5g4IFZbIAljIyP7UyMgBLGRkZAEsx2QBLBYO%2Bg8P%2Bg4WA4SW%2BmSW%2BmT7UGRkAfRkyMgAAAAEABn%2F%2FwRMBLAADwAVABsAHwAAATMyFg8BBiIvASY2OwERMwEjESM1MxMjNSMRIQcVMzUBkJYVCA7mDioO5g4IFZbIAlhkZMhkZMgBLMdkASwWDvoPD%2FoOFgOE%2FgwBkGT7UGQBkGTIyAAAAAAEABn%2F%2FwRMBLAADwAVABkAHwAAATMyFg8BBiIvASY2OwERMwEjNSMRIQcVMzUDIxEjNTMBkJYVCA7mDioO5g4IFZbIArxkyAEsx2QBZGTIASwWDvoPD%2FoOFgOE%2FgxkAZBkyMj7tAGQZAAAAAAFABn%2F%2FwSwBLAADwATABcAGwAfAAABMzIWDwEGIi8BJjY7AREzBSM1MxMhNSETITUhEyE1IQGQlhUIDuYOKg7mDggVlsgB9MjIZP7UASxk%2FnABkGT%2BDAH0ASwWDvoPD%2FoOFgOEyMj%2BDMj%2BDMj%2BDMgABQAZ%2F%2F8EsASwAA8AEwAXABsAHwAAATMyFg8BBiIvASY2OwERMwUhNSEDITUhAyE1IQMjNTMBkJYVCA7mDioO5g4IFZbIAyD%2BDAH0ZP5wAZBk%2FtQBLGTIyAEsFg76Dw%2F6DhYDhMjI%2FgzI%2FgzI%2FgzIAAIAAAAABEwETAAPAB8AAAEhMhYVERQGIyEiJjURNDYFISIGFREUFjMhMjY1ETQmAV4BkKK8u6P%2BcKW5uQJn%2FgwpOzspAfQpOzsETLuj%2FnClubmlAZClucg7Kf4MKTs7KQH0KTsAAAAAAwAAAAAETARMAA8AHwArAAABITIWFREUBiMhIiY1ETQ2BSEiBhURFBYzITI2NRE0JgUXFhQPAQYmNRE0NgFeAZClubml%2FnCju7wCZP4MKTs7KQH0KTs7%2Fm%2F9ERH9EBgYBEy5pf5wpbm5pQGQo7vIOyn%2BDCk7OykB9Ck7gr4MJAy%2BDAsVAZAVCwAAAAADAAAAAARMBEwADwAfACsAAAEhMhYVERQGIyEiJjURNDYFISIGFREUFjMhMjY1ETQmBSEyFg8BBiIvASY2AV4BkKO7uaX%2BcKW5uQJn%2FgwpOzspAfQpOzv%2BFQGQFQsMvgwkDL4MCwRMvKL%2BcKW5uaUBkKO7yDsp%2FgwpOzspAfQpO8gYEP0REf0QGAAAAAMAAAAABEwETAAPAB8AKwAAASEyFhURFAYjISImNRE0NgUhIgYVERQWMyEyNjURNCYFFxYGIyEiJj8BNjIBXgGQpbm5pf5wo7u5Amf%2BDCk7OykB9Ck7O%2F77vgwLFf5wFQsMvgwkBEy5pf5wo7u8ogGQpbnIOyn%2BDCk7OykB9Ck7z%2F0QGBgQ%2FREAAAAAAgAAAAAFFARMAB8ANQAAASEyFhURFAYjISImPQE0NjMhMjY1ETQmIyEiJj0BNDYHARYUBwEGJj0BIyImPQE0NjsBNTQ2AiYBkKW5uaX%2BcBUdHRUBwik7Oyn%2BPhUdHb8BRBAQ%2FrwQFvoVHR0V%2BhYETLml%2FnCluR0VZBUdOykB9Ck7HRVkFR3p%2FuQOJg7%2B5A4KFZYdFcgVHZYVCgAAAQDZAAID1wSeACMAAAEXFgcGAgclMhYHIggBBwYrAScmNz4BPwEhIicmNzYANjc2MwMZCQgDA5gCASwYEQ4B%2Fvf%2B8wQMDgkJCQUCUCcn%2FtIXCAoQSwENuwUJEASeCQoRC%2F5TBwEjEv7K%2FsUFDwgLFQnlbm4TFRRWAS%2FTBhAAAAACAAAAAAT%2BBEwAHwA1AAABITIWHQEUBiMhIgYVERQWMyEyFh0BFAYjISImNRE0NgUBFhQHAQYmPQEjIiY9ATQ2OwE1NDYBXgGQFR0dFf4%2BKTs7KQHCFR0dFf5wpbm5AvEBRBAQ%2FrwQFvoVHR0V%2BhYETB0VZBUdOyn%2BDCk7HRVkFR25pQGQpbnp%2FuQOJg7%2B5A4KFZYdFcgVHZYVCgACAAAAAASwBLAAFQAxAAABITIWFREUBi8BAQYiLwEmNDcBJyY2ASMiBhURFBYzITI2PQE3ERQGIyEiJjURNDYzIQLuAZAVHRUObf7IDykPjQ8PAThtDgj%2B75wpOzspAfQpO8i7o%2F5wpbm5pQEsBLAdFf5wFQgObf7IDw%2BNDykPAThtDhX%2B1Dsp%2FgwpOzsplMj%2B1qW5uaUBkKW5AAADAA4ADgSiBKIADwAbACMAAAAyHgIUDgIiLgI0PgEEIg4BFB4BMj4BNCYEMhYUBiImNAHh7tmdXV2d2e7ZnV1dnQHD5sJxccLmwnFx%2FnugcnKgcgSiXZ3Z7tmdXV2d2e7ZnUdxwubCcXHC5sJzcqBycqAAAAMAAAAABEwEsAAVAB8AIwAAATMyFhURMzIWBwEGIicBJjY7ARE0NgEhMhYdASE1NDYFFTM1AcLIFR31FAoO%2FoEOJw3%2BhQ0JFfod%2FoUD6BUd%2B7QdA2dkBLAdFf6iFg%2F%2BVg8PAaoPFgFeFR38fB0V%2BvoVHWQyMgAAAAMAAAAABEwErAAVAB8AIwAACQEWBisBFRQGKwEiJj0BIyImNwE%2BAQEhMhYdASE1NDYFFTM1AkcBeg4KFfQiFsgUGPoUCw4Bfw4n%2FfkD6BUd%2B7QdA2dkBJ7%2BTQ8g%2BhQeHRX6IQ8BrxAC%2FH8dFfr6FR1kMjIAAwAAAAAETARLABQAHgAiAAAJATYyHwEWFAcBBiInASY0PwE2MhcDITIWHQEhNTQ2BRUzNQGMAXEHFQeLBwf98wcVB%2F7cBweLCBUH1APoFR37tB0DZ2QC0wFxBweLCBUH%2FfMICAEjCBQIiwcH%2FdIdFfr6FR1kMjIABAAAAAAETASbAAkAGQAjACcAABM3NjIfAQcnJjQFNzYWFQMOASMFIiY%2FASc3ASEyFh0BITU0NgUVMzWHjg4qDk3UTQ4CFtIOFQIBHRX9qxUIDtCa1P49A%2BgVHfu0HQNnZAP%2Fjg4OTdRMDyqa0g4IFf2pFB4BFQ7Qm9T9Oh0V%2BvoVHWQyMgAAAAQAAAAABEwEsAAPABkAIwAnAAABBR4BFRMUBi8BByc3JyY2EwcGIi8BJjQ%2FAQEhMhYdASE1NDYFFTM1AV4CVxQeARUO0JvUm9IOCMNMDyoOjg4OTf76A%2BgVHfu0HQNnZASwAgEdFf2rFQgO0JrUmtIOFf1QTQ4Ojg4qDk3%2BWB0V%2BvoVHWQyMgACAAT%2F7ASwBK8ABQAIAAAlCQERIQkBFQEEsP4d%2Fsb%2BcQSs%2FTMCq2cBFP5xAacDHPz55gO5AAAAAAIAAABkBEwEsAAVABkAAAERFAYrAREhESMiJjURNDY7AREhETMHIzUzBEwdFZb9RJYVHR0V%2BgH0ZMhkZAPo%2FK4VHQGQ%2FnAdFQPoFB7%2B1AEsyMgAAAMAAABFBN0EsAAWABoALwAAAQcBJyYiDwEhESMiJjURNDY7AREhETMHIzUzARcWFAcBBiIvASY0PwE2Mh8BATYyBEwC%2FtVfCRkJlf7IlhUdHRX6AfRkyGRkAbBqBwf%2BXAgUCMoICGoHFQdPASkHFQPolf7VXwkJk%2F5wHRUD6BQe%2FtQBLMjI%2Fc5qBxUH%2FlsHB8sHFQdqCAhPASkHAAMAAAANBQcEsAAWABoAPgAAAREHJy4BBwEhESMiJjURNDY7AREhETMHIzUzARcWFA8BFxYUDwEGIi8BBwYiLwEmND8BJyY0PwE2Mh8BNzYyBExnhg8lEP72%2FreWFR0dFfoB9GTIZGQB9kYPD4ODDw9GDykPg4MPKQ9GDw%2BDgw8PRg8pD4ODDykD6P7zZ4YPAw7%2B9v5wHRUD6BQe%2FtQBLMjI%2FYxGDykPg4MPKQ9GDw%2BDgw8PRg8pD4ODDykPRg8Pg4MPAAADAAAAFQSXBLAAFQAZAC8AAAERISIGHQEhESMiJjURNDY7AREhETMHIzUzEzMyFh0BMzIWDwEGIi8BJjY7ATU0NgRM%2FqIVHf4MlhUdHRX6AfRkyGRklmQVHZYVCA7mDioO5g4IFZYdA%2Bj%2B1B0Vlv5wHRUD6BQe%2FtQBLMjI%2FagdFfoVDuYODuYOFfoVHQAAAAADAAAAAASXBLAAFQAZAC8AAAERJyYiBwEhESMiJjURNDY7AREhETMHIzUzExcWBisBFRQGKwEiJj0BIyImPwE2MgRMpQ4qDv75%2Fm6WFR0dFfoB9GTIZGTr5g4IFZYdFWQVHZYVCA7mDioD6P5wpQ8P%2Fvf%2BcB0VA%2BgUHv7UASzIyP2F5Q8V%2BhQeHhT6FQ%2FlDwADAAAAyASwBEwACQATABcAABMhMhYdASE1NDYBERQGIyEiJjURExUhNTIETBUd%2B1AdBJMdFfu0FR1kAZAETB0VlpYVHf7U%2FdoVHR0VAib%2B1MjIAAAGAAMAfQStBJcADwAZAB0ALQAxADsAAAEXFhQPAQYmPQEhNSE1NDYBIyImPQE0NjsBFyM1MwE3NhYdASEVIRUUBi8BJjQFIzU7AjIWHQEUBisBA6f4Dg74DhX%2BcAGQFf0vMhUdHRUyyGRk%2FoL3DhUBkP5wFQ73DwOBZGRkMxQdHRQzBI3mDioO5g4IFZbIlhUI%2FoUdFWQVHcjI%2FcvmDggVlsiWFQgO5g4qecgdFWQVHQAAAAACAGQAAASwBLAAFgBRAAABJTYWFREUBisBIiY1ES4ENRE0NiUyFh8BERQOAg8BERQGKwEiJjURLgQ1ETQ%2BAzMyFh8BETMRPAE%2BAjMyFh8BETMRND4DA14BFBklHRXIFR0EDiIaFiX%2B4RYZAgEVHR0LCh0VyBUdBA4iGhYBBwoTDRQZAgNkBQkVDxcZAQFkAQUJFQQxdBIUH%2FuuFR0dFQGNAQgbHzUeAWcfRJEZDA3%2BPhw%2FMSkLC%2F5BFR0dFQG%2FBA8uLkAcAcICBxENCxkMDf6iAV4CBxENCxkMDf6iAV4CBxENCwABAGQAAASwBEwAMwAAARUiDgMVERQWHwEVITUyNjURIREUFjMVITUyPgM1ETQmLwE1IRUiBhURIRE0JiM1BLAEDiIaFjIZGf5wSxn%2BDBlL%2FnAEDiIaFjIZGQGQSxkB9BlLBEw4AQUKFA78iBYZAQI4OA0lAYr%2BdiUNODgBBQoUDgN4FhkBAjg4DSX%2BdgGKJQ04AAAABgAAAAAETARMAAwAHAAgACQAKAA0AAABITIWHQEjBTUnITchBSEyFhURFAYjISImNRE0NhcVITUBBTUlBRUhNQUVFAYjIQchJyE3MwKjAXcVHWn%2B2cj%2BcGQBd%2F4lASwpOzsp%2FtQpOzspASwCvP5wAZD8GAEsArwdFf6JZP6JZAGQyGkD6B0VlmJiyGTIOyn%2BDCk7OykB9Ck7ZMjI%2FveFo4XGyMhm%2BBUdZGTIAAEAEAAQBJ8EnwAmAAATNzYWHwEWBg8BHgEXNz4BHwEeAQ8BBiIuBicuBTcRohEuDosOBhF3ZvyNdxEzE8ATBxGjAw0uMUxPZWZ4O0p3RjITCwED76IRBhPCFDERdo78ZXYRBA6IDi8RogEECBUgNUNjO0qZfHNVQBAAAAACAAAAAASwBEwAIwBBAAAAMh4EHwEVFAYvAS4BPQEmIAcVFAYPAQYmPQE%2BBRIyHgIfARUBHgEdARQGIyEiJj0BNDY3ATU0PgIB%2FLimdWQ%2FLAkJHRTKFB2N%2FsKNHRTKFB0DDTE7ZnTKcFImFgEBAW0OFR0V%2B7QVHRUOAW0CFiYETBUhKCgiCgrIFRgDIgMiFZIYGJIVIgMiAxgVyAQNJyQrIP7kExwcCgoy%2FtEPMhTUFR0dFdQUMg8BLzIEDSEZAAADAAAAAASwBLAADQAdACcAAAEHIScRMxUzNTMVMzUzASEyFhQGKwEXITcjIiY0NgMhMhYdASE1NDYETMj9qMjIyMjIyPyuArwVHR0VDIn8SokMFR0dswRMFR37UB0CvMjIAfTIyMjI%2FOAdKh1kZB0qHf7UHRUyMhUdAAAAAwBkAAAEsARMAAkAEwAdAAABIyIGFREhETQmASMiBhURIRE0JgEhETQ2OwEyFhUCvGQpOwEsOwFnZCk7ASw7%2FRv%2B1DspZCk7BEw7KfwYA%2BgpO%2F7UOyn9RAK8KTv84AGQKTs7KQAAAAAF%2F5wAAASwBEwADwATAB8AJQApAAATITIWFREUBiMhIiY1ETQ2FxEhEQUjFTMRITUzNSMRIQURByMRMwcRMxHIArx8sLB8%2FUR8sLAYA4T%2BDMjI%2FtTIyAEsAZBkyMhkZARMsHz%2BDHywsHwB9HywyP1EArzIZP7UZGQBLGT%2B1GQB9GT%2B1AEsAAAABf%2BcAAAEsARMAA8AEwAfACUAKQAAEyEyFhURFAYjISImNRE0NhcRIREBIzUjFSMRMxUzNTMFEQcjETMHETMRyAK8fLCwfP1EfLCwGAOE%2FgxkZGRkZGQBkGTIyGRkBEywfP4MfLCwfAH0fLDI%2FUQCvP2oyMgB9MjIZP7UZAH0ZP7UASwABP%2BcAAAEsARMAA8AEwAbACMAABMhMhYVERQGIyEiJjURNDYXESERBSMRMxUhESEFIxEzFSERIcgCvHywsHz9RHywsBgDhP4MyMj%2B1AEsAZDIyP7UASwETLB8%2Fgx8sLB8AfR8sMj9RAK8yP7UZAH0ZP7UZAH0AAAABP%2BcAAAEsARMAA8AEwAWABkAABMhMhYVERQGIyEiJjURNDYXESERAS0BDQERyAK8fLCwfP1EfLCwGAOE%2Fgz%2B1AEsAZD%2B1ARMsHz%2BDHywsHwB9HywyP1EArz%2BDJaWlpYBLAAAAAX%2FnAAABLAETAAPABMAFwAgACkAABMhMhYVERQGIyEiJjURNDYXESERAyERIQcjIgYVFBY7AQERMzI2NTQmI8gCvHywsHz9RHywsBgDhGT9RAK8ZIImOTYpgv4Mgik2OSYETLB8%2Fgx8sLB8AfR8sMj9RAK8%2FagB9GRWQUFUASz%2B1FRBQVYAAAAF%2F5wAAASwBEwADwATAB8AJQApAAATITIWFREUBiMhIiY1ETQ2FxEhEQUjFTMRITUzNSMRIQEjESM1MwMjNTPIArx8sLB8%2FUR8sLAYA4T%2BDMjI%2FtTIyAEsAZBkZMjIZGQETLB8%2Fgx8sLB8AfR8sMj9RAK8yGT%2B1GRkASz%2BDAGQZP4MZAAG%2F5wAAASwBEwADwATABkAHwAjACcAABMhMhYVERQGIyEiJjURNDYXESERBTMRIREzASMRIzUzBRUzNQEjNTPIArx8sLB8%2FUR8sLAYA4T9RMj%2B1GQCWGRkyP2oZAEsZGQETLB8%2Fgx8sLB8AfR8sMj9RAK8yP5wAfT%2BDAGQZMjIyP7UZAAF%2F5wAAASwBEwADwATABwAIgAmAAATITIWFREUBiMhIiY1ETQ2FxEhEQEHIzU3NSM1IQEjESM1MwMjNTPIArx8sLB8%2FUR8sLAYA4T%2BDMdkx8gBLAGQZGTIx2RkBEywfP4MfLCwfAH0fLDI%2FUQCvP5wyDLIlmT%2BDAGQZP4MZAAAAAMACQAJBKcEpwAPABsAJQAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JgchFSEVISc1NyEB4PDbnl5entvw255eXp4BxeTCcXHC5MJxcWz%2B1AEs%2FtRkZAEsBKdentvw255eXp7b8NueTHHC5MJxccLkwtDIZGTIZAAAAAAEAAkACQSnBKcADwAbACcAKwAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JgcVBxcVIycjFSMRIQcVMzUB4PDbnl5entvw255eXp4BxeTCcXHC5MJxcWwyZGRklmQBLMjIBKdentvw255eXp7b8NueTHHC5MJxccLkwtBkMmQyZGQBkGRkZAAAAv%2Fy%2F50EwgRBACAANgAAATIWFzYzMhYUBisBNTQmIyEiBh0BIyImNTQ2NyY1ND4BEzMyFhURMzIWDwEGIi8BJjY7ARE0NgH3brUsLC54qqp4gB0V%2FtQVHd5QcFZBAmKqepYKD4kVCg3fDSYN3w0KFYkPBEF3YQ6t8a36FR0dFfpzT0VrDhMSZKpi%2FbMPCv7tFxD0EBD0EBcBEwoPAAAAAAL%2F8v%2BcBMMEQQAcADMAAAEyFhc2MzIWFxQGBwEmIgcBIyImNTQ2NyY1ND4BExcWBisBERQGKwEiJjURIyImNzY3NjIB9m62LCsueaoBeFr%2Bhg0lDf6DCU9xVkECYqnm3w0KFYkPCpYKD4kVCg3HGBMZBEF3YQ%2BteGOkHAFoEBD%2Bk3NPRWsOExNkqWP9kuQQF%2F7tCg8PCgETFxDMGBMAAAABAGQAAARMBG0AGAAAJTUhATMBMwkBMwEzASEVIyIGHQEhNTQmIwK8AZD%2B8qr%2B8qr%2B1P7Uqv7yqv7yAZAyFR0BkB0VZGQBLAEsAU3%2Bs%2F7U%2FtRkHRUyMhUdAAAAAAEAeQAABDcEmwAvAAABMhYXHgEVFAYHFhUUBiMiJxUyFh0BITU0NjM1BiMiJjU0Ny4BNTQ2MzIXNCY1NDYCWF6TGll7OzIJaUo3LRUd%2FtQdFS03SmkELzlpSgUSAqMEm3FZBoNaPWcfHRpKaR77HRUyMhUd%2Bx5pShIUFVg1SmkCAhAFdKMAAAAGACcAFASJBJwAEQAqAEIASgBiAHsAAAEWEgIHDgEiJicmAhI3PgEyFgUiBw4BBwYWHwEWMzI3Njc2Nz4BLwEmJyYXIgcOAQcGFh8BFjMyNz4BNz4BLwEmJyYWJiIGFBYyNjciBw4BBw4BHwEWFxYzMjc%2BATc2Ji8BJhciBwYHBgcOAR8BFhcWMzI3PgE3NiYvASYD8m9PT29T2dzZU29PT29T2dzZ%2Fj0EBHmxIgQNDCQDBBcGG0dGYAsNAwkDCwccBAVQdRgEDA0iBAQWBhJROQwMAwkDCwf5Y4xjY4xjVhYGElE6CwwDCQMLBwgEBVB1GAQNDCIEjRcGG0dGYAsNAwkDCwcIBAR5sSIEDQwkAwPyb%2F7V%2FtVvU1dXU28BKwErb1NXVxwBIrF5DBYDCQEWYEZHGwMVDCMNBgSRAhh1UA0WAwkBFTpREgMVCyMMBwT6Y2OMY2MVFTpREQQVCyMMBwQCGHVQDRYDCQEkFmBGRxsDFQwjDQYEASKxeQwWAwkBAAAABQBkAAAD6ASwAAwADwAWABwAIgAAASERIzUhFSERNDYzIQEjNQMzByczNTMDISImNREFFRQGKwECvAEstP6s%2FoQPCgI%2FASzIZKLU1KJktP51Cg8DhA8KwwMg%2FoTIyALzCg%2F%2B1Mj84NTUyP4MDwoBi8jDCg8AAAAABQBkAAAD6ASwAAkADAATABoAIQAAASERCQERNDYzIQEjNRMjFSM1IzcDISImPQEpARUUBisBNQK8ASz%2Bov3aDwoCPwEsyD6iZKLUqv6dCg8BfAIIDwqbAyD9%2BAFe%2FdoERwoP%2FtTI%2FHzIyNT%2BZA8KNzcKD1AAAAAAAwAAAAAEsAP0AAgAGQAfAAABIxUzFyERIzcFMzIeAhUhFSEDETM0PgIBMwMhASEEiqJkZP7UotT9EsgbGiEOASz9qMhkDiEaAnPw8PzgASwB9AMgyGQBLNTUBBErJGT%2BogHCJCsRBP5w%2FnAB9AAAAAMAAAAABEwETAAZADIAOQAAATMyFh0BMzIWHQEUBiMhIiY9ATQ2OwE1NDYFNTIWFREUBiMhIic3ARE0NjMVFBYzITI2AQc1IzUzNQKKZBUdMhUdHRX%2B1BUdHRUyHQFzKTs7Kf2oARP2%2Fro7KVg%2BASw%2BWP201MjIBEwdFTIdFWQVHR0VZBUdMhUd%2BpY7KfzgKTsE9gFGAUQpO5Y%2BWFj95tSiZKIAAwBkAAAEvARMABkANgA9AAABMzIWHQEzMhYdARQGIyEiJj0BNDY7ATU0NgU1MhYVESMRMxQOAiMhIiY1ETQ2MxUUFjMhMjYBBzUjNTM1AcJkFR0yFR0dFf7UFR0dFTIdAXMpO8jIDiEaG%2F2oKTs7KVg%2BASw%2BWAGc1MjIBEwdFTIdFWQVHR0VZBUdMhUd%2BpY7Kf4M%2FtQkKxEEOykDICk7lj5YWP3m1KJkogAAAAP%2FogAABRYE1AALABsAHwAACQEWBiMhIiY3ATYyEyMiBhcTHgE7ATI2NxM2JgMVMzUCkgJ9FyAs%2BwQsIBcCfRZARNAUGAQ6BCMUNhQjBDoEGODIBK37sCY3NyYEUCf%2BTB0U%2FtIUHR0UAS4UHf4MZGQAAAAACQAAAAAETARMAA8AHwAvAD8ATwBfAG8AfwCPAAABMzIWHQEUBisBIiY9ATQ2EzMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYBMzIWHQEUBisBIiY9ATQ2ITMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYBMzIWHQEUBisBIiY9ATQ2ITMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYBqfoKDw8K%2BgoPDwr6Cg8PCvoKDw8BmvoKDw8K%2BgoPD%2Fzq%2BgoPDwr6Cg8PAZr6Cg8PCvoKDw8BmvoKDw8K%2BgoPD%2Fzq%2BgoPDwr6Cg8PAZr6Cg8PCvoKDw8BmvoKDw8K%2BgoPDwRMDwqWCg8PCpYKD%2F7UDwqWCg8PCpYKDw8KlgoPDwqWCg%2F%2B1A8KlgoPDwqWCg8PCpYKDw8KlgoPDwqWCg8PCpYKD%2F7UDwqWCg8PCpYKDw8KlgoPDwqWCg8PCpYKDw8KlgoPAAAAAwAAAAAEsAUUABkAKQAzAAABMxUjFSEyFg8BBgchJi8BJjYzITUjNTM1MwEhMhYUBisBFyE3IyImNDYDITIWHQEhNTQ2ArxkZAFePjEcQiko%2FPwoKUIcMT4BXmRkyP4%2BArwVHR0VDIn8SooNFR0dswRMFR37UB0EsMhkTzeEUzMzU4Q3T2TIZPx8HSodZGQdKh3%2B1B0VMjIVHQAABAAAAAAEsAUUAAUAGQArADUAAAAyFhUjNAchFhUUByEyFg8BIScmNjMhJjU0AyEyFhQGKwEVBSElNSMiJjQ2AyEyFh0BITU0NgIwUDnCPAE6EgMBSCkHIq%2F9WrIiCikBSAOvArwVHR0VlgET%2FEoBE5YVHR2zBEwVHftQHQUUOykpjSUmCBEhFpGRFiERCCb%2BlR0qHcjIyMgdKh39qB0VMjIVHQAEAAAAAASwBJ0ABwAUACQALgAAADIWFAYiJjQTMzIWFRQXITY1NDYzASEyFhQGKwEXITcjIiY0NgMhMhYdASE1NDYCDZZqapZqty4iKyf%2BvCcrI%2F7NArwVHR0VDYr8SokMFR0dswRMFR37UB0EnWqWamqW%2Fus5Okxra0w6Of5yHSodZGQdKh3%2B1B0VMjIVHQAEAAAAAASwBRQADwAcACwANgAAATIeARUUBiImNTQ3FzcnNhMzMhYVFBchNjU0NjMBITIWFAYrARchNyMiJjQ2AyEyFh0BITU0NgJYL1szb5xvIpBvoyIfLiIrJ%2F68Jysj%2Fs0CvBUdHRUNivxKiQwVHR2zBEwVHftQHQUUa4s2Tm9vTj5Rj2%2BjGv4KOTpMa2tMOjn%2Bch0qHWRkHSod%2FtQdFTIyFR0AAAADAAAAAASwBRIAEgAiACwAAAEFFSEUHgMXIS4BNTQ%2BAjcBITIWFAYrARchNyMiJjQ2AyEyFh0BITU0NgJYASz%2B1CU%2FP00T%2Fe48PUJtj0r%2BogK8FR0dFQ2K%2FEqJDBUdHbMETBUd%2B1AdBLChizlmUT9IGVO9VFShdksE%2FH4dKh1kZB0qHf7UHRUyMhUdAAIAyAAAA%2BgFFAAPACkAAAAyFh0BHgEdASE1NDY3NTQDITIWFyMVMxUjFTMVIxUzFAYjISImNRE0NgIvUjsuNv5wNi5kAZA2XBqsyMjIyMh1U%2F5wU3V1BRQ7KU4aXDYyMjZcGk4p%2Fkc2LmRkZGRkU3V1UwGQU3UAAAMAZP%2F%2FBEwETAAPAC8AMwAAEyEyFhURFAYjISImNRE0NgMhMhYdARQGIyEXFhQGIi8BIQcGIiY0PwEhIiY9ATQ2BQchJ5YDhBUdHRX8fBUdHQQDtgoPDwr%2B5eANGiUNWP30Vw0mGg3g%2Ft8KDw8BqmQBRGQETB0V%2FgwVHR0VAfQVHf1EDwoyCg%2FgDSUbDVhYDRslDeAPCjIKD2RkZAAAAAAEAAAAAASwBEwAGQAjAC0ANwAAEyEyFh0BIzQmKwEiBhUjNCYrASIGFSM1NDYDITIWFREhETQ2ExUUBisBIiY9ASEVFAYrASImPQHIAyBTdWQ7KfopO2Q7KfopO2R1EQPoKTv7UDvxHRVkFR0D6B0VZBUdBEx1U8gpOzspKTs7KchTdf4MOyn%2B1AEsKTv%2BDDIVHR0VMjIVHR0VMgADAAEAAASpBKwADQARABsAAAkBFhQPASEBJjQ3ATYyCQMDITIWHQEhNTQ2AeACqh8fg%2F4f%2FfsgIAEnH1n%2BrAFWAS%2F%2Bq6IDIBUd%2FHwdBI39VR9ZH4MCBh9ZHwEoH%2F5u%2FqoBMAFV%2FBsdFTIyFR0AAAAAAgCPAAAEIQSwABcALwAAAQMuASMhIgYHAwYWMyEVFBYyNj0BMzI2AyE1NDY7ATU0NjsBETMRMzIWHQEzMhYVBCG9CCcV%2FnAVJwi9CBMVAnEdKh19FROo%2Fa0dFTIdFTDILxUdMhUdAocB%2BhMcHBP%2BBhMclhUdHRWWHP2MMhUdMhUdASz%2B1B0VMh0VAAAEAAAAAASwBLAADQAQAB8AIgAAASERFAYjIREBNTQ2MyEBIzUBIREUBiMhIiY1ETQ2MyEBIzUDhAEsDwr%2Bif7UDwoBdwEsyP2oASwPCv12Cg8PCgF3ASzIAyD9wQoPAk8BLFQKD%2F7UyP4M%2FcEKDw8KA7YKD%2F7UyAAC%2F5wAZAUUBEcARgBWAAABMzIeAhcWFxY2NzYnJjc%2BARYXFgcOASsBDgEPAQ4BKwEiJj8BBisBIicHDgErASImPwEmLwEuAT0BNDY7ATY3JyY2OwE2BSMiBh0BFBY7ATI2PQE0JgHkw0uOakkMEhEfQwoKGRMKBQ8XDCkCA1Y9Pgc4HCcDIhVkFRgDDDEqwxgpCwMiFWQVGAMaVCyfExwdFXwLLW8QBxXLdAFF%2BgoPDwr6Cg8PBEdBa4pJDgYKISAiJRsQCAYIDCw9P1c3fCbqFB0dFEYOCEAUHR0UnUplNQcmFTIVHVdPXw4TZV8PCjIKDw8KMgoPAAb%2FnP%2FmBRQEfgAJACQANAA8AFIAYgAAASU2Fh8BFgYPASUzMhYfASEyFh0BFAYHBQYmJyYjISImPQE0NhcjIgYdARQ7ATI2NTQmJyYEIgYUFjI2NAE3PgEeARceAT8BFxYGDwEGJi8BJjYlBwYfAR4BPwE2Jy4BJy4BAoEBpxMuDiAOAxCL%2FCtqQ0geZgM3FR0cE%2F0fFyIJKjr%2B1D5YWLlQExIqhhALIAsSAYBALS1ALf4PmBIgHhMQHC0aPzANITNQL3wpgigJASlmHyElDR0RPRMFAhQHCxADhPcICxAmDyoNeMgiNtQdFTIVJgeEBBQPQ1g%2ByD5YrBwVODMQEAtEERzJLUAtLUD%2B24ITChESEyMgAwWzPUkrRSgJL5cvfRxYGyYrDwkLNRAhFEgJDAQAAAAAAwBkAAAEOQSwAFEAYABvAAABMzIWHQEeARcWDgIPATIeBRUUDgUjFRQGKwEiJj0BIxUUBisBIiY9ASMiJj0BNDY7AREjIiY9ATQ2OwE1NDY7ATIWHQEzNTQ2AxUhMj4CNTc0LgMjARUhMj4CNTc0LgMjAnGWCg9PaAEBIC4uEBEGEjQwOiodFyI2LUAjGg8KlgoPZA8KlgoPrwoPDwpLSwoPDwqvDwqWCg9kD9cBBxwpEwsBAQsTKRz%2B%2BQFrHCkTCwEBCxMpHASwDwptIW1KLk0tHwYGAw8UKDJOLTtdPCoVCwJLCg8PCktLCg8PCksPCpYKDwJYDwqWCg9LCg8PCktLCg%2F%2B1MgVHR0LCgQOIhoW%2FnDIFR0dCwoEDiIaFgAAAwAEAAIEsASuABcAKQAsAAATITIWFREUBg8BDgEjISImJy4CNRE0NgQiDgQPARchNy4FAyMT1AMMVnokEhIdgVL9xFKCHAgYKHoCIIx9VkcrHQYGnAIwnAIIIClJVSGdwwSuelb%2BYDO3QkJXd3ZYHFrFMwGgVnqZFyYtLSUMDPPzBQ8sKDEj%2FsIBBQACAMgAAAOEBRQADwAZAAABMzIWFREUBiMhIiY1ETQ2ARUUBisBIiY9AQHblmesVCn%2BPilUrAFINhWWFTYFFKxn%2FgwpVFQpAfRnrPwY4RU2NhXhAAACAMgAAAOEBRQADwAZAAABMxQWMxEUBiMhIiY1ETQ2ARUUBisBIiY9AQHbYLOWVCn%2BPilUrAFINhWWFTYFFJaz%2FkIpVFQpAfRnrPwY4RU2NhXhAAACAAAAFAUOBBoAFAAaAAAJASUHFRcVJwc1NzU0Jj4CPwEnCQEFJTUFJQUO%2FYL%2Bhk5klpZkAQEBBQQvkwKCAVz%2Bov6iAV4BXgL%2F%2FuWqPOCWx5SVyJb6BA0GCgYDKEEBG%2F1ipqaTpaUAAAMAZAH0BLADIAAHAA8AFwAAEjIWFAYiJjQkMhYUBiImNCQyFhQGIiY0vHxYWHxYAeh8WFh8WAHofFhYfFgDIFh8WFh8WFh8WFh8WFh8WFh8AAAAAAMBkAAAArwETAAHAA8AFwAAADIWFAYiJjQSMhYUBiImNBIyFhQGIiY0Aeh8WFh8WFh8WFh8WFh8WFh8WARMWHxYWHz%2ByFh8WFh8%2FshYfFhYfAAAAAMAZABkBEwETAAPAB8ALwAAEyEyFh0BFAYjISImPQE0NhMhMhYdARQGIyEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2fQO2Cg8PCvxKCg8PCgO2Cg8PCvxKCg8PCgO2Cg8PCvxKCg8PBEwPCpYKDw8KlgoP%2FnAPCpYKDw8KlgoP%2FnAPCpYKDw8KlgoPAAAABAAAAAAEsASwAA8AHwAvADMAAAEhMhYVERQGIyEiJjURNDYFISIGFREUFjMhMjY1ETQmBSEyFhURFAYjISImNRE0NhcVITUBXgH0ory7o%2F4Mpbm5Asv9qCk7OykCWCk7O%2F2xAfQVHR0V%2FgwVHR1HAZAEsLuj%2FgylubmlAfSlucg7Kf2oKTs7KQJYKTtkHRX%2B1BUdHRUBLBUdZMjIAAAAAAEAZABkBLAETAA7AAATITIWFAYrARUzMhYUBisBFTMyFhQGKwEVMzIWFAYjISImNDY7ATUjIiY0NjsBNSMiJjQ2OwE1IyImNDaWA%2BgVHR0VMjIVHR0VMjIVHR0VMjIVHR0V%2FBgVHR0VMjIVHR0VMjIVHR0VMjIVHR0ETB0qHcgdKh3IHSodyB0qHR0qHcgdKh3IHSodyB0qHQAAAAYBLAAFA%2BgEowAHAA0AEwAZAB8AKgAAAR4BBgcuATYBMhYVIiYlFAYjNDYBMhYVIiYlFAYjNDYDFRQGIiY9ARYzMgKKVz8%2FV1c%2FP%2F75fLB8sAK8sHyw%2FcB8sHywArywfLCwHSodKAMRBKNDsrJCQrKy%2FsCwfLB8fLB8sP7UsHywfHywfLD%2B05AVHR0VjgQAAAH%2FtQDIBJQDgQBCAAABNzYXAR4BBw4BKwEyFRQOBCsBIhE0NyYiBxYVECsBIi4DNTQzIyImJyY2NwE2HwEeAQ4BLwEHIScHBi4BNgLpRRkUASoLCAYFGg8IAQQNGyc%2FKZK4ChRUFQu4jjBJJxkHAgcPGQYGCAsBKhQaTBQVCiMUM7YDe7YsFCMKFgNuEwYS%2FtkLHw8OEw0dNkY4MhwBIBgXBAQYF%2F7gKjxTQyMNEw4PHwoBKBIHEwUjKBYGDMHBDAUWKCMAAAAAAgAAAAAEsASwACUAQwAAASM0LgUrAREUFh8BFSE1Mj4DNREjIg4FFSMRIQEjNC4DKwERFBYXMxUjNTI1ESMiDgMVIzUhBLAyCAsZEyYYGcgyGRn%2BcAQOIhoWyBkYJhMZCwgyA%2Bj9RBkIChgQEWQZDQzIMmQREBgKCBkB9AOEFSAVDggDAfyuFhkBAmRkAQUJFQ4DUgEDCA4VIBUBLP0SDxMKBQH%2BVwsNATIyGQGpAQUKEw%2BWAAAAAAMAAAAABEwErgAdACAAMAAAATUiJy4BLwEBIwEGBw4BDwEVITUiJj8BIRcWBiMVARsBARUUBiMhIiY9ATQ2MyEyFgPoGR4OFgUE%2Ft9F%2FtQSFQkfCwsBETE7EkUBJT0NISf%2B7IZ5AbEdFfwYFR0dFQPoFR0BLDIgDiIKCwLr%2FQ4jFQkTBQUyMisusKYiQTIBhwFW%2Fqr942QVHR0VZBUdHQADAAAAAASwBLAADwBHAEoAABMhMhYVERQGIyEiJjURNDYFIyIHAQYHBgcGHQEUFjMhMjY9ATQmIyInJj8BIRcWBwYjIgYdARQWMyEyNj0BNCYnIicmJyMBJhMjEzIETBUdHRX7tBUdHQJGRg0F%2FtUREhImDAsJAREIDAwINxAKCj8BCjkLEQwYCAwMCAE5CAwLCBEZGQ8B%2FuAFDsVnBLAdFfu0FR0dFQRMFR1SDP0PIBMSEAUNMggMDAgyCAwXDhmjmR8YEQwIMggMDAgyBwwBGRskAuwM%2FgUBCAAABAAAAAAEsASwAAMAEwAjACcAAAEhNSEFITIWFREUBiMhIiY1ETQ2KQEyFhURFAYjISImNRE0NhcRIREEsPtQBLD7ggGQFR0dFf5wFR0dAm0BkBUdHRX%2BcBUdHUcBLARMZMgdFfx8FR0dFQOEFR0dFf5wFR0dFQGQFR1k%2FtQBLAAEAAAAAASwBLAADwAfACMAJwAAEyEyFhURFAYjISImNRE0NgEhMhYVERQGIyEiJjURNDYXESEREyE1ITIBkBUdHRX%2BcBUdHQJtAZAVHR0V%2FnAVHR1HASzI%2B1AEsASwHRX8fBUdHRUDhBUd%2FgwdFf5wFR0dFQGQFR1k%2FtQBLP2oZAAAAAACAAAAZASwA%2BgAJwArAAATITIWFREzNTQ2MyEyFh0BMxUjFRQGIyEiJj0BIxEUBiMhIiY1ETQ2AREhETIBkBUdZB0VAZAVHWRkHRX%2BcBUdZB0V%2FnAVHR0CnwEsA%2BgdFf6ilhUdHRWWZJYVHR0Vlv6iFR0dFQMgFR3%2B1P7UASwAAAQAAAAABLAEsAADABMAFwAnAAAzIxEzFyEyFhURFAYjISImNRE0NhcRIREBITIWFREUBiMhIiY1ETQ2ZGRklgGQFR0dFf5wFR0dRwEs%2FqIDhBUdHRX8fBUdHQSwZB0V%2FnAVHR0VAZAVHWT%2B1AEs%2FgwdFf5wFR0dFQGQFR0AAAAAAgBkAAAETASwACcAKwAAATMyFhURFAYrARUhMhYVERQGIyEiJjURNDYzITUjIiY1ETQ2OwE1MwcRIRECWJYVHR0VlgHCFR0dFfx8FR0dFQFelhUdHRWWZMgBLARMHRX%2BcBUdZB0V%2FnAVHR0VAZAVHWQdFQGQFR1kyP7UASwAAAAEAAAAAASwBLAAAwATABcAJwAAISMRMwUhMhYVERQGIyEiJjURNDYXESERASEyFhURFAYjISImNRE0NgSwZGT9dgGQFR0dFf5wFR0dRwEs%2FK4DhBUdHRX8fBUdHQSwZB0V%2FnAVHR0VAZAVHWT%2B1AEs%2FgwdFf5wFR0dFQGQFR0AAAEBLAAwA28EgAAPAAAJAQYjIiY1ETQ2MzIXARYUA2H%2BEhcSDhAQDhIXAe4OAjX%2BEhcbGQPoGRsX%2FhIOKgAAAAABAUEAMgOEBH4ACwAACQE2FhURFAYnASY0AU8B7h0qKh3%2BEg4CewHuHREp%2FBgpER0B7g4qAAAAAAEAMgFBBH4DhAALAAATITIWBwEGIicBJjZkA%2BgpER3%2BEg4qDv4SHREDhCod%2FhIODgHuHSoAAAAAAQAyASwEfgNvAAsAAAkBFgYjISImNwE2MgJ7Ae4dESn8GCkRHQHuDioDYf4SHSoqHQHuDgAAAAACAAgAAASwBCgABgAKAAABFQE1LQE1ASE1IQK8%2FUwBnf5jBKj84AMgAuW2%2Fr3dwcHd%2B9jIAAAAAAIAAABkBLAEsAALADEAAAEjFTMVIREzNSM1IQEzND4FOwERFAYPARUhNSIuAzURMzIeBRUzESEEsMjI%2FtTIyAEs%2B1AyCAsZEyYYGWQyGRkBkAQOIhoWZBkYJhMZCwgy%2FOADhGRkASxkZP4MFSAVDggDAf3aFhkBAmRkAQUJFQ4CJgEDCA4VIBUBLAAAAgAAAAAETAPoACUAMQAAASM0LgUrAREUFh8BFSE1Mj4DNREjIg4FFSMRIQEjFTMVIREzNSM1IQMgMggLGRMmGBlkMhkZ%2FnAEDiIaFmQZGCYTGQsIMgMgASzIyP7UyMgBLAK8FSAVDggDAf3aFhkCAWRkAQUJFQ4CJgEDCA4VIBUBLPzgZGQBLGRkAAABAMgAZgNyBEoAEgAAATMyFgcJARYGKwEiJwEmNDcBNgK9oBAKDP4wAdAMChCgDQr%2BKQcHAdcKBEoWDP4w%2FjAMFgkB1wgUCAHXCQAAAQE%2BAGYD6ARKABIAAAEzMhcBFhQHAQYrASImNwkBJjYBU6ANCgHXBwf%2BKQoNoBAKDAHQ%2FjAMCgRKCf4pCBQI%2FikJFgwB0AHQDBYAAAEAZgDIBEoDcgASAAAAFh0BFAcBBiInASY9ATQ2FwkBBDQWCf4pCBQI%2FikJFgwB0AHQA3cKEKANCv4pBwcB1woNoBAKDP4wAdAAAAABAGYBPgRKA%2BgAEgAACQEWHQEUBicJAQYmPQE0NwE2MgJqAdcJFgz%2BMP4wDBYJAdcIFAPh%2FikKDaAQCgwB0P4wDAoQoA0KAdcHAAAAAgDZ%2F%2FkEPQSwAAUAOgAAARQGIzQ2BTMyFh8BNjc%2BAh4EBgcOBgcGIiYjIgYiJy4DLwEuAT4EHgEXJyY2A%2BiwfLD%2BVmQVJgdPBQsiKFAzRyorDwURAQQSFyozTSwNOkkLDkc3EDlfNyYHBw8GDyUqPjdGMR%2BTDA0EsHywfLDIHBPCAQIGBwcFDx81S21DBxlLR1xKQhEFBQcHGWt0bCQjP2hJNyATBwMGBcASGAAAAAACAMgAFQOEBLAAFgAaAAATITIWFREUBisBEQcGJjURIyImNRE0NhcVITX6AlgVHR0Vlv8TGpYVHR2rASwEsB0V%2FnAVHf4MsgkQFQKKHRUBkBUdZGRkAAAAAgDIABkETASwAA4AEgAAEyEyFhURBRElIREjETQ2ARU3NfoC7ic9%2FUQCWP1EZB8BDWQEsFEs%2FFt1A7Z9%2FBgEARc0%2FV1kFGQAAQAAAAECTW%2FDBF9fDzz1AB8EsAAAAADQdnOXAAAAANB2c5f%2FUf%2BcBdwFFAAAAAgAAgAAAAAAAAABAAAFFP%2BFAAAFFP9R%2FtQF3AABAAAAAAAAAAAAAAAAAAAAowG4ACgAAAAAAZAAAASwAAAEsABkBLAAAASwAAAEsABwAooAAAUUAAACigAABRQAAAGxAAABRQAAANgAAADYAAAAogAAAQQAAABIAAABBAAAAUUAAASwAGQEsAB7BLAAyASwAMgB9AAABLD%2F8gSwAAAEsAAABLD%2F8ASwAAAEsAAOBLAACQSwAGQEsP%2FTBLD%2F0wSwAAAEsAAABLAAAASwAAAEsAAABLAAJgSwAG4EsAAXBLAAFwSwABcEsABkBLAAGgSwAGQEsAAMBLAAZASwABcEsP%2BcBLAAZASwABcEsAAXBLAAAASwABcEsAAXBLAAFwSwAGQEsAAABLAAZASwAAAEsAAABLAAAASwAAAEsAAABLAAAASwAAAEsAAABLAAZASwAMgEsAAABLAAAASwADUEsABkBLAAyASw%2F7UEsAAhBLAAAASwAAAEsAAABLAAAASwAAAEsP%2BcBLAAAASwAAAEsAAABLAA2wSwABcEsAB1BLAAAASwAAAEsAAABLAACgSwAMgEsAAABLAAnQSwAMgEsADIBLAAyASwAAAEsP%2F%2BBLABLASwAGQEsACIBLABOwSwABcEsAAXBLAAFwSwABcEsAAXBLAAFwSwAAAEsAAXBLAAFwSwABcEsAAXBLAAAASwALcEsAC3BLAAAASwAAAEsABJBLAAFwSwAAAEsAAABLAAXQSw%2F9wEsP%2FcBLD%2FnwSwAGQEsAAABLAAAASwAAAEsABkBLD%2F%2FwSwAAAEsP9RBLAABgSwAAAEsAAABLABRQSwAAEEsAAABLD%2FnASwAEoEsAAUBLAAAASwAAAEsAAABLD%2FnASwAGEEsP%2F9BLAAFgSwABYEsAAWBLAAFgSwABgEsAAABMQAAASwAGQAAAAAAAD%2F2ABkADkAyAAAAScAZAAZABkAGQAZABkAGQAZAAAAAAAAAAAAAADZAAAAAAAOAAAAAAAAAAAAAAAEAAAAAAAAAAAAAAAAAAMAZABkAAAAEAAAAAAAZP%2Bc%2F5z%2FnP%2Bc%2F5z%2FnP%2Bc%2F5wACQAJ%2F%2FL%2F8gBkAHkAJwBkAGQAAAAAAGT%2FogAAAAAAAAAAAAAAAADIAGQAAAABAI8AAP%2Bc%2F5wAZAAEAMgAyAAAAGQBkABkAAAAZAEs%2F7UAAAAAAAAAAAAAAAAAAABkAAABLAFBADIAMgAIAAAAAADIAT4AZgBmANkAyADIAAAAKgAqACoAKgCyAOgA6AFOAU4BTgFOAU4BTgFOAU4BTgFOAU4BTgFOAU4BpAIGAiICfgKGAqwC5ANGA24DjAPEBAgEMgRiBKIE3AVcBboGcgb0ByAHYgfKCB4IYgi%2BCTYJhAm2Cd4KKApMCpQK4gswC4oLygwIDFgNKg1eDbAODg5oDrQPKA%2BmD%2BYQEhBUEJAQqhEqEXYRthIKEjgSfBLAExoTdBPQFCoU1BU8FagVzBYEFjYWYBawFv4XUhemGAIYLhhqGJYYsBjgGP4ZKBloGZQZxBnaGe4aNhpoGrga9hteG7QcMhyUHOIdHB1EHWwdlB28HeYeLh52HsAfYh%2FSIEYgviEyIXYhuCJAIpYiuCMOIyIjOCN6I8Ij4CQCJDAkXiSWJOIlNCVgJbwmFCZ%2BJuYnUCe8J%2FgoNChwKKwpoCnMKiYqSiqEKworeiwILGgsuizsLRwtiC30LiguZi6iLtgvDi9GL34vsi%2F4MD4whDDSMRIxYDGuMegyJDJeMpoy3jMiMz4zaDO2NBg0YDSoNNI1LDWeNeg2PjZ8Ntw3GjdON5I31DgQOEI4hjjIOQo5SjmIOcw6HDpsOpo63jugO9w8GDxQPKI8%2BD0yPew%2BOj6MPtQ%2FKD9uP6o%2F%2BkBIQIBAxkECQX5CGEKoQu5DGENCQ3ZDoEPKRBBEYESuRPZFWkW2RgZGdEa0RvZHNkd2R7ZH9kgWSDJITkhqSIZIzEkSSThJXkmESapKAkouSlIAAQAAARcApwARAAAAAAACAAAAAQABAAAAQAAuAAAAAAAAABAAxgABAAAAAAATABIAAAADAAEECQAAAGoAEgADAAEECQABACgAfAADAAEECQACAA4ApAADAAEECQADAEwAsgADAAEECQAEADgA%2FgADAAEECQAFAHgBNgADAAEECQAGADYBrgADAAEECQAIABYB5AADAAEECQAJABYB%2BgADAAEECQALACQCEAADAAEECQAMACQCNAADAAEECQATACQCWAADAAEECQDIABYCfAADAAEECQDJADACkgADAAEECdkDABoCwnd3dy5nbHlwaGljb25zLmNvbQBDAG8AcAB5AHIAaQBnAGgAdAAgAKkAIAAyADAAMQA0ACAAYgB5ACAASgBhAG4AIABLAG8AdgBhAHIAaQBrAC4AIABBAGwAbAAgAHIAaQBnAGgAdABzACAAcgBlAHMAZQByAHYAZQBkAC4ARwBMAFkAUABIAEkAQwBPAE4AUwAgAEgAYQBsAGYAbABpAG4AZwBzAFIAZQBnAHUAbABhAHIAMQAuADAAMAA5ADsAVQBLAFcATgA7AEcATABZAFAASABJAEMATwBOAFMASABhAGwAZgBsAGkAbgBnAHMALQBSAGUAZwB1AGwAYQByAEcATABZAFAASABJAEMATwBOAFMAIABIAGEAbABmAGwAaQBuAGcAcwAgAFIAZQBnAHUAbABhAHIAVgBlAHIAcwBpAG8AbgAgADEALgAwADAAOQA7AFAAUwAgADAAMAAxAC4AMAAwADkAOwBoAG8AdABjAG8AbgB2ACAAMQAuADAALgA3ADAAOwBtAGEAawBlAG8AdABmAC4AbABpAGIAMgAuADUALgA1ADgAMwAyADkARwBMAFkAUABIAEkAQwBPAE4AUwBIAGEAbABmAGwAaQBuAGcAcwAtAFIAZQBnAHUAbABhAHIASgBhAG4AIABLAG8AdgBhAHIAaQBrAEoAYQBuACAASwBvAHYAYQByAGkAawB3AHcAdwAuAGcAbAB5AHAAaABpAGMAbwBuAHMALgBjAG8AbQB3AHcAdwAuAGcAbAB5AHAAaABpAGMAbwBuAHMALgBjAG8AbQB3AHcAdwAuAGcAbAB5AHAAaABpAGMAbwBuAHMALgBjAG8AbQBXAGUAYgBmAG8AbgB0ACAAMQAuADAAVwBlAGQAIABPAGMAdAAgADIAOQAgADAANgA6ADMANgA6ADAANwAgADIAMAAxADQARgBvAG4AdAAgAFMAcQB1AGkAcgByAGUAbAAAAAIAAAAAAAD%2FtQAyAAAAAAAAAAAAAAAAAAAAAAAAAAABFwAAAQIBAwADAA0ADgEEAJYBBQEGAQcBCAEJAQoBCwEMAQ0BDgEPARABEQESARMA7wEUARUBFgEXARgBGQEaARsBHAEdAR4BHwEgASEBIgEjASQBJQEmAScBKAEpASoBKwEsAS0BLgEvATABMQEyATMBNAE1ATYBNwE4ATkBOgE7ATwBPQE%2BAT8BQAFBAUIBQwFEAUUBRgFHAUgBSQFKAUsBTAFNAU4BTwFQAVEBUgFTAVQBVQFWAVcBWAFZAVoBWwFcAV0BXgFfAWABYQFiAWMBZAFlAWYBZwFoAWkBagFrAWwBbQFuAW8BcAFxAXIBcwF0AXUBdgF3AXgBeQF6AXsBfAF9AX4BfwGAAYEBggGDAYQBhQGGAYcBiAGJAYoBiwGMAY0BjgGPAZABkQGSAZMBlAGVAZYBlwGYAZkBmgGbAZwBnQGeAZ8BoAGhAaIBowGkAaUBpgGnAagBqQGqAasBrAGtAa4BrwGwAbEBsgGzAbQBtQG2AbcBuAG5AboBuwG8Ab0BvgG%2FAcABwQHCAcMBxAHFAcYBxwHIAckBygHLAcwBzQHOAc8B0AHRAdIB0wHUAdUB1gHXAdgB2QHaAdsB3AHdAd4B3wHgAeEB4gHjAeQB5QHmAecB6AHpAeoB6wHsAe0B7gHvAfAB8QHyAfMB9AH1AfYB9wH4AfkB%2BgH7AfwB%2FQH%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%3D%29%20format%28%27truetype%27%29%2Curl%28data%3Aimage%2Fsvg%2Bxml%3Bbase64%2CPD94bWwgdmVyc2lvbj0iMS4wIiBzdGFuZGFsb25lPSJubyI%2FPgo8IURPQ1RZUEUgc3ZnIFBVQkxJQyAiLS8vVzNDLy9EVEQgU1ZHIDEuMS8vRU4iICJodHRwOi8vd3d3LnczLm9yZy9HcmFwaGljcy9TVkcvMS4xL0RURC9zdmcxMS5kdGQiID4KPHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPgo8bWV0YWRhdGE%2BPC9tZXRhZGF0YT4KPGRlZnM%2BCjxmb250IGlkPSJnbHlwaGljb25zX2hhbGZsaW5nc3JlZ3VsYXIiIGhvcml6LWFkdi14PSIxMjAwIiA%2BCjxmb250LWZhY2UgdW5pdHMtcGVyLWVtPSIxMjAwIiBhc2NlbnQ9Ijk2MCIgZGVzY2VudD0iLTI0MCIgLz4KPG1pc3NpbmctZ2x5cGggaG9yaXotYWR2LXg9IjUwMCIgLz4KPGdseXBoIGhvcml6LWFkdi14PSIwIiAvPgo8Z2x5cGggaG9yaXotYWR2LXg9IjQwMCIgLz4KPGdseXBoIHVuaWNvZGU9IiAiIC8%2BCjxnbHlwaCB1bmljb2RlPSIqIiBkPSJNNjAwIDExMDBxMTUgMCAzNCAtMS41dDMwIC0zLjVsMTEgLTFxMTAgLTIgMTcuNSAtMTAuNXQ3LjUgLTE4LjV2LTIyNGwxNTggMTU4cTcgNyAxOCA4dDE5IC02bDEwNiAtMTA2cTcgLTggNiAtMTl0LTggLTE4bC0xNTggLTE1OGgyMjRxMTAgMCAxOC41IC03LjV0MTAuNSAtMTcuNXE2IC00MSA2IC03NXEwIC0xNSAtMS41IC0zNHQtMy41IC0zMGwtMSAtMTFxLTIgLTEwIC0xMC41IC0xNy41dC0xOC41IC03LjVoLTIyNGwxNTggLTE1OCBxNyAtNyA4IC0xOHQtNiAtMTlsLTEwNiAtMTA2cS04IC03IC0xOSAtNnQtMTggOGwtMTU4IDE1OHYtMjI0cTAgLTEwIC03LjUgLTE4LjV0LTE3LjUgLTEwLjVxLTQxIC02IC03NSAtNnEtMTUgMCAtMzQgMS41dC0zMCAzLjVsLTExIDFxLTEwIDIgLTE3LjUgMTAuNXQtNy41IDE4LjV2MjI0bC0xNTggLTE1OHEtNyAtNyAtMTggLTh0LTE5IDZsLTEwNiAxMDZxLTcgOCAtNiAxOXQ4IDE4bDE1OCAxNThoLTIyNHEtMTAgMCAtMTguNSA3LjUgdC0xMC41IDE3LjVxLTYgNDEgLTYgNzVxMCAxNSAxLjUgMzR0My41IDMwbDEgMTFxMiAxMCAxMC41IDE3LjV0MTguNSA3LjVoMjI0bC0xNTggMTU4cS03IDcgLTggMTh0NiAxOWwxMDYgMTA2cTggNyAxOSA2dDE4IC04bDE1OCAtMTU4djIyNHEwIDEwIDcuNSAxOC41dDE3LjUgMTAuNXE0MSA2IDc1IDZ6IiAvPgo8Z2x5cGggdW5pY29kZT0iKyIgZD0iTTQ1MCAxMTAwaDIwMHEyMSAwIDM1LjUgLTE0LjV0MTQuNSAtMzUuNXYtMzUwaDM1MHEyMSAwIDM1LjUgLTE0LjV0MTQuNSAtMzUuNXYtMjAwcTAgLTIxIC0xNC41IC0zNS41dC0zNS41IC0xNC41aC0zNTB2LTM1MHEwIC0yMSAtMTQuNSAtMzUuNXQtMzUuNSAtMTQuNWgtMjAwcS0yMSAwIC0zNS41IDE0LjV0LTE0LjUgMzUuNXYzNTBoLTM1MHEtMjEgMCAtMzUuNSAxNC41dC0xNC41IDM1LjV2MjAwcTAgMjEgMTQuNSAzNS41dDM1LjUgMTQuNSBoMzUwdjM1MHEwIDIxIDE0LjUgMzUuNXQzNS41IDE0LjV6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4YTA7IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4YTU7IiBkPSJNODI1IDExMDBoMjUwcTEwIDAgMTIuNSAtNXQtNS41IC0xM2wtMzY0IC0zNjRxLTYgLTYgLTExIC0xOGgyNjhxMTAgMCAxMyAtNnQtMyAtMTRsLTEyMCAtMTYwcS02IC04IC0xOCAtMTR0LTIyIC02aC0xMjV2LTEwMGgyNzVxMTAgMCAxMyAtNnQtMyAtMTRsLTEyMCAtMTYwcS02IC04IC0xOCAtMTR0LTIyIC02aC0xMjV2LTE3NHEwIC0xMSAtNy41IC0xOC41dC0xOC41IC03LjVoLTE0OHEtMTEgMCAtMTguNSA3LjV0LTcuNSAxOC41djE3NCBoLTI3NXEtMTAgMCAtMTMgNnQzIDE0bDEyMCAxNjBxNiA4IDE4IDE0dDIyIDZoMTI1djEwMGgtMjc1cS0xMCAwIC0xMyA2dDMgMTRsMTIwIDE2MHE2IDggMTggMTR0MjIgNmgxMThxLTUgMTIgLTExIDE4bC0zNjQgMzY0cS04IDggLTUuNSAxM3QxMi41IDVoMjUwcTI1IDAgNDMgLTE4bDE2NCAtMTY0cTggLTggMTggLTh0MTggOGwxNjQgMTY0cTE4IDE4IDQzIDE4eiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeDIwMDA7IiBob3Jpei1hZHYteD0iNjUwIiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4MjAwMTsiIGhvcml6LWFkdi14PSIxMzAwIiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4MjAwMjsiIGhvcml6LWFkdi14PSI2NTAiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3gyMDAzOyIgaG9yaXotYWR2LXg9IjEzMDAiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3gyMDA0OyIgaG9yaXotYWR2LXg9IjQzMyIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeDIwMDU7IiBob3Jpei1hZHYteD0iMzI1IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4MjAwNjsiIGhvcml6LWFkdi14PSIyMTYiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3gyMDA3OyIgaG9yaXotYWR2LXg9IjIxNiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeDIwMDg7IiBob3Jpei1hZHYteD0iMTYyIiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4MjAwOTsiIGhvcml6LWFkdi14PSIyNjAiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3gyMDBhOyIgaG9yaXotYWR2LXg9IjcyIiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4MjAyZjsiIGhvcml6LWFkdi14PSIyNjAiIC8%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3gyNmZhOyIgZD0iTTc3NCAxMTkzLjVxMTYgLTkuNSAyMC41IC0yN3QtNS41IC0zMy41bC0xMzYgLTE4N2w0NjcgLTc0NmgzMHEyMCAwIDM1IC0xOC41dDE1IC0zOS41di00MmgtMTIwMHY0MnEwIDIxIDE1IDM5LjV0MzUgMTguNWgzMGw0NjggNzQ2bC0xMzUgMTgzcS0xMCAxNiAtNS41IDM0dDIwLjUgMjh0MzQgNS41dDI4IC0yMC41bDExMSAtMTQ4bDExMiAxNTBxOSAxNiAyNyAyMC41dDM0IC01ek02MDAgMjAwaDM3N2wtMTgyIDExMmwtMTk1IDUzNHYtNjQ2eiAiIC8%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDI0OyIgZD0iTTEzMDAgMGgtNTM4bC00MSA0MDBoLTI0MmwtNDEgLTQwMGgtNTM4bDQzMSAxMjAwaDIwOWwtMjEgLTMwMGgxNjJsLTIwIDMwMGgyMDh6TTUxNSA4MDBsLTI3IC0zMDBoMjI0bC0yNyAzMDBoLTE3MHoiIC8%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%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%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%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%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%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%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDQyOyIgZD0iTTUwMCAxMjAwbDY4MiAtNjgycTggLTggOCAtMTh0LTggLTE4bC00NjQgLTQ2NHEtOCAtOCAtMTggLTh0LTE4IDhsLTY4MiA2ODJsMSA0NzVxMCAxMCA3LjUgMTcuNXQxNy41IDcuNWg0NzR6TTgwMCAxMjAwbDY4MiAtNjgycTggLTggOCAtMTh0LTggLTE4bC00NjQgLTQ2NHEtOCAtOCAtMTggLTh0LTE4IDhsLTU2IDU2bDQyNCA0MjZsLTcwMCA3MDBoMTUwek0zMTkuNSAxMDI0LjVxLTI5LjUgMjkuNSAtNzEgMjkuNXQtNzEgLTI5LjUgdC0yOS41IC03MS41dDI5LjUgLTcxLjV0NzEgLTI5LjV0NzEgMjkuNXQyOS41IDcxLjV0LTI5LjUgNzEuNXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDQzOyIgZD0iTTMwMCAxMjAwaDgyNXE3NSAwIDc1IC03NXYtOTAwcTAgLTI1IC0xOCAtNDNsLTY0IC02NHEtOCAtOCAtMTMgLTUuNXQtNSAxMi41djk1MHEwIDEwIC03LjUgMTcuNXQtMTcuNSA3LjVoLTcwMHEtMjUgMCAtNDMgLTE4bC02NCAtNjRxLTggLTggLTUuNSAtMTN0MTIuNSAtNWg3MDBxMTAgMCAxNy41IC03LjV0Ny41IC0xNy41di05NTBxMCAtMTAgLTcuNSAtMTcuNXQtMTcuNSAtNy41aC04NTBxLTEwIDAgLTE3LjUgNy41dC03LjUgMTcuNXY5NzUgcTAgMjUgMTggNDNsMTM5IDEzOXExOCAxOCA0MyAxOHoiIC8%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDQ4OyIgZD0iTTc1MyA2NDFxNSAtMSAxNC41IC00LjV0MzYgLTE1LjV0NTAuNSAtMjYuNXQ1My41IC00MHQ1MC41IC01NC41dDM1LjUgLTcwdDE0LjUgLTg3cTAgLTY3IC0yNy41IC0xMjUuNXQtNzEuNSAtOTcuNXQtOTguNSAtNjYuNXQtMTA4LjUgLTQwLjV0LTEwMiAtMTNoLTUwMHY4OXE0MSA3IDcwLjUgMzIuNXQyOS41IDY1LjV2ODI3cTAgMjQgLTAuNSAzNHQtMy41IDI0dC04LjUgMTkuNXQtMTcgMTMuNXQtMjggMTIuNXQtNDIuNSAxMS41djcxIGw0NzEgLTFxNTcgMCAxMTUuNSAtMjAuNXQxMDggLTU3dDgwLjUgLTk0dDMxIC0xMjQuNXEwIC01MSAtMTUuNSAtOTYuNXQtMzggLTc0LjV0LTQ1IC01MC41dC0zOC41IC0zMC41ek00MDAgNzAwaDEzOXE3OCAwIDEzMC41IDQ4LjV0NTIuNSAxMjIuNXEwIDQxIC04LjUgNzAuNXQtMjkuNSA1NS41dC02Mi41IDM5LjV0LTEwMy41IDEzLjVoLTExOHYtMzUwek00MDAgMjAwaDIxNnE4MCAwIDEyMSA1MC41dDQxIDEzMC41cTAgOTAgLTYyLjUgMTU0LjUgdC0xNTYuNSA2NC41aC0xNTl2LTQwMHoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDQ5OyIgZD0iTTg3NyAxMjAwbDIgLTU3cS04MyAtMTkgLTExNiAtNDUuNXQtNDAgLTY2LjVsLTEzMiAtODM5cS05IC00OSAxMyAtNjl0OTYgLTI2di05N2gtNTAwdjk3cTE4NiAxNiAyMDAgOThsMTczIDgzMnEzIDE3IDMgMzB0LTEuNSAyMi41dC05IDE3LjV0LTEzLjUgMTIuNXQtMjEuNSAxMHQtMjYgOC41dC0zMy41IDEwcS0xMyAzIC0xOSA1djU3aDQyNXoiIC8%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDU0OyIgZD0iTTUwMCA5NTB2MTAwcTAgMjEgMTQuNSAzNS41dDM1LjUgMTQuNWg2MDBxMjEgMCAzNS41IC0xNC41dDE0LjUgLTM1LjV2LTEwMHEwIC0yMSAtMTQuNSAtMzUuNXQtMzUuNSAtMTQuNWgtNjAwcS0yMSAwIC0zNS41IDE0LjV0LTE0LjUgMzUuNXpNMTAwIDY1MHYxMDBxMCAyMSAxNC41IDM1LjV0MzUuNSAxNC41aDEwMDBxMjEgMCAzNS41IC0xNC41dDE0LjUgLTM1LjV2LTEwMHEwIC0yMSAtMTQuNSAtMzUuNXQtMzUuNSAtMTQuNWgtMTAwMCBxLTIxIDAgLTM1LjUgMTQuNXQtMTQuNSAzNS41ek0zMDAgMzUwdjEwMHEwIDIxIDE0LjUgMzUuNXQzNS41IDE0LjVoODAwcTIxIDAgMzUuNSAtMTQuNXQxNC41IC0zNS41di0xMDBxMCAtMjEgLTE0LjUgLTM1LjV0LTM1LjUgLTE0LjVoLTgwMHEtMjEgMCAtMzUuNSAxNC41dC0xNC41IDM1LjV6TTAgNTB2MTAwcTAgMjEgMTQuNSAzNS41dDM1LjUgMTQuNWgxMTAwcTIxIDAgMzUuNSAtMTQuNXQxNC41IC0zNS41di0xMDAgcTAgLTIxIC0xNC41IC0zNS41dC0zNS41IC0xNC41aC0xMTAwcS0yMSAwIC0zNS41IDE0LjV0LTE0LjUgMzUuNXoiIC8%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDY5OyIgZD0iTTI1MCAxMTAwaDEwMHEyMSAwIDM1LjUgLTE0LjV0MTQuNSAtMzUuNXYtNDM4bDQ2NCA0NTNxMTUgMTQgMjUuNSAxMHQxMC41IC0yNXYtMTAwMHEwIC0yMSAtMTAuNSAtMjV0LTI1LjUgMTBsLTQ2NCA0NTN2LTQzOHEwIC0yMSAtMTQuNSAtMzUuNXQtMzUuNSAtMTQuNWgtMTAwcS0yMSAwIC0zNS41IDE0LjV0LTE0LjUgMzUuNXYxMDAwcTAgMjEgMTQuNSAzNS41dDM1LjUgMTQuNXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDcwOyIgZD0iTTUwIDExMDBoMTAwcTIxIDAgMzUuNSAtMTQuNXQxNC41IC0zNS41di00MzhsNDY0IDQ1M3ExNSAxNCAyNS41IDEwdDEwLjUgLTI1di00MzhsNDY0IDQ1M3ExNSAxNCAyNS41IDEwdDEwLjUgLTI1di0xMDAwcTAgLTIxIC0xMC41IC0yNXQtMjUuNSAxMGwtNDY0IDQ1M3YtNDM4cTAgLTIxIC0xMC41IC0yNXQtMjUuNSAxMGwtNDY0IDQ1M3YtNDM4cTAgLTIxIC0xNC41IC0zNS41dC0zNS41IC0xNC41aC0xMDBxLTIxIDAgLTM1LjUgMTQuNSB0LTE0LjUgMzUuNXYxMDAwcTAgMjEgMTQuNSAzNS41dDM1LjUgMTQuNXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDcxOyIgZD0iTTEyMDAgMTA1MHYtMTAwMHEwIC0yMSAtMTAuNSAtMjV0LTI1LjUgMTBsLTQ2NCA0NTN2LTQzOHEwIC0yMSAtMTAuNSAtMjV0LTI1LjUgMTBsLTQ5MiA0ODBxLTE1IDE0IC0xNSAzNXQxNSAzNWw0OTIgNDgwcTE1IDE0IDI1LjUgMTB0MTAuNSAtMjV2LTQzOGw0NjQgNDUzcTE1IDE0IDI1LjUgMTB0MTAuNSAtMjV6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTA3MjsiIGQ9Ik0yNDMgMTA3NGw4MTQgLTQ5OHExOCAtMTEgMTggLTI2dC0xOCAtMjZsLTgxNCAtNDk4cS0xOCAtMTEgLTMwLjUgLTR0LTEyLjUgMjh2MTAwMHEwIDIxIDEyLjUgMjh0MzAuNSAtNHoiIC8%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDc5OyIgZD0iTTg4NSA5MDBsLTM1MiAtMzUzbDM1MiAtMzUzbC0xOTcgLTE5OGwtNTUyIDU1Mmw1NTIgNTUweiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUwODA7IiBkPSJNMTA2NCA1NDdsLTU1MSAtNTUxbC0xOTggMTk4bDM1MyAzNTNsLTM1MyAzNTNsMTk4IDE5OHoiIC8%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDg2OyIgZD0iTTYwMCAxMTc3cTExNyAwIDIyNCAtNDUuNXQxODQuNSAtMTIzdDEyMyAtMTg0LjV0NDUuNSAtMjI0dC00NS41IC0yMjR0LTEyMyAtMTg0LjV0LTE4NC41IC0xMjN0LTIyNCAtNDUuNXQtMjI0IDQ1LjV0LTE4NC41IDEyM3QtMTIzIDE4NC41dC00NS41IDIyNHQ0NS41IDIyNHQxMjMgMTg0LjV0MTg0LjUgMTIzdDIyNCA0NS41ek02NzUgMTAwMGgtMTUwcS0xMCAwIC0xNy41IC03LjV0LTcuNSAtMTcuNXYtMTUwcTAgLTEwIDcuNSAtMTcuNSB0MTcuNSAtNy41aDE1MHExMCAwIDE3LjUgNy41dDcuNSAxNy41djE1MHEwIDEwIC03LjUgMTcuNXQtMTcuNSA3LjV6TTY3NSA3MDBoLTI1MHEtMTAgMCAtMTcuNSAtNy41dC03LjUgLTE3LjV2LTUwcTAgLTEwIDcuNSAtMTcuNXQxNy41IC03LjVoNzV2LTIwMGgtNzVxLTEwIDAgLTE3LjUgLTcuNXQtNy41IC0xNy41di01MHEwIC0xMCA3LjUgLTE3LjV0MTcuNSAtNy41aDM1MHExMCAwIDE3LjUgNy41dDcuNSAxNy41djUwcTAgMTAgLTcuNSAxNy41IHQtMTcuNSA3LjVoLTc1djI3NXEwIDEwIC03LjUgMTcuNXQtMTcuNSA3LjV6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTA4NzsiIGQ9Ik01MjUgMTIwMGgxNTBxMTAgMCAxNy41IC03LjV0Ny41IC0xNy41di0xOTRxMTAzIC0yNyAxNzguNSAtMTAyLjV0MTAyLjUgLTE3OC41aDE5NHExMCAwIDE3LjUgLTcuNXQ3LjUgLTE3LjV2LTE1MHEwIC0xMCAtNy41IC0xNy41dC0xNy41IC03LjVoLTE5NHEtMjcgLTEwMyAtMTAyLjUgLTE3OC41dC0xNzguNSAtMTAyLjV2LTE5NHEwIC0xMCAtNy41IC0xNy41dC0xNy41IC03LjVoLTE1MHEtMTAgMCAtMTcuNSA3LjV0LTcuNSAxNy41djE5NCBxLTEwMyAyNyAtMTc4LjUgMTAyLjV0LTEwMi41IDE3OC41aC0xOTRxLTEwIDAgLTE3LjUgNy41dC03LjUgMTcuNXYxNTBxMCAxMCA3LjUgMTcuNXQxNy41IDcuNWgxOTRxMjcgMTAzIDEwMi41IDE3OC41dDE3OC41IDEwMi41djE5NHEwIDEwIDcuNSAxNy41dDE3LjUgNy41ek03MDAgODkzdi0xNjhxMCAtMTAgLTcuNSAtMTcuNXQtMTcuNSAtNy41aC0xNTBxLTEwIDAgLTE3LjUgNy41dC03LjUgMTcuNXYxNjhxLTY4IC0yMyAtMTE5IC03NCB0LTc0IC0xMTloMTY4cTEwIDAgMTcuNSAtNy41dDcuNSAtMTcuNXYtMTUwcTAgLTEwIC03LjUgLTE3LjV0LTE3LjUgLTcuNWgtMTY4cTIzIC02OCA3NCAtMTE5dDExOSAtNzR2MTY4cTAgMTAgNy41IDE3LjV0MTcuNSA3LjVoMTUwcTEwIDAgMTcuNSAtNy41dDcuNSAtMTcuNXYtMTY4cTY4IDIzIDExOSA3NHQ3NCAxMTloLTE2OHEtMTAgMCAtMTcuNSA3LjV0LTcuNSAxNy41djE1MHEwIDEwIDcuNSAxNy41dDE3LjUgNy41aDE2OCBxLTIzIDY4IC03NCAxMTl0LTExOSA3NHoiIC8%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%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDk2OyIgZD0iTTg1MCAxMjAwaDMwMHEyMSAwIDM1LjUgLTE0LjV0MTQuNSAtMzUuNXYtMzAwcTAgLTIxIC0xMC41IC0yNXQtMjQuNSAxMGwtOTQgOTRsLTI0OSAtMjQ5cS04IC03IC0xOCAtN3QtMTggN2wtMTA2IDEwNnEtNyA4IC03IDE4dDcgMThsMjQ5IDI0OWwtOTQgOTRxLTE0IDE0IC0xMCAyNC41dDI1IDEwLjV6TTM1MCAwaC0zMDBxLTIxIDAgLTM1LjUgMTQuNXQtMTQuNSAzNS41djMwMHEwIDIxIDEwLjUgMjV0MjQuNSAtMTBsOTQgLTk0bDI0OSAyNDkgcTggNyAxOCA3dDE4IC03bDEwNiAtMTA2cTcgLTggNyAtMTh0LTcgLTE4bC0yNDkgLTI0OWw5NCAtOTRxMTQgLTE0IDEwIC0yNC41dC0yNSAtMTAuNXoiIC8%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%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%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMTE1OyIgZD0iTTQwNCAxMDAwaDc0NnEyMSAwIDM1LjUgLTE0LjV0MTQuNSAtMzUuNXYtNTUxaDE1MHEyMSAwIDI1IC0xMC41dC0xMCAtMjQuNWwtMjMwIC0yNDlxLTE0IC0xNSAtMzUgLTE1dC0zNSAxNWwtMjMwIDI0OXEtMTQgMTQgLTEwIDI0LjV0MjUgMTAuNWgxNTB2NDAxaC0zODF6TTEzNSA5ODRsMjMwIC0yNDlxMTQgLTE0IDEwIC0yNC41dC0yNSAtMTAuNWgtMTUwdi00MDBoMzg1bDIxNSAtMjAwaC03NTBxLTIxIDAgLTM1LjUgMTQuNSB0LTE0LjUgMzUuNXY1NTBoLTE1MHEtMjEgMCAtMjUgMTAuNXQxMCAyNC41bDIzMCAyNDlxMTQgMTUgMzUgMTV0MzUgLTE1eiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUxMTY7IiBkPSJNNTYgMTIwMGg5NHExNyAwIDMxIC0xMXQxOCAtMjdsMzggLTE2Mmg4OTZxMjQgMCAzOSAtMTguNXQxMCAtNDIuNWwtMTAwIC00NzVxLTUgLTIxIC0yNyAtNDIuNXQtNTUgLTIxLjVoLTYzM2w0OCAtMjAwaDUzNXEyMSAwIDM1LjUgLTE0LjV0MTQuNSAtMzUuNXQtMTQuNSAtMzUuNXQtMzUuNSAtMTQuNWgtNTB2LTUwcTAgLTIxIC0xNC41IC0zNS41dC0zNS41IC0xNC41dC0zNS41IDE0LjV0LTE0LjUgMzUuNXY1MGgtMzAwdi01MCBxMCAtMjEgLTE0LjUgLTM1LjV0LTM1LjUgLTE0LjV0LTM1LjUgMTQuNXQtMTQuNSAzNS41djUwaC0zMXEtMTggMCAtMzIuNSAxMHQtMjAuNSAxOWwtNSAxMGwtMjAxIDk2MWgtNTRxLTIwIDAgLTM1IDE0LjV0LTE1IDM1LjV0MTUgMzUuNXQzNSAxNC41eiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUxMTc7IiBkPSJNMTIwMCAxMDAwdi0xMDBoLTEyMDB2MTAwaDIwMHEwIDQxIDI5LjUgNzAuNXQ3MC41IDI5LjVoMzAwcTQxIDAgNzAuNSAtMjkuNXQyOS41IC03MC41aDUwMHpNMCA4MDBoMTIwMHYtODAwaC0xMjAwdjgwMHoiIC8%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%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%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%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%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%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%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%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%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%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%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMTYyOyIgZD0iTTc5MyAxMTgybDkgLTlxOCAtMTAgNSAtMjdxLTMgLTExIC03OSAtMjI1LjV0LTc4IC0yMjEuNWwzMDAgMXEyNCAwIDMyLjUgLTE3LjV0LTUuNSAtMzUuNXEtMSAwIC0xMzMuNSAtMTU1dC0yNjcgLTMxMi41dC0xMzguNSAtMTYyLjVxLTEyIC0xNSAtMjYgLTE1aC05bC05IDhxLTkgMTEgLTQgMzJxMiA5IDQyIDEyMy41dDc5IDIyNC41bDM5IDExMGgtMzAycS0yMyAwIC0zMSAxOXEtMTAgMjEgNiA0MXE3NSA4NiAyMDkuNSAyMzcuNSB0MjI4IDI1N3Q5OC41IDExMS41cTkgMTYgMjUgMTZoOXoiIC8%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMTc4OyIgZD0iTTkzNSAxMTY1bDI0OCAtMjMwcTE0IC0xNCAxNCAtMzV0LTE0IC0zNWwtMjQ4IC0yMzBxLTE0IC0xNCAtMjQuNSAtMTB0LTEwLjUgMjV2MTUwaC00MDB2MjAwaDQwMHYxNTBxMCAyMSAxMC41IDI1dDI0LjUgLTEwek0yMDAgODAwaC01MHEtMjEgMCAtMzUuNSAxNC41dC0xNC41IDM1LjV2MTAwcTAgMjEgMTQuNSAzNS41dDM1LjUgMTQuNWg1MHYtMjAwek00MDAgODAwaC0xMDB2MjAwaDEwMHYtMjAwek0xOCA0MzVsMjQ3IDIzMCBxMTQgMTQgMjQuNSAxMHQxMC41IC0yNXYtMTUwaDQwMHYtMjAwaC00MDB2LTE1MHEwIC0yMSAtMTAuNSAtMjV0LTI0LjUgMTBsLTI0NyAyMzBxLTE1IDE0IC0xNSAzNXQxNSAzNXpNOTAwIDMwMGgtMTAwdjIwMGgxMDB2LTIwMHpNMTAwMCA1MDBoNTFxMjAgMCAzNC41IC0xNC41dDE0LjUgLTM1LjV2LTEwMHEwIC0yMSAtMTQuNSAtMzUuNXQtMzQuNSAtMTQuNWgtNTF2MjAweiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUxNzk7IiBkPSJNODYyIDEwNzNsMjc2IDExNnEyNSAxOCA0My41IDh0MTguNSAtNDF2LTExMDZxMCAtMjEgLTE0LjUgLTM1LjV0LTM1LjUgLTE0LjVoLTIwMHEtMjEgMCAtMzUuNSAxNC41dC0xNC41IDM1LjV2Mzk3cS00IDEgLTExIDV0LTI0IDE3LjV0LTMwIDI5dC0yNCA0MnQtMTEgNTYuNXYzNTlxMCAzMSAxOC41IDY1dDQzLjUgNTJ6TTU1MCAxMjAwcTIyIDAgMzQuNSAtMTIuNXQxNC41IC0yNC41bDEgLTEzdi00NTBxMCAtMjggLTEwLjUgLTU5LjUgdC0yNSAtNTZ0LTI5IC00NXQtMjUuNSAtMzEuNWwtMTAgLTExdi00NDdxMCAtMjEgLTE0LjUgLTM1LjV0LTM1LjUgLTE0LjVoLTIwMHEtMjEgMCAtMzUuNSAxNC41dC0xNC41IDM1LjV2NDQ3cS00IDQgLTExIDExLjV0LTI0IDMwLjV0LTMwIDQ2dC0yNCA1NXQtMTEgNjB2NDUwcTAgMiAwLjUgNS41dDQgMTJ0OC41IDE1dDE0LjUgMTJ0MjIuNSA1LjVxMjAgMCAzMi41IC0xMi41dDE0LjUgLTI0LjVsMyAtMTN2LTM1MGgxMDB2MzUwdjUuNXQyLjUgMTIgdDcgMTV0MTUgMTJ0MjUuNSA1LjVxMjMgMCAzNS41IC0xMi41dDEzLjUgLTI0LjVsMSAtMTN2LTM1MGgxMDB2MzUwcTAgMiAwLjUgNS41dDMgMTJ0NyAxNXQxNSAxMnQyNC41IDUuNXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMTgwOyIgZD0iTTEyMDAgMTEwMHYtNTZxLTQgMCAtMTEgLTAuNXQtMjQgLTN0LTMwIC03LjV0LTI0IC0xNXQtMTEgLTI0di04ODhxMCAtMjIgMjUgLTM0LjV0NTAgLTEzLjVsMjUgLTJ2LTU2aC00MDB2NTZxNzUgMCA4Ny41IDYuNXQxMi41IDQzLjV2Mzk0aC01MDB2LTM5NHEwIC0zNyAxMi41IC00My41dDg3LjUgLTYuNXYtNTZoLTQwMHY1NnE0IDAgMTEgMC41dDI0IDN0MzAgNy41dDI0IDE1dDExIDI0djg4OHEwIDIyIC0yNSAzNC41dC01MCAxMy41IGwtMjUgMnY1Nmg0MDB2LTU2cS03NSAwIC04Ny41IC02LjV0LTEyLjUgLTQzLjV2LTM5NGg1MDB2Mzk0cTAgMzcgLTEyLjUgNDMuNXQtODcuNSA2LjV2NTZoNDAweiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUxODE7IiBkPSJNNjc1IDEwMDBoMzc1cTIxIDAgMzUuNSAtMTQuNXQxNC41IC0zNS41di0xNTBoLTEwNWwtMjk1IC05OHY5OGwtMjAwIDIwMGgtNDAwbDEwMCAxMDBoMzc1ek0xMDAgOTAwaDMwMHE0MSAwIDcwLjUgLTI5LjV0MjkuNSAtNzAuNXYtNTAwcTAgLTQxIC0yOS41IC03MC41dC03MC41IC0yOS41aC0zMDBxLTQxIDAgLTcwLjUgMjkuNXQtMjkuNSA3MC41djUwMHEwIDQxIDI5LjUgNzAuNXQ3MC41IDI5LjV6TTEwMCA4MDB2LTIwMGgzMDB2MjAwIGgtMzAwek0xMTAwIDUzNWwtNDAwIC0xMzN2MTYzbDQwMCAxMzN2LTE2M3pNMTAwIDUwMHYtMjAwaDMwMHYyMDBoLTMwMHpNMTEwMCAzOTh2LTI0OHEwIC0yMSAtMTQuNSAtMzUuNXQtMzUuNSAtMTQuNWgtMzc1bC0xMDAgLTEwMGgtMzc1bC0xMDAgMTAwaDQwMGwyMDAgMjAwaDEwNXoiIC8%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%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%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%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%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%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjIxOyIgZD0iTTQ4MCAxMTY1bDY4MiAtNjgzcTMxIC0zMSAzMSAtNzUuNXQtMzEgLTc1LjVsLTEzMSAtMTMxaC00ODFsLTUxNyA1MThxLTMyIDMxIC0zMiA3NS41dDMyIDc1LjVsMjk1IDI5NnEzMSAzMSA3NS41IDMxdDc2LjUgLTMxek0xMDggNzk0bDM0MiAtMzQybDMwMyAzMDRsLTM0MSAzNDF6TTI1MCAxMDBoODAwcTIxIDAgMzUuNSAtMTQuNXQxNC41IC0zNS41di01MGgtOTAwdjUwcTAgMjEgMTQuNSAzNS41dDM1LjUgMTQuNXoiIC8%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%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%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%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%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%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjUwOyIgZD0iTTg2NSA1NjVsLTQ5NCAtNDk0cS0yMyAtMjMgLTQxIC0yM3EtMTQgMCAtMjIgMTMuNXQtOCAzOC41djEwMDBxMCAyNSA4IDM4LjV0MjIgMTMuNXExOCAwIDQxIC0yM2w0OTQgLTQ5NHExNCAtMTQgMTQgLTM1dC0xNCAtMzV6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTI1MTsiIGQ9Ik0zMzUgNjM1bDQ5NCA0OTRxMjkgMjkgNTAgMjAuNXQyMSAtNDkuNXYtMTAwMHEwIC00MSAtMjEgLTQ5LjV0LTUwIDIwLjVsLTQ5NCA0OTRxLTE0IDE0IC0xNCAzNXQxNCAzNXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjUyOyIgZD0iTTEwMCA5MDBoMTAwMHE0MSAwIDQ5LjUgLTIxdC0yMC41IC01MGwtNDk0IC00OTRxLTE0IC0xNCAtMzUgLTE0dC0zNSAxNGwtNDk0IDQ5NHEtMjkgMjkgLTIwLjUgNTB0NDkuNSAyMXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjUzOyIgZD0iTTYzNSA4NjVsNDk0IC00OTRxMjkgLTI5IDIwLjUgLTUwdC00OS41IC0yMWgtMTAwMHEtNDEgMCAtNDkuNSAyMXQyMC41IDUwbDQ5NCA0OTRxMTQgMTQgMzUgMTR0MzUgLTE0eiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUyNTQ7IiBkPSJNNzAwIDc0MXYtMTgybC02OTIgLTMyM3YyMjFsNDEzIDE5M2wtNDEzIDE5M3YyMjF6TTEyMDAgMGgtODAwdjIwMGg4MDB2LTIwMHoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjU1OyIgZD0iTTEyMDAgOTAwaC0yMDB2LTEwMGgyMDB2LTEwMGgtMzAwdjMwMGgyMDB2MTAwaC0yMDB2MTAwaDMwMHYtMzAwek0wIDcwMGg1MHEwIDIxIDQgMzd0OS41IDI2LjV0MTggMTcuNXQyMiAxMXQyOC41IDUuNXQzMSAydDM3IDAuNWgxMDB2LTU1MHEwIC0yMiAtMjUgLTM0LjV0LTUwIC0xMy41bC0yNSAtMnYtMTAwaDQwMHYxMDBxLTQgMCAtMTEgMC41dC0yNCAzdC0zMCA3dC0yNCAxNXQtMTEgMjQuNXY1NTBoMTAwcTI1IDAgMzcgLTAuNXQzMSAtMiB0MjguNSAtNS41dDIyIC0xMXQxOCAtMTcuNXQ5LjUgLTI2LjV0NCAtMzdoNTB2MzAwaC04MDB2LTMwMHoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjU2OyIgZD0iTTgwMCA3MDBoLTUwcTAgMjEgLTQgMzd0LTkuNSAyNi41dC0xOCAxNy41dC0yMiAxMXQtMjguNSA1LjV0LTMxIDJ0LTM3IDAuNWgtMTAwdi01NTBxMCAtMjIgMjUgLTM0LjV0NTAgLTE0LjVsMjUgLTF2LTEwMGgtNDAwdjEwMHE0IDAgMTEgMC41dDI0IDN0MzAgN3QyNCAxNXQxMSAyNC41djU1MGgtMTAwcS0yNSAwIC0zNyAtMC41dC0zMSAtMnQtMjguNSAtNS41dC0yMiAtMTF0LTE4IC0xNy41dC05LjUgLTI2LjV0LTQgLTM3aC01MHYzMDAgaDgwMHYtMzAwek0xMTAwIDIwMGgtMjAwdi0xMDBoMjAwdi0xMDBoLTMwMHYzMDBoMjAwdjEwMGgtMjAwdjEwMGgzMDB2LTMwMHoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjU3OyIgZD0iTTcwMSAxMDk4aDE2MHExNiAwIDIxIC0xMXQtNyAtMjNsLTQ2NCAtNDY0bDQ2NCAtNDY0cTEyIC0xMiA3IC0yM3QtMjEgLTExaC0xNjBxLTEzIDAgLTIzIDlsLTQ3MSA0NzFxLTcgOCAtNyAxOHQ3IDE4bDQ3MSA0NzFxMTAgOSAyMyA5eiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUyNTg7IiBkPSJNMzM5IDEwOThoMTYwcTEzIDAgMjMgLTlsNDcxIC00NzFxNyAtOCA3IC0xOHQtNyAtMThsLTQ3MSAtNDcxcS0xMCAtOSAtMjMgLTloLTE2MHEtMTYgMCAtMjEgMTF0NyAyM2w0NjQgNDY0bC00NjQgNDY0cS0xMiAxMiAtNyAyM3QyMSAxMXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjU5OyIgZD0iTTEwODcgODgycTExIC01IDExIC0yMXYtMTYwcTAgLTEzIC05IC0yM2wtNDcxIC00NzFxLTggLTcgLTE4IC03dC0xOCA3bC00NzEgNDcxcS05IDEwIC05IDIzdjE2MHEwIDE2IDExIDIxdDIzIC03bDQ2NCAtNDY0bDQ2NCA0NjRxMTIgMTIgMjMgN3oiIC8%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%2BCjwvZGVmcz48L3N2Zz4g%29%20format%28%27svg%27%29%7D%2Eglyphicon%7Bposition%3Arelative%3Btop%3A1px%3Bdisplay%3Ainline%2Dblock%3Bfont%2Dfamily%3A%27Glyphicons%20Halflings%27%3Bfont%2Dstyle%3Anormal%3Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%3B%2Dwebkit%2Dfont%2Dsmoothing%3Aantialiased%3B%2Dmoz%2Dosx%2Dfont%2Dsmoothing%3Agrayscale%7D%2Eglyphicon%2Dasterisk%3Abefore%7Bcontent%3A%22%5C2a%22%7D%2Eglyphicon%2Dplus%3Abefore%7Bcontent%3A%22%5C2b%22%7D%2Eglyphicon%2Deur%3Abefore%2C%2Eglyphicon%2Deuro%3Abefore%7Bcontent%3A%22%5C20ac%22%7D%2Eglyphicon%2Dminus%3Abefore%7Bcontent%3A%22%5C2212%22%7D%2Eglyphicon%2Dcloud%3Abefore%7Bcontent%3A%22%5C2601%22%7D%2Eglyphicon%2Denvelope%3Abefore%7Bcontent%3A%22%5C2709%22%7D%2Eglyphicon%2Dpencil%3Abefore%7Bcontent%3A%22%5C270f%22%7D%2Eglyphicon%2Dglass%3Abefore%7Bcontent%3A%22%5Ce001%22%7D%2Eglyphicon%2Dmusic%3Abefore%7Bcontent%3A%22%5Ce002%22%7D%2Eglyphicon%2Dsearch%3Abefore%7Bcontent%3A%22%5Ce003%22%7D%2Eglyphicon%2Dheart%3Abefore%7Bcontent%3A%22%5Ce005%22%7D%2Eglyphicon%2Dstar%3Abefore%7Bcontent%3A%22%5Ce006%22%7D%2Eglyphicon%2Dstar%2Dempty%3Abefore%7Bcontent%3A%22%5Ce007%22%7D%2Eglyphicon%2Duser%3Abefore%7Bcontent%3A%22%5Ce008%22%7D%2Eglyphicon%2Dfilm%3Abefore%7Bcontent%3A%22%5Ce009%22%7D%2Eglyphicon%2Dth%2Dlarge%3Abefore%7Bcontent%3A%22%5Ce010%22%7D%2Eglyphicon%2Dth%3Abefore%7Bcontent%3A%22%5Ce011%22%7D%2Eglyphicon%2Dth%2Dlist%3Abefore%7Bcontent%3A%22%5Ce012%22%7D%2Eglyphicon%2Dok%3Abefore%7Bcontent%3A%22%5Ce013%22%7D%2Eglyphicon%2Dremove%3Abefore%7Bcontent%3A%22%5Ce014%22%7D%2Eglyphicon%2Dzoom%2Din%3Abefore%7Bcontent%3A%22%5Ce015%22%7D%2Eglyphicon%2Dzoom%2Dout%3Abefore%7Bcontent%3A%22%5Ce016%22%7D%2Eglyphicon%2Doff%3Abefore%7Bcontent%3A%22%5Ce017%22%7D%2Eglyphicon%2Dsignal%3Abefore%7Bcontent%3A%22%5Ce018%22%7D%2Eglyphicon%2Dcog%3Abefore%7Bcontent%3A%22%5Ce019%22%7D%2Eglyphicon%2Dtrash%3Abefore%7Bcontent%3A%22%5Ce020%22%7D%2Eglyphicon%2Dhome%3Abefore%7Bcontent%3A%22%5Ce021%22%7D%2Eglyphicon%2Dfile%3Abefore%7Bcontent%3A%22%5Ce022%22%7D%2Eglyphicon%2Dtime%3Abefore%7Bcontent%3A%22%5Ce023%22%7D%2Eglyphicon%2Droad%3Abefore%7Bcontent%3A%22%5Ce024%22%7D%2Eglyphicon%2Ddownload%2Dalt%3Abefore%7Bcontent%3A%22%5Ce025%22%7D%2Eglyphicon%2Ddownload%3Abefore%7Bcontent%3A%22%5Ce026%22%7D%2Eglyphicon%2Dupload%3Abefore%7Bcontent%3A%22%5Ce027%22%7D%2Eglyphicon%2Dinbox%3Abefore%7Bcontent%3A%22%5Ce028%22%7D%2Eglyphicon%2Dplay%2Dcircle%3Abefore%7Bcontent%3A%22%5Ce029%22%7D%2Eglyphicon%2Drepeat%3Abefore%7Bcontent%3A%22%5Ce030%22%7D%2Eglyphicon%2Drefresh%3Abefore%7Bcontent%3A%22%5Ce031%22%7D%2Eglyphicon%2Dlist%2Dalt%3Abefore%7Bcontent%3A%22%5Ce032%22%7D%2Eglyphicon%2Dlock%3Abefore%7Bcontent%3A%22%5Ce033%22%7D%2Eglyphicon%2Dflag%3Abefore%7Bcontent%3A%22%5Ce034%22%7D%2Eglyphicon%2Dheadphones%3Abefore%7Bcontent%3A%22%5Ce035%22%7D%2Eglyphicon%2Dvolume%2Doff%3Abefore%7Bcontent%3A%22%5Ce036%22%7D%2Eglyphicon%2Dvolume%2Ddown%3Abefore%7Bcontent%3A%22%5Ce037%22%7D%2Eglyphicon%2Dvolume%2Dup%3Abefore%7Bcontent%3A%22%5Ce038%22%7D%2Eglyphicon%2Dqrcode%3Abefore%7Bcontent%3A%22%5Ce039%22%7D%2Eglyphicon%2Dbarcode%3Abefore%7Bcontent%3A%22%5Ce040%22%7D%2Eglyphicon%2Dtag%3Abefore%7Bcontent%3A%22%5Ce041%22%7D%2Eglyphicon%2Dtags%3Abefore%7Bcontent%3A%22%5Ce042%22%7D%2Eglyphicon%2Dbook%3Abefore%7Bcontent%3A%22%5Ce043%22%7D%2Eglyphicon%2Dbookmark%3Abefore%7Bcontent%3A%22%5Ce044%22%7D%2Eglyphicon%2Dprint%3Abefore%7Bcontent%3A%22%5Ce045%22%7D%2Eglyphicon%2Dcamera%3Abefore%7Bcontent%3A%22%5Ce046%22%7D%2Eglyphicon%2Dfont%3Abefore%7Bcontent%3A%22%5Ce047%22%7D%2Eglyphicon%2Dbold%3Abefore%7Bcontent%3A%22%5Ce048%22%7D%2Eglyphicon%2Ditalic%3Abefore%7Bcontent%3A%22%5Ce049%22%7D%2Eglyphicon%2Dtext%2Dheight%3Abefore%7Bcontent%3A%22%5Ce050%22%7D%2Eglyphicon%2Dtext%2Dwidth%3Abefore%7Bcontent%3A%22%5Ce051%22%7D%2Eglyphicon%2Dalign%2Dleft%3Abefore%7Bcontent%3A%22%5Ce052%22%7D%2Eglyphicon%2Dalign%2Dcenter%3Abefore%7Bcontent%3A%22%5Ce053%22%7D%2Eglyphicon%2Dalign%2Dright%3Abefore%7Bcontent%3A%22%5Ce054%22%7D%2Eglyphicon%2Dalign%2Djustify%3Abefore%7Bcontent%3A%22%5Ce055%22%7D%2Eglyphicon%2Dlist%3Abefore%7Bcontent%3A%22%5Ce056%22%7D%2Eglyphicon%2Dindent%2Dleft%3Abefore%7Bcontent%3A%22%5Ce057%22%7D%2Eglyphicon%2Dindent%2Dright%3Abefore%7Bcontent%3A%22%5Ce058%22%7D%2Eglyphicon%2Dfacetime%2Dvideo%3Abefore%7Bcontent%3A%22%5Ce059%22%7D%2Eglyphicon%2Dpicture%3Abefore%7Bcontent%3A%22%5Ce060%22%7D%2Eglyphicon%2Dmap%2Dmarker%3Abefore%7Bcontent%3A%22%5Ce062%22%7D%2Eglyphicon%2Dadjust%3Abefore%7Bcontent%3A%22%5Ce063%22%7D%2Eglyphicon%2Dtint%3Abefore%7Bcontent%3A%22%5Ce064%22%7D%2Eglyphicon%2Dedit%3Abefore%7Bcontent%3A%22%5Ce065%22%7D%2Eglyphicon%2Dshare%3Abefore%7Bcontent%3A%22%5Ce066%22%7D%2Eglyphicon%2Dcheck%3Abefore%7Bcontent%3A%22%5Ce067%22%7D%2Eglyphicon%2Dmove%3Abefore%7Bcontent%3A%22%5Ce068%22%7D%2Eglyphicon%2Dstep%2Dbackward%3Abefore%7Bcontent%3A%22%5Ce069%22%7D%2Eglyphicon%2Dfast%2Dbackward%3Abefore%7Bcontent%3A%22%5Ce070%22%7D%2Eglyphicon%2Dbackward%3Abefore%7Bcontent%3A%22%5Ce071%22%7D%2Eglyphicon%2Dplay%3Abefore%7Bcontent%3A%22%5Ce072%22%7D%2Eglyphicon%2Dpause%3Abefore%7Bcontent%3A%22%5Ce073%22%7D%2Eglyphicon%2Dstop%3Abefore%7Bcontent%3A%22%5Ce074%22%7D%2Eglyphicon%2Dforward%3Abefore%7Bcontent%3A%22%5Ce075%22%7D%2Eglyphicon%2Dfast%2Dforward%3Abefore%7Bcontent%3A%22%5Ce076%22%7D%2Eglyphicon%2Dstep%2Dforward%3Abefore%7Bcontent%3A%22%5Ce077%22%7D%2Eglyphicon%2Deject%3Abefore%7Bcontent%3A%22%5Ce078%22%7D%2Eglyphicon%2Dchevron%2Dleft%3Abefore%7Bcontent%3A%22%5Ce079%22%7D%2Eglyphicon%2Dchevron%2Dright%3Abefore%7Bcontent%3A%22%5Ce080%22%7D%2Eglyphicon%2Dplus%2Dsign%3Abefore%7Bcontent%3A%22%5Ce081%22%7D%2Eglyphicon%2Dminus%2Dsign%3Abefore%7Bcontent%3A%22%5Ce082%22%7D%2Eglyphicon%2Dremove%2Dsign%3Abefore%7Bcontent%3A%22%5Ce083%22%7D%2Eglyphicon%2Dok%2Dsign%3Abefore%7Bcontent%3A%22%5Ce084%22%7D%2Eglyphicon%2Dquestion%2Dsign%3Abefore%7Bcontent%3A%22%5Ce085%22%7D%2Eglyphicon%2Dinfo%2Dsign%3Abefore%7Bcontent%3A%22%5Ce086%22%7D%2Eglyphicon%2Dscreenshot%3Abefore%7Bcontent%3A%22%5Ce087%22%7D%2Eglyphicon%2Dremove%2Dcircle%3Abefore%7Bcontent%3A%22%5Ce088%22%7D%2Eglyphicon%2Dok%2Dcircle%3Abefore%7Bcontent%3A%22%5Ce089%22%7D%2Eglyphicon%2Dban%2Dcircle%3Abefore%7Bcontent%3A%22%5Ce090%22%7D%2Eglyphicon%2Darrow%2Dleft%3Abefore%7Bcontent%3A%22%5Ce091%22%7D%2Eglyphicon%2Darrow%2Dright%3Abefore%7Bcontent%3A%22%5Ce092%22%7D%2Eglyphicon%2Darrow%2Dup%3Abefore%7Bcontent%3A%22%5Ce093%22%7D%2Eglyphicon%2Darrow%2Ddown%3Abefore%7Bcontent%3A%22%5Ce094%22%7D%2Eglyphicon%2Dshare%2Dalt%3Abefore%7Bcontent%3A%22%5Ce095%22%7D%2Eglyphicon%2Dresize%2Dfull%3Abefore%7Bcontent%3A%22%5Ce096%22%7D%2Eglyphicon%2Dresize%2Dsmall%3Abefore%7Bcontent%3A%22%5Ce097%22%7D%2Eglyphicon%2Dexclamation%2Dsign%3Abefore%7Bcontent%3A%22%5Ce101%22%7D%2Eglyphicon%2Dgift%3Abefore%7Bcontent%3A%22%5Ce102%22%7D%2Eglyphicon%2Dleaf%3Abefore%7Bcontent%3A%22%5Ce103%22%7D%2Eglyphicon%2Dfire%3Abefore%7Bcontent%3A%22%5Ce104%22%7D%2Eglyphicon%2Deye%2Dopen%3Abefore%7Bcontent%3A%22%5Ce105%22%7D%2Eglyphicon%2Deye%2Dclose%3Abefore%7Bcontent%3A%22%5Ce106%22%7D%2Eglyphicon%2Dwarning%2Dsign%3Abefore%7Bcontent%3A%22%5Ce107%22%7D%2Eglyphicon%2Dplane%3Abefore%7Bcontent%3A%22%5Ce108%22%7D%2Eglyphicon%2Dcalendar%3Abefore%7Bcontent%3A%22%5Ce109%22%7D%2Eglyphicon%2Drandom%3Abefore%7Bcontent%3A%22%5Ce110%22%7D%2Eglyphicon%2Dcomment%3Abefore%7Bcontent%3A%22%5Ce111%22%7D%2Eglyphicon%2Dmagnet%3Abefore%7Bcontent%3A%22%5Ce112%22%7D%2Eglyphicon%2Dchevron%2Dup%3Abefore%7Bcontent%3A%22%5Ce113%22%7D%2Eglyphicon%2Dchevron%2Ddown%3Abefore%7Bcontent%3A%22%5Ce114%22%7D%2Eglyphicon%2Dretweet%3Abefore%7Bcontent%3A%22%5Ce115%22%7D%2Eglyphicon%2Dshopping%2Dcart%3Abefore%7Bcontent%3A%22%5Ce116%22%7D%2Eglyphicon%2Dfolder%2Dclose%3Abefore%7Bcontent%3A%22%5Ce117%22%7D%2Eglyphicon%2Dfolder%2Dopen%3Abefore%7Bcontent%3A%22%5Ce118%22%7D%2Eglyphicon%2Dresize%2Dvertical%3Abefore%7Bcontent%3A%22%5Ce119%22%7D%2Eglyphicon%2Dresize%2Dhorizontal%3Abefore%7Bcontent%3A%22%5Ce120%22%7D%2Eglyphicon%2Dhdd%3Abefore%7Bcontent%3A%22%5Ce121%22%7D%2Eglyphicon%2Dbullhorn%3Abefore%7Bcontent%3A%22%5Ce122%22%7D%2Eglyphicon%2Dbell%3Abefore%7Bcontent%3A%22%5Ce123%22%7D%2Eglyphicon%2Dcertificate%3Abefore%7Bcontent%3A%22%5Ce124%22%7D%2Eglyphicon%2Dthumbs%2Dup%3Abefore%7Bcontent%3A%22%5Ce125%22%7D%2Eglyphicon%2Dthumbs%2Ddown%3Abefore%7Bcontent%3A%22%5Ce126%22%7D%2Eglyphicon%2Dhand%2Dright%3Abefore%7Bcontent%3A%22%5Ce127%22%7D%2Eglyphicon%2Dhand%2Dleft%3Abefore%7Bcontent%3A%22%5Ce128%22%7D%2Eglyphicon%2Dhand%2Dup%3Abefore%7Bcontent%3A%22%5Ce129%22%7D%2Eglyphicon%2Dhand%2Ddown%3Abefore%7Bcontent%3A%22%5Ce130%22%7D%2Eglyphicon%2Dcircle%2Darrow%2Dright%3Abefore%7Bcontent%3A%22%5Ce131%22%7D%2Eglyphicon%2Dcircle%2Darrow%2Dleft%3Abefore%7Bcontent%3A%22%5Ce132%22%7D%2Eglyphicon%2Dcircle%2Darrow%2Dup%3Abefore%7Bcontent%3A%22%5Ce133%22%7D%2Eglyphicon%2Dcircle%2Darrow%2Ddown%3Abefore%7Bcontent%3A%22%5Ce134%22%7D%2Eglyphicon%2Dglobe%3Abefore%7Bcontent%3A%22%5Ce135%22%7D%2Eglyphicon%2Dwrench%3Abefore%7Bcontent%3A%22%5Ce136%22%7D%2Eglyphicon%2Dtasks%3Abefore%7Bcontent%3A%22%5Ce137%22%7D%2Eglyphicon%2Dfilter%3Abefore%7Bcontent%3A%22%5Ce138%22%7D%2Eglyphicon%2Dbriefcase%3Abefore%7Bcontent%3A%22%5Ce139%22%7D%2Eglyphicon%2Dfullscreen%3Abefore%7Bcontent%3A%22%5Ce140%22%7D%2Eglyphicon%2Ddashboard%3Abefore%7Bcontent%3A%22%5Ce141%22%7D%2Eglyphicon%2Dpaperclip%3Abefore%7Bcontent%3A%22%5Ce142%22%7D%2Eglyphicon%2Dheart%2Dempty%3Abefore%7Bcontent%3A%22%5Ce143%22%7D%2Eglyphicon%2Dlink%3Abefore%7Bcontent%3A%22%5Ce144%22%7D%2Eglyphicon%2Dphone%3Abefore%7Bcontent%3A%22%5Ce145%22%7D%2Eglyphicon%2Dpushpin%3Abefore%7Bcontent%3A%22%5Ce146%22%7D%2Eglyphicon%2Dusd%3Abefore%7Bcontent%3A%22%5Ce148%22%7D%2Eglyphicon%2Dgbp%3Abefore%7Bcontent%3A%22%5Ce149%22%7D%2Eglyphicon%2Dsort%3Abefore%7Bcontent%3A%22%5Ce150%22%7D%2Eglyphicon%2Dsort%2Dby%2Dalphabet%3Abefore%7Bcontent%3A%22%5Ce151%22%7D%2Eglyphicon%2Dsort%2Dby%2Dalphabet%2Dalt%3Abefore%7Bcontent%3A%22%5Ce152%22%7D%2Eglyphicon%2Dsort%2Dby%2Dorder%3Abefore%7Bcontent%3A%22%5Ce153%22%7D%2Eglyphicon%2Dsort%2Dby%2Dorder%2Dalt%3Abefore%7Bcontent%3A%22%5Ce154%22%7D%2Eglyphicon%2Dsort%2Dby%2Dattributes%3Abefore%7Bcontent%3A%22%5Ce155%22%7D%2Eglyphicon%2Dsort%2Dby%2Dattributes%2Dalt%3Abefore%7Bcontent%3A%22%5Ce156%22%7D%2Eglyphicon%2Dunchecked%3Abefore%7Bcontent%3A%22%5Ce157%22%7D%2Eglyphicon%2Dexpand%3Abefore%7Bcontent%3A%22%5Ce158%22%7D%2Eglyphicon%2Dcollapse%2Ddown%3Abefore%7Bcontent%3A%22%5Ce159%22%7D%2Eglyphicon%2Dcollapse%2Dup%3Abefore%7Bcontent%3A%22%5Ce160%22%7D%2Eglyphicon%2Dlog%2Din%3Abefore%7Bcontent%3A%22%5Ce161%22%7D%2Eglyphicon%2Dflash%3Abefore%7Bcontent%3A%22%5Ce162%22%7D%2Eglyphicon%2Dlog%2Dout%3Abefore%7Bcontent%3A%22%5Ce163%22%7D%2Eglyphicon%2Dnew%2Dwindow%3Abefore%7Bcontent%3A%22%5Ce164%22%7D%2Eglyphicon%2Drecord%3Abefore%7Bcontent%3A%22%5Ce165%22%7D%2Eglyphicon%2Dsave%3Abefore%7Bcontent%3A%22%5Ce166%22%7D%2Eglyphicon%2Dopen%3Abefore%7Bcontent%3A%22%5Ce167%22%7D%2Eglyphicon%2Dsaved%3Abefore%7Bcontent%3A%22%5Ce168%22%7D%2Eglyphicon%2Dimport%3Abefore%7Bcontent%3A%22%5Ce169%22%7D%2Eglyphicon%2Dexport%3Abefore%7Bcontent%3A%22%5Ce170%22%7D%2Eglyphicon%2Dsend%3Abefore%7Bcontent%3A%22%5Ce171%22%7D%2Eglyphicon%2Dfloppy%2Ddisk%3Abefore%7Bcontent%3A%22%5Ce172%22%7D%2Eglyphicon%2Dfloppy%2Dsaved%3Abefore%7Bcontent%3A%22%5Ce173%22%7D%2Eglyphicon%2Dfloppy%2Dremove%3Abefore%7Bcontent%3A%22%5Ce174%22%7D%2Eglyphicon%2Dfloppy%2Dsave%3Abefore%7Bcontent%3A%22%5Ce175%22%7D%2Eglyphicon%2Dfloppy%2Dopen%3Abefore%7Bcontent%3A%22%5Ce176%22%7D%2Eglyphicon%2Dcredit%2Dcard%3Abefore%7Bcontent%3A%22%5Ce177%22%7D%2Eglyphicon%2Dtransfer%3Abefore%7Bcontent%3A%22%5Ce178%22%7D%2Eglyphicon%2Dcutlery%3Abefore%7Bcontent%3A%22%5Ce179%22%7D%2Eglyphicon%2Dheader%3Abefore%7Bcontent%3A%22%5Ce180%22%7D%2Eglyphicon%2Dcompressed%3Abefore%7Bcontent%3A%22%5Ce181%22%7D%2Eglyphicon%2Dearphone%3Abefore%7Bcontent%3A%22%5Ce182%22%7D%2Eglyphicon%2Dphone%2Dalt%3Abefore%7Bcontent%3A%22%5Ce183%22%7D%2Eglyphicon%2Dtower%3Abefore%7Bcontent%3A%22%5Ce184%22%7D%2Eglyphicon%2Dstats%3Abefore%7Bcontent%3A%22%5Ce185%22%7D%2Eglyphicon%2Dsd%2Dvideo%3Abefore%7Bcontent%3A%22%5Ce186%22%7D%2Eglyphicon%2Dhd%2Dvideo%3Abefore%7Bcontent%3A%22%5Ce187%22%7D%2Eglyphicon%2Dsubtitles%3Abefore%7Bcontent%3A%22%5Ce188%22%7D%2Eglyphicon%2Dsound%2Dstereo%3Abefore%7Bcontent%3A%22%5Ce189%22%7D%2Eglyphicon%2Dsound%2Ddolby%3Abefore%7Bcontent%3A%22%5Ce190%22%7D%2Eglyphicon%2Dsound%2D5%2D1%3Abefore%7Bcontent%3A%22%5Ce191%22%7D%2Eglyphicon%2Dsound%2D6%2D1%3Abefore%7Bcontent%3A%22%5Ce192%22%7D%2Eglyphicon%2Dsound%2D7%2D1%3Abefore%7Bcontent%3A%22%5Ce193%22%7D%2Eglyphicon%2Dcopyright%2Dmark%3Abefore%7Bcontent%3A%22%5Ce194%22%7D%2Eglyphicon%2Dregistration%2Dmark%3Abefore%7Bcontent%3A%22%5Ce195%22%7D%2Eglyphicon%2Dcloud%2Ddownload%3Abefore%7Bcontent%3A%22%5Ce197%22%7D%2Eglyphicon%2Dcloud%2Dupload%3Abefore%7Bcontent%3A%22%5Ce198%22%7D%2Eglyphicon%2Dtree%2Dconifer%3Abefore%7Bcontent%3A%22%5Ce199%22%7D%2Eglyphicon%2Dtree%2Ddeciduous%3Abefore%7Bcontent%3A%22%5Ce200%22%7D%2Eglyphicon%2Dcd%3Abefore%7Bcontent%3A%22%5Ce201%22%7D%2Eglyphicon%2Dsave%2Dfile%3Abefore%7Bcontent%3A%22%5Ce202%22%7D%2Eglyphicon%2Dopen%2Dfile%3Abefore%7Bcontent%3A%22%5Ce203%22%7D%2Eglyphicon%2Dlevel%2Dup%3Abefore%7Bcontent%3A%22%5Ce204%22%7D%2Eglyphicon%2Dcopy%3Abefore%7Bcontent%3A%22%5Ce205%22%7D%2Eglyphicon%2Dpaste%3Abefore%7Bcontent%3A%22%5Ce206%22%7D%2Eglyphicon%2Dalert%3Abefore%7Bcontent%3A%22%5Ce209%22%7D%2Eglyphicon%2Dequalizer%3Abefore%7Bcontent%3A%22%5Ce210%22%7D%2Eglyphicon%2Dking%3Abefore%7Bcontent%3A%22%5Ce211%22%7D%2Eglyphicon%2Dqueen%3Abefore%7Bcontent%3A%22%5Ce212%22%7D%2Eglyphicon%2Dpawn%3Abefore%7Bcontent%3A%22%5Ce213%22%7D%2Eglyphicon%2Dbishop%3Abefore%7Bcontent%3A%22%5Ce214%22%7D%2Eglyphicon%2Dknight%3Abefore%7Bcontent%3A%22%5Ce215%22%7D%2Eglyphicon%2Dbaby%2Dformula%3Abefore%7Bcontent%3A%22%5Ce216%22%7D%2Eglyphicon%2Dtent%3Abefore%7Bcontent%3A%22%5C26fa%22%7D%2Eglyphicon%2Dblackboard%3Abefore%7Bcontent%3A%22%5Ce218%22%7D%2Eglyphicon%2Dbed%3Abefore%7Bcontent%3A%22%5Ce219%22%7D%2Eglyphicon%2Dapple%3Abefore%7Bcontent%3A%22%5Cf8ff%22%7D%2Eglyphicon%2Derase%3Abefore%7Bcontent%3A%22%5Ce221%22%7D%2Eglyphicon%2Dhourglass%3Abefore%7Bcontent%3A%22%5C231b%22%7D%2Eglyphicon%2Dlamp%3Abefore%7Bcontent%3A%22%5Ce223%22%7D%2Eglyphicon%2Dduplicate%3Abefore%7Bcontent%3A%22%5Ce224%22%7D%2Eglyphicon%2Dpiggy%2Dbank%3Abefore%7Bcontent%3A%22%5Ce225%22%7D%2Eglyphicon%2Dscissors%3Abefore%7Bcontent%3A%22%5Ce226%22%7D%2Eglyphicon%2Dbitcoin%3Abefore%7Bcontent%3A%22%5Ce227%22%7D%2Eglyphicon%2Dbtc%3Abefore%7Bcontent%3A%22%5Ce227%22%7D%2Eglyphicon%2Dxbt%3Abefore%7Bcontent%3A%22%5Ce227%22%7D%2Eglyphicon%2Dyen%3Abefore%7Bcontent%3A%22%5C00a5%22%7D%2Eglyphicon%2Djpy%3Abefore%7Bcontent%3A%22%5C00a5%22%7D%2Eglyphicon%2Druble%3Abefore%7Bcontent%3A%22%5C20bd%22%7D%2Eglyphicon%2Drub%3Abefore%7Bcontent%3A%22%5C20bd%22%7D%2Eglyphicon%2Dscale%3Abefore%7Bcontent%3A%22%5Ce230%22%7D%2Eglyphicon%2Dice%2Dlolly%3Abefore%7Bcontent%3A%22%5Ce231%22%7D%2Eglyphicon%2Dice%2Dlolly%2Dtasted%3Abefore%7Bcontent%3A%22%5Ce232%22%7D%2Eglyphicon%2Deducation%3Abefore%7Bcontent%3A%22%5Ce233%22%7D%2Eglyphicon%2Doption%2Dhorizontal%3Abefore%7Bcontent%3A%22%5Ce234%22%7D%2Eglyphicon%2Doption%2Dvertical%3Abefore%7Bcontent%3A%22%5Ce235%22%7D%2Eglyphicon%2Dmenu%2Dhamburger%3Abefore%7Bcontent%3A%22%5Ce236%22%7D%2Eglyphicon%2Dmodal%2Dwindow%3Abefore%7Bcontent%3A%22%5Ce237%22%7D%2Eglyphicon%2Doil%3Abefore%7Bcontent%3A%22%5Ce238%22%7D%2Eglyphicon%2Dgrain%3Abefore%7Bcontent%3A%22%5Ce239%22%7D%2Eglyphicon%2Dsunglasses%3Abefore%7Bcontent%3A%22%5Ce240%22%7D%2Eglyphicon%2Dtext%2Dsize%3Abefore%7Bcontent%3A%22%5Ce241%22%7D%2Eglyphicon%2Dtext%2Dcolor%3Abefore%7Bcontent%3A%22%5Ce242%22%7D%2Eglyphicon%2Dtext%2Dbackground%3Abefore%7Bcontent%3A%22%5Ce243%22%7D%2Eglyphicon%2Dobject%2Dalign%2Dtop%3Abefore%7Bcontent%3A%22%5Ce244%22%7D%2Eglyphicon%2Dobject%2Dalign%2Dbottom%3Abefore%7Bcontent%3A%22%5Ce245%22%7D%2Eglyphicon%2Dobject%2Dalign%2Dhorizontal%3Abefore%7Bcontent%3A%22%5Ce246%22%7D%2Eglyphicon%2Dobject%2Dalign%2Dleft%3Abefore%7Bcontent%3A%22%5Ce247%22%7D%2Eglyphicon%2Dobject%2Dalign%2Dvertical%3Abefore%7Bcontent%3A%22%5Ce248%22%7D%2Eglyphicon%2Dobject%2Dalign%2Dright%3Abefore%7Bcontent%3A%22%5Ce249%22%7D%2Eglyphicon%2Dtriangle%2Dright%3Abefore%7Bcontent%3A%22%5Ce250%22%7D%2Eglyphicon%2Dtriangle%2Dleft%3Abefore%7Bcontent%3A%22%5Ce251%22%7D%2Eglyphicon%2Dtriangle%2Dbottom%3Abefore%7Bcontent%3A%22%5Ce252%22%7D%2Eglyphicon%2Dtriangle%2Dtop%3Abefore%7Bcontent%3A%22%5Ce253%22%7D%2Eglyphicon%2Dconsole%3Abefore%7Bcontent%3A%22%5Ce254%22%7D%2Eglyphicon%2Dsuperscript%3Abefore%7Bcontent%3A%22%5Ce255%22%7D%2Eglyphicon%2Dsubscript%3Abefore%7Bcontent%3A%22%5Ce256%22%7D%2Eglyphicon%2Dmenu%2Dleft%3Abefore%7Bcontent%3A%22%5Ce257%22%7D%2Eglyphicon%2Dmenu%2Dright%3Abefore%7Bcontent%3A%22%5Ce258%22%7D%2Eglyphicon%2Dmenu%2Ddown%3Abefore%7Bcontent%3A%22%5Ce259%22%7D%2Eglyphicon%2Dmenu%2Dup%3Abefore%7Bcontent%3A%22%5Ce260%22%7D%2A%7B%2Dwebkit%2Dbox%2Dsizing%3Aborder%2Dbox%3B%2Dmoz%2Dbox%2Dsizing%3Aborder%2Dbox%3Bbox%2Dsizing%3Aborder%2Dbox%7D%3Aafter%2C%3Abefore%7B%2Dwebkit%2Dbox%2Dsizing%3Aborder%2Dbox%3B%2Dmoz%2Dbox%2Dsizing%3Aborder%2Dbox%3Bbox%2Dsizing%3Aborder%2Dbox%7Dhtml%7Bfont%2Dsize%3A10px%3B%2Dwebkit%2Dtap%2Dhighlight%2Dcolor%3Argba%280%2C0%2C0%2C0%29%7Dbody%7Bfont%2Dfamily%3A%22Helvetica%20Neue%22%2CHelvetica%2CArial%2Csans%2Dserif%3Bfont%2Dsize%3A14px%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23fff%7Dbutton%2Cinput%2Cselect%2Ctextarea%7Bfont%2Dfamily%3Ainherit%3Bfont%2Dsize%3Ainherit%3Bline%2Dheight%3Ainherit%7Da%7Bcolor%3A%23337ab7%3Btext%2Ddecoration%3Anone%7Da%3Afocus%2Ca%3Ahover%7Bcolor%3A%2323527c%3Btext%2Ddecoration%3Aunderline%7Da%3Afocus%7Boutline%3Athin%20dotted%3Boutline%3A5px%20auto%20%2Dwebkit%2Dfocus%2Dring%2Dcolor%3Boutline%2Doffset%3A%2D2px%7Dfigure%7Bmargin%3A0%7Dimg%7Bvertical%2Dalign%3Amiddle%7D%2Ecarousel%2Dinner%3E%2Eitem%3Ea%3Eimg%2C%2Ecarousel%2Dinner%3E%2Eitem%3Eimg%2C%2Eimg%2Dresponsive%2C%2Ethumbnail%20a%3Eimg%2C%2Ethumbnail%3Eimg%7Bdisplay%3Ablock%3Bmax%2Dwidth%3A100%25%3Bheight%3Aauto%7D%2Eimg%2Drounded%7Bborder%2Dradius%3A6px%7D%2Eimg%2Dthumbnail%7Bdisplay%3Ainline%2Dblock%3Bmax%2Dwidth%3A100%25%3Bheight%3Aauto%3Bpadding%3A4px%3Bline%2Dheight%3A1%2E42857143%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20%23ddd%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dtransition%3Aall%20%2E2s%20ease%2Din%2Dout%3B%2Do%2Dtransition%3Aall%20%2E2s%20ease%2Din%2Dout%3Btransition%3Aall%20%2E2s%20ease%2Din%2Dout%7D%2Eimg%2Dcircle%7Bborder%2Dradius%3A50%25%7Dhr%7Bmargin%2Dtop%3A20px%3Bmargin%2Dbottom%3A20px%3Bborder%3A0%3Bborder%2Dtop%3A1px%20solid%20%23eee%7D%2Esr%2Donly%7Bposition%3Aabsolute%3Bwidth%3A1px%3Bheight%3A1px%3Bpadding%3A0%3Bmargin%3A%2D1px%3Boverflow%3Ahidden%3Bclip%3Arect%280%2C0%2C0%2C0%29%3Bborder%3A0%7D%2Esr%2Donly%2Dfocusable%3Aactive%2C%2Esr%2Donly%2Dfocusable%3Afocus%7Bposition%3Astatic%3Bwidth%3Aauto%3Bheight%3Aauto%3Bmargin%3A0%3Boverflow%3Avisible%3Bclip%3Aauto%7D%5Brole%3Dbutton%5D%7Bcursor%3Apointer%7D%2Eh1%2C%2Eh2%2C%2Eh3%2C%2Eh4%2C%2Eh5%2C%2Eh6%2Ch1%2Ch2%2Ch3%2Ch4%2Ch5%2Ch6%7Bfont%2Dfamily%3Ainherit%3Bfont%2Dweight%3A500%3Bline%2Dheight%3A1%2E1%3Bcolor%3Ainherit%7D%2Eh1%20%2Esmall%2C%2Eh1%20small%2C%2Eh2%20%2Esmall%2C%2Eh2%20small%2C%2Eh3%20%2Esmall%2C%2Eh3%20small%2C%2Eh4%20%2Esmall%2C%2Eh4%20small%2C%2Eh5%20%2Esmall%2C%2Eh5%20small%2C%2Eh6%20%2Esmall%2C%2Eh6%20small%2Ch1%20%2Esmall%2Ch1%20small%2Ch2%20%2Esmall%2Ch2%20small%2Ch3%20%2Esmall%2Ch3%20small%2Ch4%20%2Esmall%2Ch4%20small%2Ch5%20%2Esmall%2Ch5%20small%2Ch6%20%2Esmall%2Ch6%20small%7Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%3Bcolor%3A%23777%7D%2Eh1%2C%2Eh2%2C%2Eh3%2Ch1%2Ch2%2Ch3%7Bmargin%2Dtop%3A20px%3Bmargin%2Dbottom%3A10px%7D%2Eh1%20%2Esmall%2C%2Eh1%20small%2C%2Eh2%20%2Esmall%2C%2Eh2%20small%2C%2Eh3%20%2Esmall%2C%2Eh3%20small%2Ch1%20%2Esmall%2Ch1%20small%2Ch2%20%2Esmall%2Ch2%20small%2Ch3%20%2Esmall%2Ch3%20small%7Bfont%2Dsize%3A65%25%7D%2Eh4%2C%2Eh5%2C%2Eh6%2Ch4%2Ch5%2Ch6%7Bmargin%2Dtop%3A10px%3Bmargin%2Dbottom%3A10px%7D%2Eh4%20%2Esmall%2C%2Eh4%20small%2C%2Eh5%20%2Esmall%2C%2Eh5%20small%2C%2Eh6%20%2Esmall%2C%2Eh6%20small%2Ch4%20%2Esmall%2Ch4%20small%2Ch5%20%2Esmall%2Ch5%20small%2Ch6%20%2Esmall%2Ch6%20small%7Bfont%2Dsize%3A75%25%7D%2Eh1%2Ch1%7Bfont%2Dsize%3A36px%7D%2Eh2%2Ch2%7Bfont%2Dsize%3A30px%7D%2Eh3%2Ch3%7Bfont%2Dsize%3A24px%7D%2Eh4%2Ch4%7Bfont%2Dsize%3A18px%7D%2Eh5%2Ch5%7Bfont%2Dsize%3A14px%7D%2Eh6%2Ch6%7Bfont%2Dsize%3A12px%7Dp%7Bmargin%3A0%200%2010px%7D%2Elead%7Bmargin%2Dbottom%3A20px%3Bfont%2Dsize%3A16px%3Bfont%2Dweight%3A300%3Bline%2Dheight%3A1%2E4%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Elead%7Bfont%2Dsize%3A21px%7D%7D%2Esmall%2Csmall%7Bfont%2Dsize%3A85%25%7D%2Emark%2Cmark%7Bpadding%3A%2E2em%3Bbackground%2Dcolor%3A%23fcf8e3%7D%2Etext%2Dleft%7Btext%2Dalign%3Aleft%7D%2Etext%2Dright%7Btext%2Dalign%3Aright%7D%2Etext%2Dcenter%7Btext%2Dalign%3Acenter%7D%2Etext%2Djustify%7Btext%2Dalign%3Ajustify%7D%2Etext%2Dnowrap%7Bwhite%2Dspace%3Anowrap%7D%2Etext%2Dlowercase%7Btext%2Dtransform%3Alowercase%7D%2Etext%2Duppercase%7Btext%2Dtransform%3Auppercase%7D%2Etext%2Dcapitalize%7Btext%2Dtransform%3Acapitalize%7D%2Etext%2Dmuted%7Bcolor%3A%23777%7D%2Etext%2Dprimary%7Bcolor%3A%23337ab7%7Da%2Etext%2Dprimary%3Afocus%2Ca%2Etext%2Dprimary%3Ahover%7Bcolor%3A%23286090%7D%2Etext%2Dsuccess%7Bcolor%3A%233c763d%7Da%2Etext%2Dsuccess%3Afocus%2Ca%2Etext%2Dsuccess%3Ahover%7Bcolor%3A%232b542c%7D%2Etext%2Dinfo%7Bcolor%3A%2331708f%7Da%2Etext%2Dinfo%3Afocus%2Ca%2Etext%2Dinfo%3Ahover%7Bcolor%3A%23245269%7D%2Etext%2Dwarning%7Bcolor%3A%238a6d3b%7Da%2Etext%2Dwarning%3Afocus%2Ca%2Etext%2Dwarning%3Ahover%7Bcolor%3A%2366512c%7D%2Etext%2Ddanger%7Bcolor%3A%23a94442%7Da%2Etext%2Ddanger%3Afocus%2Ca%2Etext%2Ddanger%3Ahover%7Bcolor%3A%23843534%7D%2Ebg%2Dprimary%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23337ab7%7Da%2Ebg%2Dprimary%3Afocus%2Ca%2Ebg%2Dprimary%3Ahover%7Bbackground%2Dcolor%3A%23286090%7D%2Ebg%2Dsuccess%7Bbackground%2Dcolor%3A%23dff0d8%7Da%2Ebg%2Dsuccess%3Afocus%2Ca%2Ebg%2Dsuccess%3Ahover%7Bbackground%2Dcolor%3A%23c1e2b3%7D%2Ebg%2Dinfo%7Bbackground%2Dcolor%3A%23d9edf7%7Da%2Ebg%2Dinfo%3Afocus%2Ca%2Ebg%2Dinfo%3Ahover%7Bbackground%2Dcolor%3A%23afd9ee%7D%2Ebg%2Dwarning%7Bbackground%2Dcolor%3A%23fcf8e3%7Da%2Ebg%2Dwarning%3Afocus%2Ca%2Ebg%2Dwarning%3Ahover%7Bbackground%2Dcolor%3A%23f7ecb5%7D%2Ebg%2Ddanger%7Bbackground%2Dcolor%3A%23f2dede%7Da%2Ebg%2Ddanger%3Afocus%2Ca%2Ebg%2Ddanger%3Ahover%7Bbackground%2Dcolor%3A%23e4b9b9%7D%2Epage%2Dheader%7Bpadding%2Dbottom%3A9px%3Bmargin%3A40px%200%2020px%3Bborder%2Dbottom%3A1px%20solid%20%23eee%7Dol%2Cul%7Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A10px%7Dol%20ol%2Col%20ul%2Cul%20ol%2Cul%20ul%7Bmargin%2Dbottom%3A0%7D%2Elist%2Dunstyled%7Bpadding%2Dleft%3A0%3Blist%2Dstyle%3Anone%7D%2Elist%2Dinline%7Bpadding%2Dleft%3A0%3Bmargin%2Dleft%3A%2D5px%3Blist%2Dstyle%3Anone%7D%2Elist%2Dinline%3Eli%7Bdisplay%3Ainline%2Dblock%3Bpadding%2Dright%3A5px%3Bpadding%2Dleft%3A5px%7Ddl%7Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A20px%7Ddd%2Cdt%7Bline%2Dheight%3A1%2E42857143%7Ddt%7Bfont%2Dweight%3A700%7Ddd%7Bmargin%2Dleft%3A0%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Edl%2Dhorizontal%20dt%7Bfloat%3Aleft%3Bwidth%3A160px%3Boverflow%3Ahidden%3Bclear%3Aleft%3Btext%2Dalign%3Aright%3Btext%2Doverflow%3Aellipsis%3Bwhite%2Dspace%3Anowrap%7D%2Edl%2Dhorizontal%20dd%7Bmargin%2Dleft%3A180px%7D%7Dabbr%5Bdata%2Doriginal%2Dtitle%5D%2Cabbr%5Btitle%5D%7Bcursor%3Ahelp%3Bborder%2Dbottom%3A1px%20dotted%20%23777%7D%2Einitialism%7Bfont%2Dsize%3A90%25%3Btext%2Dtransform%3Auppercase%7Dblockquote%7Bpadding%3A10px%2020px%3Bmargin%3A0%200%2020px%3Bfont%2Dsize%3A17%2E5px%3Bborder%2Dleft%3A5px%20solid%20%23eee%7Dblockquote%20ol%3Alast%2Dchild%2Cblockquote%20p%3Alast%2Dchild%2Cblockquote%20ul%3Alast%2Dchild%7Bmargin%2Dbottom%3A0%7Dblockquote%20%2Esmall%2Cblockquote%20footer%2Cblockquote%20small%7Bdisplay%3Ablock%3Bfont%2Dsize%3A80%25%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23777%7Dblockquote%20%2Esmall%3Abefore%2Cblockquote%20footer%3Abefore%2Cblockquote%20small%3Abefore%7Bcontent%3A%27%5C2014%20%5C00A0%27%7D%2Eblockquote%2Dreverse%2Cblockquote%2Epull%2Dright%7Bpadding%2Dright%3A15px%3Bpadding%2Dleft%3A0%3Btext%2Dalign%3Aright%3Bborder%2Dright%3A5px%20solid%20%23eee%3Bborder%2Dleft%3A0%7D%2Eblockquote%2Dreverse%20%2Esmall%3Abefore%2C%2Eblockquote%2Dreverse%20footer%3Abefore%2C%2Eblockquote%2Dreverse%20small%3Abefore%2Cblockquote%2Epull%2Dright%20%2Esmall%3Abefore%2Cblockquote%2Epull%2Dright%20footer%3Abefore%2Cblockquote%2Epull%2Dright%20small%3Abefore%7Bcontent%3A%27%27%7D%2Eblockquote%2Dreverse%20%2Esmall%3Aafter%2C%2Eblockquote%2Dreverse%20footer%3Aafter%2C%2Eblockquote%2Dreverse%20small%3Aafter%2Cblockquote%2Epull%2Dright%20%2Esmall%3Aafter%2Cblockquote%2Epull%2Dright%20footer%3Aafter%2Cblockquote%2Epull%2Dright%20small%3Aafter%7Bcontent%3A%27%5C00A0%20%5C2014%27%7Daddress%7Bmargin%2Dbottom%3A20px%3Bfont%2Dstyle%3Anormal%3Bline%2Dheight%3A1%2E42857143%7Dcode%2Ckbd%2Cpre%2Csamp%7Bfont%2Dfamily%3Amonospace%7Dcode%7Bpadding%3A2px%204px%3Bfont%2Dsize%3A90%25%3Bcolor%3A%23c7254e%3Bbackground%2Dcolor%3A%23f9f2f4%3Bborder%2Dradius%3A4px%7Dkbd%7Bpadding%3A2px%204px%3Bfont%2Dsize%3A90%25%3Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23333%3Bborder%2Dradius%3A3px%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%20%2D1px%200%20rgba%280%2C0%2C0%2C%2E25%29%3Bbox%2Dshadow%3Ainset%200%20%2D1px%200%20rgba%280%2C0%2C0%2C%2E25%29%7Dkbd%20kbd%7Bpadding%3A0%3Bfont%2Dsize%3A100%25%3Bfont%2Dweight%3A700%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%7Dpre%7Bdisplay%3Ablock%3Bpadding%3A9%2E5px%3Bmargin%3A0%200%2010px%3Bfont%2Dsize%3A13px%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23333%3Bword%2Dbreak%3Abreak%2Dall%3Bword%2Dwrap%3Abreak%2Dword%3Bbackground%2Dcolor%3A%23f5f5f5%3Bborder%3A1px%20solid%20%23ccc%3Bborder%2Dradius%3A4px%7Dpre%20code%7Bpadding%3A0%3Bfont%2Dsize%3Ainherit%3Bcolor%3Ainherit%3Bwhite%2Dspace%3Apre%2Dwrap%3Bbackground%2Dcolor%3Atransparent%3Bborder%2Dradius%3A0%7D%2Epre%2Dscrollable%7Bmax%2Dheight%3A340px%3Boverflow%2Dy%3Ascroll%7D%2Econtainer%7Bpadding%2Dright%3A15px%3Bpadding%2Dleft%3A15px%3Bmargin%2Dright%3Aauto%3Bmargin%2Dleft%3Aauto%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Econtainer%7Bwidth%3A750px%7D%7D%40media%20%28min%2Dwidth%3A992px%29%7B%2Econtainer%7Bwidth%3A970px%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Econtainer%7Bwidth%3A1170px%7D%7D%2Econtainer%2Dfluid%7Bpadding%2Dright%3A15px%3Bpadding%2Dleft%3A15px%3Bmargin%2Dright%3Aauto%3Bmargin%2Dleft%3Aauto%7D%2Erow%7Bmargin%2Dright%3A%2D15px%3Bmargin%2Dleft%3A%2D15px%7D%2Ecol%2Dlg%2D1%2C%2Ecol%2Dlg%2D10%2C%2Ecol%2Dlg%2D11%2C%2Ecol%2Dlg%2D12%2C%2Ecol%2Dlg%2D2%2C%2Ecol%2Dlg%2D3%2C%2Ecol%2Dlg%2D4%2C%2Ecol%2Dlg%2D5%2C%2Ecol%2Dlg%2D6%2C%2Ecol%2Dlg%2D7%2C%2Ecol%2Dlg%2D8%2C%2Ecol%2Dlg%2D9%2C%2Ecol%2Dmd%2D1%2C%2Ecol%2Dmd%2D10%2C%2Ecol%2Dmd%2D11%2C%2Ecol%2Dmd%2D12%2C%2Ecol%2Dmd%2D2%2C%2Ecol%2Dmd%2D3%2C%2Ecol%2Dmd%2D4%2C%2Ecol%2Dmd%2D5%2C%2Ecol%2Dmd%2D6%2C%2Ecol%2Dmd%2D7%2C%2Ecol%2Dmd%2D8%2C%2Ecol%2Dmd%2D9%2C%2Ecol%2Dsm%2D1%2C%2Ecol%2Dsm%2D10%2C%2Ecol%2Dsm%2D11%2C%2Ecol%2Dsm%2D12%2C%2Ecol%2Dsm%2D2%2C%2Ecol%2Dsm%2D3%2C%2Ecol%2Dsm%2D4%2C%2Ecol%2Dsm%2D5%2C%2Ecol%2Dsm%2D6%2C%2Ecol%2Dsm%2D7%2C%2Ecol%2Dsm%2D8%2C%2Ecol%2Dsm%2D9%2C%2Ecol%2Dxs%2D1%2C%2Ecol%2Dxs%2D10%2C%2Ecol%2Dxs%2D11%2C%2Ecol%2Dxs%2D12%2C%2Ecol%2Dxs%2D2%2C%2Ecol%2Dxs%2D3%2C%2Ecol%2Dxs%2D4%2C%2Ecol%2Dxs%2D5%2C%2Ecol%2Dxs%2D6%2C%2Ecol%2Dxs%2D7%2C%2Ecol%2Dxs%2D8%2C%2Ecol%2Dxs%2D9%7Bposition%3Arelative%3Bmin%2Dheight%3A1px%3Bpadding%2Dright%3A15px%3Bpadding%2Dleft%3A15px%7D%2Ecol%2Dxs%2D1%2C%2Ecol%2Dxs%2D10%2C%2Ecol%2Dxs%2D11%2C%2Ecol%2Dxs%2D12%2C%2Ecol%2Dxs%2D2%2C%2Ecol%2Dxs%2D3%2C%2Ecol%2Dxs%2D4%2C%2Ecol%2Dxs%2D5%2C%2Ecol%2Dxs%2D6%2C%2Ecol%2Dxs%2D7%2C%2Ecol%2Dxs%2D8%2C%2Ecol%2Dxs%2D9%7Bfloat%3Aleft%7D%2Ecol%2Dxs%2D12%7Bwidth%3A100%25%7D%2Ecol%2Dxs%2D11%7Bwidth%3A91%2E66666667%25%7D%2Ecol%2Dxs%2D10%7Bwidth%3A83%2E33333333%25%7D%2Ecol%2Dxs%2D9%7Bwidth%3A75%25%7D%2Ecol%2Dxs%2D8%7Bwidth%3A66%2E66666667%25%7D%2Ecol%2Dxs%2D7%7Bwidth%3A58%2E33333333%25%7D%2Ecol%2Dxs%2D6%7Bwidth%3A50%25%7D%2Ecol%2Dxs%2D5%7Bwidth%3A41%2E66666667%25%7D%2Ecol%2Dxs%2D4%7Bwidth%3A33%2E33333333%25%7D%2Ecol%2Dxs%2D3%7Bwidth%3A25%25%7D%2Ecol%2Dxs%2D2%7Bwidth%3A16%2E66666667%25%7D%2Ecol%2Dxs%2D1%7Bwidth%3A8%2E33333333%25%7D%2Ecol%2Dxs%2Dpull%2D12%7Bright%3A100%25%7D%2Ecol%2Dxs%2Dpull%2D11%7Bright%3A91%2E66666667%25%7D%2Ecol%2Dxs%2Dpull%2D10%7Bright%3A83%2E33333333%25%7D%2Ecol%2Dxs%2Dpull%2D9%7Bright%3A75%25%7D%2Ecol%2Dxs%2Dpull%2D8%7Bright%3A66%2E66666667%25%7D%2Ecol%2Dxs%2Dpull%2D7%7Bright%3A58%2E33333333%25%7D%2Ecol%2Dxs%2Dpull%2D6%7Bright%3A50%25%7D%2Ecol%2Dxs%2Dpull%2D5%7Bright%3A41%2E66666667%25%7D%2Ecol%2Dxs%2Dpull%2D4%7Bright%3A33%2E33333333%25%7D%2Ecol%2Dxs%2Dpull%2D3%7Bright%3A25%25%7D%2Ecol%2Dxs%2Dpull%2D2%7Bright%3A16%2E66666667%25%7D%2Ecol%2Dxs%2Dpull%2D1%7Bright%3A8%2E33333333%25%7D%2Ecol%2Dxs%2Dpull%2D0%7Bright%3Aauto%7D%2Ecol%2Dxs%2Dpush%2D12%7Bleft%3A100%25%7D%2Ecol%2Dxs%2Dpush%2D11%7Bleft%3A91%2E66666667%25%7D%2Ecol%2Dxs%2Dpush%2D10%7Bleft%3A83%2E33333333%25%7D%2Ecol%2Dxs%2Dpush%2D9%7Bleft%3A75%25%7D%2Ecol%2Dxs%2Dpush%2D8%7Bleft%3A66%2E66666667%25%7D%2Ecol%2Dxs%2Dpush%2D7%7Bleft%3A58%2E33333333%25%7D%2Ecol%2Dxs%2Dpush%2D6%7Bleft%3A50%25%7D%2Ecol%2Dxs%2Dpush%2D5%7Bleft%3A41%2E66666667%25%7D%2Ecol%2Dxs%2Dpush%2D4%7Bleft%3A33%2E33333333%25%7D%2Ecol%2Dxs%2Dpush%2D3%7Bleft%3A25%25%7D%2Ecol%2Dxs%2Dpush%2D2%7Bleft%3A16%2E66666667%25%7D%2Ecol%2Dxs%2Dpush%2D1%7Bleft%3A8%2E33333333%25%7D%2Ecol%2Dxs%2Dpush%2D0%7Bleft%3Aauto%7D%2Ecol%2Dxs%2Doffset%2D12%7Bmargin%2Dleft%3A100%25%7D%2Ecol%2Dxs%2Doffset%2D11%7Bmargin%2Dleft%3A91%2E66666667%25%7D%2Ecol%2Dxs%2Doffset%2D10%7Bmargin%2Dleft%3A83%2E33333333%25%7D%2Ecol%2Dxs%2Doffset%2D9%7Bmargin%2Dleft%3A75%25%7D%2Ecol%2Dxs%2Doffset%2D8%7Bmargin%2Dleft%3A66%2E66666667%25%7D%2Ecol%2Dxs%2Doffset%2D7%7Bmargin%2Dleft%3A58%2E33333333%25%7D%2Ecol%2Dxs%2Doffset%2D6%7Bmargin%2Dleft%3A50%25%7D%2Ecol%2Dxs%2Doffset%2D5%7Bmargin%2Dleft%3A41%2E66666667%25%7D%2Ecol%2Dxs%2Doffset%2D4%7Bmargin%2Dleft%3A33%2E33333333%25%7D%2Ecol%2Dxs%2Doffset%2D3%7Bmargin%2Dleft%3A25%25%7D%2Ecol%2Dxs%2Doffset%2D2%7Bmargin%2Dleft%3A16%2E66666667%25%7D%2Ecol%2Dxs%2Doffset%2D1%7Bmargin%2Dleft%3A8%2E33333333%25%7D%2Ecol%2Dxs%2Doffset%2D0%7Bmargin%2Dleft%3A0%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Ecol%2Dsm%2D1%2C%2Ecol%2Dsm%2D10%2C%2Ecol%2Dsm%2D11%2C%2Ecol%2Dsm%2D12%2C%2Ecol%2Dsm%2D2%2C%2Ecol%2Dsm%2D3%2C%2Ecol%2Dsm%2D4%2C%2Ecol%2Dsm%2D5%2C%2Ecol%2Dsm%2D6%2C%2Ecol%2Dsm%2D7%2C%2Ecol%2Dsm%2D8%2C%2Ecol%2Dsm%2D9%7Bfloat%3Aleft%7D%2Ecol%2Dsm%2D12%7Bwidth%3A100%25%7D%2Ecol%2Dsm%2D11%7Bwidth%3A91%2E66666667%25%7D%2Ecol%2Dsm%2D10%7Bwidth%3A83%2E33333333%25%7D%2Ecol%2Dsm%2D9%7Bwidth%3A75%25%7D%2Ecol%2Dsm%2D8%7Bwidth%3A66%2E66666667%25%7D%2Ecol%2Dsm%2D7%7Bwidth%3A58%2E33333333%25%7D%2Ecol%2Dsm%2D6%7Bwidth%3A50%25%7D%2Ecol%2Dsm%2D5%7Bwidth%3A41%2E66666667%25%7D%2Ecol%2Dsm%2D4%7Bwidth%3A33%2E33333333%25%7D%2Ecol%2Dsm%2D3%7Bwidth%3A25%25%7D%2Ecol%2Dsm%2D2%7Bwidth%3A16%2E66666667%25%7D%2Ecol%2Dsm%2D1%7Bwidth%3A8%2E33333333%25%7D%2Ecol%2Dsm%2Dpull%2D12%7Bright%3A100%25%7D%2Ecol%2Dsm%2Dpull%2D11%7Bright%3A91%2E66666667%25%7D%2Ecol%2Dsm%2Dpull%2D10%7Bright%3A83%2E33333333%25%7D%2Ecol%2Dsm%2Dpull%2D9%7Bright%3A75%25%7D%2Ecol%2Dsm%2Dpull%2D8%7Bright%3A66%2E66666667%25%7D%2Ecol%2Dsm%2Dpull%2D7%7Bright%3A58%2E33333333%25%7D%2Ecol%2Dsm%2Dpull%2D6%7Bright%3A50%25%7D%2Ecol%2Dsm%2Dpull%2D5%7Bright%3A41%2E66666667%25%7D%2Ecol%2Dsm%2Dpull%2D4%7Bright%3A33%2E33333333%25%7D%2Ecol%2Dsm%2Dpull%2D3%7Bright%3A25%25%7D%2Ecol%2Dsm%2Dpull%2D2%7Bright%3A16%2E66666667%25%7D%2Ecol%2Dsm%2Dpull%2D1%7Bright%3A8%2E33333333%25%7D%2Ecol%2Dsm%2Dpull%2D0%7Bright%3Aauto%7D%2Ecol%2Dsm%2Dpush%2D12%7Bleft%3A100%25%7D%2Ecol%2Dsm%2Dpush%2D11%7Bleft%3A91%2E66666667%25%7D%2Ecol%2Dsm%2Dpush%2D10%7Bleft%3A83%2E33333333%25%7D%2Ecol%2Dsm%2Dpush%2D9%7Bleft%3A75%25%7D%2Ecol%2Dsm%2Dpush%2D8%7Bleft%3A66%2E66666667%25%7D%2Ecol%2Dsm%2Dpush%2D7%7Bleft%3A58%2E33333333%25%7D%2Ecol%2Dsm%2Dpush%2D6%7Bleft%3A50%25%7D%2Ecol%2Dsm%2Dpush%2D5%7Bleft%3A41%2E66666667%25%7D%2Ecol%2Dsm%2Dpush%2D4%7Bleft%3A33%2E33333333%25%7D%2Ecol%2Dsm%2Dpush%2D3%7Bleft%3A25%25%7D%2Ecol%2Dsm%2Dpush%2D2%7Bleft%3A16%2E66666667%25%7D%2Ecol%2Dsm%2Dpush%2D1%7Bleft%3A8%2E33333333%25%7D%2Ecol%2Dsm%2Dpush%2D0%7Bleft%3Aauto%7D%2Ecol%2Dsm%2Doffset%2D12%7Bmargin%2Dleft%3A100%25%7D%2Ecol%2Dsm%2Doffset%2D11%7Bmargin%2Dleft%3A91%2E66666667%25%7D%2Ecol%2Dsm%2Doffset%2D10%7Bmargin%2Dleft%3A83%2E33333333%25%7D%2Ecol%2Dsm%2Doffset%2D9%7Bmargin%2Dleft%3A75%25%7D%2Ecol%2Dsm%2Doffset%2D8%7Bmargin%2Dleft%3A66%2E66666667%25%7D%2Ecol%2Dsm%2Doffset%2D7%7Bmargin%2Dleft%3A58%2E33333333%25%7D%2Ecol%2Dsm%2Doffset%2D6%7Bmargin%2Dleft%3A50%25%7D%2Ecol%2Dsm%2Doffset%2D5%7Bmargin%2Dleft%3A41%2E66666667%25%7D%2Ecol%2Dsm%2Doffset%2D4%7Bmargin%2Dleft%3A33%2E33333333%25%7D%2Ecol%2Dsm%2Doffset%2D3%7Bmargin%2Dleft%3A25%25%7D%2Ecol%2Dsm%2Doffset%2D2%7Bmargin%2Dleft%3A16%2E66666667%25%7D%2Ecol%2Dsm%2Doffset%2D1%7Bmargin%2Dleft%3A8%2E33333333%25%7D%2Ecol%2Dsm%2Doffset%2D0%7Bmargin%2Dleft%3A0%7D%7D%40media%20%28min%2Dwidth%3A992px%29%7B%2Ecol%2Dmd%2D1%2C%2Ecol%2Dmd%2D10%2C%2Ecol%2Dmd%2D11%2C%2Ecol%2Dmd%2D12%2C%2Ecol%2Dmd%2D2%2C%2Ecol%2Dmd%2D3%2C%2Ecol%2Dmd%2D4%2C%2Ecol%2Dmd%2D5%2C%2Ecol%2Dmd%2D6%2C%2Ecol%2Dmd%2D7%2C%2Ecol%2Dmd%2D8%2C%2Ecol%2Dmd%2D9%7Bfloat%3Aleft%7D%2Ecol%2Dmd%2D12%7Bwidth%3A100%25%7D%2Ecol%2Dmd%2D11%7Bwidth%3A91%2E66666667%25%7D%2Ecol%2Dmd%2D10%7Bwidth%3A83%2E33333333%25%7D%2Ecol%2Dmd%2D9%7Bwidth%3A75%25%7D%2Ecol%2Dmd%2D8%7Bwidth%3A66%2E66666667%25%7D%2Ecol%2Dmd%2D7%7Bwidth%3A58%2E33333333%25%7D%2Ecol%2Dmd%2D6%7Bwidth%3A50%25%7D%2Ecol%2Dmd%2D5%7Bwidth%3A41%2E66666667%25%7D%2Ecol%2Dmd%2D4%7Bwidth%3A33%2E33333333%25%7D%2Ecol%2Dmd%2D3%7Bwidth%3A25%25%7D%2Ecol%2Dmd%2D2%7Bwidth%3A16%2E66666667%25%7D%2Ecol%2Dmd%2D1%7Bwidth%3A8%2E33333333%25%7D%2Ecol%2Dmd%2Dpull%2D12%7Bright%3A100%25%7D%2Ecol%2Dmd%2Dpull%2D11%7Bright%3A91%2E66666667%25%7D%2Ecol%2Dmd%2Dpull%2D10%7Bright%3A83%2E33333333%25%7D%2Ecol%2Dmd%2Dpull%2D9%7Bright%3A75%25%7D%2Ecol%2Dmd%2Dpull%2D8%7Bright%3A66%2E66666667%25%7D%2Ecol%2Dmd%2Dpull%2D7%7Bright%3A58%2E33333333%25%7D%2Ecol%2Dmd%2Dpull%2D6%7Bright%3A50%25%7D%2Ecol%2Dmd%2Dpull%2D5%7Bright%3A41%2E66666667%25%7D%2Ecol%2Dmd%2Dpull%2D4%7Bright%3A33%2E33333333%25%7D%2Ecol%2Dmd%2Dpull%2D3%7Bright%3A25%25%7D%2Ecol%2Dmd%2Dpull%2D2%7Bright%3A16%2E66666667%25%7D%2Ecol%2Dmd%2Dpull%2D1%7Bright%3A8%2E33333333%25%7D%2Ecol%2Dmd%2Dpull%2D0%7Bright%3Aauto%7D%2Ecol%2Dmd%2Dpush%2D12%7Bleft%3A100%25%7D%2Ecol%2Dmd%2Dpush%2D11%7Bleft%3A91%2E66666667%25%7D%2Ecol%2Dmd%2Dpush%2D10%7Bleft%3A83%2E33333333%25%7D%2Ecol%2Dmd%2Dpush%2D9%7Bleft%3A75%25%7D%2Ecol%2Dmd%2Dpush%2D8%7Bleft%3A66%2E66666667%25%7D%2Ecol%2Dmd%2Dpush%2D7%7Bleft%3A58%2E33333333%25%7D%2Ecol%2Dmd%2Dpush%2D6%7Bleft%3A50%25%7D%2Ecol%2Dmd%2Dpush%2D5%7Bleft%3A41%2E66666667%25%7D%2Ecol%2Dmd%2Dpush%2D4%7Bleft%3A33%2E33333333%25%7D%2Ecol%2Dmd%2Dpush%2D3%7Bleft%3A25%25%7D%2Ecol%2Dmd%2Dpush%2D2%7Bleft%3A16%2E66666667%25%7D%2Ecol%2Dmd%2Dpush%2D1%7Bleft%3A8%2E33333333%25%7D%2Ecol%2Dmd%2Dpush%2D0%7Bleft%3Aauto%7D%2Ecol%2Dmd%2Doffset%2D12%7Bmargin%2Dleft%3A100%25%7D%2Ecol%2Dmd%2Doffset%2D11%7Bmargin%2Dleft%3A91%2E66666667%25%7D%2Ecol%2Dmd%2Doffset%2D10%7Bmargin%2Dleft%3A83%2E33333333%25%7D%2Ecol%2Dmd%2Doffset%2D9%7Bmargin%2Dleft%3A75%25%7D%2Ecol%2Dmd%2Doffset%2D8%7Bmargin%2Dleft%3A66%2E66666667%25%7D%2Ecol%2Dmd%2Doffset%2D7%7Bmargin%2Dleft%3A58%2E33333333%25%7D%2Ecol%2Dmd%2Doffset%2D6%7Bmargin%2Dleft%3A50%25%7D%2Ecol%2Dmd%2Doffset%2D5%7Bmargin%2Dleft%3A41%2E66666667%25%7D%2Ecol%2Dmd%2Doffset%2D4%7Bmargin%2Dleft%3A33%2E33333333%25%7D%2Ecol%2Dmd%2Doffset%2D3%7Bmargin%2Dleft%3A25%25%7D%2Ecol%2Dmd%2Doffset%2D2%7Bmargin%2Dleft%3A16%2E66666667%25%7D%2Ecol%2Dmd%2Doffset%2D1%7Bmargin%2Dleft%3A8%2E33333333%25%7D%2Ecol%2Dmd%2Doffset%2D0%7Bmargin%2Dleft%3A0%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Ecol%2Dlg%2D1%2C%2Ecol%2Dlg%2D10%2C%2Ecol%2Dlg%2D11%2C%2Ecol%2Dlg%2D12%2C%2Ecol%2Dlg%2D2%2C%2Ecol%2Dlg%2D3%2C%2Ecol%2Dlg%2D4%2C%2Ecol%2Dlg%2D5%2C%2Ecol%2Dlg%2D6%2C%2Ecol%2Dlg%2D7%2C%2Ecol%2Dlg%2D8%2C%2Ecol%2Dlg%2D9%7Bfloat%3Aleft%7D%2Ecol%2Dlg%2D12%7Bwidth%3A100%25%7D%2Ecol%2Dlg%2D11%7Bwidth%3A91%2E66666667%25%7D%2Ecol%2Dlg%2D10%7Bwidth%3A83%2E33333333%25%7D%2Ecol%2Dlg%2D9%7Bwidth%3A75%25%7D%2Ecol%2Dlg%2D8%7Bwidth%3A66%2E66666667%25%7D%2Ecol%2Dlg%2D7%7Bwidth%3A58%2E33333333%25%7D%2Ecol%2Dlg%2D6%7Bwidth%3A50%25%7D%2Ecol%2Dlg%2D5%7Bwidth%3A41%2E66666667%25%7D%2Ecol%2Dlg%2D4%7Bwidth%3A33%2E33333333%25%7D%2Ecol%2Dlg%2D3%7Bwidth%3A25%25%7D%2Ecol%2Dlg%2D2%7Bwidth%3A16%2E66666667%25%7D%2Ecol%2Dlg%2D1%7Bwidth%3A8%2E33333333%25%7D%2Ecol%2Dlg%2Dpull%2D12%7Bright%3A100%25%7D%2Ecol%2Dlg%2Dpull%2D11%7Bright%3A91%2E66666667%25%7D%2Ecol%2Dlg%2Dpull%2D10%7Bright%3A83%2E33333333%25%7D%2Ecol%2Dlg%2Dpull%2D9%7Bright%3A75%25%7D%2Ecol%2Dlg%2Dpull%2D8%7Bright%3A66%2E66666667%25%7D%2Ecol%2Dlg%2Dpull%2D7%7Bright%3A58%2E33333333%25%7D%2Ecol%2Dlg%2Dpull%2D6%7Bright%3A50%25%7D%2Ecol%2Dlg%2Dpull%2D5%7Bright%3A41%2E66666667%25%7D%2Ecol%2Dlg%2Dpull%2D4%7Bright%3A33%2E33333333%25%7D%2Ecol%2Dlg%2Dpull%2D3%7Bright%3A25%25%7D%2Ecol%2Dlg%2Dpull%2D2%7Bright%3A16%2E66666667%25%7D%2Ecol%2Dlg%2Dpull%2D1%7Bright%3A8%2E33333333%25%7D%2Ecol%2Dlg%2Dpull%2D0%7Bright%3Aauto%7D%2Ecol%2Dlg%2Dpush%2D12%7Bleft%3A100%25%7D%2Ecol%2Dlg%2Dpush%2D11%7Bleft%3A91%2E66666667%25%7D%2Ecol%2Dlg%2Dpush%2D10%7Bleft%3A83%2E33333333%25%7D%2Ecol%2Dlg%2Dpush%2D9%7Bleft%3A75%25%7D%2Ecol%2Dlg%2Dpush%2D8%7Bleft%3A66%2E66666667%25%7D%2Ecol%2Dlg%2Dpush%2D7%7Bleft%3A58%2E33333333%25%7D%2Ecol%2Dlg%2Dpush%2D6%7Bleft%3A50%25%7D%2Ecol%2Dlg%2Dpush%2D5%7Bleft%3A41%2E66666667%25%7D%2Ecol%2Dlg%2Dpush%2D4%7Bleft%3A33%2E33333333%25%7D%2Ecol%2Dlg%2Dpush%2D3%7Bleft%3A25%25%7D%2Ecol%2Dlg%2Dpush%2D2%7Bleft%3A16%2E66666667%25%7D%2Ecol%2Dlg%2Dpush%2D1%7Bleft%3A8%2E33333333%25%7D%2Ecol%2Dlg%2Dpush%2D0%7Bleft%3Aauto%7D%2Ecol%2Dlg%2Doffset%2D12%7Bmargin%2Dleft%3A100%25%7D%2Ecol%2Dlg%2Doffset%2D11%7Bmargin%2Dleft%3A91%2E66666667%25%7D%2Ecol%2Dlg%2Doffset%2D10%7Bmargin%2Dleft%3A83%2E33333333%25%7D%2Ecol%2Dlg%2Doffset%2D9%7Bmargin%2Dleft%3A75%25%7D%2Ecol%2Dlg%2Doffset%2D8%7Bmargin%2Dleft%3A66%2E66666667%25%7D%2Ecol%2Dlg%2Doffset%2D7%7Bmargin%2Dleft%3A58%2E33333333%25%7D%2Ecol%2Dlg%2Doffset%2D6%7Bmargin%2Dleft%3A50%25%7D%2Ecol%2Dlg%2Doffset%2D5%7Bmargin%2Dleft%3A41%2E66666667%25%7D%2Ecol%2Dlg%2Doffset%2D4%7Bmargin%2Dleft%3A33%2E33333333%25%7D%2Ecol%2Dlg%2Doffset%2D3%7Bmargin%2Dleft%3A25%25%7D%2Ecol%2Dlg%2Doffset%2D2%7Bmargin%2Dleft%3A16%2E66666667%25%7D%2Ecol%2Dlg%2Doffset%2D1%7Bmargin%2Dleft%3A8%2E33333333%25%7D%2Ecol%2Dlg%2Doffset%2D0%7Bmargin%2Dleft%3A0%7D%7Dtable%7Bbackground%2Dcolor%3Atransparent%7Dcaption%7Bpadding%2Dtop%3A8px%3Bpadding%2Dbottom%3A8px%3Bcolor%3A%23777%3Btext%2Dalign%3Aleft%7Dth%7B%7D%2Etable%7Bwidth%3A100%25%3Bmax%2Dwidth%3A100%25%3Bmargin%2Dbottom%3A20px%7D%2Etable%3Etbody%3Etr%3Etd%2C%2Etable%3Etbody%3Etr%3Eth%2C%2Etable%3Etfoot%3Etr%3Etd%2C%2Etable%3Etfoot%3Etr%3Eth%2C%2Etable%3Ethead%3Etr%3Etd%2C%2Etable%3Ethead%3Etr%3Eth%7Bpadding%3A8px%3Bline%2Dheight%3A1%2E42857143%3Bvertical%2Dalign%3Atop%3Bborder%2Dtop%3A1px%20solid%20%23ddd%7D%2Etable%3Ethead%3Etr%3Eth%7Bvertical%2Dalign%3Abottom%3Bborder%2Dbottom%3A2px%20solid%20%23ddd%7D%2Etable%3Ecaption%2Bthead%3Etr%3Afirst%2Dchild%3Etd%2C%2Etable%3Ecaption%2Bthead%3Etr%3Afirst%2Dchild%3Eth%2C%2Etable%3Ecolgroup%2Bthead%3Etr%3Afirst%2Dchild%3Etd%2C%2Etable%3Ecolgroup%2Bthead%3Etr%3Afirst%2Dchild%3Eth%2C%2Etable%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%3Etd%2C%2Etable%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%3Eth%7Bborder%2Dtop%3A0%7D%2Etable%3Etbody%2Btbody%7Bborder%2Dtop%3A2px%20solid%20%23ddd%7D%2Etable%20%2Etable%7Bbackground%2Dcolor%3A%23fff%7D%2Etable%2Dcondensed%3Etbody%3Etr%3Etd%2C%2Etable%2Dcondensed%3Etbody%3Etr%3Eth%2C%2Etable%2Dcondensed%3Etfoot%3Etr%3Etd%2C%2Etable%2Dcondensed%3Etfoot%3Etr%3Eth%2C%2Etable%2Dcondensed%3Ethead%3Etr%3Etd%2C%2Etable%2Dcondensed%3Ethead%3Etr%3Eth%7Bpadding%3A5px%7D%2Etable%2Dbordered%7Bborder%3A1px%20solid%20%23ddd%7D%2Etable%2Dbordered%3Etbody%3Etr%3Etd%2C%2Etable%2Dbordered%3Etbody%3Etr%3Eth%2C%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%2C%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%2C%2Etable%2Dbordered%3Ethead%3Etr%3Etd%2C%2Etable%2Dbordered%3Ethead%3Etr%3Eth%7Bborder%3A1px%20solid%20%23ddd%7D%2Etable%2Dbordered%3Ethead%3Etr%3Etd%2C%2Etable%2Dbordered%3Ethead%3Etr%3Eth%7Bborder%2Dbottom%2Dwidth%3A2px%7D%2Etable%2Dstriped%3Etbody%3Etr%3Anth%2Dof%2Dtype%28odd%29%7Bbackground%2Dcolor%3A%23f9f9f9%7D%2Etable%2Dhover%3Etbody%3Etr%3Ahover%7Bbackground%2Dcolor%3A%23f5f5f5%7Dtable%20col%5Bclass%2A%3Dcol%2D%5D%7Bposition%3Astatic%3Bdisplay%3Atable%2Dcolumn%3Bfloat%3Anone%7Dtable%20td%5Bclass%2A%3Dcol%2D%5D%2Ctable%20th%5Bclass%2A%3Dcol%2D%5D%7Bposition%3Astatic%3Bdisplay%3Atable%2Dcell%3Bfloat%3Anone%7D%2Etable%3Etbody%3Etr%2Eactive%3Etd%2C%2Etable%3Etbody%3Etr%2Eactive%3Eth%2C%2Etable%3Etbody%3Etr%3Etd%2Eactive%2C%2Etable%3Etbody%3Etr%3Eth%2Eactive%2C%2Etable%3Etfoot%3Etr%2Eactive%3Etd%2C%2Etable%3Etfoot%3Etr%2Eactive%3Eth%2C%2Etable%3Etfoot%3Etr%3Etd%2Eactive%2C%2Etable%3Etfoot%3Etr%3Eth%2Eactive%2C%2Etable%3Ethead%3Etr%2Eactive%3Etd%2C%2Etable%3Ethead%3Etr%2Eactive%3Eth%2C%2Etable%3Ethead%3Etr%3Etd%2Eactive%2C%2Etable%3Ethead%3Etr%3Eth%2Eactive%7Bbackground%2Dcolor%3A%23f5f5f5%7D%2Etable%2Dhover%3Etbody%3Etr%2Eactive%3Ahover%3Etd%2C%2Etable%2Dhover%3Etbody%3Etr%2Eactive%3Ahover%3Eth%2C%2Etable%2Dhover%3Etbody%3Etr%3Ahover%3E%2Eactive%2C%2Etable%2Dhover%3Etbody%3Etr%3Etd%2Eactive%3Ahover%2C%2Etable%2Dhover%3Etbody%3Etr%3Eth%2Eactive%3Ahover%7Bbackground%2Dcolor%3A%23e8e8e8%7D%2Etable%3Etbody%3Etr%2Esuccess%3Etd%2C%2Etable%3Etbody%3Etr%2Esuccess%3Eth%2C%2Etable%3Etbody%3Etr%3Etd%2Esuccess%2C%2Etable%3Etbody%3Etr%3Eth%2Esuccess%2C%2Etable%3Etfoot%3Etr%2Esuccess%3Etd%2C%2Etable%3Etfoot%3Etr%2Esuccess%3Eth%2C%2Etable%3Etfoot%3Etr%3Etd%2Esuccess%2C%2Etable%3Etfoot%3Etr%3Eth%2Esuccess%2C%2Etable%3Ethead%3Etr%2Esuccess%3Etd%2C%2Etable%3Ethead%3Etr%2Esuccess%3Eth%2C%2Etable%3Ethead%3Etr%3Etd%2Esuccess%2C%2Etable%3Ethead%3Etr%3Eth%2Esuccess%7Bbackground%2Dcolor%3A%23dff0d8%7D%2Etable%2Dhover%3Etbody%3Etr%2Esuccess%3Ahover%3Etd%2C%2Etable%2Dhover%3Etbody%3Etr%2Esuccess%3Ahover%3Eth%2C%2Etable%2Dhover%3Etbody%3Etr%3Ahover%3E%2Esuccess%2C%2Etable%2Dhover%3Etbody%3Etr%3Etd%2Esuccess%3Ahover%2C%2Etable%2Dhover%3Etbody%3Etr%3Eth%2Esuccess%3Ahover%7Bbackground%2Dcolor%3A%23d0e9c6%7D%2Etable%3Etbody%3Etr%2Einfo%3Etd%2C%2Etable%3Etbody%3Etr%2Einfo%3Eth%2C%2Etable%3Etbody%3Etr%3Etd%2Einfo%2C%2Etable%3Etbody%3Etr%3Eth%2Einfo%2C%2Etable%3Etfoot%3Etr%2Einfo%3Etd%2C%2Etable%3Etfoot%3Etr%2Einfo%3Eth%2C%2Etable%3Etfoot%3Etr%3Etd%2Einfo%2C%2Etable%3Etfoot%3Etr%3Eth%2Einfo%2C%2Etable%3Ethead%3Etr%2Einfo%3Etd%2C%2Etable%3Ethead%3Etr%2Einfo%3Eth%2C%2Etable%3Ethead%3Etr%3Etd%2Einfo%2C%2Etable%3Ethead%3Etr%3Eth%2Einfo%7Bbackground%2Dcolor%3A%23d9edf7%7D%2Etable%2Dhover%3Etbody%3Etr%2Einfo%3Ahover%3Etd%2C%2Etable%2Dhover%3Etbody%3Etr%2Einfo%3Ahover%3Eth%2C%2Etable%2Dhover%3Etbody%3Etr%3Ahover%3E%2Einfo%2C%2Etable%2Dhover%3Etbody%3Etr%3Etd%2Einfo%3Ahover%2C%2Etable%2Dhover%3Etbody%3Etr%3Eth%2Einfo%3Ahover%7Bbackground%2Dcolor%3A%23c4e3f3%7D%2Etable%3Etbody%3Etr%2Ewarning%3Etd%2C%2Etable%3Etbody%3Etr%2Ewarning%3Eth%2C%2Etable%3Etbody%3Etr%3Etd%2Ewarning%2C%2Etable%3Etbody%3Etr%3Eth%2Ewarning%2C%2Etable%3Etfoot%3Etr%2Ewarning%3Etd%2C%2Etable%3Etfoot%3Etr%2Ewarning%3Eth%2C%2Etable%3Etfoot%3Etr%3Etd%2Ewarning%2C%2Etable%3Etfoot%3Etr%3Eth%2Ewarning%2C%2Etable%3Ethead%3Etr%2Ewarning%3Etd%2C%2Etable%3Ethead%3Etr%2Ewarning%3Eth%2C%2Etable%3Ethead%3Etr%3Etd%2Ewarning%2C%2Etable%3Ethead%3Etr%3Eth%2Ewarning%7Bbackground%2Dcolor%3A%23fcf8e3%7D%2Etable%2Dhover%3Etbody%3Etr%2Ewarning%3Ahover%3Etd%2C%2Etable%2Dhover%3Etbody%3Etr%2Ewarning%3Ahover%3Eth%2C%2Etable%2Dhover%3Etbody%3Etr%3Ahover%3E%2Ewarning%2C%2Etable%2Dhover%3Etbody%3Etr%3Etd%2Ewarning%3Ahover%2C%2Etable%2Dhover%3Etbody%3Etr%3Eth%2Ewarning%3Ahover%7Bbackground%2Dcolor%3A%23faf2cc%7D%2Etable%3Etbody%3Etr%2Edanger%3Etd%2C%2Etable%3Etbody%3Etr%2Edanger%3Eth%2C%2Etable%3Etbody%3Etr%3Etd%2Edanger%2C%2Etable%3Etbody%3Etr%3Eth%2Edanger%2C%2Etable%3Etfoot%3Etr%2Edanger%3Etd%2C%2Etable%3Etfoot%3Etr%2Edanger%3Eth%2C%2Etable%3Etfoot%3Etr%3Etd%2Edanger%2C%2Etable%3Etfoot%3Etr%3Eth%2Edanger%2C%2Etable%3Ethead%3Etr%2Edanger%3Etd%2C%2Etable%3Ethead%3Etr%2Edanger%3Eth%2C%2Etable%3Ethead%3Etr%3Etd%2Edanger%2C%2Etable%3Ethead%3Etr%3Eth%2Edanger%7Bbackground%2Dcolor%3A%23f2dede%7D%2Etable%2Dhover%3Etbody%3Etr%2Edanger%3Ahover%3Etd%2C%2Etable%2Dhover%3Etbody%3Etr%2Edanger%3Ahover%3Eth%2C%2Etable%2Dhover%3Etbody%3Etr%3Ahover%3E%2Edanger%2C%2Etable%2Dhover%3Etbody%3Etr%3Etd%2Edanger%3Ahover%2C%2Etable%2Dhover%3Etbody%3Etr%3Eth%2Edanger%3Ahover%7Bbackground%2Dcolor%3A%23ebcccc%7D%2Etable%2Dresponsive%7Bmin%2Dheight%3A%2E01%25%3Boverflow%2Dx%3Aauto%7D%40media%20screen%20and%20%28max%2Dwidth%3A767px%29%7B%2Etable%2Dresponsive%7Bwidth%3A100%25%3Bmargin%2Dbottom%3A15px%3Boverflow%2Dy%3Ahidden%3B%2Dms%2Doverflow%2Dstyle%3A%2Dms%2Dautohiding%2Dscrollbar%3Bborder%3A1px%20solid%20%23ddd%7D%2Etable%2Dresponsive%3E%2Etable%7Bmargin%2Dbottom%3A0%7D%2Etable%2Dresponsive%3E%2Etable%3Etbody%3Etr%3Etd%2C%2Etable%2Dresponsive%3E%2Etable%3Etbody%3Etr%3Eth%2C%2Etable%2Dresponsive%3E%2Etable%3Etfoot%3Etr%3Etd%2C%2Etable%2Dresponsive%3E%2Etable%3Etfoot%3Etr%3Eth%2C%2Etable%2Dresponsive%3E%2Etable%3Ethead%3Etr%3Etd%2C%2Etable%2Dresponsive%3E%2Etable%3Ethead%3Etr%3Eth%7Bwhite%2Dspace%3Anowrap%7D%2Etable%2Dresponsive%3E%2Etable%2Dbordered%7Bborder%3A0%7D%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Etd%3Afirst%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Eth%3Afirst%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%3Afirst%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%3Afirst%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Etd%3Afirst%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Eth%3Afirst%2Dchild%7Bborder%2Dleft%3A0%7D%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Etd%3Alast%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Eth%3Alast%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%3Alast%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%3Alast%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Etd%3Alast%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Eth%3Alast%2Dchild%7Bborder%2Dright%3A0%7D%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Alast%2Dchild%3Etd%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Alast%2Dchild%3Eth%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Alast%2Dchild%3Etd%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Alast%2Dchild%3Eth%7Bborder%2Dbottom%3A0%7D%7Dfieldset%7Bmin%2Dwidth%3A0%3Bpadding%3A0%3Bmargin%3A0%3Bborder%3A0%7Dlegend%7Bdisplay%3Ablock%3Bwidth%3A100%25%3Bpadding%3A0%3Bmargin%2Dbottom%3A20px%3Bfont%2Dsize%3A21px%3Bline%2Dheight%3Ainherit%3Bcolor%3A%23333%3Bborder%3A0%3Bborder%2Dbottom%3A1px%20solid%20%23e5e5e5%7Dlabel%7Bdisplay%3Ainline%2Dblock%3Bmax%2Dwidth%3A100%25%3Bmargin%2Dbottom%3A5px%3Bfont%2Dweight%3A700%7Dinput%5Btype%3Dsearch%5D%7B%2Dwebkit%2Dbox%2Dsizing%3Aborder%2Dbox%3B%2Dmoz%2Dbox%2Dsizing%3Aborder%2Dbox%3Bbox%2Dsizing%3Aborder%2Dbox%7Dinput%5Btype%3Dcheckbox%5D%2Cinput%5Btype%3Dradio%5D%7Bmargin%3A4px%200%200%3Bmargin%2Dtop%3A1px%5C9%3Bline%2Dheight%3Anormal%7Dinput%5Btype%3Dfile%5D%7Bdisplay%3Ablock%7Dinput%5Btype%3Drange%5D%7Bdisplay%3Ablock%3Bwidth%3A100%25%7Dselect%5Bmultiple%5D%2Cselect%5Bsize%5D%7Bheight%3Aauto%7Dinput%5Btype%3Dfile%5D%3Afocus%2Cinput%5Btype%3Dcheckbox%5D%3Afocus%2Cinput%5Btype%3Dradio%5D%3Afocus%7Boutline%3Athin%20dotted%3Boutline%3A5px%20auto%20%2Dwebkit%2Dfocus%2Dring%2Dcolor%3Boutline%2Doffset%3A%2D2px%7Doutput%7Bdisplay%3Ablock%3Bpadding%2Dtop%3A7px%3Bfont%2Dsize%3A14px%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23555%7D%2Eform%2Dcontrol%7Bdisplay%3Ablock%3Bwidth%3A100%25%3Bheight%3A34px%3Bpadding%3A6px%2012px%3Bfont%2Dsize%3A14px%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23555%3Bbackground%2Dcolor%3A%23fff%3Bbackground%2Dimage%3Anone%3Bborder%3A1px%20solid%20%23ccc%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%3B%2Dwebkit%2Dtransition%3Aborder%2Dcolor%20ease%2Din%2Dout%20%2E15s%2C%2Dwebkit%2Dbox%2Dshadow%20ease%2Din%2Dout%20%2E15s%3B%2Do%2Dtransition%3Aborder%2Dcolor%20ease%2Din%2Dout%20%2E15s%2Cbox%2Dshadow%20ease%2Din%2Dout%20%2E15s%3Btransition%3Aborder%2Dcolor%20ease%2Din%2Dout%20%2E15s%2Cbox%2Dshadow%20ease%2Din%2Dout%20%2E15s%7D%2Eform%2Dcontrol%3Afocus%7Bborder%2Dcolor%3A%2366afe9%3Boutline%3A0%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%208px%20rgba%28102%2C175%2C233%2C%2E6%29%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%208px%20rgba%28102%2C175%2C233%2C%2E6%29%7D%2Eform%2Dcontrol%3A%3A%2Dmoz%2Dplaceholder%7Bcolor%3A%23999%3Bopacity%3A1%7D%2Eform%2Dcontrol%3A%2Dms%2Dinput%2Dplaceholder%7Bcolor%3A%23999%7D%2Eform%2Dcontrol%3A%3A%2Dwebkit%2Dinput%2Dplaceholder%7Bcolor%3A%23999%7D%2Eform%2Dcontrol%5Bdisabled%5D%2C%2Eform%2Dcontrol%5Breadonly%5D%2Cfieldset%5Bdisabled%5D%20%2Eform%2Dcontrol%7Bbackground%2Dcolor%3A%23eee%3Bopacity%3A1%7D%2Eform%2Dcontrol%5Bdisabled%5D%2Cfieldset%5Bdisabled%5D%20%2Eform%2Dcontrol%7Bcursor%3Anot%2Dallowed%7Dtextarea%2Eform%2Dcontrol%7Bheight%3Aauto%7Dinput%5Btype%3Dsearch%5D%7B%2Dwebkit%2Dappearance%3Anone%7D%40media%20screen%20and%20%28%2Dwebkit%2Dmin%2Ddevice%2Dpixel%2Dratio%3A0%29%7Binput%5Btype%3Ddate%5D%2Eform%2Dcontrol%2Cinput%5Btype%3Dtime%5D%2Eform%2Dcontrol%2Cinput%5Btype%3Ddatetime%2Dlocal%5D%2Eform%2Dcontrol%2Cinput%5Btype%3Dmonth%5D%2Eform%2Dcontrol%7Bline%2Dheight%3A34px%7D%2Einput%2Dgroup%2Dsm%20input%5Btype%3Ddate%5D%2C%2Einput%2Dgroup%2Dsm%20input%5Btype%3Dtime%5D%2C%2Einput%2Dgroup%2Dsm%20input%5Btype%3Ddatetime%2Dlocal%5D%2C%2Einput%2Dgroup%2Dsm%20input%5Btype%3Dmonth%5D%2Cinput%5Btype%3Ddate%5D%2Einput%2Dsm%2Cinput%5Btype%3Dtime%5D%2Einput%2Dsm%2Cinput%5Btype%3Ddatetime%2Dlocal%5D%2Einput%2Dsm%2Cinput%5Btype%3Dmonth%5D%2Einput%2Dsm%7Bline%2Dheight%3A30px%7D%2Einput%2Dgroup%2Dlg%20input%5Btype%3Ddate%5D%2C%2Einput%2Dgroup%2Dlg%20input%5Btype%3Dtime%5D%2C%2Einput%2Dgroup%2Dlg%20input%5Btype%3Ddatetime%2Dlocal%5D%2C%2Einput%2Dgroup%2Dlg%20input%5Btype%3Dmonth%5D%2Cinput%5Btype%3Ddate%5D%2Einput%2Dlg%2Cinput%5Btype%3Dtime%5D%2Einput%2Dlg%2Cinput%5Btype%3Ddatetime%2Dlocal%5D%2Einput%2Dlg%2Cinput%5Btype%3Dmonth%5D%2Einput%2Dlg%7Bline%2Dheight%3A46px%7D%7D%2Eform%2Dgroup%7Bmargin%2Dbottom%3A15px%7D%2Echeckbox%2C%2Eradio%7Bposition%3Arelative%3Bdisplay%3Ablock%3Bmargin%2Dtop%3A10px%3Bmargin%2Dbottom%3A10px%7D%2Echeckbox%20label%2C%2Eradio%20label%7Bmin%2Dheight%3A20px%3Bpadding%2Dleft%3A20px%3Bmargin%2Dbottom%3A0%3Bfont%2Dweight%3A400%3Bcursor%3Apointer%7D%2Echeckbox%20input%5Btype%3Dcheckbox%5D%2C%2Echeckbox%2Dinline%20input%5Btype%3Dcheckbox%5D%2C%2Eradio%20input%5Btype%3Dradio%5D%2C%2Eradio%2Dinline%20input%5Btype%3Dradio%5D%7Bposition%3Aabsolute%3Bmargin%2Dtop%3A4px%5C9%3Bmargin%2Dleft%3A%2D20px%7D%2Echeckbox%2B%2Echeckbox%2C%2Eradio%2B%2Eradio%7Bmargin%2Dtop%3A%2D5px%7D%2Echeckbox%2Dinline%2C%2Eradio%2Dinline%7Bposition%3Arelative%3Bdisplay%3Ainline%2Dblock%3Bpadding%2Dleft%3A20px%3Bmargin%2Dbottom%3A0%3Bfont%2Dweight%3A400%3Bvertical%2Dalign%3Amiddle%3Bcursor%3Apointer%7D%2Echeckbox%2Dinline%2B%2Echeckbox%2Dinline%2C%2Eradio%2Dinline%2B%2Eradio%2Dinline%7Bmargin%2Dtop%3A0%3Bmargin%2Dleft%3A10px%7Dfieldset%5Bdisabled%5D%20input%5Btype%3Dcheckbox%5D%2Cfieldset%5Bdisabled%5D%20input%5Btype%3Dradio%5D%2Cinput%5Btype%3Dcheckbox%5D%2Edisabled%2Cinput%5Btype%3Dcheckbox%5D%5Bdisabled%5D%2Cinput%5Btype%3Dradio%5D%2Edisabled%2Cinput%5Btype%3Dradio%5D%5Bdisabled%5D%7Bcursor%3Anot%2Dallowed%7D%2Echeckbox%2Dinline%2Edisabled%2C%2Eradio%2Dinline%2Edisabled%2Cfieldset%5Bdisabled%5D%20%2Echeckbox%2Dinline%2Cfieldset%5Bdisabled%5D%20%2Eradio%2Dinline%7Bcursor%3Anot%2Dallowed%7D%2Echeckbox%2Edisabled%20label%2C%2Eradio%2Edisabled%20label%2Cfieldset%5Bdisabled%5D%20%2Echeckbox%20label%2Cfieldset%5Bdisabled%5D%20%2Eradio%20label%7Bcursor%3Anot%2Dallowed%7D%2Eform%2Dcontrol%2Dstatic%7Bmin%2Dheight%3A34px%3Bpadding%2Dtop%3A7px%3Bpadding%2Dbottom%3A7px%3Bmargin%2Dbottom%3A0%7D%2Eform%2Dcontrol%2Dstatic%2Einput%2Dlg%2C%2Eform%2Dcontrol%2Dstatic%2Einput%2Dsm%7Bpadding%2Dright%3A0%3Bpadding%2Dleft%3A0%7D%2Einput%2Dsm%7Bheight%3A30px%3Bpadding%3A5px%2010px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%3Bborder%2Dradius%3A3px%7Dselect%2Einput%2Dsm%7Bheight%3A30px%3Bline%2Dheight%3A30px%7Dselect%5Bmultiple%5D%2Einput%2Dsm%2Ctextarea%2Einput%2Dsm%7Bheight%3Aauto%7D%2Eform%2Dgroup%2Dsm%20%2Eform%2Dcontrol%7Bheight%3A30px%3Bpadding%3A5px%2010px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%3Bborder%2Dradius%3A3px%7D%2Eform%2Dgroup%2Dsm%20select%2Eform%2Dcontrol%7Bheight%3A30px%3Bline%2Dheight%3A30px%7D%2Eform%2Dgroup%2Dsm%20select%5Bmultiple%5D%2Eform%2Dcontrol%2C%2Eform%2Dgroup%2Dsm%20textarea%2Eform%2Dcontrol%7Bheight%3Aauto%7D%2Eform%2Dgroup%2Dsm%20%2Eform%2Dcontrol%2Dstatic%7Bheight%3A30px%3Bmin%2Dheight%3A32px%3Bpadding%3A6px%2010px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%7D%2Einput%2Dlg%7Bheight%3A46px%3Bpadding%3A10px%2016px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A1%2E3333333%3Bborder%2Dradius%3A6px%7Dselect%2Einput%2Dlg%7Bheight%3A46px%3Bline%2Dheight%3A46px%7Dselect%5Bmultiple%5D%2Einput%2Dlg%2Ctextarea%2Einput%2Dlg%7Bheight%3Aauto%7D%2Eform%2Dgroup%2Dlg%20%2Eform%2Dcontrol%7Bheight%3A46px%3Bpadding%3A10px%2016px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A1%2E3333333%3Bborder%2Dradius%3A6px%7D%2Eform%2Dgroup%2Dlg%20select%2Eform%2Dcontrol%7Bheight%3A46px%3Bline%2Dheight%3A46px%7D%2Eform%2Dgroup%2Dlg%20select%5Bmultiple%5D%2Eform%2Dcontrol%2C%2Eform%2Dgroup%2Dlg%20textarea%2Eform%2Dcontrol%7Bheight%3Aauto%7D%2Eform%2Dgroup%2Dlg%20%2Eform%2Dcontrol%2Dstatic%7Bheight%3A46px%3Bmin%2Dheight%3A38px%3Bpadding%3A11px%2016px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A1%2E3333333%7D%2Ehas%2Dfeedback%7Bposition%3Arelative%7D%2Ehas%2Dfeedback%20%2Eform%2Dcontrol%7Bpadding%2Dright%3A42%2E5px%7D%2Eform%2Dcontrol%2Dfeedback%7Bposition%3Aabsolute%3Btop%3A0%3Bright%3A0%3Bz%2Dindex%3A2%3Bdisplay%3Ablock%3Bwidth%3A34px%3Bheight%3A34px%3Bline%2Dheight%3A34px%3Btext%2Dalign%3Acenter%3Bpointer%2Devents%3Anone%7D%2Eform%2Dgroup%2Dlg%20%2Eform%2Dcontrol%2B%2Eform%2Dcontrol%2Dfeedback%2C%2Einput%2Dgroup%2Dlg%2B%2Eform%2Dcontrol%2Dfeedback%2C%2Einput%2Dlg%2B%2Eform%2Dcontrol%2Dfeedback%7Bwidth%3A46px%3Bheight%3A46px%3Bline%2Dheight%3A46px%7D%2Eform%2Dgroup%2Dsm%20%2Eform%2Dcontrol%2B%2Eform%2Dcontrol%2Dfeedback%2C%2Einput%2Dgroup%2Dsm%2B%2Eform%2Dcontrol%2Dfeedback%2C%2Einput%2Dsm%2B%2Eform%2Dcontrol%2Dfeedback%7Bwidth%3A30px%3Bheight%3A30px%3Bline%2Dheight%3A30px%7D%2Ehas%2Dsuccess%20%2Echeckbox%2C%2Ehas%2Dsuccess%20%2Echeckbox%2Dinline%2C%2Ehas%2Dsuccess%20%2Econtrol%2Dlabel%2C%2Ehas%2Dsuccess%20%2Ehelp%2Dblock%2C%2Ehas%2Dsuccess%20%2Eradio%2C%2Ehas%2Dsuccess%20%2Eradio%2Dinline%2C%2Ehas%2Dsuccess%2Echeckbox%20label%2C%2Ehas%2Dsuccess%2Echeckbox%2Dinline%20label%2C%2Ehas%2Dsuccess%2Eradio%20label%2C%2Ehas%2Dsuccess%2Eradio%2Dinline%20label%7Bcolor%3A%233c763d%7D%2Ehas%2Dsuccess%20%2Eform%2Dcontrol%7Bborder%2Dcolor%3A%233c763d%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%7D%2Ehas%2Dsuccess%20%2Eform%2Dcontrol%3Afocus%7Bborder%2Dcolor%3A%232b542c%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%206px%20%2367b168%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%206px%20%2367b168%7D%2Ehas%2Dsuccess%20%2Einput%2Dgroup%2Daddon%7Bcolor%3A%233c763d%3Bbackground%2Dcolor%3A%23dff0d8%3Bborder%2Dcolor%3A%233c763d%7D%2Ehas%2Dsuccess%20%2Eform%2Dcontrol%2Dfeedback%7Bcolor%3A%233c763d%7D%2Ehas%2Dwarning%20%2Echeckbox%2C%2Ehas%2Dwarning%20%2Echeckbox%2Dinline%2C%2Ehas%2Dwarning%20%2Econtrol%2Dlabel%2C%2Ehas%2Dwarning%20%2Ehelp%2Dblock%2C%2Ehas%2Dwarning%20%2Eradio%2C%2Ehas%2Dwarning%20%2Eradio%2Dinline%2C%2Ehas%2Dwarning%2Echeckbox%20label%2C%2Ehas%2Dwarning%2Echeckbox%2Dinline%20label%2C%2Ehas%2Dwarning%2Eradio%20label%2C%2Ehas%2Dwarning%2Eradio%2Dinline%20label%7Bcolor%3A%238a6d3b%7D%2Ehas%2Dwarning%20%2Eform%2Dcontrol%7Bborder%2Dcolor%3A%238a6d3b%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%7D%2Ehas%2Dwarning%20%2Eform%2Dcontrol%3Afocus%7Bborder%2Dcolor%3A%2366512c%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%206px%20%23c0a16b%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%206px%20%23c0a16b%7D%2Ehas%2Dwarning%20%2Einput%2Dgroup%2Daddon%7Bcolor%3A%238a6d3b%3Bbackground%2Dcolor%3A%23fcf8e3%3Bborder%2Dcolor%3A%238a6d3b%7D%2Ehas%2Dwarning%20%2Eform%2Dcontrol%2Dfeedback%7Bcolor%3A%238a6d3b%7D%2Ehas%2Derror%20%2Echeckbox%2C%2Ehas%2Derror%20%2Echeckbox%2Dinline%2C%2Ehas%2Derror%20%2Econtrol%2Dlabel%2C%2Ehas%2Derror%20%2Ehelp%2Dblock%2C%2Ehas%2Derror%20%2Eradio%2C%2Ehas%2Derror%20%2Eradio%2Dinline%2C%2Ehas%2Derror%2Echeckbox%20label%2C%2Ehas%2Derror%2Echeckbox%2Dinline%20label%2C%2Ehas%2Derror%2Eradio%20label%2C%2Ehas%2Derror%2Eradio%2Dinline%20label%7Bcolor%3A%23a94442%7D%2Ehas%2Derror%20%2Eform%2Dcontrol%7Bborder%2Dcolor%3A%23a94442%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%7D%2Ehas%2Derror%20%2Eform%2Dcontrol%3Afocus%7Bborder%2Dcolor%3A%23843534%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%206px%20%23ce8483%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%206px%20%23ce8483%7D%2Ehas%2Derror%20%2Einput%2Dgroup%2Daddon%7Bcolor%3A%23a94442%3Bbackground%2Dcolor%3A%23f2dede%3Bborder%2Dcolor%3A%23a94442%7D%2Ehas%2Derror%20%2Eform%2Dcontrol%2Dfeedback%7Bcolor%3A%23a94442%7D%2Ehas%2Dfeedback%20label%7E%2Eform%2Dcontrol%2Dfeedback%7Btop%3A25px%7D%2Ehas%2Dfeedback%20label%2Esr%2Donly%7E%2Eform%2Dcontrol%2Dfeedback%7Btop%3A0%7D%2Ehelp%2Dblock%7Bdisplay%3Ablock%3Bmargin%2Dtop%3A5px%3Bmargin%2Dbottom%3A10px%3Bcolor%3A%23737373%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Eform%2Dinline%20%2Eform%2Dgroup%7Bdisplay%3Ainline%2Dblock%3Bmargin%2Dbottom%3A0%3Bvertical%2Dalign%3Amiddle%7D%2Eform%2Dinline%20%2Eform%2Dcontrol%7Bdisplay%3Ainline%2Dblock%3Bwidth%3Aauto%3Bvertical%2Dalign%3Amiddle%7D%2Eform%2Dinline%20%2Eform%2Dcontrol%2Dstatic%7Bdisplay%3Ainline%2Dblock%7D%2Eform%2Dinline%20%2Einput%2Dgroup%7Bdisplay%3Ainline%2Dtable%3Bvertical%2Dalign%3Amiddle%7D%2Eform%2Dinline%20%2Einput%2Dgroup%20%2Eform%2Dcontrol%2C%2Eform%2Dinline%20%2Einput%2Dgroup%20%2Einput%2Dgroup%2Daddon%2C%2Eform%2Dinline%20%2Einput%2Dgroup%20%2Einput%2Dgroup%2Dbtn%7Bwidth%3Aauto%7D%2Eform%2Dinline%20%2Einput%2Dgroup%3E%2Eform%2Dcontrol%7Bwidth%3A100%25%7D%2Eform%2Dinline%20%2Econtrol%2Dlabel%7Bmargin%2Dbottom%3A0%3Bvertical%2Dalign%3Amiddle%7D%2Eform%2Dinline%20%2Echeckbox%2C%2Eform%2Dinline%20%2Eradio%7Bdisplay%3Ainline%2Dblock%3Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A0%3Bvertical%2Dalign%3Amiddle%7D%2Eform%2Dinline%20%2Echeckbox%20label%2C%2Eform%2Dinline%20%2Eradio%20label%7Bpadding%2Dleft%3A0%7D%2Eform%2Dinline%20%2Echeckbox%20input%5Btype%3Dcheckbox%5D%2C%2Eform%2Dinline%20%2Eradio%20input%5Btype%3Dradio%5D%7Bposition%3Arelative%3Bmargin%2Dleft%3A0%7D%2Eform%2Dinline%20%2Ehas%2Dfeedback%20%2Eform%2Dcontrol%2Dfeedback%7Btop%3A0%7D%7D%2Eform%2Dhorizontal%20%2Echeckbox%2C%2Eform%2Dhorizontal%20%2Echeckbox%2Dinline%2C%2Eform%2Dhorizontal%20%2Eradio%2C%2Eform%2Dhorizontal%20%2Eradio%2Dinline%7Bpadding%2Dtop%3A7px%3Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A0%7D%2Eform%2Dhorizontal%20%2Echeckbox%2C%2Eform%2Dhorizontal%20%2Eradio%7Bmin%2Dheight%3A27px%7D%2Eform%2Dhorizontal%20%2Eform%2Dgroup%7Bmargin%2Dright%3A%2D15px%3Bmargin%2Dleft%3A%2D15px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Eform%2Dhorizontal%20%2Econtrol%2Dlabel%7Bpadding%2Dtop%3A7px%3Bmargin%2Dbottom%3A0%3Btext%2Dalign%3Aright%7D%7D%2Eform%2Dhorizontal%20%2Ehas%2Dfeedback%20%2Eform%2Dcontrol%2Dfeedback%7Bright%3A15px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Eform%2Dhorizontal%20%2Eform%2Dgroup%2Dlg%20%2Econtrol%2Dlabel%7Bpadding%2Dtop%3A14%2E33px%3Bfont%2Dsize%3A18px%7D%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Eform%2Dhorizontal%20%2Eform%2Dgroup%2Dsm%20%2Econtrol%2Dlabel%7Bpadding%2Dtop%3A6px%3Bfont%2Dsize%3A12px%7D%7D%2Ebtn%7Bdisplay%3Ainline%2Dblock%3Bpadding%3A6px%2012px%3Bmargin%2Dbottom%3A0%3Bfont%2Dsize%3A14px%3Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%2E42857143%3Btext%2Dalign%3Acenter%3Bwhite%2Dspace%3Anowrap%3Bvertical%2Dalign%3Amiddle%3B%2Dms%2Dtouch%2Daction%3Amanipulation%3Btouch%2Daction%3Amanipulation%3Bcursor%3Apointer%3B%2Dwebkit%2Duser%2Dselect%3Anone%3B%2Dmoz%2Duser%2Dselect%3Anone%3B%2Dms%2Duser%2Dselect%3Anone%3Buser%2Dselect%3Anone%3Bbackground%2Dimage%3Anone%3Bborder%3A1px%20solid%20transparent%3Bborder%2Dradius%3A4px%7D%2Ebtn%2Eactive%2Efocus%2C%2Ebtn%2Eactive%3Afocus%2C%2Ebtn%2Efocus%2C%2Ebtn%3Aactive%2Efocus%2C%2Ebtn%3Aactive%3Afocus%2C%2Ebtn%3Afocus%7Boutline%3Athin%20dotted%3Boutline%3A5px%20auto%20%2Dwebkit%2Dfocus%2Dring%2Dcolor%3Boutline%2Doffset%3A%2D2px%7D%2Ebtn%2Efocus%2C%2Ebtn%3Afocus%2C%2Ebtn%3Ahover%7Bcolor%3A%23333%3Btext%2Ddecoration%3Anone%7D%2Ebtn%2Eactive%2C%2Ebtn%3Aactive%7Bbackground%2Dimage%3Anone%3Boutline%3A0%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%203px%205px%20rgba%280%2C0%2C0%2C%2E125%29%3Bbox%2Dshadow%3Ainset%200%203px%205px%20rgba%280%2C0%2C0%2C%2E125%29%7D%2Ebtn%2Edisabled%2C%2Ebtn%5Bdisabled%5D%2Cfieldset%5Bdisabled%5D%20%2Ebtn%7Bcursor%3Anot%2Dallowed%3Bfilter%3Aalpha%28opacity%3D65%29%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%3Bopacity%3A%2E65%7Da%2Ebtn%2Edisabled%2Cfieldset%5Bdisabled%5D%20a%2Ebtn%7Bpointer%2Devents%3Anone%7D%2Ebtn%2Ddefault%7Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23fff%3Bborder%2Dcolor%3A%23ccc%7D%2Ebtn%2Ddefault%2Efocus%2C%2Ebtn%2Ddefault%3Afocus%7Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23e6e6e6%3Bborder%2Dcolor%3A%238c8c8c%7D%2Ebtn%2Ddefault%3Ahover%7Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23e6e6e6%3Bborder%2Dcolor%3A%23adadad%7D%2Ebtn%2Ddefault%2Eactive%2C%2Ebtn%2Ddefault%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddefault%7Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23e6e6e6%3Bborder%2Dcolor%3A%23adadad%7D%2Ebtn%2Ddefault%2Eactive%2Efocus%2C%2Ebtn%2Ddefault%2Eactive%3Afocus%2C%2Ebtn%2Ddefault%2Eactive%3Ahover%2C%2Ebtn%2Ddefault%3Aactive%2Efocus%2C%2Ebtn%2Ddefault%3Aactive%3Afocus%2C%2Ebtn%2Ddefault%3Aactive%3Ahover%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddefault%2Efocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddefault%3Afocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddefault%3Ahover%7Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23d4d4d4%3Bborder%2Dcolor%3A%238c8c8c%7D%2Ebtn%2Ddefault%2Eactive%2C%2Ebtn%2Ddefault%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddefault%7Bbackground%2Dimage%3Anone%7D%2Ebtn%2Ddefault%2Edisabled%2C%2Ebtn%2Ddefault%2Edisabled%2Eactive%2C%2Ebtn%2Ddefault%2Edisabled%2Efocus%2C%2Ebtn%2Ddefault%2Edisabled%3Aactive%2C%2Ebtn%2Ddefault%2Edisabled%3Afocus%2C%2Ebtn%2Ddefault%2Edisabled%3Ahover%2C%2Ebtn%2Ddefault%5Bdisabled%5D%2C%2Ebtn%2Ddefault%5Bdisabled%5D%2Eactive%2C%2Ebtn%2Ddefault%5Bdisabled%5D%2Efocus%2C%2Ebtn%2Ddefault%5Bdisabled%5D%3Aactive%2C%2Ebtn%2Ddefault%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Ddefault%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddefault%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddefault%2Eactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddefault%2Efocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddefault%3Aactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddefault%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddefault%3Ahover%7Bbackground%2Dcolor%3A%23fff%3Bborder%2Dcolor%3A%23ccc%7D%2Ebtn%2Ddefault%20%2Ebadge%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23333%7D%2Ebtn%2Dprimary%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23337ab7%3Bborder%2Dcolor%3A%232e6da4%7D%2Ebtn%2Dprimary%2Efocus%2C%2Ebtn%2Dprimary%3Afocus%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23286090%3Bborder%2Dcolor%3A%23122b40%7D%2Ebtn%2Dprimary%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23286090%3Bborder%2Dcolor%3A%23204d74%7D%2Ebtn%2Dprimary%2Eactive%2C%2Ebtn%2Dprimary%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dprimary%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23286090%3Bborder%2Dcolor%3A%23204d74%7D%2Ebtn%2Dprimary%2Eactive%2Efocus%2C%2Ebtn%2Dprimary%2Eactive%3Afocus%2C%2Ebtn%2Dprimary%2Eactive%3Ahover%2C%2Ebtn%2Dprimary%3Aactive%2Efocus%2C%2Ebtn%2Dprimary%3Aactive%3Afocus%2C%2Ebtn%2Dprimary%3Aactive%3Ahover%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dprimary%2Efocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dprimary%3Afocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dprimary%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23204d74%3Bborder%2Dcolor%3A%23122b40%7D%2Ebtn%2Dprimary%2Eactive%2C%2Ebtn%2Dprimary%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dprimary%7Bbackground%2Dimage%3Anone%7D%2Ebtn%2Dprimary%2Edisabled%2C%2Ebtn%2Dprimary%2Edisabled%2Eactive%2C%2Ebtn%2Dprimary%2Edisabled%2Efocus%2C%2Ebtn%2Dprimary%2Edisabled%3Aactive%2C%2Ebtn%2Dprimary%2Edisabled%3Afocus%2C%2Ebtn%2Dprimary%2Edisabled%3Ahover%2C%2Ebtn%2Dprimary%5Bdisabled%5D%2C%2Ebtn%2Dprimary%5Bdisabled%5D%2Eactive%2C%2Ebtn%2Dprimary%5Bdisabled%5D%2Efocus%2C%2Ebtn%2Dprimary%5Bdisabled%5D%3Aactive%2C%2Ebtn%2Dprimary%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Dprimary%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dprimary%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dprimary%2Eactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dprimary%2Efocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dprimary%3Aactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dprimary%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dprimary%3Ahover%7Bbackground%2Dcolor%3A%23337ab7%3Bborder%2Dcolor%3A%232e6da4%7D%2Ebtn%2Dprimary%20%2Ebadge%7Bcolor%3A%23337ab7%3Bbackground%2Dcolor%3A%23fff%7D%2Ebtn%2Dsuccess%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%235cb85c%3Bborder%2Dcolor%3A%234cae4c%7D%2Ebtn%2Dsuccess%2Efocus%2C%2Ebtn%2Dsuccess%3Afocus%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23449d44%3Bborder%2Dcolor%3A%23255625%7D%2Ebtn%2Dsuccess%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23449d44%3Bborder%2Dcolor%3A%23398439%7D%2Ebtn%2Dsuccess%2Eactive%2C%2Ebtn%2Dsuccess%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dsuccess%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23449d44%3Bborder%2Dcolor%3A%23398439%7D%2Ebtn%2Dsuccess%2Eactive%2Efocus%2C%2Ebtn%2Dsuccess%2Eactive%3Afocus%2C%2Ebtn%2Dsuccess%2Eactive%3Ahover%2C%2Ebtn%2Dsuccess%3Aactive%2Efocus%2C%2Ebtn%2Dsuccess%3Aactive%3Afocus%2C%2Ebtn%2Dsuccess%3Aactive%3Ahover%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dsuccess%2Efocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dsuccess%3Afocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dsuccess%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23398439%3Bborder%2Dcolor%3A%23255625%7D%2Ebtn%2Dsuccess%2Eactive%2C%2Ebtn%2Dsuccess%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dsuccess%7Bbackground%2Dimage%3Anone%7D%2Ebtn%2Dsuccess%2Edisabled%2C%2Ebtn%2Dsuccess%2Edisabled%2Eactive%2C%2Ebtn%2Dsuccess%2Edisabled%2Efocus%2C%2Ebtn%2Dsuccess%2Edisabled%3Aactive%2C%2Ebtn%2Dsuccess%2Edisabled%3Afocus%2C%2Ebtn%2Dsuccess%2Edisabled%3Ahover%2C%2Ebtn%2Dsuccess%5Bdisabled%5D%2C%2Ebtn%2Dsuccess%5Bdisabled%5D%2Eactive%2C%2Ebtn%2Dsuccess%5Bdisabled%5D%2Efocus%2C%2Ebtn%2Dsuccess%5Bdisabled%5D%3Aactive%2C%2Ebtn%2Dsuccess%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Dsuccess%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dsuccess%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dsuccess%2Eactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dsuccess%2Efocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dsuccess%3Aactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dsuccess%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dsuccess%3Ahover%7Bbackground%2Dcolor%3A%235cb85c%3Bborder%2Dcolor%3A%234cae4c%7D%2Ebtn%2Dsuccess%20%2Ebadge%7Bcolor%3A%235cb85c%3Bbackground%2Dcolor%3A%23fff%7D%2Ebtn%2Dinfo%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%235bc0de%3Bborder%2Dcolor%3A%2346b8da%7D%2Ebtn%2Dinfo%2Efocus%2C%2Ebtn%2Dinfo%3Afocus%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%2331b0d5%3Bborder%2Dcolor%3A%231b6d85%7D%2Ebtn%2Dinfo%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%2331b0d5%3Bborder%2Dcolor%3A%23269abc%7D%2Ebtn%2Dinfo%2Eactive%2C%2Ebtn%2Dinfo%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dinfo%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%2331b0d5%3Bborder%2Dcolor%3A%23269abc%7D%2Ebtn%2Dinfo%2Eactive%2Efocus%2C%2Ebtn%2Dinfo%2Eactive%3Afocus%2C%2Ebtn%2Dinfo%2Eactive%3Ahover%2C%2Ebtn%2Dinfo%3Aactive%2Efocus%2C%2Ebtn%2Dinfo%3Aactive%3Afocus%2C%2Ebtn%2Dinfo%3Aactive%3Ahover%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dinfo%2Efocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dinfo%3Afocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dinfo%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23269abc%3Bborder%2Dcolor%3A%231b6d85%7D%2Ebtn%2Dinfo%2Eactive%2C%2Ebtn%2Dinfo%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dinfo%7Bbackground%2Dimage%3Anone%7D%2Ebtn%2Dinfo%2Edisabled%2C%2Ebtn%2Dinfo%2Edisabled%2Eactive%2C%2Ebtn%2Dinfo%2Edisabled%2Efocus%2C%2Ebtn%2Dinfo%2Edisabled%3Aactive%2C%2Ebtn%2Dinfo%2Edisabled%3Afocus%2C%2Ebtn%2Dinfo%2Edisabled%3Ahover%2C%2Ebtn%2Dinfo%5Bdisabled%5D%2C%2Ebtn%2Dinfo%5Bdisabled%5D%2Eactive%2C%2Ebtn%2Dinfo%5Bdisabled%5D%2Efocus%2C%2Ebtn%2Dinfo%5Bdisabled%5D%3Aactive%2C%2Ebtn%2Dinfo%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Dinfo%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dinfo%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dinfo%2Eactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dinfo%2Efocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dinfo%3Aactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dinfo%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dinfo%3Ahover%7Bbackground%2Dcolor%3A%235bc0de%3Bborder%2Dcolor%3A%2346b8da%7D%2Ebtn%2Dinfo%20%2Ebadge%7Bcolor%3A%235bc0de%3Bbackground%2Dcolor%3A%23fff%7D%2Ebtn%2Dwarning%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23f0ad4e%3Bborder%2Dcolor%3A%23eea236%7D%2Ebtn%2Dwarning%2Efocus%2C%2Ebtn%2Dwarning%3Afocus%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23ec971f%3Bborder%2Dcolor%3A%23985f0d%7D%2Ebtn%2Dwarning%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23ec971f%3Bborder%2Dcolor%3A%23d58512%7D%2Ebtn%2Dwarning%2Eactive%2C%2Ebtn%2Dwarning%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dwarning%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23ec971f%3Bborder%2Dcolor%3A%23d58512%7D%2Ebtn%2Dwarning%2Eactive%2Efocus%2C%2Ebtn%2Dwarning%2Eactive%3Afocus%2C%2Ebtn%2Dwarning%2Eactive%3Ahover%2C%2Ebtn%2Dwarning%3Aactive%2Efocus%2C%2Ebtn%2Dwarning%3Aactive%3Afocus%2C%2Ebtn%2Dwarning%3Aactive%3Ahover%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dwarning%2Efocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dwarning%3Afocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dwarning%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23d58512%3Bborder%2Dcolor%3A%23985f0d%7D%2Ebtn%2Dwarning%2Eactive%2C%2Ebtn%2Dwarning%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dwarning%7Bbackground%2Dimage%3Anone%7D%2Ebtn%2Dwarning%2Edisabled%2C%2Ebtn%2Dwarning%2Edisabled%2Eactive%2C%2Ebtn%2Dwarning%2Edisabled%2Efocus%2C%2Ebtn%2Dwarning%2Edisabled%3Aactive%2C%2Ebtn%2Dwarning%2Edisabled%3Afocus%2C%2Ebtn%2Dwarning%2Edisabled%3Ahover%2C%2Ebtn%2Dwarning%5Bdisabled%5D%2C%2Ebtn%2Dwarning%5Bdisabled%5D%2Eactive%2C%2Ebtn%2Dwarning%5Bdisabled%5D%2Efocus%2C%2Ebtn%2Dwarning%5Bdisabled%5D%3Aactive%2C%2Ebtn%2Dwarning%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Dwarning%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dwarning%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dwarning%2Eactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dwarning%2Efocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dwarning%3Aactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dwarning%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dwarning%3Ahover%7Bbackground%2Dcolor%3A%23f0ad4e%3Bborder%2Dcolor%3A%23eea236%7D%2Ebtn%2Dwarning%20%2Ebadge%7Bcolor%3A%23f0ad4e%3Bbackground%2Dcolor%3A%23fff%7D%2Ebtn%2Ddanger%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23d9534f%3Bborder%2Dcolor%3A%23d43f3a%7D%2Ebtn%2Ddanger%2Efocus%2C%2Ebtn%2Ddanger%3Afocus%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23c9302c%3Bborder%2Dcolor%3A%23761c19%7D%2Ebtn%2Ddanger%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23c9302c%3Bborder%2Dcolor%3A%23ac2925%7D%2Ebtn%2Ddanger%2Eactive%2C%2Ebtn%2Ddanger%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddanger%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23c9302c%3Bborder%2Dcolor%3A%23ac2925%7D%2Ebtn%2Ddanger%2Eactive%2Efocus%2C%2Ebtn%2Ddanger%2Eactive%3Afocus%2C%2Ebtn%2Ddanger%2Eactive%3Ahover%2C%2Ebtn%2Ddanger%3Aactive%2Efocus%2C%2Ebtn%2Ddanger%3Aactive%3Afocus%2C%2Ebtn%2Ddanger%3Aactive%3Ahover%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddanger%2Efocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddanger%3Afocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddanger%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23ac2925%3Bborder%2Dcolor%3A%23761c19%7D%2Ebtn%2Ddanger%2Eactive%2C%2Ebtn%2Ddanger%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddanger%7Bbackground%2Dimage%3Anone%7D%2Ebtn%2Ddanger%2Edisabled%2C%2Ebtn%2Ddanger%2Edisabled%2Eactive%2C%2Ebtn%2Ddanger%2Edisabled%2Efocus%2C%2Ebtn%2Ddanger%2Edisabled%3Aactive%2C%2Ebtn%2Ddanger%2Edisabled%3Afocus%2C%2Ebtn%2Ddanger%2Edisabled%3Ahover%2C%2Ebtn%2Ddanger%5Bdisabled%5D%2C%2Ebtn%2Ddanger%5Bdisabled%5D%2Eactive%2C%2Ebtn%2Ddanger%5Bdisabled%5D%2Efocus%2C%2Ebtn%2Ddanger%5Bdisabled%5D%3Aactive%2C%2Ebtn%2Ddanger%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Ddanger%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddanger%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddanger%2Eactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddanger%2Efocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddanger%3Aactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddanger%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddanger%3Ahover%7Bbackground%2Dcolor%3A%23d9534f%3Bborder%2Dcolor%3A%23d43f3a%7D%2Ebtn%2Ddanger%20%2Ebadge%7Bcolor%3A%23d9534f%3Bbackground%2Dcolor%3A%23fff%7D%2Ebtn%2Dlink%7Bfont%2Dweight%3A400%3Bcolor%3A%23337ab7%3Bborder%2Dradius%3A0%7D%2Ebtn%2Dlink%2C%2Ebtn%2Dlink%2Eactive%2C%2Ebtn%2Dlink%3Aactive%2C%2Ebtn%2Dlink%5Bdisabled%5D%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dlink%7Bbackground%2Dcolor%3Atransparent%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%7D%2Ebtn%2Dlink%2C%2Ebtn%2Dlink%3Aactive%2C%2Ebtn%2Dlink%3Afocus%2C%2Ebtn%2Dlink%3Ahover%7Bborder%2Dcolor%3Atransparent%7D%2Ebtn%2Dlink%3Afocus%2C%2Ebtn%2Dlink%3Ahover%7Bcolor%3A%2323527c%3Btext%2Ddecoration%3Aunderline%3Bbackground%2Dcolor%3Atransparent%7D%2Ebtn%2Dlink%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Dlink%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dlink%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dlink%3Ahover%7Bcolor%3A%23777%3Btext%2Ddecoration%3Anone%7D%2Ebtn%2Dgroup%2Dlg%3E%2Ebtn%2C%2Ebtn%2Dlg%7Bpadding%3A10px%2016px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A1%2E3333333%3Bborder%2Dradius%3A6px%7D%2Ebtn%2Dgroup%2Dsm%3E%2Ebtn%2C%2Ebtn%2Dsm%7Bpadding%3A5px%2010px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%3Bborder%2Dradius%3A3px%7D%2Ebtn%2Dgroup%2Dxs%3E%2Ebtn%2C%2Ebtn%2Dxs%7Bpadding%3A1px%205px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%3Bborder%2Dradius%3A3px%7D%2Ebtn%2Dblock%7Bdisplay%3Ablock%3Bwidth%3A100%25%7D%2Ebtn%2Dblock%2B%2Ebtn%2Dblock%7Bmargin%2Dtop%3A5px%7Dinput%5Btype%3Dbutton%5D%2Ebtn%2Dblock%2Cinput%5Btype%3Dreset%5D%2Ebtn%2Dblock%2Cinput%5Btype%3Dsubmit%5D%2Ebtn%2Dblock%7Bwidth%3A100%25%7D%2Efade%7Bopacity%3A0%3B%2Dwebkit%2Dtransition%3Aopacity%20%2E15s%20linear%3B%2Do%2Dtransition%3Aopacity%20%2E15s%20linear%3Btransition%3Aopacity%20%2E15s%20linear%7D%2Efade%2Ein%7Bopacity%3A1%7D%2Ecollapse%7Bdisplay%3Anone%7D%2Ecollapse%2Ein%7Bdisplay%3Ablock%7Dtr%2Ecollapse%2Ein%7Bdisplay%3Atable%2Drow%7Dtbody%2Ecollapse%2Ein%7Bdisplay%3Atable%2Drow%2Dgroup%7D%2Ecollapsing%7Bposition%3Arelative%3Bheight%3A0%3Boverflow%3Ahidden%3B%2Dwebkit%2Dtransition%2Dtiming%2Dfunction%3Aease%3B%2Do%2Dtransition%2Dtiming%2Dfunction%3Aease%3Btransition%2Dtiming%2Dfunction%3Aease%3B%2Dwebkit%2Dtransition%2Dduration%3A%2E35s%3B%2Do%2Dtransition%2Dduration%3A%2E35s%3Btransition%2Dduration%3A%2E35s%3B%2Dwebkit%2Dtransition%2Dproperty%3Aheight%2Cvisibility%3B%2Do%2Dtransition%2Dproperty%3Aheight%2Cvisibility%3Btransition%2Dproperty%3Aheight%2Cvisibility%7D%2Ecaret%7Bdisplay%3Ainline%2Dblock%3Bwidth%3A0%3Bheight%3A0%3Bmargin%2Dleft%3A2px%3Bvertical%2Dalign%3Amiddle%3Bborder%2Dtop%3A4px%20dashed%3Bborder%2Dtop%3A4px%20solid%5C9%3Bborder%2Dright%3A4px%20solid%20transparent%3Bborder%2Dleft%3A4px%20solid%20transparent%7D%2Edropdown%2C%2Edropup%7Bposition%3Arelative%7D%2Edropdown%2Dtoggle%3Afocus%7Boutline%3A0%7D%2Edropdown%2Dmenu%7Bposition%3Aabsolute%3Btop%3A100%25%3Bleft%3A0%3Bz%2Dindex%3A1000%3Bdisplay%3Anone%3Bfloat%3Aleft%3Bmin%2Dwidth%3A160px%3Bpadding%3A5px%200%3Bmargin%3A2px%200%200%3Bfont%2Dsize%3A14px%3Btext%2Dalign%3Aleft%3Blist%2Dstyle%3Anone%3Bbackground%2Dcolor%3A%23fff%3B%2Dwebkit%2Dbackground%2Dclip%3Apadding%2Dbox%3Bbackground%2Dclip%3Apadding%2Dbox%3Bborder%3A1px%20solid%20%23ccc%3Bborder%3A1px%20solid%20rgba%280%2C0%2C0%2C%2E15%29%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dbox%2Dshadow%3A0%206px%2012px%20rgba%280%2C0%2C0%2C%2E175%29%3Bbox%2Dshadow%3A0%206px%2012px%20rgba%280%2C0%2C0%2C%2E175%29%7D%2Edropdown%2Dmenu%2Epull%2Dright%7Bright%3A0%3Bleft%3Aauto%7D%2Edropdown%2Dmenu%20%2Edivider%7Bheight%3A1px%3Bmargin%3A9px%200%3Boverflow%3Ahidden%3Bbackground%2Dcolor%3A%23e5e5e5%7D%2Edropdown%2Dmenu%3Eli%3Ea%7Bdisplay%3Ablock%3Bpadding%3A3px%2020px%3Bclear%3Aboth%3Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23333%3Bwhite%2Dspace%3Anowrap%7D%2Edropdown%2Dmenu%3Eli%3Ea%3Afocus%2C%2Edropdown%2Dmenu%3Eli%3Ea%3Ahover%7Bcolor%3A%23262626%3Btext%2Ddecoration%3Anone%3Bbackground%2Dcolor%3A%23f5f5f5%7D%2Edropdown%2Dmenu%3E%2Eactive%3Ea%2C%2Edropdown%2Dmenu%3E%2Eactive%3Ea%3Afocus%2C%2Edropdown%2Dmenu%3E%2Eactive%3Ea%3Ahover%7Bcolor%3A%23fff%3Btext%2Ddecoration%3Anone%3Bbackground%2Dcolor%3A%23337ab7%3Boutline%3A0%7D%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%2C%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Afocus%2C%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Ahover%7Bcolor%3A%23777%7D%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Afocus%2C%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Ahover%7Btext%2Ddecoration%3Anone%3Bcursor%3Anot%2Dallowed%3Bbackground%2Dcolor%3Atransparent%3Bbackground%2Dimage%3Anone%3Bfilter%3Aprogid%3ADXImageTransform%2EMicrosoft%2Egradient%28enabled%3Dfalse%29%7D%2Eopen%3E%2Edropdown%2Dmenu%7Bdisplay%3Ablock%7D%2Eopen%3Ea%7Boutline%3A0%7D%2Edropdown%2Dmenu%2Dright%7Bright%3A0%3Bleft%3Aauto%7D%2Edropdown%2Dmenu%2Dleft%7Bright%3Aauto%3Bleft%3A0%7D%2Edropdown%2Dheader%7Bdisplay%3Ablock%3Bpadding%3A3px%2020px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23777%3Bwhite%2Dspace%3Anowrap%7D%2Edropdown%2Dbackdrop%7Bposition%3Afixed%3Btop%3A0%3Bright%3A0%3Bbottom%3A0%3Bleft%3A0%3Bz%2Dindex%3A990%7D%2Epull%2Dright%3E%2Edropdown%2Dmenu%7Bright%3A0%3Bleft%3Aauto%7D%2Edropup%20%2Ecaret%2C%2Enavbar%2Dfixed%2Dbottom%20%2Edropdown%20%2Ecaret%7Bcontent%3A%22%22%3Bborder%2Dtop%3A0%3Bborder%2Dbottom%3A4px%20dashed%3Bborder%2Dbottom%3A4px%20solid%5C9%7D%2Edropup%20%2Edropdown%2Dmenu%2C%2Enavbar%2Dfixed%2Dbottom%20%2Edropdown%20%2Edropdown%2Dmenu%7Btop%3Aauto%3Bbottom%3A100%25%3Bmargin%2Dbottom%3A2px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dright%20%2Edropdown%2Dmenu%7Bright%3A0%3Bleft%3Aauto%7D%2Enavbar%2Dright%20%2Edropdown%2Dmenu%2Dleft%7Bright%3Aauto%3Bleft%3A0%7D%7D%2Ebtn%2Dgroup%2C%2Ebtn%2Dgroup%2Dvertical%7Bposition%3Arelative%3Bdisplay%3Ainline%2Dblock%3Bvertical%2Dalign%3Amiddle%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2C%2Ebtn%2Dgroup%3E%2Ebtn%7Bposition%3Arelative%3Bfloat%3Aleft%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Eactive%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%3Aactive%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%3Afocus%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%3Ahover%2C%2Ebtn%2Dgroup%3E%2Ebtn%2Eactive%2C%2Ebtn%2Dgroup%3E%2Ebtn%3Aactive%2C%2Ebtn%2Dgroup%3E%2Ebtn%3Afocus%2C%2Ebtn%2Dgroup%3E%2Ebtn%3Ahover%7Bz%2Dindex%3A2%7D%2Ebtn%2Dgroup%20%2Ebtn%2B%2Ebtn%2C%2Ebtn%2Dgroup%20%2Ebtn%2B%2Ebtn%2Dgroup%2C%2Ebtn%2Dgroup%20%2Ebtn%2Dgroup%2B%2Ebtn%2C%2Ebtn%2Dgroup%20%2Ebtn%2Dgroup%2B%2Ebtn%2Dgroup%7Bmargin%2Dleft%3A%2D1px%7D%2Ebtn%2Dtoolbar%7Bmargin%2Dleft%3A%2D5px%7D%2Ebtn%2Dtoolbar%20%2Ebtn%2C%2Ebtn%2Dtoolbar%20%2Ebtn%2Dgroup%2C%2Ebtn%2Dtoolbar%20%2Einput%2Dgroup%7Bfloat%3Aleft%7D%2Ebtn%2Dtoolbar%3E%2Ebtn%2C%2Ebtn%2Dtoolbar%3E%2Ebtn%2Dgroup%2C%2Ebtn%2Dtoolbar%3E%2Einput%2Dgroup%7Bmargin%2Dleft%3A5px%7D%2Ebtn%2Dgroup%3E%2Ebtn%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%3Anot%28%2Edropdown%2Dtoggle%29%7Bborder%2Dradius%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%3Afirst%2Dchild%7Bmargin%2Dleft%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%3Afirst%2Dchild%3Anot%28%3Alast%2Dchild%29%3Anot%28%2Edropdown%2Dtoggle%29%7Bborder%2Dtop%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dright%2Dradius%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%3Alast%2Dchild%3Anot%28%3Afirst%2Dchild%29%2C%2Ebtn%2Dgroup%3E%2Edropdown%2Dtoggle%3Anot%28%3Afirst%2Dchild%29%7Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%2Dgroup%7Bfloat%3Aleft%7D%2Ebtn%2Dgroup%3E%2Ebtn%2Dgroup%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%3E%2Ebtn%7Bborder%2Dradius%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%2Dgroup%3Afirst%2Dchild%3Anot%28%3Alast%2Dchild%29%3E%2Ebtn%3Alast%2Dchild%2C%2Ebtn%2Dgroup%3E%2Ebtn%2Dgroup%3Afirst%2Dchild%3Anot%28%3Alast%2Dchild%29%3E%2Edropdown%2Dtoggle%7Bborder%2Dtop%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dright%2Dradius%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%2Dgroup%3Alast%2Dchild%3Anot%28%3Afirst%2Dchild%29%3E%2Ebtn%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A0%7D%2Ebtn%2Dgroup%20%2Edropdown%2Dtoggle%3Aactive%2C%2Ebtn%2Dgroup%2Eopen%20%2Edropdown%2Dtoggle%7Boutline%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%2B%2Edropdown%2Dtoggle%7Bpadding%2Dright%3A8px%3Bpadding%2Dleft%3A8px%7D%2Ebtn%2Dgroup%3E%2Ebtn%2Dlg%2B%2Edropdown%2Dtoggle%7Bpadding%2Dright%3A12px%3Bpadding%2Dleft%3A12px%7D%2Ebtn%2Dgroup%2Eopen%20%2Edropdown%2Dtoggle%7B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%203px%205px%20rgba%280%2C0%2C0%2C%2E125%29%3Bbox%2Dshadow%3Ainset%200%203px%205px%20rgba%280%2C0%2C0%2C%2E125%29%7D%2Ebtn%2Dgroup%2Eopen%20%2Edropdown%2Dtoggle%2Ebtn%2Dlink%7B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%7D%2Ebtn%20%2Ecaret%7Bmargin%2Dleft%3A0%7D%2Ebtn%2Dlg%20%2Ecaret%7Bborder%2Dwidth%3A5px%205px%200%3Bborder%2Dbottom%2Dwidth%3A0%7D%2Edropup%20%2Ebtn%2Dlg%20%2Ecaret%7Bborder%2Dwidth%3A0%205px%205px%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3E%2Ebtn%7Bdisplay%3Ablock%3Bfloat%3Anone%3Bwidth%3A100%25%3Bmax%2Dwidth%3A100%25%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3E%2Ebtn%7Bfloat%3Anone%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2B%2Ebtn%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2B%2Ebtn%2Dgroup%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%2B%2Ebtn%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%2B%2Ebtn%2Dgroup%7Bmargin%2Dtop%3A%2D1px%3Bmargin%2Dleft%3A0%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%7Bborder%2Dradius%3A0%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%3Afirst%2Dchild%3Anot%28%3Alast%2Dchild%29%7Bborder%2Dtop%2Dright%2Dradius%3A4px%3Bborder%2Dbottom%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A0%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%3Alast%2Dchild%3Anot%28%3Afirst%2Dchild%29%7Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dtop%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A4px%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%3E%2Ebtn%7Bborder%2Dradius%3A0%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Afirst%2Dchild%3Anot%28%3Alast%2Dchild%29%3E%2Ebtn%3Alast%2Dchild%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Afirst%2Dchild%3Anot%28%3Alast%2Dchild%29%3E%2Edropdown%2Dtoggle%7Bborder%2Dbottom%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A0%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Alast%2Dchild%3Anot%28%3Afirst%2Dchild%29%3E%2Ebtn%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dtop%2Dright%2Dradius%3A0%7D%2Ebtn%2Dgroup%2Djustified%7Bdisplay%3Atable%3Bwidth%3A100%25%3Btable%2Dlayout%3Afixed%3Bborder%2Dcollapse%3Aseparate%7D%2Ebtn%2Dgroup%2Djustified%3E%2Ebtn%2C%2Ebtn%2Dgroup%2Djustified%3E%2Ebtn%2Dgroup%7Bdisplay%3Atable%2Dcell%3Bfloat%3Anone%3Bwidth%3A1%25%7D%2Ebtn%2Dgroup%2Djustified%3E%2Ebtn%2Dgroup%20%2Ebtn%7Bwidth%3A100%25%7D%2Ebtn%2Dgroup%2Djustified%3E%2Ebtn%2Dgroup%20%2Edropdown%2Dmenu%7Bleft%3Aauto%7D%5Bdata%2Dtoggle%3Dbuttons%5D%3E%2Ebtn%20input%5Btype%3Dcheckbox%5D%2C%5Bdata%2Dtoggle%3Dbuttons%5D%3E%2Ebtn%20input%5Btype%3Dradio%5D%2C%5Bdata%2Dtoggle%3Dbuttons%5D%3E%2Ebtn%2Dgroup%3E%2Ebtn%20input%5Btype%3Dcheckbox%5D%2C%5Bdata%2Dtoggle%3Dbuttons%5D%3E%2Ebtn%2Dgroup%3E%2Ebtn%20input%5Btype%3Dradio%5D%7Bposition%3Aabsolute%3Bclip%3Arect%280%2C0%2C0%2C0%29%3Bpointer%2Devents%3Anone%7D%2Einput%2Dgroup%7Bposition%3Arelative%3Bdisplay%3Atable%3Bborder%2Dcollapse%3Aseparate%7D%2Einput%2Dgroup%5Bclass%2A%3Dcol%2D%5D%7Bfloat%3Anone%3Bpadding%2Dright%3A0%3Bpadding%2Dleft%3A0%7D%2Einput%2Dgroup%20%2Eform%2Dcontrol%7Bposition%3Arelative%3Bz%2Dindex%3A2%3Bfloat%3Aleft%3Bwidth%3A100%25%3Bmargin%2Dbottom%3A0%7D%2Einput%2Dgroup%2Dlg%3E%2Eform%2Dcontrol%2C%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Daddon%2C%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bheight%3A46px%3Bpadding%3A10px%2016px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A1%2E3333333%3Bborder%2Dradius%3A6px%7Dselect%2Einput%2Dgroup%2Dlg%3E%2Eform%2Dcontrol%2Cselect%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Daddon%2Cselect%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bheight%3A46px%3Bline%2Dheight%3A46px%7Dselect%5Bmultiple%5D%2Einput%2Dgroup%2Dlg%3E%2Eform%2Dcontrol%2Cselect%5Bmultiple%5D%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Daddon%2Cselect%5Bmultiple%5D%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%2Ctextarea%2Einput%2Dgroup%2Dlg%3E%2Eform%2Dcontrol%2Ctextarea%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Daddon%2Ctextarea%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bheight%3Aauto%7D%2Einput%2Dgroup%2Dsm%3E%2Eform%2Dcontrol%2C%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Daddon%2C%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bheight%3A30px%3Bpadding%3A5px%2010px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%3Bborder%2Dradius%3A3px%7Dselect%2Einput%2Dgroup%2Dsm%3E%2Eform%2Dcontrol%2Cselect%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Daddon%2Cselect%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bheight%3A30px%3Bline%2Dheight%3A30px%7Dselect%5Bmultiple%5D%2Einput%2Dgroup%2Dsm%3E%2Eform%2Dcontrol%2Cselect%5Bmultiple%5D%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Daddon%2Cselect%5Bmultiple%5D%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%2Ctextarea%2Einput%2Dgroup%2Dsm%3E%2Eform%2Dcontrol%2Ctextarea%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Daddon%2Ctextarea%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bheight%3Aauto%7D%2Einput%2Dgroup%20%2Eform%2Dcontrol%2C%2Einput%2Dgroup%2Daddon%2C%2Einput%2Dgroup%2Dbtn%7Bdisplay%3Atable%2Dcell%7D%2Einput%2Dgroup%20%2Eform%2Dcontrol%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%2C%2Einput%2Dgroup%2Daddon%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%2C%2Einput%2Dgroup%2Dbtn%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%7Bborder%2Dradius%3A0%7D%2Einput%2Dgroup%2Daddon%2C%2Einput%2Dgroup%2Dbtn%7Bwidth%3A1%25%3Bwhite%2Dspace%3Anowrap%3Bvertical%2Dalign%3Amiddle%7D%2Einput%2Dgroup%2Daddon%7Bpadding%3A6px%2012px%3Bfont%2Dsize%3A14px%3Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%3Bcolor%3A%23555%3Btext%2Dalign%3Acenter%3Bbackground%2Dcolor%3A%23eee%3Bborder%3A1px%20solid%20%23ccc%3Bborder%2Dradius%3A4px%7D%2Einput%2Dgroup%2Daddon%2Einput%2Dsm%7Bpadding%3A5px%2010px%3Bfont%2Dsize%3A12px%3Bborder%2Dradius%3A3px%7D%2Einput%2Dgroup%2Daddon%2Einput%2Dlg%7Bpadding%3A10px%2016px%3Bfont%2Dsize%3A18px%3Bborder%2Dradius%3A6px%7D%2Einput%2Dgroup%2Daddon%20input%5Btype%3Dcheckbox%5D%2C%2Einput%2Dgroup%2Daddon%20input%5Btype%3Dradio%5D%7Bmargin%2Dtop%3A0%7D%2Einput%2Dgroup%20%2Eform%2Dcontrol%3Afirst%2Dchild%2C%2Einput%2Dgroup%2Daddon%3Afirst%2Dchild%2C%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Ebtn%2Dgroup%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Edropdown%2Dtoggle%2C%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Ebtn%2Dgroup%3Anot%28%3Alast%2Dchild%29%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Ebtn%3Anot%28%3Alast%2Dchild%29%3Anot%28%2Edropdown%2Dtoggle%29%7Bborder%2Dtop%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dright%2Dradius%3A0%7D%2Einput%2Dgroup%2Daddon%3Afirst%2Dchild%7Bborder%2Dright%3A0%7D%2Einput%2Dgroup%20%2Eform%2Dcontrol%3Alast%2Dchild%2C%2Einput%2Dgroup%2Daddon%3Alast%2Dchild%2C%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Ebtn%2Dgroup%3Anot%28%3Afirst%2Dchild%29%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Ebtn%3Anot%28%3Afirst%2Dchild%29%2C%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Ebtn%2Dgroup%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Edropdown%2Dtoggle%7Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A0%7D%2Einput%2Dgroup%2Daddon%3Alast%2Dchild%7Bborder%2Dleft%3A0%7D%2Einput%2Dgroup%2Dbtn%7Bposition%3Arelative%3Bfont%2Dsize%3A0%3Bwhite%2Dspace%3Anowrap%7D%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bposition%3Arelative%7D%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%2B%2Ebtn%7Bmargin%2Dleft%3A%2D1px%7D%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%3Aactive%2C%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%3Afocus%2C%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%3Ahover%7Bz%2Dindex%3A2%7D%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Ebtn%2Dgroup%7Bmargin%2Dright%3A%2D1px%7D%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Ebtn%2Dgroup%7Bz%2Dindex%3A2%3Bmargin%2Dleft%3A%2D1px%7D%2Enav%7Bpadding%2Dleft%3A0%3Bmargin%2Dbottom%3A0%3Blist%2Dstyle%3Anone%7D%2Enav%3Eli%7Bposition%3Arelative%3Bdisplay%3Ablock%7D%2Enav%3Eli%3Ea%7Bposition%3Arelative%3Bdisplay%3Ablock%3Bpadding%3A10px%2015px%7D%2Enav%3Eli%3Ea%3Afocus%2C%2Enav%3Eli%3Ea%3Ahover%7Btext%2Ddecoration%3Anone%3Bbackground%2Dcolor%3A%23eee%7D%2Enav%3Eli%2Edisabled%3Ea%7Bcolor%3A%23777%7D%2Enav%3Eli%2Edisabled%3Ea%3Afocus%2C%2Enav%3Eli%2Edisabled%3Ea%3Ahover%7Bcolor%3A%23777%3Btext%2Ddecoration%3Anone%3Bcursor%3Anot%2Dallowed%3Bbackground%2Dcolor%3Atransparent%7D%2Enav%20%2Eopen%3Ea%2C%2Enav%20%2Eopen%3Ea%3Afocus%2C%2Enav%20%2Eopen%3Ea%3Ahover%7Bbackground%2Dcolor%3A%23eee%3Bborder%2Dcolor%3A%23337ab7%7D%2Enav%20%2Enav%2Ddivider%7Bheight%3A1px%3Bmargin%3A9px%200%3Boverflow%3Ahidden%3Bbackground%2Dcolor%3A%23e5e5e5%7D%2Enav%3Eli%3Ea%3Eimg%7Bmax%2Dwidth%3Anone%7D%2Enav%2Dtabs%7Bborder%2Dbottom%3A1px%20solid%20%23ddd%7D%2Enav%2Dtabs%3Eli%7Bfloat%3Aleft%3Bmargin%2Dbottom%3A%2D1px%7D%2Enav%2Dtabs%3Eli%3Ea%7Bmargin%2Dright%3A2px%3Bline%2Dheight%3A1%2E42857143%3Bborder%3A1px%20solid%20transparent%3Bborder%2Dradius%3A4px%204px%200%200%7D%2Enav%2Dtabs%3Eli%3Ea%3Ahover%7Bborder%2Dcolor%3A%23eee%20%23eee%20%23ddd%7D%2Enav%2Dtabs%3Eli%2Eactive%3Ea%2C%2Enav%2Dtabs%3Eli%2Eactive%3Ea%3Afocus%2C%2Enav%2Dtabs%3Eli%2Eactive%3Ea%3Ahover%7Bcolor%3A%23555%3Bcursor%3Adefault%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20%23ddd%3Bborder%2Dbottom%2Dcolor%3Atransparent%7D%2Enav%2Dtabs%2Enav%2Djustified%7Bwidth%3A100%25%3Bborder%2Dbottom%3A0%7D%2Enav%2Dtabs%2Enav%2Djustified%3Eli%7Bfloat%3Anone%7D%2Enav%2Dtabs%2Enav%2Djustified%3Eli%3Ea%7Bmargin%2Dbottom%3A5px%3Btext%2Dalign%3Acenter%7D%2Enav%2Dtabs%2Enav%2Djustified%3E%2Edropdown%20%2Edropdown%2Dmenu%7Btop%3Aauto%3Bleft%3Aauto%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enav%2Dtabs%2Enav%2Djustified%3Eli%7Bdisplay%3Atable%2Dcell%3Bwidth%3A1%25%7D%2Enav%2Dtabs%2Enav%2Djustified%3Eli%3Ea%7Bmargin%2Dbottom%3A0%7D%7D%2Enav%2Dtabs%2Enav%2Djustified%3Eli%3Ea%7Bmargin%2Dright%3A0%3Bborder%2Dradius%3A4px%7D%2Enav%2Dtabs%2Enav%2Djustified%3E%2Eactive%3Ea%2C%2Enav%2Dtabs%2Enav%2Djustified%3E%2Eactive%3Ea%3Afocus%2C%2Enav%2Dtabs%2Enav%2Djustified%3E%2Eactive%3Ea%3Ahover%7Bborder%3A1px%20solid%20%23ddd%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enav%2Dtabs%2Enav%2Djustified%3Eli%3Ea%7Bborder%2Dbottom%3A1px%20solid%20%23ddd%3Bborder%2Dradius%3A4px%204px%200%200%7D%2Enav%2Dtabs%2Enav%2Djustified%3E%2Eactive%3Ea%2C%2Enav%2Dtabs%2Enav%2Djustified%3E%2Eactive%3Ea%3Afocus%2C%2Enav%2Dtabs%2Enav%2Djustified%3E%2Eactive%3Ea%3Ahover%7Bborder%2Dbottom%2Dcolor%3A%23fff%7D%7D%2Enav%2Dpills%3Eli%7Bfloat%3Aleft%7D%2Enav%2Dpills%3Eli%3Ea%7Bborder%2Dradius%3A4px%7D%2Enav%2Dpills%3Eli%2Bli%7Bmargin%2Dleft%3A2px%7D%2Enav%2Dpills%3Eli%2Eactive%3Ea%2C%2Enav%2Dpills%3Eli%2Eactive%3Ea%3Afocus%2C%2Enav%2Dpills%3Eli%2Eactive%3Ea%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23337ab7%7D%2Enav%2Dstacked%3Eli%7Bfloat%3Anone%7D%2Enav%2Dstacked%3Eli%2Bli%7Bmargin%2Dtop%3A2px%3Bmargin%2Dleft%3A0%7D%2Enav%2Djustified%7Bwidth%3A100%25%7D%2Enav%2Djustified%3Eli%7Bfloat%3Anone%7D%2Enav%2Djustified%3Eli%3Ea%7Bmargin%2Dbottom%3A5px%3Btext%2Dalign%3Acenter%7D%2Enav%2Djustified%3E%2Edropdown%20%2Edropdown%2Dmenu%7Btop%3Aauto%3Bleft%3Aauto%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enav%2Djustified%3Eli%7Bdisplay%3Atable%2Dcell%3Bwidth%3A1%25%7D%2Enav%2Djustified%3Eli%3Ea%7Bmargin%2Dbottom%3A0%7D%7D%2Enav%2Dtabs%2Djustified%7Bborder%2Dbottom%3A0%7D%2Enav%2Dtabs%2Djustified%3Eli%3Ea%7Bmargin%2Dright%3A0%3Bborder%2Dradius%3A4px%7D%2Enav%2Dtabs%2Djustified%3E%2Eactive%3Ea%2C%2Enav%2Dtabs%2Djustified%3E%2Eactive%3Ea%3Afocus%2C%2Enav%2Dtabs%2Djustified%3E%2Eactive%3Ea%3Ahover%7Bborder%3A1px%20solid%20%23ddd%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enav%2Dtabs%2Djustified%3Eli%3Ea%7Bborder%2Dbottom%3A1px%20solid%20%23ddd%3Bborder%2Dradius%3A4px%204px%200%200%7D%2Enav%2Dtabs%2Djustified%3E%2Eactive%3Ea%2C%2Enav%2Dtabs%2Djustified%3E%2Eactive%3Ea%3Afocus%2C%2Enav%2Dtabs%2Djustified%3E%2Eactive%3Ea%3Ahover%7Bborder%2Dbottom%2Dcolor%3A%23fff%7D%7D%2Etab%2Dcontent%3E%2Etab%2Dpane%7Bdisplay%3Anone%7D%2Etab%2Dcontent%3E%2Eactive%7Bdisplay%3Ablock%7D%2Enav%2Dtabs%20%2Edropdown%2Dmenu%7Bmargin%2Dtop%3A%2D1px%3Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dtop%2Dright%2Dradius%3A0%7D%2Enavbar%7Bposition%3Arelative%3Bmin%2Dheight%3A50px%3Bmargin%2Dbottom%3A20px%3Bborder%3A1px%20solid%20transparent%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%7Bborder%2Dradius%3A4px%7D%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dheader%7Bfloat%3Aleft%7D%7D%2Enavbar%2Dcollapse%7Bpadding%2Dright%3A15px%3Bpadding%2Dleft%3A15px%3Boverflow%2Dx%3Avisible%3B%2Dwebkit%2Doverflow%2Dscrolling%3Atouch%3Bborder%2Dtop%3A1px%20solid%20transparent%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%200%20rgba%28255%2C255%2C255%2C%2E1%29%3Bbox%2Dshadow%3Ainset%200%201px%200%20rgba%28255%2C255%2C255%2C%2E1%29%7D%2Enavbar%2Dcollapse%2Ein%7Boverflow%2Dy%3Aauto%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dcollapse%7Bwidth%3Aauto%3Bborder%2Dtop%3A0%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%7D%2Enavbar%2Dcollapse%2Ecollapse%7Bdisplay%3Ablock%21important%3Bheight%3Aauto%21important%3Bpadding%2Dbottom%3A0%3Boverflow%3Avisible%21important%7D%2Enavbar%2Dcollapse%2Ein%7Boverflow%2Dy%3Avisible%7D%2Enavbar%2Dfixed%2Dbottom%20%2Enavbar%2Dcollapse%2C%2Enavbar%2Dfixed%2Dtop%20%2Enavbar%2Dcollapse%2C%2Enavbar%2Dstatic%2Dtop%20%2Enavbar%2Dcollapse%7Bpadding%2Dright%3A0%3Bpadding%2Dleft%3A0%7D%7D%2Enavbar%2Dfixed%2Dbottom%20%2Enavbar%2Dcollapse%2C%2Enavbar%2Dfixed%2Dtop%20%2Enavbar%2Dcollapse%7Bmax%2Dheight%3A340px%7D%40media%20%28max%2Ddevice%2Dwidth%3A480px%29%20and%20%28orientation%3Alandscape%29%7B%2Enavbar%2Dfixed%2Dbottom%20%2Enavbar%2Dcollapse%2C%2Enavbar%2Dfixed%2Dtop%20%2Enavbar%2Dcollapse%7Bmax%2Dheight%3A200px%7D%7D%2Econtainer%2Dfluid%3E%2Enavbar%2Dcollapse%2C%2Econtainer%2Dfluid%3E%2Enavbar%2Dheader%2C%2Econtainer%3E%2Enavbar%2Dcollapse%2C%2Econtainer%3E%2Enavbar%2Dheader%7Bmargin%2Dright%3A%2D15px%3Bmargin%2Dleft%3A%2D15px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Econtainer%2Dfluid%3E%2Enavbar%2Dcollapse%2C%2Econtainer%2Dfluid%3E%2Enavbar%2Dheader%2C%2Econtainer%3E%2Enavbar%2Dcollapse%2C%2Econtainer%3E%2Enavbar%2Dheader%7Bmargin%2Dright%3A0%3Bmargin%2Dleft%3A0%7D%7D%2Enavbar%2Dstatic%2Dtop%7Bz%2Dindex%3A1000%3Bborder%2Dwidth%3A0%200%201px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dstatic%2Dtop%7Bborder%2Dradius%3A0%7D%7D%2Enavbar%2Dfixed%2Dbottom%2C%2Enavbar%2Dfixed%2Dtop%7Bposition%3Afixed%3Bright%3A0%3Bleft%3A0%3Bz%2Dindex%3A1030%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dfixed%2Dbottom%2C%2Enavbar%2Dfixed%2Dtop%7Bborder%2Dradius%3A0%7D%7D%2Enavbar%2Dfixed%2Dtop%7Btop%3A0%3Bborder%2Dwidth%3A0%200%201px%7D%2Enavbar%2Dfixed%2Dbottom%7Bbottom%3A0%3Bmargin%2Dbottom%3A0%3Bborder%2Dwidth%3A1px%200%200%7D%2Enavbar%2Dbrand%7Bfloat%3Aleft%3Bheight%3A50px%3Bpadding%3A15px%2015px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A20px%7D%2Enavbar%2Dbrand%3Afocus%2C%2Enavbar%2Dbrand%3Ahover%7Btext%2Ddecoration%3Anone%7D%2Enavbar%2Dbrand%3Eimg%7Bdisplay%3Ablock%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%3E%2Econtainer%20%2Enavbar%2Dbrand%2C%2Enavbar%3E%2Econtainer%2Dfluid%20%2Enavbar%2Dbrand%7Bmargin%2Dleft%3A%2D15px%7D%7D%2Enavbar%2Dtoggle%7Bposition%3Arelative%3Bfloat%3Aright%3Bpadding%3A9px%2010px%3Bmargin%2Dtop%3A8px%3Bmargin%2Dright%3A15px%3Bmargin%2Dbottom%3A8px%3Bbackground%2Dcolor%3Atransparent%3Bbackground%2Dimage%3Anone%3Bborder%3A1px%20solid%20transparent%3Bborder%2Dradius%3A4px%7D%2Enavbar%2Dtoggle%3Afocus%7Boutline%3A0%7D%2Enavbar%2Dtoggle%20%2Eicon%2Dbar%7Bdisplay%3Ablock%3Bwidth%3A22px%3Bheight%3A2px%3Bborder%2Dradius%3A1px%7D%2Enavbar%2Dtoggle%20%2Eicon%2Dbar%2B%2Eicon%2Dbar%7Bmargin%2Dtop%3A4px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dtoggle%7Bdisplay%3Anone%7D%7D%2Enavbar%2Dnav%7Bmargin%3A7%2E5px%20%2D15px%7D%2Enavbar%2Dnav%3Eli%3Ea%7Bpadding%2Dtop%3A10px%3Bpadding%2Dbottom%3A10px%3Bline%2Dheight%3A20px%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%7Bposition%3Astatic%3Bfloat%3Anone%3Bwidth%3Aauto%3Bmargin%2Dtop%3A0%3Bbackground%2Dcolor%3Atransparent%3Bborder%3A0%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%7D%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%20%2Edropdown%2Dheader%2C%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%7Bpadding%3A5px%2015px%205px%2025px%7D%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%7Bline%2Dheight%3A20px%7D%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%3Afocus%2C%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%3Ahover%7Bbackground%2Dimage%3Anone%7D%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dnav%7Bfloat%3Aleft%3Bmargin%3A0%7D%2Enavbar%2Dnav%3Eli%7Bfloat%3Aleft%7D%2Enavbar%2Dnav%3Eli%3Ea%7Bpadding%2Dtop%3A15px%3Bpadding%2Dbottom%3A15px%7D%7D%2Enavbar%2Dform%7Bpadding%3A10px%2015px%3Bmargin%2Dtop%3A8px%3Bmargin%2Dright%3A%2D15px%3Bmargin%2Dbottom%3A8px%3Bmargin%2Dleft%3A%2D15px%3Bborder%2Dtop%3A1px%20solid%20transparent%3Bborder%2Dbottom%3A1px%20solid%20transparent%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%200%20rgba%28255%2C255%2C255%2C%2E1%29%2C0%201px%200%20rgba%28255%2C255%2C255%2C%2E1%29%3Bbox%2Dshadow%3Ainset%200%201px%200%20rgba%28255%2C255%2C255%2C%2E1%29%2C0%201px%200%20rgba%28255%2C255%2C255%2C%2E1%29%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dform%20%2Eform%2Dgroup%7Bdisplay%3Ainline%2Dblock%3Bmargin%2Dbottom%3A0%3Bvertical%2Dalign%3Amiddle%7D%2Enavbar%2Dform%20%2Eform%2Dcontrol%7Bdisplay%3Ainline%2Dblock%3Bwidth%3Aauto%3Bvertical%2Dalign%3Amiddle%7D%2Enavbar%2Dform%20%2Eform%2Dcontrol%2Dstatic%7Bdisplay%3Ainline%2Dblock%7D%2Enavbar%2Dform%20%2Einput%2Dgroup%7Bdisplay%3Ainline%2Dtable%3Bvertical%2Dalign%3Amiddle%7D%2Enavbar%2Dform%20%2Einput%2Dgroup%20%2Eform%2Dcontrol%2C%2Enavbar%2Dform%20%2Einput%2Dgroup%20%2Einput%2Dgroup%2Daddon%2C%2Enavbar%2Dform%20%2Einput%2Dgroup%20%2Einput%2Dgroup%2Dbtn%7Bwidth%3Aauto%7D%2Enavbar%2Dform%20%2Einput%2Dgroup%3E%2Eform%2Dcontrol%7Bwidth%3A100%25%7D%2Enavbar%2Dform%20%2Econtrol%2Dlabel%7Bmargin%2Dbottom%3A0%3Bvertical%2Dalign%3Amiddle%7D%2Enavbar%2Dform%20%2Echeckbox%2C%2Enavbar%2Dform%20%2Eradio%7Bdisplay%3Ainline%2Dblock%3Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A0%3Bvertical%2Dalign%3Amiddle%7D%2Enavbar%2Dform%20%2Echeckbox%20label%2C%2Enavbar%2Dform%20%2Eradio%20label%7Bpadding%2Dleft%3A0%7D%2Enavbar%2Dform%20%2Echeckbox%20input%5Btype%3Dcheckbox%5D%2C%2Enavbar%2Dform%20%2Eradio%20input%5Btype%3Dradio%5D%7Bposition%3Arelative%3Bmargin%2Dleft%3A0%7D%2Enavbar%2Dform%20%2Ehas%2Dfeedback%20%2Eform%2Dcontrol%2Dfeedback%7Btop%3A0%7D%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Enavbar%2Dform%20%2Eform%2Dgroup%7Bmargin%2Dbottom%3A5px%7D%2Enavbar%2Dform%20%2Eform%2Dgroup%3Alast%2Dchild%7Bmargin%2Dbottom%3A0%7D%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dform%7Bwidth%3Aauto%3Bpadding%2Dtop%3A0%3Bpadding%2Dbottom%3A0%3Bmargin%2Dright%3A0%3Bmargin%2Dleft%3A0%3Bborder%3A0%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%7D%7D%2Enavbar%2Dnav%3Eli%3E%2Edropdown%2Dmenu%7Bmargin%2Dtop%3A0%3Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dtop%2Dright%2Dradius%3A0%7D%2Enavbar%2Dfixed%2Dbottom%20%2Enavbar%2Dnav%3Eli%3E%2Edropdown%2Dmenu%7Bmargin%2Dbottom%3A0%3Bborder%2Dtop%2Dleft%2Dradius%3A4px%3Bborder%2Dtop%2Dright%2Dradius%3A4px%3Bborder%2Dbottom%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A0%7D%2Enavbar%2Dbtn%7Bmargin%2Dtop%3A8px%3Bmargin%2Dbottom%3A8px%7D%2Enavbar%2Dbtn%2Ebtn%2Dsm%7Bmargin%2Dtop%3A10px%3Bmargin%2Dbottom%3A10px%7D%2Enavbar%2Dbtn%2Ebtn%2Dxs%7Bmargin%2Dtop%3A14px%3Bmargin%2Dbottom%3A14px%7D%2Enavbar%2Dtext%7Bmargin%2Dtop%3A15px%3Bmargin%2Dbottom%3A15px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dtext%7Bfloat%3Aleft%3Bmargin%2Dright%3A15px%3Bmargin%2Dleft%3A15px%7D%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dleft%7Bfloat%3Aleft%21important%7D%2Enavbar%2Dright%7Bfloat%3Aright%21important%3Bmargin%2Dright%3A%2D15px%7D%2Enavbar%2Dright%7E%2Enavbar%2Dright%7Bmargin%2Dright%3A0%7D%7D%2Enavbar%2Ddefault%7Bbackground%2Dcolor%3A%23f8f8f8%3Bborder%2Dcolor%3A%23e7e7e7%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dbrand%7Bcolor%3A%23777%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dbrand%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dbrand%3Ahover%7Bcolor%3A%235e5e5e%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dtext%7Bcolor%3A%23777%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3Eli%3Ea%7Bcolor%3A%23777%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3Eli%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3Eli%3Ea%3Ahover%7Bcolor%3A%23333%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Eactive%3Ea%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Eactive%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Eactive%3Ea%3Ahover%7Bcolor%3A%23555%3Bbackground%2Dcolor%3A%23e7e7e7%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Edisabled%3Ea%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Edisabled%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Edisabled%3Ea%3Ahover%7Bcolor%3A%23ccc%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dtoggle%7Bborder%2Dcolor%3A%23ddd%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dtoggle%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dtoggle%3Ahover%7Bbackground%2Dcolor%3A%23ddd%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dtoggle%20%2Eicon%2Dbar%7Bbackground%2Dcolor%3A%23888%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dcollapse%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dform%7Bborder%2Dcolor%3A%23e7e7e7%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Eopen%3Ea%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Eopen%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Eopen%3Ea%3Ahover%7Bcolor%3A%23555%3Bbackground%2Dcolor%3A%23e7e7e7%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%7Bcolor%3A%23777%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%3Ahover%7Bcolor%3A%23333%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Eactive%3Ea%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Eactive%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Eactive%3Ea%3Ahover%7Bcolor%3A%23555%3Bbackground%2Dcolor%3A%23e7e7e7%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Ahover%7Bcolor%3A%23ccc%3Bbackground%2Dcolor%3Atransparent%7D%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dlink%7Bcolor%3A%23777%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dlink%3Ahover%7Bcolor%3A%23333%7D%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%7Bcolor%3A%23777%7D%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%3Afocus%2C%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%3Ahover%7Bcolor%3A%23333%7D%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%5Bdisabled%5D%3Afocus%2C%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%3Ahover%7Bcolor%3A%23ccc%7D%2Enavbar%2Dinverse%7Bbackground%2Dcolor%3A%23222%3Bborder%2Dcolor%3A%23080808%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dbrand%7Bcolor%3A%239d9d9d%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dbrand%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dbrand%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dtext%7Bcolor%3A%239d9d9d%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3Eli%3Ea%7Bcolor%3A%239d9d9d%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3Eli%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3Eli%3Ea%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Eactive%3Ea%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Eactive%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Eactive%3Ea%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23080808%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Edisabled%3Ea%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Edisabled%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Edisabled%3Ea%3Ahover%7Bcolor%3A%23444%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dtoggle%7Bborder%2Dcolor%3A%23333%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dtoggle%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dtoggle%3Ahover%7Bbackground%2Dcolor%3A%23333%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dtoggle%20%2Eicon%2Dbar%7Bbackground%2Dcolor%3A%23fff%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dcollapse%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dform%7Bborder%2Dcolor%3A%23101010%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Eopen%3Ea%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Eopen%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Eopen%3Ea%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23080808%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edropdown%2Dheader%7Bborder%2Dcolor%3A%23080808%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%20%2Edivider%7Bbackground%2Dcolor%3A%23080808%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%7Bcolor%3A%239d9d9d%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Eactive%3Ea%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Eactive%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Eactive%3Ea%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23080808%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Ahover%7Bcolor%3A%23444%3Bbackground%2Dcolor%3Atransparent%7D%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dlink%7Bcolor%3A%239d9d9d%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dlink%3Ahover%7Bcolor%3A%23fff%7D%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%7Bcolor%3A%239d9d9d%7D%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%3Afocus%2C%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%3Ahover%7Bcolor%3A%23fff%7D%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%5Bdisabled%5D%3Afocus%2C%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%3Ahover%7Bcolor%3A%23444%7D%2Ebreadcrumb%7Bpadding%3A8px%2015px%3Bmargin%2Dbottom%3A20px%3Blist%2Dstyle%3Anone%3Bbackground%2Dcolor%3A%23f5f5f5%3Bborder%2Dradius%3A4px%7D%2Ebreadcrumb%3Eli%7Bdisplay%3Ainline%2Dblock%7D%2Ebreadcrumb%3Eli%2Bli%3Abefore%7Bpadding%3A0%205px%3Bcolor%3A%23ccc%3Bcontent%3A%22%2F%5C00a0%22%7D%2Ebreadcrumb%3E%2Eactive%7Bcolor%3A%23777%7D%2Epagination%7Bdisplay%3Ainline%2Dblock%3Bpadding%2Dleft%3A0%3Bmargin%3A20px%200%3Bborder%2Dradius%3A4px%7D%2Epagination%3Eli%7Bdisplay%3Ainline%7D%2Epagination%3Eli%3Ea%2C%2Epagination%3Eli%3Espan%7Bposition%3Arelative%3Bfloat%3Aleft%3Bpadding%3A6px%2012px%3Bmargin%2Dleft%3A%2D1px%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23337ab7%3Btext%2Ddecoration%3Anone%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20%23ddd%7D%2Epagination%3Eli%3Afirst%2Dchild%3Ea%2C%2Epagination%3Eli%3Afirst%2Dchild%3Espan%7Bmargin%2Dleft%3A0%3Bborder%2Dtop%2Dleft%2Dradius%3A4px%3Bborder%2Dbottom%2Dleft%2Dradius%3A4px%7D%2Epagination%3Eli%3Alast%2Dchild%3Ea%2C%2Epagination%3Eli%3Alast%2Dchild%3Espan%7Bborder%2Dtop%2Dright%2Dradius%3A4px%3Bborder%2Dbottom%2Dright%2Dradius%3A4px%7D%2Epagination%3Eli%3Ea%3Afocus%2C%2Epagination%3Eli%3Ea%3Ahover%2C%2Epagination%3Eli%3Espan%3Afocus%2C%2Epagination%3Eli%3Espan%3Ahover%7Bz%2Dindex%3A3%3Bcolor%3A%2323527c%3Bbackground%2Dcolor%3A%23eee%3Bborder%2Dcolor%3A%23ddd%7D%2Epagination%3E%2Eactive%3Ea%2C%2Epagination%3E%2Eactive%3Ea%3Afocus%2C%2Epagination%3E%2Eactive%3Ea%3Ahover%2C%2Epagination%3E%2Eactive%3Espan%2C%2Epagination%3E%2Eactive%3Espan%3Afocus%2C%2Epagination%3E%2Eactive%3Espan%3Ahover%7Bz%2Dindex%3A2%3Bcolor%3A%23fff%3Bcursor%3Adefault%3Bbackground%2Dcolor%3A%23337ab7%3Bborder%2Dcolor%3A%23337ab7%7D%2Epagination%3E%2Edisabled%3Ea%2C%2Epagination%3E%2Edisabled%3Ea%3Afocus%2C%2Epagination%3E%2Edisabled%3Ea%3Ahover%2C%2Epagination%3E%2Edisabled%3Espan%2C%2Epagination%3E%2Edisabled%3Espan%3Afocus%2C%2Epagination%3E%2Edisabled%3Espan%3Ahover%7Bcolor%3A%23777%3Bcursor%3Anot%2Dallowed%3Bbackground%2Dcolor%3A%23fff%3Bborder%2Dcolor%3A%23ddd%7D%2Epagination%2Dlg%3Eli%3Ea%2C%2Epagination%2Dlg%3Eli%3Espan%7Bpadding%3A10px%2016px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A1%2E3333333%7D%2Epagination%2Dlg%3Eli%3Afirst%2Dchild%3Ea%2C%2Epagination%2Dlg%3Eli%3Afirst%2Dchild%3Espan%7Bborder%2Dtop%2Dleft%2Dradius%3A6px%3Bborder%2Dbottom%2Dleft%2Dradius%3A6px%7D%2Epagination%2Dlg%3Eli%3Alast%2Dchild%3Ea%2C%2Epagination%2Dlg%3Eli%3Alast%2Dchild%3Espan%7Bborder%2Dtop%2Dright%2Dradius%3A6px%3Bborder%2Dbottom%2Dright%2Dradius%3A6px%7D%2Epagination%2Dsm%3Eli%3Ea%2C%2Epagination%2Dsm%3Eli%3Espan%7Bpadding%3A5px%2010px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%7D%2Epagination%2Dsm%3Eli%3Afirst%2Dchild%3Ea%2C%2Epagination%2Dsm%3Eli%3Afirst%2Dchild%3Espan%7Bborder%2Dtop%2Dleft%2Dradius%3A3px%3Bborder%2Dbottom%2Dleft%2Dradius%3A3px%7D%2Epagination%2Dsm%3Eli%3Alast%2Dchild%3Ea%2C%2Epagination%2Dsm%3Eli%3Alast%2Dchild%3Espan%7Bborder%2Dtop%2Dright%2Dradius%3A3px%3Bborder%2Dbottom%2Dright%2Dradius%3A3px%7D%2Epager%7Bpadding%2Dleft%3A0%3Bmargin%3A20px%200%3Btext%2Dalign%3Acenter%3Blist%2Dstyle%3Anone%7D%2Epager%20li%7Bdisplay%3Ainline%7D%2Epager%20li%3Ea%2C%2Epager%20li%3Espan%7Bdisplay%3Ainline%2Dblock%3Bpadding%3A5px%2014px%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20%23ddd%3Bborder%2Dradius%3A15px%7D%2Epager%20li%3Ea%3Afocus%2C%2Epager%20li%3Ea%3Ahover%7Btext%2Ddecoration%3Anone%3Bbackground%2Dcolor%3A%23eee%7D%2Epager%20%2Enext%3Ea%2C%2Epager%20%2Enext%3Espan%7Bfloat%3Aright%7D%2Epager%20%2Eprevious%3Ea%2C%2Epager%20%2Eprevious%3Espan%7Bfloat%3Aleft%7D%2Epager%20%2Edisabled%3Ea%2C%2Epager%20%2Edisabled%3Ea%3Afocus%2C%2Epager%20%2Edisabled%3Ea%3Ahover%2C%2Epager%20%2Edisabled%3Espan%7Bcolor%3A%23777%3Bcursor%3Anot%2Dallowed%3Bbackground%2Dcolor%3A%23fff%7D%2Elabel%7Bdisplay%3Ainline%3Bpadding%3A%2E2em%20%2E6em%20%2E3em%3Bfont%2Dsize%3A75%25%3Bfont%2Dweight%3A700%3Bline%2Dheight%3A1%3Bcolor%3A%23fff%3Btext%2Dalign%3Acenter%3Bwhite%2Dspace%3Anowrap%3Bvertical%2Dalign%3Abaseline%3Bborder%2Dradius%3A%2E25em%7Da%2Elabel%3Afocus%2Ca%2Elabel%3Ahover%7Bcolor%3A%23fff%3Btext%2Ddecoration%3Anone%3Bcursor%3Apointer%7D%2Elabel%3Aempty%7Bdisplay%3Anone%7D%2Ebtn%20%2Elabel%7Bposition%3Arelative%3Btop%3A%2D1px%7D%2Elabel%2Ddefault%7Bbackground%2Dcolor%3A%23777%7D%2Elabel%2Ddefault%5Bhref%5D%3Afocus%2C%2Elabel%2Ddefault%5Bhref%5D%3Ahover%7Bbackground%2Dcolor%3A%235e5e5e%7D%2Elabel%2Dprimary%7Bbackground%2Dcolor%3A%23337ab7%7D%2Elabel%2Dprimary%5Bhref%5D%3Afocus%2C%2Elabel%2Dprimary%5Bhref%5D%3Ahover%7Bbackground%2Dcolor%3A%23286090%7D%2Elabel%2Dsuccess%7Bbackground%2Dcolor%3A%235cb85c%7D%2Elabel%2Dsuccess%5Bhref%5D%3Afocus%2C%2Elabel%2Dsuccess%5Bhref%5D%3Ahover%7Bbackground%2Dcolor%3A%23449d44%7D%2Elabel%2Dinfo%7Bbackground%2Dcolor%3A%235bc0de%7D%2Elabel%2Dinfo%5Bhref%5D%3Afocus%2C%2Elabel%2Dinfo%5Bhref%5D%3Ahover%7Bbackground%2Dcolor%3A%2331b0d5%7D%2Elabel%2Dwarning%7Bbackground%2Dcolor%3A%23f0ad4e%7D%2Elabel%2Dwarning%5Bhref%5D%3Afocus%2C%2Elabel%2Dwarning%5Bhref%5D%3Ahover%7Bbackground%2Dcolor%3A%23ec971f%7D%2Elabel%2Ddanger%7Bbackground%2Dcolor%3A%23d9534f%7D%2Elabel%2Ddanger%5Bhref%5D%3Afocus%2C%2Elabel%2Ddanger%5Bhref%5D%3Ahover%7Bbackground%2Dcolor%3A%23c9302c%7D%2Ebadge%7Bdisplay%3Ainline%2Dblock%3Bmin%2Dwidth%3A10px%3Bpadding%3A3px%207px%3Bfont%2Dsize%3A12px%3Bfont%2Dweight%3A700%3Bline%2Dheight%3A1%3Bcolor%3A%23fff%3Btext%2Dalign%3Acenter%3Bwhite%2Dspace%3Anowrap%3Bvertical%2Dalign%3Amiddle%3Bbackground%2Dcolor%3A%23777%3Bborder%2Dradius%3A10px%7D%2Ebadge%3Aempty%7Bdisplay%3Anone%7D%2Ebtn%20%2Ebadge%7Bposition%3Arelative%3Btop%3A%2D1px%7D%2Ebtn%2Dgroup%2Dxs%3E%2Ebtn%20%2Ebadge%2C%2Ebtn%2Dxs%20%2Ebadge%7Btop%3A0%3Bpadding%3A1px%205px%7Da%2Ebadge%3Afocus%2Ca%2Ebadge%3Ahover%7Bcolor%3A%23fff%3Btext%2Ddecoration%3Anone%3Bcursor%3Apointer%7D%2Elist%2Dgroup%2Ditem%2Eactive%3E%2Ebadge%2C%2Enav%2Dpills%3E%2Eactive%3Ea%3E%2Ebadge%7Bcolor%3A%23337ab7%3Bbackground%2Dcolor%3A%23fff%7D%2Elist%2Dgroup%2Ditem%3E%2Ebadge%7Bfloat%3Aright%7D%2Elist%2Dgroup%2Ditem%3E%2Ebadge%2B%2Ebadge%7Bmargin%2Dright%3A5px%7D%2Enav%2Dpills%3Eli%3Ea%3E%2Ebadge%7Bmargin%2Dleft%3A3px%7D%2Ejumbotron%7Bpadding%2Dtop%3A30px%3Bpadding%2Dbottom%3A30px%3Bmargin%2Dbottom%3A30px%3Bcolor%3Ainherit%3Bbackground%2Dcolor%3A%23eee%7D%2Ejumbotron%20%2Eh1%2C%2Ejumbotron%20h1%7Bcolor%3Ainherit%7D%2Ejumbotron%20p%7Bmargin%2Dbottom%3A15px%3Bfont%2Dsize%3A21px%3Bfont%2Dweight%3A200%7D%2Ejumbotron%3Ehr%7Bborder%2Dtop%2Dcolor%3A%23d5d5d5%7D%2Econtainer%20%2Ejumbotron%2C%2Econtainer%2Dfluid%20%2Ejumbotron%7Bborder%2Dradius%3A6px%7D%2Ejumbotron%20%2Econtainer%7Bmax%2Dwidth%3A100%25%7D%40media%20screen%20and%20%28min%2Dwidth%3A768px%29%7B%2Ejumbotron%7Bpadding%2Dtop%3A48px%3Bpadding%2Dbottom%3A48px%7D%2Econtainer%20%2Ejumbotron%2C%2Econtainer%2Dfluid%20%2Ejumbotron%7Bpadding%2Dright%3A60px%3Bpadding%2Dleft%3A60px%7D%2Ejumbotron%20%2Eh1%2C%2Ejumbotron%20h1%7Bfont%2Dsize%3A63px%7D%7D%2Ethumbnail%7Bdisplay%3Ablock%3Bpadding%3A4px%3Bmargin%2Dbottom%3A20px%3Bline%2Dheight%3A1%2E42857143%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20%23ddd%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dtransition%3Aborder%20%2E2s%20ease%2Din%2Dout%3B%2Do%2Dtransition%3Aborder%20%2E2s%20ease%2Din%2Dout%3Btransition%3Aborder%20%2E2s%20ease%2Din%2Dout%7D%2Ethumbnail%20a%3Eimg%2C%2Ethumbnail%3Eimg%7Bmargin%2Dright%3Aauto%3Bmargin%2Dleft%3Aauto%7Da%2Ethumbnail%2Eactive%2Ca%2Ethumbnail%3Afocus%2Ca%2Ethumbnail%3Ahover%7Bborder%2Dcolor%3A%23337ab7%7D%2Ethumbnail%20%2Ecaption%7Bpadding%3A9px%3Bcolor%3A%23333%7D%2Ealert%7Bpadding%3A15px%3Bmargin%2Dbottom%3A20px%3Bborder%3A1px%20solid%20transparent%3Bborder%2Dradius%3A4px%7D%2Ealert%20h4%7Bmargin%2Dtop%3A0%3Bcolor%3Ainherit%7D%2Ealert%20%2Ealert%2Dlink%7Bfont%2Dweight%3A700%7D%2Ealert%3Ep%2C%2Ealert%3Eul%7Bmargin%2Dbottom%3A0%7D%2Ealert%3Ep%2Bp%7Bmargin%2Dtop%3A5px%7D%2Ealert%2Ddismissable%2C%2Ealert%2Ddismissible%7Bpadding%2Dright%3A35px%7D%2Ealert%2Ddismissable%20%2Eclose%2C%2Ealert%2Ddismissible%20%2Eclose%7Bposition%3Arelative%3Btop%3A%2D2px%3Bright%3A%2D21px%3Bcolor%3Ainherit%7D%2Ealert%2Dsuccess%7Bcolor%3A%233c763d%3Bbackground%2Dcolor%3A%23dff0d8%3Bborder%2Dcolor%3A%23d6e9c6%7D%2Ealert%2Dsuccess%20hr%7Bborder%2Dtop%2Dcolor%3A%23c9e2b3%7D%2Ealert%2Dsuccess%20%2Ealert%2Dlink%7Bcolor%3A%232b542c%7D%2Ealert%2Dinfo%7Bcolor%3A%2331708f%3Bbackground%2Dcolor%3A%23d9edf7%3Bborder%2Dcolor%3A%23bce8f1%7D%2Ealert%2Dinfo%20hr%7Bborder%2Dtop%2Dcolor%3A%23a6e1ec%7D%2Ealert%2Dinfo%20%2Ealert%2Dlink%7Bcolor%3A%23245269%7D%2Ealert%2Dwarning%7Bcolor%3A%238a6d3b%3Bbackground%2Dcolor%3A%23fcf8e3%3Bborder%2Dcolor%3A%23faebcc%7D%2Ealert%2Dwarning%20hr%7Bborder%2Dtop%2Dcolor%3A%23f7e1b5%7D%2Ealert%2Dwarning%20%2Ealert%2Dlink%7Bcolor%3A%2366512c%7D%2Ealert%2Ddanger%7Bcolor%3A%23a94442%3Bbackground%2Dcolor%3A%23f2dede%3Bborder%2Dcolor%3A%23ebccd1%7D%2Ealert%2Ddanger%20hr%7Bborder%2Dtop%2Dcolor%3A%23e4b9c0%7D%2Ealert%2Ddanger%20%2Ealert%2Dlink%7Bcolor%3A%23843534%7D%40%2Dwebkit%2Dkeyframes%20progress%2Dbar%2Dstripes%7Bfrom%7Bbackground%2Dposition%3A40px%200%7Dto%7Bbackground%2Dposition%3A0%200%7D%7D%40%2Do%2Dkeyframes%20progress%2Dbar%2Dstripes%7Bfrom%7Bbackground%2Dposition%3A40px%200%7Dto%7Bbackground%2Dposition%3A0%200%7D%7D%40keyframes%20progress%2Dbar%2Dstripes%7Bfrom%7Bbackground%2Dposition%3A40px%200%7Dto%7Bbackground%2Dposition%3A0%200%7D%7D%2Eprogress%7Bheight%3A20px%3Bmargin%2Dbottom%3A20px%3Boverflow%3Ahidden%3Bbackground%2Dcolor%3A%23f5f5f5%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%202px%20rgba%280%2C0%2C0%2C%2E1%29%3Bbox%2Dshadow%3Ainset%200%201px%202px%20rgba%280%2C0%2C0%2C%2E1%29%7D%2Eprogress%2Dbar%7Bfloat%3Aleft%3Bwidth%3A0%3Bheight%3A100%25%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A20px%3Bcolor%3A%23fff%3Btext%2Dalign%3Acenter%3Bbackground%2Dcolor%3A%23337ab7%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%20%2D1px%200%20rgba%280%2C0%2C0%2C%2E15%29%3Bbox%2Dshadow%3Ainset%200%20%2D1px%200%20rgba%280%2C0%2C0%2C%2E15%29%3B%2Dwebkit%2Dtransition%3Awidth%20%2E6s%20ease%3B%2Do%2Dtransition%3Awidth%20%2E6s%20ease%3Btransition%3Awidth%20%2E6s%20ease%7D%2Eprogress%2Dbar%2Dstriped%2C%2Eprogress%2Dstriped%20%2Eprogress%2Dbar%7Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3Alinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3B%2Dwebkit%2Dbackground%2Dsize%3A40px%2040px%3Bbackground%2Dsize%3A40px%2040px%7D%2Eprogress%2Dbar%2Eactive%2C%2Eprogress%2Eactive%20%2Eprogress%2Dbar%7B%2Dwebkit%2Danimation%3Aprogress%2Dbar%2Dstripes%202s%20linear%20infinite%3B%2Do%2Danimation%3Aprogress%2Dbar%2Dstripes%202s%20linear%20infinite%3Banimation%3Aprogress%2Dbar%2Dstripes%202s%20linear%20infinite%7D%2Eprogress%2Dbar%2Dsuccess%7Bbackground%2Dcolor%3A%235cb85c%7D%2Eprogress%2Dstriped%20%2Eprogress%2Dbar%2Dsuccess%7Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3Alinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%7D%2Eprogress%2Dbar%2Dinfo%7Bbackground%2Dcolor%3A%235bc0de%7D%2Eprogress%2Dstriped%20%2Eprogress%2Dbar%2Dinfo%7Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3Alinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%7D%2Eprogress%2Dbar%2Dwarning%7Bbackground%2Dcolor%3A%23f0ad4e%7D%2Eprogress%2Dstriped%20%2Eprogress%2Dbar%2Dwarning%7Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3Alinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%7D%2Eprogress%2Dbar%2Ddanger%7Bbackground%2Dcolor%3A%23d9534f%7D%2Eprogress%2Dstriped%20%2Eprogress%2Dbar%2Ddanger%7Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3Alinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%7D%2Emedia%7Bmargin%2Dtop%3A15px%7D%2Emedia%3Afirst%2Dchild%7Bmargin%2Dtop%3A0%7D%2Emedia%2C%2Emedia%2Dbody%7Boverflow%3Ahidden%3Bzoom%3A1%7D%2Emedia%2Dbody%7Bwidth%3A10000px%7D%2Emedia%2Dobject%7Bdisplay%3Ablock%7D%2Emedia%2Dobject%2Eimg%2Dthumbnail%7Bmax%2Dwidth%3Anone%7D%2Emedia%2Dright%2C%2Emedia%3E%2Epull%2Dright%7Bpadding%2Dleft%3A10px%7D%2Emedia%2Dleft%2C%2Emedia%3E%2Epull%2Dleft%7Bpadding%2Dright%3A10px%7D%2Emedia%2Dbody%2C%2Emedia%2Dleft%2C%2Emedia%2Dright%7Bdisplay%3Atable%2Dcell%3Bvertical%2Dalign%3Atop%7D%2Emedia%2Dmiddle%7Bvertical%2Dalign%3Amiddle%7D%2Emedia%2Dbottom%7Bvertical%2Dalign%3Abottom%7D%2Emedia%2Dheading%7Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A5px%7D%2Emedia%2Dlist%7Bpadding%2Dleft%3A0%3Blist%2Dstyle%3Anone%7D%2Elist%2Dgroup%7Bpadding%2Dleft%3A0%3Bmargin%2Dbottom%3A20px%7D%2Elist%2Dgroup%2Ditem%7Bposition%3Arelative%3Bdisplay%3Ablock%3Bpadding%3A10px%2015px%3Bmargin%2Dbottom%3A%2D1px%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20%23ddd%7D%2Elist%2Dgroup%2Ditem%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A4px%3Bborder%2Dtop%2Dright%2Dradius%3A4px%7D%2Elist%2Dgroup%2Ditem%3Alast%2Dchild%7Bmargin%2Dbottom%3A0%3Bborder%2Dbottom%2Dright%2Dradius%3A4px%3Bborder%2Dbottom%2Dleft%2Dradius%3A4px%7Da%2Elist%2Dgroup%2Ditem%2Cbutton%2Elist%2Dgroup%2Ditem%7Bcolor%3A%23555%7Da%2Elist%2Dgroup%2Ditem%20%2Elist%2Dgroup%2Ditem%2Dheading%2Cbutton%2Elist%2Dgroup%2Ditem%20%2Elist%2Dgroup%2Ditem%2Dheading%7Bcolor%3A%23333%7Da%2Elist%2Dgroup%2Ditem%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%3Ahover%7Bcolor%3A%23555%3Btext%2Ddecoration%3Anone%3Bbackground%2Dcolor%3A%23f5f5f5%7Dbutton%2Elist%2Dgroup%2Ditem%7Bwidth%3A100%25%3Btext%2Dalign%3Aleft%7D%2Elist%2Dgroup%2Ditem%2Edisabled%2C%2Elist%2Dgroup%2Ditem%2Edisabled%3Afocus%2C%2Elist%2Dgroup%2Ditem%2Edisabled%3Ahover%7Bcolor%3A%23777%3Bcursor%3Anot%2Dallowed%3Bbackground%2Dcolor%3A%23eee%7D%2Elist%2Dgroup%2Ditem%2Edisabled%20%2Elist%2Dgroup%2Ditem%2Dheading%2C%2Elist%2Dgroup%2Ditem%2Edisabled%3Afocus%20%2Elist%2Dgroup%2Ditem%2Dheading%2C%2Elist%2Dgroup%2Ditem%2Edisabled%3Ahover%20%2Elist%2Dgroup%2Ditem%2Dheading%7Bcolor%3Ainherit%7D%2Elist%2Dgroup%2Ditem%2Edisabled%20%2Elist%2Dgroup%2Ditem%2Dtext%2C%2Elist%2Dgroup%2Ditem%2Edisabled%3Afocus%20%2Elist%2Dgroup%2Ditem%2Dtext%2C%2Elist%2Dgroup%2Ditem%2Edisabled%3Ahover%20%2Elist%2Dgroup%2Ditem%2Dtext%7Bcolor%3A%23777%7D%2Elist%2Dgroup%2Ditem%2Eactive%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Afocus%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Ahover%7Bz%2Dindex%3A2%3Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23337ab7%3Bborder%2Dcolor%3A%23337ab7%7D%2Elist%2Dgroup%2Ditem%2Eactive%20%2Elist%2Dgroup%2Ditem%2Dheading%2C%2Elist%2Dgroup%2Ditem%2Eactive%20%2Elist%2Dgroup%2Ditem%2Dheading%3E%2Esmall%2C%2Elist%2Dgroup%2Ditem%2Eactive%20%2Elist%2Dgroup%2Ditem%2Dheading%3Esmall%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Afocus%20%2Elist%2Dgroup%2Ditem%2Dheading%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Afocus%20%2Elist%2Dgroup%2Ditem%2Dheading%3E%2Esmall%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Afocus%20%2Elist%2Dgroup%2Ditem%2Dheading%3Esmall%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Ahover%20%2Elist%2Dgroup%2Ditem%2Dheading%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Ahover%20%2Elist%2Dgroup%2Ditem%2Dheading%3E%2Esmall%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Ahover%20%2Elist%2Dgroup%2Ditem%2Dheading%3Esmall%7Bcolor%3Ainherit%7D%2Elist%2Dgroup%2Ditem%2Eactive%20%2Elist%2Dgroup%2Ditem%2Dtext%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Afocus%20%2Elist%2Dgroup%2Ditem%2Dtext%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Ahover%20%2Elist%2Dgroup%2Ditem%2Dtext%7Bcolor%3A%23c7ddef%7D%2Elist%2Dgroup%2Ditem%2Dsuccess%7Bcolor%3A%233c763d%3Bbackground%2Dcolor%3A%23dff0d8%7Da%2Elist%2Dgroup%2Ditem%2Dsuccess%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%7Bcolor%3A%233c763d%7Da%2Elist%2Dgroup%2Ditem%2Dsuccess%20%2Elist%2Dgroup%2Ditem%2Dheading%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%20%2Elist%2Dgroup%2Ditem%2Dheading%7Bcolor%3Ainherit%7Da%2Elist%2Dgroup%2Ditem%2Dsuccess%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Dsuccess%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%3Ahover%7Bcolor%3A%233c763d%3Bbackground%2Dcolor%3A%23d0e9c6%7Da%2Elist%2Dgroup%2Ditem%2Dsuccess%2Eactive%2Ca%2Elist%2Dgroup%2Ditem%2Dsuccess%2Eactive%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Dsuccess%2Eactive%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%2Eactive%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%2Eactive%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%2Eactive%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%233c763d%3Bborder%2Dcolor%3A%233c763d%7D%2Elist%2Dgroup%2Ditem%2Dinfo%7Bcolor%3A%2331708f%3Bbackground%2Dcolor%3A%23d9edf7%7Da%2Elist%2Dgroup%2Ditem%2Dinfo%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%7Bcolor%3A%2331708f%7Da%2Elist%2Dgroup%2Ditem%2Dinfo%20%2Elist%2Dgroup%2Ditem%2Dheading%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%20%2Elist%2Dgroup%2Ditem%2Dheading%7Bcolor%3Ainherit%7Da%2Elist%2Dgroup%2Ditem%2Dinfo%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Dinfo%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%3Ahover%7Bcolor%3A%2331708f%3Bbackground%2Dcolor%3A%23c4e3f3%7Da%2Elist%2Dgroup%2Ditem%2Dinfo%2Eactive%2Ca%2Elist%2Dgroup%2Ditem%2Dinfo%2Eactive%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Dinfo%2Eactive%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%2Eactive%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%2Eactive%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%2Eactive%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%2331708f%3Bborder%2Dcolor%3A%2331708f%7D%2Elist%2Dgroup%2Ditem%2Dwarning%7Bcolor%3A%238a6d3b%3Bbackground%2Dcolor%3A%23fcf8e3%7Da%2Elist%2Dgroup%2Ditem%2Dwarning%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%7Bcolor%3A%238a6d3b%7Da%2Elist%2Dgroup%2Ditem%2Dwarning%20%2Elist%2Dgroup%2Ditem%2Dheading%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%20%2Elist%2Dgroup%2Ditem%2Dheading%7Bcolor%3Ainherit%7Da%2Elist%2Dgroup%2Ditem%2Dwarning%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Dwarning%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%3Ahover%7Bcolor%3A%238a6d3b%3Bbackground%2Dcolor%3A%23faf2cc%7Da%2Elist%2Dgroup%2Ditem%2Dwarning%2Eactive%2Ca%2Elist%2Dgroup%2Ditem%2Dwarning%2Eactive%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Dwarning%2Eactive%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%2Eactive%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%2Eactive%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%2Eactive%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%238a6d3b%3Bborder%2Dcolor%3A%238a6d3b%7D%2Elist%2Dgroup%2Ditem%2Ddanger%7Bcolor%3A%23a94442%3Bbackground%2Dcolor%3A%23f2dede%7Da%2Elist%2Dgroup%2Ditem%2Ddanger%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%7Bcolor%3A%23a94442%7Da%2Elist%2Dgroup%2Ditem%2Ddanger%20%2Elist%2Dgroup%2Ditem%2Dheading%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%20%2Elist%2Dgroup%2Ditem%2Dheading%7Bcolor%3Ainherit%7Da%2Elist%2Dgroup%2Ditem%2Ddanger%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Ddanger%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%3Ahover%7Bcolor%3A%23a94442%3Bbackground%2Dcolor%3A%23ebcccc%7Da%2Elist%2Dgroup%2Ditem%2Ddanger%2Eactive%2Ca%2Elist%2Dgroup%2Ditem%2Ddanger%2Eactive%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Ddanger%2Eactive%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%2Eactive%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%2Eactive%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%2Eactive%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23a94442%3Bborder%2Dcolor%3A%23a94442%7D%2Elist%2Dgroup%2Ditem%2Dheading%7Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A5px%7D%2Elist%2Dgroup%2Ditem%2Dtext%7Bmargin%2Dbottom%3A0%3Bline%2Dheight%3A1%2E3%7D%2Epanel%7Bmargin%2Dbottom%3A20px%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20transparent%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dbox%2Dshadow%3A0%201px%201px%20rgba%280%2C0%2C0%2C%2E05%29%3Bbox%2Dshadow%3A0%201px%201px%20rgba%280%2C0%2C0%2C%2E05%29%7D%2Epanel%2Dbody%7Bpadding%3A15px%7D%2Epanel%2Dheading%7Bpadding%3A10px%2015px%3Bborder%2Dbottom%3A1px%20solid%20transparent%3Bborder%2Dtop%2Dleft%2Dradius%3A3px%3Bborder%2Dtop%2Dright%2Dradius%3A3px%7D%2Epanel%2Dheading%3E%2Edropdown%20%2Edropdown%2Dtoggle%7Bcolor%3Ainherit%7D%2Epanel%2Dtitle%7Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A0%3Bfont%2Dsize%3A16px%3Bcolor%3Ainherit%7D%2Epanel%2Dtitle%3E%2Esmall%2C%2Epanel%2Dtitle%3E%2Esmall%3Ea%2C%2Epanel%2Dtitle%3Ea%2C%2Epanel%2Dtitle%3Esmall%2C%2Epanel%2Dtitle%3Esmall%3Ea%7Bcolor%3Ainherit%7D%2Epanel%2Dfooter%7Bpadding%3A10px%2015px%3Bbackground%2Dcolor%3A%23f5f5f5%3Bborder%2Dtop%3A1px%20solid%20%23ddd%3Bborder%2Dbottom%2Dright%2Dradius%3A3px%3Bborder%2Dbottom%2Dleft%2Dradius%3A3px%7D%2Epanel%3E%2Elist%2Dgroup%2C%2Epanel%3E%2Epanel%2Dcollapse%3E%2Elist%2Dgroup%7Bmargin%2Dbottom%3A0%7D%2Epanel%3E%2Elist%2Dgroup%20%2Elist%2Dgroup%2Ditem%2C%2Epanel%3E%2Epanel%2Dcollapse%3E%2Elist%2Dgroup%20%2Elist%2Dgroup%2Ditem%7Bborder%2Dwidth%3A1px%200%3Bborder%2Dradius%3A0%7D%2Epanel%3E%2Elist%2Dgroup%3Afirst%2Dchild%20%2Elist%2Dgroup%2Ditem%3Afirst%2Dchild%2C%2Epanel%3E%2Epanel%2Dcollapse%3E%2Elist%2Dgroup%3Afirst%2Dchild%20%2Elist%2Dgroup%2Ditem%3Afirst%2Dchild%7Bborder%2Dtop%3A0%3Bborder%2Dtop%2Dleft%2Dradius%3A3px%3Bborder%2Dtop%2Dright%2Dradius%3A3px%7D%2Epanel%3E%2Elist%2Dgroup%3Alast%2Dchild%20%2Elist%2Dgroup%2Ditem%3Alast%2Dchild%2C%2Epanel%3E%2Epanel%2Dcollapse%3E%2Elist%2Dgroup%3Alast%2Dchild%20%2Elist%2Dgroup%2Ditem%3Alast%2Dchild%7Bborder%2Dbottom%3A0%3Bborder%2Dbottom%2Dright%2Dradius%3A3px%3Bborder%2Dbottom%2Dleft%2Dradius%3A3px%7D%2Epanel%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Elist%2Dgroup%20%2Elist%2Dgroup%2Ditem%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dtop%2Dright%2Dradius%3A0%7D%2Epanel%2Dheading%2B%2Elist%2Dgroup%20%2Elist%2Dgroup%2Ditem%3Afirst%2Dchild%7Bborder%2Dtop%2Dwidth%3A0%7D%2Elist%2Dgroup%2B%2Epanel%2Dfooter%7Bborder%2Dtop%2Dwidth%3A0%7D%2Epanel%3E%2Epanel%2Dcollapse%3E%2Etable%2C%2Epanel%3E%2Etable%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%7Bmargin%2Dbottom%3A0%7D%2Epanel%3E%2Epanel%2Dcollapse%3E%2Etable%20caption%2C%2Epanel%3E%2Etable%20caption%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%20caption%7Bpadding%2Dright%3A15px%3Bpadding%2Dleft%3A15px%7D%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A3px%3Bborder%2Dtop%2Dright%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A3px%3Bborder%2Dtop%2Dright%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Alast%2Dchild%7Bborder%2Dtop%2Dright%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%7Bborder%2Dbottom%2Dright%2Dradius%3A3px%3Bborder%2Dbottom%2Dleft%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%7Bborder%2Dbottom%2Dright%2Dradius%3A3px%3Bborder%2Dbottom%2Dleft%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Afirst%2Dchild%7Bborder%2Dbottom%2Dleft%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Alast%2Dchild%7Bborder%2Dbottom%2Dright%2Dradius%3A3px%7D%2Epanel%3E%2Epanel%2Dbody%2B%2Etable%2C%2Epanel%3E%2Epanel%2Dbody%2B%2Etable%2Dresponsive%2C%2Epanel%3E%2Etable%2B%2Epanel%2Dbody%2C%2Epanel%3E%2Etable%2Dresponsive%2B%2Epanel%2Dbody%7Bborder%2Dtop%3A1px%20solid%20%23ddd%7D%2Epanel%3E%2Etable%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%2C%2Epanel%3E%2Etable%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%7Bborder%2Dtop%3A0%7D%2Epanel%3E%2Etable%2Dbordered%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%7Bborder%3A0%7D%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Etd%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Eth%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Ethead%3Etr%3Etd%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Ethead%3Etr%3Eth%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Etd%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Eth%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Etd%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Eth%3Afirst%2Dchild%7Bborder%2Dleft%3A0%7D%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Etd%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Eth%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Ethead%3Etr%3Etd%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Ethead%3Etr%3Eth%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Etd%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Eth%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Etd%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Eth%3Alast%2Dchild%7Bborder%2Dright%3A0%7D%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Afirst%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Afirst%2Dchild%3Eth%2C%2Epanel%3E%2Etable%2Dbordered%3Ethead%3Etr%3Afirst%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dbordered%3Ethead%3Etr%3Afirst%2Dchild%3Eth%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Afirst%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Afirst%2Dchild%3Eth%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Afirst%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Afirst%2Dchild%3Eth%7Bborder%2Dbottom%3A0%7D%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Alast%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Alast%2Dchild%3Eth%2C%2Epanel%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Alast%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Alast%2Dchild%3Eth%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Alast%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Alast%2Dchild%3Eth%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Alast%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Alast%2Dchild%3Eth%7Bborder%2Dbottom%3A0%7D%2Epanel%3E%2Etable%2Dresponsive%7Bmargin%2Dbottom%3A0%3Bborder%3A0%7D%2Epanel%2Dgroup%7Bmargin%2Dbottom%3A20px%7D%2Epanel%2Dgroup%20%2Epanel%7Bmargin%2Dbottom%3A0%3Bborder%2Dradius%3A4px%7D%2Epanel%2Dgroup%20%2Epanel%2B%2Epanel%7Bmargin%2Dtop%3A5px%7D%2Epanel%2Dgroup%20%2Epanel%2Dheading%7Bborder%2Dbottom%3A0%7D%2Epanel%2Dgroup%20%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Elist%2Dgroup%2C%2Epanel%2Dgroup%20%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%3A1px%20solid%20%23ddd%7D%2Epanel%2Dgroup%20%2Epanel%2Dfooter%7Bborder%2Dtop%3A0%7D%2Epanel%2Dgroup%20%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%20%2Epanel%2Dbody%7Bborder%2Dbottom%3A1px%20solid%20%23ddd%7D%2Epanel%2Ddefault%7Bborder%2Dcolor%3A%23ddd%7D%2Epanel%2Ddefault%3E%2Epanel%2Dheading%7Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23f5f5f5%3Bborder%2Dcolor%3A%23ddd%7D%2Epanel%2Ddefault%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%2Dcolor%3A%23ddd%7D%2Epanel%2Ddefault%3E%2Epanel%2Dheading%20%2Ebadge%7Bcolor%3A%23f5f5f5%3Bbackground%2Dcolor%3A%23333%7D%2Epanel%2Ddefault%3E%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dbottom%2Dcolor%3A%23ddd%7D%2Epanel%2Dprimary%7Bborder%2Dcolor%3A%23337ab7%7D%2Epanel%2Dprimary%3E%2Epanel%2Dheading%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23337ab7%3Bborder%2Dcolor%3A%23337ab7%7D%2Epanel%2Dprimary%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%2Dcolor%3A%23337ab7%7D%2Epanel%2Dprimary%3E%2Epanel%2Dheading%20%2Ebadge%7Bcolor%3A%23337ab7%3Bbackground%2Dcolor%3A%23fff%7D%2Epanel%2Dprimary%3E%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dbottom%2Dcolor%3A%23337ab7%7D%2Epanel%2Dsuccess%7Bborder%2Dcolor%3A%23d6e9c6%7D%2Epanel%2Dsuccess%3E%2Epanel%2Dheading%7Bcolor%3A%233c763d%3Bbackground%2Dcolor%3A%23dff0d8%3Bborder%2Dcolor%3A%23d6e9c6%7D%2Epanel%2Dsuccess%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%2Dcolor%3A%23d6e9c6%7D%2Epanel%2Dsuccess%3E%2Epanel%2Dheading%20%2Ebadge%7Bcolor%3A%23dff0d8%3Bbackground%2Dcolor%3A%233c763d%7D%2Epanel%2Dsuccess%3E%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dbottom%2Dcolor%3A%23d6e9c6%7D%2Epanel%2Dinfo%7Bborder%2Dcolor%3A%23bce8f1%7D%2Epanel%2Dinfo%3E%2Epanel%2Dheading%7Bcolor%3A%2331708f%3Bbackground%2Dcolor%3A%23d9edf7%3Bborder%2Dcolor%3A%23bce8f1%7D%2Epanel%2Dinfo%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%2Dcolor%3A%23bce8f1%7D%2Epanel%2Dinfo%3E%2Epanel%2Dheading%20%2Ebadge%7Bcolor%3A%23d9edf7%3Bbackground%2Dcolor%3A%2331708f%7D%2Epanel%2Dinfo%3E%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dbottom%2Dcolor%3A%23bce8f1%7D%2Epanel%2Dwarning%7Bborder%2Dcolor%3A%23faebcc%7D%2Epanel%2Dwarning%3E%2Epanel%2Dheading%7Bcolor%3A%238a6d3b%3Bbackground%2Dcolor%3A%23fcf8e3%3Bborder%2Dcolor%3A%23faebcc%7D%2Epanel%2Dwarning%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%2Dcolor%3A%23faebcc%7D%2Epanel%2Dwarning%3E%2Epanel%2Dheading%20%2Ebadge%7Bcolor%3A%23fcf8e3%3Bbackground%2Dcolor%3A%238a6d3b%7D%2Epanel%2Dwarning%3E%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dbottom%2Dcolor%3A%23faebcc%7D%2Epanel%2Ddanger%7Bborder%2Dcolor%3A%23ebccd1%7D%2Epanel%2Ddanger%3E%2Epanel%2Dheading%7Bcolor%3A%23a94442%3Bbackground%2Dcolor%3A%23f2dede%3Bborder%2Dcolor%3A%23ebccd1%7D%2Epanel%2Ddanger%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%2Dcolor%3A%23ebccd1%7D%2Epanel%2Ddanger%3E%2Epanel%2Dheading%20%2Ebadge%7Bcolor%3A%23f2dede%3Bbackground%2Dcolor%3A%23a94442%7D%2Epanel%2Ddanger%3E%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dbottom%2Dcolor%3A%23ebccd1%7D%2Eembed%2Dresponsive%7Bposition%3Arelative%3Bdisplay%3Ablock%3Bheight%3A0%3Bpadding%3A0%3Boverflow%3Ahidden%7D%2Eembed%2Dresponsive%20%2Eembed%2Dresponsive%2Ditem%2C%2Eembed%2Dresponsive%20embed%2C%2Eembed%2Dresponsive%20iframe%2C%2Eembed%2Dresponsive%20object%2C%2Eembed%2Dresponsive%20video%7Bposition%3Aabsolute%3Btop%3A0%3Bbottom%3A0%3Bleft%3A0%3Bwidth%3A100%25%3Bheight%3A100%25%3Bborder%3A0%7D%2Eembed%2Dresponsive%2D16by9%7Bpadding%2Dbottom%3A56%2E25%25%7D%2Eembed%2Dresponsive%2D4by3%7Bpadding%2Dbottom%3A75%25%7D%2Ewell%7Bmin%2Dheight%3A20px%3Bpadding%3A19px%3Bmargin%2Dbottom%3A20px%3Bbackground%2Dcolor%3A%23f5f5f5%3Bborder%3A1px%20solid%20%23e3e3e3%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E05%29%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E05%29%7D%2Ewell%20blockquote%7Bborder%2Dcolor%3A%23ddd%3Bborder%2Dcolor%3Argba%280%2C0%2C0%2C%2E15%29%7D%2Ewell%2Dlg%7Bpadding%3A24px%3Bborder%2Dradius%3A6px%7D%2Ewell%2Dsm%7Bpadding%3A9px%3Bborder%2Dradius%3A3px%7D%2Eclose%7Bfloat%3Aright%3Bfont%2Dsize%3A21px%3Bfont%2Dweight%3A700%3Bline%2Dheight%3A1%3Bcolor%3A%23000%3Btext%2Dshadow%3A0%201px%200%20%23fff%3Bfilter%3Aalpha%28opacity%3D20%29%3Bopacity%3A%2E2%7D%2Eclose%3Afocus%2C%2Eclose%3Ahover%7Bcolor%3A%23000%3Btext%2Ddecoration%3Anone%3Bcursor%3Apointer%3Bfilter%3Aalpha%28opacity%3D50%29%3Bopacity%3A%2E5%7Dbutton%2Eclose%7B%2Dwebkit%2Dappearance%3Anone%3Bpadding%3A0%3Bcursor%3Apointer%3Bbackground%3A0%200%3Bborder%3A0%7D%2Emodal%2Dopen%7Boverflow%3Ahidden%7D%2Emodal%7Bposition%3Afixed%3Btop%3A0%3Bright%3A0%3Bbottom%3A0%3Bleft%3A0%3Bz%2Dindex%3A1050%3Bdisplay%3Anone%3Boverflow%3Ahidden%3B%2Dwebkit%2Doverflow%2Dscrolling%3Atouch%3Boutline%3A0%7D%2Emodal%2Efade%20%2Emodal%2Ddialog%7B%2Dwebkit%2Dtransition%3A%2Dwebkit%2Dtransform%20%2E3s%20ease%2Dout%3B%2Do%2Dtransition%3A%2Do%2Dtransform%20%2E3s%20ease%2Dout%3Btransition%3Atransform%20%2E3s%20ease%2Dout%3B%2Dwebkit%2Dtransform%3Atranslate%280%2C%2D25%25%29%3B%2Dms%2Dtransform%3Atranslate%280%2C%2D25%25%29%3B%2Do%2Dtransform%3Atranslate%280%2C%2D25%25%29%3Btransform%3Atranslate%280%2C%2D25%25%29%7D%2Emodal%2Ein%20%2Emodal%2Ddialog%7B%2Dwebkit%2Dtransform%3Atranslate%280%2C0%29%3B%2Dms%2Dtransform%3Atranslate%280%2C0%29%3B%2Do%2Dtransform%3Atranslate%280%2C0%29%3Btransform%3Atranslate%280%2C0%29%7D%2Emodal%2Dopen%20%2Emodal%7Boverflow%2Dx%3Ahidden%3Boverflow%2Dy%3Aauto%7D%2Emodal%2Ddialog%7Bposition%3Arelative%3Bwidth%3Aauto%3Bmargin%3A10px%7D%2Emodal%2Dcontent%7Bposition%3Arelative%3Bbackground%2Dcolor%3A%23fff%3B%2Dwebkit%2Dbackground%2Dclip%3Apadding%2Dbox%3Bbackground%2Dclip%3Apadding%2Dbox%3Bborder%3A1px%20solid%20%23999%3Bborder%3A1px%20solid%20rgba%280%2C0%2C0%2C%2E2%29%3Bborder%2Dradius%3A6px%3Boutline%3A0%3B%2Dwebkit%2Dbox%2Dshadow%3A0%203px%209px%20rgba%280%2C0%2C0%2C%2E5%29%3Bbox%2Dshadow%3A0%203px%209px%20rgba%280%2C0%2C0%2C%2E5%29%7D%2Emodal%2Dbackdrop%7Bposition%3Afixed%3Btop%3A0%3Bright%3A0%3Bbottom%3A0%3Bleft%3A0%3Bz%2Dindex%3A1040%3Bbackground%2Dcolor%3A%23000%7D%2Emodal%2Dbackdrop%2Efade%7Bfilter%3Aalpha%28opacity%3D0%29%3Bopacity%3A0%7D%2Emodal%2Dbackdrop%2Ein%7Bfilter%3Aalpha%28opacity%3D50%29%3Bopacity%3A%2E5%7D%2Emodal%2Dheader%7Bmin%2Dheight%3A16%2E43px%3Bpadding%3A15px%3Bborder%2Dbottom%3A1px%20solid%20%23e5e5e5%7D%2Emodal%2Dheader%20%2Eclose%7Bmargin%2Dtop%3A%2D2px%7D%2Emodal%2Dtitle%7Bmargin%3A0%3Bline%2Dheight%3A1%2E42857143%7D%2Emodal%2Dbody%7Bposition%3Arelative%3Bpadding%3A15px%7D%2Emodal%2Dfooter%7Bpadding%3A15px%3Btext%2Dalign%3Aright%3Bborder%2Dtop%3A1px%20solid%20%23e5e5e5%7D%2Emodal%2Dfooter%20%2Ebtn%2B%2Ebtn%7Bmargin%2Dbottom%3A0%3Bmargin%2Dleft%3A5px%7D%2Emodal%2Dfooter%20%2Ebtn%2Dgroup%20%2Ebtn%2B%2Ebtn%7Bmargin%2Dleft%3A%2D1px%7D%2Emodal%2Dfooter%20%2Ebtn%2Dblock%2B%2Ebtn%2Dblock%7Bmargin%2Dleft%3A0%7D%2Emodal%2Dscrollbar%2Dmeasure%7Bposition%3Aabsolute%3Btop%3A%2D9999px%3Bwidth%3A50px%3Bheight%3A50px%3Boverflow%3Ascroll%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Emodal%2Ddialog%7Bwidth%3A600px%3Bmargin%3A30px%20auto%7D%2Emodal%2Dcontent%7B%2Dwebkit%2Dbox%2Dshadow%3A0%205px%2015px%20rgba%280%2C0%2C0%2C%2E5%29%3Bbox%2Dshadow%3A0%205px%2015px%20rgba%280%2C0%2C0%2C%2E5%29%7D%2Emodal%2Dsm%7Bwidth%3A300px%7D%7D%40media%20%28min%2Dwidth%3A992px%29%7B%2Emodal%2Dlg%7Bwidth%3A900px%7D%7D%2Etooltip%7Bposition%3Aabsolute%3Bz%2Dindex%3A1070%3Bdisplay%3Ablock%3Bfont%2Dfamily%3A%22Helvetica%20Neue%22%2CHelvetica%2CArial%2Csans%2Dserif%3Bfont%2Dsize%3A12px%3Bfont%2Dstyle%3Anormal%3Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%2E42857143%3Btext%2Dalign%3Aleft%3Btext%2Dalign%3Astart%3Btext%2Ddecoration%3Anone%3Btext%2Dshadow%3Anone%3Btext%2Dtransform%3Anone%3Bletter%2Dspacing%3Anormal%3Bword%2Dbreak%3Anormal%3Bword%2Dspacing%3Anormal%3Bword%2Dwrap%3Anormal%3Bwhite%2Dspace%3Anormal%3Bfilter%3Aalpha%28opacity%3D0%29%3Bopacity%3A0%3Bline%2Dbreak%3Aauto%7D%2Etooltip%2Ein%7Bfilter%3Aalpha%28opacity%3D90%29%3Bopacity%3A%2E9%7D%2Etooltip%2Etop%7Bpadding%3A5px%200%3Bmargin%2Dtop%3A%2D3px%7D%2Etooltip%2Eright%7Bpadding%3A0%205px%3Bmargin%2Dleft%3A3px%7D%2Etooltip%2Ebottom%7Bpadding%3A5px%200%3Bmargin%2Dtop%3A3px%7D%2Etooltip%2Eleft%7Bpadding%3A0%205px%3Bmargin%2Dleft%3A%2D3px%7D%2Etooltip%2Dinner%7Bmax%2Dwidth%3A200px%3Bpadding%3A3px%208px%3Bcolor%3A%23fff%3Btext%2Dalign%3Acenter%3Bbackground%2Dcolor%3A%23000%3Bborder%2Dradius%3A4px%7D%2Etooltip%2Darrow%7Bposition%3Aabsolute%3Bwidth%3A0%3Bheight%3A0%3Bborder%2Dcolor%3Atransparent%3Bborder%2Dstyle%3Asolid%7D%2Etooltip%2Etop%20%2Etooltip%2Darrow%7Bbottom%3A0%3Bleft%3A50%25%3Bmargin%2Dleft%3A%2D5px%3Bborder%2Dwidth%3A5px%205px%200%3Bborder%2Dtop%2Dcolor%3A%23000%7D%2Etooltip%2Etop%2Dleft%20%2Etooltip%2Darrow%7Bright%3A5px%3Bbottom%3A0%3Bmargin%2Dbottom%3A%2D5px%3Bborder%2Dwidth%3A5px%205px%200%3Bborder%2Dtop%2Dcolor%3A%23000%7D%2Etooltip%2Etop%2Dright%20%2Etooltip%2Darrow%7Bbottom%3A0%3Bleft%3A5px%3Bmargin%2Dbottom%3A%2D5px%3Bborder%2Dwidth%3A5px%205px%200%3Bborder%2Dtop%2Dcolor%3A%23000%7D%2Etooltip%2Eright%20%2Etooltip%2Darrow%7Btop%3A50%25%3Bleft%3A0%3Bmargin%2Dtop%3A%2D5px%3Bborder%2Dwidth%3A5px%205px%205px%200%3Bborder%2Dright%2Dcolor%3A%23000%7D%2Etooltip%2Eleft%20%2Etooltip%2Darrow%7Btop%3A50%25%3Bright%3A0%3Bmargin%2Dtop%3A%2D5px%3Bborder%2Dwidth%3A5px%200%205px%205px%3Bborder%2Dleft%2Dcolor%3A%23000%7D%2Etooltip%2Ebottom%20%2Etooltip%2Darrow%7Btop%3A0%3Bleft%3A50%25%3Bmargin%2Dleft%3A%2D5px%3Bborder%2Dwidth%3A0%205px%205px%3Bborder%2Dbottom%2Dcolor%3A%23000%7D%2Etooltip%2Ebottom%2Dleft%20%2Etooltip%2Darrow%7Btop%3A0%3Bright%3A5px%3Bmargin%2Dtop%3A%2D5px%3Bborder%2Dwidth%3A0%205px%205px%3Bborder%2Dbottom%2Dcolor%3A%23000%7D%2Etooltip%2Ebottom%2Dright%20%2Etooltip%2Darrow%7Btop%3A0%3Bleft%3A5px%3Bmargin%2Dtop%3A%2D5px%3Bborder%2Dwidth%3A0%205px%205px%3Bborder%2Dbottom%2Dcolor%3A%23000%7D%2Epopover%7Bposition%3Aabsolute%3Btop%3A0%3Bleft%3A0%3Bz%2Dindex%3A1060%3Bdisplay%3Anone%3Bmax%2Dwidth%3A276px%3Bpadding%3A1px%3Bfont%2Dfamily%3A%22Helvetica%20Neue%22%2CHelvetica%2CArial%2Csans%2Dserif%3Bfont%2Dsize%3A14px%3Bfont%2Dstyle%3Anormal%3Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%2E42857143%3Btext%2Dalign%3Aleft%3Btext%2Dalign%3Astart%3Btext%2Ddecoration%3Anone%3Btext%2Dshadow%3Anone%3Btext%2Dtransform%3Anone%3Bletter%2Dspacing%3Anormal%3Bword%2Dbreak%3Anormal%3Bword%2Dspacing%3Anormal%3Bword%2Dwrap%3Anormal%3Bwhite%2Dspace%3Anormal%3Bbackground%2Dcolor%3A%23fff%3B%2Dwebkit%2Dbackground%2Dclip%3Apadding%2Dbox%3Bbackground%2Dclip%3Apadding%2Dbox%3Bborder%3A1px%20solid%20%23ccc%3Bborder%3A1px%20solid%20rgba%280%2C0%2C0%2C%2E2%29%3Bborder%2Dradius%3A6px%3B%2Dwebkit%2Dbox%2Dshadow%3A0%205px%2010px%20rgba%280%2C0%2C0%2C%2E2%29%3Bbox%2Dshadow%3A0%205px%2010px%20rgba%280%2C0%2C0%2C%2E2%29%3Bline%2Dbreak%3Aauto%7D%2Epopover%2Etop%7Bmargin%2Dtop%3A%2D10px%7D%2Epopover%2Eright%7Bmargin%2Dleft%3A10px%7D%2Epopover%2Ebottom%7Bmargin%2Dtop%3A10px%7D%2Epopover%2Eleft%7Bmargin%2Dleft%3A%2D10px%7D%2Epopover%2Dtitle%7Bpadding%3A8px%2014px%3Bmargin%3A0%3Bfont%2Dsize%3A14px%3Bbackground%2Dcolor%3A%23f7f7f7%3Bborder%2Dbottom%3A1px%20solid%20%23ebebeb%3Bborder%2Dradius%3A5px%205px%200%200%7D%2Epopover%2Dcontent%7Bpadding%3A9px%2014px%7D%2Epopover%3E%2Earrow%2C%2Epopover%3E%2Earrow%3Aafter%7Bposition%3Aabsolute%3Bdisplay%3Ablock%3Bwidth%3A0%3Bheight%3A0%3Bborder%2Dcolor%3Atransparent%3Bborder%2Dstyle%3Asolid%7D%2Epopover%3E%2Earrow%7Bborder%2Dwidth%3A11px%7D%2Epopover%3E%2Earrow%3Aafter%7Bcontent%3A%22%22%3Bborder%2Dwidth%3A10px%7D%2Epopover%2Etop%3E%2Earrow%7Bbottom%3A%2D11px%3Bleft%3A50%25%3Bmargin%2Dleft%3A%2D11px%3Bborder%2Dtop%2Dcolor%3A%23999%3Bborder%2Dtop%2Dcolor%3Argba%280%2C0%2C0%2C%2E25%29%3Bborder%2Dbottom%2Dwidth%3A0%7D%2Epopover%2Etop%3E%2Earrow%3Aafter%7Bbottom%3A1px%3Bmargin%2Dleft%3A%2D10px%3Bcontent%3A%22%20%22%3Bborder%2Dtop%2Dcolor%3A%23fff%3Bborder%2Dbottom%2Dwidth%3A0%7D%2Epopover%2Eright%3E%2Earrow%7Btop%3A50%25%3Bleft%3A%2D11px%3Bmargin%2Dtop%3A%2D11px%3Bborder%2Dright%2Dcolor%3A%23999%3Bborder%2Dright%2Dcolor%3Argba%280%2C0%2C0%2C%2E25%29%3Bborder%2Dleft%2Dwidth%3A0%7D%2Epopover%2Eright%3E%2Earrow%3Aafter%7Bbottom%3A%2D10px%3Bleft%3A1px%3Bcontent%3A%22%20%22%3Bborder%2Dright%2Dcolor%3A%23fff%3Bborder%2Dleft%2Dwidth%3A0%7D%2Epopover%2Ebottom%3E%2Earrow%7Btop%3A%2D11px%3Bleft%3A50%25%3Bmargin%2Dleft%3A%2D11px%3Bborder%2Dtop%2Dwidth%3A0%3Bborder%2Dbottom%2Dcolor%3A%23999%3Bborder%2Dbottom%2Dcolor%3Argba%280%2C0%2C0%2C%2E25%29%7D%2Epopover%2Ebottom%3E%2Earrow%3Aafter%7Btop%3A1px%3Bmargin%2Dleft%3A%2D10px%3Bcontent%3A%22%20%22%3Bborder%2Dtop%2Dwidth%3A0%3Bborder%2Dbottom%2Dcolor%3A%23fff%7D%2Epopover%2Eleft%3E%2Earrow%7Btop%3A50%25%3Bright%3A%2D11px%3Bmargin%2Dtop%3A%2D11px%3Bborder%2Dright%2Dwidth%3A0%3Bborder%2Dleft%2Dcolor%3A%23999%3Bborder%2Dleft%2Dcolor%3Argba%280%2C0%2C0%2C%2E25%29%7D%2Epopover%2Eleft%3E%2Earrow%3Aafter%7Bright%3A1px%3Bbottom%3A%2D10px%3Bcontent%3A%22%20%22%3Bborder%2Dright%2Dwidth%3A0%3Bborder%2Dleft%2Dcolor%3A%23fff%7D%2Ecarousel%7Bposition%3Arelative%7D%2Ecarousel%2Dinner%7Bposition%3Arelative%3Bwidth%3A100%25%3Boverflow%3Ahidden%7D%2Ecarousel%2Dinner%3E%2Eitem%7Bposition%3Arelative%3Bdisplay%3Anone%3B%2Dwebkit%2Dtransition%3A%2E6s%20ease%2Din%2Dout%20left%3B%2Do%2Dtransition%3A%2E6s%20ease%2Din%2Dout%20left%3Btransition%3A%2E6s%20ease%2Din%2Dout%20left%7D%2Ecarousel%2Dinner%3E%2Eitem%3Ea%3Eimg%2C%2Ecarousel%2Dinner%3E%2Eitem%3Eimg%7Bline%2Dheight%3A1%7D%40media%20all%20and%20%28transform%2D3d%29%2C%28%2Dwebkit%2Dtransform%2D3d%29%7B%2Ecarousel%2Dinner%3E%2Eitem%7B%2Dwebkit%2Dtransition%3A%2Dwebkit%2Dtransform%20%2E6s%20ease%2Din%2Dout%3B%2Do%2Dtransition%3A%2Do%2Dtransform%20%2E6s%20ease%2Din%2Dout%3Btransition%3Atransform%20%2E6s%20ease%2Din%2Dout%3B%2Dwebkit%2Dbackface%2Dvisibility%3Ahidden%3Bbackface%2Dvisibility%3Ahidden%3B%2Dwebkit%2Dperspective%3A1000px%3Bperspective%3A1000px%7D%2Ecarousel%2Dinner%3E%2Eitem%2Eactive%2Eright%2C%2Ecarousel%2Dinner%3E%2Eitem%2Enext%7Bleft%3A0%3B%2Dwebkit%2Dtransform%3Atranslate3d%28100%25%2C0%2C0%29%3Btransform%3Atranslate3d%28100%25%2C0%2C0%29%7D%2Ecarousel%2Dinner%3E%2Eitem%2Eactive%2Eleft%2C%2Ecarousel%2Dinner%3E%2Eitem%2Eprev%7Bleft%3A0%3B%2Dwebkit%2Dtransform%3Atranslate3d%28%2D100%25%2C0%2C0%29%3Btransform%3Atranslate3d%28%2D100%25%2C0%2C0%29%7D%2Ecarousel%2Dinner%3E%2Eitem%2Eactive%2C%2Ecarousel%2Dinner%3E%2Eitem%2Enext%2Eleft%2C%2Ecarousel%2Dinner%3E%2Eitem%2Eprev%2Eright%7Bleft%3A0%3B%2Dwebkit%2Dtransform%3Atranslate3d%280%2C0%2C0%29%3Btransform%3Atranslate3d%280%2C0%2C0%29%7D%7D%2Ecarousel%2Dinner%3E%2Eactive%2C%2Ecarousel%2Dinner%3E%2Enext%2C%2Ecarousel%2Dinner%3E%2Eprev%7Bdisplay%3Ablock%7D%2Ecarousel%2Dinner%3E%2Eactive%7Bleft%3A0%7D%2Ecarousel%2Dinner%3E%2Enext%2C%2Ecarousel%2Dinner%3E%2Eprev%7Bposition%3Aabsolute%3Btop%3A0%3Bwidth%3A100%25%7D%2Ecarousel%2Dinner%3E%2Enext%7Bleft%3A100%25%7D%2Ecarousel%2Dinner%3E%2Eprev%7Bleft%3A%2D100%25%7D%2Ecarousel%2Dinner%3E%2Enext%2Eleft%2C%2Ecarousel%2Dinner%3E%2Eprev%2Eright%7Bleft%3A0%7D%2Ecarousel%2Dinner%3E%2Eactive%2Eleft%7Bleft%3A%2D100%25%7D%2Ecarousel%2Dinner%3E%2Eactive%2Eright%7Bleft%3A100%25%7D%2Ecarousel%2Dcontrol%7Bposition%3Aabsolute%3Btop%3A0%3Bbottom%3A0%3Bleft%3A0%3Bwidth%3A15%25%3Bfont%2Dsize%3A20px%3Bcolor%3A%23fff%3Btext%2Dalign%3Acenter%3Btext%2Dshadow%3A0%201px%202px%20rgba%280%2C0%2C0%2C%2E6%29%3Bfilter%3Aalpha%28opacity%3D50%29%3Bopacity%3A%2E5%7D%2Ecarousel%2Dcontrol%2Eleft%7Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%28left%2Crgba%280%2C0%2C0%2C%2E5%29%200%2Crgba%280%2C0%2C0%2C%2E0001%29%20100%25%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%28left%2Crgba%280%2C0%2C0%2C%2E5%29%200%2Crgba%280%2C0%2C0%2C%2E0001%29%20100%25%29%3Bbackground%2Dimage%3A%2Dwebkit%2Dgradient%28linear%2Cleft%20top%2Cright%20top%2Cfrom%28rgba%280%2C0%2C0%2C%2E5%29%29%2Cto%28rgba%280%2C0%2C0%2C%2E0001%29%29%29%3Bbackground%2Dimage%3Alinear%2Dgradient%28to%20right%2Crgba%280%2C0%2C0%2C%2E5%29%200%2Crgba%280%2C0%2C0%2C%2E0001%29%20100%25%29%3Bfilter%3Aprogid%3ADXImageTransform%2EMicrosoft%2Egradient%28startColorstr%3D%27%2380000000%27%2C%20endColorstr%3D%27%2300000000%27%2C%20GradientType%3D1%29%3Bbackground%2Drepeat%3Arepeat%2Dx%7D%2Ecarousel%2Dcontrol%2Eright%7Bright%3A0%3Bleft%3Aauto%3Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%28left%2Crgba%280%2C0%2C0%2C%2E0001%29%200%2Crgba%280%2C0%2C0%2C%2E5%29%20100%25%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%28left%2Crgba%280%2C0%2C0%2C%2E0001%29%200%2Crgba%280%2C0%2C0%2C%2E5%29%20100%25%29%3Bbackground%2Dimage%3A%2Dwebkit%2Dgradient%28linear%2Cleft%20top%2Cright%20top%2Cfrom%28rgba%280%2C0%2C0%2C%2E0001%29%29%2Cto%28rgba%280%2C0%2C0%2C%2E5%29%29%29%3Bbackground%2Dimage%3Alinear%2Dgradient%28to%20right%2Crgba%280%2C0%2C0%2C%2E0001%29%200%2Crgba%280%2C0%2C0%2C%2E5%29%20100%25%29%3Bfilter%3Aprogid%3ADXImageTransform%2EMicrosoft%2Egradient%28startColorstr%3D%27%2300000000%27%2C%20endColorstr%3D%27%2380000000%27%2C%20GradientType%3D1%29%3Bbackground%2Drepeat%3Arepeat%2Dx%7D%2Ecarousel%2Dcontrol%3Afocus%2C%2Ecarousel%2Dcontrol%3Ahover%7Bcolor%3A%23fff%3Btext%2Ddecoration%3Anone%3Bfilter%3Aalpha%28opacity%3D90%29%3Boutline%3A0%3Bopacity%3A%2E9%7D%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dleft%2C%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dright%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dnext%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dprev%7Bposition%3Aabsolute%3Btop%3A50%25%3Bz%2Dindex%3A5%3Bdisplay%3Ainline%2Dblock%3Bmargin%2Dtop%3A%2D10px%7D%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dleft%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dprev%7Bleft%3A50%25%3Bmargin%2Dleft%3A%2D10px%7D%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dright%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dnext%7Bright%3A50%25%3Bmargin%2Dright%3A%2D10px%7D%2Ecarousel%2Dcontrol%20%2Eicon%2Dnext%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dprev%7Bwidth%3A20px%3Bheight%3A20px%3Bfont%2Dfamily%3Aserif%3Bline%2Dheight%3A1%7D%2Ecarousel%2Dcontrol%20%2Eicon%2Dprev%3Abefore%7Bcontent%3A%27%5C2039%27%7D%2Ecarousel%2Dcontrol%20%2Eicon%2Dnext%3Abefore%7Bcontent%3A%27%5C203a%27%7D%2Ecarousel%2Dindicators%7Bposition%3Aabsolute%3Bbottom%3A10px%3Bleft%3A50%25%3Bz%2Dindex%3A15%3Bwidth%3A60%25%3Bpadding%2Dleft%3A0%3Bmargin%2Dleft%3A%2D30%25%3Btext%2Dalign%3Acenter%3Blist%2Dstyle%3Anone%7D%2Ecarousel%2Dindicators%20li%7Bdisplay%3Ainline%2Dblock%3Bwidth%3A10px%3Bheight%3A10px%3Bmargin%3A1px%3Btext%2Dindent%3A%2D999px%3Bcursor%3Apointer%3Bbackground%2Dcolor%3A%23000%5C9%3Bbackground%2Dcolor%3Argba%280%2C0%2C0%2C0%29%3Bborder%3A1px%20solid%20%23fff%3Bborder%2Dradius%3A10px%7D%2Ecarousel%2Dindicators%20%2Eactive%7Bwidth%3A12px%3Bheight%3A12px%3Bmargin%3A0%3Bbackground%2Dcolor%3A%23fff%7D%2Ecarousel%2Dcaption%7Bposition%3Aabsolute%3Bright%3A15%25%3Bbottom%3A20px%3Bleft%3A15%25%3Bz%2Dindex%3A10%3Bpadding%2Dtop%3A20px%3Bpadding%2Dbottom%3A20px%3Bcolor%3A%23fff%3Btext%2Dalign%3Acenter%3Btext%2Dshadow%3A0%201px%202px%20rgba%280%2C0%2C0%2C%2E6%29%7D%2Ecarousel%2Dcaption%20%2Ebtn%7Btext%2Dshadow%3Anone%7D%40media%20screen%20and%20%28min%2Dwidth%3A768px%29%7B%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dleft%2C%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dright%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dnext%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dprev%7Bwidth%3A30px%3Bheight%3A30px%3Bmargin%2Dtop%3A%2D15px%3Bfont%2Dsize%3A30px%7D%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dleft%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dprev%7Bmargin%2Dleft%3A%2D15px%7D%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dright%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dnext%7Bmargin%2Dright%3A%2D15px%7D%2Ecarousel%2Dcaption%7Bright%3A20%25%3Bleft%3A20%25%3Bpadding%2Dbottom%3A30px%7D%2Ecarousel%2Dindicators%7Bbottom%3A20px%7D%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Aafter%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Abefore%2C%2Ebtn%2Dtoolbar%3Aafter%2C%2Ebtn%2Dtoolbar%3Abefore%2C%2Eclearfix%3Aafter%2C%2Eclearfix%3Abefore%2C%2Econtainer%2Dfluid%3Aafter%2C%2Econtainer%2Dfluid%3Abefore%2C%2Econtainer%3Aafter%2C%2Econtainer%3Abefore%2C%2Edl%2Dhorizontal%20dd%3Aafter%2C%2Edl%2Dhorizontal%20dd%3Abefore%2C%2Eform%2Dhorizontal%20%2Eform%2Dgroup%3Aafter%2C%2Eform%2Dhorizontal%20%2Eform%2Dgroup%3Abefore%2C%2Emodal%2Dfooter%3Aafter%2C%2Emodal%2Dfooter%3Abefore%2C%2Enav%3Aafter%2C%2Enav%3Abefore%2C%2Enavbar%2Dcollapse%3Aafter%2C%2Enavbar%2Dcollapse%3Abefore%2C%2Enavbar%2Dheader%3Aafter%2C%2Enavbar%2Dheader%3Abefore%2C%2Enavbar%3Aafter%2C%2Enavbar%3Abefore%2C%2Epager%3Aafter%2C%2Epager%3Abefore%2C%2Epanel%2Dbody%3Aafter%2C%2Epanel%2Dbody%3Abefore%2C%2Erow%3Aafter%2C%2Erow%3Abefore%7Bdisplay%3Atable%3Bcontent%3A%22%20%22%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Aafter%2C%2Ebtn%2Dtoolbar%3Aafter%2C%2Eclearfix%3Aafter%2C%2Econtainer%2Dfluid%3Aafter%2C%2Econtainer%3Aafter%2C%2Edl%2Dhorizontal%20dd%3Aafter%2C%2Eform%2Dhorizontal%20%2Eform%2Dgroup%3Aafter%2C%2Emodal%2Dfooter%3Aafter%2C%2Enav%3Aafter%2C%2Enavbar%2Dcollapse%3Aafter%2C%2Enavbar%2Dheader%3Aafter%2C%2Enavbar%3Aafter%2C%2Epager%3Aafter%2C%2Epanel%2Dbody%3Aafter%2C%2Erow%3Aafter%7Bclear%3Aboth%7D%2Ecenter%2Dblock%7Bdisplay%3Ablock%3Bmargin%2Dright%3Aauto%3Bmargin%2Dleft%3Aauto%7D%2Epull%2Dright%7Bfloat%3Aright%21important%7D%2Epull%2Dleft%7Bfloat%3Aleft%21important%7D%2Ehide%7Bdisplay%3Anone%21important%7D%2Eshow%7Bdisplay%3Ablock%21important%7D%2Einvisible%7Bvisibility%3Ahidden%7D%2Etext%2Dhide%7Bfont%3A0%2F0%20a%3Bcolor%3Atransparent%3Btext%2Dshadow%3Anone%3Bbackground%2Dcolor%3Atransparent%3Bborder%3A0%7D%2Ehidden%7Bdisplay%3Anone%21important%7D%2Eaffix%7Bposition%3Afixed%7D%40%2Dms%2Dviewport%7Bwidth%3Adevice%2Dwidth%7D%2Evisible%2Dlg%2C%2Evisible%2Dmd%2C%2Evisible%2Dsm%2C%2Evisible%2Dxs%7Bdisplay%3Anone%21important%7D%2Evisible%2Dlg%2Dblock%2C%2Evisible%2Dlg%2Dinline%2C%2Evisible%2Dlg%2Dinline%2Dblock%2C%2Evisible%2Dmd%2Dblock%2C%2Evisible%2Dmd%2Dinline%2C%2Evisible%2Dmd%2Dinline%2Dblock%2C%2Evisible%2Dsm%2Dblock%2C%2Evisible%2Dsm%2Dinline%2C%2Evisible%2Dsm%2Dinline%2Dblock%2C%2Evisible%2Dxs%2Dblock%2C%2Evisible%2Dxs%2Dinline%2C%2Evisible%2Dxs%2Dinline%2Dblock%7Bdisplay%3Anone%21important%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Evisible%2Dxs%7Bdisplay%3Ablock%21important%7Dtable%2Evisible%2Dxs%7Bdisplay%3Atable%21important%7Dtr%2Evisible%2Dxs%7Bdisplay%3Atable%2Drow%21important%7Dtd%2Evisible%2Dxs%2Cth%2Evisible%2Dxs%7Bdisplay%3Atable%2Dcell%21important%7D%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Evisible%2Dxs%2Dblock%7Bdisplay%3Ablock%21important%7D%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Evisible%2Dxs%2Dinline%7Bdisplay%3Ainline%21important%7D%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Evisible%2Dxs%2Dinline%2Dblock%7Bdisplay%3Ainline%2Dblock%21important%7D%7D%40media%20%28min%2Dwidth%3A768px%29%20and%20%28max%2Dwidth%3A991px%29%7B%2Evisible%2Dsm%7Bdisplay%3Ablock%21important%7Dtable%2Evisible%2Dsm%7Bdisplay%3Atable%21important%7Dtr%2Evisible%2Dsm%7Bdisplay%3Atable%2Drow%21important%7Dtd%2Evisible%2Dsm%2Cth%2Evisible%2Dsm%7Bdisplay%3Atable%2Dcell%21important%7D%7D%40media%20%28min%2Dwidth%3A768px%29%20and%20%28max%2Dwidth%3A991px%29%7B%2Evisible%2Dsm%2Dblock%7Bdisplay%3Ablock%21important%7D%7D%40media%20%28min%2Dwidth%3A768px%29%20and%20%28max%2Dwidth%3A991px%29%7B%2Evisible%2Dsm%2Dinline%7Bdisplay%3Ainline%21important%7D%7D%40media%20%28min%2Dwidth%3A768px%29%20and%20%28max%2Dwidth%3A991px%29%7B%2Evisible%2Dsm%2Dinline%2Dblock%7Bdisplay%3Ainline%2Dblock%21important%7D%7D%40media%20%28min%2Dwidth%3A992px%29%20and%20%28max%2Dwidth%3A1199px%29%7B%2Evisible%2Dmd%7Bdisplay%3Ablock%21important%7Dtable%2Evisible%2Dmd%7Bdisplay%3Atable%21important%7Dtr%2Evisible%2Dmd%7Bdisplay%3Atable%2Drow%21important%7Dtd%2Evisible%2Dmd%2Cth%2Evisible%2Dmd%7Bdisplay%3Atable%2Dcell%21important%7D%7D%40media%20%28min%2Dwidth%3A992px%29%20and%20%28max%2Dwidth%3A1199px%29%7B%2Evisible%2Dmd%2Dblock%7Bdisplay%3Ablock%21important%7D%7D%40media%20%28min%2Dwidth%3A992px%29%20and%20%28max%2Dwidth%3A1199px%29%7B%2Evisible%2Dmd%2Dinline%7Bdisplay%3Ainline%21important%7D%7D%40media%20%28min%2Dwidth%3A992px%29%20and%20%28max%2Dwidth%3A1199px%29%7B%2Evisible%2Dmd%2Dinline%2Dblock%7Bdisplay%3Ainline%2Dblock%21important%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Evisible%2Dlg%7Bdisplay%3Ablock%21important%7Dtable%2Evisible%2Dlg%7Bdisplay%3Atable%21important%7Dtr%2Evisible%2Dlg%7Bdisplay%3Atable%2Drow%21important%7Dtd%2Evisible%2Dlg%2Cth%2Evisible%2Dlg%7Bdisplay%3Atable%2Dcell%21important%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Evisible%2Dlg%2Dblock%7Bdisplay%3Ablock%21important%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Evisible%2Dlg%2Dinline%7Bdisplay%3Ainline%21important%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Evisible%2Dlg%2Dinline%2Dblock%7Bdisplay%3Ainline%2Dblock%21important%7D%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Ehidden%2Dxs%7Bdisplay%3Anone%21important%7D%7D%40media%20%28min%2Dwidth%3A768px%29%20and%20%28max%2Dwidth%3A991px%29%7B%2Ehidden%2Dsm%7Bdisplay%3Anone%21important%7D%7D%40media%20%28min%2Dwidth%3A992px%29%20and%20%28max%2Dwidth%3A1199px%29%7B%2Ehidden%2Dmd%7Bdisplay%3Anone%21important%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Ehidden%2Dlg%7Bdisplay%3Anone%21important%7D%7D%2Evisible%2Dprint%7Bdisplay%3Anone%21important%7D%40media%20print%7B%2Evisible%2Dprint%7Bdisplay%3Ablock%21important%7Dtable%2Evisible%2Dprint%7Bdisplay%3Atable%21important%7Dtr%2Evisible%2Dprint%7Bdisplay%3Atable%2Drow%21important%7Dtd%2Evisible%2Dprint%2Cth%2Evisible%2Dprint%7Bdisplay%3Atable%2Dcell%21important%7D%7D%2Evisible%2Dprint%2Dblock%7Bdisplay%3Anone%21important%7D%40media%20print%7B%2Evisible%2Dprint%2Dblock%7Bdisplay%3Ablock%21important%7D%7D%2Evisible%2Dprint%2Dinline%7Bdisplay%3Anone%21important%7D%40media%20print%7B%2Evisible%2Dprint%2Dinline%7Bdisplay%3Ainline%21important%7D%7D%2Evisible%2Dprint%2Dinline%2Dblock%7Bdisplay%3Anone%21important%7D%40media%20print%7B%2Evisible%2Dprint%2Dinline%2Dblock%7Bdisplay%3Ainline%2Dblock%21important%7D%7D%40media%20print%7B%2Ehidden%2Dprint%7Bdisplay%3Anone%21important%7D%7D%0A" rel="stylesheet" />
<script src="data:application/javascript;base64,/*!
 * Bootstrap v3.3.5 (http://getbootstrap.com)
 * Copyright 2011-2015 Twitter, Inc.
 * Licensed under the MIT license
 */
if("undefined"==typeof jQuery)throw new Error("Bootstrap's JavaScript requires jQuery");+function(a){"use strict";var b=a.fn.jquery.split(" ")[0].split(".");if(b[0]<2&&b[1]<9||1==b[0]&&9==b[1]&&b[2]<1)throw new Error("Bootstrap's JavaScript requires jQuery version 1.9.1 or higher")}(jQuery),+function(a){"use strict";function b(){var a=document.createElement("bootstrap"),b={WebkitTransition:"webkitTransitionEnd",MozTransition:"transitionend",OTransition:"oTransitionEnd otransitionend",transition:"transitionend"};for(var c in b)if(void 0!==a.style[c])return{end:b[c]};return!1}a.fn.emulateTransitionEnd=function(b){var c=!1,d=this;a(this).one("bsTransitionEnd",function(){c=!0});var e=function(){c||a(d).trigger(a.support.transition.end)};return setTimeout(e,b),this},a(function(){a.support.transition=b(),a.support.transition&&(a.event.special.bsTransitionEnd={bindType:a.support.transition.end,delegateType:a.support.transition.end,handle:function(b){return a(b.target).is(this)?b.handleObj.handler.apply(this,arguments):void 0}})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var c=a(this),e=c.data("bs.alert");e||c.data("bs.alert",e=new d(this)),"string"==typeof b&&e[b].call(c)})}var c='[data-dismiss="alert"]',d=function(b){a(b).on("click",c,this.close)};d.VERSION="3.3.5",d.TRANSITION_DURATION=150,d.prototype.close=function(b){function c(){g.detach().trigger("closed.bs.alert").remove()}var e=a(this),f=e.attr("data-target");f||(f=e.attr("href"),f=f&&f.replace(/.*(?=#[^\s]*$)/,""));var g=a(f);b&&b.preventDefault(),g.length||(g=e.closest(".alert")),g.trigger(b=a.Event("close.bs.alert")),b.isDefaultPrevented()||(g.removeClass("in"),a.support.transition&&g.hasClass("fade")?g.one("bsTransitionEnd",c).emulateTransitionEnd(d.TRANSITION_DURATION):c())};var e=a.fn.alert;a.fn.alert=b,a.fn.alert.Constructor=d,a.fn.alert.noConflict=function(){return a.fn.alert=e,this},a(document).on("click.bs.alert.data-api",c,d.prototype.close)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.button"),f="object"==typeof b&&b;e||d.data("bs.button",e=new c(this,f)),"toggle"==b?e.toggle():b&&e.setState(b)})}var c=function(b,d){this.$element=a(b),this.options=a.extend({},c.DEFAULTS,d),this.isLoading=!1};c.VERSION="3.3.5",c.DEFAULTS={loadingText:"loading..."},c.prototype.setState=function(b){var c="disabled",d=this.$element,e=d.is("input")?"val":"html",f=d.data();b+="Text",null==f.resetText&&d.data("resetText",d[e]()),setTimeout(a.proxy(function(){d[e](null==f[b]?this.options[b]:f[b]),"loadingText"==b?(this.isLoading=!0,d.addClass(c).attr(c,c)):this.isLoading&&(this.isLoading=!1,d.removeClass(c).removeAttr(c))},this),0)},c.prototype.toggle=function(){var a=!0,b=this.$element.closest('[data-toggle="buttons"]');if(b.length){var c=this.$element.find("input");"radio"==c.prop("type")?(c.prop("checked")&&(a=!1),b.find(".active").removeClass("active"),this.$element.addClass("active")):"checkbox"==c.prop("type")&&(c.prop("checked")!==this.$element.hasClass("active")&&(a=!1),this.$element.toggleClass("active")),c.prop("checked",this.$element.hasClass("active")),a&&c.trigger("change")}else this.$element.attr("aria-pressed",!this.$element.hasClass("active")),this.$element.toggleClass("active")};var d=a.fn.button;a.fn.button=b,a.fn.button.Constructor=c,a.fn.button.noConflict=function(){return a.fn.button=d,this},a(document).on("click.bs.button.data-api",'[data-toggle^="button"]',function(c){var d=a(c.target);d.hasClass("btn")||(d=d.closest(".btn")),b.call(d,"toggle"),a(c.target).is('input[type="radio"]')||a(c.target).is('input[type="checkbox"]')||c.preventDefault()}).on("focus.bs.button.data-api blur.bs.button.data-api",'[data-toggle^="button"]',function(b){a(b.target).closest(".btn").toggleClass("focus",/^focus(in)?$/.test(b.type))})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.carousel"),f=a.extend({},c.DEFAULTS,d.data(),"object"==typeof b&&b),g="string"==typeof b?b:f.slide;e||d.data("bs.carousel",e=new c(this,f)),"number"==typeof b?e.to(b):g?e[g]():f.interval&&e.pause().cycle()})}var c=function(b,c){this.$element=a(b),this.$indicators=this.$element.find(".carousel-indicators"),this.options=c,this.paused=null,this.sliding=null,this.interval=null,this.$active=null,this.$items=null,this.options.keyboard&&this.$element.on("keydown.bs.carousel",a.proxy(this.keydown,this)),"hover"==this.options.pause&&!("ontouchstart"in document.documentElement)&&this.$element.on("mouseenter.bs.carousel",a.proxy(this.pause,this)).on("mouseleave.bs.carousel",a.proxy(this.cycle,this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=600,c.DEFAULTS={interval:5e3,pause:"hover",wrap:!0,keyboard:!0},c.prototype.keydown=function(a){if(!/input|textarea/i.test(a.target.tagName)){switch(a.which){case 37:this.prev();break;case 39:this.next();break;default:return}a.preventDefault()}},c.prototype.cycle=function(b){return b||(this.paused=!1),this.interval&&clearInterval(this.interval),this.options.interval&&!this.paused&&(this.interval=setInterval(a.proxy(this.next,this),this.options.interval)),this},c.prototype.getItemIndex=function(a){return this.$items=a.parent().children(".item"),this.$items.index(a||this.$active)},c.prototype.getItemForDirection=function(a,b){var c=this.getItemIndex(b),d="prev"==a&&0===c||"next"==a&&c==this.$items.length-1;if(d&&!this.options.wrap)return b;var e="prev"==a?-1:1,f=(c+e)%this.$items.length;return this.$items.eq(f)},c.prototype.to=function(a){var b=this,c=this.getItemIndex(this.$active=this.$element.find(".item.active"));return a>this.$items.length-1||0>a?void 0:this.sliding?this.$element.one("slid.bs.carousel",function(){b.to(a)}):c==a?this.pause().cycle():this.slide(a>c?"next":"prev",this.$items.eq(a))},c.prototype.pause=function(b){return b||(this.paused=!0),this.$element.find(".next, .prev").length&&a.support.transition&&(this.$element.trigger(a.support.transition.end),this.cycle(!0)),this.interval=clearInterval(this.interval),this},c.prototype.next=function(){return this.sliding?void 0:this.slide("next")},c.prototype.prev=function(){return this.sliding?void 0:this.slide("prev")},c.prototype.slide=function(b,d){var e=this.$element.find(".item.active"),f=d||this.getItemForDirection(b,e),g=this.interval,h="next"==b?"left":"right",i=this;if(f.hasClass("active"))return this.sliding=!1;var j=f[0],k=a.Event("slide.bs.carousel",{relatedTarget:j,direction:h});if(this.$element.trigger(k),!k.isDefaultPrevented()){if(this.sliding=!0,g&&this.pause(),this.$indicators.length){this.$indicators.find(".active").removeClass("active");var l=a(this.$indicators.children()[this.getItemIndex(f)]);l&&l.addClass("active")}var m=a.Event("slid.bs.carousel",{relatedTarget:j,direction:h});return a.support.transition&&this.$element.hasClass("slide")?(f.addClass(b),f[0].offsetWidth,e.addClass(h),f.addClass(h),e.one("bsTransitionEnd",function(){f.removeClass([b,h].join(" ")).addClass("active"),e.removeClass(["active",h].join(" ")),i.sliding=!1,setTimeout(function(){i.$element.trigger(m)},0)}).emulateTransitionEnd(c.TRANSITION_DURATION)):(e.removeClass("active"),f.addClass("active"),this.sliding=!1,this.$element.trigger(m)),g&&this.cycle(),this}};var d=a.fn.carousel;a.fn.carousel=b,a.fn.carousel.Constructor=c,a.fn.carousel.noConflict=function(){return a.fn.carousel=d,this};var e=function(c){var d,e=a(this),f=a(e.attr("data-target")||(d=e.attr("href"))&&d.replace(/.*(?=#[^\s]+$)/,""));if(f.hasClass("carousel")){var g=a.extend({},f.data(),e.data()),h=e.attr("data-slide-to");h&&(g.interval=!1),b.call(f,g),h&&f.data("bs.carousel").to(h),c.preventDefault()}};a(document).on("click.bs.carousel.data-api","[data-slide]",e).on("click.bs.carousel.data-api","[data-slide-to]",e),a(window).on("load",function(){a('[data-ride="carousel"]').each(function(){var c=a(this);b.call(c,c.data())})})}(jQuery),+function(a){"use strict";function b(b){var c,d=b.attr("data-target")||(c=b.attr("href"))&&c.replace(/.*(?=#[^\s]+$)/,"");return a(d)}function c(b){return this.each(function(){var c=a(this),e=c.data("bs.collapse"),f=a.extend({},d.DEFAULTS,c.data(),"object"==typeof b&&b);!e&&f.toggle&&/show|hide/.test(b)&&(f.toggle=!1),e||c.data("bs.collapse",e=new d(this,f)),"string"==typeof b&&e[b]()})}var d=function(b,c){this.$element=a(b),this.options=a.extend({},d.DEFAULTS,c),this.$trigger=a('[data-toggle="collapse"][href="#'+b.id+'"],[data-toggle="collapse"][data-target="#'+b.id+'"]'),this.transitioning=null,this.options.parent?this.$parent=this.getParent():this.addAriaAndCollapsedClass(this.$element,this.$trigger),this.options.toggle&&this.toggle()};d.VERSION="3.3.5",d.TRANSITION_DURATION=350,d.DEFAULTS={toggle:!0},d.prototype.dimension=function(){var a=this.$element.hasClass("width");return a?"width":"height"},d.prototype.show=function(){if(!this.transitioning&&!this.$element.hasClass("in")){var b,e=this.$parent&&this.$parent.children(".panel").children(".in, .collapsing");if(!(e&&e.length&&(b=e.data("bs.collapse"),b&&b.transitioning))){var f=a.Event("show.bs.collapse");if(this.$element.trigger(f),!f.isDefaultPrevented()){e&&e.length&&(c.call(e,"hide"),b||e.data("bs.collapse",null));var g=this.dimension();this.$element.removeClass("collapse").addClass("collapsing")[g](0).attr("aria-expanded",!0),this.$trigger.removeClass("collapsed").attr("aria-expanded",!0),this.transitioning=1;var h=function(){this.$element.removeClass("collapsing").addClass("collapse in")[g](""),this.transitioning=0,this.$element.trigger("shown.bs.collapse")};if(!a.support.transition)return h.call(this);var i=a.camelCase(["scroll",g].join("-"));this.$element.one("bsTransitionEnd",a.proxy(h,this)).emulateTransitionEnd(d.TRANSITION_DURATION)[g](this.$element[0][i])}}}},d.prototype.hide=function(){if(!this.transitioning&&this.$element.hasClass("in")){var b=a.Event("hide.bs.collapse");if(this.$element.trigger(b),!b.isDefaultPrevented()){var c=this.dimension();this.$element[c](this.$element[c]())[0].offsetHeight,this.$element.addClass("collapsing").removeClass("collapse in").attr("aria-expanded",!1),this.$trigger.addClass("collapsed").attr("aria-expanded",!1),this.transitioning=1;var e=function(){this.transitioning=0,this.$element.removeClass("collapsing").addClass("collapse").trigger("hidden.bs.collapse")};return a.support.transition?void this.$element[c](0).one("bsTransitionEnd",a.proxy(e,this)).emulateTransitionEnd(d.TRANSITION_DURATION):e.call(this)}}},d.prototype.toggle=function(){this[this.$element.hasClass("in")?"hide":"show"]()},d.prototype.getParent=function(){return a(this.options.parent).find('[data-toggle="collapse"][data-parent="'+this.options.parent+'"]').each(a.proxy(function(c,d){var e=a(d);this.addAriaAndCollapsedClass(b(e),e)},this)).end()},d.prototype.addAriaAndCollapsedClass=function(a,b){var c=a.hasClass("in");a.attr("aria-expanded",c),b.toggleClass("collapsed",!c).attr("aria-expanded",c)};var e=a.fn.collapse;a.fn.collapse=c,a.fn.collapse.Constructor=d,a.fn.collapse.noConflict=function(){return a.fn.collapse=e,this},a(document).on("click.bs.collapse.data-api",'[data-toggle="collapse"]',function(d){var e=a(this);e.attr("data-target")||d.preventDefault();var f=b(e),g=f.data("bs.collapse"),h=g?"toggle":e.data();c.call(f,h)})}(jQuery),+function(a){"use strict";function b(b){var c=b.attr("data-target");c||(c=b.attr("href"),c=c&&/#[A-Za-z]/.test(c)&&c.replace(/.*(?=#[^\s]*$)/,""));var d=c&&a(c);return d&&d.length?d:b.parent()}function c(c){c&&3===c.which||(a(e).remove(),a(f).each(function(){var d=a(this),e=b(d),f={relatedTarget:this};e.hasClass("open")&&(c&&"click"==c.type&&/input|textarea/i.test(c.target.tagName)&&a.contains(e[0],c.target)||(e.trigger(c=a.Event("hide.bs.dropdown",f)),c.isDefaultPrevented()||(d.attr("aria-expanded","false"),e.removeClass("open").trigger("hidden.bs.dropdown",f))))}))}function d(b){return this.each(function(){var c=a(this),d=c.data("bs.dropdown");d||c.data("bs.dropdown",d=new g(this)),"string"==typeof b&&d[b].call(c)})}var e=".dropdown-backdrop",f='[data-toggle="dropdown"]',g=function(b){a(b).on("click.bs.dropdown",this.toggle)};g.VERSION="3.3.5",g.prototype.toggle=function(d){var e=a(this);if(!e.is(".disabled, :disabled")){var f=b(e),g=f.hasClass("open");if(c(),!g){"ontouchstart"in document.documentElement&&!f.closest(".navbar-nav").length&&a(document.createElement("div")).addClass("dropdown-backdrop").insertAfter(a(this)).on("click",c);var h={relatedTarget:this};if(f.trigger(d=a.Event("show.bs.dropdown",h)),d.isDefaultPrevented())return;e.trigger("focus").attr("aria-expanded","true"),f.toggleClass("open").trigger("shown.bs.dropdown",h)}return!1}},g.prototype.keydown=function(c){if(/(38|40|27|32)/.test(c.which)&&!/input|textarea/i.test(c.target.tagName)){var d=a(this);if(c.preventDefault(),c.stopPropagation(),!d.is(".disabled, :disabled")){var e=b(d),g=e.hasClass("open");if(!g&&27!=c.which||g&&27==c.which)return 27==c.which&&e.find(f).trigger("focus"),d.trigger("click");var h=" li:not(.disabled):visible a",i=e.find(".dropdown-menu"+h);if(i.length){var j=i.index(c.target);38==c.which&&j>0&&j--,40==c.which&&j<i.length-1&&j++,~j||(j=0),i.eq(j).trigger("focus")}}}};var h=a.fn.dropdown;a.fn.dropdown=d,a.fn.dropdown.Constructor=g,a.fn.dropdown.noConflict=function(){return a.fn.dropdown=h,this},a(document).on("click.bs.dropdown.data-api",c).on("click.bs.dropdown.data-api",".dropdown form",function(a){a.stopPropagation()}).on("click.bs.dropdown.data-api",f,g.prototype.toggle).on("keydown.bs.dropdown.data-api",f,g.prototype.keydown).on("keydown.bs.dropdown.data-api",".dropdown-menu",g.prototype.keydown)}(jQuery),+function(a){"use strict";function b(b,d){return this.each(function(){var e=a(this),f=e.data("bs.modal"),g=a.extend({},c.DEFAULTS,e.data(),"object"==typeof b&&b);f||e.data("bs.modal",f=new c(this,g)),"string"==typeof b?f[b](d):g.show&&f.show(d)})}var c=function(b,c){this.options=c,this.$body=a(document.body),this.$element=a(b),this.$dialog=this.$element.find(".modal-dialog"),this.$backdrop=null,this.isShown=null,this.originalBodyPad=null,this.scrollbarWidth=0,this.ignoreBackdropClick=!1,this.options.remote&&this.$element.find(".modal-content").load(this.options.remote,a.proxy(function(){this.$element.trigger("loaded.bs.modal")},this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=300,c.BACKDROP_TRANSITION_DURATION=150,c.DEFAULTS={backdrop:!0,keyboard:!0,show:!0},c.prototype.toggle=function(a){return this.isShown?this.hide():this.show(a)},c.prototype.show=function(b){var d=this,e=a.Event("show.bs.modal",{relatedTarget:b});this.$element.trigger(e),this.isShown||e.isDefaultPrevented()||(this.isShown=!0,this.checkScrollbar(),this.setScrollbar(),this.$body.addClass("modal-open"),this.escape(),this.resize(),this.$element.on("click.dismiss.bs.modal",'[data-dismiss="modal"]',a.proxy(this.hide,this)),this.$dialog.on("mousedown.dismiss.bs.modal",function(){d.$element.one("mouseup.dismiss.bs.modal",function(b){a(b.target).is(d.$element)&&(d.ignoreBackdropClick=!0)})}),this.backdrop(function(){var e=a.support.transition&&d.$element.hasClass("fade");d.$element.parent().length||d.$element.appendTo(d.$body),d.$element.show().scrollTop(0),d.adjustDialog(),e&&d.$element[0].offsetWidth,d.$element.addClass("in"),d.enforceFocus();var f=a.Event("shown.bs.modal",{relatedTarget:b});e?d.$dialog.one("bsTransitionEnd",function(){d.$element.trigger("focus").trigger(f)}).emulateTransitionEnd(c.TRANSITION_DURATION):d.$element.trigger("focus").trigger(f)}))},c.prototype.hide=function(b){b&&b.preventDefault(),b=a.Event("hide.bs.modal"),this.$element.trigger(b),this.isShown&&!b.isDefaultPrevented()&&(this.isShown=!1,this.escape(),this.resize(),a(document).off("focusin.bs.modal"),this.$element.removeClass("in").off("click.dismiss.bs.modal").off("mouseup.dismiss.bs.modal"),this.$dialog.off("mousedown.dismiss.bs.modal"),a.support.transition&&this.$element.hasClass("fade")?this.$element.one("bsTransitionEnd",a.proxy(this.hideModal,this)).emulateTransitionEnd(c.TRANSITION_DURATION):this.hideModal())},c.prototype.enforceFocus=function(){a(document).off("focusin.bs.modal").on("focusin.bs.modal",a.proxy(function(a){this.$element[0]===a.target||this.$element.has(a.target).length||this.$element.trigger("focus")},this))},c.prototype.escape=function(){this.isShown&&this.options.keyboard?this.$element.on("keydown.dismiss.bs.modal",a.proxy(function(a){27==a.which&&this.hide()},this)):this.isShown||this.$element.off("keydown.dismiss.bs.modal")},c.prototype.resize=function(){this.isShown?a(window).on("resize.bs.modal",a.proxy(this.handleUpdate,this)):a(window).off("resize.bs.modal")},c.prototype.hideModal=function(){var a=this;this.$element.hide(),this.backdrop(function(){a.$body.removeClass("modal-open"),a.resetAdjustments(),a.resetScrollbar(),a.$element.trigger("hidden.bs.modal")})},c.prototype.removeBackdrop=function(){this.$backdrop&&this.$backdrop.remove(),this.$backdrop=null},c.prototype.backdrop=function(b){var d=this,e=this.$element.hasClass("fade")?"fade":"";if(this.isShown&&this.options.backdrop){var f=a.support.transition&&e;if(this.$backdrop=a(document.createElement("div")).addClass("modal-backdrop "+e).appendTo(this.$body),this.$element.on("click.dismiss.bs.modal",a.proxy(function(a){return this.ignoreBackdropClick?void(this.ignoreBackdropClick=!1):void(a.target===a.currentTarget&&("static"==this.options.backdrop?this.$element[0].focus():this.hide()))},this)),f&&this.$backdrop[0].offsetWidth,this.$backdrop.addClass("in"),!b)return;f?this.$backdrop.one("bsTransitionEnd",b).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):b()}else if(!this.isShown&&this.$backdrop){this.$backdrop.removeClass("in");var g=function(){d.removeBackdrop(),b&&b()};a.support.transition&&this.$element.hasClass("fade")?this.$backdrop.one("bsTransitionEnd",g).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):g()}else b&&b()},c.prototype.handleUpdate=function(){this.adjustDialog()},c.prototype.adjustDialog=function(){var a=this.$element[0].scrollHeight>document.documentElement.clientHeight;this.$element.css({paddingLeft:!this.bodyIsOverflowing&&a?this.scrollbarWidth:"",paddingRight:this.bodyIsOverflowing&&!a?this.scrollbarWidth:""})},c.prototype.resetAdjustments=function(){this.$element.css({paddingLeft:"",paddingRight:""})},c.prototype.checkScrollbar=function(){var a=window.innerWidth;if(!a){var b=document.documentElement.getBoundingClientRect();a=b.right-Math.abs(b.left)}this.bodyIsOverflowing=document.body.clientWidth<a,this.scrollbarWidth=this.measureScrollbar()},c.prototype.setScrollbar=function(){var a=parseInt(this.$body.css("padding-right")||0,10);this.originalBodyPad=document.body.style.paddingRight||"",this.bodyIsOverflowing&&this.$body.css("padding-right",a+this.scrollbarWidth)},c.prototype.resetScrollbar=function(){this.$body.css("padding-right",this.originalBodyPad)},c.prototype.measureScrollbar=function(){var a=document.createElement("div");a.className="modal-scrollbar-measure",this.$body.append(a);var b=a.offsetWidth-a.clientWidth;return this.$body[0].removeChild(a),b};var d=a.fn.modal;a.fn.modal=b,a.fn.modal.Constructor=c,a.fn.modal.noConflict=function(){return a.fn.modal=d,this},a(document).on("click.bs.modal.data-api",'[data-toggle="modal"]',function(c){var d=a(this),e=d.attr("href"),f=a(d.attr("data-target")||e&&e.replace(/.*(?=#[^\s]+$)/,"")),g=f.data("bs.modal")?"toggle":a.extend({remote:!/#/.test(e)&&e},f.data(),d.data());d.is("a")&&c.preventDefault(),f.one("show.bs.modal",function(a){a.isDefaultPrevented()||f.one("hidden.bs.modal",function(){d.is(":visible")&&d.trigger("focus")})}),b.call(f,g,this)})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tooltip"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.tooltip",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.type=null,this.options=null,this.enabled=null,this.timeout=null,this.hoverState=null,this.$element=null,this.inState=null,this.init("tooltip",a,b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.DEFAULTS={animation:!0,placement:"top",selector:!1,template:'<div class="tooltip" role="tooltip"><div class="tooltip-arrow"></div><div class="tooltip-inner"></div></div>',trigger:"hover focus",title:"",delay:0,html:!1,container:!1,viewport:{selector:"body",padding:0}},c.prototype.init=function(b,c,d){if(this.enabled=!0,this.type=b,this.$element=a(c),this.options=this.getOptions(d),this.$viewport=this.options.viewport&&a(a.isFunction(this.options.viewport)?this.options.viewport.call(this,this.$element):this.options.viewport.selector||this.options.viewport),this.inState={click:!1,hover:!1,focus:!1},this.$element[0]instanceof document.constructor&&!this.options.selector)throw new Error("`selector` option must be specified when initializing "+this.type+" on the window.document object!");for(var e=this.options.trigger.split(" "),f=e.length;f--;){var g=e[f];if("click"==g)this.$element.on("click."+this.type,this.options.selector,a.proxy(this.toggle,this));else if("manual"!=g){var h="hover"==g?"mouseenter":"focusin",i="hover"==g?"mouseleave":"focusout";this.$element.on(h+"."+this.type,this.options.selector,a.proxy(this.enter,this)),this.$element.on(i+"."+this.type,this.options.selector,a.proxy(this.leave,this))}}this.options.selector?this._options=a.extend({},this.options,{trigger:"manual",selector:""}):this.fixTitle()},c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.getOptions=function(b){return b=a.extend({},this.getDefaults(),this.$element.data(),b),b.delay&&"number"==typeof b.delay&&(b.delay={show:b.delay,hide:b.delay}),b},c.prototype.getDelegateOptions=function(){var b={},c=this.getDefaults();return this._options&&a.each(this._options,function(a,d){c[a]!=d&&(b[a]=d)}),b},c.prototype.enter=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusin"==b.type?"focus":"hover"]=!0),c.tip().hasClass("in")||"in"==c.hoverState?void(c.hoverState="in"):(clearTimeout(c.timeout),c.hoverState="in",c.options.delay&&c.options.delay.show?void(c.timeout=setTimeout(function(){"in"==c.hoverState&&c.show()},c.options.delay.show)):c.show())},c.prototype.isInStateTrue=function(){for(var a in this.inState)if(this.inState[a])return!0;return!1},c.prototype.leave=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusout"==b.type?"focus":"hover"]=!1),c.isInStateTrue()?void 0:(clearTimeout(c.timeout),c.hoverState="out",c.options.delay&&c.options.delay.hide?void(c.timeout=setTimeout(function(){"out"==c.hoverState&&c.hide()},c.options.delay.hide)):c.hide())},c.prototype.show=function(){var b=a.Event("show.bs."+this.type);if(this.hasContent()&&this.enabled){this.$element.trigger(b);var d=a.contains(this.$element[0].ownerDocument.documentElement,this.$element[0]);if(b.isDefaultPrevented()||!d)return;var e=this,f=this.tip(),g=this.getUID(this.type);this.setContent(),f.attr("id",g),this.$element.attr("aria-describedby",g),this.options.animation&&f.addClass("fade");var h="function"==typeof this.options.placement?this.options.placement.call(this,f[0],this.$element[0]):this.options.placement,i=/\s?auto?\s?/i,j=i.test(h);j&&(h=h.replace(i,"")||"top"),f.detach().css({top:0,left:0,display:"block"}).addClass(h).data("bs."+this.type,this),this.options.container?f.appendTo(this.options.container):f.insertAfter(this.$element),this.$element.trigger("inserted.bs."+this.type);var k=this.getPosition(),l=f[0].offsetWidth,m=f[0].offsetHeight;if(j){var n=h,o=this.getPosition(this.$viewport);h="bottom"==h&&k.bottom+m>o.bottom?"top":"top"==h&&k.top-m<o.top?"bottom":"right"==h&&k.right+l>o.width?"left":"left"==h&&k.left-l<o.left?"right":h,f.removeClass(n).addClass(h)}var p=this.getCalculatedOffset(h,k,l,m);this.applyPlacement(p,h);var q=function(){var a=e.hoverState;e.$element.trigger("shown.bs."+e.type),e.hoverState=null,"out"==a&&e.leave(e)};a.support.transition&&this.$tip.hasClass("fade")?f.one("bsTransitionEnd",q).emulateTransitionEnd(c.TRANSITION_DURATION):q()}},c.prototype.applyPlacement=function(b,c){var d=this.tip(),e=d[0].offsetWidth,f=d[0].offsetHeight,g=parseInt(d.css("margin-top"),10),h=parseInt(d.css("margin-left"),10);isNaN(g)&&(g=0),isNaN(h)&&(h=0),b.top+=g,b.left+=h,a.offset.setOffset(d[0],a.extend({using:function(a){d.css({top:Math.round(a.top),left:Math.round(a.left)})}},b),0),d.addClass("in");var i=d[0].offsetWidth,j=d[0].offsetHeight;"top"==c&&j!=f&&(b.top=b.top+f-j);var k=this.getViewportAdjustedDelta(c,b,i,j);k.left?b.left+=k.left:b.top+=k.top;var l=/top|bottom/.test(c),m=l?2*k.left-e+i:2*k.top-f+j,n=l?"offsetWidth":"offsetHeight";d.offset(b),this.replaceArrow(m,d[0][n],l)},c.prototype.replaceArrow=function(a,b,c){this.arrow().css(c?"left":"top",50*(1-a/b)+"%").css(c?"top":"left","")},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle();a.find(".tooltip-inner")[this.options.html?"html":"text"](b),a.removeClass("fade in top bottom left right")},c.prototype.hide=function(b){function d(){"in"!=e.hoverState&&f.detach(),e.$element.removeAttr("aria-describedby").trigger("hidden.bs."+e.type),b&&b()}var e=this,f=a(this.$tip),g=a.Event("hide.bs."+this.type);return this.$element.trigger(g),g.isDefaultPrevented()?void 0:(f.removeClass("in"),a.support.transition&&f.hasClass("fade")?f.one("bsTransitionEnd",d).emulateTransitionEnd(c.TRANSITION_DURATION):d(),this.hoverState=null,this)},c.prototype.fixTitle=function(){var a=this.$element;(a.attr("title")||"string"!=typeof a.attr("data-original-title"))&&a.attr("data-original-title",a.attr("title")||"").attr("title","")},c.prototype.hasContent=function(){return this.getTitle()},c.prototype.getPosition=function(b){b=b||this.$element;var c=b[0],d="BODY"==c.tagName,e=c.getBoundingClientRect();null==e.width&&(e=a.extend({},e,{width:e.right-e.left,height:e.bottom-e.top}));var f=d?{top:0,left:0}:b.offset(),g={scroll:d?document.documentElement.scrollTop||document.body.scrollTop:b.scrollTop()},h=d?{width:a(window).width(),height:a(window).height()}:null;return a.extend({},e,g,h,f)},c.prototype.getCalculatedOffset=function(a,b,c,d){return"bottom"==a?{top:b.top+b.height,left:b.left+b.width/2-c/2}:"top"==a?{top:b.top-d,left:b.left+b.width/2-c/2}:"left"==a?{top:b.top+b.height/2-d/2,left:b.left-c}:{top:b.top+b.height/2-d/2,left:b.left+b.width}},c.prototype.getViewportAdjustedDelta=function(a,b,c,d){var e={top:0,left:0};if(!this.$viewport)return e;var f=this.options.viewport&&this.options.viewport.padding||0,g=this.getPosition(this.$viewport);if(/right|left/.test(a)){var h=b.top-f-g.scroll,i=b.top+f-g.scroll+d;h<g.top?e.top=g.top-h:i>g.top+g.height&&(e.top=g.top+g.height-i)}else{var j=b.left-f,k=b.left+f+c;j<g.left?e.left=g.left-j:k>g.right&&(e.left=g.left+g.width-k)}return e},c.prototype.getTitle=function(){var a,b=this.$element,c=this.options;return a=b.attr("data-original-title")||("function"==typeof c.title?c.title.call(b[0]):c.title)},c.prototype.getUID=function(a){do a+=~~(1e6*Math.random());while(document.getElementById(a));return a},c.prototype.tip=function(){if(!this.$tip&&(this.$tip=a(this.options.template),1!=this.$tip.length))throw new Error(this.type+" `template` option must consist of exactly 1 top-level element!");return this.$tip},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".tooltip-arrow")},c.prototype.enable=function(){this.enabled=!0},c.prototype.disable=function(){this.enabled=!1},c.prototype.toggleEnabled=function(){this.enabled=!this.enabled},c.prototype.toggle=function(b){var c=this;b&&(c=a(b.currentTarget).data("bs."+this.type),c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c))),b?(c.inState.click=!c.inState.click,c.isInStateTrue()?c.enter(c):c.leave(c)):c.tip().hasClass("in")?c.leave(c):c.enter(c)},c.prototype.destroy=function(){var a=this;clearTimeout(this.timeout),this.hide(function(){a.$element.off("."+a.type).removeData("bs."+a.type),a.$tip&&a.$tip.detach(),a.$tip=null,a.$arrow=null,a.$viewport=null})};var d=a.fn.tooltip;a.fn.tooltip=b,a.fn.tooltip.Constructor=c,a.fn.tooltip.noConflict=function(){return a.fn.tooltip=d,this}}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.popover"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.popover",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.init("popover",a,b)};if(!a.fn.tooltip)throw new Error("Popover requires tooltip.js");c.VERSION="3.3.5",c.DEFAULTS=a.extend({},a.fn.tooltip.Constructor.DEFAULTS,{placement:"right",trigger:"click",content:"",template:'<div class="popover" role="tooltip"><div class="arrow"></div><h3 class="popover-title"></h3><div class="popover-content"></div></div>'}),c.prototype=a.extend({},a.fn.tooltip.Constructor.prototype),c.prototype.constructor=c,c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle(),c=this.getContent();a.find(".popover-title")[this.options.html?"html":"text"](b),a.find(".popover-content").children().detach().end()[this.options.html?"string"==typeof c?"html":"append":"text"](c),a.removeClass("fade top bottom left right in"),a.find(".popover-title").html()||a.find(".popover-title").hide()},c.prototype.hasContent=function(){return this.getTitle()||this.getContent()},c.prototype.getContent=function(){var a=this.$element,b=this.options;return a.attr("data-content")||("function"==typeof b.content?b.content.call(a[0]):b.content)},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".arrow")};var d=a.fn.popover;a.fn.popover=b,a.fn.popover.Constructor=c,a.fn.popover.noConflict=function(){return a.fn.popover=d,this}}(jQuery),+function(a){"use strict";function b(c,d){this.$body=a(document.body),this.$scrollElement=a(a(c).is(document.body)?window:c),this.options=a.extend({},b.DEFAULTS,d),this.selector=(this.options.target||"")+" .nav li > a",this.offsets=[],this.targets=[],this.activeTarget=null,this.scrollHeight=0,this.$scrollElement.on("scroll.bs.scrollspy",a.proxy(this.process,this)),this.refresh(),this.process()}function c(c){return this.each(function(){var d=a(this),e=d.data("bs.scrollspy"),f="object"==typeof c&&c;e||d.data("bs.scrollspy",e=new b(this,f)),"string"==typeof c&&e[c]()})}b.VERSION="3.3.5",b.DEFAULTS={offset:10},b.prototype.getScrollHeight=function(){return this.$scrollElement[0].scrollHeight||Math.max(this.$body[0].scrollHeight,document.documentElement.scrollHeight)},b.prototype.refresh=function(){var b=this,c="offset",d=0;this.offsets=[],this.targets=[],this.scrollHeight=this.getScrollHeight(),a.isWindow(this.$scrollElement[0])||(c="position",d=this.$scrollElement.scrollTop()),this.$body.find(this.selector).map(function(){var b=a(this),e=b.data("target")||b.attr("href"),f=/^#./.test(e)&&a(e);return f&&f.length&&f.is(":visible")&&[[f[c]().top+d,e]]||null}).sort(function(a,b){return a[0]-b[0]}).each(function(){b.offsets.push(this[0]),b.targets.push(this[1])})},b.prototype.process=function(){var a,b=this.$scrollElement.scrollTop()+this.options.offset,c=this.getScrollHeight(),d=this.options.offset+c-this.$scrollElement.height(),e=this.offsets,f=this.targets,g=this.activeTarget;if(this.scrollHeight!=c&&this.refresh(),b>=d)return g!=(a=f[f.length-1])&&this.activate(a);if(g&&b<e[0])return this.activeTarget=null,this.clear();for(a=e.length;a--;)g!=f[a]&&b>=e[a]&&(void 0===e[a+1]||b<e[a+1])&&this.activate(f[a])},b.prototype.activate=function(b){this.activeTarget=b,this.clear();var c=this.selector+'[data-target="'+b+'"],'+this.selector+'[href="'+b+'"]',d=a(c).parents("li").addClass("active");d.parent(".dropdown-menu").length&&(d=d.closest("li.dropdown").addClass("active")),
d.trigger("activate.bs.scrollspy")},b.prototype.clear=function(){a(this.selector).parentsUntil(this.options.target,".active").removeClass("active")};var d=a.fn.scrollspy;a.fn.scrollspy=c,a.fn.scrollspy.Constructor=b,a.fn.scrollspy.noConflict=function(){return a.fn.scrollspy=d,this},a(window).on("load.bs.scrollspy.data-api",function(){a('[data-spy="scroll"]').each(function(){var b=a(this);c.call(b,b.data())})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tab");e||d.data("bs.tab",e=new c(this)),"string"==typeof b&&e[b]()})}var c=function(b){this.element=a(b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.prototype.show=function(){var b=this.element,c=b.closest("ul:not(.dropdown-menu)"),d=b.data("target");if(d||(d=b.attr("href"),d=d&&d.replace(/.*(?=#[^\s]*$)/,"")),!b.parent("li").hasClass("active")){var e=c.find(".active:last a"),f=a.Event("hide.bs.tab",{relatedTarget:b[0]}),g=a.Event("show.bs.tab",{relatedTarget:e[0]});if(e.trigger(f),b.trigger(g),!g.isDefaultPrevented()&&!f.isDefaultPrevented()){var h=a(d);this.activate(b.closest("li"),c),this.activate(h,h.parent(),function(){e.trigger({type:"hidden.bs.tab",relatedTarget:b[0]}),b.trigger({type:"shown.bs.tab",relatedTarget:e[0]})})}}},c.prototype.activate=function(b,d,e){function f(){g.removeClass("active").find("> .dropdown-menu > .active").removeClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!1),b.addClass("active").find('[data-toggle="tab"]').attr("aria-expanded",!0),h?(b[0].offsetWidth,b.addClass("in")):b.removeClass("fade"),b.parent(".dropdown-menu").length&&b.closest("li.dropdown").addClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!0),e&&e()}var g=d.find("> .active"),h=e&&a.support.transition&&(g.length&&g.hasClass("fade")||!!d.find("> .fade").length);g.length&&h?g.one("bsTransitionEnd",f).emulateTransitionEnd(c.TRANSITION_DURATION):f(),g.removeClass("in")};var d=a.fn.tab;a.fn.tab=b,a.fn.tab.Constructor=c,a.fn.tab.noConflict=function(){return a.fn.tab=d,this};var e=function(c){c.preventDefault(),b.call(a(this),"show")};a(document).on("click.bs.tab.data-api",'[data-toggle="tab"]',e).on("click.bs.tab.data-api",'[data-toggle="pill"]',e)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.affix"),f="object"==typeof b&&b;e||d.data("bs.affix",e=new c(this,f)),"string"==typeof b&&e[b]()})}var c=function(b,d){this.options=a.extend({},c.DEFAULTS,d),this.$target=a(this.options.target).on("scroll.bs.affix.data-api",a.proxy(this.checkPosition,this)).on("click.bs.affix.data-api",a.proxy(this.checkPositionWithEventLoop,this)),this.$element=a(b),this.affixed=null,this.unpin=null,this.pinnedOffset=null,this.checkPosition()};c.VERSION="3.3.5",c.RESET="affix affix-top affix-bottom",c.DEFAULTS={offset:0,target:window},c.prototype.getState=function(a,b,c,d){var e=this.$target.scrollTop(),f=this.$element.offset(),g=this.$target.height();if(null!=c&&"top"==this.affixed)return c>e?"top":!1;if("bottom"==this.affixed)return null!=c?e+this.unpin<=f.top?!1:"bottom":a-d>=e+g?!1:"bottom";var h=null==this.affixed,i=h?e:f.top,j=h?g:b;return null!=c&&c>=e?"top":null!=d&&i+j>=a-d?"bottom":!1},c.prototype.getPinnedOffset=function(){if(this.pinnedOffset)return this.pinnedOffset;this.$element.removeClass(c.RESET).addClass("affix");var a=this.$target.scrollTop(),b=this.$element.offset();return this.pinnedOffset=b.top-a},c.prototype.checkPositionWithEventLoop=function(){setTimeout(a.proxy(this.checkPosition,this),1)},c.prototype.checkPosition=function(){if(this.$element.is(":visible")){var b=this.$element.height(),d=this.options.offset,e=d.top,f=d.bottom,g=Math.max(a(document).height(),a(document.body).height());"object"!=typeof d&&(f=e=d),"function"==typeof e&&(e=d.top(this.$element)),"function"==typeof f&&(f=d.bottom(this.$element));var h=this.getState(g,b,e,f);if(this.affixed!=h){null!=this.unpin&&this.$element.css("top","");var i="affix"+(h?"-"+h:""),j=a.Event(i+".bs.affix");if(this.$element.trigger(j),j.isDefaultPrevented())return;this.affixed=h,this.unpin="bottom"==h?this.getPinnedOffset():null,this.$element.removeClass(c.RESET).addClass(i).trigger(i.replace("affix","affixed")+".bs.affix")}"bottom"==h&&this.$element.offset({top:g-b-f})}};var d=a.fn.affix;a.fn.affix=b,a.fn.affix.Constructor=c,a.fn.affix.noConflict=function(){return a.fn.affix=d,this},a(window).on("load",function(){a('[data-spy="affix"]').each(function(){var c=a(this),d=c.data();d.offset=d.offset||{},null!=d.offsetBottom&&(d.offset.bottom=d.offsetBottom),null!=d.offsetTop&&(d.offset.top=d.offsetTop),b.call(c,d)})})}(jQuery);"></script>
<script src="data:application/javascript;base64,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"></script>
<script src="data:application/javascript;base64,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"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="data:application/javascript;base64,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"></script>
<link href="data:text/css,%2Ehljs%2Dliteral%20%7B%0Acolor%3A%20%23990073%3B%0A%7D%0A%2Ehljs%2Dnumber%20%7B%0Acolor%3A%20%23099%3B%0A%7D%0A%2Ehljs%2Dcomment%20%7B%0Acolor%3A%20%23998%3B%0Afont%2Dstyle%3A%20italic%3B%0A%7D%0A%2Ehljs%2Dkeyword%20%7B%0Acolor%3A%20%23900%3B%0Afont%2Dweight%3A%20bold%3B%0A%7D%0A%2Ehljs%2Dstring%20%7B%0Acolor%3A%20%23d14%3B%0A%7D%0A" rel="stylesheet" />
<script src="data:application/javascript;base64,/*! highlight.js v9.12.0 | BSD3 License | git.io/hljslicense */
!function(e){var n="object"==typeof window&&window||"object"==typeof self&&self;"undefined"!=typeof exports?e(exports):n&&(n.hljs=e({}),"function"==typeof define&&define.amd&&define([],function(){return n.hljs}))}(function(e){function n(e){return e.replace(/&/g,"&amp;").replace(/</g,"&lt;").replace(/>/g,"&gt;")}function t(e){return e.nodeName.toLowerCase()}function r(e,n){var t=e&&e.exec(n);return t&&0===t.index}function a(e){return k.test(e)}function i(e){var n,t,r,i,o=e.className+" ";if(o+=e.parentNode?e.parentNode.className:"",t=B.exec(o))return w(t[1])?t[1]:"no-highlight";for(o=o.split(/\s+/),n=0,r=o.length;r>n;n++)if(i=o[n],a(i)||w(i))return i}function o(e){var n,t={},r=Array.prototype.slice.call(arguments,1);for(n in e)t[n]=e[n];return r.forEach(function(e){for(n in e)t[n]=e[n]}),t}function u(e){var n=[];return function r(e,a){for(var i=e.firstChild;i;i=i.nextSibling)3===i.nodeType?a+=i.nodeValue.length:1===i.nodeType&&(n.push({event:"start",offset:a,node:i}),a=r(i,a),t(i).match(/br|hr|img|input/)||n.push({event:"stop",offset:a,node:i}));return a}(e,0),n}function c(e,r,a){function i(){return e.length&&r.length?e[0].offset!==r[0].offset?e[0].offset<r[0].offset?e:r:"start"===r[0].event?e:r:e.length?e:r}function o(e){function r(e){return" "+e.nodeName+'="'+n(e.value).replace('"',"&quot;")+'"'}s+="<"+t(e)+E.map.call(e.attributes,r).join("")+">"}function u(e){s+="</"+t(e)+">"}function c(e){("start"===e.event?o:u)(e.node)}for(var l=0,s="",f=[];e.length||r.length;){var g=i();if(s+=n(a.substring(l,g[0].offset)),l=g[0].offset,g===e){f.reverse().forEach(u);do c(g.splice(0,1)[0]),g=i();while(g===e&&g.length&&g[0].offset===l);f.reverse().forEach(o)}else"start"===g[0].event?f.push(g[0].node):f.pop(),c(g.splice(0,1)[0])}return s+n(a.substr(l))}function l(e){return e.v&&!e.cached_variants&&(e.cached_variants=e.v.map(function(n){return o(e,{v:null},n)})),e.cached_variants||e.eW&&[o(e)]||[e]}function s(e){function n(e){return e&&e.source||e}function t(t,r){return new RegExp(n(t),"m"+(e.cI?"i":"")+(r?"g":""))}function r(a,i){if(!a.compiled){if(a.compiled=!0,a.k=a.k||a.bK,a.k){var o={},u=function(n,t){e.cI&&(t=t.toLowerCase()),t.split(" ").forEach(function(e){var t=e.split("|");o[t[0]]=[n,t[1]?Number(t[1]):1]})};"string"==typeof a.k?u("keyword",a.k):x(a.k).forEach(function(e){u(e,a.k[e])}),a.k=o}a.lR=t(a.l||/\w+/,!0),i&&(a.bK&&(a.b="\\b("+a.bK.split(" ").join("|")+")\\b"),a.b||(a.b=/\B|\b/),a.bR=t(a.b),a.e||a.eW||(a.e=/\B|\b/),a.e&&(a.eR=t(a.e)),a.tE=n(a.e)||"",a.eW&&i.tE&&(a.tE+=(a.e?"|":"")+i.tE)),a.i&&(a.iR=t(a.i)),null==a.r&&(a.r=1),a.c||(a.c=[]),a.c=Array.prototype.concat.apply([],a.c.map(function(e){return l("self"===e?a:e)})),a.c.forEach(function(e){r(e,a)}),a.starts&&r(a.starts,i);var c=a.c.map(function(e){return e.bK?"\\.?("+e.b+")\\.?":e.b}).concat([a.tE,a.i]).map(n).filter(Boolean);a.t=c.length?t(c.join("|"),!0):{exec:function(){return null}}}}r(e)}function f(e,t,a,i){function o(e,n){var t,a;for(t=0,a=n.c.length;a>t;t++)if(r(n.c[t].bR,e))return n.c[t]}function u(e,n){if(r(e.eR,n)){for(;e.endsParent&&e.parent;)e=e.parent;return e}return e.eW?u(e.parent,n):void 0}function c(e,n){return!a&&r(n.iR,e)}function l(e,n){var t=N.cI?n[0].toLowerCase():n[0];return e.k.hasOwnProperty(t)&&e.k[t]}function p(e,n,t,r){var a=r?"":I.classPrefix,i='<span class="'+a,o=t?"":C;return i+=e+'">',i+n+o}function h(){var e,t,r,a;if(!E.k)return n(k);for(a="",t=0,E.lR.lastIndex=0,r=E.lR.exec(k);r;)a+=n(k.substring(t,r.index)),e=l(E,r),e?(B+=e[1],a+=p(e[0],n(r[0]))):a+=n(r[0]),t=E.lR.lastIndex,r=E.lR.exec(k);return a+n(k.substr(t))}function d(){var e="string"==typeof E.sL;if(e&&!y[E.sL])return n(k);var t=e?f(E.sL,k,!0,x[E.sL]):g(k,E.sL.length?E.sL:void 0);return E.r>0&&(B+=t.r),e&&(x[E.sL]=t.top),p(t.language,t.value,!1,!0)}function b(){L+=null!=E.sL?d():h(),k=""}function v(e){L+=e.cN?p(e.cN,"",!0):"",E=Object.create(e,{parent:{value:E}})}function m(e,n){if(k+=e,null==n)return b(),0;var t=o(n,E);if(t)return t.skip?k+=n:(t.eB&&(k+=n),b(),t.rB||t.eB||(k=n)),v(t,n),t.rB?0:n.length;var r=u(E,n);if(r){var a=E;a.skip?k+=n:(a.rE||a.eE||(k+=n),b(),a.eE&&(k=n));do E.cN&&(L+=C),E.skip||(B+=E.r),E=E.parent;while(E!==r.parent);return r.starts&&v(r.starts,""),a.rE?0:n.length}if(c(n,E))throw new Error('Illegal lexeme "'+n+'" for mode "'+(E.cN||"<unnamed>")+'"');return k+=n,n.length||1}var N=w(e);if(!N)throw new Error('Unknown language: "'+e+'"');s(N);var R,E=i||N,x={},L="";for(R=E;R!==N;R=R.parent)R.cN&&(L=p(R.cN,"",!0)+L);var k="",B=0;try{for(var M,j,O=0;;){if(E.t.lastIndex=O,M=E.t.exec(t),!M)break;j=m(t.substring(O,M.index),M[0]),O=M.index+j}for(m(t.substr(O)),R=E;R.parent;R=R.parent)R.cN&&(L+=C);return{r:B,value:L,language:e,top:E}}catch(T){if(T.message&&-1!==T.message.indexOf("Illegal"))return{r:0,value:n(t)};throw T}}function g(e,t){t=t||I.languages||x(y);var r={r:0,value:n(e)},a=r;return t.filter(w).forEach(function(n){var t=f(n,e,!1);t.language=n,t.r>a.r&&(a=t),t.r>r.r&&(a=r,r=t)}),a.language&&(r.second_best=a),r}function p(e){return I.tabReplace||I.useBR?e.replace(M,function(e,n){return I.useBR&&"\n"===e?"<br>":I.tabReplace?n.replace(/\t/g,I.tabReplace):""}):e}function h(e,n,t){var r=n?L[n]:t,a=[e.trim()];return e.match(/\bhljs\b/)||a.push("hljs"),-1===e.indexOf(r)&&a.push(r),a.join(" ").trim()}function d(e){var n,t,r,o,l,s=i(e);a(s)||(I.useBR?(n=document.createElementNS("http://www.w3.org/1999/xhtml","div"),n.innerHTML=e.innerHTML.replace(/\n/g,"").replace(/<br[ \/]*>/g,"\n")):n=e,l=n.textContent,r=s?f(s,l,!0):g(l),t=u(n),t.length&&(o=document.createElementNS("http://www.w3.org/1999/xhtml","div"),o.innerHTML=r.value,r.value=c(t,u(o),l)),r.value=p(r.value),e.innerHTML=r.value,e.className=h(e.className,s,r.language),e.result={language:r.language,re:r.r},r.second_best&&(e.second_best={language:r.second_best.language,re:r.second_best.r}))}function b(e){I=o(I,e)}function v(){if(!v.called){v.called=!0;var e=document.querySelectorAll("pre code");E.forEach.call(e,d)}}function m(){addEventListener("DOMContentLoaded",v,!1),addEventListener("load",v,!1)}function N(n,t){var r=y[n]=t(e);r.aliases&&r.aliases.forEach(function(e){L[e]=n})}function R(){return x(y)}function w(e){return e=(e||"").toLowerCase(),y[e]||y[L[e]]}var E=[],x=Object.keys,y={},L={},k=/^(no-?highlight|plain|text)$/i,B=/\blang(?:uage)?-([\w-]+)\b/i,M=/((^(<[^>]+>|\t|)+|(?:\n)))/gm,C="</span>",I={classPrefix:"hljs-",tabReplace:null,useBR:!1,languages:void 0};return e.highlight=f,e.highlightAuto=g,e.fixMarkup=p,e.highlightBlock=d,e.configure=b,e.initHighlighting=v,e.initHighlightingOnLoad=m,e.registerLanguage=N,e.listLanguages=R,e.getLanguage=w,e.inherit=o,e.IR="[a-zA-Z]\\w*",e.UIR="[a-zA-Z_]\\w*",e.NR="\\b\\d+(\\.\\d+)?",e.CNR="(-?)(\\b0[xX][a-fA-F0-9]+|(\\b\\d+(\\.\\d*)?|\\.\\d+)([eE][-+]?\\d+)?)",e.BNR="\\b(0b[01]+)",e.RSR="!|!=|!==|%|%=|&|&&|&=|\\*|\\*=|\\+|\\+=|,|-|-=|/=|/|:|;|<<|<<=|<=|<|===|==|=|>>>=|>>=|>=|>>>|>>|>|\\?|\\[|\\{|\\(|\\^|\\^=|\\||\\|=|\\|\\||~",e.BE={b:"\\\\[\\s\\S]",r:0},e.ASM={cN:"string",b:"'",e:"'",i:"\\n",c:[e.BE]},e.QSM={cN:"string",b:'"',e:'"',i:"\\n",c:[e.BE]},e.PWM={b:/\b(a|an|the|are|I'm|isn't|don't|doesn't|won't|but|just|should|pretty|simply|enough|gonna|going|wtf|so|such|will|you|your|they|like|more)\b/},e.C=function(n,t,r){var a=e.inherit({cN:"comment",b:n,e:t,c:[]},r||{});return a.c.push(e.PWM),a.c.push({cN:"doctag",b:"(?:TODO|FIXME|NOTE|BUG|XXX):",r:0}),a},e.CLCM=e.C("//","$"),e.CBCM=e.C("/\\*","\\*/"),e.HCM=e.C("#","$"),e.NM={cN:"number",b:e.NR,r:0},e.CNM={cN:"number",b:e.CNR,r:0},e.BNM={cN:"number",b:e.BNR,r:0},e.CSSNM={cN:"number",b:e.NR+"(%|em|ex|ch|rem|vw|vh|vmin|vmax|cm|mm|in|pt|pc|px|deg|grad|rad|turn|s|ms|Hz|kHz|dpi|dpcm|dppx)?",r:0},e.RM={cN:"regexp",b:/\//,e:/\/[gimuy]*/,i:/\n/,c:[e.BE,{b:/\[/,e:/\]/,r:0,c:[e.BE]}]},e.TM={cN:"title",b:e.IR,r:0},e.UTM={cN:"title",b:e.UIR,r:0},e.METHOD_GUARD={b:"\\.\\s*"+e.UIR,r:0},e});hljs.registerLanguage("sql",function(e){var t=e.C("--","$");return{cI:!0,i:/[<>{}*#]/,c:[{bK:"begin end start commit rollback savepoint lock alter create drop rename call delete do handler insert load replace select truncate update set show pragma grant merge describe use explain help declare prepare execute deallocate release unlock purge reset change stop analyze cache flush optimize repair kill install uninstall checksum restore check backup revoke comment",e:/;/,eW:!0,l:/[\w\.]+/,k:{keyword:"abort abs absolute acc acce accep accept access accessed accessible account acos action activate add addtime admin administer advanced advise aes_decrypt aes_encrypt after agent aggregate ali alia alias allocate allow alter always analyze ancillary and any anydata anydataset anyschema anytype apply archive archived archivelog are as asc ascii asin assembly assertion associate asynchronous at atan atn2 attr attri attrib attribu attribut attribute attributes audit authenticated authentication authid authors auto autoallocate autodblink autoextend automatic availability avg backup badfile basicfile before begin beginning benchmark between bfile bfile_base big bigfile bin binary_double binary_float binlog bit_and bit_count bit_length bit_or bit_xor bitmap blob_base block blocksize body both bound buffer_cache buffer_pool build bulk by byte byteordermark bytes cache caching call calling cancel capacity cascade cascaded case cast catalog category ceil ceiling chain change changed char_base char_length character_length characters characterset charindex charset charsetform charsetid check checksum checksum_agg child choose chr chunk class cleanup clear client clob clob_base clone close cluster_id cluster_probability cluster_set clustering coalesce coercibility col collate collation collect colu colum column column_value columns columns_updated comment commit compact compatibility compiled complete composite_limit compound compress compute concat concat_ws concurrent confirm conn connec connect connect_by_iscycle connect_by_isleaf connect_by_root connect_time connection consider consistent constant constraint constraints constructor container content contents context contributors controlfile conv convert convert_tz corr corr_k corr_s corresponding corruption cos cost count count_big counted covar_pop covar_samp cpu_per_call cpu_per_session crc32 create creation critical cross cube cume_dist curdate current current_date current_time current_timestamp current_user cursor curtime customdatum cycle data database databases datafile datafiles datalength date_add date_cache date_format date_sub dateadd datediff datefromparts datename datepart datetime2fromparts day day_to_second dayname dayofmonth dayofweek dayofyear days db_role_change dbtimezone ddl deallocate declare decode decompose decrement decrypt deduplicate def defa defau defaul default defaults deferred defi defin define degrees delayed delegate delete delete_all delimited demand dense_rank depth dequeue des_decrypt des_encrypt des_key_file desc descr descri describ describe descriptor deterministic diagnostics difference dimension direct_load directory disable disable_all disallow disassociate discardfile disconnect diskgroup distinct distinctrow distribute distributed div do document domain dotnet double downgrade drop dumpfile duplicate duration each edition editionable editions element ellipsis else elsif elt empty enable enable_all enclosed encode encoding encrypt end end-exec endian enforced engine engines enqueue enterprise entityescaping eomonth error errors escaped evalname evaluate event eventdata events except exception exceptions exchange exclude excluding execu execut execute exempt exists exit exp expire explain export export_set extended extent external external_1 external_2 externally extract failed failed_login_attempts failover failure far fast feature_set feature_value fetch field fields file file_name_convert filesystem_like_logging final finish first first_value fixed flash_cache flashback floor flush following follows for forall force form forma format found found_rows freelist freelists freepools fresh from from_base64 from_days ftp full function general generated get get_format get_lock getdate getutcdate global global_name globally go goto grant grants greatest group group_concat group_id grouping grouping_id groups gtid_subtract guarantee guard handler hash hashkeys having hea head headi headin heading heap help hex hierarchy high high_priority hosts hour http id ident_current ident_incr ident_seed identified identity idle_time if ifnull ignore iif ilike ilm immediate import in include including increment index indexes indexing indextype indicator indices inet6_aton inet6_ntoa inet_aton inet_ntoa infile initial initialized initially initrans inmemory inner innodb input insert install instance instantiable instr interface interleaved intersect into invalidate invisible is is_free_lock is_ipv4 is_ipv4_compat is_not is_not_null is_used_lock isdate isnull isolation iterate java join json json_exists keep keep_duplicates key keys kill language large last last_day last_insert_id last_value lax lcase lead leading least leaves left len lenght length less level levels library like like2 like4 likec limit lines link list listagg little ln load load_file lob lobs local localtime localtimestamp locate locator lock locked log log10 log2 logfile logfiles logging logical logical_reads_per_call logoff logon logs long loop low low_priority lower lpad lrtrim ltrim main make_set makedate maketime managed management manual map mapping mask master master_pos_wait match matched materialized max maxextents maximize maxinstances maxlen maxlogfiles maxloghistory maxlogmembers maxsize maxtrans md5 measures median medium member memcompress memory merge microsecond mid migration min minextents minimum mining minus minute minvalue missing mod mode model modification modify module monitoring month months mount move movement multiset mutex name name_const names nan national native natural nav nchar nclob nested never new newline next nextval no no_write_to_binlog noarchivelog noaudit nobadfile nocheck nocompress nocopy nocycle nodelay nodiscardfile noentityescaping noguarantee nokeep nologfile nomapping nomaxvalue nominimize nominvalue nomonitoring none noneditionable nonschema noorder nopr nopro noprom nopromp noprompt norely noresetlogs noreverse normal norowdependencies noschemacheck noswitch not nothing notice notrim novalidate now nowait nth_value nullif nulls num numb numbe nvarchar nvarchar2 object ocicoll ocidate ocidatetime ociduration ociinterval ociloblocator ocinumber ociref ocirefcursor ocirowid ocistring ocitype oct octet_length of off offline offset oid oidindex old on online only opaque open operations operator optimal optimize option optionally or oracle oracle_date oradata ord ordaudio orddicom orddoc order ordimage ordinality ordvideo organization orlany orlvary out outer outfile outline output over overflow overriding package pad parallel parallel_enable parameters parent parse partial partition partitions pascal passing password password_grace_time password_lock_time password_reuse_max password_reuse_time password_verify_function patch path patindex pctincrease pctthreshold pctused pctversion percent percent_rank percentile_cont percentile_disc performance period period_add period_diff permanent physical pi pipe pipelined pivot pluggable plugin policy position post_transaction pow power pragma prebuilt precedes preceding precision prediction prediction_cost prediction_details prediction_probability prediction_set prepare present preserve prior priority private private_sga privileges procedural procedure procedure_analyze processlist profiles project prompt protection public publishingservername purge quarter query quick quiesce quota quotename radians raise rand range rank raw read reads readsize rebuild record records recover recovery recursive recycle redo reduced ref reference referenced references referencing refresh regexp_like register regr_avgx regr_avgy regr_count regr_intercept regr_r2 regr_slope regr_sxx regr_sxy reject rekey relational relative relaylog release release_lock relies_on relocate rely rem remainder rename repair repeat replace replicate replication required reset resetlogs resize resource respect restore restricted result result_cache resumable resume retention return returning returns reuse reverse revoke right rlike role roles rollback rolling rollup round row row_count rowdependencies rowid rownum rows rtrim rules safe salt sample save savepoint sb1 sb2 sb4 scan schema schemacheck scn scope scroll sdo_georaster sdo_topo_geometry search sec_to_time second section securefile security seed segment select self sequence sequential serializable server servererror session session_user sessions_per_user set sets settings sha sha1 sha2 share shared shared_pool short show shrink shutdown si_averagecolor si_colorhistogram si_featurelist si_positionalcolor si_stillimage si_texture siblings sid sign sin size size_t sizes skip slave sleep smalldatetimefromparts smallfile snapshot some soname sort soundex source space sparse spfile split sql sql_big_result sql_buffer_result sql_cache sql_calc_found_rows sql_small_result sql_variant_property sqlcode sqldata sqlerror sqlname sqlstate sqrt square standalone standby start starting startup statement static statistics stats_binomial_test stats_crosstab stats_ks_test stats_mode stats_mw_test stats_one_way_anova stats_t_test_ stats_t_test_indep stats_t_test_one stats_t_test_paired stats_wsr_test status std stddev stddev_pop stddev_samp stdev stop storage store stored str str_to_date straight_join strcmp strict string struct stuff style subdate subpartition subpartitions substitutable substr substring subtime subtring_index subtype success sum suspend switch switchoffset switchover sync synchronous synonym sys sys_xmlagg sysasm sysaux sysdate sysdatetimeoffset sysdba sysoper system system_user sysutcdatetime table tables tablespace tan tdo template temporary terminated tertiary_weights test than then thread through tier ties time time_format time_zone timediff timefromparts timeout timestamp timestampadd timestampdiff timezone_abbr timezone_minute timezone_region to to_base64 to_date to_days to_seconds todatetimeoffset trace tracking transaction transactional translate translation treat trigger trigger_nestlevel triggers trim truncate try_cast try_convert try_parse type ub1 ub2 ub4 ucase unarchived unbounded uncompress under undo unhex unicode uniform uninstall union unique unix_timestamp unknown unlimited unlock unpivot unrecoverable unsafe unsigned until untrusted unusable unused update updated upgrade upped upper upsert url urowid usable usage use use_stored_outlines user user_data user_resources users using utc_date utc_timestamp uuid uuid_short validate validate_password_strength validation valist value values var var_samp varcharc vari varia variab variabl variable variables variance varp varraw varrawc varray verify version versions view virtual visible void wait wallet warning warnings week weekday weekofyear wellformed when whene whenev wheneve whenever where while whitespace with within without work wrapped xdb xml xmlagg xmlattributes xmlcast xmlcolattval xmlelement xmlexists xmlforest xmlindex xmlnamespaces xmlpi xmlquery xmlroot xmlschema xmlserialize xmltable xmltype xor year year_to_month years yearweek",literal:"true false null",built_in:"array bigint binary bit blob boolean char character date dec decimal float int int8 integer interval number numeric real record serial serial8 smallint text varchar varying void"},c:[{cN:"string",b:"'",e:"'",c:[e.BE,{b:"''"}]},{cN:"string",b:'"',e:'"',c:[e.BE,{b:'""'}]},{cN:"string",b:"`",e:"`",c:[e.BE]},e.CNM,e.CBCM,t]},e.CBCM,t]}});hljs.registerLanguage("r",function(e){var r="([a-zA-Z]|\\.[a-zA-Z.])[a-zA-Z0-9._]*";return{c:[e.HCM,{b:r,l:r,k:{keyword:"function if in break next repeat else for return switch while try tryCatch stop warning require library attach detach source setMethod setGeneric setGroupGeneric setClass ...",literal:"NULL NA TRUE FALSE T F Inf NaN NA_integer_|10 NA_real_|10 NA_character_|10 NA_complex_|10"},r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"\\d+(?:[eE][+\\-]?\\d*)?L\\b",r:0},{cN:"number",b:"\\d+\\.(?!\\d)(?:i\\b)?",r:0},{cN:"number",b:"\\d+(?:\\.\\d*)?(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{cN:"number",b:"\\.\\d+(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{b:"`",e:"`",r:0},{cN:"string",c:[e.BE],v:[{b:'"',e:'"'},{b:"'",e:"'"}]}]}});hljs.registerLanguage("perl",function(e){var t="getpwent getservent quotemeta msgrcv scalar kill dbmclose undef lc ma syswrite tr send umask sysopen shmwrite vec qx utime local oct semctl localtime readpipe do return format read sprintf dbmopen pop getpgrp not getpwnam rewinddir qqfileno qw endprotoent wait sethostent bless s|0 opendir continue each sleep endgrent shutdown dump chomp connect getsockname die socketpair close flock exists index shmgetsub for endpwent redo lstat msgctl setpgrp abs exit select print ref gethostbyaddr unshift fcntl syscall goto getnetbyaddr join gmtime symlink semget splice x|0 getpeername recv log setsockopt cos last reverse gethostbyname getgrnam study formline endhostent times chop length gethostent getnetent pack getprotoent getservbyname rand mkdir pos chmod y|0 substr endnetent printf next open msgsnd readdir use unlink getsockopt getpriority rindex wantarray hex system getservbyport endservent int chr untie rmdir prototype tell listen fork shmread ucfirst setprotoent else sysseek link getgrgid shmctl waitpid unpack getnetbyname reset chdir grep split require caller lcfirst until warn while values shift telldir getpwuid my getprotobynumber delete and sort uc defined srand accept package seekdir getprotobyname semop our rename seek if q|0 chroot sysread setpwent no crypt getc chown sqrt write setnetent setpriority foreach tie sin msgget map stat getlogin unless elsif truncate exec keys glob tied closedirioctl socket readlink eval xor readline binmode setservent eof ord bind alarm pipe atan2 getgrent exp time push setgrent gt lt or ne m|0 break given say state when",r={cN:"subst",b:"[$@]\\{",e:"\\}",k:t},s={b:"->{",e:"}"},n={v:[{b:/\$\d/},{b:/[\$%@](\^\w\b|#\w+(::\w+)*|{\w+}|\w+(::\w*)*)/},{b:/[\$%@][^\s\w{]/,r:0}]},i=[e.BE,r,n],o=[n,e.HCM,e.C("^\\=\\w","\\=cut",{eW:!0}),s,{cN:"string",c:i,v:[{b:"q[qwxr]?\\s*\\(",e:"\\)",r:5},{b:"q[qwxr]?\\s*\\[",e:"\\]",r:5},{b:"q[qwxr]?\\s*\\{",e:"\\}",r:5},{b:"q[qwxr]?\\s*\\|",e:"\\|",r:5},{b:"q[qwxr]?\\s*\\<",e:"\\>",r:5},{b:"qw\\s+q",e:"q",r:5},{b:"'",e:"'",c:[e.BE]},{b:'"',e:'"'},{b:"`",e:"`",c:[e.BE]},{b:"{\\w+}",c:[],r:0},{b:"-?\\w+\\s*\\=\\>",c:[],r:0}]},{cN:"number",b:"(\\b0[0-7_]+)|(\\b0x[0-9a-fA-F_]+)|(\\b[1-9][0-9_]*(\\.[0-9_]+)?)|[0_]\\b",r:0},{b:"(\\/\\/|"+e.RSR+"|\\b(split|return|print|reverse|grep)\\b)\\s*",k:"split return print reverse grep",r:0,c:[e.HCM,{cN:"regexp",b:"(s|tr|y)/(\\\\.|[^/])*/(\\\\.|[^/])*/[a-z]*",r:10},{cN:"regexp",b:"(m|qr)?/",e:"/[a-z]*",c:[e.BE],r:0}]},{cN:"function",bK:"sub",e:"(\\s*\\(.*?\\))?[;{]",eE:!0,r:5,c:[e.TM]},{b:"-\\w\\b",r:0},{b:"^__DATA__$",e:"^__END__$",sL:"mojolicious",c:[{b:"^@@.*",e:"$",cN:"comment"}]}];return r.c=o,s.c=o,{aliases:["pl","pm"],l:/[\w\.]+/,k:t,c:o}});hljs.registerLanguage("ini",function(e){var b={cN:"string",c:[e.BE],v:[{b:"'''",e:"'''",r:10},{b:'"""',e:'"""',r:10},{b:'"',e:'"'},{b:"'",e:"'"}]};return{aliases:["toml"],cI:!0,i:/\S/,c:[e.C(";","$"),e.HCM,{cN:"section",b:/^\s*\[+/,e:/\]+/},{b:/^[a-z0-9\[\]_-]+\s*=\s*/,e:"$",rB:!0,c:[{cN:"attr",b:/[a-z0-9\[\]_-]+/},{b:/=/,eW:!0,r:0,c:[{cN:"literal",b:/\bon|off|true|false|yes|no\b/},{cN:"variable",v:[{b:/\$[\w\d"][\w\d_]*/},{b:/\$\{(.*?)}/}]},b,{cN:"number",b:/([\+\-]+)?[\d]+_[\d_]+/},e.NM]}]}]}});hljs.registerLanguage("diff",function(e){return{aliases:["patch"],c:[{cN:"meta",r:10,v:[{b:/^@@ +\-\d+,\d+ +\+\d+,\d+ +@@$/},{b:/^\*\*\* +\d+,\d+ +\*\*\*\*$/},{b:/^\-\-\- +\d+,\d+ +\-\-\-\-$/}]},{cN:"comment",v:[{b:/Index: /,e:/$/},{b:/={3,}/,e:/$/},{b:/^\-{3}/,e:/$/},{b:/^\*{3} /,e:/$/},{b:/^\+{3}/,e:/$/},{b:/\*{5}/,e:/\*{5}$/}]},{cN:"addition",b:"^\\+",e:"$"},{cN:"deletion",b:"^\\-",e:"$"},{cN:"addition",b:"^\\!",e:"$"}]}});hljs.registerLanguage("go",function(e){var t={keyword:"break default func interface select case map struct chan else goto package switch const fallthrough if range type continue for import return var go defer bool byte complex64 complex128 float32 float64 int8 int16 int32 int64 string uint8 uint16 uint32 uint64 int uint uintptr rune",literal:"true false iota nil",built_in:"append cap close complex copy imag len make new panic print println real recover delete"};return{aliases:["golang"],k:t,i:"</",c:[e.CLCM,e.CBCM,{cN:"string",v:[e.QSM,{b:"'",e:"[^\\\\]'"},{b:"`",e:"`"}]},{cN:"number",v:[{b:e.CNR+"[dflsi]",r:1},e.CNM]},{b:/:=/},{cN:"function",bK:"func",e:/\s*\{/,eE:!0,c:[e.TM,{cN:"params",b:/\(/,e:/\)/,k:t,i:/["']/}]}]}});hljs.registerLanguage("bash",function(e){var t={cN:"variable",v:[{b:/\$[\w\d#@][\w\d_]*/},{b:/\$\{(.*?)}/}]},s={cN:"string",b:/"/,e:/"/,c:[e.BE,t,{cN:"variable",b:/\$\(/,e:/\)/,c:[e.BE]}]},a={cN:"string",b:/'/,e:/'/};return{aliases:["sh","zsh"],l:/\b-?[a-z\._]+\b/,k:{keyword:"if then else elif fi for while in do done case esac function",literal:"true false",built_in:"break cd continue eval exec exit export getopts hash pwd readonly return shift test times trap umask unset alias bind builtin caller command declare echo enable help let local logout mapfile printf read readarray source type typeset ulimit unalias set shopt autoload bg bindkey bye cap chdir clone comparguments compcall compctl compdescribe compfiles compgroups compquote comptags comptry compvalues dirs disable disown echotc echoti emulate fc fg float functions getcap getln history integer jobs kill limit log noglob popd print pushd pushln rehash sched setcap setopt stat suspend ttyctl unfunction unhash unlimit unsetopt vared wait whence where which zcompile zformat zftp zle zmodload zparseopts zprof zpty zregexparse zsocket zstyle ztcp",_:"-ne -eq -lt -gt -f -d -e -s -l -a"},c:[{cN:"meta",b:/^#![^\n]+sh\s*$/,r:10},{cN:"function",b:/\w[\w\d_]*\s*\(\s*\)\s*\{/,rB:!0,c:[e.inherit(e.TM,{b:/\w[\w\d_]*/})],r:0},e.HCM,s,a,t]}});hljs.registerLanguage("python",function(e){var r={keyword:"and elif is global as in if from raise for except finally print import pass return exec else break not with class assert yield try while continue del or def lambda async await nonlocal|10 None True False",built_in:"Ellipsis NotImplemented"},b={cN:"meta",b:/^(>>>|\.\.\.) /},c={cN:"subst",b:/\{/,e:/\}/,k:r,i:/#/},a={cN:"string",c:[e.BE],v:[{b:/(u|b)?r?'''/,e:/'''/,c:[b],r:10},{b:/(u|b)?r?"""/,e:/"""/,c:[b],r:10},{b:/(fr|rf|f)'''/,e:/'''/,c:[b,c]},{b:/(fr|rf|f)"""/,e:/"""/,c:[b,c]},{b:/(u|r|ur)'/,e:/'/,r:10},{b:/(u|r|ur)"/,e:/"/,r:10},{b:/(b|br)'/,e:/'/},{b:/(b|br)"/,e:/"/},{b:/(fr|rf|f)'/,e:/'/,c:[c]},{b:/(fr|rf|f)"/,e:/"/,c:[c]},e.ASM,e.QSM]},s={cN:"number",r:0,v:[{b:e.BNR+"[lLjJ]?"},{b:"\\b(0o[0-7]+)[lLjJ]?"},{b:e.CNR+"[lLjJ]?"}]},i={cN:"params",b:/\(/,e:/\)/,c:["self",b,s,a]};return c.c=[a,s,b],{aliases:["py","gyp"],k:r,i:/(<\/|->|\?)|=>/,c:[b,s,a,e.HCM,{v:[{cN:"function",bK:"def"},{cN:"class",bK:"class"}],e:/:/,i:/[${=;\n,]/,c:[e.UTM,i,{b:/->/,eW:!0,k:"None"}]},{cN:"meta",b:/^[\t ]*@/,e:/$/},{b:/\b(print|exec)\(/}]}});hljs.registerLanguage("julia",function(e){var r={keyword:"in isa where baremodule begin break catch ccall const continue do else elseif end export false finally for function global if import importall let local macro module quote return true try using while type immutable abstract bitstype typealias ",literal:"true false ARGS C_NULL DevNull ENDIAN_BOM ENV I Inf Inf16 Inf32 Inf64 InsertionSort JULIA_HOME LOAD_PATH MergeSort NaN NaN16 NaN32 NaN64 PROGRAM_FILE QuickSort RoundDown RoundFromZero RoundNearest RoundNearestTiesAway RoundNearestTiesUp RoundToZero RoundUp STDERR STDIN STDOUT VERSION catalan e|0 eu|0 eulergamma golden im nothing pi γ π φ ",built_in:"ANY AbstractArray AbstractChannel AbstractFloat AbstractMatrix AbstractRNG AbstractSerializer AbstractSet AbstractSparseArray AbstractSparseMatrix AbstractSparseVector AbstractString AbstractUnitRange AbstractVecOrMat AbstractVector Any ArgumentError Array AssertionError Associative Base64DecodePipe Base64EncodePipe Bidiagonal BigFloat BigInt BitArray BitMatrix BitVector Bool BoundsError BufferStream CachingPool CapturedException CartesianIndex CartesianRange Cchar Cdouble Cfloat Channel Char Cint Cintmax_t Clong Clonglong ClusterManager Cmd CodeInfo Colon Complex Complex128 Complex32 Complex64 CompositeException Condition ConjArray ConjMatrix ConjVector Cptrdiff_t Cshort Csize_t Cssize_t Cstring Cuchar Cuint Cuintmax_t Culong Culonglong Cushort Cwchar_t Cwstring DataType Date DateFormat DateTime DenseArray DenseMatrix DenseVecOrMat DenseVector Diagonal Dict DimensionMismatch Dims DirectIndexString Display DivideError DomainError EOFError EachLine Enum Enumerate ErrorException Exception ExponentialBackOff Expr Factorization FileMonitor Float16 Float32 Float64 Function Future GlobalRef GotoNode HTML Hermitian IO IOBuffer IOContext IOStream IPAddr IPv4 IPv6 IndexCartesian IndexLinear IndexStyle InexactError InitError Int Int128 Int16 Int32 Int64 Int8 IntSet Integer InterruptException InvalidStateException Irrational KeyError LabelNode LinSpace LineNumberNode LoadError LowerTriangular MIME Matrix MersenneTwister Method MethodError MethodTable Module NTuple NewvarNode NullException Nullable Number ObjectIdDict OrdinalRange OutOfMemoryError OverflowError Pair ParseError PartialQuickSort PermutedDimsArray Pipe PollingFileWatcher ProcessExitedException Ptr QuoteNode RandomDevice Range RangeIndex Rational RawFD ReadOnlyMemoryError Real ReentrantLock Ref Regex RegexMatch RemoteChannel RemoteException RevString RoundingMode RowVector SSAValue SegmentationFault SerializationState Set SharedArray SharedMatrix SharedVector Signed SimpleVector Slot SlotNumber SparseMatrixCSC SparseVector StackFrame StackOverflowError StackTrace StepRange StepRangeLen StridedArray StridedMatrix StridedVecOrMat StridedVector String SubArray SubString SymTridiagonal Symbol Symmetric SystemError TCPSocket Task Text TextDisplay Timer Tridiagonal Tuple Type TypeError TypeMapEntry TypeMapLevel TypeName TypeVar TypedSlot UDPSocket UInt UInt128 UInt16 UInt32 UInt64 UInt8 UndefRefError UndefVarError UnicodeError UniformScaling Union UnionAll UnitRange Unsigned UpperTriangular Val Vararg VecElement VecOrMat Vector VersionNumber Void WeakKeyDict WeakRef WorkerConfig WorkerPool "},t="[A-Za-z_\\u00A1-\\uFFFF][A-Za-z_0-9\\u00A1-\\uFFFF]*",a={l:t,k:r,i:/<\//},n={cN:"number",b:/(\b0x[\d_]*(\.[\d_]*)?|0x\.\d[\d_]*)p[-+]?\d+|\b0[box][a-fA-F0-9][a-fA-F0-9_]*|(\b\d[\d_]*(\.[\d_]*)?|\.\d[\d_]*)([eEfF][-+]?\d+)?/,r:0},o={cN:"string",b:/'(.|\\[xXuU][a-zA-Z0-9]+)'/},i={cN:"subst",b:/\$\(/,e:/\)/,k:r},l={cN:"variable",b:"\\$"+t},c={cN:"string",c:[e.BE,i,l],v:[{b:/\w*"""/,e:/"""\w*/,r:10},{b:/\w*"/,e:/"\w*/}]},s={cN:"string",c:[e.BE,i,l],b:"`",e:"`"},d={cN:"meta",b:"@"+t},u={cN:"comment",v:[{b:"#=",e:"=#",r:10},{b:"#",e:"$"}]};return a.c=[n,o,c,s,d,u,e.HCM,{cN:"keyword",b:"\\b(((abstract|primitive)\\s+)type|(mutable\\s+)?struct)\\b"},{b:/<:/}],i.c=a.c,a});hljs.registerLanguage("coffeescript",function(e){var c={keyword:"in if for while finally new do return else break catch instanceof throw try this switch continue typeof delete debugger super yield import export from as default await then unless until loop of by when and or is isnt not",literal:"true false null undefined yes no on off",built_in:"npm require console print module global window document"},n="[A-Za-z$_][0-9A-Za-z$_]*",r={cN:"subst",b:/#\{/,e:/}/,k:c},i=[e.BNM,e.inherit(e.CNM,{starts:{e:"(\\s*/)?",r:0}}),{cN:"string",v:[{b:/'''/,e:/'''/,c:[e.BE]},{b:/'/,e:/'/,c:[e.BE]},{b:/"""/,e:/"""/,c:[e.BE,r]},{b:/"/,e:/"/,c:[e.BE,r]}]},{cN:"regexp",v:[{b:"///",e:"///",c:[r,e.HCM]},{b:"//[gim]*",r:0},{b:/\/(?![ *])(\\\/|.)*?\/[gim]*(?=\W|$)/}]},{b:"@"+n},{sL:"javascript",eB:!0,eE:!0,v:[{b:"```",e:"```"},{b:"`",e:"`"}]}];r.c=i;var s=e.inherit(e.TM,{b:n}),t="(\\(.*\\))?\\s*\\B[-=]>",o={cN:"params",b:"\\([^\\(]",rB:!0,c:[{b:/\(/,e:/\)/,k:c,c:["self"].concat(i)}]};return{aliases:["coffee","cson","iced"],k:c,i:/\/\*/,c:i.concat([e.C("###","###"),e.HCM,{cN:"function",b:"^\\s*"+n+"\\s*=\\s*"+t,e:"[-=]>",rB:!0,c:[s,o]},{b:/[:\(,=]\s*/,r:0,c:[{cN:"function",b:t,e:"[-=]>",rB:!0,c:[o]}]},{cN:"class",bK:"class",e:"$",i:/[:="\[\]]/,c:[{bK:"extends",eW:!0,i:/[:="\[\]]/,c:[s]},s]},{b:n+":",e:":",rB:!0,rE:!0,r:0}])}});hljs.registerLanguage("cpp",function(t){var e={cN:"keyword",b:"\\b[a-z\\d_]*_t\\b"},r={cN:"string",v:[{b:'(u8?|U)?L?"',e:'"',i:"\\n",c:[t.BE]},{b:'(u8?|U)?R"',e:'"',c:[t.BE]},{b:"'\\\\?.",e:"'",i:"."}]},s={cN:"number",v:[{b:"\\b(0b[01']+)"},{b:"(-?)\\b([\\d']+(\\.[\\d']*)?|\\.[\\d']+)(u|U|l|L|ul|UL|f|F|b|B)"},{b:"(-?)(\\b0[xX][a-fA-F0-9']+|(\\b[\\d']+(\\.[\\d']*)?|\\.[\\d']+)([eE][-+]?[\\d']+)?)"}],r:0},i={cN:"meta",b:/#\s*[a-z]+\b/,e:/$/,k:{"meta-keyword":"if else elif endif define undef warning error line pragma ifdef ifndef include"},c:[{b:/\\\n/,r:0},t.inherit(r,{cN:"meta-string"}),{cN:"meta-string",b:/<[^\n>]*>/,e:/$/,i:"\\n"},t.CLCM,t.CBCM]},a=t.IR+"\\s*\\(",c={keyword:"int float while private char catch import module export virtual operator sizeof dynamic_cast|10 typedef const_cast|10 const for static_cast|10 union namespace unsigned long volatile static protected bool template mutable if public friend do goto auto void enum else break extern using asm case typeid short reinterpret_cast|10 default double register explicit signed typename try this switch continue inline delete alignof constexpr decltype noexcept static_assert thread_local restrict _Bool complex _Complex _Imaginary atomic_bool atomic_char atomic_schar atomic_uchar atomic_short atomic_ushort atomic_int atomic_uint atomic_long atomic_ulong atomic_llong atomic_ullong new throw return and or not",built_in:"std string cin cout cerr clog stdin stdout stderr stringstream istringstream ostringstream auto_ptr deque list queue stack vector map set bitset multiset multimap unordered_set unordered_map unordered_multiset unordered_multimap array shared_ptr abort abs acos asin atan2 atan calloc ceil cosh cos exit exp fabs floor fmod fprintf fputs free frexp fscanf isalnum isalpha iscntrl isdigit isgraph islower isprint ispunct isspace isupper isxdigit tolower toupper labs ldexp log10 log malloc realloc memchr memcmp memcpy memset modf pow printf putchar puts scanf sinh sin snprintf sprintf sqrt sscanf strcat strchr strcmp strcpy strcspn strlen strncat strncmp strncpy strpbrk strrchr strspn strstr tanh tan vfprintf vprintf vsprintf endl initializer_list unique_ptr",literal:"true false nullptr NULL"},n=[e,t.CLCM,t.CBCM,s,r];return{aliases:["c","cc","h","c++","h++","hpp"],k:c,i:"</",c:n.concat([i,{b:"\\b(deque|list|queue|stack|vector|map|set|bitset|multiset|multimap|unordered_map|unordered_set|unordered_multiset|unordered_multimap|array)\\s*<",e:">",k:c,c:["self",e]},{b:t.IR+"::",k:c},{v:[{b:/=/,e:/;/},{b:/\(/,e:/\)/},{bK:"new throw return else",e:/;/}],k:c,c:n.concat([{b:/\(/,e:/\)/,k:c,c:n.concat(["self"]),r:0}]),r:0},{cN:"function",b:"("+t.IR+"[\\*&\\s]+)+"+a,rB:!0,e:/[{;=]/,eE:!0,k:c,i:/[^\w\s\*&]/,c:[{b:a,rB:!0,c:[t.TM],r:0},{cN:"params",b:/\(/,e:/\)/,k:c,r:0,c:[t.CLCM,t.CBCM,r,s,e]},t.CLCM,t.CBCM,i]},{cN:"class",bK:"class struct",e:/[{;:]/,c:[{b:/</,e:/>/,c:["self"]},t.TM]}]),exports:{preprocessor:i,strings:r,k:c}}});hljs.registerLanguage("ruby",function(e){var b="[a-zA-Z_]\\w*[!?=]?|[-+~]\\@|<<|>>|=~|===?|<=>|[<>]=?|\\*\\*|[-/+%^&*~`|]|\\[\\]=?",r={keyword:"and then defined module in return redo if BEGIN retry end for self when next until do begin unless END rescue else break undef not super class case require yield alias while ensure elsif or include attr_reader attr_writer attr_accessor",literal:"true false nil"},c={cN:"doctag",b:"@[A-Za-z]+"},a={b:"#<",e:">"},s=[e.C("#","$",{c:[c]}),e.C("^\\=begin","^\\=end",{c:[c],r:10}),e.C("^__END__","\\n$")],n={cN:"subst",b:"#\\{",e:"}",k:r},t={cN:"string",c:[e.BE,n],v:[{b:/'/,e:/'/},{b:/"/,e:/"/},{b:/`/,e:/`/},{b:"%[qQwWx]?\\(",e:"\\)"},{b:"%[qQwWx]?\\[",e:"\\]"},{b:"%[qQwWx]?{",e:"}"},{b:"%[qQwWx]?<",e:">"},{b:"%[qQwWx]?/",e:"/"},{b:"%[qQwWx]?%",e:"%"},{b:"%[qQwWx]?-",e:"-"},{b:"%[qQwWx]?\\|",e:"\\|"},{b:/\B\?(\\\d{1,3}|\\x[A-Fa-f0-9]{1,2}|\\u[A-Fa-f0-9]{4}|\\?\S)\b/},{b:/<<(-?)\w+$/,e:/^\s*\w+$/}]},i={cN:"params",b:"\\(",e:"\\)",endsParent:!0,k:r},d=[t,a,{cN:"class",bK:"class module",e:"$|;",i:/=/,c:[e.inherit(e.TM,{b:"[A-Za-z_]\\w*(::\\w+)*(\\?|\\!)?"}),{b:"<\\s*",c:[{b:"("+e.IR+"::)?"+e.IR}]}].concat(s)},{cN:"function",bK:"def",e:"$|;",c:[e.inherit(e.TM,{b:b}),i].concat(s)},{b:e.IR+"::"},{cN:"symbol",b:e.UIR+"(\\!|\\?)?:",r:0},{cN:"symbol",b:":(?!\\s)",c:[t,{b:b}],r:0},{cN:"number",b:"(\\b0[0-7_]+)|(\\b0x[0-9a-fA-F_]+)|(\\b[1-9][0-9_]*(\\.[0-9_]+)?)|[0_]\\b",r:0},{b:"(\\$\\W)|((\\$|\\@\\@?)(\\w+))"},{cN:"params",b:/\|/,e:/\|/,k:r},{b:"("+e.RSR+"|unless)\\s*",k:"unless",c:[a,{cN:"regexp",c:[e.BE,n],i:/\n/,v:[{b:"/",e:"/[a-z]*"},{b:"%r{",e:"}[a-z]*"},{b:"%r\\(",e:"\\)[a-z]*"},{b:"%r!",e:"![a-z]*"},{b:"%r\\[",e:"\\][a-z]*"}]}].concat(s),r:0}].concat(s);n.c=d,i.c=d;var l="[>?]>",o="[\\w#]+\\(\\w+\\):\\d+:\\d+>",u="(\\w+-)?\\d+\\.\\d+\\.\\d(p\\d+)?[^>]+>",w=[{b:/^\s*=>/,starts:{e:"$",c:d}},{cN:"meta",b:"^("+l+"|"+o+"|"+u+")",starts:{e:"$",c:d}}];return{aliases:["rb","gemspec","podspec","thor","irb"],k:r,i:/\/\*/,c:s.concat(w).concat(d)}});hljs.registerLanguage("yaml",function(e){var b="true false yes no null",a="^[ \\-]*",r="[a-zA-Z_][\\w\\-]*",t={cN:"attr",v:[{b:a+r+":"},{b:a+'"'+r+'":'},{b:a+"'"+r+"':"}]},c={cN:"template-variable",v:[{b:"{{",e:"}}"},{b:"%{",e:"}"}]},l={cN:"string",r:0,v:[{b:/'/,e:/'/},{b:/"/,e:/"/},{b:/\S+/}],c:[e.BE,c]};return{cI:!0,aliases:["yml","YAML","yaml"],c:[t,{cN:"meta",b:"^---s*$",r:10},{cN:"string",b:"[\\|>] *$",rE:!0,c:l.c,e:t.v[0].b},{b:"<%[%=-]?",e:"[%-]?%>",sL:"ruby",eB:!0,eE:!0,r:0},{cN:"type",b:"!!"+e.UIR},{cN:"meta",b:"&"+e.UIR+"$"},{cN:"meta",b:"\\*"+e.UIR+"$"},{cN:"bullet",b:"^ *-",r:0},e.HCM,{bK:b,k:{literal:b}},e.CNM,l]}});hljs.registerLanguage("css",function(e){var c="[a-zA-Z-][a-zA-Z0-9_-]*",t={b:/[A-Z\_\.\-]+\s*:/,rB:!0,e:";",eW:!0,c:[{cN:"attribute",b:/\S/,e:":",eE:!0,starts:{eW:!0,eE:!0,c:[{b:/[\w-]+\(/,rB:!0,c:[{cN:"built_in",b:/[\w-]+/},{b:/\(/,e:/\)/,c:[e.ASM,e.QSM]}]},e.CSSNM,e.QSM,e.ASM,e.CBCM,{cN:"number",b:"#[0-9A-Fa-f]+"},{cN:"meta",b:"!important"}]}}]};return{cI:!0,i:/[=\/|'\$]/,c:[e.CBCM,{cN:"selector-id",b:/#[A-Za-z0-9_-]+/},{cN:"selector-class",b:/\.[A-Za-z0-9_-]+/},{cN:"selector-attr",b:/\[/,e:/\]/,i:"$"},{cN:"selector-pseudo",b:/:(:)?[a-zA-Z0-9\_\-\+\(\)"'.]+/},{b:"@(font-face|page)",l:"[a-z-]+",k:"font-face page"},{b:"@",e:"[{;]",i:/:/,c:[{cN:"keyword",b:/\w+/},{b:/\s/,eW:!0,eE:!0,r:0,c:[e.ASM,e.QSM,e.CSSNM]}]},{cN:"selector-tag",b:c,r:0},{b:"{",e:"}",i:/\S/,c:[e.CBCM,t]}]}});hljs.registerLanguage("fortran",function(e){var t={cN:"params",b:"\\(",e:"\\)"},n={literal:".False. .True.",keyword:"kind do while private call intrinsic where elsewhere type endtype endmodule endselect endinterface end enddo endif if forall endforall only contains default return stop then public subroutine|10 function program .and. .or. .not. .le. .eq. .ge. .gt. .lt. goto save else use module select case access blank direct exist file fmt form formatted iostat name named nextrec number opened rec recl sequential status unformatted unit continue format pause cycle exit c_null_char c_alert c_backspace c_form_feed flush wait decimal round iomsg synchronous nopass non_overridable pass protected volatile abstract extends import non_intrinsic value deferred generic final enumerator class associate bind enum c_int c_short c_long c_long_long c_signed_char c_size_t c_int8_t c_int16_t c_int32_t c_int64_t c_int_least8_t c_int_least16_t c_int_least32_t c_int_least64_t c_int_fast8_t c_int_fast16_t c_int_fast32_t c_int_fast64_t c_intmax_t C_intptr_t c_float c_double c_long_double c_float_complex c_double_complex c_long_double_complex c_bool c_char c_null_ptr c_null_funptr c_new_line c_carriage_return c_horizontal_tab c_vertical_tab iso_c_binding c_loc c_funloc c_associated  c_f_pointer c_ptr c_funptr iso_fortran_env character_storage_size error_unit file_storage_size input_unit iostat_end iostat_eor numeric_storage_size output_unit c_f_procpointer ieee_arithmetic ieee_support_underflow_control ieee_get_underflow_mode ieee_set_underflow_mode newunit contiguous recursive pad position action delim readwrite eor advance nml interface procedure namelist include sequence elemental pure integer real character complex logical dimension allocatable|10 parameter external implicit|10 none double precision assign intent optional pointer target in out common equivalence data",built_in:"alog alog10 amax0 amax1 amin0 amin1 amod cabs ccos cexp clog csin csqrt dabs dacos dasin datan datan2 dcos dcosh ddim dexp dint dlog dlog10 dmax1 dmin1 dmod dnint dsign dsin dsinh dsqrt dtan dtanh float iabs idim idint idnint ifix isign max0 max1 min0 min1 sngl algama cdabs cdcos cdexp cdlog cdsin cdsqrt cqabs cqcos cqexp cqlog cqsin cqsqrt dcmplx dconjg derf derfc dfloat dgamma dimag dlgama iqint qabs qacos qasin qatan qatan2 qcmplx qconjg qcos qcosh qdim qerf qerfc qexp qgamma qimag qlgama qlog qlog10 qmax1 qmin1 qmod qnint qsign qsin qsinh qsqrt qtan qtanh abs acos aimag aint anint asin atan atan2 char cmplx conjg cos cosh exp ichar index int log log10 max min nint sign sin sinh sqrt tan tanh print write dim lge lgt lle llt mod nullify allocate deallocate adjustl adjustr all allocated any associated bit_size btest ceiling count cshift date_and_time digits dot_product eoshift epsilon exponent floor fraction huge iand ibclr ibits ibset ieor ior ishft ishftc lbound len_trim matmul maxexponent maxloc maxval merge minexponent minloc minval modulo mvbits nearest pack present product radix random_number random_seed range repeat reshape rrspacing scale scan selected_int_kind selected_real_kind set_exponent shape size spacing spread sum system_clock tiny transpose trim ubound unpack verify achar iachar transfer dble entry dprod cpu_time command_argument_count get_command get_command_argument get_environment_variable is_iostat_end ieee_arithmetic ieee_support_underflow_control ieee_get_underflow_mode ieee_set_underflow_mode is_iostat_eor move_alloc new_line selected_char_kind same_type_as extends_type_ofacosh asinh atanh bessel_j0 bessel_j1 bessel_jn bessel_y0 bessel_y1 bessel_yn erf erfc erfc_scaled gamma log_gamma hypot norm2 atomic_define atomic_ref execute_command_line leadz trailz storage_size merge_bits bge bgt ble blt dshiftl dshiftr findloc iall iany iparity image_index lcobound ucobound maskl maskr num_images parity popcnt poppar shifta shiftl shiftr this_image"};return{cI:!0,aliases:["f90","f95"],k:n,i:/\/\*/,c:[e.inherit(e.ASM,{cN:"string",r:0}),e.inherit(e.QSM,{cN:"string",r:0}),{cN:"function",bK:"subroutine function program",i:"[${=\\n]",c:[e.UTM,t]},e.C("!","$",{r:0}),{cN:"number",b:"(?=\\b|\\+|\\-|\\.)(?=\\.\\d|\\d)(?:\\d+)?(?:\\.?\\d*)(?:[de][+-]?\\d+)?\\b\\.?",r:0}]}});hljs.registerLanguage("awk",function(e){var r={cN:"variable",v:[{b:/\$[\w\d#@][\w\d_]*/},{b:/\$\{(.*?)}/}]},b="BEGIN END if else while do for in break continue delete next nextfile function func exit|10",n={cN:"string",c:[e.BE],v:[{b:/(u|b)?r?'''/,e:/'''/,r:10},{b:/(u|b)?r?"""/,e:/"""/,r:10},{b:/(u|r|ur)'/,e:/'/,r:10},{b:/(u|r|ur)"/,e:/"/,r:10},{b:/(b|br)'/,e:/'/},{b:/(b|br)"/,e:/"/},e.ASM,e.QSM]};return{k:{keyword:b},c:[r,n,e.RM,e.HCM,e.NM]}});hljs.registerLanguage("makefile",function(e){var i={cN:"variable",v:[{b:"\\$\\("+e.UIR+"\\)",c:[e.BE]},{b:/\$[@%<?\^\+\*]/}]},r={cN:"string",b:/"/,e:/"/,c:[e.BE,i]},a={cN:"variable",b:/\$\([\w-]+\s/,e:/\)/,k:{built_in:"subst patsubst strip findstring filter filter-out sort word wordlist firstword lastword dir notdir suffix basename addsuffix addprefix join wildcard realpath abspath error warning shell origin flavor foreach if or and call eval file value"},c:[i]},n={b:"^"+e.UIR+"\\s*[:+?]?=",i:"\\n",rB:!0,c:[{b:"^"+e.UIR,e:"[:+?]?=",eE:!0}]},t={cN:"meta",b:/^\.PHONY:/,e:/$/,k:{"meta-keyword":".PHONY"},l:/[\.\w]+/},l={cN:"section",b:/^[^\s]+:/,e:/$/,c:[i]};return{aliases:["mk","mak"],k:"define endef undefine ifdef ifndef ifeq ifneq else endif include -include sinclude override export unexport private vpath",l:/[\w-]+/,c:[e.HCM,i,r,a,n,t,l]}});hljs.registerLanguage("java",function(e){var a="[À-ʸa-zA-Z_$][À-ʸa-zA-Z_$0-9]*",t=a+"(<"+a+"(\\s*,\\s*"+a+")*>)?",r="false synchronized int abstract float private char boolean static null if const for true while long strictfp finally protected import native final void enum else break transient catch instanceof byte super volatile case assert short package default double public try this switch continue throws protected public private module requires exports do",s="\\b(0[bB]([01]+[01_]+[01]+|[01]+)|0[xX]([a-fA-F0-9]+[a-fA-F0-9_]+[a-fA-F0-9]+|[a-fA-F0-9]+)|(([\\d]+[\\d_]+[\\d]+|[\\d]+)(\\.([\\d]+[\\d_]+[\\d]+|[\\d]+))?|\\.([\\d]+[\\d_]+[\\d]+|[\\d]+))([eE][-+]?\\d+)?)[lLfF]?",c={cN:"number",b:s,r:0};return{aliases:["jsp"],k:r,i:/<\/|#/,c:[e.C("/\\*\\*","\\*/",{r:0,c:[{b:/\w+@/,r:0},{cN:"doctag",b:"@[A-Za-z]+"}]}),e.CLCM,e.CBCM,e.ASM,e.QSM,{cN:"class",bK:"class interface",e:/[{;=]/,eE:!0,k:"class interface",i:/[:"\[\]]/,c:[{bK:"extends implements"},e.UTM]},{bK:"new throw return else",r:0},{cN:"function",b:"("+t+"\\s+)+"+e.UIR+"\\s*\\(",rB:!0,e:/[{;=]/,eE:!0,k:r,c:[{b:e.UIR+"\\s*\\(",rB:!0,r:0,c:[e.UTM]},{cN:"params",b:/\(/,e:/\)/,k:r,r:0,c:[e.ASM,e.QSM,e.CNM,e.CBCM]},e.CLCM,e.CBCM]},c,{cN:"meta",b:"@[A-Za-z]+"}]}});hljs.registerLanguage("stan",function(e){return{c:[e.HCM,e.CLCM,e.CBCM,{b:e.UIR,l:e.UIR,k:{name:"for in while repeat until if then else",symbol:"bernoulli bernoulli_logit binomial binomial_logit beta_binomial hypergeometric categorical categorical_logit ordered_logistic neg_binomial neg_binomial_2 neg_binomial_2_log poisson poisson_log multinomial normal exp_mod_normal skew_normal student_t cauchy double_exponential logistic gumbel lognormal chi_square inv_chi_square scaled_inv_chi_square exponential inv_gamma weibull frechet rayleigh wiener pareto pareto_type_2 von_mises uniform multi_normal multi_normal_prec multi_normal_cholesky multi_gp multi_gp_cholesky multi_student_t gaussian_dlm_obs dirichlet lkj_corr lkj_corr_cholesky wishart inv_wishart","selector-tag":"int real vector simplex unit_vector ordered positive_ordered row_vector matrix cholesky_factor_corr cholesky_factor_cov corr_matrix cov_matrix",title:"functions model data parameters quantities transformed generated",literal:"true false"},r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"\\d+(?:[eE][+\\-]?\\d*)?L\\b",r:0},{cN:"number",b:"\\d+\\.(?!\\d)(?:i\\b)?",r:0},{cN:"number",b:"\\d+(?:\\.\\d*)?(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{cN:"number",b:"\\.\\d+(?:[eE][+\\-]?\\d*)?i?\\b",r:0}]}});hljs.registerLanguage("javascript",function(e){var r="[A-Za-z$_][0-9A-Za-z$_]*",t={keyword:"in of if for while finally var new function do return void else break catch instanceof with throw case default try this switch continue typeof delete let yield const export super debugger as async await static import from as",literal:"true false null undefined NaN Infinity",built_in:"eval isFinite isNaN parseFloat parseInt decodeURI decodeURIComponent encodeURI encodeURIComponent escape unescape Object Function Boolean Error EvalError InternalError RangeError ReferenceError StopIteration SyntaxError TypeError URIError Number Math Date String RegExp Array Float32Array Float64Array Int16Array Int32Array Int8Array Uint16Array Uint32Array Uint8Array Uint8ClampedArray ArrayBuffer DataView JSON Intl arguments require module console window document Symbol Set Map WeakSet WeakMap Proxy Reflect Promise"},a={cN:"number",v:[{b:"\\b(0[bB][01]+)"},{b:"\\b(0[oO][0-7]+)"},{b:e.CNR}],r:0},n={cN:"subst",b:"\\$\\{",e:"\\}",k:t,c:[]},c={cN:"string",b:"`",e:"`",c:[e.BE,n]};n.c=[e.ASM,e.QSM,c,a,e.RM];var s=n.c.concat([e.CBCM,e.CLCM]);return{aliases:["js","jsx"],k:t,c:[{cN:"meta",r:10,b:/^\s*['"]use (strict|asm)['"]/},{cN:"meta",b:/^#!/,e:/$/},e.ASM,e.QSM,c,e.CLCM,e.CBCM,a,{b:/[{,]\s*/,r:0,c:[{b:r+"\\s*:",rB:!0,r:0,c:[{cN:"attr",b:r,r:0}]}]},{b:"("+e.RSR+"|\\b(case|return|throw)\\b)\\s*",k:"return throw case",c:[e.CLCM,e.CBCM,e.RM,{cN:"function",b:"(\\(.*?\\)|"+r+")\\s*=>",rB:!0,e:"\\s*=>",c:[{cN:"params",v:[{b:r},{b:/\(\s*\)/},{b:/\(/,e:/\)/,eB:!0,eE:!0,k:t,c:s}]}]},{b:/</,e:/(\/\w+|\w+\/)>/,sL:"xml",c:[{b:/<\w+\s*\/>/,skip:!0},{b:/<\w+/,e:/(\/\w+|\w+\/)>/,skip:!0,c:[{b:/<\w+\s*\/>/,skip:!0},"self"]}]}],r:0},{cN:"function",bK:"function",e:/\{/,eE:!0,c:[e.inherit(e.TM,{b:r}),{cN:"params",b:/\(/,e:/\)/,eB:!0,eE:!0,c:s}],i:/\[|%/},{b:/\$[(.]/},e.METHOD_GUARD,{cN:"class",bK:"class",e:/[{;=]/,eE:!0,i:/[:"\[\]]/,c:[{bK:"extends"},e.UTM]},{bK:"constructor",e:/\{/,eE:!0}],i:/#(?!!)/}});hljs.registerLanguage("tex",function(c){var e={cN:"tag",b:/\\/,r:0,c:[{cN:"name",v:[{b:/[a-zA-Zа-яА-я]+[*]?/},{b:/[^a-zA-Zа-яА-я0-9]/}],starts:{eW:!0,r:0,c:[{cN:"string",v:[{b:/\[/,e:/\]/},{b:/\{/,e:/\}/}]},{b:/\s*=\s*/,eW:!0,r:0,c:[{cN:"number",b:/-?\d*\.?\d+(pt|pc|mm|cm|in|dd|cc|ex|em)?/}]}]}}]};return{c:[e,{cN:"formula",c:[e],r:0,v:[{b:/\$\$/,e:/\$\$/},{b:/\$/,e:/\$/}]},c.C("%","$",{r:0})]}});hljs.registerLanguage("xml",function(s){var e="[A-Za-z0-9\\._:-]+",t={eW:!0,i:/</,r:0,c:[{cN:"attr",b:e,r:0},{b:/=\s*/,r:0,c:[{cN:"string",endsParent:!0,v:[{b:/"/,e:/"/},{b:/'/,e:/'/},{b:/[^\s"'=<>`]+/}]}]}]};return{aliases:["html","xhtml","rss","atom","xjb","xsd","xsl","plist"],cI:!0,c:[{cN:"meta",b:"<!DOCTYPE",e:">",r:10,c:[{b:"\\[",e:"\\]"}]},s.C("<!--","-->",{r:10}),{b:"<\\!\\[CDATA\\[",e:"\\]\\]>",r:10},{b:/<\?(php)?/,e:/\?>/,sL:"php",c:[{b:"/\\*",e:"\\*/",skip:!0}]},{cN:"tag",b:"<style(?=\\s|>|$)",e:">",k:{name:"style"},c:[t],starts:{e:"</style>",rE:!0,sL:["css","xml"]}},{cN:"tag",b:"<script(?=\\s|>|$)",e:">",k:{name:"script"},c:[t],starts:{e:"</script>",rE:!0,sL:["actionscript","javascript","handlebars","xml"]}},{cN:"meta",v:[{b:/<\?xml/,e:/\?>/,r:10},{b:/<\?\w+/,e:/\?>/}]},{cN:"tag",b:"</?",e:"/?>",c:[{cN:"name",b:/[^\/><\s]+/,r:0},t]}]}});hljs.registerLanguage("markdown",function(e){return{aliases:["md","mkdown","mkd"],c:[{cN:"section",v:[{b:"^#{1,6}",e:"$"},{b:"^.+?\\n[=-]{2,}$"}]},{b:"<",e:">",sL:"xml",r:0},{cN:"bullet",b:"^([*+-]|(\\d+\\.))\\s+"},{cN:"strong",b:"[*_]{2}.+?[*_]{2}"},{cN:"emphasis",v:[{b:"\\*.+?\\*"},{b:"_.+?_",r:0}]},{cN:"quote",b:"^>\\s+",e:"$"},{cN:"code",v:[{b:"^```w*s*$",e:"^```s*$"},{b:"`.+?`"},{b:"^( {4}|	)",e:"$",r:0}]},{b:"^[-\\*]{3,}",e:"$"},{b:"\\[.+?\\][\\(\\[].*?[\\)\\]]",rB:!0,c:[{cN:"string",b:"\\[",e:"\\]",eB:!0,rE:!0,r:0},{cN:"link",b:"\\]\\(",e:"\\)",eB:!0,eE:!0},{cN:"symbol",b:"\\]\\[",e:"\\]",eB:!0,eE:!0}],r:10},{b:/^\[[^\n]+\]:/,rB:!0,c:[{cN:"symbol",b:/\[/,e:/\]/,eB:!0,eE:!0},{cN:"link",b:/:\s*/,e:/$/,eB:!0}]}]}});hljs.registerLanguage("json",function(e){var i={literal:"true false null"},n=[e.QSM,e.CNM],r={e:",",eW:!0,eE:!0,c:n,k:i},t={b:"{",e:"}",c:[{cN:"attr",b:/"/,e:/"/,c:[e.BE],i:"\\n"},e.inherit(r,{b:/:/})],i:"\\S"},c={b:"\\[",e:"\\]",c:[e.inherit(r)],i:"\\S"};return n.splice(n.length,0,t,c),{c:n,k:i,i:"\\S"}});"></script>
<script src="data:application/javascript;base64,JChkb2N1bWVudCkucmVhZHkoZnVuY3Rpb24oKXsKICAgIGlmICh0eXBlb2YgJCgnW2RhdGEtdG9nZ2xlPSJ0b29sdGlwIl0nKS50b29sdGlwID09PSAnZnVuY3Rpb24nKSB7CiAgICAgICAgJCgnW2RhdGEtdG9nZ2xlPSJ0b29sdGlwIl0nKS50b29sdGlwKCk7CiAgICB9CiAgICBpZiAoJCgnW2RhdGEtdG9nZ2xlPSJwb3BvdmVyIl0nKS5wb3BvdmVyID09PSAnZnVuY3Rpb24nKSB7CiAgICAgICAgJCgnW2RhdGEtdG9nZ2xlPSJwb3BvdmVyIl0nKS5wb3BvdmVyKCk7CiAgICB9Cn0pOwo="></script>
<link href="data:text/css,%0A%2Elightable%2Dminimal%20%7B%0Aborder%2Dcollapse%3A%20separate%3B%0Aborder%2Dspacing%3A%2016px%201px%3B%0Awidth%3A%20100%25%3B%0Amargin%2Dbottom%3A%2010px%3B%0A%7D%0A%2Elightable%2Dminimal%20td%20%7B%0Amargin%2Dleft%3A%205px%3B%0Amargin%2Dright%3A%205px%3B%0A%7D%0A%2Elightable%2Dminimal%20th%20%7B%0Amargin%2Dleft%3A%205px%3B%0Amargin%2Dright%3A%205px%3B%0A%7D%0A%2Elightable%2Dminimal%20thead%20tr%3Alast%2Dchild%20th%20%7B%0Aborder%2Dbottom%3A%202px%20solid%20%2300000050%3B%0Aempty%2Dcells%3A%20hide%3B%0A%7D%0A%2Elightable%2Dminimal%20tbody%20tr%3Afirst%2Dchild%20td%20%7B%0Apadding%2Dtop%3A%200%2E5em%3B%0A%7D%0A%2Elightable%2Dminimal%2Elightable%2Dhover%20tbody%20tr%3Ahover%20%7B%0Abackground%2Dcolor%3A%20%23f5f5f5%3B%0A%7D%0A%2Elightable%2Dminimal%2Elightable%2Dstriped%20tbody%20tr%3Anth%2Dchild%28even%29%20%7B%0Abackground%2Dcolor%3A%20%23f5f5f5%3B%0A%7D%0A%2Elightable%2Dclassic%20%7B%0Aborder%2Dtop%3A%200%2E16em%20solid%20%23111111%3B%0Aborder%2Dbottom%3A%200%2E16em%20solid%20%23111111%3B%0Awidth%3A%20100%25%3B%0Amargin%2Dbottom%3A%2010px%3B%0Amargin%3A%2010px%205px%3B%0A%7D%0A%2Elightable%2Dclassic%20tfoot%20tr%20td%20%7B%0Aborder%3A%200%3B%0A%7D%0A%2Elightable%2Dclassic%20tfoot%20tr%3Afirst%2Dchild%20td%20%7B%0Aborder%2Dtop%3A%200%2E14em%20solid%20%23111111%3B%0A%7D%0A%2Elightable%2Dclassic%20caption%20%7B%0Acolor%3A%20%23222222%3B%0A%7D%0A%2Elightable%2Dclassic%20td%20%7B%0Apadding%2Dleft%3A%205px%3B%0Apadding%2Dright%3A%205px%3B%0Acolor%3A%20%23222222%3B%0A%7D%0A%2Elightable%2Dclassic%20th%20%7B%0Apadding%2Dleft%3A%205px%3B%0Apadding%2Dright%3A%205px%3B%0Afont%2Dweight%3A%20normal%3B%0Acolor%3A%20%23222222%3B%0A%7D%0A%2Elightable%2Dclassic%20thead%20tr%3Alast%2Dchild%20th%20%7B%0Aborder%2Dbottom%3A%200%2E10em%20solid%20%23111111%3B%0A%7D%0A%2Elightable%2Dclassic%2Elightable%2Dhover%20tbody%20tr%3Ahover%20%7B%0Abackground%2Dcolor%3A%20%23F9EEC1%3B%0A%7D%0A%2Elightable%2Dclassic%2Elightable%2Dstriped%20tbody%20tr%3Anth%2Dchild%28even%29%20%7B%0Abackground%2Dcolor%3A%20%23f5f5f5%3B%0A%7D%0A%2Elightable%2Dclassic%2D2%20%7B%0Aborder%2Dtop%3A%203px%20double%20%23111111%3B%0Aborder%2Dbottom%3A%203px%20double%20%23111111%3B%0Awidth%3A%20100%25%3B%0Amargin%2Dbottom%3A%2010px%3B%0A%7D%0A%2Elightable%2Dclassic%2D2%20tfoot%20tr%20td%20%7B%0Aborder%3A%200%3B%0A%7D%0A%2Elightable%2Dclassic%2D2%20tfoot%20tr%3Afirst%2Dchild%20td%20%7B%0Aborder%2Dtop%3A%203px%20double%20%23111111%3B%0A%7D%0A%2Elightable%2Dclassic%2D2%20caption%20%7B%0Acolor%3A%20%23222222%3B%0A%7D%0A%2Elightable%2Dclassic%2D2%20td%20%7B%0Apadding%2Dleft%3A%205px%3B%0Apadding%2Dright%3A%205px%3B%0Acolor%3A%20%23222222%3B%0A%7D%0A%2Elightable%2Dclassic%2D2%20th%20%7B%0Apadding%2Dleft%3A%205px%3B%0Apadding%2Dright%3A%205px%3B%0Afont%2Dweight%3A%20normal%3B%0Acolor%3A%20%23222222%3B%0A%7D%0A%2Elightable%2Dclassic%2D2%20tbody%20tr%3Alast%2Dchild%20td%20%7B%0Aborder%2Dbottom%3A%203px%20double%20%23111111%3B%0A%7D%0A%2Elightable%2Dclassic%2D2%20thead%20tr%3Alast%2Dchild%20th%20%7B%0Aborder%2Dbottom%3A%201px%20solid%20%23111111%3B%0A%7D%0A%2Elightable%2Dclassic%2D2%2Elightable%2Dhover%20tbody%20tr%3Ahover%20%7B%0Abackground%2Dcolor%3A%20%23F9EEC1%3B%0A%7D%0A%2Elightable%2Dclassic%2D2%2Elightable%2Dstriped%20tbody%20tr%3Anth%2Dchild%28even%29%20%7B%0Abackground%2Dcolor%3A%20%23f5f5f5%3B%0A%7D%0A%2Elightable%2Dmaterial%20%7B%0Amin%2Dwidth%3A%20100%25%3B%0Awhite%2Dspace%3A%20nowrap%3B%0Atable%2Dlayout%3A%20fixed%3B%0Afont%2Dfamily%3A%20Roboto%2C%20sans%2Dserif%3B%0Aborder%3A%201px%20solid%20%23EEE%3B%0Aborder%2Dcollapse%3A%20collapse%3B%0Amargin%2Dbottom%3A%2010px%3B%0A%7D%0A%2Elightable%2Dmaterial%20tfoot%20tr%20td%20%7B%0Aborder%3A%200%3B%0A%7D%0A%2Elightable%2Dmaterial%20tfoot%20tr%3Afirst%2Dchild%20td%20%7B%0Aborder%2Dtop%3A%201px%20solid%20%23EEE%3B%0A%7D%0A%2Elightable%2Dmaterial%20th%20%7B%0Aheight%3A%2056px%3B%0Apadding%2Dleft%3A%2016px%3B%0Apadding%2Dright%3A%2016px%3B%0A%7D%0A%2Elightable%2Dmaterial%20td%20%7B%0Aheight%3A%2052px%3B%0Apadding%2Dleft%3A%2016px%3B%0Apadding%2Dright%3A%2016px%3B%0Aborder%2Dtop%3A%201px%20solid%20%23eeeeee%3B%0A%7D%0A%2Elightable%2Dmaterial%2Elightable%2Dhover%20tbody%20tr%3Ahover%20%7B%0Abackground%2Dcolor%3A%20%23f5f5f5%3B%0A%7D%0A%2Elightable%2Dmaterial%2Elightable%2Dstriped%20tbody%20tr%3Anth%2Dchild%28even%29%20%7B%0Abackground%2Dcolor%3A%20%23f5f5f5%3B%0A%7D%0A%2Elightable%2Dmaterial%2Elightable%2Dstriped%20tbody%20td%20%7B%0Aborder%3A%200%3B%0A%7D%0A%2Elightable%2Dmaterial%2Elightable%2Dstriped%20thead%20tr%3Alast%2Dchild%20th%20%7B%0Aborder%2Dbottom%3A%201px%20solid%20%23ddd%3B%0A%7D%0A%2Elightable%2Dmaterial%2Ddark%20%7B%0Amin%2Dwidth%3A%20100%25%3B%0Awhite%2Dspace%3A%20nowrap%3B%0Atable%2Dlayout%3A%20fixed%3B%0Afont%2Dfamily%3A%20Roboto%2C%20sans%2Dserif%3B%0Aborder%3A%201px%20solid%20%23FFFFFF12%3B%0Aborder%2Dcollapse%3A%20collapse%3B%0Amargin%2Dbottom%3A%2010px%3B%0Abackground%2Dcolor%3A%20%23363640%3B%0A%7D%0A%2Elightable%2Dmaterial%2Ddark%20tfoot%20tr%20td%20%7B%0Aborder%3A%200%3B%0A%7D%0A%2Elightable%2Dmaterial%2Ddark%20tfoot%20tr%3Afirst%2Dchild%20td%20%7B%0Aborder%2Dtop%3A%201px%20solid%20%23FFFFFF12%3B%0A%7D%0A%2Elightable%2Dmaterial%2Ddark%20th%20%7B%0Aheight%3A%2056px%3B%0Apadding%2Dleft%3A%2016px%3B%0Apadding%2Dright%3A%2016px%3B%0Acolor%3A%20%23FFFFFF60%3B%0A%7D%0A%2Elightable%2Dmaterial%2Ddark%20td%20%7B%0Aheight%3A%2052px%3B%0Apadding%2Dleft%3A%2016px%3B%0Apadding%2Dright%3A%2016px%3B%0Acolor%3A%20%23FFFFFF%3B%0Aborder%2Dtop%3A%201px%20solid%20%23FFFFFF12%3B%0A%7D%0A%2Elightable%2Dmaterial%2Ddark%2Elightable%2Dhover%20tbody%20tr%3Ahover%20%7B%0Abackground%2Dcolor%3A%20%23FFFFFF12%3B%0A%7D%0A%2Elightable%2Dmaterial%2Ddark%2Elightable%2Dstriped%20tbody%20tr%3Anth%2Dchild%28even%29%20%7B%0Abackground%2Dcolor%3A%20%23FFFFFF12%3B%0A%7D%0A%2Elightable%2Dmaterial%2Ddark%2Elightable%2Dstriped%20tbody%20td%20%7B%0Aborder%3A%200%3B%0A%7D%0A%2Elightable%2Dmaterial%2Ddark%2Elightable%2Dstriped%20thead%20tr%3Alast%2Dchild%20th%20%7B%0Aborder%2Dbottom%3A%201px%20solid%20%23FFFFFF12%3B%0A%7D%0A%2Elightable%2Dpaper%20%7B%0Awidth%3A%20100%25%3B%0Amargin%2Dbottom%3A%2010px%3B%0Acolor%3A%20%23444%3B%0A%7D%0A%2Elightable%2Dpaper%20tfoot%20tr%20td%20%7B%0Aborder%3A%200%3B%0A%7D%0A%2Elightable%2Dpaper%20tfoot%20tr%3Afirst%2Dchild%20td%20%7B%0Aborder%2Dtop%3A%201px%20solid%20%2300000020%3B%0A%7D%0A%2Elightable%2Dpaper%20thead%20tr%3Alast%2Dchild%20th%20%7B%0Acolor%3A%20%23666%3B%0Avertical%2Dalign%3A%20bottom%3B%0Aborder%2Dbottom%3A%201px%20solid%20%2300000020%3B%0Aline%2Dheight%3A%201%2E15em%3B%0Apadding%3A%2010px%205px%3B%0A%7D%0A%2Elightable%2Dpaper%20td%20%7B%0Avertical%2Dalign%3A%20middle%3B%0Aborder%2Dbottom%3A%201px%20solid%20%2300000010%3B%0Aline%2Dheight%3A%201%2E15em%3B%0Apadding%3A%207px%205px%3B%0A%7D%0A%2Elightable%2Dpaper%2Elightable%2Dhover%20tbody%20tr%3Ahover%20%7B%0Abackground%2Dcolor%3A%20%23F9EEC1%3B%0A%7D%0A%2Elightable%2Dpaper%2Elightable%2Dstriped%20tbody%20tr%3Anth%2Dchild%28even%29%20%7B%0Abackground%2Dcolor%3A%20%2300000008%3B%0A%7D%0A%2Elightable%2Dpaper%2Elightable%2Dstriped%20tbody%20td%20%7B%0Aborder%3A%200%3B%0A%7D%0A" rel="stylesheet" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>

<style type="text/css">code{white-space: pre;}</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>








<style type="text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
pre code {
  padding: 0;
}
</style>



<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "";
  border: none;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div id="header">



<h1 class="title toc-ignore">Shots, Shots, Shots: An Analysis of Studies of COVID-19 Vaccines in the NCBI Database</h1>
<h4 class="author">Xiaotang (Jeffrey) Zhou</h4>
<h4 class="date">13/03/2022</h4>

</div>


<div id="apis" class="section level2">
<h2>APIs</h2>
<p>To start, we will find the number of papers containing the term “sars-cov-2 vaccine” in the NCBI database using the code covered in a previous lab:</p>
<pre><code>## [1] &quot;20,866&quot;</code></pre>
<p>As we can see above, there are currently 18894 papers that come up when we search for “sars-cov-2 vaccine” in the NCBI database. Next, we will extract the first 250 papers and their IDs, followed by their respective titles, journals, publication dates, and abstracts, using regexes.</p>
<p>First, we can see below that the expression <code>!is.na(titles)</code> evaluates to <code>TRUE</code> 249 times but to <code>FALSE</code> 1 time, which means that there are 249 papers with titles but for some reason 1 paper without a title.</p>
<pre class="r"><code>table(!is.na(titles))</code></pre>
<pre><code>## 
## FALSE  TRUE 
##     3   247</code></pre>
<p>Thus, we conclude that 249 of the papers we extracted have titles while 1 does not. Next, we can see below that the expression <code>!is.na(journals)</code> evaluates to <code>TRUE</code> 250 times, which means that there are 250 non-missing journal names.</p>
<pre class="r"><code>table(!is.na(journals))</code></pre>
<pre><code>## 
## TRUE 
##  250</code></pre>
<p>Thus, we conclude that all 250 of the papers we have extracted are associated with some journal. Next, we can see below that the expression <code>!is.na(abstracts)</code> evaluates to <code>TRUE</code> 216 times but <code>FALSE</code> 34 times, which means that 216 of the papers have abstracts while 34 do not.</p>
<pre class="r"><code>table(!is.na(abstracts))</code></pre>
<pre><code>## 
## FALSE  TRUE 
##    31   219</code></pre>
<p>Next, we can see below that the expression <code>!is.na(pub_year)</code> evaluates to <code>TRUE</code> 244 times but <code>FALSE</code> 6 times, which means that 244 of the papers have publication years while 6 do not.</p>
<pre class="r"><code>table(!is.na(pub_year))</code></pre>
<pre><code>## 
## FALSE  TRUE 
##     4   246</code></pre>
<p>Next, we can see below that the expression <code>!is.na(pub_month)</code> evaluates to <code>TRUE</code> 206 times but <code>FALSE</code> 44 times, which means that 206 of the papers have publication months while 44 do not.</p>
<pre class="r"><code>table(!is.na(pub_month))</code></pre>
<pre><code>## 
## FALSE  TRUE 
##    36   214</code></pre>
<p>Finally, we can see below that the expression <code>!is.na(pub_day)</code> evaluates to <code>TRUE</code> 175 times but <code>FALSE</code> 75 times, which means that 175 of the papers have publication days while 75 do not.</p>
<pre class="r"><code>table(!is.na(pub_day))</code></pre>
<pre><code>## 
## FALSE  TRUE 
##    72   178</code></pre>
<p>Now that we have all the information we need, we can proceed to constructing the dataset containing each paper’s PubMed ID, title, journal to which it was published, publication date (split into year, month, and date to account for missing values in each), and abstract:</p>
<table class="table" style="margin-left: auto; margin-right: auto;">
<caption>
Information about the 250 papers extracted from the NCBI database
</caption>
<thead>
<tr>
<th style="text-align:left;">
PubMedID
</th>
<th style="text-align:left;">
Title
</th>
<th style="text-align:left;">
Journal
</th>
<th style="text-align:left;">
Publication Year
</th>
<th style="text-align:left;">
Publication Month
</th>
<th style="text-align:left;">
Publication Day
</th>
<th style="text-align:left;">
Abstract
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
35452692
</td>
<td style="text-align:left;">
A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients.
</td>
<td style="text-align:left;">
Journal of hepatology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
19
</td>
<td style="text-align:left;">
Immune responses of solid organ transplant recipients to two doses of the BNT162b2 mRNA anti-SARS-CoV-2 vaccine is impaired. The immunogenicity and safety of a third dose among liver transplant (LT) recipients are unknown. This work aimed to evaluate the immune response of LT recipients to a third dose of the BNT162b2 mRNA vaccine. Consecutive LT recipients (n=61) in follow-up at Sheba Medical Center were included. Receptor-binding domain (RBD) IgG, neutralizing antibody (NA) titers, and T cells levels before and 21-28 days a third vaccine dose were determined. Adverse effects after the third dose were monitored. The LT recipients were of a median age of 65 years; 57.4% were male. The humoral immune response rate improved significantly, with 56% of patients showing a response before the third vaccine to 98% after the third vaccine. The cellular response in 12 evaluated patients improved significantly (p=0.008). The geometric mean of anti-RBD IgG levels, NA levels, and T cell count also increased significantly after the third dose. NA titers after the third dose negatively correlated with age (p=0.03), mycophenolate mofetil treatment (p=0.005), and combined immunosuppression as compared to calcineurin inhibitor monotherapy (p=0.001). After the third dose, adverse effects were reported by 37% of recipients and were mostly mild (local pain and fatigue). After a third BNT162b2 mRNA vaccine, the immune response improved significantly among LT recipients, without serious adverse effects. Further studies are needed to evaluate immune response durability and determine the optimal number and schedule of boost vaccines. The Pfizer-Biotech BNT162b2SARS-CoV-2 vaccine induced significant immunity among liver transplant recipients. The majority of the patients developed sufficient levels of both humoral and cellular immune responses. Factors that predict non-response were older age and immunosuppressive medications.
</td>
</tr>
<tr>
<td style="text-align:left;">
35452552
</td>
<td style="text-align:left;">
COVID-19 Disease and Vaccination in Pregnant and Lactating Women.
</td>
<td style="text-align:left;">
American journal of reproductive immunology (New York, N.Y. : 1989)
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
22
</td>
<td style="text-align:left;">
More than 325,000 cases of coronavirus disease 2019 (COVID-19) have been reported among pregnant women in the Americas. Multiple studies indicate that pregnant women are more susceptible to adverse COVID-19 outcomes, including hospitalization, intensive care unit admission, and invasive ventilation than non-pregnant women with COVID-19. Furthermore, COVID-19 in pregnancy is associated with adverse maternal and neonatal outcomes. Adverse COVID-19 outcomes appear to disproportionately affect pregnant women from low- and middle-income countries, likely reflecting inequities in access to quality healthcare. Despite the absence of safety and efficacy data from randomized clinical trials in this subpopulation, observational studies and data from pregnancy registries thus far have demonstrated that vaccination of pregnant or lactating women against COVID-19 is safe, effective, and results in robust immune responses including transfer of antibodies to the newborn via the placenta and breast milk, respectively. These data support vaccination recommendations intending to help protect these vulnerable individuals against COVID-19 and its sequelae. Randomized clinical studies will further evaluate the safety and immunogenicity of COVID-19 vaccines in these populations. This review examines the impact of COVID-19 in pregnant women and describes available evidence on the safety, effectiveness, and immune response(s) to vaccination among pregnant and lactating women. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
</td>
</tr>
<tr>
<td style="text-align:left;">
35452357
</td>
<td style="text-align:left;">
Self-Reported adverse events among Chinese healthcare workers immunized with COVID-19 vaccines composed of inactivated SARS-CoV-2.
</td>
<td style="text-align:left;">
Human vaccines &amp;amp; immunotherapeutics
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
22
</td>
<td style="text-align:left;">
Mass vaccination is critical to control the pandemic of coronavirus disease 2019 (COVID-19). Fear of adverse events (AEs) after COVID-19 vaccination is a main factor associated with vaccination hesitancy. We aimed to analyze AEs in healthcare workers (HCWs) vaccinated with COVID-19 vaccines (Aikewei or CoronaVac) composed of inactivated virus. We used a structured self-administered questionnaire to conduct two surveys on COVID-19 vaccination among HCWs in perinatal medicine and obstetrics/gynecology from April 5 to April 21, 2021. In total, 1392 HCWs who had received at least one vaccine dose were included. Of them, 1264 (90.8%) were females and 1047 (75.2%) received two doses. The overall incidence of any AEs after the first and second dose was 38.2% (532/1392) and 31.0% (325/1047) respectively (χ2 = 13.506, P = .0002). Female and HCWs aged 18-30 y were more likely to report AEs. The most common AEs were local reaction, accounting for 48.1% and 67.4% of all AEs after the first and second dose respectively. The systemic AEs were mainly neurological (9.8% and 4.8% after the first and second injection respectively) and flu-like symptoms (6.3% and 3.2%). Overall, most of AEs were mild, only 5.1% (after the first dose) and 2.8% (after the second dose) of individuals with AEs received symptomatic treatment or sick leaves, and none of them required hospitalization. Our data added more evidence that inactivated COVID-19 vaccines are highly safe. The data are valuable to overcome vaccine hesitancy associated with concerns about the safety of COVID-19 vaccines.
</td>
</tr>
<tr>
<td style="text-align:left;">
35452345
</td>
<td style="text-align:left;">
Intention to vaccinate young children against COVID-19: a large-scale survey of Hong Kong parents.
</td>
<td style="text-align:left;">
Human vaccines &amp;amp; immunotherapeutics
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
22
</td>
<td style="text-align:left;">
COVID-19 vaccines (Sinovac and Pfizer/BioNTech) have recently been approved for Hong Kong children. Understanding parental intentions to vaccinate children against COVID-19 is important to the development of an effective COVID-19 vaccine campaign. From a large-scale, geographically representative dataset in Hong Kong (N = 11,141), we examined parents’ intentions to vaccinate their children against COVID-19 under three conditions: (1) no policy restrictions, (2) vaccination rate considered for school resumption, and (3) more choices of vaccine. Results showed that levels of vaccine hesitancy in Hong Kong parents are high. Hong Kong parents’ intention to vaccinate their children was highest when there were more vaccines to choose from, followed by when vaccination rate was considered to resume school, and when there was no policy restrictions. Finally, Hong Kong parents with higher education backgrounds and family income were less willing to vaccinate their children. Together, these findings indicate that effective vaccines campaign should consider the characteristics and preferences of parents who have little intention to vaccinate within a specific social context.
</td>
</tr>
<tr>
<td style="text-align:left;">
35451839
</td>
<td style="text-align:left;">
Smart Mushroom-Inspired Imprintable and Lightly Detachable (MILD) Microneedle Patterns for Effective COVID-19 Vaccination and Decentralized Information Storage.
</td>
<td style="text-align:left;">
ACS nano
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
22
</td>
<td style="text-align:left;">
The key to controlling the spread of the coronavirus disease 2019 (COVID-19) and reducing mortality is highly dependent on the safe and effective use of vaccines for the general population. Current COVID-19 vaccination practices (intramuscular injection of solution-based vaccines) are limited by heavy reliance on medical professionals, poor compliance, and laborious vaccination recording procedures, resulting in a waste of health resources and low vaccination coverage, etc. In this study, we developed a smart mushroom-inspired imprintable and lightly detachable (MILD) microneedle platform for the effective and convenient delivery of multidose COVID-19 vaccines and decentralized vaccine information storage. The mushroom-like structure allows the MILD system to be easily pressed into the skin and detached from the patch base, acting as a “tattoo” to record the vaccine counts in situ without any storage equipment, offering quick accessibility and effortless readout, saving a great deal of valuable time and energy for both patients and health professionals. After loading inactivated SARS-CoV-2 virus-based vaccines, MILD system induced a high level of antibodies against the SARS-CoV-2 receptor-binding domain (RBD) in vivo without eliciting systemic toxicity and local damage. Collectively, this smart delivery platform serves as a promising carrier to improve COVID-19 vaccination efficacy through its dual capabilities of vaccine delivery and in situ data storage, thus exhibiting great potential for helping to contain the COVID-19 pandemic or a resurgence.
</td>
</tr>
<tr>
<td style="text-align:left;">
35451644
</td>
<td style="text-align:left;">
COVID-19 vaccine acceptance and perceptions among dental teaching staff of a governmental university in Egypt.
</td>
<td style="text-align:left;">
The Journal of the Egyptian Public Health Association
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
21
</td>
<td style="text-align:left;">
Vaccine acceptance among healthcare workers (HCWs) is an important determinant of its acceptance among the general population. Dentists are an essential group of HCWs who are at an increased risk of COVID-19 infection. This study aimed to assess vaccine acceptance and its determinants among a group of dental teaching staff in Egypt. An Internet-based cross-sectional study was conducted where the dental teaching staff of a governmental university in Egypt were targeted using total population sampling. Data was collected on socio-demographics, attitudes towards COVID-19, risk perception, general attitudes towards vaccination, vaccine acceptance, and concerns about COVID-19 vaccines, along with barriers and motivators to vaccination. Multivariate regression was done to determine factors significantly associated with unwillingness to receive COVID-19 vaccine. A total of 171 dental faculty members participated in the study. At the time of data collection (August 2021-October 2021), 45.6% of the dental teaching staff were willing to receive the vaccine, while 46.7% were against vaccination, and 7.6% were vaccine hesitant. Female gender, not having a private practice, not intending to travel internationally, having anyone sick in the immediate social circle, and being more anxious about COVID-19 were significantly associated with unwillingness to receive the COVID-19 vaccine. At the time of conducting this study (August 2021-October 2021), less than half of the participating dental teaching staff in the studied Egyptian university were willing to receive the COVID-19 vaccine. Findings of the current study can guide Egyptian health authorities to adopt strategies that correct misconceptions among HCWs, educate them and build their trust in the efficacy and safety of COVID-19 vaccines, which can ultimately increase its acceptance in the general population.
</td>
</tr>
<tr>
<td style="text-align:left;">
35451341
</td>
<td style="text-align:left;">
Animal models for studying covid-19, prevention, and therapy: Pathology and disease phenotypes.
</td>
<td style="text-align:left;">
Veterinary pathology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
22
</td>
<td style="text-align:left;">
Translational models have played an important role in the rapid development of safe and effective vaccines and therapeutic agents for the ongoing coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Animal models recapitulating the clinical and underlying pathological manifestations of COVID-19 have been vital for identification and rational design of safe and effective vaccines and therapies. This manuscript provides an overview of commonly used COVID-19 animal models and the pathologic features of SARS-CoV-2 infection in these models in relation to their clinical presentation in humans. Also discussed are considerations for selecting appropriate animal models for infectious diseases such as COVID-19, the host determinants that can influence species-specific susceptibility to SARS-CoV-2, and the pathogenesis of COVID-19. Finally, the limitations of currently available COVID-19 animal models are highlighted.
</td>
</tr>
<tr>
<td style="text-align:left;">
35451293
</td>
<td style="text-align:left;">
Vaccine-Inducted Thrombotic Thrombocytopenia and Covid-19 Vaccines: Case Series.
</td>
<td style="text-align:left;">
Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki)
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
22
</td>
<td style="text-align:left;">
Vaccine-induced thrombotic thrombocytopenia (VITT) is a condition similar to heparin-induced thrombocytopenia (HIT), but it is associated with prior administration of COVID-19 vaccines without prior exposure to heparin. The incidence of VITT is not certain, but it appears to be extremely rare. Reports of unusual and severe thrombotic events, including cerebral and splanchnic venous thrombosis and other autoimmune adverse reactions, such as immune thrombocytopenia or thrombotic microangiopathies in connection with some of the SARS-CoV-2 vaccines, have caused a great deal of concern within the population and the medical community. We would like to present 4 clinical cases of VITT, hospitalized and treated in intensive care unit (ICU) of University clinic of cardiology in Skopje.
</td>
</tr>
<tr>
<td style="text-align:left;">
35448837
</td>
<td style="text-align:left;">
Cubital Tunnel Syndrome Temporally after COVID-19 Vaccination.
</td>
<td style="text-align:left;">
Tropical medicine and infectious disease
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
16
</td>
<td style="text-align:left;">
Coronavirus disease 2019 (COVID-19) is the most dramatic pandemic of the new millennium. To counter it, specific vaccines have been launched in record time under emergency use authorization or conditional marketing authorization and have been subjected to additional monitoring. The European Medicines Agency recommend reporting any suspected adverse reactions during this additional monitoring phase. For the first time in the available medical literature, we report a left cubital tunnel syndrome in a 28-year-old right-handed healthy male after seven days from the first dose of Spikevax® (formerly Moderna COVID-19 Vaccine). Histochemistry for Alcian Blue performed on the tissue harvested from the cubital site reveals myxoid degeneration of the small nerve collaterals, a clear sign of nerve injury. It still remains unclear why the syndrome occurs in a localized and not generalized form to all osteofibrous tunnels. Today, modified messenger ribonucleic acid vaccines as Spikevax® represent an avantgarde technological platform with a lot of potential, but one which needs careful monitoring in order to identify in advance those patients who may experience adverse events after their administration.
</td>
</tr>
<tr>
<td style="text-align:left;">
35447596
</td>
<td style="text-align:left;">
Measurements of SARS-CoV-2 antibody dissociation rate constant by chaotrope-free biolayer interferometry in serum of COVID-19 convalescent patients.
</td>
<td style="text-align:left;">
Biosensors &amp;amp; bioelectronics
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
09
</td>
<td style="text-align:left;">
Kinetics measurements of antigen-antibody binding interactions are critical to understanding the functional efficiency of SARS-CoV-2 antibodies. Previously reported chaotrope-based avidity assays that rely on artificial disruption of binding do not reflect the natural binding kinetics. This study developed a chaotrope- and label-free biolayer interferometry (BLI) assay for the real-time monitoring of receptor binding domain (RBD) binding kinetics with SARS-CoV-2 spike protein in convalescent COVID-19 patients. An improved conjugation biosensor probe coated with streptavidin-polysaccharide (SA-PS) led to a six-fold increase of signal intensities and two-fold reduction of non-specific binding (NSB) compared to streptavidin only probe. Furthermore, by utilizing a separate reference probe and biotin-human serum albumin (B-HSA) blocking process to subtracted NSB signal in serum, this BLI biosensor can measure a wide range of the dissociation rate constant (koff), which can be measured without knowledge of the specific antibody concentrations. The clinical utility of this improved BLI kinetics assay was demonstrated by analyzing the koff values in sera of 24 pediatric (≤18 years old) and 63 adult (&amp;gt;18 years old) COVID-19 convalescent patients. Lower koff values for SARS-CoV-2 serum antibodies binding to RBD were measured in samples from children. This rapid, easy to operate and chaotrope-free BLI assay is suitable for clinical use and can be readily adapted to characterize SARS-CoV-2 antibodies developed by COVID-19 patients and vaccines.
</td>
</tr>
<tr>
<td style="text-align:left;">
35447423
</td>
<td style="text-align:left;">
Identifying environmental factors that influence immune response to SARS-CoV-2: Systematic evidence map protocol.
</td>
<td style="text-align:left;">
Environment international
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
08
</td>
<td style="text-align:left;">
Widespread environmental contamination can directly interact with human immune system functions. Environmental effects on the immune system may influence human susceptibility to respiratory infections as well as the severity of infectious diseases, such as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Furthermore, the efficacy of vaccines to respiratory diseases may be impacted by environmental exposures through immune perturbations. Given the quick pace of research about COVID-19 and associated risk factors, it is critical to identify and curate the streams of evidence quickly and effectively. We developed this systematic evidence map protocol to identify and organize existing human and animal literature on high-priority environmental chemical classes (Per- and polyfluoroalkyl substances, pesticides, phthalates, quaternary ammonium compounds, and air pollutants) and their potential to influence three key outcomes: (1) susceptibility to respiratory infection, including SARS-CoV-2 (2) severity of the resultant disease progression, and (3) impact on vaccine efficacy. The result of this project will be an online, interactive database which will show what evidence is currently available between involuntary exposures to select environmental chemicals and immune health effects, data gaps that require further research, and data rich areas that may support further analysis. We will search PubMed for epidemiological or toxicological literature on select toxicants from each of the chemical classes and each of the three outcomes listed above. For each study, two independent reviewers will conduct title and abstract screening as well as full text review for data extraction of study characteristics. Study quality will not be evaluated in this evidence mapping. The main findings from the systematic evidence map will be visualized using a publicly available and interactive database hosted on Tableau Public.
</td>
</tr>
<tr>
<td style="text-align:left;">
35447123
</td>
<td style="text-align:left;">
Increasing Coronavirus Disease 2019 Vaccine Uptake in Pediatric Primary Care by Offering Vaccine to Household Members.
</td>
<td style="text-align:left;">
The Journal of pediatrics
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
18
</td>
<td style="text-align:left;">
Pediatric primary care is a trusted source for treatment and information. In the 6 months after COVID-19 vaccines became available for adolescents, we administered 2,286 doses (1,270 to patients; 1,016 to household members) to 1,376 individuals (64.1% Black; 10.1% Latinx), providing opportunities to address family concerns in a familiar location.
</td>
</tr>
<tr>
<td style="text-align:left;">
35446945
</td>
<td style="text-align:left;">
Frailty and COVID-19 mRNA Vaccine Antibody Response in The COVID-19 Community Research Partnership.
</td>
<td style="text-align:left;">
The journals of gerontology. Series A, Biological sciences and medical sciences
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
21
</td>
<td style="text-align:left;">
COVID-19 has disproportionately affected older adults. Frailty has been associated with impaired vaccine response in other vaccine types, but the impact of frailty on mRNA vaccine response is undefined. Observational study of adults aged 55 and above from one US health care system between January 22, 2021 and September 16, 2021 with self-reported Moderna or Pfizer COVID-19 mRNA vaccine and an electronic frailty index score (eFI) from their medical record (n =1677). Participants’ frailty status was compared with positive antibody detection (seroconversion) following full vaccination and subsequent loss of positive antibody detection (seroreversion) using logistic regression models. Of 1677 older adults with median (IQR) age, 67 (62, 72) years, and frailty status (non-frail: 879 (52%), pre-frail: 678 (40%), and frail: 120 (7.2%)), seroconversion was not detected in 23 (1.4%) over 60 days following full vaccination. Frail individuals were less likely to seroconvert than non-frail individuals, adjusted OR 3.75, 95%CI (1.04, 13.5).Seroreversion was detected in 50/1631 individuals (3.1%) over 6 months of median follow up antibody testing. Frail individuals were more likely to serorevert than non-frail individuals, adjusted OR 3.02, 95%CI (1.17, 7.33). Overall antibody response to COVID-19 mRNA vaccination was high across age and frailty categories. While antibody detection is an incomplete descriptor of vaccine response, the high sensitivity of this antibody combined with health system data reinforce our conclusions that frailty is an independent predictor of impaired antibody response to the COVID-19 mRNA vaccines. Frailty should be considered in vaccine studies and prevention strategies.
</td>
</tr>
<tr>
<td style="text-align:left;">
35446828
</td>
<td style="text-align:left;">
Vaccination Coverage with Selected Vaccines and Exemption Rates Among Children in Kindergarten - United States, 2020-21 School Year.
</td>
<td style="text-align:left;">
MMWR. Morbidity and mortality weekly report
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
22
</td>
<td style="text-align:left;">
State and local school vaccination requirements serve to protect students against vaccine-preventable diseases (1). This report summarizes data collected for the 2020-21 school year by state and local immunization programs* on vaccination coverage among children in kindergarten in 47 states and the District of Columbia (DC), exemptions for kindergartners in 48 states and DC, and provisional enrollment or grace period status for kindergartners in 28 states. Vaccination coverage† nationally was 93.9% for 2 doses of measles, mumps, and rubella vaccine (MMR); 93.6% for the state-required number of doses of diphtheria, tetanus, and acellular pertussis vaccine (DTaP); and 93.6% for the state-required doses of varicella vaccine. Compared with the 2019-20 school year, vaccination coverage decreased by approximately one percentage point for all vaccines. Although 2.2% of kindergartners had an exemption from at least one vaccine,§ an additional 3.9% who did not have a vaccine exemption were not up to date for MMR. The COVID-19 pandemic affected schools’ vaccination requirement and provisional enrollment policies, documentation, and assessment activities. As schools continue to return to in-person learning, enforcement of vaccination policies and follow-up with undervaccinated students are important to improve vaccination coverage.
</td>
</tr>
<tr>
<td style="text-align:left;">
35446827
</td>
<td style="text-align:left;">
Hospitalizations of Children Aged 5-11 Years with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, March 2020-February 2022.
</td>
<td style="text-align:left;">
MMWR. Morbidity and mortality weekly report
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
22
</td>
<td style="text-align:left;">
On October 29, 2021, the Food and Drug Administration expanded the Emergency Use Authorization for Pfizer-BioNTech COVID-19 vaccine to children aged 5-11 years; CDC’s Advisory Committee on Immunization Practices’ recommendation followed on November 2, 2021.* In late December 2021, the B.1.1.529 (Omicron) variant of SARS-CoV-2 (the virus that causes COVID-19) became the predominant strain in the United States,† coinciding with a rapid increase in COVID-19-associated hospitalizations among all age groups, including children aged 5-11 years (1). COVID-19-Associated Hospitalization Surveillance Network (COVID-NET)§ data were analyzed to describe characteristics of COVID-19-associated hospitalizations among 1,475 U.S. children aged 5-11 years throughout the pandemic, focusing on the period of early Omicron predominance (December 19, 2021-February 28, 2022). Among 397 children hospitalized during the Omicron-predominant period, 87% were unvaccinated, 30% had no underlying medical conditions, and 19% were admitted to an intensive care unit (ICU). The cumulative hospitalization rate during the Omicron-predominant period was 2.1 times as high among unvaccinated children (19.1 per 100,000 population) as among vaccinated¶ children (9.2).** Non-Hispanic Black (Black) children accounted for the largest proportion of unvaccinated children (34%) and represented approximately one third of COVID-19-associated hospitalizations in this age group. Children with diabetes and obesity were more likely to experience severe COVID-19. The potential for serious illness among children aged 5-11 years, including those with no underlying health conditions, highlights the importance of vaccination among this age group. Increasing vaccination coverage among children, particularly among racial and ethnic minority groups disproportionately affected by COVID-19, is critical to preventing COVID-19-associated hospitalization and severe outcomes.
</td>
</tr>
<tr>
<td style="text-align:left;">
35446781
</td>
<td style="text-align:left;">
Monitoring user opinions and side effects on COVID-19 vaccines in the Twittersphere: Infodemiology Study of Tweets.
</td>
<td style="text-align:left;">
Journal of medical Internet research
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Mar
</td>
<td style="text-align:left;">
09
</td>
<td style="text-align:left;">
In the current phase of the COVID-19 pandemic, we are witnessing the most massive vaccine rollout in human history. Like any other drug, vaccines may cause unexpected side effects, which need to be timely investigated to minimize harm in the population. If not properly dealt with, side effects may also impact the public trust in the vaccination campaigns carried out by the national governments. Monitoring social media for the early identification of side effects and understanding the public opinion on the vaccines are of paramount importance to ensure a successful and harmless rollout. The objective is to create a web portal to monitor the opinion of social media users on the vaccines, to provide a tool for journalists, scientists, and users alike to visualize how the general public is reacting to the vaccination campaign. In this paper, we present a tool to analyze the public opinion on COVID-19 vaccines from Twitter, exploiting, among the others: a state-of-the-art system for the identification of Adverse Drug Events (ADEs) on social media; Natural Language Processing models for sentiment analysis; statistical tools and open-source databases to visualize the trending hashtags, news articles and their factuality. All the modules of the system are displayed through a web portal available at <a href="http://ailab.uniud.it/covid-vaccines/" class="uri">http://ailab.uniud.it/covid-vaccines/</a>. A set of 650,000 tweets was collected and analyzed in an ongoing process started in December 2020. The results of the analysis are made public on a web portal (updated daily), together with the processing tools and data. The data provide insights on the public opinion about the vaccines and its change in time. For example, users show a high tendency to only share news from reliable sources when discussing COVID-19 vaccines (98% of the shared URLs). The general sentiment of the users towards the vaccines is negative/neutral, but the system is able to record fluctuations in the attitude towards specific vaccines in correspondence with specific events (eg, news about new outbreaks). The data also show how news coverage had a high impact on the set of discussed topics. To further investigate this point, we perform a more in-depth analysis of the data regarding AstraZeneca. We observe how media coverage of blood-clot related side effects suddenly shifted the topic of public discussions regarding both AstraZeneca and the other vaccines. This is particularly evident when visualizing the most frequently discussed symptoms for the vaccines and comparing them month-by-month. We presented a tool connected with a web portal to monitor and display some key aspects of the public’s reaction to COVID-19 vaccines. The system also provides an overview of the opinions of the Twittersphere through graphic representations and represents a tool for the extraction of suspected adverse events from tweets with a Deep Learning model. &gt;
</td>
</tr>
<tr>
<td style="text-align:left;">
35446373
</td>
<td style="text-align:left;">
De novo and relapsed immune thrombocytopenia after COVID-19 vaccines: results of French safety monitoring.
</td>
<td style="text-align:left;">
Blood
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
21
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
35446353
</td>
<td style="text-align:left;">
Evaluation of the Durability of the Immune Humoral Response to COVID-19 Vaccines in Patients With Cancer Undergoing Treatment or Who Received a Stem Cell Transplant.
</td>
<td style="text-align:left;">
JAMA oncology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
21
</td>
<td style="text-align:left;">
The durability of the antibody response to COVID-19 vaccines in patients with cancer undergoing treatment or who received a stem cell transplant is unknown and may be associated with infection outcomes. To evaluate anti-SARS-CoV-2 spike protein receptor binding domain (anti-RBD) and neutralizing antibody (nAb) responses to COVID-19 vaccines longitudinally over 6 months in patients with cancer undergoing treatment or who received a stem cell transplant (SCT). Setting, and Participants” In this prospective, observational, longitudinal cross-sectional study of 453 patients with cancer undergoing treatment or who received an SCT at the University of Kansas Cancer Center in Kansas City, blood samples were obtained before 433 patients received a messenger RNA (mRNA) vaccine (BNT162b2 or mRNA-1273), after the first dose of the mRNA vaccine, and 1 month, 3 months, and 6 months after the second dose. Blood samples were also obtained 2, 4, and 7 months after 17 patients received the JNJ-78436735 vaccine. For patients receiving a third dose of an mRNA vaccine, blood samples were obtained 30 days after the third dose. Blood samples and BNT162b2, mRNA-1273, or JNJ-78436735 vaccines. Geometric mean titers (GMTs) of the anti-RBD; the ratio of GMTs for analysis of demographic, disease, and treatment variables; the percentage of neutralization of anti-RBD antibodies; and the correlation between anti-RBD and nAb responses to the COVID-19 vaccines. This study enrolled 453 patients (mean [SD] age, 60.4 [13,1] years; 253 [56%] were female). Of 450 patients, 273 (61%) received the BNT162b2 vaccine (Pfizer), 160 (36%) received the mRNA-1273 vaccine (Moderna), and 17 (4%) received the JNJ-7846735 vaccine (Johnson &amp;amp; Johnson). The GMTs of the anti-RBD for all patients were 1.70 (95% CI, 1.04-2.85) before vaccination, 18.65 (95% CI, 10.19-34.11) after the first dose, 470.38 (95% CI, 322.07-686.99) at 1 month after the second dose, 425.80 (95% CI, 322.24-562.64) at 3 months after the second dose, 447.23 (95% CI, 258.53-773.66) at 6 months after the second dose, and 9224.85 (95% CI, 2423.92-35107.55) after the third dose. The rate of threshold neutralization (≥30%) was observed in 203 of 252 patients (80%) 1 month after the second dose and in 135 of 166 patients (81%) 3 months after the second dose. Anti-RBD and nAb were highly correlated (Spearman correlation coefficient, 0.93 [0.92-0.94]; P &amp;lt; .001). Three months after the second dose, anti-RBD titers were lower in male vs female patients (ratio of GMTs, 0.52 [95% CI, 0.34-0.81]), patients older than 65 years vs patients 50 years or younger (ratio of GMTs, 0.38 [95% CI, 0.25-0.57]), and patients with hematologic malignant tumors vs solid tumors (ratio of GMTs, 0.40 [95% CI, 0.20-0.81]). In this cross-sectional study, after 2 doses of an mRNA vaccine, anti-RBD titers peaked at 1 month and remained stable over the next 6 months. Patients older than 65 years of age, male patients, and patients with a hematologic malignant tumor had low antibody titers. Compared with the primary vaccine course, a 20-fold increase in titers from a third dose suggests a brisk B-cell anamnestic response in patients with cancer.
</td>
</tr>
<tr>
<td style="text-align:left;">
35445433
</td>
<td style="text-align:left;">
Clinical care of children and adolescents with COVID-19: recommendations from the National COVID-19 Clinical Evidence Taskforce.
</td>
<td style="text-align:left;">
The Medical journal of Australia
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
21
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
35445269
</td>
<td style="text-align:left;">
Reliably Assessing Duration of Protection for COVID-19 Vaccines.
</td>
<td style="text-align:left;">
The Journal of infectious diseases
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
21
</td>
<td style="text-align:left;">
Decision-making about vaccination and boosting schedules for COVID-19 hinges on reliable methods for evaluating the longevity of vaccine protection. We show that modeling of protection as a piecewise linear function of time since vaccination for the log hazard ratio of the vaccine effect provides more reliable estimates of vaccine effectiveness at the end of an observation period and also more reliably detects plateaus in protective effectiveness as compared with the traditional method of estimating a constant vaccine effect over each time period. This approach will be useful for analyzing data pertaining to COVID-19 vaccines and other vaccines where rapid and reliable understanding of vaccine effectiveness over time is desired.
</td>
</tr>
<tr>
<td style="text-align:left;">
35444978
</td>
<td style="text-align:left;">
Parents’ Perspectives Toward School Reopening During COVID-19 Pandemic in Indonesia-A National Survey.
</td>
<td style="text-align:left;">
Frontiers in public health
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
All sectors are affected due to COVID-19 pandemic occurring worldwide, including the education industry. School closure had been taking place for more than a year in Indonesia. Despite the controversies, Indonesian government had decided to begin school reopening. This study aims to assess parental readiness for school reopening, and factors affecting parental attitude toward school reopening. A cross-sectional study using online questionnaire distributed via official Indonesian Pediatric Society (IPS) official social media account collected between March and April 2021. The questionnaire contained the general characteristics of study participants, parents’ knowledge, and perspectives on COVID-19, and health protocols for school reopening. A total of 17,562 responses were collected, of which 55.7% parents were ready to send their children to school should school reopens. Factors significantly contribute to parental decision to keep their child at home were: presence of vulnerable population at home [OR = 1.18 (1.10-1.27), p &amp;lt; 0.001], children with comorbidities [OR = 2.56 (2.29-2.87), p &amp;lt; 0.001], perception of COVID-19 as a dangerous disease [OR = 28.87 (14.29-58.33), p &amp;lt; 0.001], experience with COVID-19 positive cases in the community [OR = 1.75 (1.61-1.90), p &amp;lt; 0.001], COVID-19 related death in the community [OR = 2.05 (1.90-2.21), P &amp;lt; 0.001], approval for adult COVID-19 vaccination [OR = 1.69 (1.53-1.87), p &amp;lt; 0.001], and ownership of private transportation [OR = 1.46 (1.30-1.66), p &amp;lt;0.001]. We identified several factors affecting parental perception on school reopening during COVID-19 pandemic that should be addressed. This study can be used for policy-maker to make further recommendations and health educations prior to school reopening in Indonesia.
</td>
</tr>
<tr>
<td style="text-align:left;">
35444866
</td>
<td style="text-align:left;">
Not All That Is Droopy Post Ad26.COV2.S (JNJ) Vaccine Is Bell’s Palsy: A Rare Case of Isolated Dorsal Pontine Stroke Causing Ipsilateral Complete Hemi-Facial Palsy.
</td>
<td style="text-align:left;">
Cureus
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Mar
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
The Ad26.COV2.S vaccine, developed by Janssen (Beerse, Belgium), the pharmaceutical wing of Johnson &amp;amp; Johnson (JNJ), is one of the three vaccines approved for use against coronavirus disease 2019 (COVID-19) infection in the United States. We present a case of a 66-year-old female who presented to the emergency department with a one-day history of nausea, vomiting, room-spinning vertigo, and complete right facial weakness immediately after getting vaccinated with Ad26.COV2.S. Initial workup focused on uncovering a possible association between the vaccine and Bell’s palsy. However, her prior history of stroke, presence of predisposing risk factors, and additional symptoms of nausea, vomiting, and vertigo prompted further neurological testing, which revealed an isolated right pontine lacunar infarct involving the right facial colliculus, mimicking Bell’s palsy. Isolated dorsal pontine lesion presenting as hemifacial palsy is very rare and can be easily missed by clinicians. Relevant history and thorough neurological examination can help guide appropriate diagnostic testing and prevent potential biases. It is crucial for clinicians to know the distinguishing features between true Bell’s palsy and acute brainstem infarction masquerading as Bell’s.
</td>
</tr>
<tr>
<td style="text-align:left;">
35444813
</td>
<td style="text-align:left;">
Knowledge and Willingness to Accept Vaccine Against SARS-CoV-2 Among Undergraduate Medical Students in Delhi, India.
</td>
<td style="text-align:left;">
Current health sciences journal
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Vaccination against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the most desired solution to combat COVID-19. Understanding the willingness to accept vaccines is essential to make appropriate strategies for the vaccination programme’s success. There was a lack of published literature in India among medical students. Hence, we conducted this online, cross-sectional study to assess the knowledge and willingness to accept COVID-19 vaccines among undergraduate medical students of a medical school in Delhi. A complete enumeration of all the undergraduate medical students was done. All the students were invited to participate in this online survey. The questionnaire through Google forms was shared through email and WhatsApp. The questionnaire contained questions on the socio-demographic details, questions related to the knowledge and perceptions about COVID-19 vaccines, willingness to accept the vaccine and vaccination status of the participant. Descriptive and multiple logistic regression analyses were carried out. Out of 320 students contacted, 298 consented to participate in the survey, and 274 participants (85%) completed the questionnaire. Three-fourths of the participants were male; the mean age of the study participants was 19.6 years. Only 70.4% were willing to accept the vaccine. Those who perceived COVID-19 vaccines as safe (AOR=3.946; 95% CI: 1.946 to 7.912); and effective (AOR=2.079; 95% CI: 1.054 to 4.101); and who has knowledge about the vaccines (AOR=2.206; 95% CI: 1.186 to 4.104) were more likely to accept the vaccine. There is a need for enhancing the knowledge on vaccines, and their safety and effectiveness to promote the vaccine acceptance.
</td>
</tr>
<tr>
<td style="text-align:left;">
35444667
</td>
<td style="text-align:left;">
Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses.
</td>
<td style="text-align:left;">
Frontiers in immunology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Vaccine-associated enhanced disease (VAED) is a difficult phenomenon to define and can be confused with vaccine failure. Using studies on respiratory syncytial virus (RSV) vaccination and dengue virus infection, we highlight known and theoretical mechanisms of VAED, including antibody-dependent enhancement (ADE), antibody-enhanced disease (AED) and Th2-mediated pathology. We also critically review the literature surrounding this phenomenon in pathogenic human coronaviruses, including MERS-CoV, SARS-CoV-1 and SARS-CoV-2. Poor quality histopathological data and a lack of consistency in defining severe pathology and VAED in preclinical studies of MERS-CoV and SARS-CoV-1 vaccines in particular make it difficult to interrogate potential cases of VAED. Fortuitously, there have been only few reports of mild VAED in SARS-CoV-2 vaccination in preclinical models and no observations in their clinical use. We describe the problem areas and discuss methods to improve the characterisation of VAED in the future.
</td>
</tr>
<tr>
<td style="text-align:left;">
35444664
</td>
<td style="text-align:left;">
Conservation and Evolution of Antigenic Determinants of SARS-CoV-2: An Insight for Immune Escape and Vaccine Design.
</td>
<td style="text-align:left;">
Frontiers in immunology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Coronavirus disease 2019 (COVID-19) is the most devastating pandemic of the century, which is still far from over. The remarkable success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is the working hope, but the evolving variants are the huge concern that can turn the tide. Potential immune escape mutations (PIEMs) in the past and circulating variants were not studied at large scale (all available data). Hence, the conservation of antigenic determinants (epitopes) was analyzed in all available sequences of SARS-CoV-2 according to time (months), proteins, hosts, and variants. Numerous highly conserved B- and T-cell epitopes were identified in 24 proteins of SARS-CoV-2. A decrease in the conservation of epitopes with time was observed in almost all proteins, which was more rapid in neutralizing epitopes. Delta variant still has the highest PIEM in the circulating strains, which pose threat to the effectiveness of current vaccines. The inclusion of identified, highly conserved, and important epitopes in subunit vaccines can increase vaccine effectiveness against evolving variants. Trends in the conservation of epitopes in different proteins, hosts, and variants with time may also help to inspire the counter measure against the current pandemic.
</td>
</tr>
<tr>
<td style="text-align:left;">
35444662
</td>
<td style="text-align:left;">
Inflammation in Cerebral Venous Thrombosis.
</td>
<td style="text-align:left;">
Frontiers in immunology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Cerebral venous thrombosis (CVT) is a rare form of cerebrovascular disease that impairs people’s wellbeing and quality of life. Inflammation is considered to play an important role in CVT initiation and progression. Several studies have reported the important role of leukocytes, proinflammatory cytokines, and adherence molecules in the CVT-related inflammatory process. Moreover, inflammatory factors exacerbate CVT-induced brain tissue injury leading to poor prognosis. Based on clinical observations, emerging evidence shows that peripheral blood inflammatory biomarkers-especially neutrophil-to-lymphocyte ratio (NLR) and lymphocyte count-are correlated with CVT [mean difference (MD) (95%CI), 0.74 (0.11, 1.38), p = 0.02 and -0.29 (-0.51, -0.06), p = 0.01, respectively]. Moreover, increased NLR and systemic immune-inflammation index (SII) portend poor patient outcomes. Evidence accumulated since the outbreak of coronavirus disease-19 (COVID-19) indicates that COVID-19 infection and COVID-19 vaccine can induce CVT through inflammatory reactions. Given the poor understanding of the association between inflammation and CVT, many conundrums remain unsolved. Further investigations are needed to elucidate the exact relationship between inflammation and CVT in the future.
</td>
</tr>
<tr>
<td style="text-align:left;">
35444478
</td>
<td style="text-align:left;">
Acceptance of COVID-19 Vaccine Among High-Risk Occupations in a Port City of China and Multifaceted Strategies for Increasing Vaccination Coverage: A Cross-Sectional Study.
</td>
<td style="text-align:left;">
Risk management and healthcare policy
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Considering high risk of imported epidemic in port cities, it is necessary to estimate COVID-19 vaccine acceptability and to promote vaccination coverage of high-risk occupations. A cross-sectional survey was carried out among the occupations in Yantai city, China, using an online questionnaire service platform. Targeted strategies were developed based on the survey results. In addition, periodic monitoring of the vaccination rate was provided in order to evaluate the effectiveness of the strategies. A total of 2231 (73.22%) of 3047 participants were willing to accept the vaccine, while 2.53% refused and 24.25% were not sure. Frontline port workers (133/152, 87.50%) and healthcare workers (999/1155, 86.49%) had higher intentions to accept, while public places and commercial service staff (584/1011, 57.76%) had the lowest. The reasons for refusal and hesitation were mainly “doubt of safety or effectiveness” (661/816, 81.00%) and “hearing previous news about vaccines” (455/816, 55.76%). Multilevel strategies such as adequate organizations, health education and promotion, and easy access to vaccination were promoted by local authorities in collaboration with schools, hospitals, enterprises and institutions. The study showed a significant increase in vaccination rate among these occupations after the implementation of these strategies (p&amp;lt;0.001), reaching 87.96%. COVID-19 vaccine acceptability among high-risk occupations was unsatisfactory before the stage of emergency vaccination. An advanced understanding of vaccine attitudes and acceptance can aid in the development of focused immunization promotion programs. It is worth emphasizing that wide strategies with the strong support and enthusiastic cooperation of the government and the industry executive can contribute to increasing occupations’ acceptance of the ongoing COVID-19 immunization project.
</td>
</tr>
<tr>
<td style="text-align:left;">
35444328
</td>
<td style="text-align:left;">
COVID’s diabetes risk, vaccine rankings and hidden industry ties.
</td>
<td style="text-align:left;">
Nature
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
35444221
</td>
<td style="text-align:left;">
Cross-reactive antibodies elicited to conserved epitopes on SARS-CoV-2 spike protein after infection and vaccination.
</td>
<td style="text-align:left;">
Scientific reports
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
20
</td>
<td style="text-align:left;">
SARS-CoV-2 is a novel betacoronavirus that caused coronavirus disease 2019 and has resulted in millions of deaths worldwide. Novel coronavirus infections in humans have steadily become more common. Understanding antibody responses to SARS-CoV-2, and identifying conserved, cross-reactive epitopes among coronavirus strains could inform the design of vaccines and therapeutics with broad application. Here, we determined that individuals with previous SARS-CoV-2 infection or vaccinated with the Pfizer-BioNTech BNT162b2 vaccine produced antibody responses that cross-reacted with related betacoronaviruses. Moreover, we designed a peptide-conjugate vaccine with a conserved SARS-CoV-2 S2 spike epitope, immunized mice and determined cross-reactive antibody binding to SARS-CoV-2 and other related coronaviruses. This conserved spike epitope also shared sequence homology to proteins in commensal gut microbiota and could prime immune responses in humans. Thus, SARS-CoV-2 conserved epitopes elicit cross-reactive immune responses to both related coronaviruses and host bacteria that could serve as future targets for broad coronavirus therapeutics and vaccines.
</td>
</tr>
<tr>
<td style="text-align:left;">
35443917
</td>
<td style="text-align:left;">
Seroconversion panels demonstrate anti-SARS-CoV-2 antibody development after administration of the mRNA-1273 vaccine.
</td>
<td style="text-align:left;">
Vaccine
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
08
</td>
<td style="text-align:left;">
Seroconversion panels are an important tool for investigating antibody responses in acute and chronic phases of disease and development of serological assays for viral diseases including COVID-19. Globally it is anticipated that vaccines against SARS-CoV-2 will facilitate control of the current pandemic. The two COVID-19 seroconversion panels analyzed in this study were obtained from healthcare workers with samples collected before vaccination with the mRNA-1273 vaccine (Moderna) and after the first and second doses of the vaccine. Panel samples were tested for antibodies to SARS-CoV-2 (IgG). Individual subjects with a positive response for anti-SARS-CoV2 IgG in their pre-vaccination samples showed a significantly enhanced response to the first vaccination. In older subjects, lower immunological responses to the first injection were observed, which were overcome by the second injection. All subjects in the study were positive for anti-SARS-CoV-2 IgG after the second dose of vaccine.
</td>
</tr>
<tr>
<td style="text-align:left;">
35443826
</td>
<td style="text-align:left;">
The Role of Immune Regulatory Molecules in COVID-19.
</td>
<td style="text-align:left;">
Viral immunology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
19
</td>
<td style="text-align:left;">
As the fifth pandemic in the 21st century, coronavirus 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become the most prominent global concern in the last 2 years. Variable manifestations characterize SARS-CoV-2 infection. Despite the design and production of effective vaccines and their considerable effect on reducing the COVID-19 prevalence and mortality rate, no definitive cure for the disease has yet been found. Mutations may also affect the effectiveness of vaccines. The host immune response to the pathogen has a critical role in the course of the disease. Positive and negative signals often balance the immune system. Immune regulatory molecules, also known as immune checkpoint receptors, balance the immune responses. These molecules mainly have inhibitory functions and prevent hyperactivation of immune cells or trigger adverse signaling pathways. For a decade, the immune checkpoint blockade, as a therapeutic target for cancer immunotherapy, has been utilized. Some of the inhibitory receptors are recognized as exhaustion markers on T cells. The signaling pathway of these markers restricts the function of T cells against viral infection. Dysregulation of T cells was observed in SARS-CoV-2 infection and can modify proliferation, differentiation, cytokine production, and type of response. The pivotal role of immune inhibitory receptors in the function of acquired, cell-mediated, immune defense T cells makes them a fascinating subject to study. This review article summarized recent findings on immune regulatory molecules and their role in SARS-CoV-2 infection, hoping to find a way to design novel treatments.
</td>
</tr>
<tr>
<td style="text-align:left;">
35443747
</td>
<td style="text-align:left;">
Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses.
</td>
<td style="text-align:left;">
Cell discovery
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
21
</td>
<td style="text-align:left;">
The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants of concern, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529) has aroused concerns over their increased infectivity and transmissibility, as well as decreased sensitivity to SARS-CoV-2-neutralizing antibodies (NAbs) and the current coronavirus disease 2019 (COVID-19) vaccines. Such exigencies call for the development of pan-sarbecovirus vaccines or inhibitors to combat the circulating SARS-CoV-2 NAb-escape variants and other sarbecoviruses. In this study, we isolated a broadly NAb against sarbecoviruses named GW01 from a donor who recovered from COVID-19. Cryo-EM structure and competition assay revealed that GW01 targets a highly conserved epitope in a wide spectrum of different sarbecoviruses. However, we found that GW01, the well-known sarbecovirus NAb S309, and the potent SARS-CoV-2 NAbs CC12.1 and REGN10989 only neutralize about 90% of the 56 tested currently circulating variants of SARS-CoV-2 including Omicron. Therefore, to improve efficacy, we engineered an IgG-like bispecific antibody GW01-REGN10989 (G9) consisting of single-chain antibody fragments (scFv) of GW01 and REGN10989. We found that G9 could neutralize 100% of NAb-escape mutants (23 out of 23), including Omicron variant, with a geometric mean (GM) 50% inhibitory concentration of 8.8 ng/mL. G9 showed prophylactic and therapeutic effects against SARS-CoV-2 infection of both the lung and brain in hACE2-transgenic mice. Site-directed mutagenesis analyses revealed that GW01 and REGN10989 bind to the receptor-binding domain in different epitopes and from different directions. Since G9 targets the epitopes for both GW01 and REGN10989, it was effective against variants with resistance to GW01 or REGN10989 alone and other NAb-escape variants. Therefore, this novel bispecific antibody, G9, is a strong candidate for the treatment and prevention of infection by SARS-CoV-2, NAb-escape variants, and other sarbecoviruses that may cause future emerging or re-emerging coronavirus diseases.
</td>
</tr>
<tr>
<td style="text-align:left;">
35443661
</td>
<td style="text-align:left;">
Cross-sectional study on COVID-19 vaccine hesitancy and determinants in healthcare students: interdisciplinary trainings on vaccination are needed.
</td>
<td style="text-align:left;">
BMC medical education
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
20
</td>
<td style="text-align:left;">
To ensure the success of COVID-19 vaccination, public authorities need to have the support of the entire population and build vaccine confidence. Identifying and understanding the determinants of vaccine acceptance is essential for conducting vaccine strategy. The aim was to estimate vaccine hesitancy among healthcare students in France and to investigate the associated factors. A web-based cross-sectional study was conducted in a large French University in greater Paris area, among 4927 healthcare students from the different training courses such as medicine studies, midwifery studies, physiotherapy studies, nurse studies and others health studies. The study was conducted between January 21 and February 8, 2021 based on a questionnaire including 25 single or multiple-choice questions, made using the free software Limesurvey. The link of the questionnaire was distributed to the students by the teachers and the student associations. The SAGE group definition of vaccine hesitancy was used. All estimates were weighted using the gender and training courses category of all healthcare students registered for the 2020-2021 year. Crude and adjusted weighted odds ratio (wOR) and 95% confidence interval (95%CI) were estimated using logistic regression. A total of 1465 healthcare students answered. A proportion of 44.5% (95%CI = [41.7-47.3]) of them were considered as hesitant. Women were more hesitant (50.9, 95%CI = [48.0-53.9]) than men (21.6, 95%CI = [15.2-28.0]). Vaccine hesitancy was significantly associated with gender (wOR = 0.27, 95%CI = [0.18-0.39]) and training courses: medical students were less likely to be hesitant than students in the common and first year of several health studies (wOR = 0.48, 95%CI = [0.33-0.70]) while nursing students were more than 5 times more likely to be hesitant (wOR = 5.20, 95%CI = [3.71-7.28]). Students who did an internship during the epidemic (wOR = 0.53, 95%CI = [0.41-0.69]) and who downloaded the mobile contact-tracing mobile app “TousAntiCovid” (wOR = 0.34, 95%CI = [0.26-0.44]) were significantly less likely to be hesitant. Overall vaccine hesitancy among healthcare students was high, substantial differences were found between training courses. To reduce these disparities, interdisciplinary lectures on vaccines for all healthcare students may be implemented and evaluated.
</td>
</tr>
<tr>
<td style="text-align:left;">
35443585
</td>
<td style="text-align:left;">
Range of Detection Rate for Seropositivity after COVID-19 Vaccination by Different Antibody Tests with same Sensitivity.
</td>
<td style="text-align:left;">
Clinical laboratory
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
01
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
35443574
</td>
<td style="text-align:left;">
COVID-19: Some unresolved issues.
</td>
<td style="text-align:left;">
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
21
</td>
<td style="text-align:left;">
Two years after the COVID-19 pandemic, many uncertainties persist about the causal agent, the disease and its future. This document contains the reflection of the COVID-19 working group of the Official College of Physicians of Madrid (ICOMEM) in relation to some questions that remain unresolved. The document includes considerations on the origin of the virus, the current indication for diagnostic tests, the value of severity scores in the onset of the disease and the added risk posed by hypertension or dementia. We also discuss the possibility of deducing viral behavior from the examination of the structure of the complete viral genome, the future of some drug associations and the current role of therapeutic resources such as corticosteroids or extracorporeal oxygenation (ECMO). We review the scarce existing information on the reality of COVID 19 in Africa, the uncertainties about the future of the pandemic and the status of vaccines, and the data and uncertainties about the long-term pulmonary sequelae of those who suffered severe pneumonia. ©The Author 2021. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(<a href="https://creativecommons.org/licenses/by-nc/4.0/" class="uri">https://creativecommons.org/licenses/by-nc/4.0/</a>).
</td>
</tr>
<tr>
<td style="text-align:left;">
35443499
</td>
<td style="text-align:left;">
Breakthrough covid 19 infections after 2 doses of covid 19 vaccination and comparing severity between hospitalized and non hospitalized in tertiary care hospital.
</td>
<td style="text-align:left;">
The Journal of the Association of Physicians of India
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
The COVID 19 infection is highly transmissible and spreading globally, including in populations with high vaccination rates. COVID-19 vaccination in India, was started in month of January 2021 with healthcare workers (HCWs) becoming the first to get vaccinated. However, there has been lot debate on the efficacy of the vaccine. This study highlights breakthrough COVID-19 infections among vaccinated HCWs comparing clinical and lab parameter among hospitalized and non hospitalized. This was a retrospective study conducted using questionnaire assessing COVID-19 like symptoms and confirmed COVID 19 infections among fully vaccinated HCWs (all faculty including nurses, wardboys, professors, post graduate students and interns) of the institute from a period of 4 months from March 2021 to June 2021. The number of infections was also matched with hospital records. Out of 36 HCWs, all had received both doses of covishield vaccine. Males were 18 and females were 18, mean age was found to ne 32.17. People with co-morbidities were 13.9% including diabetes and hypertension. Out 36 HCWs, 4 people required hospitalization ie 11%, all other cases had mild symptoms and none required oxygen support. There was no significant difference between hospitalized and non-hospitalized with regard to routine lab parameters, but there significant elevation of inflammatory marker -CRP being positive in 2 hospitalized cases, with p value being significant (p&amp;amp;lt;0.001). This study identifies that breakthrough infections among vaccinated HCWs(health care workers) were common. Most breakthrough infections were mild or asymptomatic, although persistent symptoms did occur. The findings suggested that COVID-19 were more severe in hospitalized patients compared to non-hospitalized and even though infections did occur none resulted in any severe form or mortality, it also indicates that vaccination prevents from severe form of the disease. But, preventive measures should be continued even among vaccinated individuals.
</td>
</tr>
<tr>
<td style="text-align:left;">
35443298
</td>
<td style="text-align:left;">
[Progress in research of economic evaluation of COVID-19 vaccination strategies].
</td>
<td style="text-align:left;">
Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
10
</td>
<td style="text-align:left;">
Objective: To understand the research progresses of economic evaluation of COVID-19 vaccination strategies both at home and abroad, and provide reference for the economic evaluation of COVID-19 vaccination strategies using real word data in China. Methods: Literature retrieval was conducted for related papers published from January, 2020 to December, 2021 in Chinese and English databases, including the economic evaluation of COVID-19 vaccination, and the results of the related literatures were narratively integrated. Results: A total of 16 English literatures (including 3 reviews) were included, and it was found that the COVID-19 vaccination was cost-effective or cost-saving regardless of the vaccine types, while the cost-effectiveness in different population and under different vaccination dose strategies varied due to vaccine efficacy, vaccine price, duration of natural immunity, duration of vaccination campaign, vaccine supply, and vaccination pace. Conclusions: China lacks suitable evidences of economic evaluation of COVID-19 vaccination strategies based on real-world data in the context of long-term epidemic. Therefore, further researches of suitable strategies of booster COVID-19 vaccination are needed.
</td>
</tr>
<tr>
<td style="text-align:left;">
35442581
</td>
<td style="text-align:left;">
COVID-19 Pandemic Exacerbates Childhood Immunization Disparities.
</td>
<td style="text-align:left;">
WMJ : official publication of the State Medical Society of Wisconsin
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
The objective of this study was to measure the recovery of routine pediatric immunization after a period of reduced vaccine administrations in the early weeks of the COVID-19 pandemic. We recorded data on vaccines administered in Children’s Wisconsin primary care or urgent care clinics from January 2019 through December 2020 and aggregated data by date and insurance type. During the gradual reopening period after week 21 in 2020, vaccine administration returned to prepandemic levels for children with commercial insurance but remained below baseline rates until the end of 2020 for children with Medicaid insurance. The decline in pediatric vaccination in 2020 disproportionately affected children with Medicaid insurance. Copyright
</td>
</tr>
<tr>
<td style="text-align:left;">
35442571
</td>
<td style="text-align:left;">
Multisystem Inflammatory Syndrome in Children: A Call for Improving Pediatric COVID-19 Vaccination Rates.
</td>
<td style="text-align:left;">
WMJ : official publication of the State Medical Society of Wisconsin
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
35442478
</td>
<td style="text-align:left;">
A rare case of grave’s disease after SARS-CoV-2 vaccine: is it an adjuvant effect?
</td>
<td style="text-align:left;">
European review for medical and pharmacological sciences
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
The COVID-19 virus has been responsible for the development of several systemic diseases. Recently, the COVID-19 vaccine has also been incriminated in the development of autoimmune diseases. Currently, researchers have focused on the relationship between the COVID-19 vaccine and the activation of autoimmune phenomenon. We report a case of Graves’ disease (GD) whose symptoms appeared 3 days after vaccination against COVID-19. A forty-three-year-old female, without pathological history, presented with diarrhea and palpitation. She received her first SARS-CoV-2 Vaccine dose (Pfizer-BioNTech), in August 2021. Three days after the vaccine, she felt palpitations, sleep disorders, muscle weakness, and heat intolerance. On examination, her pulse was 119 beats per minute, she weighed 63 kg, and she had lost 4 kg in only two months. GD was suspected. Thyroid hormone testing showed low thyroid-stimulating hormone, and an elevated serum free thyroxine hormone T4 level. Serology tests were positive for TSH receptor autoantibodies (TRAB). A GD induced by adjuvants of SARS-CoV-2 vaccine has been retained as a final diagnosis. Several autoimmune diseases have been attributed to adjuvant-induced autoimmune/inﬂammatory syndrome, including systemic sclerosis, systemic lupus erythematosus and rheumatoid arthritis, and recently few cases of GD have been explained by this phenomenon.
</td>
</tr>
<tr>
<td style="text-align:left;">
35442477
</td>
<td style="text-align:left;">
COVID-19 and pregnancy: clinical outcomes and scientific evidence about vaccination.
</td>
<td style="text-align:left;">
European review for medical and pharmacological sciences
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Pregnant women and their infants are at high risk to develop a severe COVID-19, with increased rates of hospitalisation to intensive care units, need for mechanical ventilation and mortality. Preterm birth, fetal vascular malperfusion, and premature rupture of membrane have been the most reported adverse pregnancy outcomes and these effects have been especially associated with the onset of the disease at early gestational age. The early expression of ACE2 and TMPRSS2 in human embryos has been proven, determining an increased susceptibility to SARS-CoV-2. Preterm infants born to women infected by SARS-CoV-2 have a higher risk of need for specialist neonatal care with prolonged hospitalization. Moreover, inflammation of developing embryos could cause long-term defects, regardless of vertical transmission of SARS-CoV-2. Due to Maternal Immune Activation (MIA), in utero inflammation is associated with neurodevelopmental, cognitive and psychiatric disorders in affected offspring. Despite risks that COVID-19 could induce in pregnancy, there are not many published data describing the safety and/or efficacy of COVID-19 vaccines in pregnant women, commonly not included in vaccine research. The evidence from the few pregnant women unintentionally enrolled in clinical trials and vaccinated suggests that COVID-19 vaccines, both based on mRNA and viral vectors, do not pose significant risks to the fetus or breastfeeding infants. Moreover, human studies using mRNA-based vaccines against Zika virus, influenza, and rabies have reported good safety and immunogenicity during pregnancy. In this review, we evaluate the role of COVID-19 in adverse pregnancy and neonatal outcomes and the need to vaccinate pregnant women.
</td>
</tr>
<tr>
<td style="text-align:left;">
35442474
</td>
<td style="text-align:left;">
Effectiveness of mRNA BNT162b2 COVID-19 vaccine against SARS-CoV-2 Delta variant among elderly residents from a long-term care facility, South of France, May 2021.
</td>
<td style="text-align:left;">
European review for medical and pharmacological sciences
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Delta variant was classified as a variant of concern in May 2021 due to its increased transmissibility. It became dominant in Europe during the summer, raising concerns on the effectiveness of vaccines. We assessed the vaccine effectiveness (VE) of mRNA BNT162b2 (BioNTech-Pfizer) against SARS-CoV-2 Delta variant during an outbreak affecting long-term care facility (LTCF) residents in southern France, May 2021. We conducted a retrospective cohort study among LTCF residents. We described sex, age, dependency level, reverse transcription PCR and sequencing results, clinical evolution, vaccination status. We compared attack rates of SARS-CoV-2 infection, symptomatic coronavirus disease 2019 (COVID-19), and severe COVID-19 (respiratory support, hospitalization, and/or death) by vaccination status (two doses administered vs. none) to estimate VE (1 - Relative Risk [RR]) with 95% confidence intervals (CI). VE was adjusted by age (Poisson regression). Among 72 LTCF residents, 75.0% (n=54) were women, mean age was 88.7 (SD 8.1) years, 69% (n=49/71) were severely dependent. SARS-CoV-2 infections were identified in 39 residents (54.2%), 11 with symptomatic, and eight with severe COVID-19. All sequenced samples (n=19, 48.7%) had the same Delta variant genomic sequence. Age-adjusted BNT162b2 VE against SARS-CoV-2 Delta variant infection was 11.2% (95% CI: 0.0-61.1%), it was 88.4% (95% CI: 59.9-96.7%) against symptomatic, and 93.5% (95% CI: 67.2-98.7%) against severe COVID-19. We found a high BNT162b2 VE against symptomatic and severe COVID-19 caused by SARS-CoV-2 Delta variant among LTCF elderly residents, but not against Delta variant infection. This supports vaccination rollout and the implementation of control measures for close contacts among vaccinated LTCF elderly residents.
</td>
</tr>
<tr>
<td style="text-align:left;">
35442453
</td>
<td style="text-align:left;">
Effectiveness of mRNA-1273, BNT162b2, and JNJ-78436735 COVID-19 Vaccines Among US Military Personnel Before and During the Predominance of the Delta Variant.
</td>
<td style="text-align:left;">
JAMA network open
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
01
</td>
<td style="text-align:left;">
No studies to date have evaluated the effectiveness of 3 COVID-19 vaccines in the US military population, especially during the circulation of the SARS-CoV-2 Delta (B.1.617.2) variant. To estimate the effectiveness of the mRNA-1273, BNT162b2, and JNJ-78436735 vaccines among US military personnel before and during the predominance of the Delta variant in the US. Setting, and Participants” This case-control study was conducted among all unvaccinated and fully vaccinated US military personnel who had a documented SARS-CoV-2 test performed in the US between January 1 and September 24, 2021. Individuals were identified using Department of Defense (DOD) electronic medical, laboratory, and surveillance databases. The pre-Delta period was defined as January 1 to May 31, 2021, and the Delta period as June 19 to September 24, 2021. Case individuals were defined by a positive polymerase chain reaction SARS-CoV-2 test result or a positive antigen test result with symptoms. Control individuals had at least 1 negative SARS-CoV-2 test result. COVID-19 vaccination with the mRNA-1273, BNT162b2, or JNJ-78436735 vaccine, assessed from DOD electronic vaccination records. COVID-19 vaccine effectiveness overall, by vaccine type, and by outcome stratified by the pre-Delta and Delta periods in the US. Vaccine effectiveness was estimated as 100 × (1 - odds ratio) in a logistic regression model with adjustment for potential confounders. The cohort included 441 379 individuals, with 290 256 in the pre-Delta period (236 555 [81%] male; median age, 25 years [range, 17-68 years]) and 151 123 in the Delta period (120 536 [80%] male; median age, 26 years [range, 17-70 years]). Adjusted vaccine effectiveness of all vaccines was significantly higher during the pre-Delta period (89.2%; 95% CI, 88.1%-90.1%) compared with the Delta period (70.2%; 95% CI, 69.3%-71.1%) for all outcomes, an overall decrease of 19%. mRNA-1273 vaccine effectiveness was highest in the pre-Delta (93.5%; 95% CI, 91.9%-94.7%) and Delta (79.4%; 95% CI, 78.3%-80.4%) periods for all outcomes, whereas the JNJ-78436735 vaccine had the lowest effectiveness during the pre-Delta (81.8%; 95% CI, 74.2%- 87.1%) and Delta (38.3%; 95% CI, 34.5%-41.9%) periods. Effectiveness for all vaccines during both periods was higher for symptomatic infection and hospitalization among individuals with SARS-CoV-2 infection. In this case-control study, among US military personnel, COVID-19 vaccine effectiveness was significantly lower during the period when the Delta variant predominated compared with the period before Delta variant predominance; this was especially true for the JNJ-78436735 vaccine. These findings were confounded by time since vaccination; this and the change in effectiveness support the need for booster doses and continued evaluation of vaccine effectiveness as new variants of SARS-CoV-2 emerge.
</td>
</tr>
<tr>
<td style="text-align:left;">
35441742
</td>
<td style="text-align:left;">
Psycho-behavioural factors influencing COVID-19 vaccine hesitancy among Korean adults: The moderating role of age.
</td>
<td style="text-align:left;">
Journal of advanced nursing
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
20
</td>
<td style="text-align:left;">
This study aimed to identify the psycho-behavioural factors influencing coronavirus disease 2019 (COVID-19) vaccine hesitancy among Korean adults. We examined the primary effects of eHealth literacy, social responsibility and self-efficacy on COVID-19 vaccine hesitancy using the information-motivation-behavioural skills (IMB) model. The moderating effect of age on the relationship between psycho-behavioural factors and COVID-19 vaccine hesitancy was also examined. The study used a cross-sectional survey design. An online survey was completed by 500 Korean adults (253 men and 247 women) aged 20-60 years. Data collection took place in May 2021. The constructed hypothetical model for eHealth literacy, social responsibility, self-efficacy and age was evaluated using partial least squares structural equation modelling (PLS-SEM). eHealth literacy, social responsibility and self-efficacy had significant negative effects on COVID-19 vaccine hesitancy. Age had a significant moderating effect on COVID-19 vaccine hesitancy. The moderating effects of age on the relationship between eHealth literacy and COVID-19 vaccine hesitancy and between social responsibility and COVID-19 vaccine hesitancy enhanced the explanatory power by high effect size. The overall fitness of the hypothetical model was good. The standardized root mean square residual value was 0.007, which explained 18.5% of the COVID-19 vaccine hesitancy. To reduce COVID-19 vaccine hesitancy among Korean adults, a strategic approach that considers age should be adopted to enhance eHealth literacy, social responsibility and self-efficacy. The findings of this study suggest that providing correct health information online related to the COVID-19 vaccine is likely to be effective in decreasing COVID-19 vaccine hesitancy in older individuals, whereas inspiring a sense of social responsibility is more likely to be effective in younger individuals. These strategic nursing interventions could contribute to improving COVID-19 vaccination rates among Korean adults.
</td>
</tr>
<tr>
<td style="text-align:left;">
35441497
</td>
<td style="text-align:left;">
Herpes zoster reactivation after COVID-19 vaccination - a retrospective case series of 22 patients.
</td>
<td style="text-align:left;">
International journal of dermatology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
May
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
35441179
</td>
<td style="text-align:left;">
A booster dose of an inactivated SARS-CoV-2 vaccine increases neutralizing antibodies and T cells that recognize Delta and Omicron variants of concern.
</td>
<td style="text-align:left;">
medRxiv : the preprint server for health sciences
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Feb
</td>
<td style="text-align:left;">
07
</td>
<td style="text-align:left;">
CoronaVac ® is an inactivated SARS-CoV-2 vaccine approved by the World Health Organization. Previous studies reported increased levels of neutralizing antibodies and specific T cells two- and four-weeks after two doses of CoronaVac ® , but the levels of neutralizing antibodies are reduced at six to eight months after two doses. Here we report the effect of a booster dose of CoronaVac ® on the anti-SARS-CoV-2 immune response generated against variants of concern (VOC) Delta and Omicron in adults participating in a phase 3 clinical trial in Chile. Volunteers immunized with two doses of CoronaVac ® in a four-week interval received a booster dose of the same vaccine between twenty-four and thirty weeks after the 2nd dose. Four weeks after the booster dose, neutralizing antibodies and T cell responses were measured. Neutralization capacities and T cell activation against VOC Delta and Omicron were detected at four weeks after the booster dose. We observed a significant increase in neutralizing antibodies at four weeks after the booster dose. We also observed an increase in CD4 + T cells numbers over time, reaching a peak at four weeks after the booster dose. Furthermore, neutralizing antibodies and SARS-CoV-2 specific T cells induced by the booster showed activity against VOC Delta and Omicron. Our results show that a booster dose of CoronaVac ® increases the anti-SARS-CoV-2 humoral and cellular immune responses in adults. Immunity induced by a booster dose of CoronaVac ® is active against VOC, suggesting an effective protection.
</td>
</tr>
<tr>
<td style="text-align:left;">
35441173
</td>
<td style="text-align:left;">
Willingness to accept COVID-19 vaccination among people living with HIV in a high HIV prevalence community.
</td>
<td style="text-align:left;">
Research square
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
12
</td>
<td style="text-align:left;">
Background People living with HIV (PLWH) may have a poorer prognosis with COVID-19 infection and are an important population for COVID-19 vaccination. We assessed the willingness and reasons for COVID-19 vaccine acceptance or hesitancy among PLWH in South Africa. Methods We conducted a cross-sectional study consisting of telephone interviews with a randomly selected subset of participants enrolled in a prospective observational cohort study evaluating a decentralized antiretroviral therapy (ART) delivery program in South Africa. Questions assessed willingness to accept a future COVID-19 vaccine, concerns regarding COVID-19 vaccination, and overall vaccine confidence. Interviews were conducted between September 2020 and January 2021. We evaluated participant demographics, sources of COVID-19 information, stigma and medical mistrust, uptake of non-pharmaceutical interventions, and socioeconomic impacts of the COVID-19 pandemic as potential covariates of willingness to accept vaccination. Results We completed interviews with 213 participants; 153 (72%) were female, median age 35y, and 100 (47%) had completed secondary school. Among the participants, 121 (57%) were willing to accept future vaccination, 46 (22%) were unsure, and 45 (21%) stated they did not intend to be vaccinated. Fear of side effects, reported by 42 (20%), was the most common concern about COVID-19 vaccination. Older age was associated with willingness to accept vaccination (aOR 1.75 for every 10-year increase in age, 95% CI 1.10-2.78, p=0.02), while higher medical mistrust related to COVID-19 (aOR 0.21, 95% CI 0.093-0.45, p&amp;lt;0.001) and use of social media for COVID-19 information (aOR 0.30, 95% CI 0.11-0.84, p=0.02) were associated with lower willingness to accept vaccination. Conclusions In this cohort of PLWH in South Africa, over half were willing to accept COVID-19 vaccination, although a substantial proportion remained unsure or were not willing to be vaccinated. Public health messaging should emphasize the safety and efficacy of COVID-19 vaccination and address misinformation and medical mistrust among PLWH. Ongoing efforts to ensure access to COVID-19 vaccines for vulnerable populations are crucial.
</td>
</tr>
<tr>
<td style="text-align:left;">
35441164
</td>
<td style="text-align:left;">
Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial.
</td>
<td style="text-align:left;">
medRxiv : the preprint server for health sciences
</td>
<td style="text-align:left;">
2021
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
01
</td>
<td style="text-align:left;">
The ongoing COVID-19 pandemic has had a significant impact worldwide, with an incommensurable social and economic burden. The rapid development of safe and protective vaccines against this disease is a global priority. CoronaVac is a vaccine prototype based on inactivated SARS-CoV-2, which has shown promising safety and immunogenicity profiles in pre-clinical studies and phase 1/2 trials in China. To this day, four phase 3 clinical trials are ongoing with CoronaVac in Brazil, Indonesia, Turkey, and Chile. This article reports the safety and immunogenicity results obtained in a subgroup of participants aged 18 years and older enrolled in the phase 3 Clinical Trial held in Chile. This is a multicenter phase 3 clinical trial. Healthcare workers aged 18 years and older were randomly assigned to receive two doses of CoronaVac or placebo separated by two weeks (0-14). We report preliminary safety results obtained for a subset of 434 participants, and antibody and cell-mediated immunity results obtained in a subset of participants assigned to the immunogenicity arm. The primary and secondary aims of the study include the evaluation of safety parameters and immunogenicity against SARS-CoV-2 after immunization, respectively. This trial is registered at clinicaltrials.gov ( NCT04651790 ). The recruitment of participants occurred between November 27 th , 2020, until January 9 th , 2021. 434 participants were enrolled, 397 were 18-59 years old, and 37 were ≥60 years old. Of these, 270 were immunized with CoronaVac, and the remaining 164 participants were inoculated with the corresponding placebo. The primary adverse reaction was pain at the injection site, with a higher incidence in the vaccine arm (55.6%) than in the placebo arm (40.0%). Moreover, the incidence of pain at the injection site in the 18-59 years old group was 58.4% as compared to 32.0% in the ≥60 years old group. The seroconversion rate for specific anti-S1-RBD IgG was 47.8% for the 18-59 years old group 14 days post immunization (p.i.) and 95.6% 28 and 42 days p.i. For the ≥60 years old group, the seroconversion rate was 18.1%, 100%, and 87.5% at 14, 28, and 42 days p.i., respectively. Importantly, we observed a 95.7% seroconversion rate in neutralizing antibodies for the 18-59 years old group 28 and 42 days p.i. The ≥60 years old group exhibited seroconversion rates of 90.0% and 100% at 28 and 42 days p.i. Interestingly, we did not observe a significant seroconversion rate of anti-N-SARS-CoV-2 IgG for the 18-59 years old group. For the participants ≥60 years old, a modest rate of seroconversion at 42 days p.i. was observed (37.5%). We observed a significant induction of a T cell response characterized by the secretion of IFN-γ upon stimulation with Mega Pools of peptides derived from SARS-CoV-2 proteins. No significant differences between the two age groups were observed for cell-mediated immunity. Immunization with CoronaVac in a 0-14 schedule in adults of 18 years and older in the Chilean population is safe and induces specific IgG production against the S1-RBD with neutralizing capacity, as well as the activation of T cells secreting IFN-γ, upon recognition of SARS-CoV-2 antigens. Ministry of Health of the Chilean Government; Confederation of Production and Commerce, Chile; Consortium of Universities for Vaccines and Therapies against COVID-19, Chile; Millennium Institute on Immunology and Immunotherapy.
</td>
</tr>
<tr>
<td style="text-align:left;">
35441151
</td>
<td style="text-align:left;">
Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis.
</td>
<td style="text-align:left;">
The Lancet. Rheumatology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
14
</td>
<td style="text-align:left;">
We estimated COVID-19 vaccine effectiveness against SARS-CoV-2 infection and severe COVID-19 outcomes among individuals with immune-mediated inflammatory diseases in Ontario, Canada. In this population-based analysis, we used a test-negative design across four immune-mediated inflammatory disease population-based cohorts, comprising individuals with rheumatoid arthritis, ankylosing spondylitis, psoriasis, and inflammatory bowel disease. We identified all SARS-CoV-2 tests done in these populations between March 1 and Nov 22, 2021 (a period in which there was rapid uptake of vaccines, and the alpha [B.1.1.7] and delta [B.1.617.2] SARS-CoV-2 variants were predominantly circulating in Canada) and separately assessed outcomes of SARS-CoV-2 infection and severe COVID-19 outcomes (hospitalisation due to COVID-19 and death due to COVID-19) for each disease group. We used multivariable logistic regression to estimate the effectiveness of one, two, and three doses of mRNA-based COVID-19 vaccine (BNT162b2 [Pfizer-BioNTech], or mRNA-1273 [Moderna]) among individuals at the time of SARS-CoV-2 testing. Between March 1 and Nov 22, 2021, we identified 2127 (5·9%) test-positive cases among 36 145 individuals (26 476 [73·2%] were female and 9669 [26·8%] were male) with rheumatoid arthritis tested, 476 (6·1%) test-positive cases among 7863 individuals (4130 [52·5%] were female and 3733 [47·5%] were male) with ankylosing spondylitis tested, 3089 (6·5%) test-positive cases among 47 199 individuals (26 062 [55·2%] were female and 21 137 [44·8%] were male) with psoriasis tested, and 1702 (5·4%) test-positive cases among 31 311 individuals (17 716 [56·6%] were female and 13 595 [43·4%] were male) with inflammatory bowel disease tested. Adjusted vaccine effectiveness of two doses against infection was 83% (95% CI 80-86) in those with rheumatoid arthritis, 89% (83-93) among those with ankylosing spondylitis, 84% (81-86) among those with psoriasis, and 79% (74-82) among those with inflammatory bowel disease. After two vaccine doses, effectiveness against infection generally peaked 31-60 days after vaccination and waned gradually with each additional month. Vaccine effectiveness against severe outcomes after two doses was 92% (95% CI 88-95) in those with rheumatoid arthritis, 97% (83-99) among those with ankylosing spondylitis, 92% (86-95) among those with psoriasis, and 94% (88-97) among those with inflammatory bowel disease. Vaccine effectiveness after a third dose against infection was similar to or higher than after the second dose (ranging from 76% [47-89] to 96% [72-99]), although due to a paucity of events, estimates could not be calculated for some subgroups for severe outcomes. Two vaccine doses were found to be highly effective against both SARS-CoV-2 infection and severe COVID-19 outcomes in patients with rheumatoid arthritis, ankylosing spondylitis, psoriasis, and inflammatory bowel disease during the study period. Research is needed to determine the durability of effectiveness of three doses over time, particularly against emerging variants. Public Health Agency of Canada.
</td>
</tr>
<tr>
<td style="text-align:left;">
35441122
</td>
<td style="text-align:left;">
When Do We Need Massive Computations to Perform Detailed COVID-19 Simulations?
</td>
<td style="text-align:left;">
Advanced theory and simulations
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Feb
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
The COVID-19 pandemic has infected over 250 million people worldwide and killed more than 5 million as of November 2021. Many intervention strategies are utilized (e.g., masks, social distancing, vaccinations), but officials making decisions have a limited time to act. Computer simulations can aid them by predicting future disease outcomes, but they also require significant processing power or time. It is examined whether a machine learning model can be trained on a small subset of simulation runs to inexpensively predict future disease trajectories resembling the original simulation results. Using four previously published agent-based models (ABMs) for COVID-19, a decision tree regression for each ABM is built and its predictions are compared to the corresponding ABM. Accurate machine learning meta-models are generated from ABMs without strong interventions (e.g., vaccines, lockdowns) using small amounts of simulation data: the root-mean-square error (RMSE) with 25% of the data is close to the RMSE for the full dataset (0.15 vs 0.14 in one model; 0.07 vs 0.06 in another). However, meta-models for ABMs employing strong interventions require much more training data (at least 60%) to achieve a similar accuracy. In conclusion, machine learning meta-models can be used in some scenarios to assist in faster decision-making.
</td>
</tr>
<tr>
<td style="text-align:left;">
35439529
</td>
<td style="text-align:left;">
Detection of SARS-CoV-2 peptide-specific antibodies in Syrian hamster serum by ELISA.
</td>
<td style="text-align:left;">
Journal of immunological methods
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
16
</td>
<td style="text-align:left;">
Golden Syrian hamsters are increasingly used as a permissive animal model for SARS-CoV-2 virus studies, but the lack of immunological assays and other immunological reagents for hamsters limits its full potential. Herein, we developed an ELISA method to detect antibodies specific to peptides and proteins derived from SARS-CoV-2 virus in immunized golden Syrian hamsters. Under optimized conditions, this assay quantitates antibodies specific for individual viral peptides, peptide pools, and proteins. Hence, this ELISA method allows investigators to quantitatively assess humoral immune responses at the peptide and protein levels and has potential application in the development of peptide-based vaccines to be tested in hamsters.
</td>
</tr>
<tr>
<td style="text-align:left;">
35439274
</td>
<td style="text-align:left;">
COVID-19 vaccination acceptance among dental students and dental practitioners: A systematic review and meta-analysis.
</td>
<td style="text-align:left;">
PloS one
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Dental practitioners and dental students are classified as high-risk exposure to COVID-19 due to the nature of dental treatments, but evidence of their acceptance towards COVID-19 vaccination is still scarce. Hence, this systemic review aims to critically appraise and analyse the acceptability of COVID-19 vaccination among dental students and dental practitioners. This review was registered in the PROSPERO database (CRD42021286108) based on PRISMA guidelines. Cross-sectional articles on the dental students’ and dental practitioners’ acceptance towards COVID-19 vaccine published between March 2020 to October 2021 were searched in eight online databases. The Joanna Briggs Institute critical appraisal tool was employed to analyse the risk of bias (RoB) of each article, whereas the Oxford Centre for Evidence-Based Medicine recommendation tool was used to evaluate the level of evidence. Data were analysed using the DerSimonian-Laird random effect model based on a single-arm approach. Ten studies were included of which three studies focused on dental students and seven studies focused on dental practitioners. Four studies were deemed to exhibit moderate RoB and the remaining showed low RoB. All the studies demonstrated Level 3 evidence. Single-arm meta-analysis revealed that dental practitioners had a high level of vaccination acceptance (81.1%) than dental students (60.5%). A substantial data heterogeneity was observed with the overall I2 ranging from 73.65% and 96.86%. Furthermore, subgroup analysis indicated that dental practitioners from the Middle East and high-income countries showed greater (p &amp;lt; 0.05) acceptance levels, while meta-regression showed that the sample size of each study had no bearing on the degree of data heterogeneity. Despite the high degree of acceptance of COVID-19 vaccination among dental practitioners, dental students still demonstrated poor acceptance. These findings highlighted that evidence-based planning with effective approaches is warranted to enhance the knowledge and eradicate vaccination hesitancy, particularly among dental students.
</td>
</tr>
<tr>
<td style="text-align:left;">
35438919
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Salud publica de Mexico
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
08
</td>
<td style="text-align:left;">
Evaluar la efectividad de las vacunas contra SARS-CoV-2 para evitar muerte e intubación en pacientes hospitalizados con Covid-19. Material y métodos. Se presentó un análisis de 3 565 hospitalizaciones por SARS-CoV-2 de personas mayores de 20 años de edad, reportadas con fines de salud pública por 10 hospitales de especialidad. Se comparó a los egresados por mejoría (2 094) con los fallecidos (1 471) en modelos mixtos de regresión logística ajustados por edad, sexo, número de comorbilidades y el hospital como variable aleatoria. Un esquema completo de vacunación, con cinco tipos de vacunas disponi-bles, tuvo un efecto protector para muerte o intubación (RM: 0.67, IC95%: 0.54,0.83, 33% de protección); y para muerte (RM: 0.80, IC95%: 0.64,0.99, 20% de protección) estos datos se compararon con los que no habían sido vacunados. Todas las vacunas aplicadas mostraron un efecto protector con un RM&amp;lt;0.8, con intervalos de confianza variables. Conclusio-nes. El antecedente de vacunación reduce los riesgos de ser intubado y morir, aun en pacientes previamente vacunados y hospitalizados con Covid-19 grave.
</td>
</tr>
<tr>
<td style="text-align:left;">
35438849
</td>
<td style="text-align:left;">
Factors predictive of anti-spike antibody titers after COVID-19 vaccination in hemodialysis patients.
</td>
<td style="text-align:left;">
Advances in clinical and experimental medicine : official organ Wroclaw Medical University
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
19
</td>
<td style="text-align:left;">
Hemodialysis (HD) patients have a high prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and mortality, but they may have a weak response to coronavirus disease 2019 (COVID-19) vaccines. This study aimed to evaluate factors predictive of humoral response in HD patients vaccinated against SARS-CoV-2 infection. This is a 2-center observational study including HD patients who received the BNT162b2 mRNA vaccine followed by serological measurements 20 days and 4 weeks after the 1st and 2nd dose, respectively. Healthy controls were included. Anti-spike antibody was measured using the chemiluminescent immunoassay (CLIA) method. The quantile regression analysis was performed to assess factors associated with anti-spike antibody titers. Seventy-two HD patients and 22 healthy controls were included. Mean age of dialysis patients and controls was 72.5 ±11.5 years and 45.7 ±17.4 years, respectively. In the HD group, median levels of anti-spike antibody were 3 (interquartile range (IQR): 0.5-26) UI/mL and 391 (IQR: 55-1642) UI/mL after the 1st and 2nd dose, respectively, with response rates of 62.5% and 96.7%. The median level of the anti-spike antibody after the 1st dose in previously infected patients was 8571 (IQR: 2586-19147) UI/mL. There was a significant correlation between anti-spike antibody levels after the 2nd dose and age and anti-hepatitis B surface (HBs) antibody and serum albumin levels (Spearman’s rho: r = -0.289, p &amp;lt; 0.001; r = 0.357, p = 0.027; r = 0.317; p = 0.026, respectively). The regression analysis showed a significant association of previous infection and anti-Hbs antibody level with anti-spike antibody level after the 1st dose of vaccine (p &amp;lt; 0.001). After a 5-month follow-up, 2 vaccinated patients contracted COVID-19. This study showed a response rate of 96.7% to 2 doses of BNT162b2 mRNA vaccine in HD patients and 100% to a single dose in previously infected patients. The level of anti-spike antibody can be predicted by age, anti-Hbs antibodies, serum albumin, and previous infection. Despite the immunization of patients, preventive measures should be maintained in all dialysis units.
</td>
</tr>
<tr>
<td style="text-align:left;">
35438751
</td>
<td style="text-align:left;">
Discordant antibody and T cell responses to the SARS-CoV-2 Omicron variant in COVID-19 mRNA vaccine recipient.
</td>
<td style="text-align:left;">
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
19
</td>
<td style="text-align:left;">
We compared antibody and T cell responses against the SARS-CoV-2 vaccine strain spike protein to responses against the Omicron variant in 15 mRNA vaccine recipients. While these individuals had significantly lower levels of antibodies that inhibited Omicron spike protein binding to ACE2, there was no difference in T cell responses.
</td>
</tr>
<tr>
<td style="text-align:left;">
35438722
</td>
<td style="text-align:left;">
Fractionating COVID-19 Vaccine Doses May Save Lives.
</td>
<td style="text-align:left;">
JAMA
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
19
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
35438579
</td>
<td style="text-align:left;">
Modified mRNA-Based Vaccines Against Coronavirus Disease 2019.
</td>
<td style="text-align:left;">
Cell transplantation
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
The pandemic of coronavirus disease 2019 (COVID-19) continuously causes deaths worldwide, representing a considerable challenge to health care and economic systems with a new precedent in human history. Many therapeutic medicines primarily focused on preventing severe organ damage and complications, which can be fatal in some confirmed cases. The synthesized modified mRNA (modRNA) represents a nonviral, integration-free, zero-footprint, efficient, and safe strategy for vaccine discovery. modRNA-based technology has facilitated the rapid development of the first COVID-19 vaccines due to its cost- and time-saving properties, thus initiating a new era of prophylactic vaccines against infectious diseases. Recently, COVID-19 modRNA vaccines were approved, and a large-scale vaccination campaign began worldwide. To date, results suggest that the modRNA vaccines are highly effective against virus infection, which causes COVID-19. Although short-term studies have reported that their safety is acceptable, long-term safety and protective immunity remain unclear. In this review, we describe two major approved modRNA vaccines and discuss their potential myocarditis complications.
</td>
</tr>
<tr>
<td style="text-align:left;">
35438576
</td>
<td style="text-align:left;">
Predictors of Intention to Vaccinate Against COVID-19 in a Peruvian Sample.
</td>
<td style="text-align:left;">
Journal of primary care &amp;amp; community health
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Vaccination against COVID-19 is considered one of the most effective strategies to control this global public health crisis. However, vaccine hesitancy is one of the main threats to mitigating the pandemic. The present study aimed to identify predictors of intention to vaccinate against COVID-19 in 3 geographical regions of Peru. An online analytical cross-sectional study was conducted. Participants were selected by non-probability convenience sampling and size was estimated using the online statistical calculator proposed by Soper. A total of 529 Peruvian nationals completed the questionnaires. Student’s t-test and Fisher’s F test (ANOVA) were used. A significance level of .05 was considered. Face-to-face work (β = 2.037, P &amp;lt; .001), fear of COVID-19 (β = .461, P &amp;lt; .001), vaccine confidence (β = 2.881, P &amp;lt; .001) and trust in health care institutions (β = .432, P &amp;lt; .01) predict a higher intention to receive the vaccine. However, the variables perception of a worldwide conspiracy (β = -1.900, P &amp;lt; .001), and practice Protestant religion (β = -2.274, P &amp;lt; .001) predict negatively their acceptance. Several positive predictors of intention to vaccinate against COVID-19 have been identified. However, having a perception of a global conspiracy and practice Protestant religion are shown to be risk variables for vaccine acceptance. Therefore, there is a need to develop strategies to ensure high uptake and success of COVID-19 vaccination campaigns.
</td>
</tr>
<tr>
<td style="text-align:left;">
35438175
</td>
<td style="text-align:left;">
Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada.
</td>
<td style="text-align:left;">
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
19
</td>
<td style="text-align:left;">
The Canadian COVID-19 immunization strategy deferred second doses and allowed mixed schedules. We compared two-dose vaccine effectiveness (VE) by vaccine type (mRNA and/or ChAdOx1), interval between doses, and time since second dose in two of Canada’s larger provinces. Two-dose VE against SARS-CoV-2 infection or hospitalization among adults ≥18-years-old, including due to Alpha, Gamma and Delta variants of concern (VOC), was assessed at ≥14 days post-vaccination by test-negative design studies separately conducted in British Columbia and Quebec, Canada between May 30 and November 27 (epi-weeks 22-47), 2021. In both provinces, all homologous or heterologous mRNA and/or ChAdOx1 two-dose schedules were associated with ≥90% reduction in SARS-CoV-2 hospitalization risk for at least 7 months. With slight decline from a peak of &amp;gt;90%, VE against infection was ≥80% for at least 6 months following homologous mRNA vaccination, lower by ∼10% when both doses were ChAdOx1 but comparably-high following heterologous ChAdOx1 + mRNA receipt. Findings were similar by age group, sex and VOC. VE was significantly higher with longer 7-8-week vs. manufacturer-specified 3-4-week interval between mRNA doses. Two doses of any mRNA and/or ChAdOx1 combination gave substantial and sustained protection against SARS-CoV-2 hospitalization, spanning Delta-dominant circulation. ChAdOx1 VE against infection was improved by heterologous mRNA series completion. A 7-8-week interval between first and second doses improved mRNA VE and may be the optimal schedule outside periods of intense epidemic surge. Findings support interchangeability and extended intervals between SARS-CoV-2 vaccine doses, with potential global implications for low-coverage areas and, going forward, for children.
</td>
</tr>
<tr>
<td style="text-align:left;">
35438137
</td>
<td style="text-align:left;">
Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the Delta variant epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS).
</td>
<td style="text-align:left;">
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
19
</td>
<td style="text-align:left;">
Although high vaccine effectiveness of messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines was reported in studies in several countries, data is limited from Asian countries, especially against the Delta (B.1.617.2) variant. We conducted a multicenter test-negative case-control study in patients aged 16 visiting hospitals or clinics with signs or symptoms consistent with COVID-19 from July 1 to September 30, 2021, when the Delta variant was dominant (90% of severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] infections) nationwide in Japan. Vaccine effectiveness of BNT162b2 or mRNA-1273 against symptomatic SARS-CoV-2 infections was evaluated. Waning immunity among patients aged 16 to 64 was also assessed. We enrolled 1936 patients, including 396 test-positive cases and 1540 test-negative controls for SARS-CoV-2. The median age was 49 years, 53.4% were male, and 34.0% had underlying medical conditions. Full vaccination (receiving two doses 14 days before symptom onset) was received by 6.6% of cases and 38.8% of controls. Vaccine effectiveness of full vaccination against symptomatic SARS-CoV-2 infections was 88.7% (95% confidence interval [CI], 78.8-93.9) among patients aged 16 to 64 and 90.3% (95% CI, 73.6-96.4) among patients aged 65. Among patients aged 16 to 64, vaccine effectiveness within one to three months after full vaccination was 91.8% (95% CI, 80.3-96.6), and was 86.4% (95% CI, 56.9-95.7) within four to six months. mRNA COVID-19 vaccines had high effectiveness against symptomatic SARS-CoV-2 infections in Japan during July 1 to September 30, 2021, when the Delta variant was dominant nationwide.
</td>
</tr>
<tr>
<td style="text-align:left;">
35437965
</td>
<td style="text-align:left;">
Autoimmune Hepatitis Following Vaccination for SARS-CoV-2 in Korea: Coincidence or Autoimmunity?
</td>
<td style="text-align:left;">
Journal of Korean medical science
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
18
</td>
<td style="text-align:left;">
Autoimmune hepatitis (AIH) is a chronic, autoimmune disease of the liver that occurs when the body’s immune system attacks liver cells, causing the liver to be inflamed. AIH is one of the manifestations of a coronavirus disease 2019 (COVID-19), as well as an adverse event occurring after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Few cases of AIH have been described after vaccination with two messenger RNA (mRNA)-based vaccines-BTN162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna)-against SARS-CoV-2. Herein, we report a case of AIH occurring after Pfizer-BioNTech COVID-19 vaccine. A 27-year-old female presented with jaundice and hepatomegaly, appearing 14 days after receiving the second dose of Pfizer-BioNTech vaccine. Her laboratory results showed abnormal liver function with high total immunoglobulin G level. She was diagnosed with AIH with histologic finding and successfully treated with oral prednisolone. We report an AIH case after COVID-19 vaccination in Korea.
</td>
</tr>
<tr>
<td style="text-align:left;">
35437772
</td>
<td style="text-align:left;">
Effect of BTN162b2 and Coronavac boosters on humoral and cellular immunity of individuals previously fully vaccinated with Coronavac against SARS-CoV-2: A longitudinal study.
</td>
<td style="text-align:left;">
Allergy
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
19
</td>
<td style="text-align:left;">
It is essential to know about immune response levels after booster doses of the two different types of vaccines, mRNA and the inactivated, currently used against COVID-19. For this purpose, we aimed to determine the effects of BNT162b2 (BNT) and CoronaVac (CV) boosters on the humoral and cellular immunity of individuals who had two doses of CV vaccination. The study was conducted in three centers (Koc University Hospital, Istanbul University Cerrahpasa Hospital, and Istanbul University, Istanbul Medical School Hospital) in Istanbul, Turkey. Individuals who had been previously immunized with two doses of CV and no history of COVID-19 were included. The baseline blood samples were collected three to five months after the second dose of CV. Follow-up blood samples were taken one and three months after administration of third doses of CV, or one dose of BNT boosters. Neutralizing antibody titers were measured by plaque reduction assay. The CD4+ T cell, CD8+ T cell, effector CD4+CD38+CD69+ T cell and effector CD8+CD38+CD69+ T cell ratios were determined by flow cytometry. The intracellular IFN-γ and IL-2 responses were measured by ELISpot assay. We found a 3.38-fold increase in neutralizing antibody geometric mean titers (NA GMT, 78.69) one month after BNT booster and maintained at the third month ( NA GMT, 80). Nevertheless, in the CV booster group, significantly lower NA GMT than BNT after 1 month and 3 months were observed (21.44 and 28.44, respectively) (p&amp;lt;0.001). In the ELISpot assay, IL-2 levels after BNT were higher than baseline and CV booster (p&amp;lt;0.001) while IFN-γ levels were significantly higher than baseline (P&amp;lt;0.001). The CD8+CD38+CD69+ and CD4+CD38+CD69+ T cells were stimulated predominantly in the third month of the BNT boosters. The neutralizing antibody levels after three months of the BNT booster were higher than the antibody levels after CV in fully vaccinated individuals. On the other hand, ratio of the effector T cells increased along with greater IFN-γ activation after BNT booster. By considering the waning immunity, we suggest a new booster dose with BNT for the countries that already had two doses of primary CV regimens. This article is protected by copyright. All rights reserved.
</td>
</tr>
<tr>
<td style="text-align:left;">
35437544
</td>
<td style="text-align:left;">
Emerging mRNA technologies: delivery strategies and biomedical applications.
</td>
<td style="text-align:left;">
Chemical Society reviews
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
19
</td>
<td style="text-align:left;">
The great success achieved by the two highly-effective messenger RNA (mRNA) vaccines during the COVID-19 pandemic highlights the great potential of mRNA technology. Through the evolution of mRNA technology, chemistry has played an important role from mRNA modification to the synthesis of mRNA delivery platforms, which allows various applications of mRNA to be achieved both in vitro and in vivo. In this tutorial review, we provide a summary and discussion on the significant progress of emerging mRNA technologies, as well as the underlying chemical designs and principles. Various nanoparticle (NP)-based delivery strategies including protein-mRNA complex, lipid-based carriers, polymer-based carriers, and hybrid carriers for the efficient delivery of mRNA molecules are presented. Furthermore, typical mRNA delivery platforms for various biomedical applications (e.g., functional protein expression, vaccines, cancer immunotherapy, and genome editing) are highlighted. Finally, our insights into the challenges and future development towards clinical translation of these mRNA technologies are provided.
</td>
</tr>
<tr>
<td style="text-align:left;">
35437521
</td>
<td style="text-align:left;">
Cerebral venous thrombosis after COVID-19 vaccines: Do we know the mechanism?
</td>
<td style="text-align:left;">
The Lancet regional health. Europe
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
14
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
35437511
</td>
<td style="text-align:left;">
Risk Factors Associated With Hospitalization and Death in COVID-19 Breakthrough Infections.
</td>
<td style="text-align:left;">
Open forum infectious diseases
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
May
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Characterizations of coronavirus disease 2019 (COVID-19) vaccine breakthrough infections are limited. We aim to characterize breakthrough infections and identify risk factors associated with outcomes. This was a retrospective case series of consecutive fully vaccinated patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a multicenter academic center in Southeast Michigan, between December 30, 2020, and September 15, 2021. A total of 982 patients were identified; the mean age was 57.9 years, 565 (59%) were female, 774 (79%) were White, and 255 (26%) were health care workers (HCWs). The median number of comorbidities was 2; 225 (23%) were immunocompromised. BNT162b2 was administered to 737 (75%) individuals. The mean time to SARS-CoV-2 detection was 135 days. The majority were asymptomatic or exhibited mild to moderate disease, 154 (16%) required hospitalization, 127 (13%) had severe-critical illness, and 19 (2%) died. Age (odds ratio [OR], 1.14; 95% CI, 1.04-1.07; P &amp;lt; .001), cardiovascular disease (OR, 3.02; 95% CI, 1.55-5.89; P = .001), and immunocompromised status (OR, 2.57; 95% CI, 1.70-3.90; P &amp;lt; .001) were independent risk factors for hospitalization. Additionally, age (OR, 1.06; 95% CI, 1.02-1.11; P = .006) was significantly associated with mortality. HCWs (OR, 0.15; 95% CI, 0.05-0.50; P = .002) were less likely to be hospitalized, and prior receipt of BNT162b2 was associated with lower odds of hospitalization (OR, 0.436; 95% CI, 0.303-0.626; P &amp;lt; .001) and/or death (OR, 0.360; 95% CI, 0.145-0.898; P = .029). COVID-19 vaccines remain effective at attenuating disease severity. However, patients with breakthrough infections necessitating hospitalization may benefit from early treatment modalities and COVID-19-mitigating strategies, especially in areas with substantial or high transmission rates.
</td>
</tr>
<tr>
<td style="text-align:left;">
35437478
</td>
<td style="text-align:left;">
COVID-19 in Finland: Vaccination strategy as part of the wider governing of the pandemic.
</td>
<td style="text-align:left;">
Health policy and technology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
14
</td>
<td style="text-align:left;">
: To analyse the vaccination strategy as part of wider public governing of the COVID-19 pandemic in Finland. The study provides a synthesis of vaccination strategy and health policy measures, as well as economic challenges, in the COVID-19 pandemic in Finland. The analysis is based on the systematic collection and reviewing of documents and reports. The review was complemented with relevant pandemic and vaccination monitoring data from Finland. The vaccination strategy approved by the Finnish Government in December 2020 prioritised various risk groups and health and social care professionals attending to COVID-19 patients. The Government has purchased COVID-19 vaccines through the EU joint procurement programme. Vaccinations were organised by municipalities and offered free of charge. The Government recommends universal vaccinations, including foreign residents and undocumented migrants. In 2021, the Government adopted a revised COVID-19 hybrid strategy, which aimed to dismantle wide restrictions as a means to control the epidemic. Despite high vaccination coverage, the Omicron variant became widespread in the population. The economic consequences of the pandemic have been less severe than expected. In the approach to manage the pandemic, the vaccination strategy has a central role. Finland has probably benefitted from the EU joint vaccine procurement programme. The rapid launch of the vaccinations was supported by the existing vaccination capacity in municipalities. High vaccine coverage was seen as a key in opening society. Although a relatively high vaccination rate was not able to stop the spread of Omicron in late 2021, it has efficiently curbed serious cases and kept the death rate low.
</td>
</tr>
<tr>
<td style="text-align:left;">
35437418
</td>
<td style="text-align:left;">
Clinical progress of therapeutics and vaccines: Rising hope against COVID-19 treatment.
</td>
<td style="text-align:left;">
Process biochemistry (Barking, London, England)
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
14
</td>
<td style="text-align:left;">
Cases of deaths due to COVID-19 (COrona VIrus Disease-19) infection are increasing gradually worldwide. Immense research is ongoing to control this pandemic condition. Continual research outcomes are indicating that therapeutic and prophylactic agents are the possible hope to prevent the pandemic from spreading and to combat this increasing death count. Experience gained from previous coronavirus infections (eg., SARS (Severe Acute Respiratory Syndrome), MERS (Middle Ease Respiratory Syndrome), accumulated clinical knowledge during this pandemic, and research helped to identify a few therapeutic agents for emergency treatment of COVID-19. Thereby, monoclonal antibodies, antivirals, broad-spectrum antimicrobials, immunomodulators, and supplements are being suggested for treatment depending on the stage of the disease. These recommended treatments are authorized under medical supervision in emergency conditions only. Urgent need to control the pandemic condition had resulted in various approaches of repurposing the existing drugs, However, poorly designed clinical trials and associated outcomes do not provide enough evidence to fully approve treatments against COVID-19. So far, World Health Organization (WHO) authorized three vaccines as prophylactic against SARS-CoV-2. Here, we discussed about various therapeutic agents, their clinical trials, and limitations of trials for the management of COVID-19. Further, we have also spotlighted different vaccines in research in combating COVID-19.
</td>
</tr>
<tr>
<td style="text-align:left;">
35437192
</td>
<td style="text-align:left;">
Evaluation of weekly COVID-19 vaccination and case data supports negative correlation between incidence and vaccination in German federal states and cities during 4th wave.
</td>
<td style="text-align:left;">
Vaccine
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
11
</td>
<td style="text-align:left;">
Global efforts have been made to end the COVID-19 pandemic. Among other things, various vaccines against SARS-CoV-2, partly based on novel principles, have been developed internationally within a short time. While initially the hardly available vaccines were distributed according to criteria according to defined priorities, in Germany, after the prioritization has been lifted, attempts are being made to provide as many people as possible with vaccinations. The study examines the relationship between vaccination and incidence in 16 German federal states and city states using data from the Robert Koch Institute (RKI). Clear trends became apparent, showing a negative correlation between the vaccination rate and the infection incidence. This indicates that during the 4th corona wave in Germany, the lower the incidence, the higher the vaccination rate.
</td>
</tr>
<tr>
<td style="text-align:left;">
35437149
</td>
<td style="text-align:left;">
COVID-19 Vaccines in Pancreatic Transplant Recipients: A Single-Center Observative Study.
</td>
<td style="text-align:left;">
Transplantation proceedings
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Mar
</td>
<td style="text-align:left;">
15
</td>
<td style="text-align:left;">
The SARS-CoV-2 pandemic was a real test of doctors’ abilities to adapt and respond to patients’ needs. The course of infection varied from influenza-like symptoms to severe infections with multi-organ failure and death. Therefore, the possibility of vaccination against the COVID-19 virus brought great hope. Since 2004, 240 pancreas and pancreas with kidney (simultaneous pancreas and kidney transplantation, pancreas after kidney, pancreas transplants alone) transplants were performed in our center. Currently, 130 transplant patients are under the care of the transplant clinic. All patients were informed about the possibility of vaccination against SARS-CoV-2 with the mRNA vaccine. The aim of the study was to evaluate the development of antibodies to SARS-CoV-2 in patients who had previously undergone transplantation. Fifty-three patients were vaccinated with the full double dose and 37 patients received an additional third dose. The level of antibodies in the IgM and IgG classes was assessed in patients’ serum. The level of antibodies was assessed before administration of the vaccine and then after administration of the first and second doses. Most patients had no response to vaccination after 1 dose of the vaccine and 21 patients achieved therapeutic antibody levels after the full dose of vaccination. However, the highest titer of immunoglobulins was found in recipients who received the third dose. The use of vaccinations is safe and can protect the group of patients after pancreas transplantation from serious complications of SARS-CoV-2 infection despite the use of immunosuppressive drugs.
</td>
</tr>
<tr>
<td style="text-align:left;">
35437144
</td>
<td style="text-align:left;">
Multi-omics insights into host-viral response and pathogenesis in Crimean-Congo hemorrhagic fever viruses for novel therapeutic target.
</td>
<td style="text-align:left;">
eLife
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
19
</td>
<td style="text-align:left;">
The pathogenesis and host-viral interactions of the Crimean-Congo hemorrhagic fever orthonairovirus (CCHFV) are convoluted and not well evaluated. Application of the multi-omics system biology approaches, including biological network analysis in elucidating the complex host-viral response, interrogates the viral pathogenesis. The present study aimed to fingerprint the system-level alterations during acute CCHFV-infection and the cellular immune responses during productive CCHFV-replication in vitro. We used system-wide network-based system biology analysis of peripheral blood mononuclear cells (PBMCs) from a longitudinal cohort of CCHF patients during the acute phase of infection and after one year of recovery (convalescent phase) followed by untargeted quantitative proteomics analysis of the most permissive CCHFV-infected Huh7 and SW13 cells. In the RNAseq analysis of the PBMCs, comparing the acute and convalescent-phase, we observed system-level host’s metabolic reprogramming towards central carbon and energy metabolism (CCEM) with distinct upregulation of oxidative phosphorylation (OXPHOS) during CCHFV-infection. Upon application of network-based system biology methods, negative coordination of the biological signaling systems like FOXO/Notch axis and Akt/mTOR/HIF-1 signaling with metabolic pathways during CCHFV-infection were observed. The temporal quantitative proteomics in Huh7 showed a dynamic change in the CCEM over time and concordant with the cross-sectional proteomics in SW13 cells. By blocking the two key CCEM pathways, glycolysis and glutaminolysis, viral replication was inhibited in vitro. Activation of key interferon stimulating genes during infection suggested the role of type I and II interferon-mediated antiviral mechanisms both at the system level and during progressive replication.
</td>
</tr>
<tr>
<td style="text-align:left;">
35436986
</td>
<td style="text-align:left;">
Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques.
</td>
<td style="text-align:left;">
Signal transduction and targeted therapy
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
18
</td>
<td style="text-align:left;">
Variants of concern (VOCs) like Delta and Omicron, harbor a high number of mutations, which aid these viruses in escaping a majority of known SARS-CoV-2 neutralizing antibodies (NAbs). In this study, Rhesus macaques immunized with 2-dose inactivated vaccines (Coronavac) were boosted with an additional dose of homologous vaccine or an RBD-subunit vaccine, or a bivalent inactivated vaccine (Beta and Delta) to determine the effectiveness of sequential immunization. The booster vaccination significantly enhanced the duration and levels of neutralizing antibody titers against wild-type, Beta, Delta, and Omicron. Animals administered with an indicated booster dose and subsequently challenged with Delta or Omicron variants showed markedly reduced viral loads and improved histopathological profiles compared to control animals, indicating that sequential immunization could protect primates against Omicron. These results suggest that sequential immunization of inactivated vaccines or polyvalent vaccines could be a potentially effective countermeasure against newly emerging variants.
</td>
</tr>
<tr>
<td style="text-align:left;">
35436817
</td>
<td style="text-align:left;">
To Study Adverse Effect following Immunization (AEFI) and COVID-19 Infection amongst COVID-19 Vaccine Benefeciaries.
</td>
<td style="text-align:left;">
The Journal of the Association of Physicians of India
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Feb
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
COVID-19 vaccines have been rolled out recently in several parts of the world. Little is known about the post-vaccination experience outside of clinical trial conditions. The aim of this study was to investigate the adverse effects and infection rate of vaccinated people in a community scenario. It will help to educate the public, dispel misinformation and reduce vaccine hesitancy. Assessing total beneficiaries of COVID-19 vaccination and finding among them COVID-19 infection and AEFI after vaccination. Cross sectional Study at COVID-19 Vaccination centre at DCH in Mumbai, since 1st February2021-31st July 2021, Data was collected by calling telephonically the registered beneficiaries in Vaccination Centre, data was collected and analysed in MS-excel sheet and SPSS using CHI-square test. 49.68% of the beneficiaries were from the age group of 45-60 years followed by &amp;amp;gt;60 years age group (34.70%). 97.08% beneficiaries were from Mumbai. 3593(43.59%) had taken both the doses of COVID-19 vaccine while 4650(56.41%) had taken only first dose of COVID -19 vaccine. 36(0.44%) had contracted COVID-19 infection after vaccination. 88.71% had no AEFI after taking vaccine. 1.65% had mild AEFI 9.63% had moderate AEFI. Very few had contracted COVID-19 infection after vaccination. Out of all AEFI maximum were mild to moderate.
</td>
</tr>
<tr>
<td style="text-align:left;">
35436777
</td>
<td style="text-align:left;">
COVID-19 updates: Second booster vaccine dose for older and immunocompromised persons.
</td>
<td style="text-align:left;">
The Medical letter on drugs and therapeutics
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
18
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
35436559
</td>
<td style="text-align:left;">
Temporal relationship of myocarditis and pericarditis following COVID-19 vaccination: A pragmatic approach.
</td>
<td style="text-align:left;">
International journal of cardiology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
15
</td>
<td style="text-align:left;">
Complications following COVID-19 vaccination, particularly with mRNA vaccines, rarely include myocarditis and pericarditis. This work principally aimed at defining a realistic temporal relationship between vaccination and myocarditis/pericarditis development. All relevant cases reported from week 52/2020 through week 41/2021 in the VAERS database were retrieved and analyzed for licensed vaccines. These included BNT162b2, mRNA-1273, and AD26.COV2·S. Incidence rates were calculated using the corresponding administered vaccine doses as denominators. Additionally, analyzed parameters included demographics, dose series, hospitalization length and outcome. Overall, 2016 myocarditis and 1380 pericarditis cases, (4.96/106 and 3.40/106 administered vaccine doses, respectively), were recorded. Most myocarditis cases occurred following BNT162b2 (5.60/106 doses) in males &amp;lt;30 years. Pericarditis affected predominantly males &amp;lt;40, both sexes &amp;gt;40 years, and was most common post AD26.COV2·S (4.78/106 doses). Hospitalization was required for 40.3% and 27.2% of myocarditis and pericarditis cases, respectively. A bimodal pattern was found for both myocarditis and pericarditis, with two peaks that coincided temporally, but were reversed in intensity. The first peak was recorded 1-3 days post-vaccination and was more pronounced in myocarditis, while the second was recorded 15-30 days post-vaccination and was more intense in pericarditis. Myocarditis/pericarditis after COVID-19 vaccination is rare and depicts a bimodal pattern.
</td>
</tr>
<tr>
<td style="text-align:left;">
35436552
</td>
<td style="text-align:left;">
Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs.
</td>
<td style="text-align:left;">
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
15
</td>
<td style="text-align:left;">
The mRNA SARS-CoV-2 vaccines were brought to market in response to the public health crises of Covid-19. The utilization of mRNA vaccines in the context of infectious disease has no precedent. The many alterations in the vaccine mRNA hide the mRNA from cellular defenses and promote a longer biological half-life and high production of spike protein. However, the immune response to the vaccine is very different from that to a SARS-CoV-2 infection. In this paper, we present evidence that vaccination induces a profound impairment in type I interferon signaling, which has diverse adverse consequences to human health. Immune cells that have taken up the vaccine nanoparticles release into circulation large numbers of exosomes containing spike protein along with critical microRNAs that induce a signaling response in recipient cells at distant sites. We also identify potential profound disturbances in regulatory control of protein synthesis and cancer surveillance. These disturbances potentially have a causal link to neurodegenerative disease, myocarditis, immune thrombocytopenia, Bell’s palsy, liver disease, impaired adaptive immunity, impaired DNA damage response and tumorigenesis. We show evidence from the VAERS database supporting our hypothesis. We believe a comprehensive risk/benefit assessment of the mRNA vaccines questions them as positive contributors to public health.
</td>
</tr>
<tr>
<td style="text-align:left;">
35436331
</td>
<td style="text-align:left;">
COVID-19 Vaccine Trials (and Tribulations): How to improve the process of clinical trials in a pandemic.
</td>
<td style="text-align:left;">
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
18
</td>
<td style="text-align:left;">
Vaccine clinical trials have been essential to develop effective SARS-CoV-2 vaccines. The challenges of supply chain disruptions, infection control, study designs, and participant factors that affect trial procedures are reviewed, with specific solutions to streamline the clinical trial process.
</td>
</tr>
<tr>
<td style="text-align:left;">
35436296
</td>
<td style="text-align:left;">
6 month serologic response to the Pfizer-BioNTech COVID-19 vaccine among healthcare workers.
</td>
<td style="text-align:left;">
PloS one
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Healthcare workers (HCWs) were among the first group of people vaccinated with the Pfizer-BioNTech Covid-19 vaccine (BNT162b2). Characterization of the kinetics of antibody response to vaccination is important to devise future vaccination strategies. To better characterize the antibody response to BNT162b2, we analyzed the kinetics of IgG and IgM antibody response to 5 different SARS-CoV-2 epitopes over a period of 6 months. An observational single-centered study was conducted to evaluate the temporal dynamics of anti-SARS-CoV-2 antibodies following immunization with two doses of BNT162b2. Anti-SARS-CoV-2 antibodies were assessed using the Maverick SARS-CoV-2 multi-antigen panel (Genalyte Inc.). Healthcare workers aged ≥18 receiving BNT162b2 vaccination who self-reported no prior symptoms of COVID-19 nor prior COVID-19 PCR test positivity, were included in this study. HCWs developed an IgG antibody response to SARS-CoV-2 Spike S1, Spike S1 receptor binding domain (RBD), Spike S1S2 and Spike S2 after vaccination. IgG response was observed at two weeks following immunization in most participant samples and continued to increase at week 4, but subsequently decreased significantly starting at 3 months and up to 6 months. In contrast, IgM response to respective epitopes was minimal. Multiplex results demonstrate that, contrary to natural infection, immunization with BNT162b2 produces minimal anti-Spike IgM response. Polyclonal IgG response to Spike declined at 3 months and continued to do so up to 6 months.
</td>
</tr>
<tr>
<td style="text-align:left;">
35436173
</td>
<td style="text-align:left;">
COVID-19 vaccine hesitancy: Considerations for reluctance and improving vaccine uptake.
</td>
<td style="text-align:left;">
Human vaccines &amp;amp; immunotherapeutics
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
18
</td>
<td style="text-align:left;">
The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; COVID-19) pandemic during the fall of 2019 led to the rapid development of vaccines aimed at curbing viral infection, spread, and its potential eradication. A recent trend is an overall increase in vaccine hesitancy, leading to the World Health Organization citing this as a problem which needs to be addressed. With the development and approval of vaccines for COVID-19, this trend has quickened, leading to potential negative ramifications in the ability controlling COVID-19 spread. Here we describe reported examples in overall vaccine hesitancy prior to the emergence of COVID-19, as well as summarizing recent reports on vaccine hesitancy related to COVID-19 vaccines. Gaining a better understanding of the reasons individuals have, as well as potential methods for decreasing hesitancy in the future, will hopefully lead to a greater percentage of vaccinated individuals and aid in ending the current pandemic.
</td>
</tr>
<tr>
<td style="text-align:left;">
35435973
</td>
<td style="text-align:left;">
Short-term Adverse Events After the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine in Adults 60 Years or Older.
</td>
<td style="text-align:left;">
JAMA network open
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
01
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
35435849
</td>
<td style="text-align:left;">
Cardiovascular Events After COVID-19 Vaccination: A Comment.
</td>
<td style="text-align:left;">
Anatolian journal of cardiology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
35435798
</td>
<td style="text-align:left;">
COVID-19 vaccine demand protest might have increased vaccine acceptance and uptake in South Africa.
</td>
<td style="text-align:left;">
Human vaccines &amp;amp; immunotherapeutics
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
18
</td>
<td style="text-align:left;">
Safe and efficacious COVID-19 vaccines exist, but their success against the disease depends on public willingness to receive them. Vaccine hesitancy is one major obstacle to the achievement of herd immunity. On 25 June 2021, about 2000 supporters of the Economic Freedom Fighters (EFF) (the third biggest political party in South Africa) marched to the offices of the national regulatory authority (NRA) supporting COVID-19 vaccination and demanding approval of two additional vaccines (Sputnik V and Sinovac) in South Africa. The march was led by EFF leader, Julius Malema. By then, only three COVID-19 vaccines had received emergency use authorization in the country-the Janssen, AstraZeneca and Pfizer-BioNtech vaccines. It is worth noting that NRAs should only approve a vaccine if they are satisfied that its benefits outweigh any potential risks and not through political pressure. Nevertheless, we believe that this march might have increased COVID-19 vaccine acceptance and uptake among EFF supporters. The endorsement of COVID-19 vaccines by Malema, an influential political figure in South Africa, probably convinced some vaccine hesitant South Africans that COVID-19 vaccination is important. Therefore, we suggest vaccine endorsement by influential individuals in South Africa as one of the strategies to increase COVID-19 vaccine uptake.
</td>
</tr>
<tr>
<td style="text-align:left;">
35435622
</td>
<td style="text-align:left;">
A de novo case of minimal change disease following the first dose of the Moderna mRNA-1273 SARS-CoV-2 vaccine without relapse after the second dose.
</td>
<td style="text-align:left;">
CEN case reports
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
18
</td>
<td style="text-align:left;">
In recent times, new onset or relapse of nephrotic syndrome following the first dose of SARS-CoV-2 vaccines has been reported. Although the vaccination could trigger nephrotic syndrome, the question of whether the same vaccine should be administered as the second dose remains unanswered. A 25-year-old woman had taken the Moderna mRNA-1273 SARS-CoV-2 vaccine (mRNA-1273) and 26 days later, she noticed facial and peripheral edema. One week later she was referred and admitted to our hospital, wherein laboratory tests revealed that her serum creatinine level, serum albumin level, and urine protein-creatinine ratio were respectively 0.79 mg/dL, 2.5 g/dL, and 7.0 g/gCr. After a thorough inpatient examination including renal biopsy, she was diagnosed with minimal change disease (MCD) and treatment with steroids was initiated. She achieved complete remission the next day and did not experience a relapse upon receiving the second mRNA-1273 dose 56 days after the first, under treatment with 35 mg/day of oral prednisolone. This case report yields insight into determining whether patients who develop de novo MCD after the first mRNA-1273 dose should receive the second dose.
</td>
</tr>
<tr>
<td style="text-align:left;">
35434988
</td>
<td style="text-align:left;">
Coronavirus disease 2019 vaccination in patients with psoriasis: A position statement from India by SIG psoriasis (IADVL Academy).
</td>
<td style="text-align:left;">
Indian journal of dermatology, venereology and leprology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Jan
</td>
<td style="text-align:left;">
21
</td>
<td style="text-align:left;">
Coronavirus disease 2019 (COVID-19) pandemic has affected every sphere of life including management of psoriasis. The availability of COVID-19 vaccines has given rise to hope and at the same time some apprehensions as well. With the general population becoming eligible for vaccination, there is some confusion, on the eligibility of patients with different medical conditions and patients on immunosuppressive or immunomodulating medications for COVID-19 vaccination. Dermatologists treating psoriasis patients frequently face questions from them, whether they can undergo coronavirus disease 2019 vaccination. A PUBMED search was performed using the following strategy: ‘COVID-19’ AND ‘Vaccine’ AND ‘Psoriasis’. We also performed a PUBMED search using the following strategy: ‘SARS-CoV-2’ AND ‘Vaccine’ AND ‘Psoriasis’. All articles irrespective of language and publication date were included to arrive at this position statement. This position statement deals with the safety, eligibility and modifications of treatment, if needed among psoriasis patients with regards to the coronavirus disease 2019 vaccines currently available in India.
</td>
</tr>
<tr>
<td style="text-align:left;">
35434827
</td>
<td style="text-align:left;">
COVID-19 transmission among vaccinated laboratory workers during the second wave in eastern Uttar Pradesh, India.
</td>
<td style="text-align:left;">
Journal of medical virology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
17
</td>
<td style="text-align:left;">
We read with interest the article by Kaur et al., 2022. The authors have reported high rate (27%) of SARS-CoV2 infections among ChAdOx1 nCoV-19 (AZD1222/Covishield) vaccinated participants (healthcare workers and elderly non-healthcare general public). Based on findings, we would like to share our experience at Indian Council of Medical Research-Regional Medical Research Centre (ICMR-RMRC), Gorakhpur (ICMR recognised nodal centre for COVID-19 diagnosis in eastern Uttar Pradesh) situated at Gorakhpur, a city near Varanasi in Uttar Pradesh, India during the same timeline (April 2021). This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
</td>
</tr>
<tr>
<td style="text-align:left;">
35434826
</td>
<td style="text-align:left;">
Erythema nodosum induced by Covid-19 Pfizer-BioNTech mRNA Vaccine: A case report and brief literature review.
</td>
<td style="text-align:left;">
British journal of clinical pharmacology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
17
</td>
<td style="text-align:left;">
Erythema nodosum (EN), the most form of panniculitis, is a reactive inflammation of the subcutaneous fat clinically presented with a sudden onset of painful, erythematous, nodular, subcutaneous lesions, typically localized to the pretibial area. EN is commonly caused by numerous infective (especially Beta-hemolytic streptococcal infections), autoimmune diseases (sarcoidosis), inflammatory bowel disease and drugs. EN induced by Covid-19 vaccines is rarely reported. We describe an original clinical observation of a 75 year-old woman who presented with erythema nodosum after receiving the second dose of BNT162b2, an mRNA vaccine. This article is protected by copyright. All rights reserved.
</td>
</tr>
<tr>
<td style="text-align:left;">
35434713
</td>
<td style="text-align:left;">
Antigenicity comparison of SARS-CoV-2 Omicron sublineages with other variants contained multiple mutations in RBD.
</td>
<td style="text-align:left;">
MedComm
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Jun
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, particularly those with multiple mutations in receptor-binding domain (RBD), pose a critical challenge to the efficacy of coronavirus disease 2019 (COVID-19) vaccines and therapeutic neutralizing monoclonal antibodies (mAbs). Omicron sublineages BA.1, BA.2, BA.3, as well as the recent emergence of C.1.2, B.1.630, B.1.640.1, and B.1.640.2, have multiple mutations in RBD and may lead to severe neutralizing antibody evasion. It is urgent to evaluate the antigenic change of the above seven variants against mAbs and sera from guinea pigs immunized with variants of concern (VOCs) (Alpha, Beta, Gamma, Delta, Omicron) and variants of interest (VOIs) (Lambda, Mu) immunogens. Only seven out of the 24 mAbs showed no reduction in neutralizing activity against BA.1, BA.2, and BA.3. However, among these seven mAbs, the neutralization activity of XGv337 and XGv338 against C.1.2, B.1.630, B.1.640.1, and B.1.640.2 were decreased. Therefore, only five neutralizing mAbs showed no significant change against these seven variants. Using VOCs and VOIs as immunogens, we found that the antigenicity of variants could be divided into three clusters, and each cluster showed similar antigenicity to different immunogens. Among them, D614G, B.1.640.1, and B.1.630 formed a cluster, C.1.2 and B.1.640.2 formed a cluster, and BA.1, BA.2, and BA.3 formed a cluster.
</td>
</tr>
<tr>
<td style="text-align:left;">
35434685
</td>
<td style="text-align:left;">
Dosing interval strategies for two-dose COVID-19 vaccination in 13 middle-income countries of Europe: Health impact modelling and benefit-risk analysis.
</td>
<td style="text-align:left;">
The Lancet regional health. Europe
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
11
</td>
<td style="text-align:left;">
In settings where the COVID-19 vaccine supply is constrained, extending the intervals between the first and second doses of the COVID-19 vaccine may allow more people receive their first doses earlier. Our aim is to estimate the health impact of COVID-19 vaccination alongside benefit-risk assessment of different dosing intervals in 13 middle-income countries (MICs) of Europe. We fitted a dynamic transmission model to country-level daily reported COVID-19 mortality in 13 MICs in Europe (Albania, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Bulgaria, Georgia, Republic of Moldova, Russian Federation, Serbia, North Macedonia, Turkey, and Ukraine). A vaccine product with characteristics similar to those of the Oxford/AstraZeneca COVID-19 (AZD1222) vaccine was used in the base case scenario and was complemented by sensitivity analyses around efficacies similar to other COVID-19 vaccines. Both fixed dosing intervals at 4, 8, 12, 16, and 20 weeks and dose-specific intervals that prioritise specific doses for certain age groups were tested. Optimal intervals minimise COVID-19 mortality between March 2021 and December 2022. We incorporated the emergence of variants of concern (VOCs) into the model and conducted a benefit-risk assessment to quantify the tradeoff between health benefits versus adverse events following immunisation. In all countries modelled, optimal strategies are those that prioritise the first doses among older adults (60+ years) or adults (20+ years), which lead to dosing intervals longer than six months. In comparison, a four-week fixed dosing interval may incur 10.1% [range: 4.3% - 19.0%; n = 13 (countries)] more deaths. The rapid waning of the immunity induced by the first dose (i.e. with means ranging 60-120 days as opposed to 360 days in the base case) resulted in shorter optimal dosing intervals of 8-20 weeks. Benefit-risk ratios were the highest for fixed dosing intervals of 8-12 weeks. We infer that longer dosing intervals of over six months could reduce COVID-19 mortality in MICs of Europe. Certain parameters, such as rapid waning of first-dose induced immunity and increased immune escape through the emergence of VOCs, could significantly shorten the optimal dosing intervals. World Health Organization.
</td>
</tr>
<tr>
<td style="text-align:left;">
35434597
</td>
<td style="text-align:left;">
Risk Prediction for Acute Kidney Injury in Patients Hospitalized With COVID-19.
</td>
<td style="text-align:left;">
Kidney medicine
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
08
</td>
<td style="text-align:left;">
mp; Objective” Acute kidney injury (AKI) is common in patients hospitalized with COVID-19, but validated, predictive models for AKI are lacking. We aimed to develop the best predictive model for AKI in hospitalized patients with COVID-19 and assess its performance over time with the emergence of vaccines and the delta variant. Longitudinal cohort study. mp; Participants” Hospitalized patients with a positive SARS CoV-2 PCR between 3/1/2020 and 8/20/2021 at 19 Texas hospitals. Comorbidities, baseline laboratory data, inflammatory biomarkers. AKI defined by KDIGO creatinine criteria. Three nested models for AKI were built in a development cohort and validated in two out-of-time cohorts. Model discrimination and calibration measures were compared among cohorts to assess performance over time. Of 10,034 patients, 5,676, 2,917, and 1,441 were in the development, validation 1, and validation 2 cohorts, of whom 776 (13.7%), 368 (12.6%), and 179 (12.4%) developed AKI (P=0.33). Patients in validation 2 had fewer comorbidities and were younger than the development or validation 1 cohorts (mean age, 54±16.8 years vs. 61.4±17.5 and 61.7±17.3 years, respectively, P&amp;lt;0.001). Validation 2 had higher median hsCRP, 81.7 mg/L, vs. development cohort, 74.5 mg/L (P&amp;lt;0.01), and higher median ferritin, 696 ng/mL, vs. both development, 444 ng/mL, and validation 1, 496 ng/mL, (P&amp;lt;0.001). The final model, which added hsCRP, ferritin, and D-dimer, had AUC=0.781 (95% CI, 0.763, 0.799). Compared to the development cohort, discrimination by AUC (validation 1: 0.785 [0.760, 0.810], P=0.79, and validation 2: 0.754 [0.716, 0.795], P=0.47) and calibration by ECI (validation 1: 0.116 [0.041, 0.281], P=0.11, and validation 2: 0.081 [0.045, 0.295], P=0.11) showed stable performance over time. Potential billing and coding bias. We developed and externally validated a model to accurately predict AKI in patients with COVID-19. Performance withstood changes in practice patterns and virus variants.
</td>
</tr>
<tr>
<td style="text-align:left;">
35434422
</td>
<td style="text-align:left;">
Attitude, perceptions and willingness to receive COVID-19 vaccine and its associated factors among general population of Uttar Pradesh, Northern India.
</td>
<td style="text-align:left;">
Clinical epidemiology and global health
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
08
</td>
<td style="text-align:left;">
Several vaccines have been developed and tested against COVID-19 around the globe. Vaccine hesitancy and misinformation poses major challenges to the achievement of coverage and population immunity. Understanding key determinants that influence the preferences and demands of a COVID-19 vaccine by the community may help to develop strategies for improving coverage. To assess willingness to receive coronavirus disease 2019 (COVID-19) vaccine and identify the factors associated with it among the general population of Uttar Pradesh, North India. A web-based cross sectional study was conducted in the month of May 2021 among the unvaccinated general adult population of Uttar Pradesh, Northern India adopting an exponential, non-discriminative snowball sampling technique. A bilingual, self-administered anonymous semi-structured questionnaire in google form was designed and sent to the study participants through social media platform, WhatsApp. Data collected were extracted into excel sheets and was analyzed using SPSS software, version 21.0. Bivariate analysis was performed to identify the key determinants for vaccine acceptance among the participants. Out of 254 participants completing the questionnaire, 219 (86.2%) showed willingness to receive a COVID-19 vaccine, whereas 10 (4.0%) admitted hesitancy and 25 (9.8%) were not sure. Younger age-group (18-44 years), female gender, absence of any co-morbidity, lower education level, current employment status, positive history of confirmed COVID-19 infection in the person and positive history of confirmed COVID-19 infection in any family member/friend were the factors found to be significantly associated with the willingness to receive a COVID-19 vaccine. During the second wave of COVID-19 pandemic in India, high acceptance for COVID-19 vaccination was found among the general population of Uttar Pradesh, whereas concerns about vaccine safety may hinder the actual vaccine uptake.
</td>
</tr>
<tr>
<td style="text-align:left;">
35433614
</td>
<td style="text-align:left;">
Cellular and Humoral Immune Responses and Breakthrough Infections After Two Doses of BNT162b Vaccine in Healthcare Workers (HW) 180 Days After the Second Vaccine Dose.
</td>
<td style="text-align:left;">
Frontiers in public health
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Immunity and clinical protection induced by mRNA vaccines against SARS-CoV-2 have been shown to decline overtime. To gather information on the immunity profile deemed sufficient in protecting against hospitalization, we tested IgG levels, interferon-gamma (IFN-γ) secretion, and neutralizing antibodies 180 days (d180) after the second shot of BNT162b vaccine, in HW. A total of 392 subjects were enrolled. All received BioNTech/Pfizer from February 2020 to April 2021. The vaccine-specific humoral response was quantitatively determined by testing for IgG anti-S1 domain of SARS-CoV-spike protein. Live virus microneutralization (MN) was evaluated by an assay performing incubation of serial 2-fold dilution of human serum samples, starting from 1:10 to 1:5120, with an equal volume of Wuhan strain and Delta VOC viral solution and assessing the presence/absence of a cytopathic effect. SARS-CoV-2-spike protein-specific T-cell response was determined by a commercial IFN-γ release assay. In 352 individuals, at d180, IgG levels decreased substantially but no results below the assay’s positivity threshold were observed. Overall, 22 naive (8.1%) had values above the highest threshold. Among COVID-naive, the impact of age, which was observed at earlier stages, disappeared at d180, while it remained significant for 81 who had experienced a previous infection. Following the predictive model of protection by Khoury, we transformed the neutralizing titers in IU/ml and used a 54 IU/ml threshold to identify subjects with 50% protective immunity. Overall, live virus MN showed almost all subjects with previous exposure to SARS-CoV-2 neutralized the virus as compared to 33% of naive double-dosed subjects (p &amp;lt; 0.0001). All previously exposed subjects had strong IFN-γ secretion (&amp;gt;200 mIU/ml); among 271 naive, 7 (2.58%) and 17 (6.27%) subjects did not show borderline or strong secretion, respectively. In naive subjects, low IgG titers are relatively long-lasting. Only a third of naive subjects maintain neutralizing responses. After specific stimulation, a very limited number of naive were unable to produce IFN-γ. The results attained in the small group of subjects with breakthrough infection suggest that simultaneous neutralizing antibody titers &amp;lt;20, binding antibody levels/ml &amp;lt;200, and IFN-γ &amp;lt;1,000 mIU/ml in subjects older than 58 may identify at-risk groups.
</td>
</tr>
<tr>
<td style="text-align:left;">
35433579
</td>
<td style="text-align:left;">
Parents’ Hesitancy to Vaccinate Their 5-11-Year-Old Children Against COVID-19 in Saudi Arabia: Predictors From the Health Belief Model.
</td>
<td style="text-align:left;">
Frontiers in public health
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Data exploring parents’ hesitancy to vaccinate their 5-11-year-old children against COVID-19, and associated factors, is limited. This study aims to investigate parents’ beliefs and intentions to vaccinate their 5-11-year-old children using the Health Belief Model in Saudi Arabia. A national, cross-sectional, questionnaire-based study was conducted in November, 2021. The self-administered online questionnaire was distributed to a random sample of parents. Adult parents with at least one 5-11-year-old child were included. The main outcome was parents’ intention to vaccinate their 5-11-year-old children. Variability in parents’ intention was assessed by demographics, COVID-19-related factors, children’s health status, and constructs from the Health Belief Model. Univariate and multivariable logistic regression were used to investigate each factor and adjust for the intervariable effect on parental intention to vaccinate their children. Of the 4,135 participants, 61.9% were hesitant to vaccinate their 5-11-year-old children. Parents aged 31 to 40 years (OR = 1.23; 95% CI, 1.02-1.49) and females (OR = 1.52; 95% CI, 1.25-1.84) had higher odds of being hesitant to vaccinate their children than parents from other groups. Parents who perceived low benefit from the vaccine (OR = 16.3; 95% CI, 12.1-21.9) or who had safety or efficacy concerns (OR = 3.76; 95% CI, 3.10-4.58) were among the most hesitant to vaccinate their children. In conclusion, vaccine hesitancy is prevalent among parents of 5-11-year-old children in Saudi Arabia and those who had beliefs of minimal benefits or lack of safety from the COVID-19 vaccine were more hesitant. Government efforts must be directed toward increasing parents’ vaccine awareness and tackling the constructs of the Health Belief Model through a well-designed vaccination campaign.
</td>
</tr>
<tr>
<td style="text-align:left;">
35433495
</td>
<td style="text-align:left;">
Role of the Microbiome in the Pathogenesis of COVID-19.
</td>
<td style="text-align:left;">
Frontiers in cellular and infection microbiology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
The ongoing pandemic coronavirus disease COVID-19 is caused by the highly contagious single-stranded RNA virus, SARS-coronavirus 2 (SARS-CoV-2), which has a high rate of evolution like other RNA viruses. The first genome sequences of SARS-CoV-2 were available in early 2020. Subsequent whole-genome sequencing revealed that the virus had accumulated several mutations in genes associated with viral replication and pathogenesis. These variants showed enhanced transmissibility and infectivity. Soon after the first outbreak due to the wild-type strain in December 2019, a genetic variant D614G emerged in late January to early February 2020 and became the dominant genotype worldwide. Thereafter, several variants emerged, which were found to harbor mutations in essential viral genes encoding proteins that could act as drug and vaccine targets. Numerous vaccines have been successfully developed to assuage the burden of COVID-19. These have different rates of efficacy, including, although rarely, a number of vaccinated individuals exhibiting side effects like thrombosis. However, the recent emergence of the Britain strain with 70% more transmissibility and South African variants with higher resistance to vaccines at a time when several countries have approved these for mass immunization has raised tremendous concern regarding the long-lasting impact of currently available prophylaxis. Apart from studies addressing the pathophysiology, pathogenesis, and therapeutic targets of SARS-CoV-2, analysis of the gut, oral, nasopharyngeal, and lung microbiome dysbiosis has also been undertaken to find a link between the microbiome and the pathogenesis of COVID-19. Therefore, in the current scenario of skepticism regarding vaccine efficacy and challenges over the direct effects of currently available drugs looming large, investigation of alternative therapeutic avenues based on the microbiome can be a rewarding finding. This review presents the currently available understanding of microbiome dysbiosis and its association with cause and consequence of COVID-19. Taking cues from other inflammatory diseases, we propose a hypothesis of how the microbiome may be influencing homeostasis, pro-inflammatory condition, and the onset of inflammation. This accentuates the importance of a healthy microbiome as a protective element to prevent the onset of COVID-19. Finally, the review attempts to identify areas where the application of microbiome research can help in reducing the burden of the disease.
</td>
</tr>
<tr>
<td style="text-align:left;">
35433241
</td>
<td style="text-align:left;">
COVID-19 AND COUNTERFEIT VACCINES: GLOBAL IMPLICATIONS, NEW CHALLENGES AND OPPORTUNITIES.
</td>
<td style="text-align:left;">
Health policy and technology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
10
</td>
<td style="text-align:left;">
This research note (RN) examines the drivers and consequences of proliferation of counterfeit (substandard and falsified) COVID-19 vaccines. An integrated framework was advanced which sheds light on the domestic contributory factors such a desperation by citizens to “return to normalcy”, institutional impediments, minimum standards of enforcement of laws related to intellectual property rights and lack of access to vaccines in tandem with international environmental drivers such as the growth of online pharmacies, international market intermediaries and vaccine nationalism. Consequently, counterfeit COVID-19 vaccines appear to serve as a disincentive to innovation and investment in research and development activities. The analysis highlights health-related consequences including providing a false sense of security against a dangerous virus and potentially loss of confidence in reliable medicines. This analysis led to the generation of some vital socio-economic implications for public policy and enterprises, which are discussed.
</td>
</tr>
<tr>
<td style="text-align:left;">
35432993
</td>
<td style="text-align:left;">
Implications of COVID-19 vaccine boosters amid the emergence of novel variants of SARS-CoV-2.
</td>
<td style="text-align:left;">
Annals of medicine and surgery (2012)
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
May
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
35432364
</td>
<td style="text-align:left;">
Combined Subcutaneous-Intranasal Immunization With Epitope-Based Antigens Elicits Binding and Neutralizing Antibody Responses in Serum and Mucosae Against PRRSV-2 and SARS-CoV-2.
</td>
<td style="text-align:left;">
Frontiers in immunology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
New vaccine design approaches, platforms, and immunization strategies might foster antiviral mucosal effector and memory responses to reduce asymptomatic infection and transmission in vaccinated individuals. Here, we investigated a combined parenteral and mucosal immunization scheme to induce local and serum antibody responses, employing the epitope-based antigens 3BT and NG19m. These antigens target the important emerging and re-emerging viruses PRRSV-2 and SARS-CoV-2, respectively. We assessed two versions of the 3BT protein, which contains conserved epitopes from the GP5 envelope protein of PRRSV-2: soluble and expressed by the recombinant baculovirus BacDual-3BT. On the other hand, NG19m, comprising the receptor-binding motif of the S protein of SARS-CoV-2, was evaluated as a soluble recombinant protein only. Vietnamese mini-pigs were immunized employing different inoculation routes: subcutaneous, intranasal, or a combination of both (s.c.-i.n.). Animals produced antigen-binding and neut1ralizing antibodies in serum and mucosal fluids, with varying patterns of concentration and activity, depending on the antigen and the immunization schedule. Soluble 3BT was a potent immunogen to elicit binding and neutralizing antibodies in serum, nasal mucus, and vaginal swabs. The vectored immunogen BacDual-3BT induced binding antibodies in serum and mucosae, but PRRSV-2 neutralizing activity was found in nasal mucus exclusively when administered intranasally. NG19m promoted serum and mucosal binding antibodies, which showed differing neutralizing activity. Only serum samples from subcutaneously immunized animals inhibited RBD-ACE2 interaction, while mini-pigs inoculated intranasally or via the combined s.c.-i.n. scheme produced subtle neutralizing humoral responses in the upper and lower respiratory mucosae. Our results show that intranasal immunization, alone or combined with subcutaneous delivery of epitope-based antigens, generates local and systemic binding and neutralizing antibodies. Further investigation is needed to evaluate the capability of the induced responses to prevent infection and reduce transmission.
</td>
</tr>
<tr>
<td style="text-align:left;">
35432335
</td>
<td style="text-align:left;">
Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.
</td>
<td style="text-align:left;">
Frontiers in immunology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Immunomodulatory/immunosuppressive activity of multiple sclerosis (MS) disease modifying therapies (DMTs) might affect immune responses to SARS-CoV-2 exposure or vaccination in patients with MS (PwMS). We evaluated the effect of DMTs on humoral and cell-mediated immune responses to 2 and 3 vaccinations and the longevity of SARS-Cov-2 IgG levels in PwMS. 522 PwMS and 68 healthy controls vaccinated with BNT162b2-Pfizer mRNA vaccine against SARS-CoV-2, or recovering from COVID-19, were recruited in a nation-wide multi-center study. Blood was collected at 3 time-points: 2-16 weeks and ~6 months post 2nd vaccination and 1-16 weeks following 3rd vaccination. Serological responses were measured by quantifying IgG levels against the spike-receptor-binding-domain of SARS-CoV-2, and cellular responses (in a subgroup analysis) by quantifying IFNγ secretion in blood incubated with COVID-19 spike-antigen. 75% PwMS were seropositive post 2nd or 3rd vaccination. IgG levels decreased by 82% within 6 months from vaccination (p&amp;lt;0.0001), but were boosted 10.3 fold by the 3rd vaccination (p&amp;lt;0.0001), and 1.8 fold compared to ≤3m post 2nd vaccination (p=0.025). Patients treated with most DMTs were seropositive post 2nd and 3rd vaccinations, however only 38% and 44% of ocrelizumab-treated patients and 54% and 46% of fingolimod-treated patients, respectively, were seropositive. Similarly, in COVID-19-recovered patients only 54% of ocrelizumab-treated, 75% of fingolimod-treated and 67% of cladribine-treated patients were seropositive. A time interval of ≥5 months between ocrelizumab infusion and vaccination was associated with higher IgG levels (p=0.039 post-2nd vaccination; p=0.036 post-3rd vaccination), and with higher proportions of seropositive patients. Most fingolimod- and ocrelizumab-treated patients responded similarly to 2nd and 3rd vaccination. IFNγ-T-cell responses were detected in 89% and 63% of PwMS post 2nd and 3rd vaccination, however in only 25% and 0% of fingolimod-treated patients, while in 100% and 86% of ocrelizumab-treated patients, respectively. PwMS treated with most DMTs developed humoral and T-cell responses following 2 and 3 mRNA SARS-CoV-2 vaccinations. Fingolimod- or ocrelizumab-treated patients had diminished humoral responses, and fingolimod compromised the cellular responses, with no improvement after a 3rd booster. Vaccination following &amp;gt;5 months since ocrelizumab infusion was associated with better sero-positivity. These findings may contribute to the development of treatment-stratified vaccination guidelines for PwMS.
</td>
</tr>
<tr>
<td style="text-align:left;">
35432316
</td>
<td style="text-align:left;">
Computer-Based Immunoinformatic Analysis to Predict Candidate T-Cell Epitopes for SARS-CoV-2 Vaccine Design.
</td>
<td style="text-align:left;">
Frontiers in immunology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Since the first outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019, its high infectivity led to its prevalence around the world in an exceptionally short time. Efforts have been made to control the ongoing outbreak, and among them, vaccine developments are going on high priority. New clinical trials add to growing evidence that vaccines from many countries were highly effective at preventing SARS-CoV-2 virus infection. One of them is B cell-based vaccines, which were common during a pandemic. However, neutralizing antibody therapy becomes less effective when viruses mutate. In order to tackle the problem, we focused on T-cell immune mechanism. In this study, the mutated strains of the virus were selected globally from India (B.1.617.1 and B.1.617.2), United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1), and the overlapping peptides were collected based on mutation sites of S-protein. After that, residue scanning was used to predict the affinity between overlapping peptide and HLA-A*11:01, the most frequent human leukocyte antigen (HLA) allele among the Chinese population. Then, the binding free energy was evaluated with molecular docking to further verify the affinity changes after the mutations happen in the virus genomes. The affinity test results of three epitopes on spike protein from experimental validation were consistent with our predicted results, thereby supporting the inclusion of the epitope 374FSTFKCYGL382 in future vaccine design and providing a useful reference route to improve vaccine development.
</td>
</tr>
<tr>
<td style="text-align:left;">
35432314
</td>
<td style="text-align:left;">
Humoral and Cellular Immunogenicity and Safety of Five Different SARS-CoV-2 Vaccines in Patients With Autoimmune Rheumatic and Musculoskeletal Diseases in Remission or With Low Disease Activity and in Healthy Controls: A Single Center Study.
</td>
<td style="text-align:left;">
Frontiers in immunology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Vaccine-induced immunity is essential for controlling the COVID-19 pandemic. Data on humoral and cellular immunogenicity and safety of different SARS-CoV-2 vaccines in patients with autoimmune rheumatic and musculoskeletal diseases (RMDs) are limited. A single center observational study evaluated the immunogenicity and safety of the two-dose regimen of the BBIBP-CorV inactivated, Gam-COVID-Vac and AZD1222 adenovirus-based, and BNT162b2 and mRNA-1273 mRNA-based vaccines in patients with RMDs (n = 89) compared with healthy controls (n = 74). Neutralizing anti-RBD (receptor binding domain) specific antibodies and SARS-CoV-2 specific T-cell response were measured one and four months after the second vaccine dose in parallel with vaccination efficacy and safety. Disease-specific comparison showed that antibody response at four months was higher in spondylarthropathies compared to rheumatoid arthritis and autoimmune RMDs. Risk factors for reduced immunogenicity included longer disease duration, positive immunoserological profile and anti-CD20 therapy of patients. The rate of positive anti-RBD antibody response for healthy controls versus patients after 4 months post vaccination was 69% vs. 55% for the inactivated viral vaccine BBIBP-CorV, 97% vs. 53% for the pooled data of adenovirus vector-based vaccines Gam-COVID-Vac and AZD1222, or 100% vs. 81% for the pooled data of mRNA vaccines BNT162b2 and mRNA-1273, respectively. Patients who received the Gam-COVID-Vac or mRNA-1273 vaccines had a higher proportion of TNF-α producing CD4+ T-cells upon SARS-CoV-2 antigen stimulation compared to the inactivated viral vaccine. All five investigated vaccines were immunogenic in the majority of patients and healthy controls with variable antibody and T-cell response and an acceptable safety profile.
</td>
</tr>
<tr>
<td style="text-align:left;">
35431989
</td>
<td style="text-align:left;">
Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Pregnancy. A Non-systematic Review of Clinical Presentation, Potential Effects of Physiological Adaptations in Pregnancy, and Placental Vascular Alterations.
</td>
<td style="text-align:left;">
Frontiers in physiology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
In December 2019, the novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) rapidly spread to become a pandemic. To date, increasing evidence has described the potential negative impact of SARS-CoV-2 infection on pregnant women. Although the pathophysiology of coronavirus disease 2019 (COVID-19) is not entirely understood, there is emerging evidence that it causes a severe systemic inflammatory response associated with vascular alterations that could be of special interest considering some physiological changes in pregnancy. Additionally, these alterations may affect the physiology of the placenta and are associated with pregnancy complications and abnormal histologic findings. On the other hand, data about the vaccine against SARS-CoV-2 are limited, but the risks of administering COVID-19 vaccines during pregnancy appear to be minimal. This review summarizes the current literature on SARSCoV2 virus infection, the development of COVID-19 and its relationship with physiological changes, and angiotensin-converting enzyme 2 (ACE2) function during pregnancy. We have particularly emphasized evidence coming from Latin American countries.
</td>
</tr>
<tr>
<td style="text-align:left;">
35431762
</td>
<td style="text-align:left;">
Impact of the COVID-19 Pandemic on Human Papillomavirus Vaccination in Brazil.
</td>
<td style="text-align:left;">
International journal of public health
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Objective: To analyze the number of applied HPV vaccine doses before (from April 2019 to March 2020) and after (from April 2020 to September 2020) social distancing measures in response to the COVID-19 pandemic in states and regions of Brazil. Methods: Ecological time-series study, using data from the Brazilian National Immunization Program (PNI). Using the Mann-Whitney test, we evaluated the difference between the median number of applied doses during the periods April 2019 to March 2020 and from April 2020 to September 2020. Spatial analysis identified clusters with a high or low percentage reduction in the median applied doses. Prais-Winsten regression models identified temporal trends in the applieddoses from both periods. Results: There was a significant reduction in the median HPV vaccine doses applied, formation of spatial clusters and, after a sharp drop in the number of applieddoses during the months following social distancing. There was a tendency to increase the applied vaccines doses. Conclusion: The COVID-19 pandemic resulted in reduction of the number of HPV vaccine doses applied as a possible effect of restrictive measures caused by the pandemic.
</td>
</tr>
<tr>
<td style="text-align:left;">
35431536
</td>
<td style="text-align:left;">
Could anakinra outmatch dexamethasone/tocilizumab in COVID-19?
</td>
<td style="text-align:left;">
Bulletin of the National Research Centre
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
The hyperinflammatory state leading to an aberrant cytokine production, culminating in acute respiratory distress syndrome, sepsis and multi-organ dysfunction contribute much to the pathophysiologies of severe COVID-19. These severe patients have similar clinical manifestations with patients suffering from certain auto-inflammatory disorders and cytokine storm syndromes. Interestingly, anakinra (blocking both IL-1α and IL-1β) has shown promises in treating these patients with hyperinflammatory disorders, sepsis with multiorgan failures. Another inflammasome, AIM2, involved in production of IL-1 has also been found to be implicated in COVID-19. IL-1β, a known procoagulant, causes induction of tissue factor with increasing vascular endothelial permeability loss ensuing in hypercoagulability-one of the cardinal features of the disease. Hence, anakinra a 17kD recombinant human IL-1 receptor antagonist, used widely in Rheumatoid Arthritis treatments might prove efficacious in attenuating the hyperinflammatory state of the disease. Indeed, some of the controlled clinical trials have shown anakinra to effectively decrease mortality and hospital stay. Targeted cytokine blocking are always preferable in comparison with non-specific blocking (steroids) as it is more restrained with the chances of dampening of systemic immune system being much less. Early cell death and neutrophil migration have been one of the pivotal events in COVID-19 pathogenesis. Hence, suPAR levels which measures IL-1α (necroptosis) and S100A8/A9 (neutrophil migration) can perhaps be a good early biomarker predicting the disease progression. Lastly and importantly, as the vaccines are raised against spike protein and the different variants of concern are known to evade the neutralizing antibodies by varying degrees, it will be deserving to assess anakinra, against the variants of concern as an immunomodulatory drug.
</td>
</tr>
<tr>
<td style="text-align:left;">
35431535
</td>
<td style="text-align:left;">
COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants.
</td>
<td style="text-align:left;">
Bulletin of the National Research Centre
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
The world has been suffering from the COVID-19 pandemic (officially declared by WHO in March 2020), caused by the severe acute respiratory β-coronavirus 2 (SARS-CoV-2) since the last week of December 2019. The disease was initially designated as a Public Health Emergency of International Concern on January 30, 2020. In order to protect the health of mass public, an array of research on drugs and vaccines against SARS-CoV-2 has been conducted globally. However, the emerging variants of SARS-CoV-2, i.e., Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2) variants which evolved in late 2020 and the Omicron variant (B.1.1.529) which emerged in November 2021 along with its subvariant BA.2 which was first identified in India and South Africa in late December 2021, have raised the doubt about the efficiency of the currently used vaccines especially in terms of the consistent potential to produce neutralizing antibodies targeting the viral spike (S) protein. The present review discussed the functional details of major vaccines regarding their efficiency against such variants during the pandemic. Overall, the mRNA vaccines have shown around 94% effectiveness; the adenovector vaccine showed approximately 70% efficacy, whereas Sputnik V vaccines showed around 92% effectiveness; the inactivated whole-virus vaccine CoronaVac/PiCoVacc and BBIBP-CorV showed a varying effectiveness of 65-86% according to the geographic locations; the subunit vaccine NVX-CoV2373 has shown 60-89% effectiveness along with the global regions against the wild-type SARS-CoV-2 strain. However, reduced effectiveness of these vaccines against the SARS-CoV-2 variants was noticed which is suggestive for the further administration of booster dose. Maximum variants of SARS-CoV-2 emerged during the second wave of COVID-19; and extensive studies on the viral genomic sequences from all geographical locations around the world have been conducted by an array of groups to assess the possible occurrence of mutations(s) specially within the receptor binding domain of the viral spike (S) protein. Mutational similarities and the new or critical mutations within all variants have been clearly identified so far. The study of effectiveness of the currently used vaccines is also ongoing. The persistence of memory B cell action and the other immune components as well as the administration of booster dose is expected to mitigate the disease.
</td>
</tr>
<tr>
<td style="text-align:left;">
35431534
</td>
<td style="text-align:left;">
Delayed adverse reaction to a natural dermal filler mimicking salivary gland neoplasia.
</td>
<td style="text-align:left;">
Bulletin of the National Research Centre
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Cosmetic dermal fillers are a sought-after procedure globally. However, despite the safety claims of filler materials by the manufacturers, adverse reactions still occur. This case report is of a 66-year-old female who presented with a late-onset complication of a hyaluronic acid dermal filler that clinically mimicked a salivary gland neoplasm. The patient presented with firm peri-oral swellings of short duration that clinically mimicked a pleomorphic adenoma and mucoepidermoid carcinoma. The diagnosis was that of a foreign-body granulomatous response to dermal fillers. Although other mimics of a similar nature are reported a knowledgeable clinician, careful choice of filler material, knowledge of the product, thorough pre-procedural history taking and post-procedural patient follow-up can drastically minimize a possible misdiagnosis. The reaction was treated with a combination of hyaluronidase, betamethasone and 5-flurouracil intra-lesional injections monthly for 11 consecutive months, with total clinical resolution. Patient education of the procedure, product name and the possibility of an adverse reaction occurring, even years later or at a site distant to the initial site of placement, is vital. Further, we review the recent reported adverse association of the new mRNA COVID-19 vaccines and dermal filler placement.
</td>
</tr>
<tr>
<td style="text-align:left;">
35431517
</td>
<td style="text-align:left;">
Perceiving SARS-CoV-2 Mpro and PLpro dual inhibitors from pool of recognized antiviral compounds of endophytic microbes: an in silico simulation study.
</td>
<td style="text-align:left;">
Structural chemistry
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
08
</td>
<td style="text-align:left;">
Coronavirus disease 2019 (COVID-19) persists and shook the global population where the endgame to this pandemic is brought on by developing vaccines in record-breaking time. Nevertheless, these vaccines are far from perfect where their efficiency ranges from 65 to 90%; therefore, vaccines are not the one only solution to overcome this situation, and apart from administration of vaccines, the scientific community is at quest for finding alternative solutions to incumber SARS-CoV-2 infection. In this study, our research group is keen on identifying a bioactive molecule that is independent in its mode of action from existing vaccines which can potentially target the SARS-CoV-2 virus replicative efficacy. Papain-like protease (PLpro) and main protease (Mpro) are the most lucrative targets of COVIDs against which the drugs can be developed, as these proteases play a vital role in the replication and development of viral particles. Researchers have modelled a compound such as GRL0617 and X77 as an inhibitor of Mpro and PLpro, respectively, but use of these compounds has several limitations on hosts like toxicity and solubility. Under the current study by deploying rigorous computational assessments, pool of microbial secondary metabolites was screened and handpicked to search a structural or functional analogue of GRL0617 and X77, with an idea to identify a compound that can serve as dual inhibitor for both PLpro and Mpro. From the manually curated database of known antiviral compounds from fungal origin, we found cytonic acids A and B to potentially serve as dual inhibitor of PLpro and Mpro.
</td>
</tr>
<tr>
<td style="text-align:left;">
35431416
</td>
<td style="text-align:left;">
Phase transitions may explain why SARS-CoV-2 spreads so fast and why new variants are spreading faster.
</td>
<td style="text-align:left;">
Physica A
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
12
</td>
<td style="text-align:left;">
The novel coronavirus SARS CoV-2 responsible for the COVID-19 pandemic and SARS CoV-1 responsible for the SARS epidemic of 2002-2003 share an ancestor yet evolved to have much different transmissibility and global impact 1. A previously developed thermodynamic model of protein conformations hypothesized that SARS CoV-2 is very close to a new thermodynamic critical point, which makes it highly infectious but also easily displaced by a spike-based vaccine because there is a tradeoff between transmissibility and robustness 2. The model identified a small cluster of four key mutations of SARS CoV-2 that predicts much stronger viral attachment and viral spreading compared to SARS CoV-1. Here we apply the model to the SARS-CoV-2 variants Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2)3 and predict, using no free parameters, how the new mutations will not diminish the effectiveness of current spike based vaccines and may even further enhance infectiousness by augmenting the binding ability of the virus.
</td>
</tr>
<tr>
<td style="text-align:left;">
35431374
</td>
<td style="text-align:left;">
Charge-transfer chemistry of two corticosteroids used adjunctively to treat COVID-19. Part I: Complexation of hydrocortisone and dexamethasone donors with DDQ acceptor in five organic solvents.
</td>
<td style="text-align:left;">
Journal of molecular liquids
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Jul
</td>
<td style="text-align:left;">
01
</td>
<td style="text-align:left;">
COVID-19 is the disease caused by a novel coronavirus (CoV) named the severe acute respiratory syndrome coronavirus 2 (termed SARS coronavirus 2 or SARS-CoV-2). Since the first case reported in December 2019, infections caused by this novel virus have led to a continuous global pandemic that has placed an unprecedented burden on health, economic, and social systems worldwide. In response, multiple therapeutic options have been developed to stop this pandemic. One of these options is based on traditional corticosteroids, however, chemical modifications to enhance their efficacy remain largely unexplored. Obtaining additional insight into the chemical and physical properties of pharmacologically effective drugs used to combat COVID-19 will help physicians and researchers alike to improve current treatments and vaccines (i.e., Pfizer-BioNTech, AstraZeneca, Moderna, Janssen). Herein, we examined the charge-transfer properties of two corticosteroids used as adjunctive therapies in the treatment of COVID-19, hydrocortisone and dexamethasone, as donors with 2,3-dichloro-5,6-dicyano-p-benzoquinone as an acceptor in various solvents. We found that the examined donors reacted strongly with the acceptor in CH2Cl2 and CHCl3 solvents to create stable compounds with novel clinical potential.
</td>
</tr>
<tr>
<td style="text-align:left;">
35431254
</td>
<td style="text-align:left;">
Prevalence and Safety of COVID-19 Vaccination in Community-Dwelling People with Dementia: Findings from a Tertiary Memory Clinic in Italy.
</td>
<td style="text-align:left;">
Journal of Alzheimer’s disease : JAD
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
11
</td>
<td style="text-align:left;">
This study aimed to explore the prevalence and safety of SARS-CoV-2 vaccination in individuals with dementia. Patients with mild cognitive impairment or dementia were recruited at a tertiary memory clinic, from March 15 to September 15, 2021. Information on COVID-19 vaccination and adverse events experienced after vaccine administration were collected from caregivers. Two-hundred-seventy subjects were finally recruited. Among them, 253 (93.7%) had received the vaccine and only 69 (27.3%) experienced adverse events. Cognitive and behavioral changes following immunization were only rarely reported. COVID-19 vaccination is safe and well-tolerated in patients with cognitive impairment who should be prioritized in the vaccination campaign.
</td>
</tr>
<tr>
<td style="text-align:left;">
35429788
</td>
<td style="text-align:left;">
The association of intensity and duration of non-pharmacological interventions and implementation of vaccination with COVID-19 infection, death, and excess mortality: Natural experiment in 22 European countries.
</td>
<td style="text-align:left;">
Journal of infection and public health
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Mar
</td>
<td style="text-align:left;">
24
</td>
<td style="text-align:left;">
Critical questions remain regarding the need for intensity to continue NPIs as the public was vaccinated. We evaluated the association of intensity and duration of non-pharmaceutical interventions (NPIs) and vaccines with COVID-19 infection, death, and excess mortality in Europe. Data comes from Our Word in Data. We included 22 European countries from January 20, 2020, to May 30, 2021. The time-varying constrained distribution lag model was used in each country to estimate the impact of different intensities and duration of NPIs on COVID-19 control, considering vaccination coverage. Country-specific effects were pooled through meta-analysis. This study found that high-intensity and long-duration of NPIs showed a positive main effect on reducing infection in the absence of vaccines, especially in the intensity above the 80th percentile and lasted for 7 days (RR = 0.93, 95% CI: 0.89-0.98). However, the adverse effect on excess mortality also increased with the duration and intensity. Specifically, it was associated with an increase of 44.16% (RR = 1.44, 95% CI: 1.27-1.64) in the excess mortality under the strict intervention (the intensity above the 80th percentile and lasted for 21 days). As the vaccine rollouts, the inhibition of the strict intervention on cases growth rate was increased (RR dropped from 0.95 to 0.87). Simultaneously, vaccination also alleviated the negative impact of the strict intervention on excess mortality (RR decreased from 1.44 to 1.25). Besides, maintaining the strict intervention appeared to more reduce the cases, as well as avoids more overall burden of death compared with weak intervention. Our study highlights the importance of continued high-intensity NPIs in low vaccine coverage. Lifting of NPIs in insufficient vaccination coverage may cause increased infections and death burden. Policymakers should coordinate the intensity and duration of NPIs and allocate medical resources reasonably with widespread vaccination.
</td>
</tr>
<tr>
<td style="text-align:left;">
35429774
</td>
<td style="text-align:left;">
Editorial overview: Vaccines: Reinvigorating therapeutic cancer vaccines.
</td>
<td style="text-align:left;">
Current opinion in immunology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
12
</td>
<td style="text-align:left;">
Lessons learned from the rapid deployment of vaccines during the COVID-19 pandemic are reinvigorating the cancer vaccine field. Using delivery platforms including mRNA and synthetic long peptides, recent clinical trials have demonstrated that cancer vaccines are safe, feasible, and can be associated with the generation of antigen-specific memory T cells and, in some cases, durable clinical responses. Despite these advances, fundamental questions remain regarding the optimal delivery platforms and antigen targets to use in cancer vaccines. Ongoing and future studies that harness advances in the identification of novel sources of antigens, the prediction of immunogenic antigens, and the use of single-cell technologies to profile antigen-specific T cells will hopefully reveal correlates with clinical outcomes and provide a mechanistic basis for future progress.
</td>
</tr>
<tr>
<td style="text-align:left;">
35429463
</td>
<td style="text-align:left;">
Defining the determinants of vaccine uptake and undervaccination in migrant populations in Europe to improve routine and COVID-19 vaccine uptake: a systematic review.
</td>
<td style="text-align:left;">
The Lancet. Infectious diseases
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
13
</td>
<td style="text-align:left;">
Understanding why some migrants in Europe are at risk of underimmunisation and show lower vaccination uptake for routine and COVID-19 vaccines is critical if we are to address vaccination inequities and meet the goals of WHO’s new Immunisation Agenda 2030. We did a systematic review (PROSPERO: CRD42020219214) exploring barriers and facilitators of vaccine uptake (categorised using the 5As taxonomy: access, awareness, affordability, acceptance, activation) and sociodemographic determinants of undervaccination among migrants in the EU and European Economic Area, the UK, and Switzerland. We searched MEDLINE, CINAHL, and PsycINFO from 2000 to 2021 for primary research, with no restrictions on language. 5259 data sources were screened, with 67 studies included from 16 countries, representing 366 529 migrants. We identified multiple access barriers-including language, literacy, and communication barriers, practical and legal barriers to accessing and delivering vaccination services, and service barriers such as lack of specific guidelines and knowledge of health-care professionals-for key vaccines including measles-mumps-rubella, diphtheria-pertussis-tetanus, human papillomavirus, influenza, polio, and COVID-19 vaccines. Acceptance barriers were mostly reported in eastern European and Muslim migrants for human papillomavirus, measles, and influenza vaccines. We identified 23 significant determinants of undervaccination in migrants (p&amp;lt;0·05), including African origin, recent migration, and being a refugee or asylum seeker. We did not identify a strong overall association with gender or age. Tailored vaccination messaging, community outreach, and behavioural nudges facilitated uptake. Migrants’ barriers to accessing health care are already well documented, and this Review confirms their role in limiting vaccine uptake. These findings hold immediate relevance to strengthening vaccination programmes in high-income countries, including for COVID-19, and suggest that tailored, culturally sensitive, and evidence-informed strategies, unambiguous public health messaging, and health system strengthening are needed to address access and acceptance barriers to vaccination in migrants and create opportunities and pathways for offering catch-up vaccinations to migrants.
</td>
</tr>
<tr>
<td style="text-align:left;">
35429381
</td>
<td style="text-align:left;">
Impact of preexisting anti-Ad26 humoral immunity on immunogenicity of the Ad26.COV2.S COVID-19 vaccine.
</td>
<td style="text-align:left;">
The Journal of infectious diseases
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
16
</td>
<td style="text-align:left;">
This secondary analysis of the phase 3 ENSEMBLE trial (NCT04505722) assessed the impact of preexisting humoral immunity to adenovirus type 26 (Ad26) on the immunogenicity of Ad26.COV2.S-elicited SARS-CoV-2-specific antibody levels in 380 participants in Brazil, South Africa, and the United States. Among those vaccinated in Brazil and South Africa, 31% and 66%, respectively, had prevaccination serum-neutralizing activity against Ad26, with little preexisting immunity detected in the United States. Vaccine recipients in each country had similar post-vaccination spike-binding antibody levels, indicating that baseline immunity to Ad26 has no clear impact on vaccine-induced immune responses.
</td>
</tr>
<tr>
<td style="text-align:left;">
35429291
</td>
<td style="text-align:left;">
Rheumatologists’ knowledge and perception of COVID-19 and related vaccines: the vaXurvey2 online survey.
</td>
<td style="text-align:left;">
Rheumatology international
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
16
</td>
<td style="text-align:left;">
The study aimed to explore the experience of coronavirus disease-2019 (COVID-19) infection and vaccine adverse events (AEs) among rheumatologists. A validated questionnaire was distributed as a Google form to rheumatologists across the country via social networking sites from late December 2021 till early January 2022. The questionnaire included questions regarding participants’ socio-demographic details, COVID-19 infection and vaccination details with special emphasis on AEs. Out of 246 responses, 228 were valid. 200 (81.3%) responders had received the vaccine. The mean age of the 228 participants was 37.9 ± 8.5 years, 196 were females and 32 males (F:M 6.1:1) from 18 governorates across the country. Comorbidities were present in 54 subjects (27%). There was a history of highly suspicious or confirmed COVID-19 infection in 66.7% that were all managed at home. The COVID-19 vaccine was received by 200 and a booster dose of 18.5%. Obesity and musculoskeletal involvement co-morbidities were present only in those with AEs (9.1% and 5.5% respectively). AEs were present in 82%; 66.7% had injection-site tenderness, 50% fatigue, 35.5% fever, 15% chills, 42.5% myalgia, 14.5% arthralgia, 8% low back pain, headache 31%, dizziness 10%, sleepliness 16% and 15% developed post-vaccine. There were no differences according to the geolocation regarding the occurrence of COVID-19 infection (p = 0.19) or AEs post-vaccine (p = 0.58). The adverse events were mostly mild to moderate and tolerable which makes this work in agreement with other studies that support the broad safety of the vaccine in favor of the global benefit from mass vaccination.
</td>
</tr>
<tr>
<td style="text-align:left;">
35429238
</td>
<td style="text-align:left;">
Differences in COVID-19 vaccination uptake in the first 12 months of vaccine availability in Switzerland - a prospective cohort study.
</td>
<td style="text-align:left;">
Swiss medical weekly
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Mar
</td>
<td style="text-align:left;">
28
</td>
<td style="text-align:left;">
Widespread vaccination uptake has been shown to be crucial in controlling the COVID-19 pandemic and its consequences on healthcare infrastructures. Infection numbers, hospitalisation rates and mortality can be mitigated if large parts of the population are being vaccinated. However, one year after the introduction of COVID-19 vaccines, a substantial share of the Swiss population still refrains from being vaccinated. We analysed COVID-19 vaccination uptake during the first 12 months of vaccine availability. We compared vaccination rates of different socioeconomic subgroups (e.g., education, income, migration background) and regions (urban vs rural, language region) and investigated associations between uptake and individual traits such as health literacy, adherence to COVID-19 prevention measures and trust in government or science. Our analysis was based on self-reported vaccination uptake of a longitudinal online panel of Swiss adults aged 18 to 79 (the “COVID-19 Social Monitor”, analysis sample n = 2448). The panel is representative for Switzerland with regard to age, gender, and language regions. Participants have been periodically surveyed about various public health issues from 30 March 2020, to 16 December 2021. We report uptake rates and age-stratified hazard ratios (HRs) by population subgroups without and with additional covariate adjustment using Cox regression survival analysis. Higher uptake rates were found for individuals with more than just compulsory schooling (secondary: unadjusted HR 1.39, 95% confidence interval [CI] 1.10-1.76; tertiary: HR 1.94, 95% CI 1.52-2.47), household income above CHF 4999 (5000-9999: unadj. HR 1.42, 95% CI 1.25-1.61; ≥10,000 HR 1.99, 95% CI 1.72-2.30), those suffering from a chronic condition (unadj. HR 1.38, 95% CI 1.25-1.53), and for individuals with a sufficient or excellent level of health literacy (sufficient: unadj. HR 1.13, 95% CI 0.98-1.29; excellent: HR 1.21, 95% CI 1.10-1.34). We found lower rates for residents of rural regions (unadj. HR 0.79, 95% CI 0.70-0.88), those showing less adherence to COVID-19 prevention measures, and those with less trust in government or science. Vaccination uptake is multifactorial and influenced by sociodemographic status, health literacy, trust in institutions and expected risk of severe COVID-19 illness. Fears of unwanted vaccine effects and doubts regarding vaccine effectiveness appear to drive uptake hesitancy and demand special attention in future vaccination campaigns.
</td>
</tr>
<tr>
<td style="text-align:left;">
35429211
</td>
<td style="text-align:left;">
Brief Communication: Heterologous Ad.26.COV2.S versus Homologous BNT162b2/mRNA-1273 as a Third Dose in Solid Organ Transplant Recipients Seronegative After 2-Dose mRNA Vaccination.
</td>
<td style="text-align:left;">
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
16
</td>
<td style="text-align:left;">
Heterologous vaccination (“mixing platforms”) for the third (D3) dose of SARS-CoV-2 vaccine is a potential strategy to improve antibody responses in solid organ transplant recipients (SOTRs), but data are mixed regarding potential differential immunogenicity. We assessed for differences in immunogenicity and tolerability of homologous (BNT162b2 or mRNA-1273; D3-mRNA) versus heterologous (Ad.26.COV2.S; D3-JJ) D3 among 377 SARS-CoV-2-infection naïve SOTRs who remained seronegative after two mRNA vaccines. We measured anti-spike titers and used weighted Poisson regression to evaluate seroconversion and development of high-titers, comparing D3-JJ to D3-mRNA, at 1, 3 and 6-months post-D3. 1-month post-D3, seroconversion (63% vs. 52%, p=0.3) and development of high-titers (29% vs. 25%, p=0.7) were comparable between D3-JJ and D3-mRNA recipients. 3-months post-D3, D3-JJ recipients were 1.4-fold more likely to seroconvert (80% vs. 57%, weighted incidence-rate-ratio: wIRR=1.10 1.401.77 , p=0.006) but not more likely to develop high-titers (27% vs. 22%, wIRR=0.44 0.921.93 , p=0.8). 6-months post-D3, D3-JJ recipients were 1.41-fold more likely to seroconvert (88% vs. 59%, wIRR=1.04 1.41 1.93 , p=0.029) and 2.63-fold more likely to develop high-titers (59% vs. 21%, wIRR=1.38 2.635.00 , p=0.003). There was no differential signal in alloimmune events or reactogenicity between platforms. SOTRs without antibody response after two mRNA vaccines may derive benefit from heterologous Ad.26.COV2.S D3. This article is protected by copyright. All rights reserved.
</td>
</tr>
<tr>
<td style="text-align:left;">
35428717
</td>
<td style="text-align:left;">
Post SARS-CoV-2 Vaccine Chilblains-like Lesions.
</td>
<td style="text-align:left;">
The Journal of rheumatology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
15
</td>
<td style="text-align:left;">
We would like to share ideas on the article, “A Case of Chilblains-like Lesions Post SARS-CoV-2 Vaccine?”1 Meara et al reported a female case and concluded, “The chilblains-like lesions suggest that she had an antibody response from either 1 vaccine dose or a previous PCR-negative COVID-19 [coronavirus disease 2019] infection.”1.
</td>
</tr>
<tr>
<td style="text-align:left;">
35428626
</td>
<td style="text-align:left;">
Health workers’ Perceptions and REsponses in implementing COVID-19 Immunisation StratEgy in South Western Sydney (PRECISE): an observational study.
</td>
<td style="text-align:left;">
BMJ open
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
15
</td>
<td style="text-align:left;">
To understand the views and motivations of healthcare workers at a vaccination hub who received a COVID-19 vaccination in March-May 2021. This is an observational study via an anonymous electronic survey of seven questions focus on where survey recipients received information about the vaccine roll-out, their motivations for receiving the vaccine and their level of comfort in receiving the vaccine. The Liverpool Vaccination Hub is located in South Western Sydney. Participants were healthcare workers who received the first dose of a COVID-19 vaccine in the Australian Government’s Phase 1a and 1b priority categories. The majority of survey respondents (70%) were female (median aged between 35 and 44 years). The majority of survey respondents were clinical workers, such as nurse, paramedics and doctors. χ2 analysis was used for analysis of survey responses in univariate analysis. Logistic regression was used to analyse survey responses, adjusting for week, type of health worker and age. 4746 healthcare workers responded to the survey after receiving their first vaccine dose, a response rate of 23%. Over 90% of respondents said that COVID-19 vaccination information from their organisation was easily available. Most of them reported that they were comfortable receiving a COVID-19 vaccine. The majority of respondents were motivated to receive the vaccine due to concern about contracting COVID-19 themselves (75%), or concerns about transmitting it to other people such as patients (52%), family members (65%) or other community members (54%). Younger respondents were more likely to have preferred more information on vaccine safety (p&amp;lt;0.0001) and the effectiveness of the vaccine (p&amp;lt;0.0001). The majority of healthcare workers who received a COVID-19 vaccine reported that it was easy to find useful information about the vaccination roll-out and they had a positive experience being vaccinated.
</td>
</tr>
<tr>
<td style="text-align:left;">
35428543
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Revue d’epidemiologie et de sante publique
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Mar
</td>
<td style="text-align:left;">
28
</td>
<td style="text-align:left;">
To report the characteristics of vaccine-hesitant individuals in a French-speaking adult population in the context of the SARS-CoV-2 pandemic; and to identify predictors of hesitancy about Covid-19-related vaccines. Between April and May 2020, 1640 French-speaking adults participating in an online cohort were classified according to their attitudes towards vaccination as: “hesitant”, “anti-vaccination”, and “pro-vaccination”. Descriptive statistics, univariate multinomial regression models and multivariate analyses were compiled and carried out. At the time of inclusion, compared to pro-vaccination participants, hesitant participants were more frequently females (p=0.044), not annually vaccinated against flu (p=0.026), less optimistic about the discovery of a treatment against Covid-19 in a few months (p&amp;lt;0.001), less ready to undergo this treatment (p&amp;lt;0.001), presenting less trust in the ability of public health authorities to control the pandemic (p=0.036) and reporting lower scores on knowledge-related scales (p values from &amp;lt;0.001 to 0.002). Univariate analyses confirmed these results with odds ratios ranging from 1.51 [1.05-2.17] to 2.19 [1.56-3.07]. In the multivariate models, the remaining variables associated with hesitant compared to pro-vaccination attitudes were discovery of a treatment against Covid-19 in a few months (OR=2.57 [1.73-3.81]), being ready to undergo this treatment (OR=7.07 [4.89-10.22]), digital vaccine literacy (OR=1.70 [1.14-2.54]) and general health literacy (OR=1.49 [1.03-2.15]). In a continuum of relative acceptance of Covid-19-related vaccines, hesitant individuals were situated in between the behaviours and characteristics of pro-vaccination and anti-vaccination groups. While their characteristics were in line with the literature, this study was the first to report data on health literacy, digital vaccine literacy and capacity to detect fake news associated with vaccine hesitancy. While failing to identify straightforward predictors, findings suggest that continued education and communication campaigns focused on improving vaccine literacy, particularly among women younger than 35 years, could heighten the proportion of persons accepting vaccination.
</td>
</tr>
<tr>
<td style="text-align:left;">
35428499
</td>
<td style="text-align:left;">
Differences by region of birth in SARS-CoV-2 vaccine coverage and positive SARS-CoV-2 test among 400 000 healthcare workers and the general population in Sweden.
</td>
<td style="text-align:left;">
Vaccine
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
11
</td>
<td style="text-align:left;">
Globally SARS-CoV-2 vaccine coverage varies among healthcare workers. Based on Swedish registers, data on vaccination status as of 31 October 2021 were analysed for all adults aged 35-64 years, 3 861 565 individuals, in Sweden by healthcare worker occupation group and region of birth. For both men and women vaccination coverage decreased in a graded manner by healthcare worker group with physicians having the highest coverage (96%), followed by registered nurses, licensed practical nurses, and nurse aides. Coverage also differed by region of birth for all groups of healthcare workers and non-healthcare workers with those born in Sweden with Sweden born parents having the highest coverage, and those born outside Sweden but within EU the lowest. The difference in vaccine coverage by region of birth among healthcare workers, regardless of whether it results from socioeconomic inequalities or sociocultural beliefs, puts them at a great occupational hazard and increased risk of nosocomial transmission.
</td>
</tr>
<tr>
<td style="text-align:left;">
35428497
</td>
<td style="text-align:left;">
Dashboard development for near real-time visualization of COVID-19 vaccine safety surveillance data in the vaccine safety datalink.
</td>
<td style="text-align:left;">
Vaccine
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
08
</td>
<td style="text-align:left;">
The Vaccine Safety Datalink (VSD) conducts active surveillance and vaccine safety research studies. Since the start of the U.S. COVID-19 vaccination program, the VSD has conducted near real-time safety surveillance of COVID-19 vaccines using Rapid Cycle Analysis. VSD investigators developed an internal dashboard to facilitate visualization and rapid reviews of large weekly automated vaccine safety surveillance data. Dashboard development and maintenance was informed by vaccine surveillance data users and vaccine safety partners. Key metrics include population demographics, vaccine uptake, pre-specified safety outcomes, sequential analyses results, and descriptive data on potential vaccine safety signals. Dashboard visualizations are used to provide situational awareness on dynamic vaccination coverage and the status of multiple safety analyses conducted among the VSD population. This report describes the development and implementation of the internal VSD COVID-19 Vaccine Dashboard, including metrics used to develop the dashboard, which may have application across various other public health settings. Published by Elsevier Ltd. 
</td>
</tr>
<tr>
<td style="text-align:left;">
35428185
</td>
<td style="text-align:left;">
COVID-profiler: a webserver for the analysis of SARS-CoV-2 sequencing data.
</td>
<td style="text-align:left;">
BMC bioinformatics
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
15
</td>
<td style="text-align:left;">
SARS-CoV-2 virus sequencing has been applied to track the COVID-19 pandemic spread and assist the development of PCR-based diagnostics, serological assays, and vaccines. With sequencing becoming routine globally, bioinformatic tools are needed to assist in the robust processing of resulting genomic data. We developed a web-based bioinformatic pipeline (“COVID-Profiler”) that inputs raw or assembled sequencing data, displays raw alignments for quality control, annotates mutations found and performs phylogenetic analysis. The pipeline software can be applied to other (re-) emerging pathogens. The webserver is available at <a href="http://genomics.lshtm.ac.uk/" class="uri">http://genomics.lshtm.ac.uk/</a> . The source code is available at <a href="https://github.com/jodyphelan/covid-profiler" class="uri">https://github.com/jodyphelan/covid-profiler</a> .
</td>
</tr>
<tr>
<td style="text-align:left;">
35427999
</td>
<td style="text-align:left;">
High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients.
</td>
<td style="text-align:left;">
Journal of autoimmunity
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
11
</td>
<td style="text-align:left;">
To evaluate B-cell- and T-cell-mediated immune response to SARS-CoV-2 mRNA vaccination in patients with complex or rare systemic autoimmune diseases previously been treated with or under continuous treatment with B-cell-targeted therapies including rituximab (RTX) and belimumab (BEL). Twenty-eight consecutive patients receiving RTX (n = 11) or BEL (n = 17) treatment and 13 age-/sex-matched controls (non-rheumatic healthcare personnel) were recruited. None of the patients had detectable anti-SARS-CoV-2 antibodies caused by prior exposure to the virus. All the patients and controls received mRNA vaccines and were tested three to four weeks after completion of vaccination. In all the RTX patients, vaccination was started within 5 months from the last infusion, and B-cell depletion was confirmed in all but one of them. Total anti-SARS-CoV-2 RBD antibodies were analyzed using a diagnostic assay, while T-cell response was evaluated using the interferon-gamma release assay (IGRA). Further, SARS-CoV-2 pseudoviruses were employed to verify the strain-specific neutralizing capacity of the antibodies. Detectable anti-SARS-CoV-2 antibodies were documented in 1 out of the 11 RTX patients and 16 of the 17 BEL patients. The median concentration in the RTX and BEL patients was significantly lower than that in the controls (39.6 AU/ml vs. 1133 AU/ml, p = 0.002). The result of IGRA was positive in 8 of the 11 (72.7%) RTX patients and 16 of the 17 (94.1%) BEL patients, and interferon release in both the RTX and BEL patients was comparable to that in the control participants. B-cell-targeted therapies do not preclude SARS-CoV-2 vaccination, since virus-specific cellular immunity can be induced even in the absence of circulating B cells. An important finding was that lupus patients treated with BEL developed immune responses to SARS-CoV-2; this indicates retention of the immunogenicity of the COVID-19 vaccine.
</td>
</tr>
<tr>
<td style="text-align:left;">
35427985
</td>
<td style="text-align:left;">
Subtractive proteomics assisted therapeutic targets mining and designing ensemble vaccine against Candida auris for immune response induction.
</td>
<td style="text-align:left;">
Computers in biology and medicine
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
01
</td>
<td style="text-align:left;">
The emergence of variants and the reports of co-infection caused by Candida auris in COVID-19 patients adds a further complication to the global pandemic situation. To date, no effective therapy is available for C. auris infections. Thus, characterization of therapeutic targets and designing effective vaccine candidates using subtractive proteomics and immune-informatics approaches is useful tool in controlling the emerging infections associated with SARS-CoV-2. In the current study, subtractive proteomics-assisted annotation of the vaccine targets was performed, which revealed seven vaccine targets. An immunoinformatic-driven approach was then employed to map protein-specific and proteome-wide immunogenic peptides (CTL, B cell, and HTL) for the design of multi-epitope vaccine candidates (MEVCs). The results demonstrated that the vaccine candidates possess strong antigenic features (&amp;gt;0.4 threshold score) and are classified as non-allergenic. Validation of the designed MEVCs through molecular docking, in-silico cloning, and immune simulation further demonstrated the efficacy of the vaccines by producing immune factor titers (ranging from 2500 to 16000 au/mL) i.e., IgM, IgG, IL-6, and Interferon-α. In conclusion, the current study provides a strong impetus in designing anti-fungal strategies against Candida auris.
</td>
</tr>
<tr>
<td style="text-align:left;">
35427915
</td>
<td style="text-align:left;">
Development of COVID 19 vaccine: A summarized review on global trials, efficacy, and effectiveness on variants.
</td>
<td style="text-align:left;">
Diabetes &amp;amp; metabolic syndrome
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
08
</td>
<td style="text-align:left;">
The emergence of SARS CoV2 or COVID 19 pandemic has shocking results on major global public health. This review aims to discuss the nine prominent COVID 19 vaccines with regard to their immunogenicity, efficacy, and effectiveness against the SARS CoV2 variants. Electronic databases such as Medline/PubMed, EMBASE, Scopus, science websites, and Google scholar were accessed to retrieve the research published about COVID 19 vaccines. All the adverse impact ranging from mild to moderate in the clinical trials were analysed, however, there were less reports in which COVID 19 patients either developed severe reactions or died due to the different experimental vaccines. Moreover, SARS CoV2 variants like Delta could escape the immune response. Overall, the data suggest that the two doses of COVID 19 vaccines are extremely effective against the original SARS CoV2 virus, and also provide well protection against SARS CoV2 variants, especially in severe illnesses. However, a third dose of the COVID 19 vaccine (also said to be the booster dose) will be needed in some immune-compromised people.
</td>
</tr>
<tr>
<td style="text-align:left;">
35427852
</td>
<td style="text-align:left;">
Tuberculosis vaccines in the era of Covid-19 - what is taking us so long?
</td>
<td style="text-align:left;">
EBioMedicine
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
12
</td>
<td style="text-align:left;">
The Mycobacterium bovis BCG vaccine was first used in 1921, but has not controlled the global spread of tuberculosis (TB). There are still no new licensed tuberculosis vaccines, although there much active research and a vaccine development pipeline, with vaccines designed to prevent infection, prevent disease, or accelerate TB treatment. These vaccines are of different types, and designed to replace BCG, or to boost immunity following BCG vaccination. This viewpoint discusses why, when it has been possible to develop new vaccines for SARS-CoV-2 so quickly, it is taking so long to develop new tuberculosis vaccines.
</td>
</tr>
<tr>
<td style="text-align:left;">
35427842
</td>
<td style="text-align:left;">
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study.
</td>
<td style="text-align:left;">
ESMO open
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Mar
</td>
<td style="text-align:left;">
11
</td>
<td style="text-align:left;">
Although a full course of coronavirus disease 2019 (COVID-19) vaccine is effective in cancer patients, the duration of the protection and the efficacy of a booster dose against the new variants remain unknown. We prospectively evaluated the immunogenicity of the third dose of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BNT162b2 messenger RNA vaccine in cancer patients undergoing active treatment. Patients with solid cancer, vaccinated with a booster dose during active treatment, were enrolled in this study. Patients were classified into SARS-CoV-2 naïve (without previous COVID-19 infection) and SARS-CoV-2 experienced (with previous COVID-19 infection). Neutralizing antibody (NT Ab) titer and total anti-Spike immunoglobulin G (IgG) concentration were quantified in serum. Heparinized whole blood samples were used for SARS-CoV-2 Interferon Gamma Release Assay (IGRA). The primary endpoint was to assess the increase of IgG antibody level between baseline and 3 weeks after the booster. One hundred and forty-two consecutive patients were recruited. In SARS-CoV-2-naïve subjects, the median level of IgG was 157 BAU/ml [interquartile range (IQR) 62-423 BAU/ml] at T0 and reached a median of 2080 BAU/ml (IQR 2080-2080 BAU/ml) at 3 weeks after booster administration (T1; P &amp;lt; 0.0001). A median 16-fold increase of SARS-CoV-2 NT Ab titer (IQR 4-32) was observed in naïve subjects (from median 20, IQR 10-40, to median 640, IQR 160-640; P &amp;lt; 0.0001). Median interferon-γ level at T1 was significantly higher than that measured at T0 in SARS-CoV-2-naïve subjects (P = 0.0049) but not in SARS-CoV-2-experienced patients. The median level of SARS-CoV-2 NT Abs was 32-fold lower against Omicron compared to the wild-type strain (P = 0.0004) and 12-fold lower compared to the Delta strain (P = 0.0110). The third dose is able to trigger both the humoral and the cell-mediated immune response in cancer patients on active treatment. Our preliminary data about the neutralization of the SARS-CoV-2 vaccine against variants of concern seem to confirm the lower vaccine activity.
</td>
</tr>
<tr>
<td style="text-align:left;">
35427467
</td>
<td style="text-align:left;">
Acceptance, effects, and tolerability in the vaccination process against SARS-CoV-2 among cancer patients in Bosnia and Herzegovina: a single-center cross-sectional study.
</td>
<td style="text-align:left;">
Bosnian journal of basic medical sciences
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
08
</td>
<td style="text-align:left;">
The SARS-CoV-2 pandemic has been the main public health issue since the end of 2019. The vaccination campaign in Bosnia and Herzegovina started in April 2021, with several vaccines available. Our study aimed to evaluate the acceptance, effects, and tolerability of vaccines against SARS-COV-2 among cancer patients. We conducted a cross-sectional, observational study between 22 October and 30 November 2021, at the Clinic of Oncology, Clinical Center University of Sarajevo. Patients were enrolled during their regular visit to the Clinic of Oncology by agreeing to completean individual paper questionnaire. The study included 1063 patients with malignant diseases, of whom 681 (64.1%) were adequately vaccinated patients. In the study population, 76.9% of patients reported that they did not experience any side effects due to vaccination, while only 0.5% had side effects, causing a delay in their treatment. Among adequately vaccinated patients, there were 40 patients (3.8%) who were infected with SARS-CoV-2 after the second or booster dose of the vaccine. Five patients (0.5%) were hospitalized due to COVID-19 after being adequately vaccinated. The findings of our study suggest that cancer patients have a higher acceptance of vaccines against SARS-CoV-2 than the general population in Bosnia and Herzegovina. Vaccination side effects are tolerable and do not cause major delays in specific cancer treatment. The protective effects of COVID-19 vaccines in the cancer patients presented in our study are comparable to available results of similar studies, which included the general population.
</td>
</tr>
<tr>
<td style="text-align:left;">
35427282
</td>
<td style="text-align:left;">
Neuro-Ophthalmological Complications of the COVID-19 Vaccines: A Systematic Review.
</td>
<td style="text-align:left;">
Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Mar
</td>
<td style="text-align:left;">
25
</td>
<td style="text-align:left;">
A worldwide mass vaccination campaign against the coronavirus disease 2019 (COVID-19) pandemic is currently underway. Although the safety data of the clinical trials did not report specific concerns regarding neuro-ophthalmological adverse events, they involved a limited number of individuals and were conducted over a relatively short time. The aim of the current review is to summarize the available postmarketing data regarding the occurrence of neuro-ophthalmological and other ocular complications of the COVID-19 vaccines. Electronic searches for published literature were conducted using Ovid MEDLINE, Embase, Web of Science, Google Scholar, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and ClinicalTrials.gov. The search strategy incorporated controlled vocabulary and free-text synonyms for the concepts of COVID, vaccines, and visual and neuro-ophthalmologic diseases and symptoms. A total of 14 case reports and 2 case series have been selected for inclusion in the final report, reporting 76 cases of post-COVID-vaccination adverse events. The most common adverse event was optic neuritis (n = 61), followed by uveitis (n = 3), herpes zoster ophthalmicus (n = 2), acute macular neuroretinopathy (n = 2), optic disc edema as an atypical presentation of Guillain-Barré syndrome (n = 1), (arteritic anterior ischemic optic neuropathy; n = 1), abducens nerve palsy (n = 1), oculomotor nerve palsy (n = 1), Tolosa-Hunt syndrome (n = 1), central serous retinopathy (n = 1), acute zonal occult outer retinopathy (n = 1), and bilateral choroiditis (n = 1). Most cases were treated with high-dose steroids and had a favorable clinical outcome. Since the implementation of the COVID-19 vaccination campaign in the past year, several post-COVID-vaccination neuro-ophthalmological complications have been described. However, considering the number of individuals that have been exposed to the vaccines, the risk seems very low, and the clinical outcome in most cases is favorable. Therefore, on a population level, the benefits of the vaccines far outweigh the risk of neuro-ophthalmological complications.
</td>
</tr>
<tr>
<td style="text-align:left;">
35427236
</td>
<td style="text-align:left;">
Psychedelics and Mental Health: An Alternative Strategy to Treat Mental Impairments Triggered or Aggravated by COVID-19.
</td>
<td style="text-align:left;">
Alternative therapies in health and medicine
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
15
</td>
<td style="text-align:left;">
Despite the discovery of vaccines for COVID-19, one of the best security measures to contain the spread of the virus is social distancing and isolation. However, isolation might trigger negative mental outcomes, such as onset of a depressive and anxious condition, increased consumption of alcohol and drugs, relapse to substances of abuse, and even induce post-traumatic stress disorder. Interestingly, recent research with psychedelics suggests that when these substances are used in combination with psychotherapy, they may reduce these mental impairments. Nevertheless, scientists are still working to elucidate the possible mechanisms behind these phenomena.
</td>
</tr>
<tr>
<td style="text-align:left;">
35426888
</td>
<td style="text-align:left;">
Antibody Response to a Fourth Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: An Update.
</td>
<td style="text-align:left;">
Transplantation
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
15
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
35426773
</td>
<td style="text-align:left;">
COVID-19 immunization in people with cancer-Is it safe and efficient? What do we know?
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
15
</td>
<td style="text-align:left;">
Prior to the COVID-19 pandemic, vaccination of people with cancer or a recent history of cancer was advisable under specific conditions, depending on the type of vaccine (inactivated or live attenuated virus or bacterium), type of cancer, and whether they had undergone treatment for cancer. Some malignancies, especially hematological malignancies, and cancer treatments such as chemotherapy, radiotherapy, and splenectomy negatively impact the immune response. The clinical trials of currently used vaccines against COVID-19 did not include people with active cancer; thus, there is an important gap in the knowledge of safety and efficiency data for COVID-19 immunization in this population. However, considering the risk of mortality and morbidity due to possible infection with SARS-CoV-2, medical experts recommend immunization on an individual basis. As the worldwide prevalence of malignancies is high, reliable information on COVID-19 vaccination is expected to be revealed in future clinical trials. In this review, we examine the key aspects of cancer that may be affected by COVID-19 and summarize the current literature on COVID-19 immunization.
</td>
</tr>
<tr>
<td style="text-align:left;">
35426755
</td>
<td style="text-align:left;">
Efficacy and effectiveness of covid-19 vaccine - absolute vs. relative risk reduction.
</td>
<td style="text-align:left;">
Expert review of vaccines
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
19
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
35426744
</td>
<td style="text-align:left;">
Letter to the Editor: COVID-19 Vaccination During Breastfeeding and Its Possible Negative Effect on Milk Production and Supply: A Preliminary Observation.
</td>
<td style="text-align:left;">
Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
14
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
35426382
</td>
<td style="text-align:left;">
COVID-19 Vaccination Gap in Admitted Trauma Patients: A Critical Opportunity.
</td>
<td style="text-align:left;">
Journal of the American College of Surgeons
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
May
</td>
<td style="text-align:left;">
01
</td>
<td style="text-align:left;">
Coronavirus disease 2019 (COVID-19) vaccination is the core strategy for pandemic management. We hypothesized that a vaccination gap might exist between emergency department (ED) patients admitted for trauma and other ED patients. This was an observational quality improvement study using electronic health record data at an academic level-1 trauma center. Participants were all patients presenting to the adult ED with a Tennessee home address between January 1 and June 1, 2021. We measured the proportional difference in vaccination between admitted trauma patients and other ED patients over time (by week) and association via Spearman’s rank correlation coefficient. Binary logistic regression facilitated covariate analysis to account for age, sex, race, home county, and ethnicity without and then with interaction between trauma admission and time. Geographic visual analysis compared county-level vaccination rates with odds of trauma admission by home county using a bivariate chloropleth map. The proportional difference in vaccination between trauma-admitted and other ED patients increased over time (Spearman’s = 0.699). Adjusting for age, sex, race, home county, and ethnicity, there was a statistically significant vaccination difference between trauma-admitted and other ED patients (odds ratio = 0.53, 95% CI 0.43-0.65, p &amp;lt; 0.0001). Geographic analysis revealed increased trauma admission odds and lower vaccination rates in surrounding counties compared with Davidson County. We observed a widening COVID-19 vaccination gap between trauma-admitted and other ED patients. Vaccine outreach during trauma admission may provide a valuable point of contact for unvaccinated patients.
</td>
</tr>
<tr>
<td style="text-align:left;">
35426364
</td>
<td style="text-align:left;">
Influenza returns with a season dominated by clade 3C.2a1b.2a.2 A(H3N2) viruses, WHO European Region, 2021/22.
</td>
<td style="text-align:left;">
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
In the WHO European Region, COVID-19 non-pharmaceutical interventions continued slowing influenza circulation in the 2021/22 season, with reduced characterisation data. A(H3) predominated and, in some countries, co-circulated with A(H1)pdm09 and B/Victoria viruses. No B/Yamagata virus detections were confirmed. Substantial proportions of characterised circulating virus subtypes or lineages differed antigenically from their respective northern hemisphere vaccine components. Appropriate levels of influenza virus characterisations should be maintained until the season end and in future seasons, when surveillance is adapted to integrate SARS-CoV-2.
</td>
</tr>
<tr>
<td style="text-align:left;">
35426361
</td>
<td style="text-align:left;">
A late sharp increase in influenza detections and low interim vaccine effectiveness against the circulating A(H3N2) strain, Denmark, 2021/22 influenza season up to 25 March 2022.
</td>
<td style="text-align:left;">
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
We estimated interim influenza A vaccine effectiveness (VE) following a late sharp rise in cases during an influenza A(H3N2)-dominated 2021/22 season, after lifting COVID-19 restrictions. In children aged 2-6 years offered a live attenuated influenza vaccine, adjusted VE was 62.7% (95% CI: 10.9-84.4) in hospitalised and 64.2% (95% CI: 50.5-74.1) in non-hospitalised children. In non-hospitalised patients aged 7-44 years, VE was 24.8% (95% CI: 12.8-35.2); VE was non-significant in remaining age groups and hospital/non-hospital settings.
</td>
</tr>
<tr>
<td style="text-align:left;">
35426198
</td>
<td style="text-align:left;">
Stem Cell-based therapies for COVID-19-related acute respiratory distress syndrome.
</td>
<td style="text-align:left;">
Journal of cellular and molecular medicine
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
14
</td>
<td style="text-align:left;">
As the number of confirmed cases and resulting death toll of the COVID-19 pandemic continue to increase around the globe - especially with the emergence of new mutations of the SARS-CoV-2 virus in addition to the known alpha, beta, gamma, delta and omicron variants - tremendous efforts continue to be dedicated to the development of interventive therapeutics to mitigate infective symptoms or post-viral sequelae in individuals for which vaccines are not accessible, viable or effective in the prevention of illness. Many of these investigations aim to target the associated acute respiratory distress syndrome, or ARDS, which induces damage to lung epithelia and other physiologic systems and is associated with progression in severe cases. Recently, stem cell-based therapies have demonstrated preliminary efficacy against ARDS based on a number of preclinical and preliminary human safety studies, and based on promising outcomes are now being evaluated in phase II clinical trials for ARDS. A number of candidate stem cell therapies have been found to exhibit low immunogenicity, coupled with inherent tropism to injury sites. In recent studies, these have demonstrated the ability to modulate suppression of pro-inflammatory cytokine signals such as those characterizing COVID-19-associated ARDS. Present translational studies are aiming to optimize the safety, efficacy and delivery to fully validate stem cell-based strategies targeting COVID-19 associated ARDS for viable clinical application.
</td>
</tr>
<tr>
<td style="text-align:left;">
35426142
</td>
<td style="text-align:left;">
Vaccination strategy for preventing the spread of SARS-CoV-2 in the limited supply condition: a mathematical modelling study.
</td>
<td style="text-align:left;">
Journal of medical virology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
14
</td>
<td style="text-align:left;">
To mitigate SARS-CoV-2 transmission, eight vaccines have been urgently approved. With their limited availability, it is critical to distribute the vaccines reasonably. We simulated the SARS-CoV-2 transmission for 365 days over four intervention periods: free transmission, structural mitigation, personal mitigation, and vaccination. Sensitivity analyses were performed to obtain the robust results. We further evaluated two proposed vaccination allocations, including one-dose-high-coverage and two-doses-low-coverage, when the supply was low. The infected rate (in 10 million people) reduced from 2.68 to 2.36 and 33.35% and 40.54% confirmed cases can be avoided as the nonpharmaceutical interventions (NPIs) adherence rate rose from 50% to 70%. As the vaccination coverage reached 60% and 80%, the total infections can be reduced by about 32.72% and 41.19%, compared to the number without vaccination. When the duration of immunity was 90 and 120 days, the infected rate was 2.67 and 2.38. As asymptomatic infection rate rose from 30% to 50%, the infected rate was 1.92 (standard deviation [SD], 0.16) times higher. Condistion on 70% adherence rate, with the same amount of limited available vaccines, the 20% and 40% vaccination coverage of one-dose-high-coverage, the infected rate were 2.70 and 2.35; corresponding to the two-doses-low-coverage with 10% and 20% vaccination coverage, the number of infections were 3.22and 2.92. Our results indicated as the duration of immunity prolonged, the second wave of SARS-CoV-2 will be delayed and the scale will be declined. On average, the total infections in two-doses-low-coverage was 1.48 times (SD, 0.24) higher than that in one-dose-high-coverage. It is crucial to encourage people to vaccinate in establishing immune barriers. Especially, when the supply is limit, a wiser strategy to restrict the SARS-CoV-2 transmission is equally distributing doses to the same amounts of individuals. Despite vaccination, it still needs NPIs to prevent widespread outbreaks. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
</td>
</tr>
<tr>
<td style="text-align:left;">
35425724
</td>
<td style="text-align:left;">
Changes in Childhood Immunizations and Intermittent Preventive Malaria Treatment in a Peripheral, Referral Immunization Center During the First 12 Months of COVID-19 Pandemic in Sierra Leone, Western Africa.
</td>
<td style="text-align:left;">
Frontiers in pediatrics
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
There is increasing evidence that the COVID-19 pandemic disrupted childhood immunization services. However, detailed reports on immunizations and preventive antimalarial prophylactic treatments delivered and how the trends changed in referral centers in low-income countries are still missing. We performed a retrospective cross-sectional study. Data for vaccinations administered to children &amp;lt;5 years of age, according to the local vaccination schedule, were extracted from the official records of the Kent Community Health Post, Sierra Leone, in the period between April 2019 and March 2021. We compared the vaccinations performed in the first year, considered as a pre-Covid period, with the second year, post-Covid period. Both the period was then divided in four trimester each and the same analysis was operated for each trimester. A Chi-square goodness of fit test was performed to compare the number of vaccinations performed both in the 2 years and in the 8 trimesters. Seven thousand two hundred and eighty-three vaccinations were administered: 4,641 in the period between April 2019 and March 2020 and 2,642 between April 2020 and March 2021. The drop in immunizations performed began as soon as the first cases were described in China. The drops were statistically significant when the first three trimesters of the two study periods were compared, while no statistically significant differences were observed for all the vaccines performed in the 4th trimesters. Vaccines administered at birth (BCG) were less affected compared to booster vaccinations. Immunizations administered in a referral health center in Sierra Leone significantly declined during the pandemic. Although the decline was less pronounced in the last months of the pandemic, we don’t think that the small increase would indicate the recovery of previously missed vaccinations. These findings open new public health challenges for the coming years.
</td>
</tr>
<tr>
<td style="text-align:left;">
35425676
</td>
<td style="text-align:left;">
Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Series of Five Cases.
</td>
<td style="text-align:left;">
Cureus
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Mar
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Autoimmune bullous diseases (AIBDs) are a heterogeneous group of diseases characterized by cutaneous and mucosal vesicles, blisters, and erosions. Several factors can trigger this disease, including vaccines; but this entity remains very rare. We hypothesized that vaccination against coronavirus disease 2019 (COVID-19) could trigger an immunological response in genetically predisposed individuals. We report five cases of new-onset autoimmune bullous diseases triggered by the COVID-19 vaccine. Clinical and histopathological examinations confirmed the diagnosis of bullous pemphigoid (BP) in three patients and pemphigus in the other two. According to the French method of imputability, the pharmacovigilance investigation showed an I5B4 causality assessment score for the vaccines, interpreted as highly probable, for all the patients. The diagnosis of vaccine-induced autoimmune bullous dermatosis was highly suspected. One patient’s condition improved by dermocorticoids alone, while the other four required oral corticosteroid therapy at 0.5 mg/kg/day, which led to a favorable outcome.
</td>
</tr>
<tr>
<td style="text-align:left;">
35423213
</td>
<td style="text-align:left;">
A comprehensive review on antimicrobial face masks: an emerging weapon in fighting pandemics.
</td>
<td style="text-align:left;">
RSC advances
</td>
<td style="text-align:left;">
2021
</td>
<td style="text-align:left;">
Feb
</td>
<td style="text-align:left;">
04
</td>
<td style="text-align:left;">
The world has witnessed several incidents of epidemics and pandemics since the beginning of human existence. The gruesome effects of microbial threats create considerable repercussions on the healthcare systems. The continually evolving nature of causative viruses due to mutation or re-assortment sometimes makes existing medicines and vaccines inactive. As a rapid response to such outbreaks, much emphasis has been placed on personal protective equipment (PPE), especially face mask, to prevent infectious diseases from airborne pathogens. Wearing face masks in public reduce disease transmission and creates a sense of community solidarity in collectively fighting the pandemic. However, excessive use of single-use polymer-based face masks can pose a significant challenge to the environment and is increasingly evident in the ongoing COVID-19 pandemic. On the contrary, face masks with inherent antimicrobial properties can help in real-time deactivation of microorganisms enabling multiple-use and reduces secondary infections. Given the advantages, several efforts are made incorporating natural and synthetic antimicrobial agents (AMA) to produce face mask with enhanced safety, and the literature about such efforts are summarised. The review also discusses the literature concerning the current and future market potential and environmental impacts of face masks. Among the AMA tested, metal and metal-oxide based materials are more popular and relatively matured technology. However, the repeated use of such a face mask may pose a danger to the user and environment due to leaching/detachment of nanoparticles. So careful consideration is required to select AMA and their incorporation methods to reduce their leaching and environmental impacts. Also, systematic studies are required to establish short-term and long-term benefits. This journal is
</td>
</tr>
<tr>
<td style="text-align:left;">
35422564
</td>
<td style="text-align:left;">
Atypical Presentation of Erythema Nodosum Following Pfizer-BioNTech COVID-19 Vaccine.
</td>
<td style="text-align:left;">
Medical archives (Sarajevo, Bosnia and Herzegovina)
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Feb
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Erythema nodosum (EN) is a common form of panniculitis that could be triggered by numerous conditions including infectious and non-infectious conditions. So far, few cases of EN caused by COVID-19 vaccine had been reported. We report a case of atypical presentation of EN mimicking cellulitis in a patient who received the first dose of the Pfizer-BioNTech COVID-19 vaccine. A 38-year-old healthy woman who developed painful swelling on the left leg one week after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine. Skin biopsy was revealed septal panniculitis. Due to the temporal association and the absence of other identifiable causes, Pfizer-BioNTech COVID-19 vaccine-related EN would be the most likely explanation. COVID-19 vaccines could be associated with rare side effects that should be reported for a better understanding of related outcomes of COVID-19 vaccination. This case was reported to keep in mind that EN can have atypical presentation as a rare side effect of COVID-19 vaccines.
</td>
</tr>
<tr>
<td style="text-align:left;">
35422423
</td>
<td style="text-align:left;">
Covid-19: UK approves Valneva vaccine for adults under 50.
</td>
<td style="text-align:left;">
BMJ (Clinical research ed.)
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
14
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
35421999
</td>
<td style="text-align:left;">
Optimization of a new adaptive intervention using the SMART Design to increase COVID-19 testing among people at high risk in an urban community.
</td>
<td style="text-align:left;">
Trials
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
14
</td>
<td style="text-align:left;">
COVID-19 has impacted the health and social fabric of individuals and families living across the USA, and it has disproportionately affected people living in urban communities with co-morbidities, those working in high-risk settings, refusing or unable to adhere to CDC guidelines, and more. Social determinants of health (SDH), such as stigmatization, incarceration, and poverty, have been associated with increased exposure to COVID-19 and increased deaths. While vaccines and booster shots are available, it will take time to reach herd immunity, and it is unclear how long newly developed vaccines provide protection and how effective they are against emerging variants. Therefore, prevention methods recommended by the Centers for Disease and Control (CDC)-i.e., testing, hand-washing, social distancing, contact tracing, vaccination and booster shots, and quarantine-are essential to reduce the rates of COVID-19 in marginalized communities. This project will adapt and test evidence-based HIV interventions along the prevention and treatment cascade to help address COVID-19 prevention needs. The study aims to (1) optimize an adaptive intervention that will increase rates of testing and adherence to New Jersey State COVID-19 recommendations (testing, social distancing, quarantine, hospitalization, contact tracing, and acceptance of COVID-19 vaccination and booster shots) among high-risk populations and (2) identify predictors of testing completion and adherence to New Jersey recommendations. This study follows Community Based Participatory Research (CBPR) principles to conduct a Sequential, Multiple Assignment Randomized Trial (SMART) with 670 COVID-19 medically/socially vulnerable people. Participants will be recruited using a variety of strategies including advertisements on social media, posting fliers in public places, street outreach, facility-based, and snowball sampling. Participants complete a baseline survey and are randomized to receive navigation services or an electronic brochure. They then complete a follow-up 7 days after baseline and are randomized again to either continue with their original assignment or switch to the other intervention or critical dialog or brief counseling. Participants then complete a 5-week post-baseline follow-up. Guided by the COVID-19 Continuum of Prevention, Care, and Treatment, the analysis will explore the factors associated with COVID-19 testing within 7 days of the intervention. This paper describes the protocol of the first study to use SMART following CBPR to adapt evidence-based HIV prevention interventions to COVID-19. The findings will inform the development of an effective and scalable adaptive intervention to increase COVID-19 testing and adherence to public health recommendations, including vaccination and booster shots, among a marginalized and difficult-to-engage population. ClinicalTrials.gov NCT04757298 . Registered on February 17, 2021.
</td>
</tr>
<tr>
<td style="text-align:left;">
35421989
</td>
<td style="text-align:left;">
Opening up safely: public health system requirements for ongoing COVID-19 management based on evaluation of Australia’s surveillance system performance.
</td>
<td style="text-align:left;">
BMC medicine
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
15
</td>
<td style="text-align:left;">
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) community transmission was eliminated in Australia from 1/11/2020 to 30/6/2021, allowing evaluation of surveillance system performance in detecting novel outbreaks, including against variants of concern (VoCs). This paper aims to define system requirements for coronavirus disease 2019 (COVID-19) surveillance under future transmission and response scenarios, based on surveillance system performance to date. This study described and evaluated surveillance systems and epidemiological characteristics of novel outbreaks based on publicly available data, and assessed surveillance system sensitivity and timeliness in outbreak detection. These findings were integrated with analysis of other critical COVID-19 public health measures to establish future COVID-19 management requirements. Twenty-five epidemiologically distinct outbreaks and five distinct clusters were identified in the study period, all linked through genomic sequencing to novel introductions from international travellers. Seventy percent (21/30) were detected through community testing of people with acute respiratory illness, and 30% (9/30) through quarantine screening. On average, 2.07% of the State population was tested in the week preceding detection for those identified through community surveillance. From 17/30 with publicly available data, the average time from seeding to detection was 4.9 days. One outbreak was preceded by unexpected positive wastewater results. Twenty of the 24 outbreaks in 2021 had publicly available sequencing data, all of which identified VoCs. A surveillance strategy for future VoCs similar to that used for detecting SARS-CoV-2 would require a 100-1000-fold increase in genomic sequencing capacity compared to the study period. Other essential requirements are maintaining outbreak response capacity and developing capacity to rapidly engineer, manufacture, and distribute variant vaccines at scale. Australia’s surveillance systems performed well in detecting novel introduction of SARS-CoV-2 while community transmission was eliminated; introductions were infrequent and case numbers were low. Detection relied on quarantine screening and community surveillance in symptomatic members of the general population, supported by comprehensive genomic sequencing. Once vaccine coverage is maximised, future COVID-19 control should shift to detection of SARS-CoV-2 VoCs, requiring maintenance of surveillance systems and testing all international arrivals, alongside greatly increased genomic sequencing capacity. Effective government support of localised public health response mechanisms and engagement of all sectors of the community is crucial to current and future COVID-19 management.
</td>
</tr>
<tr>
<td style="text-align:left;">
35421841
</td>
<td style="text-align:left;">
Nanoplasmonic multiplex biosensing for COVID-19 vaccines.
</td>
<td style="text-align:left;">
Biosensors &amp;amp; bioelectronics
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Mar
</td>
<td style="text-align:left;">
31
</td>
<td style="text-align:left;">
The ongoing emergence of severe acute respiratory syndrome caused by the new coronavirus (SARS-CoV-2) variants requires swift actions in identifying specific antigens and optimizing vaccine development to maximize the humoral response of the patient. Measuring the specificity and the amount of antibody produced by the host immune system with high throughput and accuracy is critical to develop timely diagnostics and therapeutic strategies. Motivated by finding an easy-to-use and cost-effective alternative to existing serological methodologies for multiplex analysis, we develop a proof-of-concept multiplex nanoplasmonic biosensor to capture the humoral response in serums against multiple antigens. Nanoplasmonic sensing relies on the wavelength shift of the localized surface plasmon resonance (LSPR) peak of gold nanostructures upon binding interactions between the antibodies and the immobilized antigens. Here the antigens are first immobilized on different sensing areas by using a mono-biotinylation system based on the high affinity interaction between biotin and streptavidin. We then validate the multiplex platform by detecting the presence of 3 monoclonal antibodies against 3 antigens (2 different hemagglutinins (HAs) from influenza viruses, and the SARS-CoV-2 Spike RBD (receptor binding domain)). We also measure the humoral response in murine sera collected before and after its immunization with the SARS-CoV-2 Spike protein, in good agreement with the results obtained by the ELISA assay. Our nanoplasmonic assays have successfully demonstrated multiple serum antibody profiling, which can be further integrated with microfluidics as an effective high throughput screening platform in future studies for the ongoing SARS-CoV-2 vaccine development.
</td>
</tr>
<tr>
<td style="text-align:left;">
35421782
</td>
<td style="text-align:left;">
Humoral response to SARS-CoV-2 infection and vaccines against COVID-19 in patients with neuromyelitis optica spectrum disorders: Impact of immunosuppressive treatment.
</td>
<td style="text-align:left;">
Multiple sclerosis and related disorders
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
06
</td>
<td style="text-align:left;">
The aim of this study was to evaluate the humoral response to the SARS-CoV-2 infection and vaccination in the NMOSD patients, treated with various immunosuppresants (ISs). Serum IgG against the complete sequence of the receptor binding domain of the spike protein was measured using ELISA SARS-CoV-2 IgG, INEP, Belgrade. Seroconversion occurred in 8/10 patients with COVID-19, and in 5/9 after vaccination. One out of four patients treated with inebilizumab seroconverted (after COVID-19); antibodies were not detected in any of the remaining 3 patients who were vaccinated. Antibodies developed after COVID-19 in 4/5 patients treated with azathioprine and all treated with mycophenolate-mofetil, and after vaccination, in 5/6 patients treated with these ISs. Post-vaccination humoral response was impaired in our NMOSD patients treated with B-cell depleting therapies; seroconversion occurred in almost all patients treated with conventional synthetic disease modifying ISs.
</td>
</tr>
<tr>
<td style="text-align:left;">
35421449
</td>
<td style="text-align:left;">
Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity.
</td>
<td style="text-align:left;">
The Journal of allergy and clinical immunology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
11
</td>
<td style="text-align:left;">
Patients with inborn errors of immunity (IEI) are at increased risk of severe coronavirus disease-2019 (COVID-19). Effective vaccination against COVID-19 is therefore of great importance in this group, but little is known about the immunogenicity of COVID-19 vaccines in these patients. We sought to study humoral and cellular immune responses after mRNA-1273 COVID-19 vaccination in adult patients with IEI. In a prospective, controlled, multicenter study, 505 patients with IEI (common variable immunodeficiency [CVID], isolated or undefined antibody deficiencies, X-linked agammaglobulinemia, combined B- and T-cell immunodeficiency, phagocyte defects) and 192 controls were included. All participants received 2 doses of the mRNA-1273 COVID-19 vaccine. Levels of severe acute respiratory syndrome coronavirus-2-specific binding antibodies, neutralizing antibodies, and T-cell responses were assessed at baseline, 28 days after first vaccination, and 28 days after second vaccination. Seroconversion rates in patients with clinically mild antibody deficiencies and phagocyte defects were similar to those in healthy controls, but seroconversion rates in patients with more severe IEI, such as CVID and combined B- and T-cell immunodeficiency, were lower. Binding antibody titers correlated well to the presence of neutralizing antibodies. T-cell responses were comparable to those in controls in all IEI cohorts, with the exception of patients with CVID. The presence of noninfectious complications and the use of immunosuppressive drugs in patients with CVID were negatively correlated with the antibody response. COVID-19 vaccination with mRNA-1273 was immunogenic in mild antibody deficiencies and phagocyte defects and in most patients with combined B- and T-cell immunodeficiency and CVID. Lowest response was detected in patients with X-linked agammaglobulinemia and in patients with CVID with noninfectious complications. The assessment of longevity of immune responses in these vulnerable patient groups will guide decision making for additional vaccinations.
</td>
</tr>
<tr>
<td style="text-align:left;">
35421378
</td>
<td style="text-align:left;">
Efficacy of vaccination and previous infection against the Omicron BA.1 variant in Syrian hamsters.
</td>
<td style="text-align:left;">
Cell reports
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
19
</td>
<td style="text-align:left;">
The emergence of the SARS-CoV-2 Omicron (B.1.1.529) variant with a surprising number of spike mutations raises concerns about reduced sensitivity of this virus to antibody neutralization and subsequent vaccine breakthrough infections. Here, we infect Moderna mRNA-vaccinated or previously infected hamsters with the Omicron BA.1 variant. While the Moderna mRNA vaccine reduces viral loads in the respiratory tissues upon challenge with an early S-614G isolate, the vaccine efficacy is not as pronounced after infection with the Omicron variant. Previous infection with the early SARS-CoV-2 isolate prevents replication after rechallenge with either virus in the lungs of previously infected hamsters, but the Omicron variant replicates efficiently in nasal turbinate tissue. These results experimentally demonstrate in an animal model that the antigenic changes in the Omicron variant are responsible for vaccine breakthrough and re-infection.
</td>
</tr>
<tr>
<td style="text-align:left;">
35421376
</td>
<td style="text-align:left;">
Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis.
</td>
<td style="text-align:left;">
The Lancet. Respiratory medicine
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
11
</td>
<td style="text-align:left;">
Myopericarditis is a rare complication of vaccination. However, there have been increasing reports of myopericarditis following COVID-19 vaccination, especially among adolescents and young adults. We aimed to characterise the incidence of myopericarditis following COVID-19 vaccination, and compare this with non-COVID-19 vaccination. We did a systematic review and meta-analysis, searching four international databases from Jan 1, 1947, to Dec 31, 2021, for studies in English reporting on the incidence of myopericarditis following vaccination (the primary outcome). We included studies reporting on people in the general population who had myopericarditis in temporal relation to receiving vaccines, and excluded studies on a specific subpopulation of patients, non-human studies, and studies in which the number of doses was not reported. Random-effects meta-analyses (DerSimonian and Laird) were conducted, and the intra-study risk of bias (Joanna Briggs Institute checklist) and certainty of evidence (Grading of Recommendations, Assessment, Development and Evaluations approach) were assessed. We analysed the difference in incidence of myopericarditis among subpopulations, stratifying by the type of vaccine (COVID-19 vs non-COVID-19) and age group (adult vs paediatric). Among COVID-19 vaccinations, we examined the effect of the type of vaccine (mRNA or non-mRNA), sex, age, and dose on the incidence of myopericarditis. This study was registered with PROSPERO (CRD42021275477). The overall incidence of myopericarditis from 22 studies (405 272 721 vaccine doses) was 33·3 cases (95% CI 15·3-72·6) per million vaccine doses, and did not differ significantly between people who received COVID-19 vaccines (18·2 [10·9-30·3], 11 studies [395 361 933 doses], high certainty) and those who received non-COVID-19 vaccines (56·0 [10·7-293·7], 11 studies [9 910 788 doses], moderate certainty, p=0·20). Compared with COVID-19 vaccination, the incidence of myopericarditis was significantly higher following smallpox vaccinations (132·1 [81·3-214·6], p&amp;lt;0·0001) but was not significantly different after influenza vaccinations (1·3 [0·0-884·1], p=0·43) or in studies reporting on various other non-smallpox vaccinations (57·0 [1·1-3036·6], p=0·58). Among people who received COVID-19 vaccines, the incidence of myopericarditis was significantly higher in males (vs females), in people younger than 30 years (vs 30 years or older), after receiving an mRNA vaccine (vs non-mRNA vaccine), and after a second dose of vaccine (vs a first or third dose). The overall risk of myopericarditis after receiving a COVID-19 vaccine is low. However, younger males have an increased incidence of myopericarditis, particularly after receiving mRNA vaccines. Nevertheless, the risks of such rare adverse events should be balanced against the risks of COVID-19 infection (including myopericarditis). None.
</td>
</tr>
<tr>
<td style="text-align:left;">
35421324
</td>
<td style="text-align:left;">
Dynamics of SARS-CoV-2 Antibody Response to CoronaVac followed by Booster Dose of BNT162b2 Vaccine.
</td>
<td style="text-align:left;">
Emerging infectious diseases
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
14
</td>
<td style="text-align:left;">
We evaluated the longitudinal dynamics of antibody response to the SARS-CoV-2 vaccine CoronaVac and the effect of a booster dose of BNT162b2 vaccine. We found a robust antibody response after the second dose of CoronaVac that wanes over time. The response was recovered by BNT162b2, which boosted anti-spike antibody titers.
</td>
</tr>
<tr>
<td style="text-align:left;">
35421266
</td>
<td style="text-align:left;">
An overview on inactivated and live-attenuated SARS-CoV-2 vaccines.
</td>
<td style="text-align:left;">
Journal of clinical laboratory analysis
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
14
</td>
<td style="text-align:left;">
After about 2 years since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first infections were detected in Wuhan city of China in December 2019, which was followed by a worldwide pandemic with a record of 5.41 million deaths. Due to urgent need for the development of a safe and effective vaccine for coronavirus disease 2019 (COVID-19), attempts for producing efficient vaccines are inexhaustibly continuing. According to a report by the World Health Organization (WHO) on COVID-19 vaccine tracker and landscape, there are 149 vaccine candidates all over the world. Inactivated SARS-CoV-2 vaccines as a conventional vaccine platform consist of whole virus particles grown in cell culture and inactivated by chemicals. Because of benefits such as antigenic similarity to real virion inducing humoral and cellular immune responses and ease for transport and storage, these vaccines, including the vaccines produced by Bharat Biotech, Sinopharm, and Sinovac, are in use at large scales. In this study, we have a review on inactivated SARS-CoV-2 vaccines that are passing their phase 3 and 4 clinical trials, population which was included in the trials, vaccine producers, the efficiency, adverse effects, and components of vaccines, and other vaccine features.
</td>
</tr>
<tr>
<td style="text-align:left;">
35421211
</td>
<td style="text-align:left;">
COVID-19: The question of genetic diversity and therapeutic intervention approaches.
</td>
<td style="text-align:left;">
Genetics and molecular biology
</td>
<td style="text-align:left;">
2021
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Coronavirus disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome Coronavirus type 2 (SARS-CoV-2), is the largest pandemic in modern history with very high infection rates and considerable mortality. The disease, which emerged in China’s Wuhan province, had its first reported case on December 29, 2019, and spread rapidly worldwide. On March 11, 2020, the World Health Organization (WHO) declared the COVID-19 outbreak a pandemic and global health emergency. Since the outbreak, efforts to develop COVID-19 vaccines, engineer new drugs, and evaluate existing ones for drug repurposing have been intensively undertaken to find ways to control this pandemic. COVID-19 therapeutic strategies aim to impair molecular pathways involved in the virus entrance and replication or interfere in the patients’ overreaction and immunopathology. Moreover, nanotechnology could be an approach to boost the activity of new drugs. Several COVID-19 vaccine candidates have received emergency-use or full authorization in one or more countries, and others are being developed and tested. This review assesses the different strategies currently proposed to control COVID-19 and the issues or limitations imposed on some approaches by the human and viral genetic variability.
</td>
</tr>
<tr>
<td style="text-align:left;">
35419956
</td>
<td style="text-align:left;">
Adult-onset Still disease and adenovirus vector COVID-19 vaccination.
</td>
<td style="text-align:left;">
Internal medicine journal
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
35419851
</td>
<td style="text-align:left;">
Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS COV-2 Delta variant dominant period and their clinical characteristics.
</td>
<td style="text-align:left;">
Journal of medical virology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
13
</td>
<td style="text-align:left;">
The exposure of healthcare workers (HCWs) to SARS-CoV-2 has been a major concern since the beginning of the COVID-19 pandemic. The study aimed to investigate the relationship between vaccination status and the status of catching COVID-19 in HCWs working in a Training and Research Hospital in Turkey, and the clinical course of the disease in those who were caught. In the current study, the vaccination status of 1279 HCWs working at Siirt Training and Research Hospital during the period when the SARS CoV-2 Delta variant was dominant, their cases of catching COVID-19 during this period, and the clinical course of the disease in patients with COVID-19 were investigated retrospectively. We found that the rate of COVID-19 transmission was lowest in fully vaccinated HCWs (p&amp;lt;0.05). The rate of COVID-19 transmission in HCWs who received 2 doses of BioNTech vaccine (4.4%) and 2 doses of CoronaVac+1 dose of BioNTech vaccines (2.7%) was considerably lower than those without vaccination (26.2%) (p&amp;lt;0.05). The transmission rate was lowest among those vaccinated with 2 doses of CoronaVac+1 dose of BioNTech. Hospitalization was not required in fully vaccinated HCWs. The lymphocyte count was found to be significantly higher in fully vaccinated patients than incompletely vaccinated and unvaccinated patients. Although CRP, d-dimer, ferritin values were higher in unvaccinated and partially vaccinated patients than in fully vaccinated patients, the differences were not statistically significant. As a result, the transmission rate of COVID-19 was lowest in fully vaccinated HCWs and in those vaccinated with 2 doses of CoronaVac+1 dose of BioNTech. In fully vaccinated HCWs, hospitalization was not needed. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
</td>
</tr>
<tr>
<td style="text-align:left;">
35419776
</td>
<td style="text-align:left;">
The Impact of COVID-19 in Bone Metabolism: Basic and Clinical Aspects.
</td>
<td style="text-align:left;">
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
13
</td>
<td style="text-align:left;">
The use of standard procedures for the diagnosis of osteoporosis and assessment of fracture risk significantly decreased during the COVID-19 pandemic, while the incidence of fragility fractures was mostly unaltered. Both COVID-19 per se and its treatments are associated with a negative impact on bone health. Preclinical models show that mice infected with SARS-CoV2 even without symptoms display loss of trabecular bone mass two weeks post infection, due to increased numbers of osteoclasts. Osteoporosis medications do not aggravate the clinical course of COVID-19, while preclinical data suggests possible beneficial effects of some therapies. While vitamin D deficiency is clearly associated with a worse clinical course of COVID-19, evidence of improved patient outcome with vitamin D supplementation is lacking. Osteoporosis treatment should not be generally discontinued, and recommendations for substituting therapies are available. Osteoporosis therapies do not interfere with the efficacy or side-effect profiles of COVID-19 vaccines and should not be stopped or indefinitely delayed because of vaccination. Thieme. All rights reserved.
</td>
</tr>
<tr>
<td style="text-align:left;">
35419694
</td>
<td style="text-align:left;">
Use of hyphenated analytical techniques to identify the bioactive constituents of Gunnera perpensa L., a South African medicinal plant, which potently inhibit SARS-CoV-2 spike glycoprotein-host ACE2 binding.
</td>
<td style="text-align:left;">
Analytical and bioanalytical chemistry
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
14
</td>
<td style="text-align:left;">
SARS-CoV-2, the causative agent of COVID-19, continues to cause global morbidity and mortality despite the increasing availability of vaccines. Alongside vaccines, antivirals are urgently needed to combat SARS-CoV-2 infection and spread, particularly in resource-limited regions which lack access to existing therapeutics. Small molecules isolated from medicinal plants may be able to block cellular entry by SARS-CoV-2 by antagonising the interaction of the viral spike glycoprotein receptor-binding domain (RBD) with the host angiotensin-converting enzyme II (ACE2) receptor. As the medicinal plant Gunnera perpensa L. is being used by some South African traditional healers for SARS-CoV-2/COVID-19 management, we hypothesised that it may contain chemical constituents that inhibit the RBD-ACE2 interaction. Using a previously described AlphaScreen-based protein interaction assay, we show here that the DCM:MeOH extract of G. perpensa readily disrupts RBD (USA-WA1/2020)-ACE2 interactions with a half-maximal inhibition concentration (IC50) of &amp;lt; 0.001 µg/mL, compared to an IC50 of 0.025 µg/mL for the control neutralising antibody REGN10987. Employing hyphenated analytical techniques like UPLC-IMS-HRMS (method developed and validated as per the International Conference on Harmonization guidelines), we identified two ellagitannins, punicalin (2.12% w/w) and punicalagin (1.51% w/w), as plant constituents in the DCM:MeOH extract of G. perpensa which antagonised RBD-ACE2 binding with respective IC50s of 9 and 29 nM. This good potency makes both compounds promising leads for development of future entry-based SARS-CoV-2 antivirals. The results also highlight the advantages of combining reverse pharmacology (based on medicinal plant use) with hyphenated analytical techniques to expedite identification of urgently needed antivirals.
</td>
</tr>
<tr>
<td style="text-align:left;">
35419561
</td>
<td style="text-align:left;">
Optimization of Anti-SARS-CoV-2 Neutralizing Antibody Therapies: Roadmap to Improve Clinical Effectiveness and Implementation.
</td>
<td style="text-align:left;">
Frontiers in medical technology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
One of the major breakthroughs to combat the current Coronavirus Disease 2019 (COVID-19) pandemic has been the development of highly effective vaccines against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Still, alternatives are needed for individuals who are at high risk of developing severe COVID-19 and are not protected by vaccination. Monoclonal antibodies against the spike protein of SARS-CoV-2 have been shown to be effective as prophylaxis and treatment against COVID-19. However, the emergence of variants of concern (VOCs) challenges the efficacy of antibody therapies. This review describes the neutralization resistance of the clinically-approved monoclonal antibody therapies against the Alpha (B.1.1.7), Beta (B.1.351), Gamma (P1), Delta (B.1.617.2), and the Omicron (B.1.1.529) variants. To guide the development of monoclonal antibody therapies and to anticipate on the continuous evolution of SARS-CoV-2, we highlight different strategies to broaden the antibody activity by targeting more conserved epitopes and/or simultaneously targeting multiple sites of vulnerability of the virus. This review further describes the contribution of antibody Fc effector functions to optimize the antibody efficacy. In addition, the main route of SARS-CoV-2 antibody administration is currently intravenously and dictates a monthly injection when used as prophylactic. Therefore, we discusses the concept of long-acting antibodies (LAABs) and non-intravenously routes of antibody administration in order to broaden the clinical applicability of antibody therapies.
</td>
</tr>
<tr>
<td style="text-align:left;">
35419368
</td>
<td style="text-align:left;">
Shedding of SARS-CoV-2 for 85 Days in COVID-19 Patients With Type 2 Diabetes Mellitus and Lung Metastasis: A Case Report.
</td>
<td style="text-align:left;">
Frontiers in medicine
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
COVID-19 (coronavirus disease 2019) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seriously endangers people’s lives. The variation in SARS-CoV-2 makes the research and development of vaccines and specific drugs particularly important. However, the prevention and diagnosis of COVID-19 cannot be underestimated in the control of the epidemic. We introduced a 65-year-old female patient who was diagnosed with COVID-19. The SARS-CoV-2 nucleic acid test result of this patient was positive again during treatment. It took 85 days from the first symptom to the final cure. According to the known reports, she is currently the patient with the longest virus shedding in Sichuan Province, China. Due to the patient’s special condition, she was treated in four hospitals before and after, and she was diagnosed with type 2 diabetes mellitus (T2DM) and right lung metastatic adenocarcinoma. We fully introduced the patient’s epidemiological history, diagnosis, testing, and treatment process. The patient was finally discharged from the hospital under the treatment of antiviral, hypoglycaemic, anti-anxiety, and a combination of Chinese and Western medicine. The epidemic is still rampant, and we should not relax our efforts in the prevention and control of viruses. For the elderly, especially those who are suffering from complications or vulnerable to diseases, it is recommended to extend the observation time. Additionally, medical workers should pay attention to the mental state of patients.
</td>
</tr>
<tr>
<td style="text-align:left;">
35418996
</td>
<td style="text-align:left;">
Sex, Age, and Ethnic Background Shape Adaptive Immune Responses Induced by the SARS-CoV-2 mRNA Vaccine.
</td>
<td style="text-align:left;">
Frontiers in immunology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine-induced adaptive responses have been well investigated. However, the effects of sex, age, and ethnic background on the immune responses elicited by the mRNA vaccine remain unclear. Here, we performed comprehensive analyses of adaptive immune responses elicited by the SARS-CoV-2 mRNA vaccine. Vaccine-induced antibody and T cell responses declined over time but persisted after 3 months, and switched memory B cells were even increased. Spike-specific CD4+ T and CD8+ T cell responses were decreased against the B.1.351 variant, but not against B.1.1.7. Interestingly, T cell reactivity against B.1.617.1 and B.1.617.2 variants was decreased in individuals carrying HLA-A24, suggesting adaptive immune responses against variants are influenced by different HLA haplotypes. T follicular helper cell responses declined with increasing age in both sexes, but age-related decreases in antibody levels were observed only in males, and this was associated with the decline of T peripheral helper cell responses. In contrast, vaccine-induced CD8+ T cell responses were enhanced in older males. Taken together, these findings highlight that significant differences in the reactogenicity of the adaptive immune system elicited by mRNA vaccine were related to factors including sex, age, and ethnic background.
</td>
</tr>
<tr>
<td style="text-align:left;">
35418817
</td>
<td style="text-align:left;">
Why Vaccinate Against COVID-19? A Population-Based Survey in Switzerland.
</td>
<td style="text-align:left;">
International journal of public health
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Objectives: This study examined factors associated with COVID-19 vaccination intention at the very beginning of the vaccination campaign in a representative sample of the population in southern Switzerland. Methods: In March 2021, we measured vaccination intention, beliefs, attitudes, and trust in a sample of the Corona Immunitas Ticino study. Results: Of the 2681 participants, 1933 completed the questionnaire (response rate = 72%; 55% female; meanage = 41, SD = 24, rangeage = 5-91). Overall, 68% reported an intention to get vaccinated. Vaccination intention was higher in social/healthcare workers, and increased with age, trust in public health institutions, and confidence in the vaccine efficacy. Prior infection of a family member, predilection for waiting for more evidence on the safety and efficacy of the vaccine, and for alternative protective means were negatively associated with intention. Conclusion: In view of needs of COVID-19 vaccine boosters and of suboptimal vaccination coverage, our results have relevant public health implications and suggest that communication about vaccine safety and efficacy, and aims of vaccination programs, should be bi-directional, proportionate, and tailored to the concerns, expectations, and beliefs of different population subgroups.
</td>
</tr>
<tr>
<td style="text-align:left;">
35418729
</td>
<td style="text-align:left;">
Epitope Identification and Designing a Potent Multi-epitope Vaccine Construct against SARS-CoV-2 Including the Emerging Variants.
</td>
<td style="text-align:left;">
Journal of global infectious diseases
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
The emergence of a novel coronavirus in China has turned into a SARS-CoV-2 pandemic with high fatality. As vaccines are developed through various strategies, their immunogenic potential may drastically vary and thus pose several challenges in offering immune responses against the virus. In this study, we adopted an immunoinformatics-aided approach for developing a new multi-epitope vaccine construct (MEVC). In silico approach was taken for the identification of B-cell and T-cell epitopes in the Spike protein, for MEVC various cytotoxic T-lymphocyte, helper T-lymphocyte, and B-cell epitopes with the highest affinity for the respective HLA alleles were assembled and joined by linkers. The computational data suggest that the MEVC is nontoxic, nonallergenic and thermostable and elicit both humoral and cell-mediated immune responses. Subsequently, the biological activity of MEVC was assessed by bioinformatic tools using the interaction between the vaccine candidate and the innate immune system receptors TLR3 and TLR4. The epitopes of the construct were analyzed with that of the strains belonging to various clades including the emerging variants having multiple unique mutations in S protein. Due to the advantageous features, the MEVC can be tested in vitro for more practical validation and the study offers immense scope for developing a potential vaccine candidate against SARS-CoV-2 in view of the public health emergency associated with COVID-19 disease caused by SARS-CoV-2. Copyright:
</td>
</tr>
<tr>
<td style="text-align:left;">
35418695
</td>
<td style="text-align:left;">
COVID-19 and kidney disease: insights from epidemiology to inform clinical practice.
</td>
<td style="text-align:left;">
Nature reviews. Nephrology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
13
</td>
<td style="text-align:left;">
Over the course of the COVID-19 pandemic, numerous studies have aimed to address the challenges faced by patients with kidney disease and their caregivers. These studies addressed areas of concern such as the high infection and mortality risk of patients on in-centre haemodialysis and transplant recipients. However, the ability to draw meaningful conclusions from these studies has in some instances been challenging, owing to barriers in aspects of usual care, data limitations and problematic methodological practices. In many settings, access to SARS-CoV-2 testing differed substantially between patient groups, whereas the incidence of SARS-CoV-2 infection varied over time and place because of differences in viral prevalence, targeted public health policies and vaccination rates. The absence of baseline kidney function data posed problems in the classification of chronic kidney disease and acute kidney injury in some studies, potentially compromising the generalizability of findings. Study findings also require attentive appraisal in terms of the effects of confounding, collider bias and chance. As this pandemic continues and in the future, the implementation of sustainable and integrated research infrastructure is needed in settings across the world to minimize infection transmission and both prevent and plan for the short-term and long-term complications of infectious diseases. Registries can support the real-world evaluation of vaccines and therapies in patients with advanced kidney disease while enabling monitoring of rare complications.
</td>
</tr>
<tr>
<td style="text-align:left;">
35418646
</td>
<td style="text-align:left;">
COVID vaccine IP waiver agreed.
</td>
<td style="text-align:left;">
Nature biotechnology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
35418628
</td>
<td style="text-align:left;">
Funny paper titles, COVID immunity and carbon storage.
</td>
<td style="text-align:left;">
Nature
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
35418436
</td>
<td style="text-align:left;">
Factors influencing hesitancy towards adult and child COVID-19 vaccines in rural and urban West Africa: a cross-sectional study.
</td>
<td style="text-align:left;">
BMJ open
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
13
</td>
<td style="text-align:left;">
This study aims: (1) to identify and describe similarities and differences in both adult and child COVID-19 vaccine hesitancy, and (2) to examine sociodemographic, perception-related and behavioural factors influencing vaccine hesitancy across five West African countries. Cross-sectional survey carried out between 5 May and 5 June 2021. 4198 individuals from urban and rural settings in Burkina Faso, Guinea, Mali, Senegal and Sierra Leone participated in the survey. The general protocol is registered on clinicaltrial.gov. Findings show that in West Africa at the time only 53% of all study participants reported to be aware of COVID-19 vaccines, and television (60%, n=1345), radio (56%; n=1258), social media (34%; n=764) and family/friends/neighbours (28%; n=634) being the most important sources of information about COVID-19 vaccines. Adult COVID-19 vaccine acceptance ranges from 60% in Guinea and 50% in Sierra Leone to 11% in Senegal. This is largely congruent with acceptance levels of COVID-19 vaccinations for children. Multivariable regression analysis shows that perceived effectiveness and safety of COVID-19 vaccines increased the willingness to get vaccinated. However, sociodemographic factors, such as sex, rural/urban residence, educational attainment and household composition (living with children and/or elderly), and the other perception parameters were not associated with the willingness to get vaccinated in the multivariable regression model. Primary sources of information about COVID-19 vaccines include television, radio and social media. Communication strategies addressed at the adult population using mass and social media, which emphasise COVID-19 vaccine effectiveness and safety, could encourage greater acceptance also of COVID-19 child vaccinations in sub-Saharan countries. NCT04912284.
</td>
</tr>
<tr>
<td style="text-align:left;">
35418174
</td>
<td style="text-align:left;">
COVID-19 Vaccine and Fertility: The Male Perspective.
</td>
<td style="text-align:left;">
Irish medical journal
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Feb
</td>
<td style="text-align:left;">
17
</td>
<td style="text-align:left;">
Aims The expedited development of multiple COVID-19 vaccines has raised concerns for some, with vaccine hesitancy described in many populations. A U.S. study assessing fertility patients attitudes towards the COVID -19 vaccine revealed that over half were unsure, or would not accept the vaccine if offered. Only 7.4% of participants in this study were male. We therefore sought to assess the perspective of male fertility patients towards COVID-19 vaccination. Methods Men with a fertility appointment were invited to complete an anonymous 21-item questionnaire. Results Willingness to accept the COVID-19 vaccination was influenced by stage of fertility journey. Overall, 76% (n=102) of participants were willing to receive the COVID-19 vaccine. Men with a pregnant partner were most likely to accept or have already accepted the vaccine (97%, 30/31). Conclusion Although concerns around COVID-19 vaccines persist, this study demonstrates the growing rate of acceptance and engagement among the male fertility population.
</td>
</tr>
<tr>
<td style="text-align:left;">
35417991
</td>
<td style="text-align:left;">
Clinical profile of patients infected with suspected SARS-CoV-2 Omicron variant of concern, Tamil Nadu, India, December 2021-January 2022.
</td>
<td style="text-align:left;">
The Indian journal of medical research
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
14
</td>
<td style="text-align:left;">
mp; objectives” COVID-19 cases have been rising rapidly in countries where the SARS-CoV-2 variant of concern (VOC), Omicron (B.1.1.529) has been reported. We conducted a study to describe the epidemiological and clinical characteristics and outcomes of COVID-19 patients with ‘S’ gene target failure (SGTF, suspected Omicron). Furthermore, their clinical outcomes with COVID-19 patients with non-SGTF (non-Omicron) were also compared. This study was conducted in Tamil Nadu, India, between December 14, 2021 and January 7, 2022 among patients who underwent reverse transcription-PCR testing for SARS-CoV-2 in four laboratories with facilities for S gene screening. Consecutively selected COVID-19 patients with SGTF were telephonically contacted, 7 and 14 days respectively after their date of positive result to collect information on the socio-demographic characteristics, previous history of COVID-19, vaccination status and clinical course of illness along with treatment details. To compare their outcomes with non-SGTF patients, one randomly suspected non-Omicron case for every two suspected Omicron cases from the line-list were selected, matching for the date of sample collection and the testing laboratory. A total of 1175 SGTF COVID-19 patients were enrolled for this study. Almost 6 per cent (n=72) reported a history of previous infection. 141 (13.5%) suspected Omicron cases were non-vaccinated, while 148 (14.2%) and 703 (67.4%) had received valid one and two doses of COVID-19 vaccines, respectively. Predominant symptoms reported included fever (n=508, 43.2%), body pain (n=275, 23.4%), running nose (n=261, 22.2%) and cough (n=249, 21.2%). Five (0.4%) of the 1175 suspected Omicron cases required oxygen supplementation as compared to ten (1.6%) of the 634 suspected non-Omicron cases. No deaths were reported among omicron suspects, whereas there were four deaths among suspected non-Omicron cases. mp; conclusions” Majority of the suspected Omicron cases had a mild course of illness. The overall severity of these cases was less compared to the suspected non-Omicron cases.
</td>
</tr>
<tr>
<td style="text-align:left;">
35417874
</td>
<td style="text-align:left;">
SEVERE LEUKOCYTOCLASTIC VASCULITIS AFTER COVID-19 VACCINATION - CAUSE OR COINCIDENCE? CASE REPORT AND LITERATURE REVIEW.
</td>
<td style="text-align:left;">
Georgian medical news
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Mar
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Vaccination has been the most powerful tool to fight the COVID-19 pandemic while the specific treatment options in clinical practice have been under review for approval and authorization by regulatory bodies. After registration of different vaccines, it is important to ensure a post-marketing surveillance to identify potential risks not observed in controlled trials. Authors report on the case of an 80-year-old male patient who developed severe leukocytoclastic vasculitis of skin and oral mucous membrane after receiving the second dose of COVID-19 mRNA vaccine. He was treated successfully with prednisolone. We also provide a literature review on other reported cases of COVID-19 vaccine induced vasculitis. This type of an adverse reaction seems to be rare. Fortunately, most cases were temporary and well controlled by corticosteroids. The majority of vaccine-associated vasculitis cases have been observed in association with BONT162b2 mRNA vaccine although other vaccines also may cause the event. The knowledge of this possible adverse event is important for early diagnosis and intervention.
</td>
</tr>
<tr>
<td style="text-align:left;">
35417663
</td>
<td style="text-align:left;">
Willingness toward COVID-19 vaccination, coadministration with other vaccines and receive a COVID-19 vaccine booster: a cross-sectional study on the guardians of children in China.
</td>
<td style="text-align:left;">
Human vaccines &amp;amp; immunotherapeutics
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
13
</td>
<td style="text-align:left;">
This study aimed to investigate the changes in the willingness of guardians to administer the COVID-19 vaccine to their children, allow the coadministration of other vaccines, and administer the COVID-19 vaccine booster dose. This was a follow-up study conducted 6 months after a similar previous study. The self-administered questionnaire was distributed through the “Xiao Dou Miao” app and 9424 guardians with access to this app participated in the survey that was conducted from September 15 to October 8, 2021. Of all the participating guardians, 86.68% were willing to vaccinate their children with the COVID-19 vaccine, which was approximately 16% more than those in our previous study. Guardians aged ≥40 years, healthcare workers, and those with children aged ≥3 years were more willing to vaccinate their children. Approximately 77% of the guardians were willing toward the coadministration of COVID-19 and influenza vaccines. Approximately 64% of the guardians were willing toward the coadministration of other nonimmunization program vaccines with the COVID-19 vaccine for their children. The primary reasons for reluctance toward the coadministration of vaccines were concerns about vaccine safety and effectiveness. If necessary, 92% of the guardians were willing to receive a COVID-19 vaccine booster and 82% were willing to vaccinate their children with a COVID-19 vaccine booster. We hope that this research will facilitate the formulation of successful strategies for the implementation of COVID-19 vaccinations, covaccinations, and COVID-19 booster doses, particularly for children aged &amp;lt;6 years.
</td>
</tr>
<tr>
<td style="text-align:left;">
35417394
</td>
<td style="text-align:left;">
[Non-specific effect of vaccines, types of immunity and variants of SARS-CoV-2].
</td>
<td style="text-align:left;">
Medicina
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
35417318
</td>
<td style="text-align:left;">
SARS-CoV-2 vaccine breakthrough reinfection in a health-care worker of Iraq: a case report.
</td>
<td style="text-align:left;">
Human vaccines &amp;amp; immunotherapeutics
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
13
</td>
<td style="text-align:left;">
The COVID-19 pandemic has severely affected the entire globe since the first isolation of SARS-CoV-2 from patients with severe respiratory illness in Wuhan, China. Although the global vaccination drive is in full swing, many cases of reinfection have also been reported after vaccination. Currently, there is a scarcity of data available on the reinfection and vaccine breakthrough infections in Iraq. In this letter, we have presented a case report on the SARS-CoV-2 vaccine breakthrough reinfection in a health-care worker after completion of the double-dose vaccination. An increased symptom severity was reported on the second infection, which was confirmed to be of Delta variant. Such vaccine breakthrough infection reports have raised important questions regarding the duration of vaccine-mediated immunity and vaccine effectiveness against all circulating variants. These have further emphasized the importance of following non-pharmaceutical interventions by fully vaccinated individuals, especially at health-care settings.
</td>
</tr>
<tr>
<td style="text-align:left;">
35417285
</td>
<td style="text-align:left;">
Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines.
</td>
<td style="text-align:left;">
Human vaccines &amp;amp; immunotherapeutics
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
13
</td>
<td style="text-align:left;">
It is unknown how long the immunity following COVID-19 vaccination lasts. The current systematic review provides a perspective on the persistence of various antibodies for available vaccines.Both the BNT162b2 and the mRNA-1273 induce the production of IgA antibodies, reflecting the possible prevention of the asymptomatic spread. The mRNA-1273 vaccine’s antibodies were detectable until 6 months, followed by the AZD1222, 3 months, the Ad26.COV2.S and the BNT162b2 vaccines within 2 months.The BNT162b2 produced anti-spike IgGs 11 days after the first dose and peaked at day 21, whereas the AZD1222 induced a neutralizing effect 22 days after the first dose.These vaccines induce T-cell mediated immune responses too. Each one of the AZD1222, Ad26.COV2.S, mRNA-1273 mediates T-cell response immunity at days 14-22, 15, and 43 after the first dose, respectively. Whereas for the BNT162b1 and BNT162b2 vaccines, T-cell immunity is induced 7 days and 12 weeks after the booster dose, respectively.
</td>
</tr>
<tr>
<td style="text-align:left;">
35417284
</td>
<td style="text-align:left;">
Exploring the impact of media and information on self-reported intentions to vaccinate against COVID-19: A qualitative interview-based study.
</td>
<td style="text-align:left;">
Human vaccines &amp;amp; immunotherapeutics
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
13
</td>
<td style="text-align:left;">
The World Health Organization declared vaccine hesitancy a top threat to global health following resurgence of vaccine-preventable diseases close to eradication in many countries (e.g. measles). Vaccines are effective in preventing severe illness, hospitalization, and death from COVID-19, yet there remains a small proportion of the eligible population who choose not to vaccinate. Social media and online news sources are opportunities for targeted public health interventions to improve vaccine uptake. This study reports the results of a semi-structured interview study that explored the influence of media and information on individuals’ self-reported intentions to vaccinate against COVID-19. A qualitative descriptive study was employed to gain insight from a diverse group of individuals. Adult participants were recruited through a related COVID-19 study; we used a maximum variation sampling technique and purposively sampled participants based on demographics. Interviews were conducted from February 2021 to May 2021. Themes from interviews were summarized with representative quotations according to the 3C Theoretical Framework (Confidence, Complacency, Convenience). Key themes identified following thematic analysis from 60 participants included: vaccine safety, choice of vaccine, fear mongering, trust in authority, belief in vaccinations (Confidence); delaying vaccination (Complacency); confusing information, access to vaccines and information (Convenience). While most participants intended to vaccinate, many expressed concerns and hesitancy. COVID-19 vaccine hesitancy prevents universal immunization and contradictory messages in media are a source of concern and fear. The success of future vaccine campaigns will depend upon authorities’ ability to disseminate accessible, detailed, and consistent information promoting public confidence.
</td>
</tr>
<tr>
<td style="text-align:left;">
35417115
</td>
<td style="text-align:left;">
A Fourth Dose of COVID-19 Vaccine Does Not Induce Neutralization of the Omicron Variant Among Solid Organ Transplant Recipients With Suboptimal Vaccine Response.
</td>
<td style="text-align:left;">
Transplantation
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
04
</td>
<td style="text-align:left;">
Humoral responses to coronavirus disease 2019 (COVID-19) vaccines are attenuated in solid organ transplant recipients (SOTRs), necessitating additional booster vaccinations. The Omicron variant demonstrates substantial immune evasion, and it is unknown whether additional vaccine doses increase neutralizing capacity versus this variant of concern (VOC) among SOTRs. Within an observational cohort, 25 SOTRs with low seroresponse underwent anti-severe acute respiratory syndrome coronavirus 2 spike and receptor-binding domain immunoglobulin (Ig)G testing using a commercially available multiplex ELISA before and after a fourth COVID-19 vaccine dose (D4). Surrogate neutralization (percent angiotensin-converting enzyme 2 inhibition [%ACE2i], range 0%-100% with &amp;gt;20% correlating with live virus neutralization) was measured against full-length spike proteins of the vaccine strain and 5 VOCs including Delta and Omicron. Changes in IgG level and %ACE2i were compared using the paired Wilcoxon signed-rank test. Anti-receptor-binding domain and anti-spike seropositivity increased post-D4 from 56% to 84% and 68% to 88%, respectively. Median (interquartile range) anti-spike antibody significantly increased post-D4 from 42.3 (4.9-134.2) to 228.9 (1115.4-655.8) World Health Organization binding antibody units. %ACE2i (median [interquartile range]) also significantly increased against the vaccine strain (5.8% [0%-16.8%] to 20.6% [5.8%-45.9%]) and the Delta variant (9.1% [4.9%-12.8%] to 17.1% [10.3%-31.7%]), yet neutralization versus Omicron was poor, did not increase post-D4 (4.1% [0%-6.9%] to 0.5% [0%-5.7%]), and was significantly lower than boosted healthy controls. Although a fourth vaccine dose increases anti-spike IgG and neutralizing capacity against many VOCs, some SOTRs may remain at high risk for Omicron infection despite boosting. Thus, additional protective interventions or alternative vaccination strategies should be urgently explored.
</td>
</tr>
<tr>
<td style="text-align:left;">
35416747
</td>
<td style="text-align:left;">
The need for vaccination in adults with chronic (noncommunicable) diseases in India - lessons from around the world.
</td>
<td style="text-align:left;">
Human vaccines &amp;amp; immunotherapeutics
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
13
</td>
<td style="text-align:left;">
Worldwide, chronic diseases (noncommunicable diseases [NCDs]) cause 41 million (71%) deaths annually. They are the leading cause of mortality in India, contributing to 60% of total deaths each year. Individuals with these diseases are more susceptible to vaccine-preventable diseases (VPDs) and have an increased risk of associated disease severity and complications. This poses a substantial burden on healthcare systems and economies, exemplified by the COVID-19 pandemic. Vaccines are an effective strategy to combat these challenges; however, utilization rates are inadequate. With India running one of the world’s largest COVID-19 vaccination programs, this presents an opportunity to improve vaccination coverage for all VPDs. Here we discuss the burden of VPDs in those with NCDs, the benefit of vaccinations, current challenges and possible strategies that may facilitate implementation and accessibility of vaccination programs. Effective vaccination will have a significant impact on the disease burden of both VPDs and NCDs and beyond.
</td>
</tr>
<tr>
<td style="text-align:left;">
35416291
</td>
<td style="text-align:left;">
Natural killer cell-mediated ADCC in SARS-CoV-2-infected individuals and vaccine recipients.
</td>
<td style="text-align:left;">
European journal of immunology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
13
</td>
<td style="text-align:left;">
COVID-19, caused by SARS-CoV-2, has emerged as a global pandemic. While immune responses of the adaptive immune system have been in the focus of research, the role of NK cells in COVID-19 remains less well understood. Here, we characterized NK cell-mediated SARS-CoV-2 antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 spike-1 (S1) and nucleocapsid (NC) protein. Serum samples from SARS-CoV-2 resolvers induced significant CD107a-expression by NK cells in response to S1 and NC, while serum samples from SARS-CoV-2-negative individuals did not. Furthermore, serum samples from individuals that received the BNT162b2 vaccine induced strong CD107a expression by NK cells that increased with the second vaccination and was significantly higher than observed in infected individuals. As expected, vaccine-induced responses were only directed against S1 and not against NC protein. S1-specific CD107a responses by NK cells were significantly correlated to NK cell-mediated killing of S1-expressing cells. Interestingly, screening of serum samples collected prior to the COVID-19 pandemic identified two individuals with cross-reactive antibodies against SARS-CoV-2 S1, which also induced degranulation of NK cells. Taken together, these data demonstrate that antibodies induced by SARS-CoV-2 infection and anti-SARS-CoV-2 vaccines can trigger significant NK cell-mediated ADCC activity, and identify some cross-reactive ADCC-activity against SARS-CoV-2 by endemic coronavirus-specific antibodies.
</td>
</tr>
<tr>
<td style="text-align:left;">
35415189
</td>
<td style="text-align:left;">
Influence of sex, season and environmental air quality on experimental human pneumococcal carriage acquisition: a retrospective cohort analysis.
</td>
<td style="text-align:left;">
ERJ open research
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Streptococcus pneumoniae (pneumococcus) is the most commonly identified bacterial cause of pneumonia and the leading infectious cause of death in children under 5 years of age worldwide. Pneumococcal disease follows a seasonal pattern with increased incidence during winter. Pneumonia burden is also associated with poor air quality. Nasopharyngeal carriage of the bacterium is a pre-requisite of invasive disease. We aimed to determine if susceptibility to nasopharyngeal pneumococcal carriage varied by season and which environmental factors might explain such variation. We also evaluated the influence of sex on susceptibility of carriage. We collated data from five studies in which human volunteers underwent intranasal pneumococcal challenge. Generalised linear mixed-effects models were used to identify factors associated with altered risk of carriage acquisition, specifically climate and air-quality data. During 2011-2017, 374 healthy adults were challenged with type 6B pneumococcus. Odds of carriage were significantly lower in males (OR, 0.61; 95% CI, 0.40-0.92; p=0.02), and higher with cooler temperatures (OR, 0.79; 95% CI, 0.63-0.99; p=0.04). Likelihood of carriage was also associated with lower concentrations of local fine particulate matter concentrations (PM2.5) and increased local rainfall. In contrast to epidemiological series, experimental challenge allowed us to test propensity to acquisition during controlled exposures; immunological explanations for sex and climatic differences should be sought.
</td>
</tr>
<tr>
<td style="text-align:left;">
35414631
</td>
<td style="text-align:left;">
Immunogenicity and safety of COVID-19 vaccination in patients with primary Sjögren’s syndrome.
</td>
<td style="text-align:left;">
RMD open
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
To evaluate humoral and cellular immune responses and adverse events (AEs) after COVID-19 vaccination in patients with primary Sjögren’s syndrome (pSS) compared to healthy controls (HC), and disease activity following vaccination in patients with pSS. 67 patients with pSS and 33 HC (ratio 2:1) received COVID-19 vaccinations following the Dutch vaccination programme. Patients with pSS did not use immunomodulatory drugs, except hydroxychloroquine. Anti-spike 1 receptor binding domain IgG serum antibody levels were measured 28 days after complete vaccination. AEs were collected 7 days after vaccination. In a subgroup, salivary anti-SARS-CoV-2 antibodies and T-cell response by interferon-γ enzyme-linked immune absorbent spot was measured. 47 patients with pSS (70%) and 14 HC (42%) received BNT162b2 (Pfizer-BioNtech), 13 (19%) and 5 (15%) received ChAdOx1 nCoV-19 (AstraZeneca), 6 (9%) and 8 (24%) received mRNA-1273 (Moderna), and 1 (1%) and 6 (18%) received Ad.26.COV2.S (Janssen). All participants had positive anti-SARS-CoV-2 antibody levels (&amp;gt;2500 AU/mL) postvaccination. No differences in anti-SARS-CoV-2 antibody levels were observed between patients with pSS and HC, for each vaccine type. Salivary anti-SARS-CoV-2 IgG antibodies also increased, and a T-cell response was observed in patients with pSS and HC. Frequencies of systemic AEs were comparable between patients with pSS and HC (first vaccination: 34/67 (51%) vs 16/33 (48%), p=0.83; second: 41/66 (62%) vs 14/25 (56%), p=0.59). No significant worsening was observed in patient-reported and systemic disease activity, including auto-antibodies. Patients with pSS had similar humoral and cellular immune responses as HC, suggesting COVID-19 vaccination is effective in patients with pSS. AEs were also comparable, and no increase in disease activity was seen in patients with pSS.
</td>
</tr>
<tr>
<td style="text-align:left;">
35414629
</td>
<td style="text-align:left;">
COVAX delivers its 1 billionth COVID-19 vaccine doseCOVID-19 pandemic triggers 25% increase in prevalence of anxiety and depression worldwide.
</td>
<td style="text-align:left;">
Saudi medical journal
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
35414617
</td>
<td style="text-align:left;">
Side-effects of COVID-19 vaccines among the Saudi population: A cross-sectional study.
</td>
<td style="text-align:left;">
Saudi medical journal
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
To measure and assess the side-effects of Pfizer/BioNTech and AstraZeneca vaccines on residents of Saudi Arabia, as well as provide a database that gives insight into the relative safety of these 2 COVID-19 vaccines. A community-based cross-sectional study was conducted to determine the side-effects of the two COVID-19 vaccines. The study was initiated on the 5th of June 2021 at Hail University, Hail, Saudi Arabia. The information was collected through an online survey designed on Google forms. The questionnaire was pre-tested for validity, with all information carefully reviewed. The study included 2,530 participants from different regions of Saudi Arabia, with a mean age of 26.9 ± 12.4 years old. The most common vaccine among the study group was Pfizer, which 73.8% of the population were provided; the remaining 26.2% received the AstraZeneca vaccine. Regarding the Pfizer vaccine, the common systemic side-effects followed the first dose, included headaches, followed by muscle pain, fever, and joint pain. Those who had the AstraZeneca vaccine reported a few more side-effects. For example, during the first dose fever was reported as the most common side-effect, followed by headache, muscle pain and fatigue. The present study confirmed that vaccine side-effects are more frequently reported by smokers and those who received the AstraZeneca vaccine. Further studies are needed to acquire a better understanding of the association between risk factors and the experiencing of post-vaccine side-effects. Copyright:
</td>
</tr>
<tr>
<td style="text-align:left;">
35414417
</td>
<td style="text-align:left;">
Factors associated with COVID-19 vaccination intent in Singapore, Australia and Hong Kong.
</td>
<td style="text-align:left;">
Vaccine
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
05
</td>
<td style="text-align:left;">
COVID-19 pandemic has caused significant morbidity and mortality globally. As vaccines have been developed under expedited conditions, their safety and efficacy are being questioned by some populations leading to vaccine hesitancy, resulting in delayed vaccine uptake and herd immunity. This study aims to adopt a combination of Health Belief Model and other independent risk factors associated with high vaccine acceptance. An anonymized cross-sectional survey was distributed between 15 January and 3 February 2021 across Singapore, Hong Kong and Australia among adult respondents through a certified online panel. Exploratory factor analysis and confirmatory factor analysis were carried out to assess perception constructs followed by multivariate regression modelling to assess factors associated with high vaccine acceptance against SARS_CoV-2. A total of 3,133 anonymised participants from Singapore (n = 1,009), Australia (n = 1,118) and Hong Kong (n = 1,006) completed the survey. While age and gender were not significantly associated, Asian ethnicity, current smokers and self-efficacy were significant associated factors of increased vaccine acceptance. While specific practices like taking micronutrients more frequently, cleaning and disinfecting their house more often were positively associated with increased vaccine acceptance, seeking medical help for COVID-19 symptoms like loss of smell/taste and overall COVID-19 knowledge score were negatively associated. Increased likelihood of vaccine acceptance was seen among those that obtained COVID-19 information less frequently and used digital media or non-health-related sources like influencers as a source of information. Among the eight perception constructs, perceived susceptibility and perceived response efficacy were positively associated, while perceived barriers were negatively associated with high vaccine acceptance. While demographic parameters have weak association with vaccine acceptance, perceptions and practices parameters can help to better understand and influence vaccine acceptance. Study findings should provide guidance on the risk communication strategy to enhance vaccine acceptance for vaccination and boosters against new SARS-CoV-2 variants.
</td>
</tr>
<tr>
<td style="text-align:left;">
35414326
</td>
<td style="text-align:left;">
Myocarditis following COVID-19 vaccination: incidence, mechanisms, and clinical considerations.
</td>
<td style="text-align:left;">
Expert review of cardiovascular therapy
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
18
</td>
<td style="text-align:left;">
Vaccines have demonstrated protection against the morbidity and mortality of COVID-19, but concerns regarding the rare side effect of acute myocarditis have stymied immunization efforts. This review aims to describe the incidence and theorized mechanisms of COVID vaccine-associated myocarditis and review relevant principles for management of vaccine-associated myocarditis. Epidemiologic studies of myocarditis after COVID vaccination are reviewed, which show an incidence of approximately 20-30 per million patients. The vast majority of these cases are seen with mRNA vaccines especially in male patients under 30 years of age. Mechanisms are largely theoretical, but molecular mimicry and dysregulated innate immune reactions have been proposed. While studies suggest that this subtype of myocarditis is mild and self-limited, long-term evidence is lacking. Principles of myocarditis treatment and surveillance are outlined as they apply to COVID vaccine-associated myocarditis. COVID vaccine-associated myocarditis is rare but well described in certain at-risk groups. Better understanding of its pathogenesis is key to mitigating this complication and advancing vaccination efforts. Risk-benefit analyses demonstrate that individual- and population-level benefits of vaccination exceed the risks of this rare and mild form of myocarditis.
</td>
</tr>
<tr>
<td style="text-align:left;">
35414311
</td>
<td style="text-align:left;">
Exposure Effects or Confirmation Bias? Examining Reciprocal Dynamics of Misinformation, Misperceptions, and Attitudes Toward COVID-19 Vaccines.
</td>
<td style="text-align:left;">
Health communication
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
12
</td>
<td style="text-align:left;">
This longitudinal study integrates exposure effects and confirmation bias under the theoretical framework of dynamic motivation activation (DMA) to examine the dynamic reciprocity of misinformation, misperceptions, and attitudes in the context of COVID-19 vaccination. Results from a three- national survey showed that misinformation exposure, misperceptions, and attitudes toward COVID-19 vaccines reinforced themselves over time. Further, misperceptions reduced subsequent pro-vaccine attitudes, and pro-vaccine attitudes in turn decreased subsequent misperceptions. Longitudinal mediation analysis also indicated that attitudes reinforced themselves through misperceptions. Surprisingly, we did not find a significant impact of misinformation exposure on subsequent misperceptions or effects of attitudes on subsequent misinformation exposure. These findings highlight the importance of addressing misperceptions regarding COVID-19 vaccines and provide insights for theoretical development in research on exposure effects and confirmation bias.
</td>
</tr>
<tr>
<td style="text-align:left;">
35414157
</td>
<td style="text-align:left;">
Reverse vaccinology approach for multi-epitope centered vaccine design against delta variant of the SARS-CoV-2.
</td>
<td style="text-align:left;">
Environmental science and pollution research international
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
12
</td>
<td style="text-align:left;">
The ongoing COVID-19 outbreak, initially identified in Wuhan, China, has impacted people all over the globe and new variants of concern continue to threaten hundreds of thousands of people. The delta variant (first reported in India) is currently classified as one of the most contagious variants of SARS-CoV-2. It is estimated that the transmission rate of delta variant is 225% times faster than the alpha variant, and it is causing havoc worldwide (especially in the USA, UK, and South Asia). The mutations found in the spike protein of delta variant make it more infective than other variants in addition to ruining the global efficacy of available vaccines. In the current study, an in silico reverse vaccinology approach was applied for multi-epitope vaccine construction against the spike protein of delta variant, which could induce an immune response against COVID-19 infection. Non-toxic, highly conserved, non-allergenic and highly antigenic B-cell, HTL, and CTL epitopes were identified to minimize adverse effects and maximize the efficacy of chimeric vaccines that could be developed from these epitopes. Finally, V1 vaccine construct model was shortlisted and 3D modeling was performed by refinement, docking against HLAs and TLR4 protein, simulation and in silico expression. In silico evaluation showed that the designed chimeric vaccine could elicit an immune response (i.e., cell-mediated and humoral) identified through immune simulation. This study could add to the efforts of overcoming global burden of COVID-19 particularly the variants of concern.
</td>
</tr>
<tr>
<td style="text-align:left;">
35413911
</td>
<td style="text-align:left;">
Studying SARS-CoV-2 vaccine hesitancy among health professionals in Tunisia.
</td>
<td style="text-align:left;">
BMC health services research
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
12
</td>
<td style="text-align:left;">
People’s lives were seriously affected by the emergence and the spread of the COVID-19 disease. Several vaccines were developed in record time to overcome this pandemic. However, putting an end to this public health problem requires substantial vaccination coverage rate. This latter depends on the acceptance of these vaccines especially by health professionals; the leaders of the current war against COVID-19. In fact, they have a central role in promoting vaccination against the SARS-CoV-2. In the developed countries, hesitancy rates towards these vaccines among health professionals vary from 4.3% to 72%. In the developing countries, few studies focused on this issue. To estimate the prevalence and the predictors of SARS-CoV-2 vaccine hesitancy among the Tunisian health professionals. A cross-sectional study was led online between the 7th and the 21th of January 2021 among Tunisian health professionals. At least 460 participants were required. Snowball sampling method served to recruit participants. Data were collected using a pre-established and pre-tested questionnaire recorded in a free Google form. The link of the questionnaire was disseminated online to be self-administered anonymously to the participants. The generated online Google Sheet was uploaded and exported to SPSS software for analysis. Of the 546 responses, 493 were retained. The mean age of participants was 37.4 (± 9.5) years. Females represented 70.2% of participants. Social media represented the most frequently used source of information about COVID-19. The prevalence of SARS-CoV-2 vaccine hesitancy among participants was 51.9% (95% CI: 47.5-56.3)). Female sex, working far from the capital and having concerns about the vaccines components predicted more hesitancy among participants. In contrast, the use of the national COVID-19 information website predicted less hesitancy among them. The current Tunisian communication plan about COVID-19 vaccines must be reinforced. Social media represent a cost effective communication channel that can serve to reassure Tunisian health professionals regarding the safety of COVID-19 vaccines. Special interest should be paid to females, paramedical professionals and those working far from the capital.
</td>
</tr>
<tr>
<td style="text-align:left;">
35413894
</td>
<td style="text-align:left;">
Prioritizing COVID-19 vaccination efforts and dose allocation within Madagascar.
</td>
<td style="text-align:left;">
BMC public health
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
12
</td>
<td style="text-align:left;">
While mass COVID-19 vaccination programs are underway in high-income countries, limited availability of doses has resulted in few vaccines administered in low and middle income countries (LMICs). The COVID-19 Vaccines Global Access (COVAX) is a WHO-led initiative to promote vaccine access equity to LMICs and is providing many of the doses available in these settings. However, initial doses are limited and countries, such as Madagascar, need to develop prioritization schemes to maximize the benefits of vaccination with very limited supplies. There is some consensus that dose deployment should initially target health care workers, and those who are more vulnerable including older individuals. However, questions of geographic deployment remain, in particular associated with limits around vaccine access and delivery capacity in underserved communities, for example in rural areas that may also include substantial proportions of the population. To address these questions, we developed a mathematical model of SARS-CoV-2 transmission dynamics and simulated various vaccination allocation strategies for Madagascar. Simulated strategies were based on a number of possible geographical prioritization schemes, testing sensitivity to initial susceptibility in the population, and evaluating the potential of tests for previous infection. Using cumulative deaths due to COVID-19 as the main outcome of interest, our results indicate that distributing the number of vaccine doses according to the number of elderly living in the region or according to the population size results in a greater reduction of mortality compared to distributing doses based on the reported number of cases and deaths. The benefits of vaccination strategies are diminished if the burden (and thus accumulated immunity) has been greatest in the most populous regions, but the overall strategy ranking remains comparable. If rapid tests for prior immunity may be swiftly and effectively delivered, there is potential for considerable gain in mortality averted, but considering delivery limitations modulates this. At a subnational scale, our results support the strategy adopted by the COVAX initiative at a global scale.
</td>
</tr>
<tr>
<td style="text-align:left;">
35413588
</td>
<td style="text-align:left;">
Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan.
</td>
<td style="text-align:left;">
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
06
</td>
<td style="text-align:left;">
In Taiwan, the vaccination program started in March 2021, with ChAdOx1-S being the first available WHO-approved COVID-19 vaccine, followed by Moderna vaccine. This study aimed to investigate the immunogenicity and safety of homologous and heterologous prime-boost regimens with ChAdOx1-S and mRNA-1273. From March to November 2021, homologous or heterologous regimens with ChAdOx1-S and mRNA-1273 vaccination (ChAdOx1-S/ChAdOx1-S, mRNA-1273/mRNA-1273, ChAdOx1-S/mRNA-1273) were given to 945 healthy participants. Serum samples were collected at designated time points. The anti-RBD/S1 antibody titers and neutralizing ability were measured by three different immunoassays: Elecsys® Anti-SARS-CoV-2 S (Roche Diagnostics, Mannheim, Germany), AdviseDx SARS-CoV-2 IgG II (Abbott Diagnostics Division, Sligo, Ireland), and cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit (GenScript, New Jersey, USA). We found that heterologous vaccination with ChAdOx1-S/mRNA-1273 had an acceptable safety profile and induced higher total anti-RBD/S1 antibody production (p &amp;lt; 0.0001), yet lower anti-RBD/S1 IgG titer (p &amp;lt; 0.0001) and neutralizing ability (p = 0.0101) than mRNA-1273/mRNA-1273 group. Both regimens showed higher antibody titers and superior neutralizing abilities than ChAdOx1-S/ChAdOx1-S. An age-dependent antibody response to ChAdOx1-S/mRNA-1273 was shown after both the priming and the booster doses. Younger age was associated with higher antibody production and neutralizing ability. Heterologous ChAdOx1-S/mRNA-1273 vaccination regimen is generally safe and induces a robust humoral immune response that is non-inferior to that of mRNA-1273/mRNA-1273.
</td>
</tr>
<tr>
<td style="text-align:left;">
35413468
</td>
<td style="text-align:left;">
Worsening of Graves’ ophthalmopathy after SARS-CoV-2 mRNA vaccination.
</td>
<td style="text-align:left;">
Autoimmunity reviews
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
09
</td>
<td style="text-align:left;">
More reports are documenting how vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could represent new external triggers for autoimmune endocrine diseases (AIED) in patients with individual predisposition. We report two cases of Graves’ Ophthalmopathy (GO) recrudescence few days after the administration of BNT162B2 (Pfizer-BioNTech) SARS-CoV-2 vaccine. Even if causality relationship cannot be excluded, the development of these events could be explained through immune mediated mechanism such as the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). While further investigations are necessary to improve our knowledge of the underlying pathogenesis of these phenomena, caution may be warranted when vaccinating individuals with known autoimmune diseases.
</td>
</tr>
<tr>
<td style="text-align:left;">
35413166
</td>
<td style="text-align:left;">
Dynamics of hospitalizations and in-hospital deaths from COVID-19 in Northeast Brazil: a retrospective analysis based on the circulation of SARS-CoV-2 variants and vaccination coverage.
</td>
<td style="text-align:left;">
Epidemiology and health
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
05
</td>
<td style="text-align:left;">
This study investigated the dynamics of hospitalizations and in-hospital deaths from COVID-19 throughout the pandemic in Northeast Brazil, a region with the worst socioeconomic indicators in the country. A total of 141,445 cases, 8,213 hospital admissions and 1,644 in-hospital deaths from COVID-19 were registered from 14 March 2020 to 5 February 2022. The overall rates of hospitalization and in-hospital deaths were 5.8% and 20%, respectively. Our study showed a significant decrease in hospitalization and death rates over time, which may be related to the advance of vaccination in the region. During the spread of the Gamma variant (January - June 2021), most hospitalized individuals were young adults and circa 40% of deaths occurred in this age group. During predominance of Delta (July - December 2021), at least 75% of deaths occurred among the elderly and unvaccinated or partially vaccinated individuals. This rate has been reduced to 42.3% due to the transmission of the Omicron variant (January - February 2022), while 34.6% of deaths were recorded among fully vaccinated individuals at 2 doses and 23.1% among those fully vaccinated plus a booster dose. The Omicron-driven third wave has been associated to the rise in the proportion of deaths among vaccinated individuals, especially among those who had not received a booster dose.
</td>
</tr>
<tr>
<td style="text-align:left;">
35412949
</td>
<td style="text-align:left;">
Explaining COVID-19 postvaccination-related immune thrombotic thrombocytopenia: a hypothesis-generating in-silico approach.
</td>
<td style="text-align:left;">
Human vaccines &amp;amp; immunotherapeutics
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
12
</td>
<td style="text-align:left;">
Cases that experienced COVID-19 postvaccination-related thrombosis have been reported after the first dose of ChAdOx1 nCov-19 (Vaxzevria, AstraZeneca) or Ad26.COV2.S (Johnson &amp;amp; Johnson/Janssen) vaccine. These rare thrombotic events were observed within the expected vaccine-induced seroconversion period and could be attributed to platelet-activating (auto)antibodies against platelet factor 4 (PF4). Newly, vaccine-induced, cross-reactive anti-PF4 antibodies could explain this observation. An in-silico analysis using the Basic Local Alignment Search Tool was used to identify sequence similarity between PF4 and antigens contained in or encoded by ChAdOx1 nCov-19 or Ad26.COV2.S vaccines. Only one sequence within the signaling peptide of the SARS-CoV-2 spike protein exhibited a high percent identity (85.71%) with PF4. This sequence overlaps with a proven immunogenic peptide recognized from convalescent COVID-19 sera and could be responsible for the formation of platelet-activating immunocomplexes in susceptible patients. Manipulation of the immunogenicity of this particular sequence within the encoded SARS-CoV-2 spike protein signaling peptide may eliminate this iatrogenic severe adverse effect.
</td>
</tr>
<tr>
<td style="text-align:left;">
35412628
</td>
<td style="text-align:left;">
Association of State COVID-19 Vaccination Prioritization With Vaccination Rates Among Incarcerated Persons.
</td>
<td style="text-align:left;">
JAMA network open
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
01
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
35412626
</td>
<td style="text-align:left;">
Immunogenicity and Risk Factors Associated With Poor Humoral Immune Response of SARS-CoV-2 Vaccines in Recipients of Solid Organ Transplant: A Systematic Review and Meta-Analysis.
</td>
<td style="text-align:left;">
JAMA network open
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
01
</td>
<td style="text-align:left;">
Recipients of solid organ transplant (SOT) experience decreased immunogenicity after COVID-19 vaccination. To summarize current evidence on vaccine responses and identify risk factors for diminished humoral immune response in recipients of SOT. A literature search was conducted from existence of database through December 15, 2021, using MEDLINE, Embase, Web of Science, Cochrane Library, and ClinicalTrials.gov. Studies reporting humoral immune response of the COVID-19 vaccines in recipients of SOT were reviewed. Two reviewers independently extracted data from each eligible study. Descriptive statistics and a random-effects model were used. This report was prepared following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. Data were analyzed from December 2021 to February 2022. The total numbers of positive immune responses and percentage across each vaccine platform were recorded. Pooled odds ratios (pORs) with 95% CIs were used to calculate the pooled effect estimates of risk factors for poor antibody response. A total of 83 studies were included for the systematic review, and 29 studies were included in the meta-analysis, representing 11 713 recipients of SOT. The weighted mean (range) of total positive humoral response for antispike antibodies after receipt of mRNA COVID-19 vaccine was 10.4% (0%-37.9%) for 1 dose, 44.9% (0%-79.1%) for 2 doses, and 63.1% (49.1%-69.1%) for 3 doses. In 2 studies, 50% of recipients of SOT with no or minimal antibody response after 3 doses of mRNA COVID-19 vaccine mounted an antibody response after a fourth dose. Among the factors associated with poor antibody response were older age (mean [SE] age difference between responders and nonresponders, 3.94 [1.1] years), deceased donor status (pOR, 0.66 [95% CI, 0.53-0.83]; I2 = 0%), antimetabolite use (pOR, 0.21 [95% CI, 0.14-0.29]; I2 = 70%), recent rituximab exposure (pOR, 0.21 [95% CI, 0.07-0.61]; I2 = 0%), and recent antithymocyte globulin exposure (pOR, 0.32 [95% CI, 0.15-0.71]; I2 = 0%). In this systematic review and meta-analysis, the rates of positive antibody response in solid organ transplant recipients remained low despite multiple doses of mRNA vaccines. These findings suggest that more efforts are needed to modulate the risk factors associated with reduced humoral responses and to study monoclonal antibody prophylaxis among recipients of SOT who are at high risk of diminished humoral response.
</td>
</tr>
<tr>
<td style="text-align:left;">
35412612
</td>
<td style="text-align:left;">
Comparative Effectiveness of mRNA and Inactivated Whole Virus Vaccines against COVID-19 Infection and Severe Disease in Singapore.
</td>
<td style="text-align:left;">
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
12
</td>
<td style="text-align:left;">
Compared to individuals vaccinated with Pfizer-BioNTech/Comirnaty, recipients of Sinovac-CoronaVac and Sinopharm were 2.37 (95% CI 2.29-2.46) and 1.62 (95% CI 1.43-1.85) times more likely to be infected with COVID-19 respectively, while individuals vaccinated with Moderna were 0.42 (95% CI 0.25-0.70) times less likely to develop severe disease.
</td>
</tr>
<tr>
<td style="text-align:left;">
35412579
</td>
<td style="text-align:left;">
Large US Study Examines First 6 Months of COVID-19 Vaccine Safety Data.
</td>
<td style="text-align:left;">
JAMA
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
12
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
35412578
</td>
<td style="text-align:left;">
Vaccine Booster Dose Appears to Reduce Omicron Hospitalizations.
</td>
<td style="text-align:left;">
JAMA
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
12
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
35412558
</td>
<td style="text-align:left;">
Myocarditis Adverse Event Less Common After COVID-19 Vaccine Booster.
</td>
<td style="text-align:left;">
JAMA
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
12
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
35412479
</td>
<td style="text-align:left;">
Case Report: Acute Posterior Multifocal Placoid Pigment Epitheliopathy following SARS-CoV-2 Vaccination.
</td>
<td style="text-align:left;">
Optometry and vision science : official publication of the American Academy of Optometry
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
12
</td>
<td style="text-align:left;">
Acute posterior multifocal placoid pigment epitheliopathy is an uncommon inflammatory chorioretinopathy that has been reported post-vaccination. This is the first reported case to our knowledge following vaccination for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a healthy adolescent male. This report aims to inform the eyecare community about a possible ocular sequela of SARS-CoV-2 vaccination. A 17-year-old male presented to clinic for a second opinion following sudden onset blind spots in his right eye. His medical history was remarkable for receiving the first dose of the Pfizer-BioNTech SARS-CoV-2 vaccine two weeks prior to symptom onset. He had no prior history of ocular inflammation, auto-immune disease, or systemic infection. A diagnosis of unilateral acute posterior multifocal placoid pigment epitheliopathy was made based on presence of typical fundus lesions and non-invasive imaging with fundus autofluorescence, retinal optical coherence tomography (OCT), and OCT-angiography. The diagnosis was further confirmed with fluorescein angiography. The patient developed an anterior vitritis in the right eye 42 days after initial symptom onset. His unilateral intraocular inflammation resolved after a five-week course of prednisone. Acute posterior multifocal placoid pigment epitheliopathy is a self-limited inflammatory condition of the outer retina that usually affects young adults and often does not require treatment. It has been reported to occur following vaccination for influenza, polio, hepatitis B, meningococcus C, and varicella zoster virus. This is the first known case to occur post SARS-CoV-2 vaccination in a healthy adolescent male.
</td>
</tr>
<tr>
<td style="text-align:left;">
35412347
</td>
<td style="text-align:left;">
Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.
</td>
<td style="text-align:left;">
Journal of virology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
12
</td>
<td style="text-align:left;">
Increasing cases of SARS-CoV-2 breakthrough infections from immunization with current spike protein-based COVID-19 vaccines highlight the need to develop alternative vaccines using different platforms and/or antigens. In this study, we expressed SARS-CoV-2 spike and nucleocapsid proteins based on a novel vaccinia virus (VACV) ACAM2000 platform (rACAM2000). In this platform, the vaccinia virus host range and immunoregulatory gene E3L was deleted to make the virus attenuated and to enhance innate immune responses, and another host range gene, K3L, was replaced with a poxvirus ortholog gene, taterapox virus 037 (TATV037), to make virus replication competent in both hamster and human cells. Following a single intramuscular immunization, the rACAM2000 coexpressing the spike and nucleocapsid proteins induced significantly improved protection against SARS-CoV-2 challenge in comparison to rACAM2000 expressing the individual proteins in a hamster model, as shown by reduced weight loss and shorter recovery time. The protection was associated with reduced viral loads, increased neutralizing antibody titer, and reduced neutrophil-to-lymphocyte ratio. Thus, our study demonstrates that rACAM2000 expressing a combination of the spike and nucleocapsid antigens is a promising COVID-19 vaccine candidate, and further studies will investigate if the rACAM2000 vaccine candidate can induce a long-lasting immunity against infection by SARS-CoV-2 variants of concern. IMPORTANCE Continuous emergence of SARS-CoV-2 variants which cause breakthrough infection from the immunity induced by current spike protein-based COVID-19 vaccines highlights the need for new generations of vaccines that will induce long-lasting immunity against a wide range of the variants. To this end, we investigated the protective efficacy of the recombinant COVID-19 vaccine candidates based on a novel VACV ACAM2000 platform, in which an immunoregulatory gene, E3L, was deleted and both the SARS-CoV-2 spike (S) and nucleocapsid (N) antigens were expressed. Thus, it is expected that the vaccine candidate we constructed should be more immunogenic and safer. In the initial study described in this work, we demonstrated that the vaccine candidate expressing both the S and N proteins is superior to the constructs expressing an individual protein (S or N) in protecting hamsters against SARS-CoV-2 challenge after a single-dose immunization, and further investigation against different SARS-CoV-2 variants will warrant future clinical evaluations.
</td>
</tr>
<tr>
<td style="text-align:left;">
35412265
</td>
<td style="text-align:left;">
Patients with B-cell lymphoma receiving anti-CD20 monoclonal antibody-containing chemotherapies and seroreactive patterns in response to COVID-19 vaccination.
</td>
<td style="text-align:left;">
International journal of hematology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
12
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
35412137
</td>
<td style="text-align:left;">
Coronavirus Entry Inhibitors.
</td>
<td style="text-align:left;">
Advances in experimental medicine and biology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Coronaviruses (CoVs) are enveloped RNA viruses that widely exist in the environment. Several CoVs possess a strong ability to infect humans, termed as human coronavirus (HCoVs). Among seven known HCoVs, SARS-CoV-2, SARS-CoV, and MERS-CoV belong to highly pathogenic HCoVs, which can cause severe clinical symptoms and even death. Especially, the current COVID-19 pandemic severely threatens human survival and health, which emphasizes the importance of developing effective CoV vaccines and anti-CoV agents to protect humans from HCoV infections. Coronavirus entry inhibitors can block various processes in viral entry, such as receptor binding, proteolytic activation of spike protein, or virus-cell membrane fusion. Coronavirus entry inhibitors, alone or in combination with other drugs, play important roles in the treatment of coronavirus diseases. Thus, we summarize and discuss the development of coronavirus entry inhibitors in this chapter.
</td>
</tr>
<tr>
<td style="text-align:left;">
35411819
</td>
<td style="text-align:left;">
Communications to Promote Interest and Confidence in COVID-19 Vaccines.
</td>
<td style="text-align:left;">
American journal of health promotion : AJHP
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
12
</td>
<td style="text-align:left;">
Communicating about COVID-19 vaccine side effects and efficacy is crucial for promoting transparency and informed decision-making, but there is limited evidence on how to do so effectively. A within-subjects experiment. Online survey from January 21 to February 6, 2021. 596 US Veterans and 447 non-Veterans. 5 messages about COVID-19 vaccine side effects and 4 messages about COVID-19 vaccine efficacy. COVID-19 vaccine interest (1 = “I definitely do NOT want the vaccine” to 7 = “I definitely WANT the vaccine” with the midpoint 4 = “Unsure”). Confidence about COVID-19 vaccine efficacy (1= “Not at all confident,” 2 = “Slightly confident,” 3 = “Somewhat confident,” 4 = “Moderately confident,” 5 = “Extremely confident”). Compared to providing information about side effects alone (M = 5.62 [1.87]), messages with additional information on the benefits of vaccination (M = 5.77 [1.82], P &amp;lt; .001, dz = .25), reframing the likelihood of side effects (M = 5.74 [1.84], P &amp;lt; .001, dz = .23), and emphasizing that post-vaccine symptoms indicate the vaccine is working (M = 5.72 [1.84], P &amp;lt; .001, dz = .17) increased vaccine interest. Compared to a vaccine efficacy message containing verbal uncertainty and an efficacy range (M = 3.97 [1.25]), messages conveying verbal certainty with an efficacy range (M = 4.00 [1.24], P = .042, dz=.08), verbal uncertainty focused on the upper efficacy limit (M = 4.03 [1.26], P &amp;lt; .001, dz = .13), and communicating the point estimate with certainty (M = 4.02 [1.25], P &amp;lt; .001, dz = .11) increased confidence. Overall, Veteran respondents were more interested (MVeterans = 5.87 [1.72] vs MNonVeterans = 5.45 [2.00], P &amp;lt; .001, d = .22) and confident (MVeterans = 4.13 [1.19] vs MNonVeterans = 3.84 [1.32], P &amp;lt; .001, d = .23) about COVID-19 vaccines than non-Veterans. These strategies can be implemented in large-scale communications (e.g., webpages, social media, and leaflets/posters) and can help guide healthcare professionals when discussing vaccinations in clinics to promote interest and confidence in COVID-19 vaccines.
</td>
</tr>
<tr>
<td style="text-align:left;">
35411681
</td>
<td style="text-align:left;">
Humoral antibody response to the first dose of the ChAdOx1 nCoV-19 vaccine in Asian patients undergoing hemodialysis.
</td>
<td style="text-align:left;">
Hemodialysis international. International Symposium on Home Hemodialysis
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
11
</td>
<td style="text-align:left;">
The immunogenicity of vaccines is known to be attenuated in patients with end-stage kidney disease due to uremia. Patients on dialysis were excluded from coronavirus disease 2019 (COVID-19) vaccine trials; thus, the effectiveness of vaccines for this population is unclear. The aim of this study was to explore whether Asian dialysis patients can effectively produce an immune response after being vaccinated with the first dose of the ChAdOx1 nCoV-19 vaccine. PARTICIPANTS, AND MEASUREMENTS” In this prospective cohort study, we included Asian hemodialysis patients who received the ChAdOx1 nCoV-19 vaccine. At 3 weeks after the first dose of vaccination, we assessed the humoral immune response by measuring anti-SARS-CoV-2 S antibody titers. The primary outcome was the seropositive rate following vaccination, defined as an antibody titer greater than or equal to 0.8 U/ml. Factors associated with seropositivity were explored in multivariate logistic regression analyses. In total, 434 participants were included. The mean age was 64 years, the mean dialysis vintage was 6 years, and 61% of the participants were men. At a mean time of 22 days from vaccination, 56% of the participants were seropositive. The vast majority (88%) had low antibody titers (&amp;lt; 15 U/ml). The multivariate logistic regression analyses showed that older age (every increase of 10 years, odds ratio [OR] 0.80, 95% CI 0.65-0.98, p = 0.03) was negatively associated with seropositivity and that higher Kt/V (every increase of 0.1, OR 1.14, 95% CI 1.01-1.28, p = 0.03) and higher serum albumin level (every increase of 0.1 g/dl, OR 1.09, 95% CI 1.02-1.18, p = 0.02) were positively associated with seropositivity. In Asian hemodialysis patients, the seropositive rate was low, and most had low antibody titers after the first dose of the ChAdOx1 nCoV-19 vaccine. Younger age, better dialysis adequacy, and higher albumin levels were associated with seropositivity.
</td>
</tr>
<tr>
<td style="text-align:left;">
35411533
</td>
<td style="text-align:left;">
Community Health Worker Perspectives on Engaging Unhoused Peer Ambassadors for COVID-19 Vaccine Outreach in Homeless Encampments and Shelters.
</td>
<td style="text-align:left;">
Journal of general internal medicine
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
11
</td>
<td style="text-align:left;">
COVID-19 vaccination is a priority for people experiencing homelessness. However, there are barriers to vaccine access driven in part by mistrust towards clinicians and healthcare. Community health workers (CHWs) and Peer Ambassadors (PAs) may be able to overcome mistrust in COVID-19 vaccine outreach. An unhoused PA program for COVID-19 vaccine outreach by CHWs was implemented in Los Angeles using a participatory academic-community partnership. The purpose of this study was to evaluate CHW perspectives on an unhoused PA COVID-19 vaccine outreach program in Los Angeles. This study used a participatory community conference and qualitative focus groups to understand CHW perspectives on the PA program. The one-day conference was held in November 2021. Of the 42 conference participants, 19 CHWs participated in focus groups for two-way knowledge exchange between CHWs and researchers. Four focus groups were held during the conference, with 4-6 CHWs per group. Each group had a facilitator and two notetakers. Focus group notes were then analyzed using content analysis to derive categories of findings. CHWs reviewed the qualitative analysis to ensure that findings represented their experiences with the PA program. The five categories of findings from focus groups were as follows: (1) PAs were effective liaisons to their peers to promote COVID-19 vaccines; (2) CHWs recognized the importance of establishing genuine trust and equitable working relationships within CHW/PA teams; (3) there were tradeoffs of integrating unhoused PAs into the existing CHW workflow; (4) CHWs had initial misgivings about the research process; and (5) there were lingering questions about the ethics of “exploiting” the invaluable trust unhoused PAs have with unhoused communities. CHWs were in a unique position to empower unhoused PAs to take a leadership role in reaching their peers with COVID-19 vaccines and advocate for long-term employment and housing needs.
</td>
</tr>
<tr>
<td style="text-align:left;">
35411376
</td>
<td style="text-align:left;">
Antibody Response to SARS-CoV-2 mRNA Vaccines in Patients with Rheumatic Diseases in Japan: Interim Analysis of a Multicenter Cohort Study.
</td>
<td style="text-align:left;">
Modern rheumatology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
12
</td>
<td style="text-align:left;">
To evaluate the impact of medication on antibody response to SARS-CoV-2 mRNA vaccines in Japanese patients with rheumatic diseases. This prospective multicenter cohort study evaluated the humoral response in 12 different medication groups. Antibody levels before the first vaccination and 3-6 weeks after the second vaccination were measured using the Elecsys Anti-SARS-CoV-2 S assay. Statistical analysis included comparing antibody titers among the different medication groups using the Kruskal-Wallis test followed by the Bonferroni-Dunn test and multiple linear regression analysis. Two hundred and ninety-five patients were analyzed. The seroconversion rate was 92.2% and the median antibody titer was 255 U/ml (interquartile range, 34.1-685) after the second mRNA vaccination. Antibody levels were significantly lower in the groups treated with TNF inhibitor (TNFi) with methotrexate (MTX), abatacept, mycophenolate mofetil (MMF), MMF or mizoribine (MMF/MZR) combined with calcineurin inhibitor (CNI), and rituximab or cyclophosphamide (RTX/CPA) compared with those treated with sulfasalazine and/or bucillamine or CNI (p&amp;lt;0.01). The correlation between antibody titer and treatment was significant after adjusting for age, gender, and glucocorticoid dose (p&amp;lt;0.01). Additional early vaccination is required in patients treated with TNFi and MTX, abatacept, MMF, MMF or MZR combined with CNI and CPA/RTX.
</td>
</tr>
<tr>
<td style="text-align:left;">
35399992
</td>
<td style="text-align:left;">
Vaccines’ effects on the heart.
</td>
<td style="text-align:left;">
New scientist (1971)
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
02
</td>
<td style="text-align:left;">
With the mRNA covid-19 vaccines being delivered to growing numbers of young people, researchers are looking again at the rare risk of myocarditis, reports Clare Wilson.
</td>
</tr>
<tr>
<td style="text-align:left;">
35399819
</td>
<td style="text-align:left;">
Insights into forsythia honeysuckle (Lianhuaqingwen) capsules: A Chinese herbal medicine repurposed for COVID-19 pandemic.
</td>
<td style="text-align:left;">
Phytomedicine Plus : International journal of phytotherapy and phytopharmacology
</td>
<td style="text-align:left;">
2021
</td>
<td style="text-align:left;">
May
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
In December 2019, a novel coronavirus, SARS-CoV-2 caused a series of acute atypical respiratory diseases worldwide. However, there is still a lack of drugs with clear curative effects, and the clinical trial research of vaccines has not been completely finished. LH capsules are approved TCM patent medicine that are widely used for the treatment of respiratory tract infectious diseases caused by colds and flu. On April 12, 2020, LH capsules and granules were officially repurposed by the China Food and Drug Administration (CFDA) for patients with mild COVID-19 based on their safety and efficacy demonstrated through multicentre, randomized, controlled clinical trials. We hope to conduct a comprehensive review of it through modern pharmacy methods, and try to explain its possible mechanism. Using the full names of LH capsules Lianhuaqingwen, Lianhua Qingwen andSARS-COV-2, COVID-19 as the keywords of the search terms, systemically search for existing related papers in various databases such as Web of Science and PubMed. And completed the collection of clinical data in ClinicalTrials.gov and Chinese Clinical Trial Registry. Last but not least, we have sorted out the anti-inflammatory and antiviral mechanisms of LH capsules through literature and Selleck. This review systematically sorted out the active ingredients in LH capsules. Furthermore, the related pharmacological and clinical trials of LH capsule on SARS-CoV-2, IAV and IBV were discussed in detail. Moreover, the present review provides the first summary of the potential molecular mechanism of specific substances in LH capsules involved in resistance to SARS-COV-2 infection and the inhibition of cytokine storm syndrome (CSS) caused by IL-6. This review summarizes the available reports and evidence that support the use of LH capsules as potential drug candidates for the prevention and treatment of COVID-19. However, TCM exerts its effects through multiple targets and multiple pathways, and LH capsules are not an exception. Therefore, the relevant mechanisms need to be further improved and experimentally verified.
</td>
</tr>
<tr>
<td style="text-align:left;">
35399561
</td>
<td style="text-align:left;">
Identifying gaps in hand hygiene practice to support tailored target audience messaging in Soweto: A cross-sectional community survey.
</td>
<td style="text-align:left;">
Southern African journal of infectious diseases
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Effective risk communication is essential for outbreak mitigation, as recently highlighted during the coronavirus disease 2019 (COVID-19) pandemic. Hand hygiene is one of the proposed public health interventions to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) acquisition and transmission along with social distancing, improved ventilation, environmental cleaning, and wearing of masks. Improving hand hygiene practices in the community requires an understanding of the socio-behavioural context. This cross-sectional community survey in Soweto identified gaps in hand hygiene, which can inform appropriate messaging at the community level. Only 42% of survey respondents practiced adequate hand hygiene. Tailored educational messaging should be targeted at young adults in particular, and the importance of soap for hand hygiene must be emphasised for all age groups. Risk communication should expand to focus on preventing multiple infectious diseases during and beyond the COVID-19 pandemic.
</td>
</tr>
<tr>
<td style="text-align:left;">
35399463
</td>
<td style="text-align:left;">
A Case of Recurrent Acute Anterior Uveitis After the Administration of COVID-19 Vaccine.
</td>
<td style="text-align:left;">
Cureus
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Mar
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
We present a case of a 37-year-old healthy man who developed acute anterior uveitis after receiving the first and second doses of the Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine. To the best of our knowledge, this is the first report of a recurring incidence of ocular side effects associated with COVID-19 immunization. Based on the timing of the start of symptoms with the first and second vaccinations, the absence of prior medical conditions, and unremarkable investigations, we believe that the patient’s anterior uveitis may have been induced by the vaccine itself. This case suggests that vaccination could be a risk factor in uveitis development and recurrence following redosing. As a result, we recommend that ophthalmologists investigate the recent immunization status in each case of uveitis with a temporal association with COVID-19 vaccine administration and record these cases to improve the quality of data tracking of potential adverse responses to vaccines.
</td>
</tr>
<tr>
<td style="text-align:left;">
35399324
</td>
<td style="text-align:left;">
Rapid emergence of SARS-CoV-2 Omicron variant is associated with an infection advantage over Delta in vaccinated persons.
</td>
<td style="text-align:left;">
Med (New York, N.Y.)
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
06
</td>
<td style="text-align:left;">
The SARS-CoV-2 Omicron variant became a global concern due to its rapid spread and displacement of the dominant Delta variant. We hypothesized that part of Omicron’s rapid rise was based on its increased ability to cause infections in persons that are vaccinated compared to Delta. We analyzed nasal swab PCR tests for samples collected between 12-26 December 2021 in Connecticut when the proportion of Delta and Omicron variants were relatively equal. We used the spike gene target failure (SGTF) to classify probable Delta and Omicron infections. We fitted an exponential curve to the estimated infections to determine the doubling times for each variant. We compared the test positivity rates for each variant by vaccination status, number of doses, and vaccine manufacturer. Generalized linear models were used to assess factors associated with odds of infection with each variant among persons testing positive for SARS-CoV-2. For infections with high virus copies (Ct &amp;lt; 30) among vaccinated persons, we found higher odds that they were infected with Omicron compared to Delta, and that the odds increased with increased number of vaccine doses. Compared to unvaccinated persons, we found significant reduction in Delta positivity rates after two (43.4-49.1%) and three vaccine doses (81.1%), while we only found a significant reduction in Omicron positivity rates after three doses (62.3%). The rapid rise in Omicron infections was likely driven by Omicron’s escape from vaccine-induced immunity. This work was supported by the Centers for Disease Control and Prevention (CDC).
</td>
</tr>
<tr>
<td style="text-align:left;">
35398975
</td>
<td style="text-align:left;">
Risk of venous thromboembolism after COVID-19 vaccination.
</td>
<td style="text-align:left;">
Journal of thrombosis and haemostasis : JTH
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
10
</td>
<td style="text-align:left;">
COVID-19 vaccinations in the United States are effective in preventing illness and hospitalization yet concern over post-vaccination venous thromboembolism (VTE) risk has led to vaccine hesitancy. The aim of this study was to compare VTE rates before and after COVID-19 vaccination. COVID-19 vaccinated patients ≥18 years between November 1, 2020 through November 1, 2021 were analyzed using electronic medical records across the Mayo Clinic enterprise. The primary outcome was imaging confirmed acute VTE (upper or lower deep vein thrombosis or pulmonary embolism) occurring 90 days before and after the date of first vaccine dose. A total of 792 010 patients with at least one COVID-19 vaccination were identified (Pfizer, n = 452 950, Moderna, n = 290 607, and Janssen [Johnson &amp;amp; Johnson], n = 48 453). A total of 1565 VTE events occurred in the 90 days before (n = 772) and after (n = 793) COVID-19 vaccination. VTE post-vaccination occurred in 326 patients receiving Moderna (0.11%, incidence rate [IR] 4.58 per 1000p-years), 425 patients receiving Pfizer (0.09%, IR 3.84 per 1000p-years), and 42 receiving Janssen (0.09%, IR 3.56 per 1000p-years). Compared to the pre-vaccination timeframe, the adjusted hazard ratio (aHR) for VTE after the Janssen vaccination was 0.97 (95% confidence interval [CI] 0.63-1.50), aHR 1.02 (95% CI 0.87-1.19) for Moderna, and aHR 1.00 (95% CI 0.87-1.15) for Pfizer. In this large cohort of COVID-19 vaccinated patients, no increased risk for acute VTE post-vaccination was identified for the authorized vaccines in the United States.
</td>
</tr>
<tr>
<td style="text-align:left;">
35398876
</td>
<td style="text-align:left;">
COVID-19 vaccination-associated ipsilateral supraclavicular lymphadenopathy.
</td>
<td style="text-align:left;">
Australian journal of general practice
</td>
<td style="text-align:left;">
2021
</td>
<td style="text-align:left;">
Dec
</td>
<td style="text-align:left;">
10
</td>
<td style="text-align:left;">
Lymphadenopathy associated with COVID-19 vaccination can be a clinical conundrum for clinicians.
</td>
</tr>
<tr>
<td style="text-align:left;">
35398786
</td>
<td style="text-align:left;">
Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines.
</td>
<td style="text-align:left;">
EBioMedicine
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
07
</td>
<td style="text-align:left;">
SARS-CoV-2 Omicron variant evades immunity from past infection or vaccination and is associated with a greater risk of reinfection among recovered COVID-19 patients. We assessed the serum neutralizing antibody (NAb) activity against Omicron variant (Omicron NAb) among recovered COVID-19 patients with or without vaccination. In this prospective cohort study with 135 recovered COVID-19 patients, we determined the serum NAb titers against ancestral virus or variants using a live virus NAb assay. We used the receiver operating characteristic analysis to determine the optimal cutoff for a commercially-available surrogate NAb assay. Among recovered COVID-19 patients, the serum live virus geometric mean Omicron NAb titer was statistically significantly higher among BNT162b2 recipients compared to non-vaccinated individuals (85.4 vs 5.6,P &amp;lt; 0.0001). The Omicron seropositive rates in live virus NAb test (NAb titer ≥10) were statistically significantly higher among BNT162b2 (90.6% [29/32];P &amp;lt; 0.0001) or CoronaVac (36.7% [11/30]; P = 0.0115) recipients when compared with non-vaccinated individuals (12.3% [9/73]). Subgroup analysis of CoronaVac recipients showed that the Omicron seropositive rates were higher among individuals with two doses than those with one dose (85.7% vs 21.7%; P = 0.0045). For the surrogate NAb assay, a cutoff of 109.1 AU/ml, which is 7.3-fold higher than the manufacturer’s recommended cutoff, could achieve a sensitivity and specificity of 89.5% and 89.8%, respectively, in detecting Omicron NAb. Among individuals with prior COVID-19, one dose of BNT162b2 or two doses of CoronaVac could induce detectable serum Omicron NAb. Our result would be particularly important for guiding vaccine policies in countries with COVID-19 vaccine shortage. Health and Medical Research Fund, Richard and Carol Yu, Michael Tong (see acknowledgments for full list).
</td>
</tr>
<tr>
<td style="text-align:left;">
35398776
</td>
<td style="text-align:left;">
Genomic evolution of the Coronaviridae family.
</td>
<td style="text-align:left;">
Virology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Mar
</td>
<td style="text-align:left;">
30
</td>
<td style="text-align:left;">
The current outbreak of coronavirus disease-2019 (COVID-19) caused by SARS-CoV-2 poses unparalleled challenges to global public health. SARS-CoV-2 is a Betacoronavirus, one of four genera belonging to the Coronaviridae subfamily Orthocoronavirinae. Coronaviridae, in turn, are members of the order Nidovirales, a group of enveloped, positive-stranded RNA viruses. Here we present a systematic phylogenetic and evolutionary study based on protein domain architecture, encompassing the entire proteomes of all Orthocoronavirinae, as well as other Nidovirales. This analysis has revealed that the genomic evolution of Nidovirales is associated with extensive gains and losses of protein domains. In Orthocoronavirinae, the sections of the genomes that show the largest divergence in protein domains are found in the proteins encoded in the amino-terminal end of the polyprotein (PP1ab), the spike protein (S), and many of the accessory proteins. The diversity among the accessory proteins is particularly striking, as each subgenus possesses a set of accessory proteins that is almost entirely specific to that subgenus. The only notable exception to this is ORF3b, which is present and orthologous over all Alphacoronaviruses. In contrast, the membrane protein (M), envelope small membrane protein (E), nucleoprotein (N), as well as proteins encoded in the central and carboxy-terminal end of PP1ab (such as the 3C-like protease, RNA-dependent RNA polymerase, and Helicase) show stable domain architectures across all Orthocoronavirinae. This comprehensive analysis of the Coronaviridae domain architecture has important implication for efforts to develop broadly cross-protective coronavirus vaccines.
</td>
</tr>
<tr>
<td style="text-align:left;">
35398583
</td>
<td style="text-align:left;">
Safety of 3rd SARS-CoV-2 vaccine (booster dose) during pregnancy.
</td>
<td style="text-align:left;">
American journal of obstetrics &amp;amp; gynecology MFM
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
07
</td>
<td style="text-align:left;">
COVID-19 during pregnancy is associated with adverse outcomes for mother and fetus. SARS-CoV-2 vaccination has significantly reduced the risk of symptomatic disease. Several studies have reported the safety of SARS-CoV-2 vaccination during pregnancy, with no adverse effect on obstetric outcomes. However, obstetric outcomes following a booster dose of the SARS CoV-2 vaccination during pregnancy have yet been published. To examine the association between booster dose of the SARS CoV-2 vaccination during pregnancy and obstetric outcomes. A retrospective cohort study of women who delivered between July and October 2021 at a large tertiary medical center. We compared women who received the booster vaccine during pregnancy to women who were not vaccinated and to those who had only received two vaccines. Primary outcomes were the incidence of preterm labor and of small for gestational age. Secondary outcomes were other maternal and neonatal complications. A secondary analysis investigating the association between the timing from vaccination to delivery and outcomes was also performed. Multivariable logistic regression models were used to adjust for potential confounders. There were 6507 women who met the inclusion criteria: 294 women received three vaccines, 2,845 women received only two vaccines and 3,368 were unvaccinated. Patients receiving three vaccines were older and more likely to smoke compared to unvaccinated patients. No differences were noted between triple-vaccinated, twice-vaccinated and unvaccinated groups with regards to preterm birth and small for gestational age. Regarding secondary outcomes, women in the triple vaccine group had higher rates of PPH (9.5 vs 3.21%, P&amp;lt;0.001), gestational diabetes (12.2 vs. 8.3 %, p=0.02), and were less likely to have hypertensive disorders of pregnancy (0% vs 1.4%, p=0.041) compared to the unvaccinated group. Compared to twice-vaccinated patients, patients with three vaccines were more likely to experience PPH (9.5 vs. 3.5%, p&amp;lt;0.001), and were less likely to have a low umbilical artery pH (0.7 vs 6.1%, p&amp;lt;0.001). In the sensitivity analysis comparing patients delivered within 2 weeks of the third vaccination (n=53) to those delivered at least 6 weeks after vaccination (n=96), there were no differences in the rates of SGA, preterm birth, PPH, or cesarean delivery. The booster dose of the SARS-CoV-2 vaccine during pregnancy was not associated with adverse obstetric outcomes compared to unvaccinated or twice-vaccinated women. However, higher rates of PPH were observed. Further studies on a larger scale are needed to confirm these findings.
</td>
</tr>
<tr>
<td style="text-align:left;">
35398454
</td>
<td style="text-align:left;">
A novel plant lectin, NTL-125, interferes with SARS-CoV-2 interaction with hACE2.
</td>
<td style="text-align:left;">
Virus research
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
07
</td>
<td style="text-align:left;">
COVID-19 caused by SARS-CoV-2 virus has had profound impact on the world in the past two years. Intense research is going on to find effective drugs to combat the disease. Over the past year several vaccines were approved for immunization. But SARS-CoV-2 being an RNA virus is continuously mutating to generate new variants, some of which develop features of immune escape. This raised serious doubts over the long-term efficacy of the vaccines. We have identified a unique mannose binding plant lectin from Narcissus tazetta bulb, NTL-125, which effectively inhibits SARS-CoV-2 replication in Vero-E6 cell line. In silico docking studies revealed that NTL-125 has strong affinity to viral Spike RBD protein, preventing it from attaching to hACE2 receptor, the gateway to cellular entry. Binding analyses revealed that all the mutant variants of Spike protein also have stronger affinity for NTL-125 than hACE2. The unique α-helical tail of NTL-125 plays most important role in binding to RBD of Spike. NTL-125 also interacts effectively with some glycan moieties of S-protein in addition to amino acid residues adding to the binding strength. Thus, NTL-125 is a highly potential antiviral compound of natural origin against SARS-CoV-2 and may serve as an important therapeutic for management of COVID-19.
</td>
</tr>
<tr>
<td style="text-align:left;">
35398412
</td>
<td style="text-align:left;">
Rapid Progress in Our Understanding of Covid-19 Vaccine Allergy: A Cause for Optimism, not Hesitancy.
</td>
<td style="text-align:left;">
The Journal of allergy and clinical immunology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
07
</td>
<td style="text-align:left;">
Anaphylaxis is a life-threatening condition and when associated with vaccination, leads to vaccine hesitancy. The concerns around vaccine related anaphylaxis have become even more important during the COVID-19 pandemic where the COVID-19 vaccines remain one of our most important tools. While rates of anaphylaxis to COVID-19 vaccines are not significantly different from other vaccines, CDC guidance recommends avoidance of the same COVID-19 vaccine in individuals who had an allergic reaction or are allergic to a COVID-19 vaccine component. Fortunately, our understanding of COVID-19 vaccine allergic reactions has improved dramatically in the past year in large part due to significant research efforts from individuals in the allergy community. Initially, researchers published algorithmic approaches using risk stratification and excipient skin testing. However, as our experience and knowledge improved with ongoing research, we have better data showing safety of repeat vaccination despite an initial reaction. We review our progress starting in December 2020 when the FDA approved the first COVID-19 vaccine in the United States through early 2022 highlighting our success in understanding COVID-19 vaccine reactions.
</td>
</tr>
<tr>
<td style="text-align:left;">
35397947
</td>
<td style="text-align:left;">
Supporting immunization programs to address COVID-19 vaccine hesitancy: Recommendations for national and community-based stakeholders.
</td>
<td style="text-align:left;">
Vaccine
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Mar
</td>
<td style="text-align:left;">
28
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
35397946
</td>
<td style="text-align:left;">
Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: Implications for vaccine strategies.
</td>
<td style="text-align:left;">
Vaccine
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
01
</td>
<td style="text-align:left;">
Little is known about the efficacy and durability of anti-RBD IgG antibodies induced by certain SARS-CoV-2 vaccines. It has been shown that neutralizing antibodies are associated with the protection against re-infection. This study aims to compare the mean titers, duration, and efficacy of generating protective anti-RBD IgG antibody response among recipients of Pfizer/BioNTech, AstraZeneca, Sputnik V, Johnson &amp;amp; Johnson, Moderna, and Sinopharm COVID-19 vaccines. In addition, we aimed to compare the susceptibility of getting COVID-19 breakthrough infections after various types of vaccines. Samples from 2065 blood bank donors and healthcare workers at King Hussein Cancer Center (KHCC) were collected between February and September 2021. Anti-Spike/RBD IgG levels were measured using Chemiluminescent microparticle-immunoassay (CMIA) (ARCHITECT IgG II Quant test, Abbott, USA). The mean titer of anti-RBD IgG levels was significantly diverse among different types of vaccines. The highest titer level was seen in participants who took a third booster vaccine shot, followed by Pfizer/BioNTech, AstraZeneca, and Sinopharm vaccine. The mean titer levels of anti-RBD IgG antibodies in the Pfizer vaccinated group was the highest after vaccination but started to drop after 60 days from vaccination unlike AstraZeneca and Sinopharm vaccine-induced antibodies where the mean titers continued to be stable until 120 days but their levels were significantly lower. Most of the breakthrough infections were among the Sinopharm vaccinated group and these breakthroughs happened at random times for the three main types of vaccines. Our data demonstrate that the mean-titer of anti-RBD IgG levels drop after four months which is the best time to take the additional booster shot from a more potent vaccine type such as mRNA vaccines that might be needed in Jordan and worldwide.
</td>
</tr>
<tr>
<td style="text-align:left;">
35397867
</td>
<td style="text-align:left;">
COVID-19 vaccination and HIV-1 acquisition - Authors’ reply.
</td>
<td style="text-align:left;">
Lancet (London, England)
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
09
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
35397866
</td>
<td style="text-align:left;">
COVID-19 vaccination and HIV-1 acquisition.
</td>
<td style="text-align:left;">
Lancet (London, England)
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
09
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
35397851
</td>
<td style="text-align:left;">
Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study.
</td>
<td style="text-align:left;">
Lancet (London, England)
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
07
</td>
<td style="text-align:left;">
The SARS-CoV-2 variant of concern, omicron, appears to be less severe than delta. We aim to quantify the differences in symptom prevalence, risk of hospital admission, and symptom duration among the vaccinated population. In this prospective longitudinal observational study, we collected data from participants who were self-reporting test results and symptoms in the ZOE COVID app (previously known as the COVID Symptoms Study App). Eligible participants were aged 16-99 years, based in the UK, with a body-mass index between 15 and 55 kg/m2, had received at least two doses of any SARS-CoV-2 vaccine, were symptomatic, and logged a positive symptomatic PCR or lateral flow result for SARS-CoV-2 during the study period. The primary outcome was the likelihood of developing a given symptom (of the 32 monitored in the app) or hospital admission within 7 days before or after the positive test in participants infected during omicron prevalence compared with those infected during delta prevalence. Between June 1, 2021, and Jan 17, 2022, we identified 63 002 participants who tested positive for SARS-CoV-2 and reported symptoms in the ZOE app. These patients were matched 1:1 for age, sex, and vaccination dose, across two periods (June 1 to Nov 27, 2021, delta prevalent at &amp;gt;70%; n=4990, and Dec 20, 2021, to Jan 17, 2022, omicron prevalent at &amp;gt;70%; n=4990). Loss of smell was less common in participants infected during omicron prevalence than during delta prevalence (16·7% vs 52·7%, odds ratio [OR] 0·17; 95% CI 0·16-0·19, p&amp;lt;0·001). Sore throat was more common during omicron prevalence than during delta prevalence (70·5% vs 60·8%, 1·55; 1·43-1·69, p&amp;lt;0·001). There was a lower rate of hospital admission during omicron prevalence than during delta prevalence (1·9% vs 2·6%, OR 0·75; 95% CI 0·57-0·98, p=0·03). The prevalence of symptoms that characterise an omicron infection differs from those of the delta SARS-CoV-2 variant, apparently with less involvement of the lower respiratory tract and reduced probability of hospital admission. Our data indicate a shorter period of illness and potentially of infectiousness which should impact work-health policies and public health advice. Wellcome Trust, ZOE, National Institute for Health Research, Chronic Disease Research Foundation, National Institutes of Health, and Medical Research Council.
</td>
</tr>
<tr>
<td style="text-align:left;">
35397838
</td>
<td style="text-align:left;">
[“The right of nurses to prescribe vaccinations should be extended to other vaccines.”]
</td>
<td style="text-align:left;">
Revue de l’infirmiere
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Mar
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
The year 2021 was marked by the opening of the prescription right to nurses in the framework of the vaccination against COVID-19. Vaccination is an important public health tool that seeks on a collective level a protective effect of vaccinated individuals and contributes to reducing the circulation of the infectious agent within the population. Patrick Chamboredon, President of the National Order of Nurses, discusses the skills of nurses in the service of vaccination.
</td>
</tr>
<tr>
<td style="text-align:left;">
35397836
</td>
<td style="text-align:left;">
[Social representations of the vaccine].
</td>
<td style="text-align:left;">
Revue de l’infirmiere
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Mar
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Vaccination has made it possible to combat many infectious diseases by reducing their impact in terms of mortality as well as morbidity. However, reservations about this primary prevention measure, as demonstrated by the difficulties in introducing vaccination against COVID-19. Through the analysis of social representations, we try to understand the reasons for these obstacles.
</td>
</tr>
<tr>
<td style="text-align:left;">
35397835
</td>
<td style="text-align:left;">
[Involvement of nurses in vaccine prevention policies].
</td>
<td style="text-align:left;">
Revue de l’infirmiere
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Mar
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
The Covid-19 health crisis demonstrates that a world without vaccines would expose us to epidemics with certainly, still today, appalling consequences. Today, more than an act, vaccination is a major public health issue.
</td>
</tr>
<tr>
<td style="text-align:left;">
35397834
</td>
<td style="text-align:left;">
[The mechanism and techniques of vaccination].
</td>
<td style="text-align:left;">
Revue de l’infirmiere
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Mar
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
From the discovery of the first vaccines to the development of the latest ones, such as the one against Covid-19, research has improved the service rendered against infectious diseases by diversifying vaccination techniques to evolve responses to aggression by microorganisms.
</td>
</tr>
<tr>
<td style="text-align:left;">
35397679
</td>
<td style="text-align:left;">
The SARS-CoV-2 spike residues 616/644 and 1138/1169 delineate two antibody epitopes in COVID-19 mRNA COMINARTY vaccine (Pfizer/BioNTech).
</td>
<td style="text-align:left;">
Scientific reports
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
09
</td>
<td style="text-align:left;">
The newly identified coronavirus SARS-CoV-2 is responsible for the worldwide pandemic COVID-19. Considerable efforts have been devoted for the development of effective vaccine strategies against COVID-19. The SARS-CoV-2 spike protein has been identified as the major antigen candidate for the development of COVID-19 vaccines. The Pfizer-BioNTech COVID-19 vaccine COMIRNATY is a lipid nanoparticle-encapsulated mRNA encoding a full-length and prefusion-stabilized SARS-CoV-2 spike protein. In the present study, synthetic peptide-based ELISA assays were performed to identify linear B-cell epitopes into the spike protein that contribute to elicitation of antibody response in COMIRNATY-vaccinated individuals. The synthetic S2P6 peptide containing the spike residues 1138/1169 and to a lesser extent, the synthetic S1P4 peptide containing the spike residues 616/644 were recognized by the immune sera from COMIRNATY vaccine recipients but not COVID-19 recovered patients. We assume that the synthetic S2P6 peptide and to a lesser extent the synthetic S1P4 peptide, could be of interest to measure the dynamic of antibody response to COVID-19 mRNA vaccines. The S2P6 peptide has been identified as immunogenic in adult BALB/c mice that received protein-peptide conjugates in a prime-boost schedule. This raises the question on the role of the B-cell epitope peptide containing the SARS-CoV-2 spike residues 1138/1169 in protective efficacy of the Pfizer-BioNTech COVID-19 vaccine COMIRNATY.
</td>
</tr>
<tr>
<td style="text-align:left;">
35397666
</td>
<td style="text-align:left;">
Anti-coronavirus vaccines will not accelerate the transition of humanity to a non-pandemic period, but the pandemic will take fewer victims.
</td>
<td style="text-align:left;">
Inflammation research : official journal of the European Histamine Research Society … [et al.]
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
10
</td>
<td style="text-align:left;">
The vaccination rate worldwide has reached enormous proportions, and it is likely that at least 75% of the world’s population will be vaccinated. The controversy is that, while people aged 65 and older suffer a significantly higher mortality rate from COVID-19, plans are being made to vaccinate young people under the age of 20. Equally thorny is the question of vaccinating people who already have antibodies to SARS-CoV-2, as well as B and T memory cells, because they contracted and survived the virus. The possible consequences of large-scale vaccination are difficult to predict, when some people do not have access to the vaccine at all and others have already received 3 doses of the vaccine. SARS-CoV-2 will circulate through the human population forever and continue to mutate, as viruses do. Therefore, in the coming years, the need to develop and use effective vaccines and medicines for the prevention and treatment of COVID-19 will remain urgent in view of the high mortality rate from this disease. To date, three vaccine platforms have been most used: adenoviral vector, inactivated, and mRNA. There is some concern about the side effects that occur after vaccination. Whether modern anti-coronavirus vaccines can raise the safety threshold, only time will answer. It is obvious that the pandemic will end, but the virus will remain in the human population, leaving behind invaluable experience and tens of millions of victims. This article is based on search retrieves in research articles devoted to COVID-19 mainly published in 2020-2021 and examines the possible consequences of the worldwide vaccination against SARS-CoV-2 and suggests that, while anti-coronavirus vaccines will not magically transport humanity to a non-pandemic world, they may greatly reduce the number of victims of the pandemic and help us learn how to live with COVID-19.
</td>
</tr>
<tr>
<td style="text-align:left;">
35397331
</td>
<td style="text-align:left;">
Antiviral potential of nanoparticles for the treatment of Coronavirus infections.
</td>
<td style="text-align:left;">
Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS)
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Mar
</td>
<td style="text-align:left;">
26
</td>
<td style="text-align:left;">
On 31st December 2019 in Wuhan, China, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), was acknowledged. This virus spread quickly throughout the world causing a global pandemic. The World Health Organization declared COVID-19 a pandemic disease on 11th March 2020. Since then, the whole world has come together and have developed several vaccines against this deadly virus. Similarly, several alternative searches for pandemic disease therapeutics are still ongoing. One of them has been identified as nanotechnology. It has demonstrated significant promise for detecting and inhibiting a variety of viruses, including coronaviruses. Several nanoparticles, including gold nanoparticles, silver nanoparticles, quantum dots, carbon dots, graphene oxide nanoparticles, and zinc oxide nanoparticles, have previously demonstrated remarkable antiviral activity against a diverse array of viruses. This review aims to provide a basic and comprehensive overview of COVID-19’s initial global outbreak and its mechanism of infiltration into human host cells, as well as the detailed mechanism and inhibitory effects of various nanoparticles against this virus. In addition to nanoparticles, this review focuses on the role of several antiviral drugs used against COVID-19 to date. COVID-19 has severely disrupted the social and economic lives of people all over the world. Due to a lack of adequate medical facilities, countries have struggled to maintain control of the situation. Neither a drug nor a vaccine has a 100% efficacy rate. As a result, nanotechnology may be a better therapeutic alternative for this pandemic disease.
</td>
</tr>
<tr>
<td style="text-align:left;">
35396511
</td>
<td style="text-align:left;">
Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage.
</td>
<td style="text-align:left;">
Nature communications
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
08
</td>
<td style="text-align:left;">
Global genomic surveillance of SARS-CoV-2 has identified variants associated with increased transmissibility, neutralization resistance and disease severity. Here we report the emergence of the PANGO lineage C.1.2, detected at low prevalence in South Africa and eleven other countries. The initial C.1.2 detection is associated with a high substitution rate, and includes changes within the spike protein that have been associated with increased transmissibility or reduced neutralization sensitivity in SARS-CoV-2 variants of concern or variants of interest. Like Beta and Delta, C.1.2 shows significantly reduced neutralization sensitivity to plasma from vaccinees and individuals infected with the ancestral D614G virus. In contrast, convalescent donors infected with either Beta or Delta show high plasma neutralization against C.1.2. These functional data suggest that vaccine efficacy against C.1.2 will be equivalent to Beta and Delta, and that prior infection with either Beta or Delta will likely offer protection against C.1.2.
</td>
</tr>
<tr>
<td style="text-align:left;">
35396297
</td>
<td style="text-align:left;">
Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults.
</td>
<td style="text-align:left;">
BMJ open
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
08
</td>
<td style="text-align:left;">
Assessing safety and immunogenicity of an inactivated whole virus particle vaccine. Single-centre, double-blind, randomised, placebo-controlled, phase I (stage I: 18-50, stage II: 51-75 years), phase II (18-75 years) clinical trials. 29 December 2020 to 22 April 2021. Stage I-phase I: 56 participants; stage II-phase I: 32; phase II: 280. During stage I, participants randomly (3:3:1) received 3 µg, 5 µg vaccine or placebo in a 14-day interval. Participants in stage II received two shots of 5 µg vaccine or placebo (3:1). In phase II, participants received 5 µg vaccine or placebo (4:1) in a 28-day interval. Safety assessment and immunogenicity assessment via antibody response and conventional virus neutralisation test (cVNT). All adverse events (AEs) were mild or moderate and transient in both phase I and phase II, and no AEs of special interest were reported. The seroconversion-rate of neutralising, antireceptor binding-domain (RBD) and anti-spike-glycoprotein (anti-S) antibodies 14-days after second dose of 5 µg vaccine in stage I was 70.8% (95% CI 48.9% to 87.4%), 87.5% (95% CI 67.6% to 97.3%), 91.7% (95% CI 73.0% to 99.0%). The antibody titres increased more among 5 µg than 3 µg. The corresponding rates for 3 µg vaccine were 45.8% (95% CI 25.6% to 67.2%), 54.2% (95% CI 32.8% to 74.5%) and 70.8% (95% CI 48.9% to 87.4%), respectively. In stage II, 100% (95% CI 84.6% to 100%), 86.4% (95% CI 65.1% to 97.1%) and 86.4% (95% CI 65.1% to 97.1%) of participants seroconverted for neutralising, anti-RBD and anti-S antibodies. In phase II, the seroconversion rate of neutralising-antibody was 82.8% (95% CI 77.0% to 87.6%), anti-RBD 77.0% (95% CI 70.7% to 82.6%) and anti-S 79.9% (95% CI 73.8% to 85.1%) on day 42. In the cVNT, the sera at 1/64 times dilution would neutralise SARS-CoV-2 among 91.7%, 77.3% and 82.5% of vaccinated participants in phase I-stage I, phase I-stage II and phase II clinical trials, respectively. These results support further evaluation of this inactivated whole virus particle vaccine. IRCT20201202049567N1 and IRCT20201202049567N2 for phase I and IRCT20201202049567N3 for phase II.
</td>
</tr>
<tr>
<td style="text-align:left;">
35395612
</td>
<td style="text-align:left;">
Cognitive underpinnings of COVID-19 vaccine hesitancy.
</td>
<td style="text-align:left;">
Social science &amp;amp; medicine (1982)
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Mar
</td>
<td style="text-align:left;">
15
</td>
<td style="text-align:left;">
Vaccines save lives. Despite the undisputed value of vaccination, vaccine hesitancy continues to be a major global challenge, particularly throughout the COVID-19 global pandemic. Since vaccination decisions are counter-intuitive and cognitively demanding, we propose that vaccine hesitancy is associated with executive function-a group of high-level cognitive skills including attentional control, working memory, inhibition, self-regulation, cognitive flexibility, and strategic planning. We set out to test (i) whether vaccine hesitancy is driven by individual differences in executive function beyond established socio-demographic factors (e.g., education, political orientation, gender, ethnicity, age, religiosity) and depressed mood, and (ii) whether this relationship is exacerbated by situational stress. Two studies were conducted with U.S. residents. Using a cross-sectional design, Study 1 examined the associations between executive function, socio-demographic factors, COVID-19 conspiracy beliefs, trust in health authorities, and COVID-19 vaccine hesitancy. Using an experimental design, Study 2 focused solely on unvaccinated individuals and tested the interactive effect of executive function and stress on willingness to receive a COVID-19 vaccine. We used ordinal logistic regressions to analyze the data. Individual differences in executive function predicted participants’ COVID-19 conspiracy beliefs, trust in health authorities, and their willingness to vaccinate against COVID-19. Importantly, the unique contribution of executive function to vaccine hesitancy could not be explained by socio-demographic factors or depressed mood. Furthermore, Study 2 revealed that weaker executive function had detrimental effects on COVID-19 vaccine acceptance and trust in health authorities mainly under heightened stress. Individual differences in executive function and situational stress jointly impact COVID-19 vaccination decisions and need to be considered together when designing health communications aimed at reducing COVID-19 vaccine hesitancy. Interventions that lower stress and promote trust have the potential to increase vaccine acceptance, especially for individuals with weaker executive function.
</td>
</tr>
<tr>
<td style="text-align:left;">
35395191
</td>
<td style="text-align:left;">
mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron.
</td>
<td style="text-align:left;">
Cell reports
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
12
</td>
<td style="text-align:left;">
Knowledge about the impact of prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection of the elderly on mRNA vaccination response is needed to appropriately address the demand for additional vaccinations in this vulnerable population. Here, we show that octogenarians, a high-risk population, mount a sustained SARS-CoV-2 spike-specific immunoglobulin G (IgG) antibody response for 15 months following infection. This response boosts antibody levels 35-fold upon receiving a single dose of BNT162b2 mRNA vaccine 15 months after recovery from coronavirus disease 2019 (COVID-19). In contrast, antibody responses in naive individuals boost only 6-fold after a second vaccine. Spike-specific angiotensin-converting enzyme 2 (ACE2) antibody binding responses in the previously infected octogenarians following two vaccine doses exceed those found in a naive cohort after two doses. RNA sequencing (RNA-seq) demonstrates activation of interferon-induced genetic programs, which persist only in the previously infected. A preferential increase of specific immunoglobulin G heavy chain variable (IGHV) clonal transcripts that are the basis of neutralizing antibodies is observed only in the previously infected nuns. Published by Elsevier Inc. 
</td>
</tr>
<tr>
<td style="text-align:left;">
35394853
</td>
<td style="text-align:left;">
Recurrent Anterior Non-necrotizing Scleritis as an Adverse Event of ChAdOx1 nCoV-19 (Vaxzevria) Vaccine.
</td>
<td style="text-align:left;">
Ocular immunology and inflammation
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
08
</td>
<td style="text-align:left;">
To describe a case of anterior scleritis related to SARS-CoV-2 vaccine. SARS-CoV-2 vaccines appear safe; however vaccination has triggered thromboembolic events in predisposed patients. A retrospective case report of anterior scleritis in a woman following administration of both ChAdOx1nCoV-19 vaccine doses was studied by complete ophthalmologic examination and complementary tests. The patient has overcome SARS-CoV-2 infection a year prior. Ancillary tests including autoimmune and infectious diseases were negative. The chronology between ChAdOx1nCoV-19 vaccine and the sequential episodes of scleritis may have a cause-and-effect relationship. Ophthalmologists may be aware of scleritis as an ocular manifestation following ChAdOx1nCoV-19 vaccine, in otherwise healthy patients.
</td>
</tr>
<tr>
<td style="text-align:left;">
35394833
</td>
<td style="text-align:left;">
COVID-19 in low-tolerance border quarantine systems: Impact of the Delta variant of SARS-CoV-2.
</td>
<td style="text-align:left;">
Science advances
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
08
</td>
<td style="text-align:left;">
In controlling transmission of coronavirus disease 2019 (COVID-19), the effectiveness of border quarantine strategies is a key concern for jurisdictions in which the local prevalence of disease and immunity is low. In settings like this such as China, Australia, and New Zealand, rare outbreak events can lead to escalating epidemics and trigger the imposition of large-scale lockdown policies. Here, we develop and apply an individual-based model of COVID-19 to simulate case importation from managed quarantine under various vaccination scenarios. We then use the output of the individual-based model as input to a branching process model to assess community transmission risk. For parameters corresponding to the Delta variant, our results demonstrate that vaccination effectively counteracts the pathogen’s increased infectiousness. To prevent outbreaks, heightened vaccination in border quarantine systems must be combined with mass vaccination. The ultimate success of these programs will depend sensitively on the efficacy of vaccines against viral transmission.
</td>
</tr>
<tr>
<td style="text-align:left;">
35394545
</td>
<td style="text-align:left;">
Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
</td>
<td style="text-align:left;">
Journal of the Pediatric Infectious Diseases Society
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
08
</td>
<td style="text-align:left;">
Human milk (HM) permits transfer of immunity against infections to infants via bioactive factors. The role of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in HM is poorly understood [1, 2]. This study evaluated SARS-CoV-2 antibodies in the HM of vaccinated healthcare workers (HCW). This prospective study of 122 HCWs was performed from February to April 2021 at the Hospital Universitario Nuestra Señora de Candelaria. Immunoglobulin G (IgG) against nucleocapsid protein and IgG, immunoglobulin M (IgM), and immunoglobulin A (IgA) antibodies against spike 1 protein receptor-binding domain against SARS-CoV-2 (anti-SARS-CoV-2 RBD-S1) were analyzed. Unvaccinated breastfeeding mothers without COVID-19 were the control group.The 98 vaccinated participants underwent serum and HM evaluation 14 days after receiving 2 doses of either BNT162b2 mRNA (94%) or mRNA-1273 (6%) coronavirus disease 2019 (COVID-19) vaccines. The mean SARS-CoV-2 RBD-S1 IgG serum concentration was 3379.64 binding antibody units (BAUs)/mL with neutralizing antibody titers &amp;gt;560.9 BAUs/mL. Serum SARS-CoV-2 antibodies in the 24 unvaccinated participants were negative. The HM from vaccinated participants had anti-SARS-CoV-2 RBD-S1 IgG with a mean of 12.19 BAUs/mL compared to 0.02 BAUs/mL (P &amp;lt; .001) in HM from unvaccinated participants. Anti-SARS-CoV-2 S1 IgA was noted in 89% of HM from vaccinated women; no anti-SARS-CoV-2 S1 IgM was detected.A positive correlation was reported between anti-SARS-CoV-2 RBD-S1 IgG in serum and HM (r = 0.36; P &amp;lt; .001). This association was stronger if breastfeeding had been &amp;lt;24 months (r = 0.67; P &amp;lt; .001) vs ≥24 months (r = 0.32; P = 0.19). In subgroup analysis, breastfeeding for &amp;gt;24 months and high serum anti-SARS-CoV-2 RBD-S1 IgG levels predicted high HM IgG levels. This was an independent association in both linear and multiple regression models. Compared with breastfeeding &amp;lt;24 months, lactation &amp;gt;24 months was associated with increased HM anti-SARS-CoV-2 RBD-S1 levels. This study in breastfeeding HCWs showed that the HM antibody levels were higher in women who had been breastfeeding for &amp;gt;24 months prior to receiving 2 doses of COVID-19 vaccine compared to participants who had been breastfeeding &amp;lt;24 months. Limitations include lack of in vitro plaque reduction neutralization tests which is the gold standard for evaluating SARS-CoV-2 antibody deactivation effectiveness. The study was conducted at a single site and did not assess infant serology or clinical outcome.According to the authors, breastfeeding by vaccinated women during a pandemic when young children are ineligible for vaccination may be encouraged. These results support findings from other studies of vaccines, such as influenza, in which the HM of vaccinated women may confer protection to their infants [3]. The benefits of maternal immunization, including the duration of protection afforded by HM from maternal recipients of mRNA COVID-19 vaccines, are research areas deserving of additional exploration. Additionally, further understanding of the association of the duration of receipt of HM from vaccinated women on infant immune responses would be beneficial in understanding the potential for passive protection through nutrition.
</td>
</tr>
<tr>
<td style="text-align:left;">
35394529
</td>
<td style="text-align:left;">
Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry.
</td>
<td style="text-align:left;">
Inflammatory bowel diseases
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
08
</td>
<td style="text-align:left;">
Four EMA-approved vaccines against SARS-CoV-2 are currently available. Data regarding antibody responses to initial vaccination regimens in patients with inflammatory bowel diseases (IBD) are limited. We conducted a prospective, controlled, multicenter study in tertiary Greek IBD centers. Participating patients had completed the initial vaccination regimens (1 or 2 doses, depending on the type of COVID-19 vaccine) at least 2 weeks before study enrolment. Anti-S1 IgG antibody levels were measured. Demographic and adverse events data were collected. We tested 403 patients (Crohn’s disease, 58.9%; male, 53.4%; median age, 45 years) and 124 healthy controls (HCs). Following full vaccination, 98% of patients seroconverted, with mRNA vaccines inducing higher seroconversion rates than viral vector vaccines (P = .021). In total, IBD patients had lower anti-S1 levels than HCs (P &amp;lt; .001). In the multivariate analysis, viral vector vaccines (P &amp;lt; .001), longer time to antibody testing (P &amp;lt; .001), anti-TNFα treatment (P = .013), and age (P = .016) were independently associated with lower anti-S1 titers. Vedolizumab monotherapy was associated with higher antibody levels than anti-TNFα or anti-interleukin-12/IL-23 monotherapy (P = .023 and P = .032). All anti- SARS-CoV-2 vaccines were safe. Patients with IBD have impaired antibody responses to anti-SARS-CoV-2 vaccination, particularly those receiving viral vector vaccines and those on anti-TNFα treatment. Older age also hampers antibody production after vaccination. For those low-response groups, administration of accelerated or prioritized booster vaccination may be considered.
</td>
</tr>
<tr>
<td style="text-align:left;">
35394172
</td>
<td style="text-align:left;">
Cerebral venous sinus thrombosis in the setting of COVID-19 vaccination: a systematic review and meta-analysis.
</td>
<td style="text-align:left;">
Journal of neurology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
08
</td>
<td style="text-align:left;">
Cerebral venous sinus thrombosis (CVST) has been reported as a rare adverse event in association with thrombosis-thrombocytopenia syndrome (TTS) following COVID-19 vaccination. We performed a systematic review and meta-analysis of investigator-initiated registries including confirmed CVST cases, with the aim to calculate (1) the odds ratio of TTS-CVST versus non-TTS-CVST after vector-based vaccines and (2) after non-vector-based vaccines, (3) the in-hospital mortality ratio of TTS-CVST compared to non-TTS-CVST; and (4) the dependency or death at discharge among TTS-CVST compared to non-TTS-CVST cases. Two eligible studies were included in the meta-analysis, comprising a total of 211 patients with CVST associated with COVID-19 vaccination. Vector-based COVID-19 vaccination was associated with a higher likelihood of TTS-associated CVST than with non-TTS-CVST (OR: 52.34, 95% CI 9.58-285.98). TTS-CVST was also associated with higher likelihood of in-hospital mortality (OR: 13.29; 95% CI 3.96-44.60) and death or dependency at discharge compared to non-TTS-CVST (OR: 6.70; 95% CI 3.15-14.26). TTS-CVST was recorded with a shorter interval between vaccination and symptom onset [Mean Difference (MD):-6.54 days; 95% CI - 12.64 to - 0.45], affecting younger patients (MD:-9.00 years; 95% CI - 14.02 to - 3.99) without risk factors for thromboses (OR:2.34; 95% CI 1.26-4.33), and was complicated more frequently with intracerebral hemorrhage (OR:3.60; 95% CI 1.31-9.87) and concomitant thromboses in other sites (OR:11.85; 95% CI 3.51-39.98) compared to non-TTS-CVST cases. TTS-CVST following COVID-19 vaccination has distinct risk factor profile, clinical phenotype and prognosis compared to non-TTS-CVST. Further epidemiological data are required to evaluate the impact of different treatment strategies on outcome of TTS-CVST cases following COVID-19 vaccination.
</td>
</tr>
<tr>
<td style="text-align:left;">
35393922
</td>
<td style="text-align:left;">
Comparison of health-oriented cross-regional allocation strategies for the COVID-19 vaccine: a mathematical modelling study.
</td>
<td style="text-align:left;">
Annals of medicine
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Dec
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Controlling the epidemic spread and establishing the immune barrier in a short time through accurate vaccine demand prediction and optimised vaccine allocation strategy are still urgent problems to be solved under the condition of frequent virus mutations. A cross-regional Susceptible-Exposed-Infected-Removed dynamic model was used for scenario simulation to systematically elaborate and compare the effects of different cross-regional vaccine allocation strategies on the future development of the epidemic in regions with different population sizes, prevention and control capabilities, and initial risk levels. Furthermore, the trajectory of the cross-regional vaccine allocation strategy, calculated using a particle swarm optimisation algorithm, was compared with the trajectories of other strategies. By visualising the final effect of the particle swarm optimisation vaccine allocation strategy, this study revealed the important role of prevention and control (including the level of social distancing control, the speed of tracking and isolating exposed and infected individuals, and the initial frequency of mask-wearing) in determining the allocation of vaccine resources. Most importantly, it supported the idea of prioritising control in regions with a large population and low initial risk level, which broke the general view that high initial risk needs to be given priority and proposed that outbreak risk should be firstly considered instead. This is the first study to use a particle swarm optimisation algorithm to study the cross-regional allocation of COVID-19 vaccines. These data provide a theoretical basis for countries and regions to develop more targeted and sustainable vaccination strategies.KEY MESSAGEThe innovative combination of particle swarm optimisation and cross-regional SEIR model to simulate the pandemic trajectory and predict the vaccine demand helped to speed up and stabilise the construction of the immune barrier, especially faced with new virus mutations.We proposed that priority should be given to regions where it is possible to prevent more infections rather than regions where it is at high initial risk, thus regional outbreak risk should be considered when making vaccine allocation decisions.An optimal health-oriented strategy for vaccine allocation in the COVID-19 pandemic is determined considering both pharmaceutical and non-pharmaceutical policy interventions, including speed of isolation, degree of social distancing control, and frequency of mask-wearing.
</td>
</tr>
<tr>
<td style="text-align:left;">
35393599
</td>
<td style="text-align:left;">
Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines.
</td>
<td style="text-align:left;">
Nature nanotechnology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
After over a billion of vaccinations with messenger RNA-lipid nanoparticle (mRNA-LNP) based SARS-CoV-2 vaccines, anaphylaxis and other manifestations of hypersensitivity can be considered as very rare adverse events. Although current recommendations include avoiding a second dose in those with first-dose anaphylaxis, the underlying mechanisms are unknown; therefore, the risk of a future reaction cannot be predicted. Given how important new mRNA constructs will be to address the emergence of new viral variants and viruses, there is an urgent need for clinical approaches that would allow a safe repeated immunization of high-risk individuals and for reliable predictive tools of adverse reactions to mRNA vaccines. In many aspects, anaphylaxis symptoms experienced by the affected vaccine recipients resemble those of infusion reactions to nanomedicines. Here we share lessons learned over a decade of nanomedicine research and discuss the current knowledge about several factors that individually or collectively contribute to infusion reactions to nanomedicines. We aim to use this knowledge to inform the SARS-CoV-2 lipid-nanoparticle-based mRNA vaccine field.
</td>
</tr>
<tr>
<td style="text-align:left;">
35393481
</td>
<td style="text-align:left;">
Seroprevalence of SARS-CoV-2 spike IgG antibodies after the second BNT162b2 mRNA vaccine in Japanese kidney transplant recipients.
</td>
<td style="text-align:left;">
Scientific reports
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
07
</td>
<td style="text-align:left;">
We aimed to evaluate the seroprevalence and investigated factors associated with seropositivity after the second SARS-CoV-2 mRNA vaccination in kidney transplant (KT) recipients. This retrospective study conducted between June and November 2021 included 106 KT recipients and 127 healthy controls who received the second dose of the BNT162b2 mRNA vaccine at least 7 days before the measurement of antibody titers. The antibody titer against the receptor-binding domain of SARS-CoV-2 spike (S) protein was determined. We compared seroprevalence rates (immunoglobulin G [IgG] level of ≥ 0.8 or ≥ 15 U/mL) between the healthy controls and KT recipients and identified factors associated with impaired humoral response. The seroprevalence rate of the healthy controls and KT recipients was 98% and 22%, respectively. Univariate logistic regression analysis revealed that age &amp;gt; 53 years, rituximab use, mycophenolate mofetil use, and KT vintage &amp;lt; 7 years were negatively associated with the rate of anti-SARS-CoV-2 S IgG ≥ 15 U/mL in KT recipients. ABO blood type incompatible KT was not significantly associated with seroprevalence. Humoral response after the second BNT162b2 mRNA vaccine was greatly hindered by immunosuppression therapy in KT recipients. Older age, rituximab use, mycophenolate mofetil use, and KT vintage may play key roles in seroconversion.
</td>
</tr>
<tr>
<td style="text-align:left;">
35393315
</td>
<td style="text-align:left;">
Vaccination coverage among COVID-19 prevention and control management teams at primary healthcare facilities in China and their attitudes towards COVID-19 vaccine: a cross-sectional online survey.
</td>
<td style="text-align:left;">
BMJ open
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
07
</td>
<td style="text-align:left;">
To investigate the COVID-19 vaccination coverage rate and differences among various COVID-19 prevention primary healthcare (PHC) facilities in China and understand their attitudes towards COVID-19 vaccine. These findings are helpful to provide important suggestions to further improve national COVID-19 vaccination rate. A nationwide cross-sectional online survey was designed and conducted among COVID-19 prevention and control management teams at PHC facilities in mainland China. In the self-designed questionnaires, each subject was asked to evaluate on a 1-10 scale (10=extremely important/acceptable/influential) the COVID-19 vaccination importance, acceptance and factors related to vaccine hesitancy. Subjects from 31 provinces and autonomous regions including minorities across mainland China were invited to complete the questionnaire between 22 February 2021 and 2 March 2021. Were selected by multistage stratified sampling, 998 valid questionnaires (valid rate 99.11%) were collected. The respondents were divided into group A (≤5 respondents within each PHC facility, n1=718) and group B (&amp;gt;5 respondents within each PHC facility, n2=280). Survey on vaccination rate and attitude towards COVID-19 vaccine included the following: (1) if the subjects think the vaccination is important in containment of COVID-19 pandemic (1-10 scale, 10=extremely important), (2) if they would accept COVID-19 vaccine (1-10 scale, 10=extremely acceptable) and (3) their opinions on 7 factors possibly related to vaccine hesitancy (1-10 scale, 10=extremely influential). All the items were designed based on the previous expert interviews. Our results showed vaccination rate was greater in group A (85.93%) than in group B (66.43%) (p&amp;lt;0.001). Detailed analyses revealed that in group A, male members were twice as likely to get vaccinated as compared with female members (adjusted OR (aOR): 2.07; 95% CI: 1.26 to 3.43, p=0.004). In group B, those who were at or under the median age had twice the odds of vaccination coverage compared with those who were over the median age (aOR: 2.29; 95% CI: 1.22 to 4.33, p=0.010). In addition, those who were specialised in traditional Chinese medicine were less likely to get vaccinated against COVID-19 compared with those who were specialised in general medicine, with the aOR: 0.10 (95% CI: 0.01 to 0.83, p=0.033). By analysing the factors that influenced the vaccination attitudes among the 998 respondents, we found no significant difference between the vaccinated and unvaccinated participants. However, further detailed analyses found that team members with undergraduate college education were less likely to score higher in COVID-19 vaccination importance than those with technical secondary school education (aOR: 0.35; 95% CI: 0.13 to 0.93, p=0.035); Furthermore, those with non-medical job titles had nearly twice the odds of giving a higher score for the uncertainty of vaccine efficacy compared with those with junior medical titles (aOR: 1.70; 95% CI: 1.02 to 2.85, p=0.016). Team members with a non-medical title were more likely to give a higher score for advice on social sources compared with those with a junior medical title (aOR: 1.70; 95% CI: 1.02 to 2.85, p=0.042). In PHC facilities, although there was a higher COVID-19 vaccination rate among COVID-19 prevention and control teams, some subgroups with different descriptive characters showed negative attitudes towards COVID-19 vaccination. Because primary care workers in China are highly expected to receive the vaccination, and support and educate the public for COVID-19 vaccination. Thus, it is important and necessary to continue to educate them about their vaccination concerns and change their attitudes towards vaccination. Our findings are highly beneficial for designing public vaccination education strategies.
</td>
</tr>
<tr>
<td style="text-align:left;">
35393149
</td>
<td style="text-align:left;">
The early impact of vaccination against SARS-CoV-2 in Region Stockholm, Sweden.
</td>
<td style="text-align:left;">
Vaccine
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Mar
</td>
<td style="text-align:left;">
29
</td>
<td style="text-align:left;">
Vaccination against SARS-CoV-2 started in Region Stockholm, Sweden in December 2020 with those in long-term care facilities or receiving home care vaccinated first followed by those aged over 80 years. In this population-based, retrospective cohort study, we performed a Poisson regression to model the expected incidence of infections and deaths which we compared to the observed incidence and compared this to an unvaccinated control group of those aged 18-79 years. The aim of this study was to measure the early impact of the vaccination programme in Region Stockholm. Infections and deaths reduced substantially amongst the first two groups targeted for SARS-CoV-2 vaccination with an estimated total 3112 infections prevented, and 854 deaths prevented in these two groups from 4 weeks after the introduction of vaccination through to 2nd May 2021.
</td>
</tr>
<tr>
<td style="text-align:left;">
35393148
</td>
<td style="text-align:left;">
Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein.
</td>
<td style="text-align:left;">
Vaccine
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
04
</td>
<td style="text-align:left;">
Despite substantial efforts, no effective treatment has been discovered for severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection. Therefore, vaccination to reach herd immunity is the ultimate solution to control the coronavirus disease 2019 (COVID-19) pandemic. This study aimed to evaluate the potency, toxicity, and protection of candidate PastoCoAd vaccines as novel mix and match of recombinant adenovirus type 5 (rAd5) containing the full-length spike protein (rAd5-S), rAd5 containing the receptor-binding domain of S protein and nucleoprotein (rAd5 RBD-N), and SOBERANA dimeric RBD protein of SARS-CoV-2. Three vaccine candidates were developed against SARS-CoV-2 using adenoviral vectors, including the prime-boost (rAd5-S/rAd5 RBD-N), heterologous prime-boost (rAd5-S/ SOBERANA vaccine), and prime only (mixture of rAd5-S and rAd5 RBD-N). The rAd5-S and rAd5 RBD-N were produced with a Cytomegalovirus promoter and the human tissue plasminogen activator (tPA) leader sequence. The immunogenicity of vaccine candidates was also evaluated in mouse, rabbit, and hamster models and protection was evaluated in a hamster model. Following the injection of vaccine candidates, no significant toxicity was observed in the tissues of animal models. The immunogenicity studies of mice, rabbits, and hamsters showed that responses of total IgG antibodies were significantly higher with the prime-only and heterologous prime-boost vaccines as compared to the other groups (P &amp;lt; 0.009). Virus neutralizing antibodies were detected, and the level of cytokines related to humoral and cellular immunity increased significantly in all vaccinated models. A high cellular immunity response was found in the vaccinated groups compared to the controls. On the other hand, the vaccine challenge test showed that the virus titers significantly decreased in the pharynx and lung tissues of vaccinated hamsters compared to the control group. These successful findings suggest the safety and protection produced by the heterologous prime-boost vaccine (adenovector/ SOBERANA RBD), as well as a single dose of adenovector vaccine in animal models.
</td>
</tr>
<tr>
<td style="text-align:left;">
35392838
</td>
<td style="text-align:left;">
IgA nephropathy relapse following COVID-19 vaccination treated with corticosteroid therapy: case report.
</td>
<td style="text-align:left;">
BMC nephrology
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
07
</td>
<td style="text-align:left;">
The flare of immune-mediated disease following coronavirus disease of 2019 (COVID-19) vaccination is a rare adverse event following immunization. De novo, as well as relapsing IgA nephropathy (IgAN) cases, have been reported following either mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech) vaccination. To our knowledge, the majority of IgAN relapses did not result in severe acute kidney injury (AKI) and resolved spontaneously. This is a case of a 54-year-old female with a previous diagnosis of IgAN who developed IgAN relapse following the second dose of Moderna vaccine. Gross hematuria developed 2 days after vaccination, which was accompanied by significant AKI. Kidney biopsy showed mild tubular atrophy and IgA staining in mesangium without crescent formation. Significant improvement in serum creatinine (Cr) was observed on day 10 after initiating prednisone. Cr came back to normal within 3 months after initiating corticosteroid. COVID-19 vaccination is associated with a flare of IgAN that may cause significant AKI. Steroid therapy is associated with recovery. IgAN flare after COVID-19 vaccination should be closely monitored to elucidate any adverse effect associated with the novel vaccine.
</td>
</tr>
<tr>
<td style="text-align:left;">
35392535
</td>
<td style="text-align:left;">
Antigen-Antibody Complex-Guided Exploration of the Hotspots Conferring the Immune-Escaping Ability of the SARS-CoV-2 RBD.
</td>
<td style="text-align:left;">
Frontiers in molecular biosciences
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
The COVID-19 pandemic resulting from the spread of SARS-CoV-2 spurred devastating health and economic crises around the world. Neutralizing antibodies and licensed vaccines were developed to combat COVID-19, but progress was slow. In addition, variants of the receptor-binding domain (RBD) of the spike protein confer resistance of SARS-CoV-2 to neutralizing antibodies, nullifying the possibility of human immunity. Therefore, investigations into the RBD mutations that disrupt neutralization through convalescent antibodies are urgently required. In this study, we comprehensively and systematically investigated the binding stability of RBD variants targeting convalescent antibodies and revealed that the RBD residues F456, F490, L452, L455, and K417 are immune-escaping hotspots, and E484, F486, and N501 are destabilizing residues. Our study also explored the possible modes of actions of emerging SARS-CoV-2 variants. All results are consistent with experimental observations of attenuated antibody neutralization and clinically emerging SARS-CoV-2 variants. We identified possible immune-escaping hotspots that could further promote resistance to convalescent antibodies. The results provide valuable information for developing and designing novel monoclonal antibody drugs to combat emerging SARS-CoV-2 variants.
</td>
</tr>
<tr>
<td style="text-align:left;">
35392471
</td>
<td style="text-align:left;">
Determinants of COVID-19 Vaccine Uptake in Adolescents 12-17 Years Old: Examining Pediatric Vaccine Hesitancy Among Racially Diverse Parents in the United States.
</td>
<td style="text-align:left;">
Frontiers in public health
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
As of December 8, 2021, 9.9 million U.S. adolescents ages 12-17 years old remain unvaccinated against COVID-19 (SARS-CoV-2) despite FDA emergency approval of the Pfizer-BioNTech COVID-19 vaccine for use among this age group in May 2021. A slow-down in adolescent vaccine uptake and increased likelihood of hospitalization among unvaccinated youth highlight the importance of understanding parental hesitancy in vaccinating their adolescent children against COVID-19. Racial/ethnic disparities in pediatric COVID-19 infection and hospitalization further underscore the need to examine parental vaccine acceptance and hesitancy among diverse U.S. parent populations. In October 2021, 242 Hispanic and non-Hispanic Asian, Black, and White parents of adolescents ages 12-17 years participated in a national online survey assessing determinants of COVID-19 pediatric vaccine hesitancy. Compared to Asian, Black, and Hispanic parents, non-Hispanic White parents reported reduced odds of having vaccinated their adolescent. Bivariate analyses and a multivariable binomial logistic regression indicated that identification as non-Hispanic White, parental COVID-19 vaccine status and safety measures, COVID-19 misconceptions, general vaccine mistrust and COVID-19 related collectivist and individualist attitudes accounted for 45.5% of the variance in the vaccine status of their adolescent children. Our findings draw attention to the urgent need to consider the COVID-19 beliefs, attitudes, and behaviors of parents from diverse racial/ethnic groups in developing population tailored public health messaging to increase adolescent COVID-19 vaccine uptake.
</td>
</tr>
<tr>
<td style="text-align:left;">
35392137
</td>
<td style="text-align:left;">
Modelling the Effect of the Interaction between Vaccination and Nonpharmaceutical Measures on COVID-19 Incidence.
</td>
<td style="text-align:left;">
Global health, epidemiology and genomics
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Since December 2019, the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly from Wuhan (China) across the globe, affecting more than 200 countries by mid-2021, with over 190 M reported cases and around 4 M fatalities. During the first year of the pandemic, affected countries implemented a variety of nonpharmaceutical interventions to control virus transmission. In December 2020, countries started administering several authorised vaccines under a limited supply scenario. In this context, the aim of this study was to develop a SEIR-type continuous-time deterministic disease model, to determine the impact of interaction between different vaccination scenarios and levels of protection measures on disease incidence. For this, the model incorporates (i) a protection measure including low (self-protection), medium (mobility limitation), high (closure of indoor facilities), and very high (lockdown) protection levels, (ii) quarantine for confirmed cases, and (iii) vaccination rate and efficacy of four types of vaccines (Pfizer, Moderna, Astra Zeneca, and Janssen). The model was verified and evaluated using the response timeline and vaccination strategies and rates in the Basque Country (N. Spain). Once the model performance was validated, different initial phase (when 30% of the population is vaccinated) vaccination scenarios were simulated, including (i) a realistic vaccine limited supply scenario and (ii) four potential full vaccine supply scenarios where a unique vaccine type is administered. Significant differences in disease prevalence and cumulative mortality were found between vaccination scenarios for low and medium-level protection measures. For high-level protection measures, any vaccine scenario is effective at limiting the virus transmission and disease mortality. The results obtained here may vary in further studies since there may be some unpredictable factors/covariates. With this in mind, the model here could be easily applied to other regions or countries, modifying the strategies implemented and initial conditions.
</td>
</tr>
<tr>
<td style="text-align:left;">
35391899
</td>
<td style="text-align:left;">
Enhanced SARS-CoV-2 Antibody Response After a Third Heterologous Vector Vaccine Ad26COVS1 Dose in mRNA Vaccine-Primed Kidney Transplant Recipients.
</td>
<td style="text-align:left;">
Transplant international : official journal of the European Society for Organ Transplantation
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
35391714
</td>
<td style="text-align:left;">
COVID-19 Vaccine Hesitancy and Experiences of Discrimination Among Black Adults.
</td>
<td style="text-align:left;">
Journal of racial and ethnic health disparities
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
07
</td>
<td style="text-align:left;">
Early in the COVID-19 vaccine rollout, Black adults consistently reported more hesitancy than White adults, but few studies have examined variation in hesitancy among Black adults or its associations with racial discrimination. Data were collected from Black Arkansas residents age 18 and older (n = 350) between July 12th and July 30th, 2021, as part of a larger survey of Arkansans (N = 1500). Participants were recruited through random digit dialing of both landline and cell phones, with oversampling of Black and Hispanic residents. Respondents reported COVID-19 vaccine hesitancy, sociodemographic information, influenza vaccination history, pandemic-related experiences, and experiences of racial discrimination. Almost half (48.9%) of Black adults in Arkansas were not hesitant towards COVID-19 vaccines, while the remainder reported some level of hesitancy. Nearly a quarter were very hesitant (22.4%), while fewer reported being somewhat (14.0%) and a little (14.7%) hesitant. Using an ordered logistic regression with partial proportional odds, we find odds of COVID-19 vaccine hesitancy decreased as age and influenza vaccination increased. Odds of COVID-19 vaccine hesitancy were 1.70 times greater for Black adults who experienced the death of a close friend/family member due to COVID-19 and 2.61 times greater for individuals reporting discrimination with police or in the courts. Within-group analysis revealed nearly half of Black adults did not report any COVID-19 vaccine hesitancy and heterogeneity among those who were hesitant. Findings suggest there may be an important link between racial discrimination in the criminal justice system and COVID-19 vaccine hesitancy among Black adults.
</td>
</tr>
<tr>
<td style="text-align:left;">
35391673
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
MMW Fortschritte der Medizin
</td>
<td style="text-align:left;">
2022
</td>
<td style="text-align:left;">
Apr
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
</div>
<div id="text-mining" class="section level2">
<h2>Text Mining</h2>
<p>Now, we can shift our attention to text mining by first loading in the <code>pubmed.csv</code> data from the class GitHub repository. Then, we can tokenize each abstract and visualize the top 10 tokens in both tabular and graphical form below:</p>
<table class="table" style="margin-left: auto; margin-right: auto;">
<caption>
The Frequencies of the Top 10 Most Common Words in the PubMed Data
</caption>
<thead>
<tr>
<th style="text-align:left;">
Word
</th>
<th style="text-align:right;">
Frequency
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
the
</td>
<td style="text-align:right;">
28126
</td>
</tr>
<tr>
<td style="text-align:left;">
of
</td>
<td style="text-align:right;">
24760
</td>
</tr>
<tr>
<td style="text-align:left;">
and
</td>
<td style="text-align:right;">
19993
</td>
</tr>
<tr>
<td style="text-align:left;">
in
</td>
<td style="text-align:right;">
14653
</td>
</tr>
<tr>
<td style="text-align:left;">
to
</td>
<td style="text-align:right;">
10920
</td>
</tr>
<tr>
<td style="text-align:left;">
a
</td>
<td style="text-align:right;">
8245
</td>
</tr>
<tr>
<td style="text-align:left;">
with
</td>
<td style="text-align:right;">
8038
</td>
</tr>
<tr>
<td style="text-align:left;">
covid
</td>
<td style="text-align:right;">
7275
</td>
</tr>
<tr>
<td style="text-align:left;">
19
</td>
<td style="text-align:right;">
7080
</td>
</tr>
<tr>
<td style="text-align:left;">
is
</td>
<td style="text-align:right;">
5649
</td>
</tr>
</tbody>
</table>
<p><img src="data:image/png;base64,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" width="672" /></p>
<p>As we can see, the top 10 tokens aren’t very interesting as they are all just regularly used English words with the exception of “covid” and “19”, so our next step is to remove all of these stopwords. The following table shows the top 5 tokens after removing stopwords for each of the search terms:</p>
<table class="table" style="margin-left: auto; margin-right: auto;">
<caption>
The Frequencies of the Top 5 Most Common Words Corresponding to the 5 Search Terms in the PubMed Data
</caption>
<thead>
<tr>
<th style="text-align:left;">
Search Term
</th>
<th style="text-align:left;">
Word
</th>
<th style="text-align:right;">
Frequency
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
covid
</td>
<td style="text-align:left;">
covid
</td>
<td style="text-align:right;">
7275
</td>
</tr>
<tr>
<td style="text-align:left;">
covid
</td>
<td style="text-align:left;">
19
</td>
<td style="text-align:right;">
7035
</td>
</tr>
<tr>
<td style="text-align:left;">
covid
</td>
<td style="text-align:left;">
patients
</td>
<td style="text-align:right;">
2293
</td>
</tr>
<tr>
<td style="text-align:left;">
covid
</td>
<td style="text-align:left;">
disease
</td>
<td style="text-align:right;">
943
</td>
</tr>
<tr>
<td style="text-align:left;">
covid
</td>
<td style="text-align:left;">
pandemic
</td>
<td style="text-align:right;">
800
</td>
</tr>
<tr>
<td style="text-align:left;">
cystic fibrosis
</td>
<td style="text-align:left;">
fibrosis
</td>
<td style="text-align:right;">
867
</td>
</tr>
<tr>
<td style="text-align:left;">
cystic fibrosis
</td>
<td style="text-align:left;">
cystic
</td>
<td style="text-align:right;">
862
</td>
</tr>
<tr>
<td style="text-align:left;">
cystic fibrosis
</td>
<td style="text-align:left;">
cf
</td>
<td style="text-align:right;">
625
</td>
</tr>
<tr>
<td style="text-align:left;">
cystic fibrosis
</td>
<td style="text-align:left;">
patients
</td>
<td style="text-align:right;">
586
</td>
</tr>
<tr>
<td style="text-align:left;">
cystic fibrosis
</td>
<td style="text-align:left;">
disease
</td>
<td style="text-align:right;">
400
</td>
</tr>
<tr>
<td style="text-align:left;">
meningitis
</td>
<td style="text-align:left;">
patients
</td>
<td style="text-align:right;">
446
</td>
</tr>
<tr>
<td style="text-align:left;">
meningitis
</td>
<td style="text-align:left;">
meningitis
</td>
<td style="text-align:right;">
429
</td>
</tr>
<tr>
<td style="text-align:left;">
meningitis
</td>
<td style="text-align:left;">
meningeal
</td>
<td style="text-align:right;">
219
</td>
</tr>
<tr>
<td style="text-align:left;">
meningitis
</td>
<td style="text-align:left;">
csf
</td>
<td style="text-align:right;">
206
</td>
</tr>
<tr>
<td style="text-align:left;">
meningitis
</td>
<td style="text-align:left;">
clinical
</td>
<td style="text-align:right;">
187
</td>
</tr>
<tr>
<td style="text-align:left;">
preeclampsia
</td>
<td style="text-align:left;">
pre
</td>
<td style="text-align:right;">
2038
</td>
</tr>
<tr>
<td style="text-align:left;">
preeclampsia
</td>
<td style="text-align:left;">
eclampsia
</td>
<td style="text-align:right;">
2005
</td>
</tr>
<tr>
<td style="text-align:left;">
preeclampsia
</td>
<td style="text-align:left;">
preeclampsia
</td>
<td style="text-align:right;">
1863
</td>
</tr>
<tr>
<td style="text-align:left;">
preeclampsia
</td>
<td style="text-align:left;">
women
</td>
<td style="text-align:right;">
1196
</td>
</tr>
<tr>
<td style="text-align:left;">
preeclampsia
</td>
<td style="text-align:left;">
pregnancy
</td>
<td style="text-align:right;">
969
</td>
</tr>
<tr>
<td style="text-align:left;">
prostate cancer
</td>
<td style="text-align:left;">
cancer
</td>
<td style="text-align:right;">
3840
</td>
</tr>
<tr>
<td style="text-align:left;">
prostate cancer
</td>
<td style="text-align:left;">
prostate
</td>
<td style="text-align:right;">
3832
</td>
</tr>
<tr>
<td style="text-align:left;">
prostate cancer
</td>
<td style="text-align:left;">
patients
</td>
<td style="text-align:right;">
934
</td>
</tr>
<tr>
<td style="text-align:left;">
prostate cancer
</td>
<td style="text-align:left;">
treatment
</td>
<td style="text-align:right;">
926
</td>
</tr>
<tr>
<td style="text-align:left;">
prostate cancer
</td>
<td style="text-align:left;">
disease
</td>
<td style="text-align:right;">
652
</td>
</tr>
</tbody>
</table>
<p>Next, we can look at the most common pairs of words among the abstracts in the data. The following table and barplot visualize the top 10 bigrams:</p>
<table class="table" style="margin-left: auto; margin-right: auto;">
<caption>
The Frequencies of the Top 10 Most Common Bigrams in the PubMed Data After Removing Stopwords
</caption>
<thead>
<tr>
<th style="text-align:left;">
Bigram
</th>
<th style="text-align:left;">
First Word
</th>
<th style="text-align:left;">
Second Word
</th>
<th style="text-align:right;">
Frequency
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
covid 19
</td>
<td style="text-align:left;">
covid
</td>
<td style="text-align:left;">
19
</td>
<td style="text-align:right;">
6969
</td>
</tr>
<tr>
<td style="text-align:left;">
prostate cancer
</td>
<td style="text-align:left;">
prostate
</td>
<td style="text-align:left;">
cancer
</td>
<td style="text-align:right;">
3222
</td>
</tr>
<tr>
<td style="text-align:left;">
pre eclampsia
</td>
<td style="text-align:left;">
pre
</td>
<td style="text-align:left;">
eclampsia
</td>
<td style="text-align:right;">
1854
</td>
</tr>
<tr>
<td style="text-align:left;">
cystic fibrosis
</td>
<td style="text-align:left;">
cystic
</td>
<td style="text-align:left;">
fibrosis
</td>
<td style="text-align:right;">
860
</td>
</tr>
<tr>
<td style="text-align:left;">
19 patients
</td>
<td style="text-align:left;">
19
</td>
<td style="text-align:left;">
patients
</td>
<td style="text-align:right;">
447
</td>
</tr>
<tr>
<td style="text-align:left;">
19 pandemic
</td>
<td style="text-align:left;">
19
</td>
<td style="text-align:left;">
pandemic
</td>
<td style="text-align:right;">
419
</td>
</tr>
<tr>
<td style="text-align:left;">
coronavirus disease
</td>
<td style="text-align:left;">
coronavirus
</td>
<td style="text-align:left;">
disease
</td>
<td style="text-align:right;">
361
</td>
</tr>
<tr>
<td style="text-align:left;">
95 ci
</td>
<td style="text-align:left;">
95
</td>
<td style="text-align:left;">
ci
</td>
<td style="text-align:right;">
322
</td>
</tr>
<tr>
<td style="text-align:left;">
sars cov
</td>
<td style="text-align:left;">
sars
</td>
<td style="text-align:left;">
cov
</td>
<td style="text-align:right;">
317
</td>
</tr>
<tr>
<td style="text-align:left;">
cov 2
</td>
<td style="text-align:left;">
cov
</td>
<td style="text-align:left;">
2
</td>
<td style="text-align:right;">
299
</td>
</tr>
</tbody>
</table>
<p><img src="data:image/png;base64,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" width="672" /></p>
<p>Finally, we can look at the words associated with the top 5 TF-IDF values for each of the 5 search terms in the table and plot below:</p>
<table class="table" style="margin-left: auto; margin-right: auto;">
<caption>
The 5 Largest TF-IDF Values For Words Corresponding to the 5 Search Terms in the PubMed Data
</caption>
<thead>
<tr>
<th style="text-align:left;">
Search Term
</th>
<th style="text-align:left;">
Word
</th>
<th style="text-align:right;">
TF-IDF Value
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
covid
</td>
<td style="text-align:left;">
covid
</td>
<td style="text-align:right;">
0.1041177
</td>
</tr>
<tr>
<td style="text-align:left;">
covid
</td>
<td style="text-align:left;">
pandemic
</td>
<td style="text-align:right;">
0.0114494
</td>
</tr>
<tr>
<td style="text-align:left;">
covid
</td>
<td style="text-align:left;">
19
</td>
<td style="text-align:right;">
0.0000000
</td>
</tr>
<tr>
<td style="text-align:left;">
covid
</td>
<td style="text-align:left;">
disease
</td>
<td style="text-align:right;">
0.0000000
</td>
</tr>
<tr>
<td style="text-align:left;">
covid
</td>
<td style="text-align:left;">
patients
</td>
<td style="text-align:right;">
0.0000000
</td>
</tr>
<tr>
<td style="text-align:left;">
cystic fibrosis
</td>
<td style="text-align:left;">
cf
</td>
<td style="text-align:right;">
0.0214528
</td>
</tr>
<tr>
<td style="text-align:left;">
cystic fibrosis
</td>
<td style="text-align:left;">
fibrosis
</td>
<td style="text-align:right;">
0.0165906
</td>
</tr>
<tr>
<td style="text-align:left;">
cystic fibrosis
</td>
<td style="text-align:left;">
cystic
</td>
<td style="text-align:right;">
0.0164949
</td>
</tr>
<tr>
<td style="text-align:left;">
cystic fibrosis
</td>
<td style="text-align:left;">
disease
</td>
<td style="text-align:right;">
0.0000000
</td>
</tr>
<tr>
<td style="text-align:left;">
cystic fibrosis
</td>
<td style="text-align:left;">
patients
</td>
<td style="text-align:right;">
0.0000000
</td>
</tr>
<tr>
<td style="text-align:left;">
meningitis
</td>
<td style="text-align:left;">
meningitis
</td>
<td style="text-align:right;">
0.0263883
</td>
</tr>
<tr>
<td style="text-align:left;">
meningitis
</td>
<td style="text-align:left;">
meningeal
</td>
<td style="text-align:right;">
0.0134709
</td>
</tr>
<tr>
<td style="text-align:left;">
meningitis
</td>
<td style="text-align:left;">
csf
</td>
<td style="text-align:right;">
0.0072141
</td>
</tr>
<tr>
<td style="text-align:left;">
meningitis
</td>
<td style="text-align:left;">
clinical
</td>
<td style="text-align:right;">
0.0000000
</td>
</tr>
<tr>
<td style="text-align:left;">
meningitis
</td>
<td style="text-align:left;">
patients
</td>
<td style="text-align:right;">
0.0000000
</td>
</tr>
<tr>
<td style="text-align:left;">
preeclampsia
</td>
<td style="text-align:left;">
eclampsia
</td>
<td style="text-align:right;">
0.0410837
</td>
</tr>
<tr>
<td style="text-align:left;">
preeclampsia
</td>
<td style="text-align:left;">
preeclampsia
</td>
<td style="text-align:right;">
0.0381741
</td>
</tr>
<tr>
<td style="text-align:left;">
preeclampsia
</td>
<td style="text-align:left;">
pregnancy
</td>
<td style="text-align:right;">
0.0063020
</td>
</tr>
<tr>
<td style="text-align:left;">
preeclampsia
</td>
<td style="text-align:left;">
pre
</td>
<td style="text-align:right;">
0.0000000
</td>
</tr>
<tr>
<td style="text-align:left;">
preeclampsia
</td>
<td style="text-align:left;">
women
</td>
<td style="text-align:right;">
0.0000000
</td>
</tr>
<tr>
<td style="text-align:left;">
prostate cancer
</td>
<td style="text-align:left;">
prostate
</td>
<td style="text-align:right;">
0.0906033
</td>
</tr>
<tr>
<td style="text-align:left;">
prostate cancer
</td>
<td style="text-align:left;">
cancer
</td>
<td style="text-align:right;">
0.0000000
</td>
</tr>
<tr>
<td style="text-align:left;">
prostate cancer
</td>
<td style="text-align:left;">
disease
</td>
<td style="text-align:right;">
0.0000000
</td>
</tr>
<tr>
<td style="text-align:left;">
prostate cancer
</td>
<td style="text-align:left;">
patients
</td>
<td style="text-align:right;">
0.0000000
</td>
</tr>
<tr>
<td style="text-align:left;">
prostate cancer
</td>
<td style="text-align:left;">
treatment
</td>
<td style="text-align:right;">
0.0000000
</td>
</tr>
</tbody>
</table>
<p>We can see in the table above which words (after removing stopwords, of course) have the highest TF-IDF values for each of the 5 search terms in the PubMed dataset. By comparing these words with the words with the highest frequencies for each search term, we can see that the words with the highest frequencies for each search term match exactly with the words with the highest TF-IDF values for each search term.</p>
<p>This may seem counterintuitive as TF-IDF values are generally understood to be larger for rare words and smaller for more common words, but upon closer inspection, this contrast can be explained by the fact that TF-IDF values can also be understood as a balancing measure with regards to whether a word is rare or common. As some words for some search terms can intuitively be seen as making up a massive proportion of all the words present for that search term (for example, take the word “covid” with the “covid” search term, it is natural for this word to make up the bulk of the words in abstracts under the “covid” search term), it is possible that these words are so overrepresented that their TF-IDF values get pushed upward, as the balancing measure is just skewed in the direction of having a larger frequency instead of a smaller frequency.</p>
</div>




</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
